<SEC-DOCUMENT>0000950170-23-006092.txt : 20230306
<SEC-HEADER>0000950170-23-006092.hdr.sgml : 20230306
<ACCEPTANCE-DATETIME>20230306061124
ACCESSION NUMBER:		0000950170-23-006092
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230306
DATE AS OF CHANGE:		20230306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIODESIX INC
		CENTRAL INDEX KEY:			0001439725
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				203986492
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39659
		FILM NUMBER:		23707464

	BUSINESS ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		303-417-0500

	MAIL ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bdsx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-06T02:56:20.8765+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:bdsx="http://biodesix.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_0980ea39-5787-4d2b-b800-5afec28cfc63" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_1c8b26c8-0d32-4ca1-816d-9b4d8b664166" format="ixt-sec:durwordsen">four years</ix:nonNumeric><ix:nonFraction id="F_4d32ba86-04c2-4e99-bbda-0fc5bb64105e" name="us-gaap:NumberOfOperatingSegments" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" unitRef="U_Segment" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction><ix:nonNumeric id="F_7fd39517-ff33-41f8-ae14-0d40bd4ae488" name="us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric id="F_69f529c7-a6b6-4870-92d2-707a07490f78" name="bdsx:LeaseExpirationMonthYear" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc">2023-01</ix:nonNumeric><ix:nonNumeric id="F_c127f513-dd4b-4997-b27b-a9cd90962444" name="us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric id="F_1533d1c6-8aba-4416-aa35-27b40158e631" name="dei:EntityCentralIndexKey" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc">0001439725</ix:nonNumeric><ix:nonNumeric id="F_562b0db7-e661-4048-b92b-a268fcb490b2" name="dei:CurrentFiscalYearEndDate" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc">--12-31</ix:nonNumeric><ix:nonNumeric id="F_558ae46e-8ea1-4c0a-9a4d-100dfe66de89" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_9d118b38-1b14-47f9-afe0-3a294fa48513">P1Y</ix:nonNumeric><ix:nonNumeric id="F_bead42bb-d6fc-4814-b77a-f8147f03c7e2" name="dei:DocumentFiscalPeriodFocus" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc">FY</ix:nonNumeric><ix:nonFraction id="F_b89a5dda-48e9-42c4-9317-c53410857718" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_9b0044c9-456b-40db-b304-cbb2a4cddf06" name="bdsx:LeaseExpirationMonthYear" contextRef="C_6c1150e6-1985-4c11-9339-33b27033da6e">2023-10</ix:nonNumeric><ix:nonNumeric id="F_7af1e3c8-01b6-4f0f-8209-47648e9fba35" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric id="F_06324b01-1be5-4c23-bbaa-fc1231d74b49" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_dc17e439-b12a-4b73-b3ee-aa4575f60d3e">P3Y</ix:nonNumeric><ix:nonNumeric id="F_bd934ce6-93a4-4c03-8768-1ed24686b2e3" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" contextRef="C_14ac9e9e-e1ed-4025-b9a7-8d5598f7e903">http://fasb.org/us-gaap/2022#InterestExpense</ix:nonNumeric><ix:nonNumeric id="F_fc797632-f319-44da-86cb-db80cce9dc28" name="dei:AmendmentFlag" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc">false</ix:nonNumeric><ix:nonFraction id="F_f737795f-9e9a-466d-855d-23c129fc9e09" name="us-gaap:PreferredStockValue" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ee27f4b8-44a6-44ae-b187-f23c3af6af75" name="us-gaap:PreferredStockValue" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_619e0fd9-df0a-4ffa-8df0-66030beb9821" name="us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_38785f87-07c1-43cc-ac73-db1f587fe1ec">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction id="F_cf430efd-6ac3-4dc9-9262-706a09fd0cf7" name="us-gaap:CommitmentsAndContingencies" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_212e7808-bfbd-4077-abc2-795e910b5233" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" contextRef="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397">http://fasb.org/us-gaap/2022#OperatingLeaseLiability</ix:nonNumeric><ix:nonNumeric id="F_67b38028-3a72-49aa-81eb-6a352ab4c65b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_d7bd6b0a-4041-4e97-93ad-79b76be80350" format="ixt-sec:durwordsen">five years</ix:nonNumeric><ix:nonNumeric id="F_1f6e0faa-935f-477f-be66-d4008a184239" name="bdsx:LeaseExpirationMonthYear" contextRef="C_a78a8177-5e02-4e56-9772-382439d0939c">2024-01</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bdsx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_73bf8719-9ed7-4a80-941c-ebed989aedcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheStateOfColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5a47bb8-865d-46aa-9b99-e3a31978f62d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04d1a84d-a61f-43b4-b180-30e7a26cd32d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_187c775a-a3b7-42da-bfab-78d163765caf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5556e5f1-5117-4c3b-bc0c-a41a3e2ea92b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf4e748d-3074-47c8-b2fc-51fe7c3e9765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a86f3ed-b059-49f8-929d-392ed1b5aefa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bdsx:ExistingShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-07</xbrli:startDate><xbrli:endDate>2022-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d301989c-2ae7-4a05-901c-aeb97c5075f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7ae35e9-9d7c-47bb-a677-d141d7cc9457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcd01088-6b6b-4233-b784-8c76ca2c0480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a2949cc-e81d-4125-b746-f22e110c97c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-07</xbrli:startDate><xbrli:endDate>2022-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a72d645a-776a-4a74-9706-b63f1bd0e7e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_394dc411-8890-456c-88fb-38cd9c45e342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bdsx:CashCollateralizedLetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eee382e8-1805-4f39-907d-bfda41055f0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31da1c0e-91e4-449a-b28c-c8ca4cad2ca2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bdcfef7-9637-41fa-aeb1-09f6ca1e0d5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3422fe75-7e5a-45a7-ac6a-9088eeb3e5b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_daba2c85-8b46-41a0-aced-c3772e54ec5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3c04a86-27e5-41b0-aa97-cc3628b22f88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_949016fe-f937-4caf-b84d-58db21b5e5ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_059b1c27-6f4f-4d72-9faa-e166f7b41f76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02bbb7a6-c4e5-4790-a0f3-3a027542791f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b08f51c-d57a-4f72-8c72-dd0f2eae99a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b9afec0-72f8-4476-a4ee-4fd773a715d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c8760f8-4bfb-43a9-838d-4e0b93c9f2aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_438ec078-c687-429c-a769-d3742dbe11a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a78a8177-5e02-4e56-9772-382439d0939c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd5b1882-de5e-4e68-853c-732d34730afe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-07</xbrli:startDate><xbrli:endDate>2022-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23d25b67-f820-41e5-bbdb-0e27c1391956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acff4fd7-67d1-4f52-bbff-d251e168be02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61e5c055-428e-4280-b39a-813cfb48033b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c73395a4-9ee2-430d-9509-2e0c8ad1a49e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_973930aa-eb0f-4e7d-b68b-2549035fffb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38785f87-07c1-43cc-ac73-db1f587fe1ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4142ff53-afcb-497b-81d5-d370a5bf3011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a20eac41-6dd7-40e8-be7a-37569efa0136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03d24aeb-78a1-4c8d-b568-cfca0d3fc997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d29ffb11-8aeb-454a-b02f-a1cd08996dde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_585442c6-63fc-4616-91c6-831a62abd477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1092db51-6294-44e3-bb69-6fad5f7f2e8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91cf71d9-5882-46d2-af72-be7057b1fa70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8be89166-bad4-409c-881c-a9f3f86a21e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f76d7ba-2692-45b1-bf5a-feaf239555c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc7252ad-b58c-4241-b1ba-4346c1180e60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9ac9aa4-ea3e-4802-8754-c8e9edd2adc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26541884-e077-4463-84ef-77608f72fe54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec8d24b6-eeb6-4535-a95a-f96122922dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b796b863-ace9-4b62-946c-082d3b02817c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5a69a51-44ec-42e5-af14-fd5467f50c5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7401865-053c-4260-997b-b04309ea03f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_903652eb-e3f1-4c1e-a925-53ae57d7cd2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46b3650b-f200-468e-a19b-82906029b2e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8821775-e1c7-4b43-bef0-f192ca32577a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-19</xbrli:startDate><xbrli:endDate>2021-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5034939-1d40-46e1-96f5-cb3cc77d9692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_305b45e3-aa77-4038-91ca-a8b9641f321c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e3f888f-0695-472c-8a11-9658d99a93b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:AstrazenecaUkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a129ea3-f356-49fc-afa3-38f6d02880ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d3d5033-be47-4149-b009-902d32d7a987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d44de77-80d9-49db-a99d-64d8c9816a6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86159b8d-7aed-4b03-b26e-bca866fbd61a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91f72376-23e0-4941-9051-8d330ee61b8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:AtTheMarketFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_630425c2-c257-4e6f-9752-038cef3e8e65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dedd5c19-93b3-496c-9876-ed47d4aade8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91b0e376-daf5-48b6-b4e6-bf780df858cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_214b2dd0-9feb-4b1f-8486-54f0069ba088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb388fb2-b1a4-41c7-b2e6-24847a05c97b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bf6cb5e-cf65-4a16-838b-e866908b46c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ba0380c-8303-431e-a874-ef43625cd063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5407a72b-1be5-441a-baf7-31f7a5742f30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d12dc7db-6c0d-498f-95b8-ead1e40b9fb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f73c574-d57f-4230-9899-1c2a407c3ca8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fbf4b04-42d9-42a3-afc9-b3a2b00cabdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7aa72bf-d149-40f3-98f1-4045959748af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c90072a7-3113-4e95-b308-f449c6e53790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9494a794-f77b-4a40-af81-4b90b746a8d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0124565-7566-42cd-9811-8f85b4b00b29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbc53b33-ca6f-4327-b8af-2aabe16a0af6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6060929-cc88-48de-ac6e-4ff5aee26e2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef9be249-05dd-46fb-9453-58ae75b42808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fd3ded3-11d4-4f58-b776-f582e91d8799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dc925fe-1445-4fb6-b137-670c99ed2615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60e05c27-67bc-4257-a0d2-dc24ad762e3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1eeb3ca-40cd-466c-ae9e-ca7ba7b2a2f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bdsx:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_169bf5c0-fabd-48e8-9e19-f178074d2e74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6852849f-4a20-4832-b763-1f583ecb4c09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80d972be-0e12-4624-abfc-02988b9d378b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd92a88e-0c45-4130-9ceb-be9f1169e806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_283a264a-b0e0-4031-81ad-45b20ea79543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c85c73e5-0596-4390-a44f-00d4c2b63b97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad7793e4-8ed9-4613-ac91-79c78797a90e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5db1c006-3d07-4be3-b5ff-a7b2fbf3e25f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cade502d-a93b-4d54-80ee-98f26b9246c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c534b800-3720-4995-a5a1-9c5c21659307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e75a16fb-16cc-42be-83c6-46117bcf8255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0add87f4-39bd-4cf3-8e49-bc5d9b0a3039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a0dc852-f2b0-48bc-b2b6-1620c601a50d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14ac9e9e-e1ed-4025-b9a7-8d5598f7e903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75202e38-b7dd-49df-9825-87dfcdc551d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f69117e-f3cb-4597-a131-338489bdc295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b84975b5-0a2a-4c6a-a970-bca06808dbba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e152fca-a16d-497a-a116-d749fe3f576a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddfc8a81-b490-496e-95ab-ca6e0d3c6f71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4844e46c-01bd-4e1b-8bbd-3eb015874131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c480ebc-4937-47fd-b5c4-871edf51ca48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8cbb7ea-0740-4eb6-9874-287b74dc5289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_237703f9-d5ea-4653-8904-ce72f3e0e459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba2be62b-8085-45a3-bc77-13c26ae016ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12180992-8c3b-4583-9f45-a6c1fac1d121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c8b26c8-0d32-4ca1-816d-9b4d8b664166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16894d39-c0b9-473f-996a-ea5e902b6bc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_281dc173-6094-4689-8129-e75bfea9ac17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57134a4c-8578-40a1-813d-312feaa45a92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5dc3743-ca85-4769-8c11-523bc0854b31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2944650-b682-45bf-91f6-43c4a2e81e26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8f8214a-ba5d-4798-9bc4-3c9348a307cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca1e3e4c-8bde-4650-aaca-f298f81e530f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59d365ab-7a43-4adf-a882-c16ac6390192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c410de4f-8ea6-4061-8764-66e62ab89b16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_086ca540-28e1-44ca-a323-2ad2636c5784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d118b38-1b14-47f9-afe0-3a294fa48513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7af4e047-0257-4b41-8cb2-aa865601cded"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e91484b1-4de4-45b4-9435-ca540a78f9e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbe57b7b-14db-40d9-b4e3-fcea2a1e2a81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26e73e01-b546-4645-b525-02a9ce64f5a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_186ed4eb-26b5-4313-aca7-752df70e6114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ddc96a7-546d-43f8-87c6-9287c6d330e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2847f431-ac31-433e-ac37-df0cd6d38d6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae3277b8-5cce-47e3-bdd2-81eecc7c9a41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0aa9545-138b-4cb5-9486-69e3ff5ba91b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_313360eb-54d3-44bc-b6b3-5158c6afb114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9aa5426-d887-4faf-a862-0f860b5f1148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_537fd16e-de8c-489b-89dc-da0dcaa87884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_706d33fb-1152-4e58-a444-b5203cd4a996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:LabcorpDdFormerlyCovanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2f28597-f68b-4e5f-938b-bbefedd01c35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8fb8fa4-a259-49a8-a73c-91b175e11aa7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21a7ecc0-40b0-408b-8b87-7d9c2a5f031b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96c6822f-7b22-47f1-bb03-2ae7e3cb1efc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_231071bd-b44d-4ace-82af-b86707b2357a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cd7907e-e91e-4e55-9162-5fb14ec9f02d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b302bad2-98d3-4851-b88b-540dd7c490b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2fe46f8-1653-48ec-9a32-c95a2b1ef531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7bd6b0a-4041-4e97-93ad-79b76be80350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60a8bfcb-40c2-4451-aa67-8593932c5757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f705742-9a2c-4dc7-a282-98868e21f468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_746a7287-f9b5-4d12-831b-35d4b70d784d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac1ef5ae-331a-42b9-b66f-a867d9104059"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7879ad8c-ea5d-4043-a09d-e45c5b04d104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d280c57-4f0c-4087-bfc5-09e23f264b72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd3c756b-0fd0-4580-b35c-5bd0c430ca65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-07</xbrli:startDate><xbrli:endDate>2022-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d722c30e-d139-43c4-b526-3699892348c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b4b65a0-9eab-4198-9d03-64c0e6fc1646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a4e3ec5-40de-461c-b6a5-3cb9963618ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0afd3f5-8310-4844-a4d2-63f0d27ddf88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82d37d69-01a3-41f1-a628-a553ba9b0c62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12bd700e-0b10-4fb5-af15-894d72263e90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee837150-7dcc-4823-b2b5-2d0c51a4dd17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cfbccdc-31c5-4e8a-bfdc-7649f1ec0117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5de36142-f81f-4d20-84f5-a31e77b6a83f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94e70836-502c-461e-9146-5d8aa063080e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9034f42b-c563-4c25-99ba-56b8bc692ac4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ad6809c-68cb-4c96-8ae0-d9bd24aa0db0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9c9e703-63dc-4dfe-8c83-2d95a5dd5cd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_037983b4-6196-4ce5-8ade-33f68a42d303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6d03a98-3b4e-401e-b7cc-82e792333d3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efe1b90e-7787-4cc2-bfbe-359fbdc3c5ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd581c08-91c5-4205-b952-ae033f5f32d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a480b51a-4a24-4df0-bc08-5701140469ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f60b5bcb-f424-4895-a729-730037e7a52d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8159f7a-5617-4338-a333-06a6ca7f3337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d5836ee-d2bb-477b-8e85-8cfcb55b699e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17924754-ecbd-43e7-95c0-61af5078762a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:LPCFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff1c3404-9746-40e4-8ce6-168f0d8cde24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc17e439-b12a-4b73-b3ee-aa4575f60d3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d224c460-5bc5-4c51-b5e3-0c74f540798a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13ad713e-d35e-41ad-b2d9-9738e144f092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1332991-a124-414c-9607-7eb5c2b60415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cc619c2-53d7-4761-a81a-9a741927fe13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d05b24fd-4c4f-402b-8b97-295956c2f519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fabf356-719c-4221-916d-d8ca81752d4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f9bbf97-b166-4fc4-9dad-f1870f5628ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a8e4fde-5800-4383-b5b8-8d6b6fb5e8d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-31</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94f8365d-9f16-480b-9a94-8b6de443e738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_997a32b2-9786-430b-9d46-e8bde7a02bee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5caae45d-0db4-4d63-b236-a9aa359641a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6b61263-79d7-4ad5-80e3-c6488dc15d6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be756e56-47b7-41eb-ad9c-716214c84904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:NSCLCPOCTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1abda95-a10b-462f-b26e-ff79238c4eda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c1150e6-1985-4c11-9339-33b27033da6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fdff006-70ae-43ff-b822-eb5c9877e323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55e36f95-2f43-434a-8af9-06f6e131a730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29c745e0-902e-4e00-abf2-c8cab42148d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c54806e2-2b86-435c-963e-bcc3bba05c0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41cb42fe-1fc1-4fe5-95d4-e30f3d31ec21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15d0eb8a-d853-4db8-a265-c8d1b3c9cc49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0281633c-de51-4d41-b3dd-b1224984423b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_744f7b6a-4217-4a66-a0e3-ea5eed3003f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc669b6e-18c4-48ce-89aa-f437eaa9dea7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5208be1b-25c5-466d-81db-5a3e876f9370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_672ae1be-bd0c-48a6-8adf-0a1565ae2ef1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a85d3cdf-c6db-43af-b1d3-58080059098c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e26e9fe8-1d8c-4a5e-9771-49e0ddbb567d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c393b81-f0da-48af-813c-5c496799a235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11b8abe5-606c-445b-ada4-84273d36bcbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b44b5df-e1bf-421f-890e-33e01c1a22ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e1cb9f9-1f35-4466-a46d-cf526d23b935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64b0a895-45ab-4c6f-ac10-827ab0a951df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba733271-8a6c-457b-aa81-58381d47b3b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d741d82-1d89-43bd-aeaf-d5d87b0316cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_086e1296-a025-4723-b82e-9492b0c68ec9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70355a48-c284-4639-9391-77b924c70e70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dec83647-9b4a-474f-a223-9e24cfba7a30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d36f7fa-49dc-413d-a2bd-8d9342f8e774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d76dbc1-8a85-42e5-96cd-ef88d8ad1938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_255e0eec-7e39-40eb-adba-086563b7ec90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1526a220-9742-4789-9d47-4ce3ee95d398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d12b5949-e029-409e-b622-3df88edf97a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6015f8d-bccb-4bb9-99f1-6b9aa57149f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-02</xbrli:startDate><xbrli:endDate>2020-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf14dbee-c366-4746-bd13-0ca64d12de01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a297dcbf-e7eb-4a6b-b8b7-17cecdbd5a6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75178c23-f72c-42e0-a591-2de6aea0caff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf44b711-ec2f-4b0b-ad81-b0a574373c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be80ae2a-a108-4cd4-aef7-5a62e28a06e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_943b8db7-988c-4af2-94ee-41515857328f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8822067-11ee-4730-84e6-37f46f386c88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71e6a261-6445-4aef-9b90-6aa8258c393b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7de21cc0-f9c4-4529-94a5-c125fe2ca78f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaa55565-82f2-477b-b6d4-79f13c784eb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dc8b832-6352-466d-a5da-07ecf35ded3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4716ca07-4302-4a9c-9ea0-0d87608ecb4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cde4147-0171-4e88-8504-bba1e5f0b211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e3e3184-45f3-43eb-b6eb-3e2a5df33941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1043f2a6-0e14-46df-bbaa-a20764b5e9c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_deba999b-e5c6-4df4-a80e-17fb0c1de3fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_217f72b0-cf7e-4c4d-b942-59ada45d53c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d74f0750-6f1c-442f-84b0-83d80d96838d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_599ead4f-c94c-4dc6-8441-4c817adf1b16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64a79dd5-c87c-429b-863e-00e581d3a825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e895deb9-d4dd-4ee8-a0c9-733eb5b9aee7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ed704bd-7ad3-4b26-ad05-362e6ae5c9c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4d0476a-83e8-40bf-8317-6bc7b409e5d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_965f19ae-0f96-4ce2-8e48-5b6071e81159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7fdeca4f-00cf-4beb-b46e-1e1eae6fa90a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Test"><xbrli:measure>bdsx:Test</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>bdsx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Facility"><xbrli:measure>bdsx:Facility</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>bdsx:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U_RenewalOption"><xbrli:measure>bdsx:RenewalOption</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 	 	&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_90778e32-51ed-4729-997f-b5e8d0215ffd" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c1eadb48-991f-4a9d-a5e6-c814b69f441b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1f52dc73-c6e7-45f7-a393-4b96ffc5c7b6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c0a30336-fa6c-4cc5-b4f7-60109e9ad243" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f6c9ddc5-c1f0-4aeb-8c81-c1f10b663092" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d8f8674-e4ca-488b-b2e1-d7d47eac04d7" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39659</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eb8c15ad-5788-420f-93f8-edc83db3b6be" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3f662a86-b1dd-4bbb-bf48-9eb51e0afb9f" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_817b8740-873f-4302-9912-b7ed846f0f03" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20-3986492</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6dcd2cee-8ae5-4eaa-a36c-4522113b4e71" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2970 Wilderness Place</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_770f3be6-875e-4a5d-ac63-3fe1578542e0" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b85faf0a-1124-4004-ad1d-7a22dcf8c2ad" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boulder</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_814e86d7-49de-4735-929d-e06534cb8470" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CO</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cbd35e6a-cb11-42e5-a464-d90e0e5a2300" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80301</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_45a6cfe9-acc6-4a5d-bb27-9079e7045006" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">303</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e0877b6e-197d-4f12-b05a-5b6655cc0ad1" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">417-0500</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:39.0%;"></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cc50ca00-1555-4136-8fbf-7b5cd7e8a1ef" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5a3993fc-d204-40bd-8d5e-80e40b106f44" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BDSX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d16dcf66-44b3-49aa-9941-2c8aad46557c" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NASDAQ Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_feaf2536-fd16-47ad-9bc6-7c489328cce7" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_734cc776-aa24-4d95-a7d3-bc854d90b345" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f3c0027-6653-4cc0-b8e5-f8a6c0452fe8" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_31b792cf-b90c-44c2-96d2-335f476d1c98" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.898%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4cf447cf-a29d-45b5-b252-8c7f5e949eb7" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a2b6c337-e714-42b9-84e0-e4c8a7895099" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dd9d45d4-9ed6-4255-8f7c-c8874d6db936" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_445932ba-89f6-423a-a385-07a29f300ece" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2048fada-f969-49c3-85ae-00498f006a00" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4e5e8f23-f1a6-4cf4-8526-b7e180679b2f" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2022, the aggregate market value of common stock held by non-affiliates of the Registrant wa</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s $</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75b60db2-1e68-42f9-9a3a-1072bcd782a9" contextRef="C_e9aa5426-d887-4faf-a862-0f860b5f1148" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> based on the closing price of the common stock as reported on the NASDAQ Global Market for that date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 2, 2023 was </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82df41c7-4c81-4e44-b529-9661e6407c67" contextRef="C_5db1c006-3d07-4be3-b5ff-a7b2fbf3e25f" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">77,974,861</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_180ae8e7-28ab-4487-b914-1bb67a6b632b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Company&#x2019;s definitive Proxy Statement for its 2023 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.)</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.102%;"></td>
    <td style="width:83.0%;"></td>
    <td style="width:6.898%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factor"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#n1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosures Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potentially,&#x201d; &#x201c;predict,&#x201d; &#x201c;should,&#x201d; &#x201c;will&#x201d; or the negative of these terms or other similar expressions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors, and assumptions described under the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this annual Report on Form 10-K, regarding, among other things:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to achieve or sustain profitability;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our audited financial statements include a statement that there is a substantial doubt about our ability to continue as a going concern and a continuation of negative financial trends could result in our inability to continue as a going concern.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attain significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties managing our growth, which could disrupt our operations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to retain sales and marketing personnel, and failure to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests to generate revenue growth;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to maintain our current relationships, or enter into new relationships, with biopharmaceutical companies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant fluctuation in our operating results, causing our operating results to fall below expectations or any guidance we provide;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the demand for our COVID-19 and antibody testing program and our ability to meet such demand;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product performance and reliability to maintain and grow our business;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third-party suppliers, including courier services, contract manufacturers and single source suppliers; making us vulnerable to supply problems and price fluctuations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of a pandemic, epidemic, or outbreak of an infectious disease in the United States (U.S.) or worldwide, including the COVID-19 pandemic on our business;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">natural or man-made disasters and other similar events negatively impacting our business, financial condition, and results of operations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to offer high-quality support for our diagnostic tests, which may adversely affect our relationships with providers and negatively impact our reputation among patients and providers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to continue to innovate and improve our diagnostic tests and services we offer;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">security or data privacy breaches or other unauthorized or improper access;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant disruptions in our information technology systems;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the incurrence of substantial liabilities and limiting or halting the marketing and sale of our diagnostic tests due to product liability lawsuits;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to compete successfully with competition from many sources, including larger companies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance issues, service interruptions or price increases by our shipping carriers and warehousing providers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-containment efforts of our customers, purchasing groups and integrated delivery networks having a material adverse effect on our sales and profitability;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential effects of litigation and other proceedings;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic and financial market conditions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract and retain key personnel;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">current and future debt financing placing restrictions on our operating and financial flexibility;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests, or expand our operations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the acquisition of other businesses, which could require significant management attention;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the uncertainty of the insurance coverage and reimbursement status of newly approved diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future healthcare reform measures that could hinder or prevent the commercial success of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with anti-corruption, anti-bribery, anti-money laundering and similar laws;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with healthcare fraud and abuse laws;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to comply with ongoing FDA or other domestic and foreign regulatory authority requirements, or unanticipated problems with our diagnostic tests, causing them to be subject to restrictions or withdrawal from the market;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future product recalls;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">legal proceedings initiated by third parties alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the volatility of the trading price of our common stock;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inaccurate estimates or judgments relating to our critical accounting policies, which could cause our operating results to fall below the expectations of securities analysts and investors; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other risks, uncertainties and factors, including those set forth under Risk Factors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These risks are not exhaustive. Other sections of this Annual Report on Form 10-K may include additional factors that could harm our business and financial performance. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K or to conform these statements to actual results or to changes in our expectations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we reference and have filed as exhibits with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mission</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is to unite biopharma, physicians, and patients to transform the standard of care and improve outcomes with personalized diagnostics.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vision</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is a world where all critical diseases are diagnosed early and treated quickly with the guidance of personalized diagnostic solutions, so humanity can thrive without the burden of disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc. (&#x201c;Biodesix&#x201d;, &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; or the &#x201c;Company&#x201d;) is a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize testing solutions for clinical unmet needs, with a primary focus in lung disease. By combining a multi-omic approach with a holistic view of the patient&#x2019;s disease state, we believe our testing solutions provide physicians with greater insights to help personalize their patient&#x2019;s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe improves overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex&#174;, to discover innovative diagnostic tests for clinical use. Because of this approach, we believe we are unique in the diagnostics market as this approach allows for a broader and more holistic understanding of each patient&#x2019;s disease state. Our data-driven and multi-omic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, patients, researchers, and biopharmaceutical companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate in a single segment and derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services). We derived 90% of our total revenues for fiscal 2022 and 2021 from our diagnostic testing business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. Since our inception, we have performed over 550,000 tests and continue to generate a large and growing body of clinical evidence. We have participated in 27 clinical studies, four of which are ongoing, and have published over 300 clinical and scientific peer-reviewed publications, presentations, and abstracts. We have a variety of samples with associated data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development initiatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have commercialized eight diagnostic tests which are currently on market and we perform over 30 assays for research use as part of our laboratory services that have been used by over 60 biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Blood-Based Lung Tests</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have five diagnostic blood-based tests across the lung cancer continuum of care, which generated $29.3 million and $18.7 million in revenue for fiscal 2022 and 2021, respectively, an annual growth rate of 57%.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diagnosis</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nodify XL2&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nodify CDT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; tests, together marketed as part of our Nodify Lung</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nodule Risk Assessment testing strategy, assess a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treatment &amp; Monitoring</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GeneStrat&#174; ddPCR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VeriStrat&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tests, marketed as part of our IQLung&#153; testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a turnaround time of two business days, providing physicians with timely results to facilitate treatment decisions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GeneStrat NGS&#153; (NGS) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">test, also marketed as part of our IQLung testing strategy, is our blood-based NGS test with results in three business days. The NGS test was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations in genes, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19 Tests</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe&#153; testing program. We generated $5.2 million and $30.2 million in revenue from COVID-19 testing during fiscal 2022 and 2021, respectively. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two United States Food and Drug Administration (FDA) Emergency Use Authorization (EUA)-authorized tests, a part of our customizable WorkSafe program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bio-Rad SARS-CoV-2 Droplet Digital&#153; polymerase chain reaction (ddPCR) test and the Platelia SARS-CoV-2 Total Ab test have been granted FDA EUA pursuant to the current emergency declaration. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020. Prior to using the Bio-Rad SARS-CoV-2 tests as part of our testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Beginning in second quarter 2021, we began partnering with GenScript Biotech Corporation to commercialize the blood-based cPass</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> SARS-CoV-2 Neutralizing Antibody testing as a service. The test is the first surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. The EUA declaration under Section 564 of the FDCA is distinct from and independent of the declaration by the Secretary of HHS of a public health emergency under Section 319 of the Public Health Service Act (the PHS Act). On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#x2019;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. Because the EUA declaration from the FDA is distinct from the declaration under Section 319 of the PHS Act, the FDA EUA may remain in effect beyond the duration of the Section 319 declaration. We cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We announced multiple partnerships for COVID-19 testing, and maintained an agreement with the State of Colorado to be one of the diagnostic companies to support widespread COVID-19 testing for the State which expired on August 31, 2022. Additionally, we oversaw and managed onsite testing and validating testing for the Big Ten Conference athletic competitions through the term of our contract which expired on June 30, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 Pandemic</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic has disrupted, and may continue to disrupt, our lung diagnostic testing operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees working on-site, implemented social distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#x2019; public health orders and the guidance from the Centers for Disease Control and Prevention (CDC). Employees who can perform their duties remotely have the option to work from home. Our sales, marketing and business development efforts may be constrained by our operational response to future COVID-19 variant outbreaks. We will continue to adjust our operational norms, as needed, to help slow the spread of COVID-19, including complying with government directives and guidelines as they are modified and supplemented.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic and the surge associated with multiple variants have negatively affected our lung diagnostic testing-related revenue and our clinical studies. Beginning in the third quarter 2020, the Company&#x2019;s COVID-19 testing services began to experience rapid growth with a peak in the first quarter 2021; however, subsequent to this peak, we experienced a rapid decline in COVID-19 testing revenue primarily as a result of a few significant contracts that expired as well as the ongoing increase in COVID-19 vaccination rates across the U.S. and the adoption and availability of at-home testing. We do not anticipate the need for COVID-19 testing to be commensurate with the peak demand experienced during the first quarter 2021 and instead expect the demand to substantially decline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as our society adapts to a post-pandemic era. There is no assurance that our COVID-19 testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain and the need for COVID-19 testing may vary, which could have a significant effect on our results of operations and profitability. As a result, increases in revenue, if any, due to any increase in demand for these diagnostic tests may not be indicative of our future revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See &#x201c;Risk Factors&#x201d; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Full Year Results for 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, compared to the prior year:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Total Revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was $38.2 million, a decrease of 30% primarily driven by the expected decline in COVID-19 diagnostic testing;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lung Diagnostic Revenue of $29.3 million, an increase of 57%</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Services Revenue of $3.7 million, a decrease of 34%</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19 Revenue of $5.2 million, a decrease of 83%</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gross Margin </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was $24.1 million resulting in a 63% overall gross margin percentage as compared to 44% in the prior year;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses, excluding Direct costs and expenses, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">were $74.6 million, an increase of 15% and including non-cash share-based compensation expense of $6.0 million as compared to $4.9 million in the prior year;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was $65.4 million, an increase of 52%, which includes approximately $7.0 million of loss on debt extinguishment in 2022 as compared to a gain on debt modification of $2.3 million in the prior year;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basic and Diluted Net Loss Per Common Share </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was $1.55;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Cash Used by Operating Activities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was $45.0 million, compared to $28.2 million used in the prior year; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was $43.1 million as of December 31, 2022.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Market Opportunity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diagnostic Testing Market Size and Opportunity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite significant advances over the last decade, lung cancer is still the deadliest type of cancer in both men and women in the United States. While diagnostic testing has become routinely used at certain points in the lung cancer continuum of care (diagnosis, treatment and monitoring), we believe there is substantial need for novel, advanced testing to improve on the current standard of care. We estimate that in the United States, the lung cancer continuum of care currently represents over 10 million annual testing opportunities and is over a $27 billion market annually for testing alone.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img34454307_0.jpg" alt="img34454307_0.jpg" style="width:609px;height:178px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 15% of oncology trials involving the use of biomarker testing in 2000, compared to 55% in 2018. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical companies seek to de-risk their research and development pipelines and increase chances of drug development success. We estimate that biopharmaceutical partnering and research opportunities represents over a $2 billion market annually.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lung Cancer Continuum of Care &#x2013; Clinical Unmet Needs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standards of care in lung cancer have evolved rapidly over the past decade, along with our understanding of the disease. With the introduction of numerous treatment options, physicians need an ever-increasing amount of information in order to select the best treatment plan for each individual patient. We believe that the lung cancer continuum of care has a variety of clinical unmet needs ranging from initial diagnosis of lung cancer after discovery of a lung nodule to treatment guidance for early and advanced stage disease, and monitoring for disease progression.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnosis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We estimate approximately 1.6 million new incidental lung nodules and potentially 4 million lung nodules from the adoption of screening could be identified annually in the United States. Following initial discovery of a nodule, patients are typically evaluated by a pulmonologist for risk of lung cancer before an invasive procedure is carried out to obtain a tissue sample to confirm diagnosis. This risk assessment is based on clinical factors such as the patient&#x2019;s smoking history and age, and radiological features such as the size and location of the nodule, obtained from a computed tomography (CT) scan. On initial assessment, we estimate that approximately 80% of patients are identified as low to moderate risk (5-65%) where guideline recommendations for their care plan are unclear, often</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">resulting in either </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">overtreatment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of patients with benign nodules or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">undertreatment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in patients with cancer. An estimated 17% of patients with malignant nodules are initially sent to watchful waiting, where a follow-up CT scan is scheduled in three to six months, potentially delaying their diagnosis. Conversely, we estimate that 62% of biopsies and 35% of surgeries performed on lung nodules find benign disease, representing a significant overtreatment that incurs both risk and cost to the patient and their providers. We therefore believe that there is a clear clinical need for blood-based diagnostic testing to help improve the initial risk assessment of pulmonary nodules, helping direct patients to the relevant treatment pathway, and ultimately improving patient outcomes and saving costs to the system.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment Guidance &#x2013; Early Stage</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We estimate that there are over 700,000 testing opportunities annually in the United States in early-stage lung cancer to assess a patient&#x2019;s risk of recurrence following curative-intent surgery, and to detect potential target mutations for therapeutics. Depending on a patient&#x2019;s risk of recurrence, they may also receive chemotherapy, radiotherapy or chemoradiation post-surgery. The assessment of risk of recurrence is primarily based on the stage of cancer at diagnosis, with stage I patients typically receiving no additional treatment beyond surgery. However, 20 to 40% of patients with stage I disease do still recur within five years following surgery, representing a sub-group of patients who may have benefited from more intensive treatment protocol. We believe there is a clear clinical need for blood-based diagnostic testing prior to surgery to identify stage I patients who may benefit from a more intensive treatment protocol and we also believe there is the need for identifying stage II and IIIA patients where low risk patients may benefit from a less intensive treatment protocol. There have also been recent advances in the use of targeted therapies in early-stage lung disease. These therapies typically target specific genomic mutations or alterations found in some tumors. We believe there is therefore an emerging need for testing designed specifically for mutation detection in early-stage disease.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment Guidance &#x2013; Advanced Stage: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimate that there are over three million diagnostic testing opportunities annually in the United States to guide advanced stage lung cancer treatment decisions. With nearly 50 FDA-approved systemic treatment regimens listed in national treatment guidelines for non-small cell lung cancer (NSCLC), there is an elevated need for personalized biomarkers to help physicians identify the right patient for the right treatment. Multiple tissue-based diagnostic tests have been approved to identify patients eligible for targeted therapies and immunotherapy; however, about 50% of patients do not have sufficient tissue collected following diagnosis to facilitate testing. To compound the issue, different molecular tests take varying amounts of time (days versus weeks) to report results back to the ordering physician, which often leads to treatment decisions being made on incomplete information. Therefore, we believe there is an imminent need for a blood-based testing solution that measures tumor mutations and the patient&#x2019;s immune profile, to provide physicians with more comprehensive and timely information to assess the overall prognosis of the patient and personalize treatment.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Monitoring</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We estimate that there are over 800,000 testing opportunities in the United States for blood-based tumor and immune profiling to monitor for disease recurrence and progression in NSCLC patients. Unfortunately, advanced stage lung cancer is often terminal, so repeat tissue biopsy to assess the evolution of resistance mutations or to detect disease progression is not feasible from either a cost or risk perspective to the patient, which we believe demonstrates an important need for blood-based testing to help routinely monitor these patients. As a patient progresses through therapies, changes in their immune system occur and blood-based immune profiling could help physicians identify these changes prior to subsequent therapy selection.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Limitations in Biomarker Discovery and Companion Diagnostics</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimate that the biopharmaceutical biomarker testing and companion diagnostic market opportunity represents a $2 billion market annually</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 15% of oncology trials involving the use of biomarker testing in 2000 compared to 55% in 2018. From 2005 to 2015, a study identified that incorporating biomarkers into clinical development programs increased their probability of therapeutic success rate from phase 1 to FDA-approval by 570%, representing an increase from 1.6% without biomarkers to 10.7% with biomarkers. We believe the field of biomarker discovery and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical companies seek to de-risk their product development efforts and increase chances of drug development success. However, we believe as the market continues to advance, inherent limitations of both biomarker discovery and companion diagnostic development have become more apparent.</span></p>
  <p style="margin-left:4.16%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biomarker Discovery</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are many limitations with biomarker discovery in biopharmaceutical drug development, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biomarkers with clinical utility are difficult to discover and validate in independent datasets. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Classical statistical approaches to biomarker discovery are limited. Single-omic tests fail to see the whole biological picture.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tissue biopsies are limited by the amount of a sample that can be collected: longitudinal testing is difficult and the biology is only from the profile of the tumor (host response is not accounted for).</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials are expensive and take a long period of time. It is often difficult to meet enrollment goals for clinical trials with slow diagnostic testing turnaround times.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companion Diagnostics (CDx): </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While developing companion diagnostics is critical to precision medicine, the promise of companion diagnostics has not been fully realized and there are multiple limitations that still need resolution. The path to co-develop a successful companion diagnostic with a corresponding drug has several challenges, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Traditional companion diagnostic agreements may fail to realize the full value of a testing opportunity, leading to difficulty in funding appropriate commercialization.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug development is a lengthy, complex and costly process. There can be a financial impact to a pharmaceutical company to have a drug selected by a test.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current diagnostic reimbursement policies may not always support the coverage and payment of new companion diagnostics.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory agencies continue to work on defining the co-development process, but the environment is continually changing.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Diagnostic Cortex - Our Proprietary Artificial Intelligence (AI) Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex, to discover innovative diagnostic tests for clinical use. We focus on developing technologies that are capable of single and multi-omic research and development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of clinical diagnostic tests, which we believe overcomes standard machine learning challenges faced in life sciences research. Researchers commonly encounter issues with machine learning-based biological discoveries that cannot be repeated or validated when assessed in additional specimen cohorts. This challenge, commonly referred to as overfitting, occurs when the machine identifies a perfect pattern in an initial training dataset but is unable to identify the same pattern in a new dataset. For over 15 years we have focused on developing our platform to overcome this challenge through proprietary computational techniques to ensure each diagnostic test that is discovered can be further developed to perform consistently in the clinical testing environment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are able to combine blood-based biological information related to the tumor, immune system, and host-status with clinical and radiomic data through our proprietary AI platform, which enables us to interpret the holistic disease state of each patient or clinical dataset we encounter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continuously evolve and improve the Diagnostic Cortex platform. These improvements range from basic code optimization to complex improvements such as the incorporation of novel computational methods for the optimization of multi-omic diagnostic tests. Any AI platform is inherently limited without the highest quality data inputs. Therefore, all of the technologies that we employ have been chosen and developed to provide high-quality data to enable our Diagnostic Cortex platform. We feel that this level of data integrity is crucial for the development of diagnostic tests that require the advanced pattern matching abilities of deep learning algorithms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and learn about biological discoveries that are clinically meaningful. Additionally, we incorporate clinical and molecular profiling data aggregated through our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, into our platform. We have a variety of samples with associated data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development initiatives. With our data-driven and multi-omic approach as data inputs into the Diagnostic Cortex, we are able to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a diagram outlining our innovative diagnostic test discovery, development and commercialization infrastructure as outlined in the text above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><img src="img34454307_1.jpg" alt="img34454307_1.jpg" style="width:720px;height:315px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We employ multiple technologies, as illustrated below, including genomics, proteomics, transcriptomics, and radiomics, generated by different assay techniques, including ddPCR, NGS, LC-MS, ELISA, and our proprietary DeepMALDI mass spectrometry platform for the blood-based molecular analysis of the tumor, immune system, and host-status of each patient and/or clinical dataset. Through our learning loop, we continuously revisit our technology strategy and roadmap to integrate new technologies into our evolving platform, which ultimately support the addition of new service and product revenue offerings. We focus on developing technologies that are capable of single and multi-omic research and development.</span></p>
  <p style="text-indent:4.16%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img34454307_2.jpg" alt="img34454307_2.jpg" style="width:709px;height:368px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most diagnostic companies focus their strategy on using a single technology to discover biomarkers for a broad range of clinical questions. We believe that no single technology can interrogate the complexity of the human disease state to help solve all clinical questions. For that reason, we employ a multi-omic approach to solving diagnostic challenges leveraging our proprietary transparent AI</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">platform, the Diagnostic Cortex. Because of this approach, we believe we are unique in the diagnostics market, allowing for a broader and more holistic understanding of each patient&#x2019;s disease state.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are experts in many technologies, but we are a true market leader with over 15 years of experience in the field of clinical proteomics. For over 10 years, we have been discovering and developing proteomic-based diagnostic tests and have a deep understanding of how to incorporate technologies that can be applied to blood samples in order to extract important protein-based biological information in the form of diagnostic tests, which can aid clinicians and scientists in understanding the dynamic biology of their system of interest, such as a patient with cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our suite of technologies that assist us in discovery, development and commercialization of novel diagnostic tests includes:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">DeepMALDI Mass Spectrometry</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have developed DeepMALDI, a proprietary high-density matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectrometry (MS) technology, to produce blood-based proteomic data for disease diagnosis, personalized health care, precision medicine for direct treatment options, and disease screening in lung and other disease states. DeepMALDI overcomes the limitations of conventional MALDI and other mass spectrometry methods to produce highly sensitive, stable, and reproducible data by: (1) utilizing optimized signal-to-noise reduction and signal processing algorithms; and (2) novel batch correction methods and spectral alignment methods. The combination of these improvements yields substantially higher quality data content and is thereby much better suited for the discovery of biomarkers with clinical utility.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current DeepMALDI methods allow us to achieve finer mass resolution, greater sensitivity, and 20-times faster imaging speeds than other instruments. Additionally, we believe recent enhancements to our DeepMALDI methods and MALDI-ToF technology evolution now allows us to measure more than 2,000 proteins, an improvement from the previously estimated 900 proteins. We intend to maintain our leadership role in the discovery of proteomics-based diagnostic tests. We utilize our DeepMALDI and MALDI-ToF technologies in our discovery and development efforts and as part of our collaborations with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquid Chromatography Mass Spectrometry MS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use Multiple Reaction Monitoring (MRM) MS with triple quadrupole mass spectrometers and up-front liquid chromatography (LC) sample injection in the Nodify XL2 test. This mass spectrometry method offers highly sensitive, specific, and cost-effective analysis for simultaneous quantitation of hundreds to several thousands of targeted peptides in a single experiment. We have since included the MRM technologies as part of our services for discovery and development with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enzyme-Linked Immunosorbent Assay (ELISA)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ELISA is the most widely used ligand binding assay platform within and outside the pharmaceutical industry. Formats include direct, indirect and sandwich assays and are typically run in manually or semi-automated modes. We use a semi-automated implementation of ELISA in clinical testing for the Nodify CDT test and the Platelia SARS-CoV-2 Total Ab test, and the cPASS neutralizing antibody test for COVID-19. The acquisition of Oncimmune USA in 2019 expanded our ability to conduct very high throughput and cost-effective ELISAs in our clinical testing laboratory. We have now included the ELISA technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Droplet Digital Polymerase Chain Reaction Technology (ddPCR)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use the ddPCR technology for multiplexed, semi-automated nucleic acid detection. This allows high sensitivity, fast turn-around times, flexibility in our laboratory workflows, rapid scaling from low to moderate anolyte complexity, and high-volume scalability. ddPCR is an absolute quantitation method based on the partitioning of circulating nucleic acids into up to 20,000 droplets per reaction and is used for the GeneStrat ddPCR test and Bio-Rad SARS-CoV-2 ddPCR test for COVID-19. We have included the ddPCR technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Next Generation Sequencing Technology (NGS)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use an NGS technology for broad genomic sequencing of clinical specimens. Our strategy with NGS relies on a menu of off-the-shelf and custom research use assays, which we develop and make available as a part of our commercial pipeline and biopharmaceutical test services. The NGS technology integrates automated systems to yield high sensitivity results with a rapid turnaround time. Since adoption of this technology, we have included the NGS technologies for research and product development both internally and externally with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Solutions and Products</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To help address the current limitations with standard of care in lung cancer diagnosis, treatment, and monitoring, we use combinations of tumor, immune and host profiling, radiological imaging, patient clinical profiling, and our proprietary AI platform to provide a holistic view of each patient&#x2019;s dynamic disease state.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have five blood-based diagnostic tests across the lung cancer continuum of care to help address clinical unmet needs by physicians.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnosis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We believe there is a clinical need to help physicians reclassify risk of malignancy in patients presenting with suspicious lung nodules. We offer the blood-based Nodify Lung Nodule Risk Assessment testing strategy to aid physicians in stratifying patients into distinct nodule management treatment pathways: diagnostic procedure or imaging surveillance. Nodify Lung consists of two blood-based proteomic tests: the Nodify CDT test helps identify patients with lung nodules that are likely malignant and the Nodify XL2 test conversely helps identify those that are likely benign.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment Guidance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We believe there is an imminent need for a blood-based testing solution that measures tumor-specific mutations and the patient&#x2019;s immune profile to provide physicians with more comprehensive information to assess the overall prognosis of the patient and personalize treatment plans. We offer the blood-based IQLung testing strategy, which consists of the GeneStrat ddPCR and GeneStrat NGS tumor profiling tests and the VeriStrat immune profiling test for patients diagnosed with NSCLC. With an average turnaround time of three business days, we are able to quickly provide critical diagnostic information to physicians to facilitate personalized treatment decisions for their patients.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Monitoring</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We believe longitudinally monitoring advanced NSCLC patients for the dynamic evolution of their tumor and immune profile while on treatment can provide an earlier indication of treatment resistance and/or disease progression. We offer the IQLung testing strategy as a blood-based monitoring tool for physicians to track their patients&#x2019; disease evolution.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img34454307_3.jpg" alt="img34454307_3.jpg" style="width:720px;height:183px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diagnosis &#x2013; Nodule Management</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our blood-based nodule management offering, Nodify Lung Nodule Risk Assessment assists physicians in reclassifying a patient&#x2019;s risk of lung cancer by incorporating their protein biomarker results with radiographic imaging and clinical characteristics. Nodify Lung consists of the Nodify CDT and Nodify XL2 proteomic tests, which can be ordered separately or together from a single blood draw to help reclassify risk of cancer to aid physicians in stratifying patients into distinct nodule management pathways: intervention or surveillance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nodify CDT test is used to help identify lung nodules that are likely malignant and the Nodify XL2 test helps identify lung nodules that are likely benign. Nodify Lung is available for patients 40 years or older, with nodules between 8 and 30mm, and less than 65% pre-test risk of lung cancer. The testing strategy starts with the Nodify CDT test to determine if a nodule is likely malignant or at a higher risk of lung cancer. The Nodify CDT test helps physicians identify cancer more quickly by prioritizing patients with a higher risk of malignancy for a diagnostic procedure, such as biopsy or surgery. If the nodule is not identified as having a high risk of malignancy by the Nodify CDT test, then the Nodify XL2 test is performed to help determine if the patient&#x2019;s nodule is likely benign or has a reduced risk of lung cancer and may be a candidate for CT imaging surveillance. The Nodify Lung testing strategy is represented graphically in the image below starting with the patient&#x2019;s pre-test risk of malignancy and ending with the guideline-recommended diagnostic procedure for each risk category.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img34454307_4.jpg" alt="img34454307_4.jpg" style="width:709px;height:303px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We launched the Nodify Lung combined offering of the Nodify CDT and Nodify XL2 tests in March 2020. However, the Nodify XL2 test has been available to all physicians since September 2019 and has been available to a select group of physicians since October 2018. We acquired the Nodify XL2 test from Integrated Diagnostics (Indi) in July 2018 and acquired the Nodify CDT test from Oncimmune USA in October 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nodify CDT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nodify CDT test is a blood-based proteomic test that helps identify patients who have a suspicious lung nodule that is likely malignant or at a higher risk of being cancerous. Results allow physicians to identify patients who may be better candidates for timely invasive diagnostic procedures such as bronchoscopy, transthoracic needle biopsy, or surgical resection, with the hope of catching cancer earlier. The Nodify CDT test enhances lung nodule risk assessment to facilitate compliance with clinical treatment guidelines such as those of the American College of Chest Physicians (ACCP). The Nodify CDT test is intended for use in patients who are 40 years or older, have nodules between 8 and 30mm, and pre-test risk of lung cancer of less than 65%.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The test measures the levels of seven circulating autoantibodies (P53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4) associated with lung cancer, combined with an algorithm to report out three potential results: High Level, Moderate Level, or No Significant Levels of Antibodies Detected (NSLAD). The seven autoantibodies have shown to be elevated for all types of lung cancer, and from the earliest stage of the disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unlike the tumor antigens themselves, the autoantibody levels can be measured accurately through a blood sample, based upon the signal amplification generated by the immune response to cancer. This mechanism of action likely reflects very early events in a tumor&#x2019;s evolution; as the immune system initiates a response to the cancer, it can also trigger an expansion of self-reactive antibodies that can be measured in circulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the test result of High Level, Moderate Level, or NSLAD, each test report includes the patient&#x2019;s pre-test risk of malignancy as calculated by the Solitary Pulmonary Nodule (SPN) Risk Assessment calculator, and their post-test risk of cancer incorporating the result of the test. The SPN Risk Assessment calculator was developed by Stephen Swensen, M.D., of the Mayo Clinic and is designed to provide a risk of malignancy for a patient with a newly discovered incidental nodule. The model incorporates six clinical and radiologic factors into the equation: age, nodule size, smoking status, nodule location, spiculation (nodule edge characteristic), and previous history of lung cancer. Incorporating the autoantibody levels with the risk model provides physicians with a more accurate assessment of risk. The test has been studied in 14 peer reviewed published studies and presentations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nodify XL2</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nodify XL2 test is a blood-based proteomic test that helps identify patients who have a suspicious lung nodule that is likely benign or at a reduced risk of being cancerous. Results allow physicians to identify patients who may be better candidates for routine CT surveillance to monitor for growth or shrinkage of the nodule over time instead of an invasive diagnostic procedure. The Nodify XL2 test is used for patients who are 40 years or older, have nodules between 8 and 30mm, and have a pre-test risk of lung cancer of less than or equal to 50%.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nodify XL2 test integrates peptides measured by LC-MS with clinical and radiological characteristics that are combined by an algorithm to report out three potential results: Likely Benign, Reduced Risk, or Indeterminate. Specifically, the Nodify XL2 test measures the relative abundance of two peptides (LG3BP and C163A) in circulation in the patient&#x2019;s blood. The native proteins from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which the peptides are derived have been associated with an inflammatory response to cancer. The clinical factors are patient age and smoking status, and radiological factors are nodule size, location, and edge characteristics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the test result of Likely Benign, Reduced Risk, or Indeterminate, each test report includes the patient&#x2019;s pre-test risk of lung cancer as calculated by the SPN Risk Assessment calculator, and their post-Nodify XL2 risk of malignancy incorporating the result of the test. Incorporating the peptide levels with the risk model provides physicians with a revised assessment of risk incorporating the patient&#x2019;s biology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In summary, the inclusion of the Nodify Lung testing strategy into clinical practice helps physicians reclassify risk of malignancy of low to moderate risk lung nodules by incorporating the patient&#x2019;s own biology into the assessment. The Nodify CDT test helps physicians identify patients with a high-risk lung nodule who may benefit from timely intervention, which can ultimately help identify lung cancer earlier. The Nodify XL2 test helps physicians identify patients with a very low risk lung nodule who may benefit from CT surveillance and could avoid unnecessary invasive procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Blood samples for the Nodify XL2 and Nodify CDT tests can be collected in the physician&#x2019;s office, laboratory, or at home through use of mobile phlebotomy. Mobile phlebotomy options facilitate testing for patients even if they are not seen in person by the physician and instead are seen through telehealth visits. This benefits the patient as scheduling can be conveniently fit to their needs and can keep them away from a physician&#x2019;s office or hospital for safety concerns. Additionally, mobile phlebotomy benefits the physician as the logistics around a blood draw or tissue sampling are out of their hands. We have a national network of contracted Nurses and Phlebotomists to support at-home or mobile blood collection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both tests require a single blood sample shipped at ambient temperature to our certified, high-complexity clinical laboratory in De Soto, Kansas. Nodify CDT testing requires whole blood and Nodify XL2 testing requires either a whole blood K2EDTA tube, or whole blood spotted onto our proprietary Blood Collection Device (BCD). The introduction of the BCD and now the stand-alone whole blood tube as qualified specimen collection methods for use with the Nodify XL2 test alleviated the need for serum separation processing steps by phlebotomists at blood draw sites such as centrifugation, and cold chain (dry ice) shipments, which has increased the market access to our proteomic-based tests. Results for the Nodify CDT test alone are typically available within one day. If both tests are ordered for the patient and Nodify CDT returns a result of NSLAD, then both test results are typically available within four to five business days. All results are available through secure communication methods, including a portal, fax, hard copy, or mobile device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treatment Guidance and Monitoring</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Profiling the tumor through blood-based testing can help identify mutations in genes that may be driving growth of the tumor and may be targets for therapeutics. However, tumors also suppress intrinsic mechanisms that prevent the patient&#x2019;s immune system from identifying and eliminating the cancer cells. Profiling the immune system can show if the patient&#x2019;s immune system may have been subverted and therefore, is less likely to be responsive to immunotherapies. Our blood-based IQLung testing strategy consists of the GeneStrat ddPCR and GeneStrat NGS tumor profiling tests and the VeriStrat immune profiling test, which can be ordered together or separately for patients with NSCLC. Together, the tests typically have an average turnaround time of three business days, providing physicians with timely results to facilitate treatment decisions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img34454307_5.jpg" alt="img34454307_5.jpg" style="width:576px;height:263px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GeneStrat ddPCR</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The GeneStrat test is a blood-based tumor profiling test that detects the guideline recommended, actionable mutations in lung cancer: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR, KRAS, BRAF, EML4-ALK, ROS-1, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RET. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Physicians can order one or any combination of the gene tests, whichever they</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">deem medically necessary for the individual patient. The presence of a mutation in one of the genes could indicate the patient is a candidate for the associated guideline-recommended targeted therapy. The GeneStrat test performance and potential clinical utility have been published in three peer reviewed studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The GeneStrat test results are typically available within two business days from our receipt of the sample in our Boulder, Colorado clinical laboratory. In a study at Eastern Carolina University, it was observed that blood-based testing was up to three weeks faster than tissue-based testing, with tissue-based testing taking a median of 26 days from sample collection. With GeneStrat testing, results are typically available in time for the patients first oncology visit, allowing the patient to start front-line treatment as quickly as possible. In the same study, it was observed that only 4% of patients had tissue-based molecular test results prior to start of front-line treatment. Meanwhile, after integrating Biodesix testing at the institution, 72% of patients had molecular test results available. Testing with the GeneStrat test can help physicians identify driver mutations quickly to help speed up time to treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GeneStrat NGS Test</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The GeneStrat NGS test is a blood-based 52-gene tumor profiling test panel that detects the guideline recommended, actionable mutations in lung cancer including five gene classes (SNV, INDELS, CNA, fusions, and exon-skipping). Specific variants of relevance to NSCLC include EGFR, KRAS, BRAF, EML4-ALK, ROS-1, RET, MET, NTRK. The GeneStrat NGS test is used for late-stage, metastatic NSCLC and Physicians can order one or any combination of the IQLung tests, whichever they deem medically necessary for the individual patient. The presence of a mutation in one of the genes could indicate the patient is a candidate for the associated guideline-recommended targeted therapy. The GeneStrat NGS test performance and potential clinical utility have been published in two published studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GeneStrat NGS test results are typically available within three business days from the start of processing of the sample in our Boulder, Colorado clinical laboratory.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img34454307_6.jpg" alt="img34454307_6.jpg" style="width:720px;height:291px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that rapid, blood-based tumor profiling with the GeneStrat ddPCR and GeneStrat NGS tests can be complementary to both targeted tissue-based testing (including PD-L1) and tissue-based broad genomic sequencing. Testing with GeneStrat ddPCR and GeneStrat NGS tests at diagnosis can help quickly identify patients who are eligible for targeted therapies. Additionally, blood-based testing upfront can help save valuable tissue for diagnostic evaluation, PD-L1 testing and broad genomic profiling for rare mutations to enroll in clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VeriStrat</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The VeriStrat test is a blood-based proteomic test that provides a personalized view of each patient&#x2019;s immune response to their lung cancer. Results help inform physicians whether their patient has a more aggressive cancer and can help with treatment planning. The VeriStrat test profiles the patient&#x2019;s immune system by measuring eight protein features measured by mass spectrometry and interpreted by a proprietary machine learning-based algorithm to produce either a VeriStrat Good or VeriStrat Poor test result.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The presence of a VeriStrat Poor result indicates the presence of chronic inflammation and a chronic acute phase immune response. A chronic acute phase immune response can trigger the immune system to provide growth factors to the tumor to increase blood flow and tumor growth. The test has been studied in over 85 peer-reviewed and published clinical studies across many different types of therapies such as chemotherapy, targeted therapies, immune therapies, and combinations. The results consistently show the test to be predictive of outcomes, independent of other prognostic factors including PD-L1 expression and performance status. Patients who test as VeriStrat</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Poor, on average, have an overall survival that is less than half of those who test as VeriStrat Good, independent of treatment type, demonstrating that the test is strongly prognostic. Conversely, patients with a VeriStrat Good test result typically respond better to standard of care treatments than those patients that test as VeriStrat Poor. By using the VeriStrat test for immune profiling, physicians can help identify the patients with an immune status associated with generally poor prognosis who should be treated with alternate therapies or in clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GeneStrat ddPCR testing is performed using PCR technology, GeneStrat NGS testing is performed using NGS technology, and the protein features in VeriStrat are measured using MALDI-ToF mass spectrometry. Results are typically available within three business days through secure communication methods, including a portal, fax, hard copy, or mobile device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The GeneStrat ddPCR and GeneStrat NGS tests require whole blood specimen collection tubes, and VeriStrat requires a whole blood sample spotted onto our proprietary BCD. Both sample types are shipped at ambient temperature and testing is performed in our certified, high-complexity clinical laboratory in Boulder, Colorado.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biodesix WorkSafe COVID-19 Testing Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe testing program. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two FDA EUA authorized tests, a part of our customizable program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic services. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020. Prior to using the Bio-Rad SARS-CoV-2 tests as part of our testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Beginning in second quarter 2021, we began partnering with GenScript Biotech Corporation to commercialize the blood-based cPass SARS-CoV-2 Neutralizing Antibody testing as a service. The test is the first surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the RBD in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bio-Rad SARS-CoV-2 ddPCR Test</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bio-Rad SARS-CoV-2 ddPCR test, also known as a molecular or viral test, is intended for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19. The test targets detection of the nucleic acid from SARS-CoV-2 (not from any other viruses or pathogens) in respiratory specimens to identify and isolate infected individuals. Recent studies have shown that ddPCR-based testing is more sensitive than qPCR for detecting SARS-CoV-2, specifically in the reduction of false negative results. In one study, the ddPCR test demonstrated 95% accuracy vs. 47% for other &#x201c;bulk&#x201d; RT-PCR technologies used in other molecular tests. Specimens are shipped at ambient temperature or dry ice depending on the viral transport media (VTM) used, and testing is performed using ddPCR in our certified, high-complexity clinical laboratory in Boulder, Colorado. Results are typically available through secure communication methods, including fax, hard copy, or encrypted email within 24 to 48 hours on average from receipt of the sample.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platelia SARS-CoV-2 Total Ab Test</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Platelia SARS-CoV-2 Total Ab test (also known as a serology or antibody test) is intended for use as an aid in identifying individuals who have developed an adaptive immune response to the SARS-CoV-2 virus, indicating recent or prior infection. The test uses whole blood to detect circulating antibodies against the virus. The sensitivity is 98% and specificity is 99% eight days after the onset of symptoms. At this time, it is not known how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The test is intended for the qualitative detection of total anti-SARS-CoV-2 nucleocapsid antibodies (IgG, IgM and IgA) in human serum or plasma specimens. The test requires a 3 mL blood draw, and samples are shipped at ambient temperature. Testing is conducted using semi-automated ELISA technology in our certified, high-complexity clinical laboratory in De Soto, Kansas. Results are typically available within 24 to 48 hours from receipt of the sample through secure communication methods, including fax, hard copy, or encrypted email.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">cPass SARS-CoV-2 Neutralization Antibody Test</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cPass SARS-CoV-2 Neutralization Antibody Test is the first blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the RBD in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection. This test was commercially introduced in partnership with GenScript Biotech Corporation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biopharmaceutical Diagnostic Discovery, Development and Testing Services Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our leadership in clinical proteomics and our multi-omic approach to probe the cancer disease state provides our customers with a clear and distinct advantage over other diagnostic service providers who solely focus on either genomics or proteomics. Similar to our commercial clinical testing business, our biopharmaceutical diagnostic discovery, development and testing services business leverages the Diagnostic Cortex to provide an extensively validated and deep learning approach to discovering new biomarkers, which in turn helps drive the clinical development of therapeutics. We recognize each clinical development program is complex, which is why we offer end-to-end diagnostic solutions, ranging from initial biomarker discovery and feasibility projects to commercialization of companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To address the increasing complexity of disease biology and new drug mechanisms of action, we employ a range of genomic and proteomic technologies to uncover insights about the tumor biology and patient&#x2019;s immune response to cancer for therapeutics in clinical development. With our broad technology and service offering, including the performance of over 30 assays for research use as part of our laboratory services (see diagram below), we are able to provide the depth and breadth of biomarker tools for our partners for multi-omic analyses across their product development efforts. Although we recognize the importance of a multi-omic, approach in translational research, we are experts in discovering and developing proteomic-based diagnostic tests to help interrogate the immune profile and host disease state of patients on particular therapeutics. Traditionally, oncology biomarkers have been discovered from tumor tissue, but with the increased trend in the number of programs featuring immuno-oncology agents in therapeutic development, we believe there is a clinical unmet need for blood-based tumor markers and host/immune biomarkers to complement information obtained from tissue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img34454307_7.jpg" alt="img34454307_7.jpg" style="width:683px;height:253px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe we provide benefit to our biopharmaceutical customers as they integrate strategies for increasing the probability of success for pivotal clinical trials. Specifically, our diagnostic testing services may help enable quicker enrollment rates for patients in prospective clinical trials, ranging from phase 1 to phase 3, and could help identify patient populations who may experience the greatest benefit from new therapeutics. Ultimately, our goal is to help biopharmaceutical customers realize greater efficiency in their clinical development programs. Additionally, we have the ability to access and leverage our large sample and data biobank for our partners&#x2019; data mining needs, including new test discovery.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our biopharmaceutical discovery, diagnostic development and testing revenue continues to grow, it is important to note that we benefit greatly from these partnerships in many ways that expand beyond revenue. We are continuously expanding our knowledge and biological understanding of multiple diseases and the rapidly evolving treatment landscape, while our Diagnostic Cortex continues to be powered through these biomarker analyses. Additionally, our sample and data biobank continue to grow and can be further leveraged for internal test development and external partnering. Importantly, we look to supplement our product development efforts with companion diagnostics as they are developed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have over 60 biopharmaceutical customers and academic partners who have utilized our diagnostic tests and services. The following are a few case studies of early-stage biomarker discovery and development with our biopharmaceutical customers.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AstraZeneca: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We provided services to AstraZeneca to retrospectively analyze samples from the FLAURA clinical trial (NCT02296125). The goal of this analysis was to interpret and establish the clinical utility of blood-based longitudinal monitoring of EGFR sensitizing and resistance mutations by ddPCR in advanced NSCLC patients treated with osimertinib. The data demonstrated that these circulating DNA mutations could be tracked in blood to interpret the patient&#x2019;s prognosis, and could help AstraZeneca to identify disease progression three months (median) in advance of standard imaging. We have used our ddPCR assay to monitor EGFR sensitizing and resistance mutations in clinical trial samples from seven different clinical trials for Tagrisso.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Genentech: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We partnered with Genentech to discover a novel proteomic classifier for advanced NSCLC patients treated with atezolizumab. The test was discovered on a small clinical cohort (n=77) and was independently validated on blinded samples (n=270) from the POPLAR clinical trial (NCT01903993). The validation revealed that the proteomic test was predictive of progression free survival and overall survival for atezolizumab versus the control arm docetaxel. Additionally, an analysis compared the correlation between our proteomic classifier with standard of care biomarkers (PD-L1 expression status and tumor mutation burden), which revealed there was no significant correlation. We published additional work on the Genentech classifier with three posters presented at the society of immunotherapy conference (SITC). This data reinforces that our classifier provides unique and valuable information in the treatment of patients with advanced NSCLC. It is our belief that Genentech could use this strategy to identify patients that could derive a longer progression free survival from atezolizumab.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HiberCell:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In January 2021, we announced a broad collaboration with HiberCell for companion diagnostic discovery, development and commercialization. The agreement initially focuses on the further development of an ELISA as a companion diagnostic in future registrational trials for Imprime PGG programs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Competitive Advantages</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the following are our key competitive advantages:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our proprietary extensively validated deep learning platform, which is tailored to discover diagnostic tests that address clinical unmet needs. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our platform is an extensively validated deep learning platform optimized for discovery of diagnostic tests. By combining our data-driven and multi-omic approach with deep learning techniques, we believe we have overcome many standard machine learning challenges. This has enabled us to develop commercial tests for clinical unmet needs and collaborate with our biopharmaceutical customers and academic partners.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our data-driven approach to precision medicine combined with our biobank, which enables us to accelerate development of new tests. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a variety of samples with associated data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development initiatives. Our biobank, clinical trials, commercial testing and other partnerships provide an ongoing source of new data that further enhances our proprietary AI platform. We are continuously identifying and incorporating new market insights and input from our customers, key opinion leaders, and scientific experts to leverage this data in developing our diagnostic tests.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our leadership in clinical proteomics, demonstrated research, development, and scientific expertise, combined with our intellectual property portfolio. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our leadership in clinical proteomics and our multi-omic approach, we believe provides us with a distinct advantage over our competitors, who focus on any single technology, such as genomics or proteomics. Our certified, high-complexity laboratories offer significant advantages in development of commercial tests.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our proprietary technologies and processes are protected by a portfolio of approximately 122 issued patents in the United States and internationally, and 22 uniquely registered United States trademarks. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We take efforts to protect our proprietary position using a variety of methods, such as a pursuit of United States and foreign patent applications related to our proprietary technology, use of trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing and acquisition opportunities.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our demonstrated success commercializing diagnostic tests in lung disease as well as unprecedented turnaround times. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With eight diagnostic tests launched and three currently in development, our commercial portfolio of blood-based solutions currently addresses clinical unmet needs within diagnosis, treatment and monitoring of lung cancer. Our diagnostic tests provide rapid, actionable, and holistic diagnostic information to help inform physicians on the next steps in a patient&#x2019;s care plan. For example, the blood based IQLung strategy for lung cancer patients integrates the GeneStrat ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer with results in an unprecedented two to three business days, expediting time to treatment.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have displayed agility in our R&amp;D and commercial launch efforts and within a month of initiating a development collaboration, launched three diagnostic tests for COVID-19 for commercial use.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our depth and breadth of point of care access to physicians allows us to drive adoption of our diagnostic tests while incorporating real-life feedback to inform new product development. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial team&#x2019;s primary focus is to articulate the scientific and clinical evidence behind our tests, how they impact clinical care and can ultimately help to improve patient outcomes. Our demonstrated scientific expertise, leadership in clinical proteomics and breadth of data, including peer-reviewed publications, presentations and clinical studies, forms the basis of our relationships with major hospitals and physician networks across the United States.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial infrastructure, which includes our extensive knowledge and experience in sales, marketing, reimbursement and operations, provides us with the ability to launch, scale and drive revenue. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our commitment to commercial excellence helps us to leverage insights, operational excellence and proven approaches to deliver revenue growth and enhance the brand of our company and products. We are able to deploy rapid clinical testing turnaround </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">times and develop commercial tests at scale. Scaling of our test capacity to meet volumes is then achieved by adding instrumentation and qualified personnel to our quality systems.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to provide swift, comprehensive and actionable insights to improve patient outcomes across lung disease and to help answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies. To achieve this, we intend to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drive increased awareness, adoption, and reimbursement coverage of our diagnostic tests by:</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continuously educating physicians, key opinion leaders, hospital systems, advocacy groups, patients, payers, academic research organizations, and technology assessment and guideline organizations on the clinical data and benefits of our tests;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">utilizing our pulmonology- and oncology-focused sales force and commercial reach with targeted awareness campaigns to employ highly targeted sales and marketing tactics in pulmonology clinics specializing in the management of lung nodules and the diagnosis of lung cancer;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continuing to invest in the expansion of our sales force and commercial support team;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporating our testing services into diagnostic pathways and protocols via a top-down strategy that introduces our diagnostic tests to the largest United States health systems; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">leveraging our clinical data to gain broad coverage from public and private payers for our tests.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deepen our relationships with current biopharmaceutical customers and establish new customer opportunities by:</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">selling our complete offering of tests and services to biopharmaceutical companies in the United States and internationally;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">leveraging existing projects and relationships to expand sales with our current biopharmaceutical customers; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">targeting companies developing novel companion diagnostic strategies and drug development projects best suited to our platform for new test discovery, development and commercialization.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further demonstrate the clinical utility and health economic benefits of our diagnostic tests by:</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investing in commercial clinical testing, research studies and clinical trials to further demonstrate the clinical utility of our tests;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">providing rapid, actionable, and holistic diagnostic information to help inform physicians on the next steps in a patient&#x2019;s care plan; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">providing timely and actionable clinical information to help improve overall patient outcomes and lower the overall healthcare cost.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Introduce new diagnostic tests in lung disease by:</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">engaging with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and to identify additional clinical unmet needs;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entering strategic partnerships with biopharmaceutical companies, academic research organizations, technology providers, and other diagnostic companies; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing companion diagnostic tests to support the therapeutics&#x2019; regulatory approval and adoption process for our biopharmaceutical customers.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enhance our proprietary AI platform and expand our technology portfolio by:</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continuing to invest in R&amp;D capabilities to foster innovation in test discovery and development;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, acquiring technologies and integrating new data types into our proprietary AI platform;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entering strategic partnerships across our commercial product portfolio and product development efforts in order to further our development capabilities, accelerate launch of commercial products, or expand our service offering; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achieving &#x201c;Explainable AI&#x201d; by developing and incorporating computational tools that determine how the Diagnostic Cortex makes decisions for patient classification and outcome prediction.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continue to expand and leverage our biobank by:</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expanding and enhancing the robustness of our samples and the data set, including through our collaborations and partnerships;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pursuing commercial opportunities with companies and researchers who are interested in utilizing our biobank for their own discovery and development efforts; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">monetizing these commercial opportunities.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Diagnostic Tests in Development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With the goal of finding solutions for clinical unmet needs related to diagnosis, treatment and monitoring in lung disease, our diagnostic tests in development include the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Early-Stage NSCLC&#x2014;Risk of Recurrence (ROR)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, surgical resection of the tumor without systemic or radiation therapy is standard of care for stage I NSCLC patients. However, 20 to 40% of surgically treated patients will suffer a recurrence within five years after surgery. From market research with pulmonologists, thoracic surgeons, and medical oncologists, we identified a significant clinical unmet need for a blood-based test to help identify stage I NSCLC patients who are at a higher risk of recurrence and may benefit from a more aggressive surgical procedure, or from neoadjuvant or adjuvant systemic treatment. Based on this unmet diagnostic need, we discovered the Risk of Recurrence (ROR) test, which is a pre-surgery blood-based proteomic test, designed with the Diagnostic Cortex to predict whether a stage I NSCLC patient has a higher risk of recurrence post-surgical resection. Knowing this information early and before surgery may change the surgical plan and/or support treatment decisions such as neoadjuvant or adjuvant therapy, which have the potential to reduce tumor volume and address micro-metastatic disease as early as possible. Our ROR test validated in an independent sample set, and we are currently working with major academic institutions across the United States to further validate the test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Late-Stage NSCLC&#x2014;Immunotherapy Treatment Guidance (PIR)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2015, the first immunotherapy-based treatment regimen was approved by the FDA for use in lung cancer. Currently, there are 9 immune checkpoint inhibitor (ICI) regimens (single agent or combinations) recommended by the NCCN guidelines for treatment of advanced NSCLC patients. For a portion of patients treated, these drugs can result in significant improvement in overall survival compared with platinum-based chemotherapy options.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The combination ICI regimens see some improvement in performance over single agent ICI, but side effect profiles are worse, and costs are higher than for single agent ICI. In addition, recent data have shown that a subset of patients experience more rapid disease progression on ICI compared with chemotherapy. We utilized the Diagnostic Cortex platform to discover our Primary Immune Response (PIR) test. PIR is a blood-based proteomic test designed to profile a patient's potential to mount an immune response to their cancer and predict those patients likely to respond to ICI monotherapy treatment, ICI + chemotherapy combination treatment, or who would be highly resistant to ICI therapy. Our PIR test has been validated in multiple independent sample sets for advanced stage NSCLC patients treated with single agent ICI, and we are currently working with major academic institutions across the United States to further validate the test in a prospective study called BEACON-Lung.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Monitoring &#x2013; Progression &amp; Resistance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Blood-based monitoring with our ddPCR technology may offer a feasible method to non-invasively evaluate therapeutic mechanism of action, disease progression, and the emergence of resistance mutations in patients treated with targeted therapies. Our internal validation studies have shown the utility of the GeneStrat </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ddPCR test as an example in all three of these indications. The test can identify disease progression up to three months (median) in advance of standard imaging. Using ddPCR for longitudinal blood-based monitoring of EGFR cell-free DNA mutations is a cost-effective testing method while patients are being treated with targeted therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Trials</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. We have participated in 27 clinical studies, four of which are ongoing, and have published over 300 peer-reviewed publications and presentations. The following are our ongoing clinical studies for our diagnostic testing solutions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ORACLE Registry Study (NCT03766958)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ORACLE registry study was designed to develop real-world clinical utility data for Nodify XL2 and is titled &#x201c;An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test&#x201d;. The study objectives are to show a reduction in invasive procedures on patients with benign nodules compared to a historical control obtained from chart review. The first patient enrolled on October 16, 2018. Study enrollment was closed on May 12, 2022, with 494 prospective registry patients enrolled and 348 retrospective chart review patients accrued. As of February 9, 2023, 21 subjects remain in 2-year follow-up.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ALTITUDE Clinical Utility Study (NCT04171492)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ALTITUDE clinical utility study is designed to evaluate the performance of Nodify Lung (Nodify XL2 and Nodify CDT) in a randomized controlled study (RCT). The study is titled &#x201c;A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules&#x201d;. We received central investigational review board (IRB) approval in December 2019 and have an enrollment goal of 2,000 patients. The study objectives are to evaluate how the addition of the Nodify Lung test result impacts the clinical decision making for patients with new, incidentally identified solid lung nodules assessed as low to moderate risk of lung cancer. The trial has an adaptive study design with a blinded standard of care arm and 2:1 randomization for open-label results for Nodify XL2. The study launched in December of 2020. Phase 1 of the study with only Nodify XL2 is expected to enroll 500 patients. Phase 2 of the adaptive study design will include an open-label arm for Nodify CDT, which is aligned with our commercial testing algorithm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">INSIGHT Observational Study (NCT03289780)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The INSIGHT observational study is designed to evaluate the real-world clinical utility and performance of the IQLung (GeneStrat ddPCR, GeneStrat NGS and VeriStrat) testing strategy. The title is &#x201c;Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)&#x201d; and the first patient enrolled on May 11, 2016. To date, we have over 4,700 patients enrolled with a target 5,000 enrollment goal. Final analysis with 3-year follow-up is estimated to be completed by 2026. Results of an interim analysis were presented most recently at AACR 2021.  Additionally data on the first 2,000 patients with 1-year follow-up data was published in the Journal for ImmunoTherapy of Cancer in September 2021. The study rationale is to guide the adoption of VeriStrat and inform medical decision making, including treatment choice, and enable the validation of additional mass spectrometry-based proteomic tests. The primary study objective is to describe the impact of the VeriStrat test results on treatment decisions, including but not limited to the percentage change in treatment decision, differences in chosen treatments between patients classified as VeriStrat Good and those classified as VeriStrat Poor, and the percentage of patients receiving systemic therapy or supportive therapies only.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">BEACON-Lung Clinical Study (NCT04676386 - Suspended)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In partnership with ALCMI (Addario Lung Cancer Medical Institute), the BEACON-Lung clinical study is intended to evaluate the performance and utility of our proteomic product currently in development, PIR, in advanced stage NSCLC patients who express high PD-L1. The study title is &#x201c;A Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated with An Immune Checkpoint Inhibitor (ICI) With or Without Platinum-Based Chemotherapy.&#x201d; The study design is an observational, multicenter, open-label study to assess biomarkers (serum, microbiome, radiomics and tissue) as predictive of early progression in 390 treatment-naive patients with advanced stage NSCLC and PD-L1 greater than or equal to 50% treated with two standard of care regimens, triplet therapy (platinum-based chemotherapy plus ICI regimen) and ICI monotherapy (single agent ICI). The objectives are to collect biospecimens and evaluate candidate biomarkers, with a focus on PIR, to detect early progression on ICI monotherapy versus triplet therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our lung cancer and nodule management tests, commercial efforts are focused on the promotion of our testing strategies to healthcare professionals actively involved in the diagnosis and treatment of lung cancer. Primarily focusing on pulmonology and oncology, the commercial team, consisting of specialty sales representatives, medical affairs, marketing and customer care representatives, works to educate and inform the entire patient care group consisting of physicians, nurses, office staff, laboratory personnel, and administration as to the appropriate use and value provided by our testing. The team&#x2019;s goal is to drive test adoption through articulating the scientific and clinical evidence behind our tests, how they impact the clinical care of a patient, and how the tests can ultimately help to improve patient outcomes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients with pulmonary nodules are concentrated in the pulmonology sub-specialty, where additional resources such as lung cancer screening and nodule management clinics may exist to provide an increased level of care. We are also engaging large hospital systems in a &#x201c;top-down&#x201d; approach, with a goal of incorporating our tests into system wide pathways and protocols.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After a physician orders our tests, blood is collected either in the physician office or laboratory, third-party &#x201c;store front&#x201d; patient service centers, or it can be collected in the patient&#x2019;s home or workplace. We have contracted with a network of patient service centers and mobile phlebotomy services to be enable collection of blood samples outside of the physician office, at home or work for patients across the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our Biodesix WorkSafe testing program, we have a dedicated outreach team that works with the State of Colorado healthcare providers and hospitals, and employers looking to safely return to work across many industries, including food services, oil and gas, biotechnology and pharmaceuticals, sports teams, universities, and many small businesses. We recognize everyone&#x2019;s COVID-19 situation is unique, which is why we provide end-to-end customized solutions to support testing for our different customers, such as risk assessment tools, physician ordering services, on-site testing, phlebotomy services, shipping logistics, and ongoing client support.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business development team is focused on selling our complete offering of tests and services to biopharmaceutical companies in the United States and internationally. We currently hold a medical device establishment license in accordance with the Health Canada</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medical Devices Regulations of the Food and Drugs Act and successfully passed an international Health Canada inspection in October 2021. Our team consists of customer facing business development associates that work with our biopharmaceutical customers to identify projects, draw up statements of work and negotiate service agreements. Alliance managers help to manage the contractual obligations and scope of the project, whereas our operations team assures the project is managed with adequate resources and delivers on time. We take a two-pronged approach generating business in this segment. Primarily, we leverage existing projects and relationships to expand sales in current accounts. We also actively map ongoing drug development projects in biopharmaceutical companies and target programs best suited to our platform for new test development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary source of reimbursement for our tests in the United States is from third-party payers including government payers, such as Medicare, and commercial payers, such as insurance companies. Reimbursement for laboratory tests in the United States is determined by various payers, including private third-party payers, managed care organizations, and state and federal health care programs, such as Medicare and Medicaid. In Medicare, coverage of an item or service depends on whether it is &#x201c;reasonable and necessary&#x201d; under the section 1862(a)(1)(A) of the Social Security Act (SSA). For single-source laboratory tests, this determination is typically made by the Medicare Administrative Contractor (MAC) with jurisdiction over the laboratory where the test is performed. Our Boulder, Colorado laboratory is currently under the jurisdiction of Novitas Solutions, Inc. Our De Soto, Kansas laboratory is under the jurisdiction of Wisconsin Physicians Service Insurance Corporation (WPS), which participates in the MolDX program (administered by another MAC, Palmetto GBA) to set coverage policy for molecular diagnostic tests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medicare pays for clinical diagnostic laboratory tests (CDLTs), on the Clinical Laboratory Fee Schedule (CLFS). Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) added section 1834A to the SSA, which established the current CLFS rate setting processes and coding provisions for CDLTs, and created a new subcategory of CDLTs called Advanced Diagnostic Laboratory Tests (ADLTs), with separate reporting and payment requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under section 1834A and its implementing regulations, clinical laboratories that receive the majority of their Medicare revenues from payments made under the CLFS and the Physician Fee Schedule report on a triennial basis (or annually for ADLTs), private payer rates and volumes for their tests with specific billing codes based on final payments made during a set data collection period. The payment rate for a test for the ensuing three-year period (or one year for ADLTs) is set at the weighted median of the rates reported under the specific billing code for that test. Newly established codes for CDLTs are priced until the next private payer rate reporting cycle either based on the payment rate of a comparable code on the CLFS, as determined by CMS (&#34;crosswalking&#34;) or at the median of rates submitted by the individual MACs based on statutory and regulatory factors (&#34;gapfilling&#34;). New ADLTs are initially priced at &#x201c;actual list charge&#x201d; for a nine-month period, after which they are priced based on private payer rates, with a recoupment provision if actual list charge is more than 130% of the weighted median of private payer rates reported.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The various payers in the United States also determine their own billing rules. In December 2020, Medicare revised its billing rules for clinical laboratory tests to require cancer-related protein-based Multianalyte Assays with Algorithmic Analyses to be billed directly to Medicare by the performing laboratory in most cases when performed on a specimen collected from a hospital outpatient. Molecular pathology tests and most ADLTs are also generally required to be billed directly to Medicare by the laboratory under these circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our COVID-19 testing program, the primary source of reimbursement is through contracts with hospitals, companies providing wellness testing for their employees, or direct pay from patients. We believe that our lung cancer tests can both improve patient outcomes and help guide cost-effective treatment choices for patients with and at-risk of lung cancer. Achieving broad coverage and adequate reimbursement for each of our tests is a key component of our financial success and will continue to be important over time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Families First Coronavirus Response Act (FFCRA) and Coronavirus Aid, Relief, and Economic Security Act (CARES), Congress has imposed a broad requirement that Medicare fee-for-service, Medicare Advantage, Medicaid, and commercial payers generally cover clinical diagnostic laboratory tests administered during the Public Health Emergency for the detection of SARS-CoV-2 or the diagnosis of the virus that causes COVID-19. Where applicable, the FFCRA and CARES require payers to cover COVID-19 tests without cost sharing or medical management techniques like prior authorization. Medicare fee-for-service does not require cost sharing or prior authorization for any clinical diagnostic laboratory tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Department of Health &amp; Human Services (HHS) has indicated in guidance that the coverage requirements of the FFCRA and CARES can apply both to infection and serological testing, but that they are only applicable to testing that is &#x201c;diagnostic,&#x201d; which &#x201c;may include testing of individuals with signs or symptoms compatible with COVID-19, as well as asymptomatic individuals with known or suspected recent exposure to SARS-CoV-2.&#x201d; Testing that is &#x201c;not primarily intended for individualized diagnosis or treatment of COVID-19 or another health condition,&#x201d; including &#x201c;testing conducted to screen for general workplace health and safety,&#x201d; is beyond the scope of the statutory coverage requirements. We believe these coverage requirements apply to the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test when performed for diagnostic purposes. In some cases, we submit claims to insurance payers for the Bio-Rad SARS-CoV-2 ddPCR test and/or the Platelia SARS-CoV-2 Total Ab test. In these cases, insurance payers may have a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">different position on the scope of mandatory coverage of our tests under the FFCRA and CARES. More commonly, we enter into arrangements with clients under which the client pays us directly for testing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with applicable laws and regulations, as well as internal compliance policies and procedures adds complexity to the billing process. The Centers for Medicare &amp; Medicaid Services (CMS) is responsible for overseeing the establishment of new Healthcare Common Procedure Coding System (HCPCS) codes for billing the Medicare program and other payers. CMS continuously evaluates and implements changes to the Medicare billing, coding, and reimbursement processes. To receive reimbursement from third-party payers, we bill our tests using a variety of HCPCS codes or Current Procedural Terminology (CPT) codes, as defined by the American Medical Association. For some of the tests we conduct, there may not be a specific CPT or HCPCS code, in which case the test may be billed under a miscellaneous code for an unlisted molecular pathology procedure or unlisted multiple anolyte test with algorithmic analysis (MAAA) procedure. Because these miscellaneous codes do not describe a specific service, the third-party payer claim may be examined to determine the service provided, whether the service was appropriate and medically necessary and whether payment should be rendered. This process can result in a delay in processing the claim, a lower reimbursement amount, and/or denial of the claim.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We primarily face competition from lung cancer diagnostic solutions companies in the United States, Europe and Asia seeking to answer clinical questions in the space, all of whom provide cancer-focused diagnostic tests to hospitals, researchers, clinicians, laboratories and other medical facilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diagnosis&#x2014;Nodule Management</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are not aware of any other company that offers two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. We are aware of efforts by Veracyte, Inc. to develop and validate a test that may be competitive to the Nodify XL2 and/or Nodify CDT tests in the future. Additionally, Veracyte currently markets a test that is used post-bronchoscopy that is not competitive with our pre-bronchoscopy nodule risk assessment tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prognosis, Treatment Guidance and Monitoring&#x2014;NSCLC</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are unaware of any other diagnostic test available, commercially or in development, that will compete with our VeriStrat immune profiling test. There is substantial interest and activity in tumor profiling through liquid biopsy. Our genomic test offerings, the GeneStrat ddPCR and GeneStrat NGS tests, face competition from academic hospital laboratories, and companies such as Guardant Health and Foundation Medicine. We believe that there are several companies and academic research institutions in the process of developing tests for monitoring patients on or following treatment for recurrence or progression of lung cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biopharmaceutical Diagnostic Discovery, Development &amp; Testing Services</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are aware of a number of companies who compete with our diagnostic tests and services, including diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. From the perspective of tumor profiling, we believe Guardant Health and Foundation Medicine are our most significant competitors. Conversely, in the immune profiling market, we believe Adaptive Biotechnologies and Personalis are our most significant competitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Laboratory Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We perform the VeriStrat, GeneStrat ddPCR, GeneStrat NGS, and COVID-19 ddPCR tests in our Boulder, Colorado high-complexity CLIA certified clinical laboratory. The laboratory is College of American Pathology (CAP) accredited, New York State Department of Health (NYSDOH)&#x2014;permitted and licensed, ISO 13485:2016 Quality Management Systems&#x2014;Requirements for Regulatory Purposes for Medical Devices certified, along with all other states that require licensing: California, Maryland, Pennsylvania, and Rhode Island. All aspects of the testing process from receipt of the test requisition form through to delivery of test results are performed in the Boulder, Colorado facility. The proprietary testing methods use semi-automated workflows that facilitate the successful delivery of greater than 90% of our tests within three days, and we believe our existing workflows will continue to successfully deliver our tests within this timeframe.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nodify XL2, Nodify CDT, COVID cPASS and COVID-19 total antibody tests are performed in our De Soto, Kansas high-complexity CLIA certified clinical laboratory. This clinical laboratory is also CAP-accredited, NYSDOH&#x2014;permitted and licensed, ISO 13485:2016 Quality Management Systems&#x2014;Requirements for Regulatory Purposes for Medical Devices certified and licensed by California, Maryland, Pennsylvania, and Rhode Island. Receipt of requisitions and testing is performed in our De Soto, Kansas clinical laboratory. Delivery of the test results is performed by personnel from our Boulder, Colorado headquarters. The proprietary testing methods use semi-automated workflows that facilitate the successful delivery of greater than 90% of our tests within five days, and we believe our existing workflows will continue to successfully deliver our tests within this timeframe.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel in both facilities are responsible for quality assurance oversight, licensing, and regulation compliance and maintenance to ensure data integrity and consistent, validated processes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply Chain</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party suppliers, including in some instances single source suppliers, to provide us with certain components of our diagnostic tests. The number of suppliers feeding into the production of our diagnostic tests is in excess of 65 worldwide. We consider a select few of these suppliers, located in the United States, Europe and China, as critical single source providers of components. Bio-Rad, as described below, is the sole source supplier for our GeneStrat test, COVID-19, and antibody testing program. Oncimmune is also the sole source supplier for our Nodify CDT tests but there are known secondary suppliers for these materials. We have initiated the second source qualification process for the majority of these critical components.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we purchase supplies through purchase orders without long-term supply agreements with, or guaranteed commitments from, many of our suppliers, including single source suppliers. Additionally, at present, we have a limited contract with a contract manufacturer for the production of certain of our diagnostic testing kits; however, during 2022 we transitioned the majority of kitting performed outside of the Company to our internal operations team for cost savings and risk management. We depend on our suppliers and contract manufacturers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We entered into a nonexclusive license and supply agreement with Bio-Rad in August 2019. We rely on Bio-Rad to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test, but these supplies are able to be supplied by known suppliers. A disruption to this supply would negatively impact our ability to perform the GeneStrat tests until alternatives could be validated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we have initiated the second source qualification process for the majority of these critical components, we may not be successful in securing second sourcing for all of them at all or on a timely basis. A disruption to this supply would negatively impact our ability to perform these tests until an alternative supplier could be validated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All materials for our VeriStrat test and Nodify XL2 tests have alternative suppliers readily available, and a disruption in any single supplier would not materially impact our ability to deliver the test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends, in part, on our ability to obtain and maintain intellectual property and proprietary protection for our products and other know-how, to operate our business without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of others, and to defend and enforce our intellectual property and proprietary rights. We take efforts to protect our proprietary position using a variety of methods, which include pursuit of United States and foreign patent applications related to our proprietary technology, inventions and improvements that we determine are important to our business. We also may rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing and acquisition opportunities to develop and maintain our proprietary position. For more information regarding risks relating to intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have invested heavily in the protection of our key assets, namely the VeriStrat&#174; and GeneStrat&#174; tests, and we acquired a patent portfolio relating to the Nodify XL2&#174; and Nodify CDT&#174; tests in our acquisitions of Indi in June 2018, and of Oncimmune USA in October 2019 from Oncimmune Limited (Oncimmune). We own patents and patent applications as well as trade secrets relating to our products currently in development, a collection device for whole blood, our business strategy, client lists and business methods. Further, we have expanded our access to key intellectual property through license and co-development agreements, including our Non-Exclusive License Agreement with Bio-Rad (the Bio-Rad License), which allows us to use the Droplet Digital PCR&#153; technology developed by Bio-Rad and which we employ in our GeneStrat test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patent strategy has focused on creating and acquiring protection for our VeriStrat and Nodify XL2 proteomic tests, while utilizing trade secret and some methods patent protection for our genomic test (the GeneStrat ddPCR and GeneStrat NGS&#153; tests) and ELISA test (the Nodify CDT test). We have entered into a non-exclusive license agreement with Bio-Rad, without the right to grant sublicenses, to utilize certain of Bio-Rad&#x2019;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. Bio-Rad owns patents relating to ddPCR and to which we have a non-exclusive license to utilize for the performance of ddPCR in cancer detection testing for third parties as set forth in the Bio-Rad License Agreement. In addition, we have separately been granted permission by Bio-Rad to use the Bio-Rad SARS-CoV-2 ddPCR test and Platelia SARS-CoV-2 Total Ab test for commercial diagnostic services. We are unaware of patents owned by Bio-Rad relating to its COVID-19 antibody test but acknowledge that Bio-Rad has know-how and trade secrets relating to this test. We have patent protection in the United States and other countries around the world for the primary use of the VeriStrat test for profiling of patients with NSCLC, and various other uses of the VeriStrat test, such as breast cancer, prostate cancer, head and neck cancer have received patent protection. We have also received patent protection relating to our core classifier development program, our Diagnostic Cortex&#174; technologies and our approaches to using MALDI-ToF technology (DeepMALDI&#174; techniques). Additionally, our first device patent was issued in 2019 for our internally designed blood collection device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our patent portfolio includes 53 issued United States patents, 69 issued foreign patents, which includes five European patents that were nationalized in multiple European countries, and 51 pending applications (including 29 foreign patent applications). With regard to our product development efforts, new applications have been filed around developments relating to ARDS and COVID diagnostics, new analytic methodologies using Shapley values and semi-quantitative spectra analysis in MALDI, and national stage applications are now in active prosecution to protect our pipeline ROR and PIR tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent portfolio can be broken down into five major categories:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued patents and patent applications relating to the VeriStrat and Nodify tests and uses of these tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued patents and patent applications relating to methods for developing classifiers, including using the Diagnostic Cortex and DeepMALDI technologies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued patents and patent applications relating to tests currently in development;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued patents and patent applications relating to our novel blood collection device; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">5)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued patents and patent applications relating to tests developed for our third-party partners.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents relating to the VeriStrat test are scheduled to expire between 2026 and 2032. The patents relating to the Nodify XL2 test are scheduled to expire beginning in 2031 (excluding any patent term extension granted by the United States Patent and Trademark Office (USPTO)), and the patents relating to the Nodify CDT test are scheduled to expire in 2027. The patent related to the blood collection device is scheduled to expire in 2039. Should our current patent applications in prosecution in the United States issue, the resulting patents would be scheduled to have expiration dates between 2036 and 2040 (excluding any patent term extension(s) granted by the USPTO).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have one pending Patent Cooperation Treaty (PCT) application. PCT patent applications are not eligible to become issued patents until, among other things, we file such PCT applications as national stage patent application(s) within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to any such PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. Provisional patent applications are not eligible to become issued patents but can become the basis of PCT foreign stage and United States non-provisional patent applications, if such applications are filed within 12 months of filing the related provisional patent application. If we do not timely file any non-provisional patent applications, we will lose our priority date and any patent protection on the inventions disclosed in any such provisional patent application.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the term of individual issued patents depends upon the legal term for patents in the countries in which they are obtained. In most countries in which we have filed, including the United States, the patent term is generally 20 years from the earliest filing date of a non-provisional patent application, assuming the patent has not been terminally disclaimed over a commonly-owned patent or a patent naming a common inventor, or over a patent not commonly owned but that was disqualified as prior art as the result of activities undertaken within the scope of a joint research agreement. The life of a patent, and the protection it affords, is therefore limited and once the patent lives of our issued patents have expired, we may face competition, including from other competing technologies. In the United States, the term of a patent may also be eligible for patent term adjustment for delays within the USPTO. The term of a patent that covers a biological product may also be eligible for patent term extension when FDA approval is granted for a portion of the term effectively lost as a result of the FDA regulatory review period, subject to certain limitations and provided statutory and regulatory requirements are met. Any such patent term extension can be for no more than five years, only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those claims covering the approved biological product, a method for using it or a method for manufacturing it may be extended. We may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. There can be no assurance that we will benefit from any patent term extension or favorable adjustment to the term of any of our patents. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to maintain and solidify our proprietary and intellectual property position will depend on our success in obtaining effective patent claims and maintaining and enforcing claims that are granted. However, our owned and licensed patents could be invalidated or narrowed or otherwise fail to adequately protect our proprietary and intellectual property position and our pending owned and licensed patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because branding is as much a part of any intellectual property strategy as patent or trade secret protection we have a number of registered and pending trademarks relating to our company and products. We have received or filed for trademark protection in the United States for our tradename (Biodesix), the names of five of our commercial tests (namely the VeriStrat, GeneStrat ddPCR, GeneStrat NGS, Nodify XL2 and Nodify CDT tests), and a suite of research tests (ImmunoStrat), as well as having trademark protection for our core development and methodological platforms, such as our Diagnostic Cortex and DeepMALDI technologies. In all, as of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, we have 22 uniquely registered United States trademarks, 11 of which (including Biodesix, VeriStrat, and GeneStrat) have received foreign issuances as well, with three trademarks pending approval from the USPTO. We will continue to pursue protection in the United States and abroad for our branded assets and will continue to use branding to protect products currently in development, key Biodesix developments and non-trade secret methodologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also rely on trade secrets, including know-how, confidential information, unpatented technologies and other proprietary information, to strengthen or enhance our competitive position, protect and maintain aspects of our business that are not amenable to, or that we do not presently consider appropriate for, patent protection, and prevent competitors from reverse engineering or copying our technologies. We have decided that some technologies, such as our laboratory methodologies (including sample preparation and assay development), and some information (such as client and billing information) are best kept as trade secrets. However, trade secrets and confidential know-how are difficult to protect. To avoid inadvertent and improper disclosure of trade secrets, and to avoid the risks of former employees using these trade secrets to future employment, it is our policy to require employees, consultants and independent contractors to assign all rights to intellectual property they develop in connection with their employment with or services for the Company to the Company. We also protect our existing and developing intellectual property expressly through confidentiality provisions in agreements with third parties. There can be no assurance, however, that these agreements will be self-executing or otherwise provide meaningful protection for our trade secrets or other intellectual property or proprietary information, or adequate remedies in the event of unauthorized use or disclosure of such trade secrets or other intellectual property or proprietary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our trade secrets and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to pursue additional intellectual property protection to the extent we believe it would advance our business objectives, which may include objectives within and outside the United States. Despite our efforts to protect our intellectual property rights, and despite the breadth of protection that has issued around our key assets, these rights may not be respected in the future or may be circumvented or challenged (and potentially invalidated) in a legal proceeding in any jurisdiction where we have intellectual property rights. In addition, the laws of various foreign countries where we have received intellectual property protection and where we may eventually distribute our products may not afford the same protections or assurances to the same extent as the laws in the United States. See &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property&#x201d; for additional information regarding these and other risks related to our intellectual property portfolio and their potential effect on us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical laboratory tests like our diagnostic tests are regulated under CLIA and State law. The FDA regulates medical devices pursuant to the FDCA, including many diagnostic test kits, such as in vitro diagnostic tests (IVDs). However, most Laboratory Developed Tests (LDTs) are not currently subject to the FDA&#x2019;s regulation (although reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to such regulation) because the FDA has historically exercised enforcement discretion over LDTs. LDTs are a subset of IVDs that are intended for clinical use and developed, validated, and offered within a single laboratory for use only in that laboratory. FDA&#x2019;s authority to regulate LDTs has been contested for many years, and there have been several legislative and administrative proposals regarding LDT regulation seeking to end or limit enforcement discretion and to bring LDTs under new or existing FDA regulatory frameworks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the likelihood that Congress will pass legislation or the extent to which such legislation may affect the FDA&#x2019;s plans to regulate certain LDTs as medical devices or pursuant to a new framework. Until legislation is passed reforming the federal government&#x2019;s regulation of LDTs, it is unknown how the FDA may regulate our tests in the future and what testing and data may be required to support any required clearance or approval. It is also unclear at this time when or if, the FDA will finalize its plans to end enforcement discretion in the absence of legislation, via notice and comment rulemaking or otherwise. Even if a new framework is not established via legislative or administrative action, the FDA may attempt to regulate and enforce against certain LDTs on a case-by-case basis at any time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently market our GeneStrat, VeriStrat, Nodify XL2 and Nodify CDT tests as LDTs in the United States. As a result, we believe our diagnostic services are not currently subject to the FDA&#x2019;s enforcement of its medical device regulations and the applicable FDCA provisions. If the FDA disagrees with the LDT status of any of our tests, the FDA may consider the test to be an unapproved medical device and may subject us to FDA enforcement action, including, without limitation, requiring us to seek clearance, authorization or approval for the laboratory test. If the FDA were to begin enforcement with respect to our LDTs, we could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the FDA has not engaged in notice-and-comment rulemaking or released broad-sweeping guidance over LDTs, but it could choose to do so in the future and if pre-market review is required, our business could be negatively impacted as a result of commercial delay that may be caused by the new requirements. The cost of conducting clinical trials and otherwise developing data and information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to support pre-market applications may be significant. If we are required to submit applications for our currently marketed tests, we may be required to conduct additional studies, which may be time-consuming, costly and could result in our currently-marketed tests being withdrawn from the market. Continued compliance with the FDA&#x2019;s regulations would increase the cost of conducting our business, and subject us to heightened regulation by the FDA including penalties for failure to comply with these requirements. Failure to comply with applicable regulatory requirements could result in an enforcement action by the FDA, such as fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. There are other regulatory and legislative proposals that would increase general FDA oversight of clinical laboratories and LDTs. Until the FDA finalizes its regulatory position regarding LDTs, or the VALID Act or other legislation is passed reforming the federal government&#x2019;s regulation of LDTs, it is unknown how the FDA may regulate our tests in the future and what testing and data may be required to support any required clearance or approval. The outcome and ultimate impact of such proposals on the business is difficult to predict at this time and we are monitoring developments and anticipate that our products will be able to comply with requirements that may be imposed by the FDA. In the meantime, we maintain our CLIA accreditation, which permits the use of LDTs for diagnostics purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA Emergency Use Authorization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 564 of the FDCA allows the FDA to authorize the shipment of drugs, biological products, or medical devices that either lack required approval, licensure, or clearance (unapproved products), or are approved but are to be used for unapproved ways to diagnose, treat, or prevent serious diseases or conditions in the event of an emergency declaration by the HHS Secretary. 21 U.S.C. &#167; 360bbb-3(a)(1)-(2).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 31, 2020, HHS Secretary Alex M. Azar II declared a public health emergency for COVID-19, under 21 U.S.C. &#167; 360bbb-3(b)(1), justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19. This determination was published in the Federal Register on February 7, 2020. 85 Fed. Reg. 7316 (Feb. 7, 2020). The EUA declaration under Section 564 of the FDCA is distinct from and independent of the declaration by the Secretary of HHS of a public health emergency under Section 319 of the Public Health Service Act. On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#x2019;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. Because the EUA declaration under Section 564 of the FDCA is distinct from the declaration under Section 319 of the PHS Act, an EUA may remain in effect beyond the duration of the Section 319 declaration. Before HHS terminates an EUA declaration, it will publish a notice of termination in the Federal Register.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the emergency declaration for COVID-19 IVDs under Section 564 of the FDCA remains in effect, the FDA may authorize the use of an unapproved product or an unapproved use of an approved product if it concludes that:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an agent referred to in the emergency declaration could cause a serious or life-threatening disease or condition;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is reasonable to believe that the authorized product may be effective in diagnosing, treating, or preventing that disease or condition or a serious or life-threatening disease or condition caused by an approved product or a product marketed under an EUA;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the known and potential benefits of the authorized product, when used for that disease or condition, outweigh known and potential risks, taking into consideration the material threat of agents identified in the emergency declaration;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there is no adequate, approved, and available alternative to the authorized product for diagnosing, preventing, or treating the relevant disease or condition;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any other criteria prescribed by the FDA is satisfied. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Id. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#167; 360bbb-3(c).</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bio-Rad SARS-CoV-2 ddPCR test, the cPASS neutralization antibody test kit, and the Platelia SARS-CoV-2 Total Ab test have been granted FDA EUA pursuant to the current emergency declaration. We have completed all required performance verification studies to validate the use of the tests in our laboratories in accordance with the FDA Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency, CAP and New York State Clinical Laboratory Standards of Practice (NYS CLEP) requirements. The FDA Policy for COVID-19 tests is a guidance document that explains the FDA&#x2019;s current thinking on the topic, is subject to change, and does not establish any legally enforceable responsibilities. The FDA does not expect a separate notification or EUA request from high complexity CLIA laboratories that are performing testing for SARS-CoV-2 using only EUA-authorized test kits purchased from commercial manufacturers or their distributors. According to previous versions of the FDA's Policy for COVID-19 tests, a laboratory may make certain modifications to an EUA-authorized test if the modified test is validated using a bridging study without submitting an EUA amendment or formal notification. According to the current FDA Policy for COVID-19 tests (January 12, 2023), a laboratory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that modified an EUA authorized test pursuant to the previous policy for use of a new specimen through a bridging study when the new specimen type had been previously authorized for another test of the same technology may continue to offer the modified test without submitting an EUA amendment or formal notification.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and State Laboratory Licensing Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biodesix Boulder, Colorado clinical laboratory is a CAP-accredited clinical laboratory regulated by CMS pursuant to CLIA. CMS has granted CAP deeming authority under CLIA, which allows CAP to inspect laboratories in lieu of CMS. In addition to holding a CLIA Certificate and CAP laboratory accreditation, Biodesix&#x2019;s Quality Management System (QMS) holds an ISO 13485:2016 certificate (passed recertification audit in December 2021). The Biodesix Boulder, Colorado clinical laboratory has received approval from the NYSDOH, NYS CLEP in Soluble Tumor Markers, and Molecular and Cellular Tumor Markers and Virology as well as holding state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode Island.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CLIA regulations establish standards for proficiency testing; facility administration; general laboratory systems; pre-analytic, analytic systems, post- analytic systems; personnel qualifications and responsibilities; quality control, quality assessment; and specific provisions for laboratories performing moderate to high complexity tests. Our Boulder, Colorado clinical laboratory is inspected biennially as part of its ongoing certification under CLIA certificate of accreditation by CAP. The Boulder, Colorado clinical laboratory most recently passed its CAP inspection in April 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of or assessment of health. CLIA requires that a laboratory hold a certificate applicable to the type of laboratory examinations it performs and that it complies with, among other things, standards covering operations, personnel, facilities administration, quality systems and proficiency testing, which are intended to ensure, among other things, that clinical laboratory testing services are accurate, reliable and timely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biodesix De Soto, Kansas clinical laboratory is a CAP-accredited clinical laboratory regulated by CMS pursuant to CLIA. CMS has granted CAP deeming authority under CLIA, which allows CAP to inspect laboratories in lieu of CMS. In addition to holding a CLIA Certificate and CAP laboratory accreditation, the De Soto, Kansas clinical laboratory passed its first CAP inspection in June 2021. Biodesix&#x2019;s QMS holds an ISO 13485:2016 certificate (recently passed surveillance audit in January 2023). The De Soto, Kansas clinical laboratory has received approval from the NYSDOH, NYS CLEP in Soluble Tumor Markers and Diagnostic Immunology as well as holding state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode Island.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The International Organization for Standardization (ISO) is an independent, non-governmental international organization that defines world-class specifications for products, services and systems, to ensure quality, safety and efficiency. ISO 13485:2016 is a harmonized, international regulatory benchmark for quality management systems that addresses most or all of the QMS requirements in markets including the United States, European Union, Australia, Japan and Canada. The ISO 13485:2016 certificate confirms that an organization operates a QMS that conforms to the standards established by ISO. The FDA has proposed a rule to harmonize and modernize its Quality System Regulation (QSR), which would supplant the existing requirements with ISO 13485:2016. Although this rule has been delayed several times since spring 2018, the Office of Management and Budget (OMB) updated its website (January 2022) to indicate that the FDA&#x2019;s proposed rule to harmonize the agency&#x2019;s medical device QSR with the ISO 13485 standard has been finished and is now under review by OMB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. Laboratories such as ours, which are performing high complexity testing, are required to meet more stringent CLIA requirements than laboratories performing less complex tests, and therefore our laboratories are also subject to random, unannounced survey and inspection at any time. In addition, a laboratory that is certified as &#x201c;high complexity&#x201d; under CLIA may develop, manufacture, validate and use proprietary LDTs. CLIA requires analytical validation including accuracy, precision, specificity, sensitivity and establishment of a reference range for any LDT used in clinical testing. The regulatory and compliance standards applicable to the testing we perform may change over time and any such changes could have a material effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. State laws may require that out-of-state laboratories maintain an in-state laboratory license to perform tests on samples from patients who reside in that state. As a condition of licensure, certain states may require that laboratory personnel meet qualifications, quality control procedures, facility requirements, record maintenance requirements or other state-specific requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because our Boulder, Colorado clinical laboratory is located in the State of Colorado, we do not need a specific State of Colorado laboratory license, however, we maintain licenses to conduct testing in other states where nonresident laboratories are required to obtain state laboratory licenses. We maintain licenses for our Boulder, Colorado and De Soto, Kansas laboratories with the NYSDOH. We also hold licenses in other states in which we operate, including California, Maryland, Pennsylvania and Rhode Island, that require licensing of out-of-state laboratories under certain circumstances. Other states may currently have or adopt similar licensure requirements in the future, which may require us to modify, delay or stop its operations in those states until such requirements are met.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with CLIA certification and state clinical laboratory licensure requirements may result in a range of enforcement actions, including certificate or license suspension, limitation, or revocation, directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions, and revocation of the laboratory&#x2019;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CLIA and state laws and regulations, operating together, sometimes limit the ability of laboratories to offer consumer-initiated testing, also known as direct access testing. We do not offer direct access testing and instead require that our tests be ordered by licensed healthcare providers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Boulder, Colorado and De Soto, Kansas laboratories are certified and adhere to the NYS CLEP, based on New York State Public Health Law, Article 5 Title 5. NYS CLEP is exempt from CLIA and establishes their own method of laboratory certification and test validation approval. To process New York State patient specimens a laboratory must submit a robust analytical and clinical validation package to demonstrate clinical utility of the test and receive approval prior to offering the test in the state of New York. All of our tests have obtained NYS CLEP approval including GeneStrat ddPCR, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT tests. NYS CLEP requires semi-annual inspections to ensure the laboratory meets all general and specialty standards. Both Biodesix laboratories passed NYS CLEP inspections in May 2019. Due to the pandemic, routine re-inspections have been delayed by NYS CLEP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory framework for medical devices in the United States</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, which are defined to include, among other things, IVDs. The FDA regulates the research, design, development, pre-clinical and clinical testing, manufacturing, safety, effectiveness, packaging, labeling, storage, recordkeeping, pre-market clearance or approval, adverse event reporting, marketing, promotion, sales, distribution and import and export of medical devices. It is possible that one of our current, or future, tests will be subject to FDA authority and oversight as either an IVD or a CDx pursuant to the FDA&#x2019;s authority to regulate medical devices under the FDCA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medical devices are subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product design, development, manufacture, and release;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laboratory and clinical testing, labeling, packaging, storage and distribution;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product safety and efficacy;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">premarketing clearance or approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">service operations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">record keeping;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product marketing, promotion and advertising, sales and distribution;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">post-market approval studies; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product import and export</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market access, sales and marketing of medical devices in non-U.S. countries are subject to foreign regulatory requirements that vary widely from country to country. For example, in the European Economic Area (EEA), a medical device must meet the Medical Devices Directive&#x2019;s (MDD)/In Vitro Medical Devices Directive&#x2019;s (IVDD) Essential Requirements or, applicable on May 26, 2021, the Medical Devices Regulation&#x2019;s (MDR) / applicable on May 26, 2022, In Vitro Medical Devices Regulation&#x2019;s (IVDR) General Safety and Performance Requirements which apply to it, taking into account its intended purpose as defined by the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation. Before placing a medical device on the EEA market, the manufacturer must draw up a declaration of conformity, certifying that the device complies with the MDD/IVDD/MDR/IVDR, and must then affix the CE mark. For medium and high-risk devices as well as low risk devices that are placed on the market in sterile condition, have a measuring function, or are reusable surgical instruments, the manufacturer must obtain a CE Certificate from a notified body. The notified body typically audits and examines the device&#x2019;s technical documentation, including the clinical evaluation, and the quality system for the manufacture, design and final inspection of the relevant device before issuing a CE Certificate. Following the issuance of this CE Certificate, manufacturers may draw up the declaration of conformity and affix the CE mark to the devices covered by this CE Certificate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers of medical devices must document in a clinical evaluation report (CER) the evaluation of the clinical data related to the device. The CER is part of the device&#x2019;s technical file. The evaluation shall document that the applicable Essential Requirements/General Safety and Performance Requirements are met and document the evaluation of the undesirable side-effects and the acceptability of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">benefit-risk ratio. The CER must be updated based on information from the post-market surveillance and vigilance activities related to the device. The CER shall consist, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, of analyzed clinical data collected from a clinical investigation of the device, or the results of other studies on substantially equivalent devices. Reliance on &#x201c;substantially equivalent&#x201d; devices is very restrictive and requires, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the manufacturer has full access to the technical documentation of the equivalent device on an ongoing basis and, if the &#x201c;equivalent device&#x201d; is not its own, that the manufacture has in place a contract with the manufacturer of the &#x201c;equivalent device.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar requirements apply in the UK. For access to the UK market, manufacturers must obtain a UKCA Certificate and affix a UKCA mark to their medical devices. However, the CE mark will be accepted in the UK until July 1, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Device classification</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the FDCA, medical devices are classified into one of three classes: Class I, Class II or Class III, depending on the degree of risk to patients that is associated with each medical device and the amount of oversight needed to provide reasonable assurances with respect to safety and effectiveness of the medical device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA&#x2019;s QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Class II devices are subject to the General Controls as well as any special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process, although some Class II devices are exempt from the 510(k) requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Class III devices include devices deemed by the FDA to pose the greatest risk: such as life-supporting or life-sustaining devices, implantable devices, or those deemed novel and not substantially equivalent to a predicate device following the 510(k) process. CDx tests are regularly considered Class III devices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Premarket submission process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless a statutory or regulatory exemption or enforcement discretion policy applies, before a new medical device, or a new intended use of, claim for, or significant modification to an existing device, can be marketed in the United States, the manufacturer must obtain the FDA&#x2019;s: (1) permission for commercial distribution under section 510(k) of the FDCA (510(k) clearance); or (2) approval of a Premarket Approval (PMA); or (3) de novo classification and authorization. These processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 510(k)-clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#x201c;substantially equivalent&#x201d; to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and therefore a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be &#x201c;substantially equivalent,&#x201d; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Premarket notifications typically include bench, analytical, and preclinical data. Clinical data is sometimes required to support substantial equivalence. If a manufacturer obtains a 510(k) clearance for its device and then makes a modification that could significantly affect the device&#x2019;s safety or effectiveness or constitutes a major change or modification in the intended use of the device, a new clearance, authorization or approval may be required.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. If the FDA determines that the device is not &#x201c;substantially equivalent&#x201d; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous, costly, and time-consuming PMA approval process or seek reclassification of the device through the De Novo process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a predicate device is not available, the FDA allows the submission of a direct De Novo petition. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. A De Novo request includes a description of the device, a discussion of the general controls and any specific controls recommended to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide reasonable assurance of the safety and effectiveness of the device, a description of the probable benefits of the device when compared to the probable risks when the device is used as intended, non-clinical data including bench performance and animal testing, technical information about the device, and clinical data (if applicable). FDA&#x2019;s goal is to review a De Novo request within 150 review days after receiving the petition. As with a 510(k) submission or PMA, the length of the review can be prolonged if the FDA requests additional information from the applicant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To obtain a PMA, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#x2019;s satisfaction. Accordingly, a PMA typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling, and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#x2019;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once filed as a PMA, the FDA has 180 days to review the filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#x2019;s response to deficiencies communicated by the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to approval of a PMA, the FDA may conduct inspections of any clinical trial data and clinical trial sites, as well as inspections of any manufacturing facility and processes. The FDA can delay, limit or deny approval of a PMA application for many reasons, including (1) the device may not be shown safe or effective to the FDA&#x2019;s satisfaction; (2) the data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval; (3) the manufacturing process or facilities may not meet applicable requirements; and (4) changes in FDA approval policies or adoption of new regulations may require additional data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when data is available. The PMA process can be expensive, uncertain and lengthy. A number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing. New PMA applications or PMA supplements are required for any modifications to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a condition of PMA application approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer-term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 510(k), De Novo or PMA processes can be expensive, lengthy and unpredictable. The FDA&#x2019;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k)-clearance process and generally takes from one to three years, or even longer, from the time the application is filed with the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device, which may limit the market for the device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companion Diagnostics and the Premarket Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that one of our future product candidates may include a companion diagnostic or complementary diagnostic (collectively CDx). CDx&#x2019;s can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. The use of the CDx will be stipulated in the labeling of both the CDx and the therapeutic product. The FDA may require an application for the CDx to be separate from the drug approval process, and this could potentially delay the approval of any new drug application or the CDx, or complicate the review process. CDx&#x2019;s are generally regulated as Class III medical devices by the FDA and are therefore most often subject to the PMA approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA issued guidance in July 2016 for the co-development of CDx tests with a therapeutic product and issued another draft guidance in December 2018 specific to oncology CDx tests. The FDA finalized this draft guidance in April 2020 in &#x201c;Developing and Labeling In</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products.&#x201d; The guidance is meant to guide the development of CDx products, which are defined as IVDs that provide information that is essential for the safe and effective use of the therapeutic product. A CDx is often developed and approved or cleared contemporaneously with the therapeutic, and the use of the CDx is stipulated in the labeling of both the CDx and the corresponding therapeutic product. While it supports contemporaneous marketing authorizations, if there are any deficiencies in the submissions, the FDA may place a PMA review of a CDx on hold or request additional testing, which could potentially delay the approval of the corresponding new drug application or the marketing authorization of the CDx, or otherwise complicate the review process. Some oncology CDx tests can be developed in a way that results in labeling for a specific group of oncology therapeutic products, rather than a single therapeutic product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-Market FDA Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if regulatory clearance, authorization or approval of a device is granted, the FDA may impose limitations on the uses and indications for which the device may be labeled and promoted, and the device remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared, authorized or approved. After a device, including a device exempt from FDA premarket review, is placed on the market, numerous post-market regulatory requirements apply, and the FDA has broad authority to enforce these requirements. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as: warning letters, fines, injunctions, consent decrees and civil penalties; unanticipated expenditures, including requirements to repair, replace, and/or refund the cost of the devices, recall or seizure of our products; operating restrictions, partial suspension or total shutdown of production; the FDA&#x2019;s refusal of our requests for 510(k) clearance, De Novo classification, or PMA of new products, new intended uses or modifications to existing products; the FDA&#x2019;s refusal to issue certificates to foreign governments needed to export products for sale in other countries; and withdrawing 510(k) clearance or PMAs that have already been granted and criminal prosecution. In the event that a supplier fails to maintain compliance with the FDA&#x2019;s or our quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and State Fraud and Abuse Laws</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to federal fraud and abuse laws such as the federal Anti-Kickback Statute (AKS), the federal prohibition against physician self-referral (Stark Law), the Eliminating Kickbacks in Recovery Act (EKRA), and the federal False Claims Act (FCA). We are also subject to similar state and foreign fraud and abuse laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The AKS (Social Security Act &#167; 1128B(b)) prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for, or recommend purchasing, leasing or ordering, any item or service that may be reimbursable, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. There are a number of statutory exceptions and regulatory safe harbors to the AKS that provide protection from AKS liability to arrangements that fully satisfy the applicable requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EKRA (18 USC &#167; 220) prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program. The term &#x201c;health care benefit program&#x201d; is broadly defined such that EKRA extends to referrals reimbursed by both governmental and commercial third-party payers. EKRA includes a number of statutory exceptions that provide protection from EKRA liability if the applicable requirements are met.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Stark Law (Social Security Act &#167; 1877) generally prohibits, among other things, clinical laboratories and other so-called &#x201c;designated health services&#x201d; entities from billing Medicare for any designated health services when the physician ordering the service, or any member of such physician&#x2019;s immediate family, has a financial relationship, such as a direct or indirect investment interest in or compensation arrangement with the billing entity, unless the arrangement meets an exception to the prohibition. The Stark Law also prohibits physicians from making such referrals to a designated health services entity. There are also similar state laws that apply where Medicaid and/or commercial payers are billed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FCA (31 USC &#167; 3729) imposes penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment to the government that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also permits a private individual acting as a &#x201c;qui tam&#x201d; whistleblower to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $13,508 to $27,018 per false claim or statement for penalties assessed after January 30, 2023, with respect to violations occurring after November 2, 2015.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payer knows or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular provider, practitioner, or supplier, and contracting with an individual or entity that the person knows or should know is excluded from participation in a federal health care program. In addition, federal criminal statutes created by the Health Insurance Portability and Accountability Act (HIPAA) prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to these federal laws, there are often similar state anti-kickback and false claims laws that typically apply to arrangements involving reimbursement by a state-funded Medicaid or other health care program. Often, these laws closely follow the language of their federal law counterparts, although they do not always have the same exceptions or safe harbors. In some states, these anti-kickback laws apply with respect to all payers, including commercial payers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A number of states have enacted laws that require pharmaceutical and medical device companies to monitor and report payments, gifts and other remuneration made to physicians and other healthcare providers, and, in some states, marketing expenditures. In addition, some state statutes impose outright bans on certain manufacturer gifts to physicians or other health care professionals. Some of these laws, referred to as &#x201c;aggregate spend&#x201d; or &#x201c;gift&#x201d; laws, carry substantial fines if they are violated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs and extensive annual trainings for all of our employees and contractors. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Corruption</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Foreign Corrupt Practices Act of 1977 (FCPA) and similar international bribery laws make it unlawful for persons or entities to make payments to foreign government officials to assist in obtaining and maintaining business. Specifically, the anti-bribery provisions of the FCPA prohibit any offer, payment, promise to pay, or authorizing the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to do or omit to do an act in violation of his or her duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business, to any person. In addition to the anti-bribery provisions of the FCPA, the statute also contains accounting requirements designed to operate in tandem with the anti-bribery provisions. Covered companies are required to make and keep books and records that accurately and fairly reflect the transactions of the company and devise and maintain an adequate system of internal accounting controls. With our international operations through our third-party partnerships, we could incur significant fines and penalties, as well as criminal liability, if we fail to comply with either the anti-bribery or accounting requirements of the FCPA, or similar international bribery laws. Even an unsuccessful challenge of our compliance with these laws could cause us to incur adverse publicity and significant legal and related costs. We successfully passed our first FCPA compliance review in 2021 with no findings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Privacy and Data Protection Laws</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerous federal and state laws and regulations, including HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (HITECH) Act, govern the collection, dissemination, security, use and confidentiality of protected health information (PHI) and personal information. In the course of performing our business we obtain personal information, including PHI. Laws and regulations relating to privacy, data protection, and consumer protection are evolving and, in some cases, particularly with regard to newer laws, may be subject to potentially differing interpretations. Under HIPAA and HITECH, the HHS issues regulations that establish uniform standards governing the conduct of certain electronic healthcare transactions and requirements for protecting the privacy and security of PHI, used or disclosed by covered entities (CEs) and their authorized business associates (BAs). Because we are a health care provider that electronically transmits health care information, and we also provide certain services to CEs and receive PHI from them, we are at times either a CE or a BA, as defined by HIPAA. Our subcontractors that create, receive, maintain, transmit or otherwise process PHI on our behalf are HIPAA BAs and must also comply with HIPAA, as applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA and HITECH include the privacy and security rules, breach notification requirements and electronic transaction standards. The privacy rule governs the use and disclosure of PHI, generally prohibits the use or disclosure of PHI except as permitted under the rule, and mandates certain safeguards to protect the privacy of PHI. The privacy rule also sets forth individual rights, such as the right to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">access or amend certain records containing such individual&#x2019;s PHI, or to request restrictions on the use or disclosure of such individual&#x2019;s PHI. The security rule requires CEs and BAs to safeguard the confidentiality, integrity, and availability of electronically transmitted or stored PHI (also referred to as ePHI) by implementing administrative, physical and technical safeguards. Under HIPAA&#x2019;s breach notification rule, a CE must notify individuals, the Secretary of HHS, and in some circumstances, the media of certain breaches of unsecured PHI or ePHI, and similar breach notification provisions apply to certain BAs under the HITECH Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Penalties for failure to comply with a requirement of HIPAA and HITECH vary depending on the number and nature of the violations and any history of prior violations, but can be significant and include civil monetary or criminal penalties. HIPAA is enforced by the Department of Health and Human Services, Office for Civil Rights, and HIPAA also authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#x2019; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in improper use, access to or disclosure of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA CEs, such as us, and their BAs for compliance with the HIPAA privacy and security standards and breach notification rules. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the civil monetary penalty paid by the violator.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may be subject to state privacy, cybersecurity, and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. California, for example, has enacted the Confidentiality of Medical Information Act, which, in addition to HIPAA and HITECH, sets forth standards with which all California health care providers must abide. Colorado has enacted the Colorado Privacy Act, and Virginia has enacted the Consumer Data Protection Act, both of which also have standards that must be complied with that supplement Federal data protection requirements, State laws may be more stringent, broader in scope or offer greater individual rights with respect to PHI than HIPAA, and state laws may differ from each other in regards to personal information treatment, which may complicate compliance efforts. For instance, the California Consumer Privacy Act (CCPA) became effective on January 1, 2020 and was amended by the passage of the California Privacy Rights Act (CPRA) in November of 2020, which amendments came into force on January 1, 2023. The CCPA, among other things, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. Although there are certain exemptions for PHI and clinical trial data, the CCPA&#x2019;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future and the CCPA may increase our compliance costs and potential liability. Additionally, the CPRA imposes additional data protection obligations on companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency &#x2013; the California Privacy Protection Agency &#x2013; specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. Similar laws have been proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that could continue to make compliance challenging and costly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the Federal Trade Commission (FTC) and state attorneys general enforce consumer protection laws that prohibit unfair and deceptive acts and practices, including Section 5 of the FTC Act, which creates standards for the collection, use, dissemination and security of health-related and other personal information. Claims of unfair or deceptive trade practices regarding privacy and security can lead to significant liabilities and consequences, including regulatory investigations, penalties, fines and orders as well as civil claims, which could impact our data practices and operations or cause reputational damage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may add additional compliance burden and complexity. For example, in the EEA, the collection and use of personal data is governed by the European Union's General Data Protection Regulation (GDPR). In the United Kingdom, the GDPR has been adopted in substantially the same form, however the UK may potentially make revisions in the coming years. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data. European and United Kingdom data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices is often updated or otherwise revised. GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to ensure a legal bases to process personal information, provide robust disclosures to individuals, facilitate data subject rights, provide data security breach notifications within 72 hours after discovering a breach in certain circumstances, limit retention of personal information and apply enhanced protections to health data and other categories of sensitive personal information. The GDPR also has requirements around international transfers of personal data. Requirements around transfers to the United States and other jurisdictions have increased since a July 2020 decision by the Court of Justice of the European Union invalidated the Privacy Shield as a basis to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">transfer personal data from Europe to the United States, and added requirements for reliance on Standard Contractual Clauses. Regulatory guidance on requirements for international transfers, and other GDPR compliance matters, continues to evolve; for example, the European Commission in December 2022 announced that it was beginning the process of drafting a new adequacy decision that would ease regulatory barriers for data transfers to the United States. However, it is widely expected that the new adequacy decision will itself face scrutiny from the Court of Justice, underscoring that GDPR compliance is an ongoing endeavor. Failure to comply with the requirements of the GDPR may result in fines of up to &#x20ac;20 million or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. To comply with the GDPR and other applicable international data protection laws and regulations, we may be required to put in place additional mechanisms ensuring compliance, which may result in other substantial expenditures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cybersecurity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business relies on secure and continuous processing of information and the availability of our IT networks and IT resources, as well as critical IT vendors that support our technology, research and other data processing operations. While we take steps to protect our systems and data, security incidents, data breaches, computer malware and computer hacking attacks have become more prevalent across industries, including the life sciences sector, and may occur on our systems or those of our third-party service providers. Unauthorized persons may in the future be able to exploit weaknesses in the security systems of our (or our third-party service providers) IT networks and gain access to PHI and other personal information, sensitive trade secrets, or other proprietary information. Any wrongful use or disclosure of PHI, other personal information, trade secrets or other proprietary information by us or our third-party service providers could subject us to regulatory fines or penalties, third-party claims or otherwise could adversely affect our business and results of operations. Although HIPAA and the regulations promulgated thereunder do not provide for a private right of action, failures to adequately protect PHI or our IT systems could be viewed as violations of the HIPAA security rule or violations of other applicable information security laws, regulations, contractual obligations or industry standards, and could further result in costly data breach notification obligations that negatively impact our reputation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, data security incidents or data breaches, as well as attacks on our IT systems, could result in operational disruptions or data loss or corruption that could adversely impact our business and operations, resulting in substantial investment of resources to investigate, recover and remediate and subject us to heightened regulatory scrutiny.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International Regulations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many countries in which we may offer any of our diagnostic tests in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national health care program. In situations involving physicians employed by state-funded institutions or national health care agencies, violation of the local anti-kickback law may also constitute a violation of the FCPA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FCPA prohibits any United States individual, business entity or employee of a United States business entity to offer or provide, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the Securities and Exchange Commission (SEC) to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors&#x2019; activities that may fall within the purview of the FCPA, its books and records provisions and its anti-bribery provisions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The standard of intent and knowledge in anti-bribery cases is minimal. Intent and knowledge are usually inferred from that fact that bribery took place. The accounting provisions do not require intent. Violations of the FCPA&#x2019;s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2 million and officers, directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption regulations, such as the United Kingdom Anti-Bribery Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When marketing our diagnostic tests outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our diagnostic tests or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market access, sales and marketing of medical devices in non-U.S. countries are subject to foreign regulatory requirements that vary widely from country to country. For example, in the EEA, a medical device must meet MDDs/IVDD Essential Requirements or, applicable on May 26, 2021, the MDR applicable on May 26, 2022, IVDR General Safety and Performance Requirements which apply to it, taking into account its intended purpose as defined by the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation. Before placing a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">medical device on the EEA market, the manufacturer must draw up a declaration of conformity, certifying that the device complies with the MDD/IVDD/MDR/IVDR, and must then affix the CE mark. For medium and high-risk devices as well as low risk devices that are placed on the market in sterile condition, have a measuring function, or are reusable surgical instruments, the manufacturer must obtain a CE Certificate from a notified body. The notified body typically audits and examines the device&#x2019;s technical documentation, including the clinical evaluation, and the quality system for the manufacture, design and final inspection of the relevant device before issuing a CE Certificate. Following the issuance of this CE Certificate, manufacturers may draw up the declaration of conformity and affix the CE mark to the devices covered by this CE Certificate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers of medical devices must document in a CER the evaluation of the clinical data related to the device. The CER is part of the device&#x2019;s technical file. The evaluation shall document that the applicable Essential Requirements/General Safety and Performance Requirements are met and document the evaluation of the undesirable side-effects and the acceptability of the benefit-risk ratio. The CER must be updated based on information from the post-market surveillance and vigilance activities related to the device. The CER shall consist, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, of analyzed clinical data collected from a clinical investigation of the device, or the results of other studies on substantially equivalent devices. Reliance on &#x201c;substantially equivalent&#x201d; devices is very restrictive and requires, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the manufacturer has full access to the technical documentation of the equivalent device on an ongoing basis and, if the &#x201c;equivalent device&#x201d; is not its own, that the manufacture has in place a contract with the manufacturer of the &#x201c;equivalent device.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar requirements apply in the UK. For access to the UK market, manufacturers must obtain a UKCA Certificate and affix a UKCA mark to their medical devices. However, the CE mark will be accepted in the UK until July 1, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2010, the Patient Protection and Affordable Care Act (ACA) was enacted in the United States. The ACA made a number of substantial changes to the way healthcare is financed both by governmental and private insurers. For example, the ACA requires each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices. The medical device tax was permanently repealed at the end of 2019. The ACA also contains a number of other provisions, including provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse, which we expect will impact our industry and our operations in ways that we cannot currently predict.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning in 2017, the Trump administration sought to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. The Trump administration issued three executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. For example, on December 20, 2019, President Trump signed appropriations legislation for fiscal year 2020 that repealed certain ACA-mandated fees, including the so-called &#x201c;Cadillac&#x201d; tax on certain high-cost employer-sponsored insurance plans, for tax years beginning after December 31, 2019; the annual fee imposed on certain health insurance providers based on market share, for calendar years beginning December 31, 2020; and the medical device excise tax on non-exempt medical devices, for sales after December 31, 2019. While Congress did not pass comprehensive legislation that would repeal all or part of the ACA, two bills affecting the implementation of certain taxes under the ACA have been signed into law. Specifically, the Tax Cuts and Jobs Act of 2017 (TCJA), among other things, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment, or penalty, imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; Beginning in 2021, the Biden administration has signaled its intent to pursue policies strengthening the ACA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that started in 2013 and, due to subsequent statutory amendments, will remain in effect through 2030 unless additional Congressional action is taken. In 2020, the CARES Act temporarily suspended the 2% cut in Medicare payments from May 1, 2020 through December 31, 2020, and it extended the sequestration reductions through fiscal year 2030 to offset the cost of such temporary suspension. The Consolidated Appropriations Act of 2021 further extended the temporary suspension through March 31, 2021. On April 14, 2021, Congress enacted legislation that further extended the suspension through December 31, 2021. On December 10, 2021, further legislation was enacted to extend the suspension through March 31, 2022, after which a 1.0% sequestration applied for Medicare payments made between April 1, 2022 and June 30, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The American Taxpayer Relief Act of 2012 made other changes, including reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve R&amp;D, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. Additionally, the Biden administration has already indicated a shift in direction from Trump administration policies by issuing orders and other documents rolling back regulations and Executive Orders from the Trump administration, and as noted, indicating that it will pursue policies strengthening the ACA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, in its enactment of the Consolidated Appropriations Act, Congress enacted the No Surprises Act. This law, which took effect January 1, 2022, bars an out-of-network providers from billing patients in excess of the in-network cost sharing for services furnished with respect to a visit at certain in-network health care facilities. The law establishes an independent dispute resolution process between the provider and the payer to determine the appropriate payment rate to the provider. As written, the No Surprises Act may apply to laboratory tests furnished by an independent laboratory with respect to a hospital visit. The law establishes a notice and consent exception that generally does not apply to laboratory tests, although it allows HHS to apply this exception to certain advanced tests. Regulations and subregulatory guidance were issued by HHS, the Department of Labor, and the Department of the Treasury in 2021 and 2022, with the first set of regulations was issued as an Interim Final Rule on July 1, 2021, a second set issued as an Interim Final Rule on September 30, 2021, and a third set issued as a Final Rule on August 19, 2022. These regulations and subregulatory guidance have provided additional information on the applicability of the No Surprises Act, the rules governing the independent dispute resolution process, and specific provider requirements (including the obligation to furnish a &#x201c;good faith estimates&#x201d; of &#x201c;expected charges&#x201d; to uninsured or self-pay patients), as well as areas of temporary enforcement discretion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Environmental, Health and Safety Regulations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to various federal, state, local, and foreign environmental, health and safety laws and regulations and permitting and licensing requirements. Such laws include those governing laboratory practices, the generation, storage, use, manufacture, handling, transportation, treatment, remediation, release and disposal of, and exposure to, hazardous materials and wastes and worker health and safety. Our operations involve the generation, use, storage and disposal of hazardous materials, and the risk of injury, contamination or non-compliance with environmental, health and safety laws and regulations or permitting or licensing requirements cannot be eliminated. In particular, the introduction of our Bio-Rad SARS-CoV-2 ddPCR and Platelia SARS-CoV-2 Total Ab tests requires that we maintain compliance with applicable and evolving federal and state laws and regulations relating to COVID-19, including the generation, use, storage, and disposal of testing materials and agents. Compliance with environmental laws and regulations has not had a material effect on our capital expenditures, earning or competitive position. Most recently, the Boulder, Colorado clinical laboratory passed an on-site inspection from the CDC in June 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in Delaware in 2005 as Elston Technologies, Inc. Our principal executive offices are located at 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301, and our telephone number is (303) 417-0500. On June 20, 2006, we changed our name to Biodesix, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the Securities Act), for complying with new or revised accounting standards. In other words, an &#x201c;emerging growth company&#x201d; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.24 billion in annual revenue; (ii) the date we qualify as a &#x201c;large accelerated filer,&#x201d; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) the last day of the fiscal year ending after the fifth anniversary of the completion of our initial public offering (IPO).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we are a &#x201c;smaller reporting company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201d; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the end of that year&#x2019;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as of the end of that year&#x2019;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For certain risks related to our status as an emerging growth company, see &#x201c;Risk Factors&#x2014;General Risk Factors&#x2014;We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our culture is underpinned by our cultural beliefs including an unwavering commitment to inclusion and diversity. We are committed to fostering a diverse and inclusive workplace that attracts and retains exceptional talent offering opportunities for our team members to grow and develop in their careers, supported by a competitive suite of benefits and health and wellness programs. We regularly engage our team members in monthly all-hands meetings to align and focus on the current state of affairs of our business, our partnerships, new products, clinical trials, and other pertinent information about our business. We engage our team members in programs such as peer recognition and recruitment that focuses on recognizing outstanding individual contributions to company performance, cultural fit of new team members and acknowledging the diversity of our team to ensure our team members feel valued and can do their best work. We have a national annual community service initiative, &#x201c;Biodesix Gives Back&#x201d; that allows each team member to invest ten hours of paid community service to organizations of their choosing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had approximately 245 full-time and part-time employees, all of whom are located in the United States. Of our 245 full-time and part-time team members, the majority of our team member base is located in proximity to our corporate office and testing facilities located in Boulder, Colorado and our laboratory in De Soto, Kansas.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diversity, Equity and Inclusion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that a diverse employee population, including cultural background, gender, ethnicity, sexual orientation and lived experiences, is critical to our success. Our employees are encouraged to leverage their personal strengths and experiences to continually innovate and contribute to the development of new ideas and process improvements that drive better experiences for our partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Engagement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our company culture emphasizes the satisfaction and well-being of our team members and a diverse, engaged workforce. We solicit the opinion and views of our team members through surveys and peer focus groups. We have an established and valued Peer Recognition Culture. Teammates recognize other teammates publicly for their support and contributions fostering collaboration, engagement and retention. We regularly review feedback we receive on our current cultural beliefs to determine if any modifications are needed. During 2021, we updated our cultural beliefs to align with our core values that reflect our current focus on Teamwork, Innovation, Making an Impact and Excel. Additionally, the Company annually celebrates our top sales performers through our President&#x2019;s Club and other top company performers as nominated by fellow team members through our four (4) Performance Excellence Awards that recognize creativity and innovation, an entrepreneurial spirit, a strategic impact on the success of the Company and lastly, embodying the Biodesix cultural beliefs and goes &#x201c;above and beyond&#x201d; daily.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Training and Development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invest in our team members career growth and provide team members with a wide range of development opportunities, including face-to-face, virtual, and self-directed learning, mentoring, coaching, and external development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Health, Safety and Wellness</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The physical health, financial stability, life balance and mental health of each of our team members is vital to our success. We sponsor several cancer awareness activities in our local communities to bring engagement and awareness of health, safety and wellness to positively impact lives. We provide an Employee Assistance Program to enhance physical, financial, and mental well-being for all our team members. Since the onset of the COVID-19 pandemic, we have successfully transitioned a significant portion of our workforce to a remote working environment and implemented strict safety and social distancing measures in our sites to protect the health and safety of our team members. We also have provided extraordinary safety protocols and standards for all &#x201c;essential&#x201d; team members who work in our laboratories and our field sales organization including regularly scheduled serial testing for COVID-19. We also have an active &#x201c;Friends and Family&#x201d; COVID-19 testing program for our team members, their families and close friends.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pay Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The main objective of our compensation program is to provide a compensation package that will attract, retain, motivate, and reward superior team members who operate in a highly competitive and technologically challenging environment. We emphasize overall Company performance and provide equity incentives for all team members to align their financial interests with the interests of shareholders. In addition, we offer an employee stock purchase plan to all employees in which participants are eligible to purchase shares at a discount to market. We think like customers and act like owners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix seeks fairness in total compensation. We benchmark with external comparisons, internal comparisons and look at the relationship between team member roles within the organization. We also review our compensation practices, both in terms of our overall workforce and individual team members, to ensure our pay is fair and equitable. We currently have no pay disparities based on gender, race, or ethnicity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We file with, or furnish to, the SEC reports including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. These reports are available free of charge on our corporate website (</span><span><span style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">www.biodesix.com</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Copies of any materials we file with the SEC can be obtained at </span><span><span style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">www.sec.gov</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The information provided on our website (or any other website referred to in this report) is not part of this report and is not incorporated by reference as part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Risk</span><span id="item_1a_risk_factor"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a summary of the principal risks that could adversely affect our business, operations and financial results. This summary does not address all of the risk that we face and should be read in conjunction with the entire Risk Factors section below beginning at &#x201c;Risks Related to Our Business and Industry&#x201d; within this Item 1A. Risk Factors.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audited financial statements include a statement that there is a substantial doubt about our ability to continue as a going concern and a continuation of negative financial trends could result in our inability to continue as a going concern.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The commercial success of our current and future diagnostic tests and services depends upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may encounter difficulties in managing our growth, which could disrupt our operations.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success and revenue growth are highly dependent on the demand for, and increased adoption of, our diagnostic tests, including our COVID-19 testing program, which are subject to a number of risks and uncertainty.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We need to ensure strong product performance and reliability to maintain and grow our business.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply problems and price fluctuations.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Natural or man-made disasters, pandemics, outbreaks, or other similar events, including a sustained outbreak or future waves of the novel strain of coronavirus disease, COVID-19, could significantly disrupt our business, and negatively impact our business, financial condition and results of operations.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our industry is highly competitive and subject to rapid change, which could make our diagnostic tests and services obsolete. If we are unable to continue to innovate and expand and enhance our diagnostic tests and service offerings, we could lose customers or market share.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are disruptions in our information technology systems, including any security or data privacy breaches or other unauthorized or improper access.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, and results of operations and cash flows. All of the risks described below should be carefully considered together with the other information contained and incorporated by reference in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Business and Industry</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred losses since our inception and expect to continue to incur losses for the foreseeable future. We reported net losses of $65.4 million and $43.2 million the years ended December 31, 2022 and 2021, respectively. As a result of these losses, as of December 31, 2022, we had an accumulated deficit of approximately $367.4 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our sales and marketing, research and development, regulatory and other expenses will continue to increase as we expand our marketing efforts for our diagnostic tests and services, expand existing relationships with our customers, obtain regulatory clearances or approvals or certifications for future enhancements to our existing diagnostic tests and services and conduct further clinical trials. In addition, we expect our general and administrative expenses to increase due to the additional costs associated with scaling our business operations and testing capacity as well as being a public company, including due to legal, accounting, insurance, exchange listing and compliance, investor relations and other expenses. As a result, we expect to continue to incur operating losses and may never achieve profitability. We will need to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. If we do not achieve or sustain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The spread of COVID-19, particularly during 2020 and 2021, and the impact to our business has had, and may continue to have, a material and adverse effect on our ability to generate revenues, maintain compliance with our financial covenants and result in our inability to continue as a going concern. Any such impacts could have a material and adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financial statements as of and for the period ended December 31, 2022 were prepared on the assumption that we would continue as a going concern. These financial statements did not include any adjustments that might result from the outcome of this uncertainty. As of December 31, 2022, we maintained cash and cash equivalents of $43.1 million and we have $30.0 million in principal balance remaining on our Perceptive Term Loan (as defined below). We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in our follow-on underwritten public offering in November 2022, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in the Perceptive Term Loan Facility or to obtain waivers or amendments that impact the related covenants. However, due to the continued uncertainty caused by the COVID-19 pandemic and the associated impacts on the recovery of our diagnostic testing and services, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants. As a result of the items mentioned above, our management has determined that there is a substantial doubt about our ability to continue as a going concern over the next twelve months from the date these financial statements were issued. Although we have taken steps to improve our liquidity, including through entering into the Perceptive Term Loan Facility and terminating the 2021 Term Loan, and have taken measures to reduce planned capital expenditures and operating expenses, these actions alone may not be sufficient to mitigate our liquidity concerns in the wake of potential impacts to our revenues, operating results and cash flows from the continued uncertainty caused by the COVID-19 pandemic and adjustments to the post-pandemic environment. In addition, if we are not able to improve our operating results, we may need to limit our operations substantially. We will need to raise additional capital in the form of equity or debt to increase our liquidity but there is no assurance that we will be able to secure any such funding in a sufficient amount or on terms that are acceptable to us. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. Furthermore, the reaction of investors to the inclusion of a going concern statement in this report, and our potential inability to continue as a going concern, could materially adversely affect the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The commercial success of our current and future diagnostic tests and services and our revenue growth depends upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends, in part, on the acceptance of our diagnostic tests and services as being safe and relatively simple for medical personnel to learn and use, clinically flexible, operationally versatile and, with respect to providers and payers, cost effective.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict how quickly, if at all, payers, providers, clinics and patients will accept future diagnostic tests and services or, if accepted, how frequently they will be used. These constituents must believe that our diagnostic tests offer benefits over other available alternatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of market acceptance of our current and future diagnostic tests and services depends on a number of factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether there is adequate utilization of our tests by clinicians, biopharmaceutical companies and other target groups based on the potential and perceived advantages of our diagnostic tests over those of our competitors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience and ease of use of our diagnostic tests relative to those currently on the market;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of our sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to provide incremental data that show the clinical benefits and cost effectiveness, and operational benefits, of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the coverage and reimbursement acceptance of our products and services;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pricing pressure, including from group purchasing organizations (GPOs), seeking to obtain discounts on our diagnostic tests based on the collective bargaining power of the GPO members;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative publicity regarding our or our competitors&#x2019; diagnostic tests resulting from defects or errors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the accuracy of our tests relative to those of our competitors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product labeling or product insert requirements by the FDA or other regulatory authorities or conformity assessment bodies; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the labeling cleared or approved by the FDA or other regulatory authorities or conformity assessment bodies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, even if our diagnostic tests achieve widespread market acceptance, they may not maintain that market acceptance over time if competing diagnostic tests or technologies, which are more cost effective or are received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no assurance that our COVID-19 and antibody testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#x2019;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to the availability of vaccines, or otherwise, the need for a COVID-19 test could decrease significantly and this could have an adverse effect on our results of operation and profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may encounter difficulties in managing our growth, which could disrupt our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had approximately 245 full and part-time employees. Over the next several years, we expect to significantly increase the number of our employees and the scope of our operations, particularly in the areas of sales, marketing and reimbursement, product development, regulatory affairs and other functional areas, including finance, accounting, quality and legal. Additionally, we expect to expand our testing capacity as we commercialize additional diagnostic tests. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational quality and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to manage the expansion of our operations or recruit and train additional qualified personnel in an effective manner. Any inability to manage growth could delay the execution of our business plans or disrupt our operations and have a material and adverse effect on our prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have experienced multiple cycles of growth and anticipate further growth in our business operations. This future growth could create strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue to increase headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, and sales and marketing staff and improve and maintain our technology to properly manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to maintain the quality or expected turnaround times of our diagnostic tests and services, or satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a timely and efficient manner could materially adversely affect our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if we are required to reduce expenses substantially to sustain our operations, we may not have the human resources to maintain growth in our business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited experience marketing and selling our diagnostic tests. We currently rely on our direct sales force to sell our diagnostic tests in the United States, and any failure to maintain and grow our direct sales force will negatively affect our business, financial condition and results of operations. The members of our direct sales force are highly trained and possess substantial technical expertise, which we believe is critical in increasing adoption of our diagnostic tests. The members of our United States sales force are at-will employees. The loss of these personnel to competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise in replacement personnel, it may negatively affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to generate future growth, we plan to continue to expand and leverage our sales and marketing infrastructure. Identifying and recruiting qualified sales and marketing personnel and training them on how to promote our diagnostic tests, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing techniques or diagnostic tests that utilize independent third parties, which could place us at a competitive disadvantage. It will negatively affect our business, financial condition and results of operations if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our diagnostic tests. Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time, or timely reduce fixed costs, could negatively affect our business, financial condition and results of operations. Our ability to increase our customer base and achieve broader market acceptance of our diagnostic tests will depend to a significant extent on our ability to expand our marketing efforts. We plan to dedicate significant resources to our marketing programs. It will negatively affect our business, financial condition and results of operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our diagnostic tests in a cost-effective manner is critical to achieving broad acceptance of our diagnostic tests. Promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad use of our diagnostic tests, which in turn could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We collaborate with biopharmaceutical companies to analyze patient samples for multiple applications primarily to support clinical trials, including patient identification, companion or complementary diagnostics and retrospective testing. The revenue attributable to our biopharmaceutical customers may also fluctuate in the future, which could have a material adverse effect on our financial condition and results of operations. In addition, the termination of these relationships could result in a temporary or permanent loss of revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future success depends in part on our ability to maintain these relationships and to establish new relationships. Many factors have the potential to impact such collaborations, including the type of biomarker support required and our ability to deliver it and our biopharmaceutical customers&#x2019; satisfaction with our tests or services and other factors that may be beyond our control. Furthermore, our biopharmaceutical customers may decide to decrease or discontinue their use of our tests due to changes in research and product development plans, failures in their clinical trials, financial constraints, or utilization of internal testing resources or tests performed by other parties, or other circumstances outside of our control. In addition to reducing our revenue, the loss of one or more of these relationships may reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our biobank and proprietary AI platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We engage in conversations with biopharmaceutical companies regarding potential commercial opportunities on an ongoing basis. There is no assurance that any of these conversations will result in a commercial agreement, or if an agreement is reached, that the resulting relationship will be successful or that clinical or research studies conducted as part of the engagement will produce successful outcomes. Speculation in the industry about our existing or potential relationships with biopharmaceutical companies can also be a catalyst for adverse speculation about us, our tests and our technology, which can adversely affect our reputation and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our quarterly and annual revenue and operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our control and, as a result, may not fully reflect the underlying performance of our business. These fluctuations may occur due to a variety of factors, including, but not limited to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of demand for our diagnostic tests, which may vary significantly;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and cost of manufacturing our diagnostic tests, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenditures that we may incur to acquire, develop, or commercialize additional tests and technologies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated pricing pressures;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the rate at which we grow our sales force and the speed at which newly hired salespeople become effective, and the cost and level of investment therein;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">coverage and reimbursement policies with respect to lung cancer treatment equipment, and potential future diagnostic tests that compete with our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and success or failure of clinical trials for our diagnostic tests or any enhancements to such tests we develop or competing diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">positive or negative coverage, or public perception, of our diagnostic tests or those of our competitors or broader industry trends;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact, if any, of the spread of COVID-19 and any newly discovered variants, and the resulting effects on the number of patients treated or the demand for our non-COVID-19 tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and cost of, and level of investment in, research, development, licenses, regulatory approval, conformity certification, commercialization activities, acquisitions and other strategic transactions, or other significant events relating to our diagnostic tests, which may change from time to time;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and cost of obtaining regulatory approvals, conformity certifications or clearances for planned or future improvements or enhancements to our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulatory requirements or in the status of regulatory approvals or applications or conformity certifications;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pricing, discounts, and incentives for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general market conditions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we can provide no assurances that the demand for our COVID-19 and antibody testing program will be sustained, and even if it is, the period of time for which it would be sustained. As vaccines for COVID-19 become more available and widespread in the future, we have seen the demand for our COVID-19 diagnostic and antibody tests decrease. As a result, the increase in revenue, if any, due to any increase in demand for our COVID-19 and antibody testing program is not indicative of results expected for any future period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cumulative effects of these factors has resulted in large fluctuations and unpredictability in our quarterly and annual financial results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other period, and accordingly should not be relied upon as indicative of future performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any publicly stated guidance we may provide, and could in turn negatively impact our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We need to ensure strong product performance and reliability to maintain and grow our business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We need to maintain and continuously improve the performance and reliability of our diagnostic tests, including our Biodesix WorkSafe testing program, the Nodify XL2 and Nodify CDT tests, and the GeneStrat and VeriStrat tests, to achieve our profitability objectives. Poor product performance and reliability could lead to customer dissatisfaction, adversely affect our reputation and revenues, and increase our service and distribution costs and working capital requirements. Our diagnostic tests may contain errors or defects, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">while we have made efforts to test them extensively, we cannot assure that our current diagnostic tests, or those developed in the future, will not have performance problems. Performance issues with our diagnostic tests will increase our costs in the near-term and accordingly adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply problems and price fluctuations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party suppliers, including in some instances single source suppliers, to provide us with certain components of our diagnostic tests. The number of suppliers feeding into the production of our diagnostic tests is in excess of 65 worldwide. We consider a select few of these suppliers, located in the United States, Europe and China, as critical single source providers of components. Bio-Rad Laboratories, as described below, is the sole source supplier for our GeneStrat tests and COVID-19 diagnostic and antibody testing program. Oncimmune is also the sole source supplier for our Nodify CDT tests. While we have initiated the second source qualification process for the majority of these critical components, we may not be successful in securing second sourcing for all of them at all or on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may purchase supplies through purchase orders and may not have long-term supply agreements with, or guaranteed commitments from, many of our suppliers, including single source suppliers. Additionally, at present, we have a limited contract with a contract manufacturer for the production of certain of our diagnostic testing kits; however, during 2022 we transitioned the majority of kitting performed outside of the Company to our internal operations team for cost savings and risk management. Many of our suppliers and contract manufacturers are not obligated to perform services or supply diagnostic testing materials for any specific period, in any specific quantity or at any specific price, except as may be provided in a particular purchase order. We depend on our suppliers and contract manufacturers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements. These suppliers and contract manufacturers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet our demand. These suppliers and contract manufacturers may cease producing the components we purchase from them or otherwise decide to cease doing business with us. Further, we maintain limited volumes of inventory from most of our suppliers and contract manufacturers. If we inaccurately forecast demand for finished goods, we may be unable to meet customer demand which could harm our competitive position and reputation. In addition, if we fail to effectively manage our relationships with our suppliers and contract manufacturers, we may be required to change suppliers or contract manufacturers. While we believe replacement suppliers exist for all materials, components and services necessary to manufacture our diagnostic tests, establishing additional or replacement suppliers for any of these materials, components or services, if required, could be time-consuming and expensive, may result in interruptions in our operations and product delivery, may affect the performance of our diagnostic tests or could require that we modify their processes. Even if we are able to find replacement suppliers, we will be required to verify that the new supplier maintains facilities, procedures and operations that comply with our quality expectations and applicable regulatory requirements. Any of these events could require that we obtain a new regulatory authority approval before we implement the change, which we may not obtain on a timely basis or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our third-party suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement suppliers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the continued commercialization of our diagnostic tests, the supply of our diagnostic tests to customers and the development of any future diagnostic tests will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We entered into a nonexclusive license and supply agreement with Bio-Rad in August 2019. We rely on Bio-Rad to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test. Under the terms of this arrangement, we were granted non-exclusive rights to utilize the intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. We agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad. As further consideration for the non-exclusive license, we agreed to pay a royalty of two and one half percent (2.5%) on net service fees (such fees are defined in the Non-Exclusive License Agreement with Bio-Rad) collected from contracted third parties who receive ddPCR services from us. In addition, we have separately been granted permission by Bio-Rad to use the Bio-Rad SARS-CoV-2 ddPCR test and Platelia SARS-CoV-2 Total Ab test for commercial diagnostic services. On May 24, 2021, we entered into the First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc. which amended the original agreement such that, effective May 1, 2021, we are not required to pay a royalty of two and one half percent (2.5%) on net service fees. For more information regarding this license and supply agreement and the permission granted to us by Bio-Rad with respect to such tests, please see &#x201c;Business&#x2014;Material Agreements&#x2014;Agreements with Bio-Rad&#x201d; previously filed with our Form S-1 on October 23, 2020 and &#x201c;First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021&#x201d; previously filed with our Form 10-Q on August 10, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This relationship may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in entering into new strategic partnership agreements with Bio-Rad, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to sufficiently reduce costs in the performance, manufacturing and production of our diagnostic tests to achieve sustainable gross margins.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We partner with contract manufacturers in the development and production of supplies for our diagnostic tests. While we are undertaking a number of initiatives designed to reduce the cost of performing our diagnostic tests, including reducing the costs of supplies, there is no guarantee that we will be able to achieve planned cost reductions from our various cost savings initiatives. There may also be unforeseen occurrences that increase our costs, such as increased prices of the components of our diagnostic tests, changes to labor costs or less favorable terms with third-party suppliers or contract manufacturing partners. If we are unable to reduce our costs, or if cost reductions are less significant or less timely than projected, we will not be able to achieve sustainable gross margins, which would adversely affect our ability to invest in and grow our business and adversely impact our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, including the outbreak of the novel strain of coronavirus disease, COVID-19, and its variants could adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected. For much of 2020 and 2021, COVID-19 spread throughout the United States and to most countries globally, creating significant uncertainty and economic disruption. Numerous U.S. state and local jurisdictions chose to impose &#x201c;shelter-in-place&#x201d; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. In March 2020, the Governor of Colorado, where our headquarters are located, issued &#x201c;stay at home&#x201d; orders limiting non-essential activities, travel and business operations. Disruptions or potential disruptions due to the orders and restrictions have included, and in the future may continue to include, the inability of our suppliers to manufacture components and parts and to deliver these to us on a timely basis, or at all; disruptions in our production schedule and ability to assemble diagnostic tests; inventory shortages or obsolescence; delays in actions of regulatory bodies; diversion of or limitations on employee resources that would otherwise be focused on the operations of our business; delays in growing or reductions in our sales organization, including through delays in hiring, lay-offs, furloughs or other losses of sales representatives; business adjustments or disruptions of certain third parties, including suppliers, medical institutions and clinical investigators with whom we conduct business; and additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers&#x2019; capacity to manufacture our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic also has negatively affected our non-COVID-19 testing-related revenue and our clinical studies. For example, cancer patients have had more limited access to hospitals, healthcare providers and medical resources as they took steps to control the spread of COVID-19. Our biopharmaceutical customers have faced, and are continuing to face, challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. Further, our clinical studies, such as our ongoing INSIGHT study and our recently launched ALTITUDE study, as well as our arrangements with our biopharmaceutical customers, are expected to take longer to complete than what we expected before the outbreak of the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic created an opportunity for our diagnostic tests and we have commercialized three diagnostic tests to test for the presence of COVID-19 and antibodies. However, there is no assurance that our COVID-19 diagnostic and antibody testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or be accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to the availability of vaccines, or otherwise, the need for a COVID-19 test could decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue, if any, due to any increase in demand for these diagnostic tests may not be indicative of our future revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the resurgence of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Furthermore, there is no assurance that our diagnostic tests will continue to be effective against the virus in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the potential economic impact brought by, and the duration of, any pandemic, epidemic or outbreak of an infectious disease, including COVID-19, may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets and a reduction in our ability to access capital, which could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread of an infectious disease, including COVID-19, could materially affect our business. Such economic recession could have a material adverse effect on our long-term business. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#x201c;Risk Factors&#x201d; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Natural or man-made disasters and other similar events may significantly disrupt our business, and negatively impact our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A significant portion of our employee base, operating facilities and infrastructure are centralized in Boulder, Colorado and we operate a laboratory facility in De Soto, Kansas. Any of our facilities may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, wildfires, floods, nuclear disasters, riots, acts of terrorism or other criminal activities, infectious disease outbreaks or pandemic events power outages and other infrastructure failures, which may render it difficult or impossible for us to operate our business for some period of time. Our facilities would likely be costly to repair or replace, and any such efforts would likely require substantial time. Any disruptions in our operations could adversely affect our business, financial condition and results of operations and harm our reputation. Moreover, although we have disaster recovery plans, they may prove inadequate. We may not carry sufficient business insurance to compensate for losses that may occur. Any such losses or damages could have a material adverse effect on our business, financial condition and results of operations. In addition, the facilities of our suppliers and manufacturers may be harmed or rendered inoperable by such natural or man-made disasters, which may cause disruptions, difficulties or otherwise materially and adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In implementing and using our diagnostic tests and services, providers depend on our support to resolve issues in a timely manner. We may be unable to respond quickly enough to accommodate short-term increases in demand for customer support. Increased customer demand for support could increase costs and adversely affect our business, financial condition and results of operations. Our sales are highly dependent on our reputation and on positive recommendations from our existing patients, care partners, providers and clinics. Any failure to maintain high-quality customer support, or a market perception that we do not maintain high-quality customer support, could adversely affect our reputation, our ability to sell our diagnostic tests and services, and in turn our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The sizes of the markets for our diagnostic tests and services and any future diagnostic tests and services may be smaller than we estimate and may decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our estimates of the annual total addressable market for our diagnostic tests and services are based on a number of internal and third-party estimates and assumptions, including, without limitation, the assumed prices at which we can sell our diagnostic tests and services in the market. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result, our estimates of the annual total addressable market for our diagnostic tests and services in different market segments may prove to be incorrect. If the actual number of patients who would benefit from our diagnostic tests, the price at which we can sell them or the annual total addressable market for them is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer, obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services we offer, we could lose customers or market share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current diagnostic tests and others we are developing obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our offerings and develop new and improved diagnostic tests to keep pace with evolving standards of care. If we do not leverage or scale our sample and data biobank to discover new diagnostic tests or applications or update our diagnostic tests to reflect new scientific knowledge, including about lung cancer biology, information about new cancer therapies or relevant clinical trials, our diagnostic tests could become obsolete and sales of our current diagnostic tests and any new tests we develop could decline or fail to grow as expected. This failure to make continuous improvements to our diagnostic tests to keep ahead of those of our competitors could result in the loss of customers or market share that would adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are any security or data privacy breaches or other unauthorized or improper access.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with various facets of our business, we collect and use a variety of personal data, such as names, mailing addresses, email addresses, mobile phone numbers, location information, prescription information and other medical information. Any failure to prevent or mitigate security breaches or improper access to, use, disclosure or other misappropriation of our data or consumers&#x2019; personal data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">could result in significant liability under state, (e.g., state breach notification and privacy laws such as the CCPA) federal (e.g., HIPAA), and the HITECH Act and laws in other jurisdictions (e.g., the GDPR). Such an incident may also cause a material loss of revenue from the potential adverse impact to our reputation and brand, affect our ability to retain or attract new users of our diagnostic tests and services and potentially disrupt our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unauthorized disclosure of sensitive or confidential patient or employee data, including personally identifiable information, whether through a breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates would likely result in delays in our marketing approval efforts and significantly increased costs in an effort to recover or reproduce the data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we become more dependent on information technologies to conduct our operations, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, may increase in frequency and sophistication. These threats pose a risk to the security of our systems and networks, the confidentiality and the availability and integrity of our data and these risks apply both to us, and to third parties on whose systems we rely for the conduct of our business. Because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and often are not recognized until launched against a target, we and our partners may be unable to anticipate these techniques or to implement adequate preventative measures. We have in the past experienced, and may in the future, experience security incidents. While no security incidents in the past have had a material adverse effect on our business, financial condition and results of operations, we cannot predict the impact of any such future events. Further, we do not have any control over the operations of the facilities or technology of our cloud and service providers, including any third-party vendors that collect, process and store personal data on our behalf. Our systems, servers and platforms and those of our service providers may be vulnerable to computer viruses or physical or electronic break-ins that our or their security measures may not detect. Individuals able to circumvent such security measures may misappropriate our confidential or proprietary information, disrupt our operations, damage our computers or otherwise impair our reputation and business. We may need to expend significant resources and make significant capital investments to protect against security breaches or to mitigate the impact of any such breaches. In addition, to the extent that our cloud and other service providers, experience security breaches that result in the unauthorized or improper use of confidential data, employee data or personal data, we may not be indemnified for any losses resulting from such breaches. There can be no assurance that we or our third-party providers will be successful in preventing cyber-attacks or successfully mitigating their effects. Recent cyber-attacks purportedly originated by Russian controlled entities have exacerbated in the wake of Russia&#x2019;s invasion of Ukraine and our systems may be infiltrated by foreign actors. If we are unable to prevent or mitigate the impact of such security breaches, our ability to attract and retain new customers, patients and other partners could be harmed as they may be reluctant to entrust their data to us, and we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business or other adverse consequences.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have significant payer concentration, with a limited number of customers accounting for a substantial portion of our revenues.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For year ended December 31, 2022, Medicare reimbursed 37% of our diagnostic test revenue to us and one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">customer accounted for 10% of our total revenue. For the year ended December 31, 2021, Medicare reimbursed 18% of our diagnostic test revenue to us and one customer accounted for 40% of our total revenue. There are risks whenever a large percentage of total revenues are concentrated with a limited number of payers and customers. It is not possible for us to predict the level of demand for our diagnostic tests and services that will be generated by any of these customers in the future. In addition, revenues from these larger customers may fluctuate from time to time based on these customers&#x2019; business needs, the timing of which may be affected by market conditions or other factors outside of our control. These payers and customers could also potentially pressure us to reduce the prices we charge for our diagnostic tests and services, which could have an adverse effect on our margins and financial position and could negatively affect our revenues and results of operations. If any of our largest payers terminates its relationship with us or our tests are no longer reimbursable by such payer, such termination could negatively affect our revenues and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our diagnostic tests and manage our inventory.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To ensure adequate inventory supply, we must forecast inventory needs and manufacture our diagnostic tests based on our estimates of future demand for our diagnostic tests. Our ability to accurately forecast demand for them could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our diagnostic tests or for those of our competitors, our failure to accurately forecast customer acceptance of new diagnostic tests, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for our diagnostic tests, our supply chain, manufacturing partners and/or internal manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">team may not be able to deliver components and diagnostic tests to meet our requirements, and this could result in damage to our reputation, sales growth and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, which will adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we experience significant disruptions in our information technology systems, our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We depend on our information technology systems for the efficient functioning of our business, including the performance, distribution and maintenance of our diagnostic tests and services, as well as for accounting, data storage, compliance, purchasing and inventory management. We do not have redundant information technology in all aspects of our systems at this time. Our information technology systems may be subject to computer viruses, ransomware or other malware, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, damage or interruption from fires or other natural disasters, hardware failures, telecommunication failures and user errors, among other malfunctions. We could be subject to an unintentional event that involves a third party gaining unauthorized access to our systems, which could disrupt our operations, corrupt our data or result in release of our confidential information. Technological interruptions would disrupt our operations, including our ability to timely ship and track diagnostic test orders and results, project inventory requirements, manage our supply chain and otherwise adequately service our customers or disrupt our customers&#x2019; ability to use our diagnostic tests. In the event we experience significant disruptions, we may be unable to repair our systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, we carry business interruption coverage to mitigate certain potential losses but this insurance is limited in amount, and we cannot be certain that such potential losses will not exceed our policy limits. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, financial condition and results of operations. We are increasingly dependent on complex information technology to manage our infrastructure. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance our existing systems. Failure to maintain or protect our information systems and data integrity effectively could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our diagnostic tests and services. The expense and potential unavailability of insurance coverage for liabilities resulting from issues with our diagnostic tests and services could harm us and negatively impact sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability as a result of the marketing and sale of our diagnostic tests and services. For example, we may be sued if our diagnostic tests or services cause or are perceived to cause injury or are found to be otherwise unsuitable during manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health of the patient. For example, medical personnel, care partners and patients collect samples for our diagnostic tests. If these medical personnel, care partners or patients are not properly trained, are negligent or use our diagnostic tests incorrectly, the capabilities of such tests may be diminished or the patient may suffer critical injury. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub-assemblies for our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt the marketing and sale of our diagnostic tests and services. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for our diagnostic tests and services;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">harm to our reputation;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals, or labeling, marketing, or promotional restrictions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse impact on the market price of our common stock; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exhaustion of any available insurance and our capital resources.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of our diagnostic tests and services. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face competition from many sources, including larger companies, and we may be unable to compete successfully.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are a number of lung cancer diagnostic solutions companies in the United States, Europe and Asia. Notable competitors in the United States include Veracyte, Inc., Guardant Health, Inc., and Foundation Medicine, Inc. These competitors all provide cancer-focused diagnostic tests to hospitals, researchers, clinicians, laboratories and other medical facilities. Many of these organizations are significantly larger with greater financial and personnel resources than us, and enjoy significantly greater market share and have greater resources than we do. As a consequence, they may be able to spend more on product development, marketing, sales and other product initiatives than we can. Some of our competitors have:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantially greater name recognition;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">broader, deeper, or longer-term relations with healthcare professionals, customers, and third-party payers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">more established distribution networks;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional lines of diagnostic tests and the ability to offer rebates or bundle them to offer greater discounts or other incentives to gain a competitive advantage;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval or certification for diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater financial and human resources for product development, sales and marketing and patent litigation.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our continued success depends on our ability to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">further penetrate the lung disease diagnostic solutions market and increase utilization of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain and widen our technology lead over competitors by continuing to innovate and deliver new product enhancements on a continuous basis; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-effectively manufacture our diagnostic tests and their component parts as well as drive down the cost of service.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or diagnostic tests that could effectively compete with our existing diagnostic tests, which may cause our revenue to decline and would harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, as well as in acquiring technologies complementary to, or necessary for, development of our diagnostic tests. Because of the complex and technical nature of diagnostic testing and the dynamic market in which we compete, any failure to attract and retain a sufficient number of qualified employees could materially harm our ability to develop and commercialize our diagnostic tests, which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we attain greater commercial success, our competitors are likely to develop diagnostic tests that offer features and functionality similar to our diagnostic tests that are currently on the market. Improvements in existing competitive diagnostic tests or the introduction of new competitive diagnostic tests may make it more difficult for us to compete for sales, particularly if those competitive diagnostic tests demonstrate better reliability, convenience or effectiveness or are offered at lower prices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Performance issues, service interruptions or price increases by our shipping carriers and warehousing providers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expedited, reliable shipping and delivery services and secure warehousing are essential to our operations. We rely heavily on providers of transport services for reliable and secure point-to-point transport of our diagnostic tests to our customers and for tracking of these shipments, and from time to time require warehousing for our diagnostic tests, sample collection kits and supplies. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any systems, it would be costly to replace such systems in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a timely manner and such occurrences may damage our reputation and lead to decreased demand for our diagnostic tests and increased cost and expense to our business. In addition, any significant increase in shipping or warehousing rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters, civil unrest and disturbances or other service interruptions affecting delivery or warehousing services we use would adversely affect our ability to process orders for our diagnostic tests on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed. Our business depends on our ability to quickly and reliably deliver test results to our customers. Blood samples are typically received within days from the United States and outside the United States for analysis at our Boulder, Colorado and De Soto, Kansas facilities. Disruptions in delivery service, whether due to labor disruptions, bad weather, natural disaster, civil unrest or disturbances, terrorist acts or threats or for other reasons could adversely affect specimen integrity and our ability to process samples in a timely manner and to service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cost-containment efforts of our customers, purchasing groups and governmental purchasing organizations could have a material adverse effect on our sales and profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In an effort to reduce costs, many hospitals in the United States have become members of GPOs and Integrated Delivery Networks (IDNs). GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors on behalf of their members, which may include hospitals and other providers. GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our diagnostic tests, thereby reducing our revenue and margins.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#x2019; notice. Accordingly, the members of such groups may choose to purchase alternative diagnostic tests due to the price or quality offered by other companies, which could result in a decline in our revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pricing and reimbursement of medical devices is not harmonized at European level, but is the exclusive competence of the EU Member States. In Europe, pricing and reimbursement decisions are generally made by regional or centralized bodies based on an assessment of the efficacy and clinical effectiveness of the devices or broad device types or procedures. There is a general trend for EU Member States to adopt cost containment measures to control public spend on medical devices. Due to the competitive nature of product offers and prices, we may not be able to obtain new, or maintain existing, contract positions with the EU Member States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Litigation and other legal proceedings may adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#x2019; confidence and reduce long-term demand for our diagnostic tests and services, even if the regulatory or legal action is unfounded or not material to our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General economic and financial market conditions may exacerbate our business risks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global macroeconomic conditions and the world&#x2019;s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. As a result of uncertainties with respect to financial institutions and the global credit markets and other macroeconomic challenges such as inflationary pressures currently or potentially affecting the economy of the United States and other parts of the world, customers and distributors may experience serious cash flow problems and other financial difficulties,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreasing demand for our products. Our customers and distributors may respond to such economic pressures by reducing or deferring their capital spending or reducing staff.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, events in the United States or foreign markets, such as the United Kingdom&#x2019;s exit from the European Union, the worldwide effects from the spread of COVID-19, Russia's invasion of Ukraine and political and social unrest in various countries around the world, can impact the global economy and capital markets. Additionally, if our customers and distributors are not successful in generating sufficient revenue or are precluded from securing financing, their businesses will suffer, which may materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not realize the benefits or costs of our Co-Development and Collaboration Agreement with AVEO Oncology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2014, we entered into a Co-Development and Collaboration Agreement with AVEO Oncology (formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) whereby the two parties agreed to various terms and conditions necessary for the co-development of AVEO&#x2019;s compound ficlatuzumab (the Collaboration Agreement).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were granted a limited legal interest in ficlatuzumab and may not have the right to control the development and exploitation of ficlatuzumab. As consideration for the grant, we agreed to cover the first $15.0 million of ficlatuzumab&#x2019;s clinical development costs, with both parties then sharing all costs equally after the cap was reached.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October of 2016, the Collaboration Agreement was amended to eliminate the requirement that we cover all of the initial costs. Under the amended terms, we agreed to allow AVEO to recapture its cost that it otherwise would not have been responsible for said recapture to occur out of any royalties or revenues eventually derived from the Collaboration Agreement. As part of the Collaboration Agreement, unless we or AVEO exercise our right to opt-out of co-development, we equally share in any income received from licensing rights to ficlatuzumab to any third parties. In September 2020, we exercised our opt-out right for the payment of half of the development and regulatory costs for ficlatuzumab. This opt-out was effective as of December 2, 2020 with remaining obligations estimated to be $0.1 million. Following the effective date, we will be entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab. Ficlatuzumab is currently being evaluated in squamous cell carcinoma of the head and neck (SCCHN), metastatic pancreatic ductal cancer (PDAC), and acute myeloid leukemia (AML).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our relationship with AVEO may require us to incur non-recurring and other charges, increase our near and long-term expenditures, or disrupt our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering into new strategic partnership agreements with AVEO, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are exposed to significant future payments and other obligations associated with our acquisitions of Integrated Diagnostics and Oncimmune, U.S.A., and may not realize the advantages we expect from these acquisitions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2018, we purchased select assets and liabilities from Integrated Diagnostics, Inc. and IND Funding, LLC (collectively, the Seller or Indi) which included the CLIA lab in Seattle, Washington, and all rights to the Nodify XL2 test and intellectual property rights related to that test. The purchase was made for total consideration of $27.6 million, consisting of $8.0 million (10,649,604 shares) of our Series G Preferred Stock and contingent consideration with an initial fair market value of $19.6 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The acquisition of Indi included a contingent consideration arrangement that requires additional consideration to be paid by us to the Seller based on the milestone of the attainment of a three consecutive month gross margin target of $2 million within a seven-year period. Under the terms of the original agreement, when the gross margin target was achieved, the Company was required to issue 2,520,108 shares of common stock. For the six months following the achievement of the milestone, Indi had the option to require the Company to redeem the common shares for $37.0 million in cash over eight equal installments. If Indi elected not to exercise this option, we had 12 months to repurchase the common stock in two equal quarterly cash installments totaling $37 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2021, the Company entered into an amendment to the original agreement in which all parties agreed to forgo the issuance of common stock and agreed that the Company would instead make six quarterly installments of approximately $4.6 million each, which began in January 2022, and final payment of approximately $9.3 million in July 2023 for a total of $37.0 million (together, the Milestone Payments). The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which the parties agreed to restructure the Milestone Payments whereby the Company will make five quarterly installments of $2.0 million each beginning in April 2022, three quarterly installments of $3.0 million beginning in July 2023, one installment of $5.0 million in April 2024, and one installment of approximately $8.4 million in July 2024. In addition, the Company agreed to an exit fee of approximately $6.1 million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to 10%, with such interest to be payable quarterly on the following installment payment date. Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan and commencing January 1, 2024, consent from Perceptive.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, on October 31, 2019 we completed an acquisition of United Kingdom-based Oncimmune, Ltd.&#x2019;s (Oncimmune) United States operations including its CLIA lab in De Soto, Kansas and its incidental pulmonary nodule (IPN) malignancy test, then marketed in the United States as the EarlyCDT&#174;-Lung. We renamed the test and relaunched the test on February 28, 2020 as the Nodify CDT test and the De Soto, Kansas lab is the sole United States provider of the Nodify CDT test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the acquisition, we and Oncimmune entered into several agreements to govern the relationship between the parties and to allow us to provide the Nodify CDT test. The overarching umbrella Purchase and Commercialization Agreement (PCA) defines the general relationship between the parties. Included under the PCA was (a) an APA whereby we acquired all of the United States assets associated with the De Soto, Kansas clinical laboratory, as well as the trademarks and patent application associated with the test; (b) an intellectual property license granting us the rights necessary under Oncimmune&#x2019;s background intellectual property rights to perform the Nodify CDT test; (c) a supply agreement for supplying us with the necessary materials and reagents needed to run the Nodify CDT test; and (d) a development agreement where Oncimmune agrees to assist us in further developing the Nodify CDT test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We agreed to a revenue share payment of 8% of recognized revenue for non-screening tests up to an annual minimum volume and 5% thereafter, with an escalating minimum through the first four years of sales. Royalty expenses were $0.9 million and $0.7 million for the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our acquisitions may require us to incur non-recurring and other charges, increase our near and long-term expenditures, or disrupt our management and business. We cannot be certain that, following the realization of these acquisitions, we will achieve the revenue or specific net income that justifies our entry into them. This could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our senior management and other key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, scientists, clinical specialists, and other highly skilled personnel and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists could result in delays in product development and harm our business. If we are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our headquarters in Boulder, Colorado and our laboratory facility in De Soto, Kansas. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting, or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued and may continue to issue equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain &#x201c;key man&#x201d; insurance policies on the lives of these individuals or the lives of any of our other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity and teamwork fostered by our culture and our business may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our culture has been and will continue to be a critical contributor to our success. We expect to continue to hire aggressively as we expand, and we believe our corporate culture has been crucial in our success and our ability to attract highly skilled personnel. If we do not continue to develop our corporate culture or maintain and preserve our core values as we grow and evolve, we may be unable to foster the innovation, curiosity, creativity, focus on execution, teamwork and the facilitation of critical knowledge transfer and knowledge sharing we believe we need to support our growth. Moreover, liquidity available to our employee securityholders could lead to disparities of wealth among our employees, which could adversely impact relations among employees and our culture in general. Our anticipated headcount growth may result in a change to our corporate culture, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and research and development credit may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) a corporation that undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership by certain shareholders over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and its research and development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">credit carryforwards to offset future taxable income. The applicable rules generally operate by focusing on changes in ownership among stockholders considered by the rules as owning, directly or indirectly, 5% or more of the stock of a company, as well as changes in ownership arising from new issuances of stock by the company. We believe that our NOLs are currently not subject to limitation under these rules. However, if we undergo an ownership change now or in the future, our ability to utilize NOLs and research and development credit carryforwards could be limited by Sections 382 and 383 of the Code. Future changes in stock ownership may be beyond our control. In addition, our ability to deduct net interest expense may be limited if we have insufficient taxable income for the year during which the interest is incurred, and any carryovers of such disallowed interest would be subject to the limitation rules similar to those applicable to NOLs and other attributes. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs, research and development credit carryforwards or disallowed interest expense carryovers, even if we attain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The terms of the Perceptive Term Loan Facility require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 16, 2022 (Closing Date), we entered into a credit agreement and guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as the lender and administrative agent (the Lender) that provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $50.0 million (the Perceptive Term Loan Facility) to refinance long-term debt. The initial funding of the Perceptive Term Loan Facility was subject to a capital raise of at least $30.0 million in gross proceeds from an equity offering of our common stock, and provides for an &#x201c;interest-only&#x201d; period during the term of the loan with principal due at the maturity date, which will be November 21, 2027.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Perceptive Term Loan Facility may be prepaid at any time, subject to a prepayment premium equal to 2% to 10% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment. The Perceptive Term Loan Facility contains customary affirmative and negative covenants for a loan, requires us to comply with a minimum cash requirement covenant, and has a trailing twelve month net revenue requirement. Failure to comply with the covenants and loan requirements may result in an event of default.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Perceptive Term Loan Facility contains certain covenants limiting our ability to, among other things, engage in certain corporate changes, make certain restricted payments, repay other certain indebtedness or enter into, amend or terminate any other agreements that have the impact of restricting the our ability to make loan repayments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Credit Agreement also contains certain customary events of default, the occurrence of which could result in the declaration that all outstanding principal and interest under the Perceptive Term Loan Facility is immediately due and payable in whole or in part, which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests or expand our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need to raise additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increase our sales and marketing efforts to drive market adoption of and address competitive developments;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fund development and marketing efforts of our diagnostic tests or any other future diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expand our technologies into other types of cancer management and lung disease detection diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire, license, or invest in technologies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire or invest in complementary businesses or assets; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">finance capital expenditures and general and administrative expenses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our present and future funding requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to achieve revenue growth;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our rate of progress in establishing payer coverage and reimbursement arrangements with domestic and international commercial third-party payers and government payers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of and reimbursement for our diagnostic tests;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our rate of progress in, and cost of research and development activities associated with, diagnostic tests in research and early development;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to international expansion; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential cost of and delays in product development as a result of any regulatory oversight applicable to our diagnostic tests.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, our stockholders could experience dilution. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or diagnostic tests, pay a portion of our royalties, or grant licenses on terms that are not favorable to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Governmental Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The insurance coverage and reimbursement status of newly approved diagnostic tests, particularly in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future diagnostic tests could limit our ability, and that of our collaborators, to fully commercialize our diagnostic tests and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford the clinical diagnostic tests and cellular therapeutics that we and our collaborators currently or in the future plan to develop and sell. In addition, because our clinical diagnostics and diagnostic tests represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our diagnostic tests, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of our diagnostic tests will depend substantially, both domestically and internationally, on the extent to which the costs of our diagnostic tests are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payers. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize some of our diagnostic tests or services. Even if coverage is provided, the available reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment in any of our diagnostic tests or services. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly launched, cleared, authorized or approved diagnostic tests. In the United States, many significant decisions about reimbursement for new diagnostics and medicines are typically made by the CMS, an agency within the HHS. CMS decides whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare, although it frequently delegates this authority to local Medicare Administrative Contractors (MACs). Private payers tend to follow Medicare to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel diagnostic tests such as ours. Additionally, reimbursement authorities or bodies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement, or have been approved under restricted conditions, in certain European countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside the United States, the reimbursement process and timelines vary significantly. In Europe, pricing and reimbursement of medical devices is the exclusive competence of the European Union (EU) Member States. However, the European Commission is facilitating a voluntary corporation between the EU Member States on health technology assessments (HTA) which consists of a network of the EU Member States&#x2019; national authorities and bodies responsible for HTA and a joint action to support cooperation at scientific and technical level between the HTA bodies. We cannot be sure that such prices and reimbursement decisions will be acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products in those countries would be negatively affected. An increasing number of countries are taking initiatives to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a lesser extent, medical devices, provided under their state-run healthcare systems. These price control efforts have impacted all regions of the world, but have been most prominent in the EU. Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of that product or service in that particular country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payers, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized, certified or approved devices and medicines and, as a result, they may not cover or provide adequate payment for our clinical diagnostics to be sold by us or our collaborators. For example, in May 2018 the United States government released a &#x201c;blueprint,&#x201d; or plan, to reduce the cost of drugs. This blueprint contains certain measures that HHS has been working to implement, although it is possible that HHS&#x2019;s regulatory priorities may change under the Biden administration. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to experience pricing pressures on our clinical diagnostics sold by us and our collaborators due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Measures to reduce healthcare costs may hurt our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The majority of our customers are healthcare providers who depend upon reimbursement by government and commercial insurance payers for lung cancer diagnostic solutions services. With a majority of United States patients with lung cancer covered by Medicare, the Medicare reimbursement rate is an important factor in a customer&#x2019;s decision to use our diagnostic tests and limits the prices we may charge for them. Commercial insurance payers may also exert downward pressure on payment rates for lung cancer treatment services. A reduction in reimbursement rates for lung cancer treatments may adversely affect our customers&#x2019; businesses and cause them to enact cost reduction measures that may include reducing the scope of their programs, thereby potentially reducing demand for our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare reform measures could hinder or prevent the commercial success of our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that may harm our future revenues and profitability and the demand for our diagnostic tests. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our diagnostic tests. The effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our diagnostic tests. For example, the ACA, contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been judicial challenges to certain aspects of the ACA, as well as efforts by the Trump administration and Congress to repeal, replace or alter the implementation of certain aspects of the ACA. For example, as part of the TCJA, Congress eliminated the tax penalty, starting January 1, 2019, for not complying with the ACA&#x2019;s individual mandate to carry health insurance. The Further Consolidated Appropriations Act of 2020, Pub. L. No. 116-94, signed into law December 20, 2019, fully repealed the ACA&#x2019;s &#x201c;Cadillac Tax&#x201d; on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share (repeal effective in 2021), and the medical device excise tax on non-exempt medical devices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken, with the exception of a temporary suspension of the 2% cut in Medicare payments from May 1, 2020 through March 31, 2022, and a reduction of the cut to 1% from April 1, 2022 through June 30, 2022. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biden administration and Congress may continue to pursue significant changes to the current healthcare laws, and the Biden administration has indicated its intent to strengthen the ACA and focus on reducing the cost of healthcare. We face uncertainties that might result from modifications or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. Any changes to the ACA are likely to have an impact on our results of operations, and may negatively affect our business, financial condition and results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may harm:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to set a price that we believe is fair for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. Future changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Future changes in healthcare policy could also decrease our revenue and impact sales of and reimbursement for our current and future diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We must comply with anti-corruption, anti-bribery, anti-money laundering and similar laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the FCPA, which generally prohibits companies in the United States from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and internal controls. We are also subject to requirements under the United States Treasury Department&#x2019;s Office of Foreign Assets Control, United States domestic bribery laws and other anti-corruption, anti-bribery and anti-money laundering laws. While we have policies and procedures in place designed to promote compliance with such laws, our employees or other agents may nonetheless engage in prohibited conduct under these laws for which we or our executives might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, international customers may currently order our diagnostic tests, either directly from us or through a potential joint venture, and we are subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-United States government officials for the purpose of obtaining or retaining business or securing any other improper advantage. Our reliance on independent distributors to sell our diagnostic tests internationally demands a high degree of vigilance in maintaining our policy against participation in corrupt activity, because these distributors could be deemed to be our agents and we could be held responsible for their actions. Other United States companies in the medical device and biopharmaceutical field have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with these individuals. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including laws promulgated by OECD countries in which we operate, such as Israel. These laws are complex and far-reaching in nature, and, as a result, we cannot assure you that we would not be required in the future to alter one or more of our practices to be in compliance with these laws or any changes in these laws or the interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees and could result in a material adverse effect on our business, prospects, financial condition and results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We must comply with healthcare fraud and abuse laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Various federal and state laws, as well as the laws of foreign countries, prohibit payments to induce the referral, purchase, order or use of healthcare products or services and require medical device companies to limit prevent, and/or monitor, and report certain payments to third-party payers, health care professionals, and other individuals. These healthcare fraud and abuse, anti-kickback, public reporting and aggregate spend laws affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with lung cancer treatment providers, hospitals, physicians or other potential purchasers or users, including patients, of medical devices and services. They also impose additional administrative and compliance burdens on us. In particular, these laws influence, among other things, how we structure our sales offerings, including discount practices, customer support, education and training programs and physician consulting and other service arrangements. These laws prohibit certain marketing initiatives that are commonplace in other industries. If we were to offer or pay inappropriate inducements for the purchase, order or use of our diagnostic tests or our services, or our arrangements are perceived as inappropriate inducements, we could be subject to claims under various healthcare fraud and abuse laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions under applicable United States federal and state healthcare laws and regulations include the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, a criminal law, prohibits, among other things, persons and entities from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, leasing, ordering, or arranging for, referring, or recommending the purchase, lease, order of any good or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Eliminating Kickbacks in Recovery Act, which prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Beneficiary Inducement Statute, which prohibits any person, organization, or entity from giving anything of value to a federal health care program beneficiary that is likely to induce or influence the beneficiary&#x2019;s choice of provider, practitioner, or supplier for covered services;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal civil False Claims Act, which may be enforced through civil whistleblower or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">qui tam </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actions and is often used to enforce the federal Anti-Kickback Statute and other healthcare laws and regulations, imposes civil penalties and potential exclusion from federal healthcare programs, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or for making a false record or statement material to an obligation to pay the federal government or for knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal criminal statutes created by HIPAA impose criminal liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private insurance plans, or, in any matter involving a healthcare benefit program, for knowingly and willfully making materially false, fictitious, or fraudulent statements in connection with the delivery of or payment for health care benefits; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other federal and state laws, as well as the laws of foreign countries, generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payments to government or commercial payers that are false or fraudulent, or for items or services that were not provided as claimed. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates and medical devices from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Moreover, any investigation into our practices could cause adverse publicity and require a costly and time-consuming response. If any physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers can also be held liable under these laws if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers, by providing improper financial inducements, or through certain other activities. We attempt to ensure that any billing and coding information we provide for our diagnostic tests emphasizes the need for physicians and other providers to make independent judgments, use accurate and appropriate billing and coding that complies with all applicable payer policies, and document the medical need for their patients as appropriate. Nevertheless, the government may not regard any billing errors that may be made by our customers as inadvertent and may examine our role in providing information to our customers, physicians and patients concerning the benefits and potential coverage of more frequent therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA regulation of our industry generally or our tests specifically could be disruptive to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations are subject to extensive federal, state, local and foreign laws and regulations, including FDA laws and regulations, all of which are subject to change. These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. We believe that we are in material compliance with all statutory and regulatory requirements applicable to us, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has recently increased its attention to marketing of pharmacogenetic tests. For example, in late 2018, the FDA issued a safety communication regarding genetic laboratory tests with claims to predict a patient&#x2019;s response to specific medications that have not been reviewed by the FDA and may not be supported by clinical evidence. Among other tests, the FDA notice cited genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications. As explained by the FDA in its update to this safety communication, the FDA sent notices to several firms marketing such pharmacogenetic tests where the FDA believes the relationship between genetic variations and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">medication&#x2019;s effects has not been established, including a warning letter sent to a laboratory, in part, for failing to obtain premarket review of its test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA were to determine that our tests are not within the enforcement discretion policy for LDTs for any reason, or if FDA issues new rules, policies, or guidance, due to new legislation or on its own accord, our tests may become subject to FDA requirements, including pre-market review. If this were to happen, it may impact our marketing practices relating to the relevant tests, which in turn may have an adverse impact on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The SARS-CoV-2 tests we perform are currently the subject of EUAs, which permit the use of unapproved medical products or unapproved uses of medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when there are no adequate, approved, and available alternatives, as provided under section 564 of the FDCA. EUAs are temporary authorizations that are revoked at the end of the public health emergency, when there is an adequate, approved, or available alternative, or when there are performance or safety concerns. These EUAs also set out conditions for laboratories who are authorized to perform the particular test. Because the EUA declaration under Section 564 of the FDCA is distinct from the declaration under Section 319 of the PHS Act, an EUA may remain in effect beyond the duration of the Section 319 declaration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EUA for Bio-Rad&#x2019;s SARS-CoV-2 ddPCR test provides several conditions for authorized laboratories, including that the test result reports will include Fact Sheets that are authorized as part of the EUA, deviations from the authorized procedures, including specimen types, are not permitted, notification of public health authorities of intent to run the test prior to initiating testing, collection and reporting of performance data to the FDA, including false positives, false negatives, and significant deviations from the established performance characteristics, and appropriate training and protective equipment for laboratory staff. This EUA also states that authorized laboratories must maintain records associated with the EUA and be made available to the FDA for inspection upon request. Printed materials, advertising, and promotion related to use of the test must be consistent with the authorized labeling and Fact Sheets, as well as other terms set forth in the EUA and any applicable requirements under the FDCA and its implementing regulations, and conspicuously bear the following statements:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This test has not been FDA cleared or approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This test has been authorized by the FDA under an EUA for use by authorized laboratories;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. &#167; 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other statements that appear in advertising and promotional materials must not represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EUA for Bio-Rad&#x2019;s serological test for the antibodies associated with SARS-CoV-2, also sets out several conditions for authorized laboratories that mirror the conditions for the PCR test described above, except that the printed materials, advertising, and promotion of the test must conspicuously bear the following statements:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This test has not been FDA cleared or approved;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This test has been authorized by the FDA under an EUA for use by authorized laboratories;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This test has been authorized only for the detection of total antibodies, including IgM/IgG/IgA, against SARS-CoV-2, not for any other viruses or pathogens; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. &#167; 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The diagnostic testing industry is subject to extensive laws and regulations, many of which have not been interpreted by the courts, including the application of the FDA&#x2019;s EUA authority. As noted above, the EUAs for the COVID-19 tests that are part of our Biodesix WorkSafe testing program set out certain conditions for authorized laboratories using the tests, which have not received premarket clearance, approval, or a De Novo authorization from the FDA. If we fail to meet these conditions, the FDA may take enforcement action, such as issuing a warning letter, seeking an injunction, seizure, fines, or criminal penalties. Moreover, if we or others fail to meet applicable conditions, the FDA may revoke the EUAs for the COVID-19 tests that are part of our Biodesix WorkSafe testing program. Laboratory tests that have already received an EUA to detect the COVID-19 virus were &#x201c;unaffected&#x201d; by the announcement. Tests without</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA clearance, approval, or authorization would not be considered covered countermeasures under the Public Readiness and Emergency Preparedness Act (PREP Act), which authorizes HHS to provide limited liability immunity protection to certain individuals and entities against a claim of loss under federal and state law &#x201c;caused by, arising out of, relating to, or resulting from&#x201d; the manufacture, distribution, administration, or use of a covered medical countermeasure, except for claims involving willful misconduct. Consequently, any violations of applicable laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees and could result in a material adverse effect on our business, prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA requires virtually all laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is also a prerequisite to be eligible to bill state and federal health care programs, as well as many private third-party payers, for laboratory testing services. As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other year, in addition to being subject to additional random inspections. The biennial survey is conducted by CMS, a CMS agent (typically a state agency), or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation, or limitation of a laboratory&#x2019;s CLIA certificate, which is necessary to conduct our business, as well as the imposition of significant fines or criminal penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business. If the CLIA certificate of any one of our laboratories is revoked, CMS could seek revocation of the CLIA certificates of our other laboratories based on their common ownership or operation, even though they are separately certified.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we are subject to state laws and regulations governing laboratory licensure. Some states have enacted state licensure laws that are more stringent than CLIA. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our tests or such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations that may limit our ability to make our tests available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays. Changes in state or foreign licensure laws that affect our ability to offer and provide diagnostic services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA certificate and/or state licenses, imposition of a directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions and revocation of the laboratory&#x2019;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure or our failure to renew our CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Boulder, Colorado and De Soto, Kansas laboratories are both CAP-accredited clinical laboratories regulated by CMS pursuant to CLIA. We also have a current CLIA certificate for each facility. To maintain these certificates, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time. Furthermore, our diagnostic tests are categorized as LDTs and are not currently subject to FDA regulation, although certain components provided by third parties and used to create and/or administer the test may be. LDTs are a subset of IVDs that are intended for clinical use and developed, validated, and offered within a single laboratory for use only in that laboratory. Failure to adhere to any new FDA regulation would result in fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our current line of diagnostic tests is covered under CLIA and CMS, however, changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future. In addition, our COVID testing program and select partnerships we may enter may cause us to be subject to additional FDA requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, including in vitro diagnostics and, therefore, potentially our clinical laboratory tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. Although the FDA has asserted that it has authority to regulate the development and use of LDTs, such as our and many other laboratories&#x2019; tests, as medical devices, it has generally exercised enforcement discretion and is currently not otherwise regulating most tests developed and performed within a single high complexity CLIA-certified laboratory. Pursuant to this enforcement discretion policy, FDA does not require laboratories that furnish LDTs to comply with the agency&#x2019;s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls). In recent years, however, the FDA publicly announced its intention to regulate certain LDTs and has set forth various proposals for a phased-in risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA&#x2019;s policies to date have been articulated through guidance documents, compliance manuals, website statements, and other informal issuances. The FDA could, at any time, engage in notice-and-comment rulemaking, or Congress could take action to amend the law to change the current regulatory framework for in vitro diagnostics and LDTs to require premarket review of LDTs, which could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our tests, as utilized in our clinical laboratory, are and would be considered LDTs and that as a result, the FDA does not require that we obtain regulatory clearances or approvals for our LDTs or their components pursuant to the FDA&#x2019;s current policies and guidance. Although we believe that our tests and test components are either exempt from FDA medical device regulations or are subject to an enforcement discretion policy, it is possible that the FDA would not agree with our determinations or that the FDA will change its regulations and policies such that our products become regulated as medical devices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In contrast with our LDTs, the FDA has regulatory jurisdiction over the three FDA EUA-authorized COVID-19 tests which we offer as part of our Biodesix WorkSafe testing program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, therefore, are or may become subject to extensive regulation by the FDA in the United States. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">test design, development, manufacture, and release;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laboratory and clinical testing, labeling, packaging, storage, and distribution;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product safety and efficacy;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">premarketing clearance or approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">service operations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">record keeping;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product marketing, promotion and advertising, sales, and distribution;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">post-market approval studies; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product import and export.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The premarket submission process for medical devices can be expensive, lengthy and unpredictable. The FDA can delay, limit, or deny clearance or approval of a device for many reasons, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or conformity assessment body that the diagnostic tests are safe or effective for their proposed intended uses;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the disagreement of the FDA with the design or implementation of our clinical trials or the interpretation of data from clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">serious and unexpected adverse device effects experienced by participants in our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the data from our clinical trials may be insufficient to support clearance or approval, where required;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the manufacturing process or facilities we use may not meet applicable requirements; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse publicity, warning letters, untitled letters, it has come to our attention letters, fines, injunctions, consent decrees and civil penalties;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">repair, replacement, refunds, recall or seizure of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating restrictions, partial suspension, or total shutdown of production;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">denial of our requests for regulatory clearance or premarket approval of new diagnostic tests or services, new intended uses, or modifications to existing diagnostic tests or services;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of regulatory clearance or premarket approvals that have already been granted; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">criminal prosecution.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed above, we believe that our current line of diagnostic tests and their components are LDTs, which are subject to state licensing requirements and federal regulation by CMS under CLIA, although our COVID-19 testing program and select partnerships we may enter may cause us to be subject to additional FDA regulations discussed above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we believe that we are currently in material compliance with applicable laws and regulations, it is possible that the FDA, or other regulatory agencies, would not agree with our determinations. If our products became become subject to premarket submission and other FDA requirements, we would need to comply with the applicable regulations or face significant civil and criminal penalties. In addition, IVDs and CDx tests are widely considered to be Class III devices, and it is possible that in the future, we may develop tests that fall into this category. CDx tests in particular may require further administrative procedures in the PMA process. Exposure to these additional regulatory requirements would also affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future success depends on our ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance, De Novo authorization, or PMA approval of our future diagnostic tests and failure to obtain necessary clearances or approvals for our future diagnostic tests would adversely affect our ability to grow our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is important to our business that we build a pipeline of diagnostic test offerings that address limitations of current lung disease diagnostic tests. As such, our success will depend in part on our ability to develop and introduce new diagnostic tests. However, we may not be able to successfully develop and obtain regulatory clearance or approval or certification for enhancements to our existing diagnostic tests, or new diagnostic tests for any number of reasons, including due to the cost associated with certain regulatory approval requirements, or these diagnostic tests may not be accepted by physicians or users.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of any new diagnostic test or enhancement to an existing diagnostic test will depend on a number of factors, including our ability to, among others:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identify and anticipate physician and patient needs properly;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">develop and introduce new diagnostic tests or enhancements to our existing diagnostic tests in a timely manner;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">avoid infringing upon, misappropriating, or violating the intellectual property rights of third parties;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">demonstrate, if required, the safety and efficacy of new diagnostic tests with data from clinical studies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain the necessary regulatory clearances or approvals or certifications for new diagnostic tests or enhancements to existing diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">comply fully with FDA and foreign regulations on marketing of new diagnostic tests or modified diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide adequate training to potential users of our diagnostic tests.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we do not develop new diagnostic tests or enhancements to our existing diagnostic tests in time to meet market demand or if there is insufficient demand for these diagnostic tests or enhancements, or if our competitors introduce new diagnostic tests with functionalities that are superior to ours, our results of operations will suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our future diagnostic tests may require FDA clearance of a 510(k) submission. Other diagnostic tests may require the approval of a PMA. In addition, some of our future diagnostic tests may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA may not approve or clear these diagnostic tests for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance, De Novo authorization, or premarket approval of new diagnostic tests. Failure to receive clearance or approval for our new diagnostic tests would have an adverse effect on our ability to expand our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Modifications to our marketed tests may require new 510(k) clearances, De Novo authorizations, or PMA approvals, or may require us to cease marketing or recall the modified tests until clearances or approvals are obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Modifications to our diagnostic tests may require new regulatory approvals or clearances, including 510(k) clearances, De Novo authorizations, or premarket approvals, or require us to recall or cease marketing the modified systems until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new submission is necessary. However, the FDA can review a manufacturer&#x2019;s decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to our diagnostic tests in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our diagnostic tests as modified, which could require us to redesign our diagnostic tests and harm our operating results. In these circumstances, we may be subject to significant enforcement actions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where we determine that modifications to our diagnostic tests require a new premarket submission, we may not be able to obtain the additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced diagnostic tests in a timely manner, which in turn would harm our future growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or our suppliers fail to comply with ongoing FDA or other domestic and foreign regulatory authority or conformity assessment body requirements, or if we experience unanticipated problems with our diagnostic tests, they could be subject to restrictions or withdrawal from the market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any medical device that we manufacture, including those for which we obtain regulatory clearance or approval or certification, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such diagnostic test, will be subject to continued regulatory review, oversight, and periodic inspections by the FDA and other domestic and foreign regulatory bodies or conformity assessment bodies. In particular, we and our suppliers may be required to comply with FDA&#x2019;s QSR (QSR codified at 21 C.F.R. &#167; 820) for medical devices and ISO regulations for the manufacture of our diagnostic tests and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any diagnostic test for which we obtain clearance or approval. Regulatory bodies, such as the FDA, and conformity assessment bodies enforce the QSR and other regulations through periodic inspections and audits. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies or conformity assessment bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, one or more of the following enforcement actions:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated expenditures to address or defend such actions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">customer notifications for repair, replacement, or refunds;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recall, detention, or seizure of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating restrictions or partial suspension or total shutdown of production;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusing or delaying our requests for 510(k) clearance, De Novo authorization, or premarket approval of new diagnostic tests or modified versions of current diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating restrictions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawing 510(k) clearances, De Novo authorization, or PMA approvals that have already been granted;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">revocation of EUAs that have been authorized previously;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to grant export approval for our diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">criminal prosecution.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of these actions were to occur it would harm our reputation and cause our diagnostic test sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our diagnostic tests on a timely basis and in the required quantities, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we are required to conduct surveillance to monitor the safety or effectiveness of our diagnostic tests, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our diagnostic tests. Later discovery of previously unknown problems with our diagnostic tests, including unanticipated adverse events or adverse events of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such diagnostic tests or manufacturing processes, withdrawal of the diagnostic tests from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our diagnostic tests and services may in the future be subject to product recalls that could harm our reputation, business and financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medical devices can experience performance problems in the field that require review and possible corrective action. The occurrence of component failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated or voluntary recall by the device manufacturer, in particular when such deficiencies may endanger health. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our diagnostic tests and services in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations. Other jurisdictions have similar recall requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval or certification of any future diagnostic tests and to manufacture, market and distribute our diagnostic tests after clearance or approval is obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. For example, the Verifying Accurate, Leading-edge IVCT Development (VALID) Act recently introduced in Congress would codify into law the term &#x201c;in vitro clinical test&#x201d; in order to create a new medical product category separate from medical devices that would include products currently regulated as in vitro diagnostics as well as LDTs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our diagnostic tests. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future diagnostic tests. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future diagnostic tests could make it more difficult and costly to obtain clearance or approval for new diagnostic tests or to produce, market and distribute existing diagnostic tests. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for any new diagnostic tests would have an adverse effect on our ability to expand our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical trials may be necessary to support future product submissions to FDA. These clinical trials are expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new diagnostic tests and will adversely affect our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiating and completing clinical trials necessary to support any future PMA applications, De Novo requests, and additional safety and efficacy data beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our diagnostic tests or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our diagnostic tests or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA may not consider our data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval or certification for or commercialize our diagnostic tests and services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have the ability to independently conduct our pre-clinical and clinical trials for our future diagnostic tests and services and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our diagnostic tests and services on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our use, disclosure, and other processing of personally identifiable information, including health information, is subject to HIPAA and other federal, state, and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain and process, and our third-party vendors, collaborators, contractors and consultants maintain and process on our behalf, a large quantity of sensitive information, including confidential business, personal and patient health information in connection with our clinical studies and our employees, and are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. Failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any of these laws and regulations could result in notification obligations or enforcement actions against us, which could result in fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. These laws, rules and regulations evolve frequently and their scope may continually change, through new legislation, amendments to existing legislation and changes in enforcement, and may be inconsistent from one jurisdiction to another. The interpretation and application of consumer, health-related and data protection laws, especially with respect to genetic samples and data, in the United States, the EU and elsewhere, are often uncertain, contradictory and in flux. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Domestic laws in this area are complex and developing rapidly. Many state legislatures have adopted legislation relating to privacy, data security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. States are also frequently amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California recently enacted the CCPA, which became effective on January 1, 2020. The CCPA, among other things, requires new disclosures to California consumers and affords such consumers new abilities to access and delete their personal information, opt-out of certain sales of personal information and receive detailed information about how their personal information is used. The CCPA provides for fines of up to $7,500 per violation, as well as a private right of action for data breaches that is expected to increase the frequency of data breach litigation. While the CCPA has already been amended multiple times, it is unclear how this legislation will be further modified or how it will be interpreted. Interpretations of the CCPA may continue to evolve with regulatory guidance and the CCPA continue to be amended, including through a ballot initiative, adopted by voters in November 2020, known as the California Privacy Rights Act, or CPRA. The CPRA imposes additional data protection obligations on companies doing business in California, including additional consumer rights, including regarding certain uses of sensitive data. It also creates a new California data protection agency - the California Privacy Protection Agency - specifically tasked to enforce the law, which may likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The effects of this legislation potentially are far-reaching, however, and may require us to modify our data processing practices and policies and incur substantial compliance-related costs and expenses. The CCPA and other changes in state and federal laws or regulations relating to privacy, data protection and information security, particularly any new or modified laws or regulations that require enhanced protection of certain types of data or new obligations with regard to data retention, transfer or disclosure, could increase the cost of providing our offerings, require significant changes to our operations or even prevent us from providing certain offerings in jurisdictions in which we currently operate and in which we may operate in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data privacy and security issues. Although we endeavor to comply with our published policies and documentation and ensure their compliance with current laws, rules and regulations, we may at times fail to do so or be alleged to have failed to do so. The publication of our privacy policy and other documentation that provide promises and assurances about privacy and security can subject us to potential state and federal action in the United States if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Any failure by us or other parties with whom we do business to comply with this documentation or with federal, state, local or international regulations could result in proceedings against us by governmental entities, private parties or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private qui tam actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corrective action plan or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of PHI and PII. These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA, PHI) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities (CE), and the business associates (BA) with whom such covered entities contract for services. We are a CE under HIPAA when we are conducting our clinical trials. We are a CE with regard to our observational studies and clinical trials, and also a BA under HIPAA for certain other business activities, and we execute BA agreements with our clients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA requires CEs and BAs, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations start at $119 per violation and are subject to a cap of $1,785,651 for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys&#x2019; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA CEs and BAs. With regard to BAs, those audits assess the business associate&#x2019;s compliance with the HIPAA Privacy and Security Standards. Such audits are conducted randomly and after an entity experiences a breach affecting more than 500 individuals&#x2019; data. Undergoing an audit can be costly, can result in fines or onerous obligations, and can damage a BAs reputation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to HIPAA, numerous other federal, state, and foreign laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of PII. Some of these laws and regulations may be preempted by HIPAA with respect to PHI, or may exclude PHI from their scope but impose obligations with regard to PII that is not PHI, and in some cases, can impose additional obligations with regard to PHI. These laws and regulations are often uncertain, contradictory, and subject to changing or differing interpretations, and we expect new laws, rules and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. HHS is also proposing amendments to the HIPAA Privacy Rule to modernize certain data sharing provisions and enhance patient access to their information. This complex, dynamic legal landscape regarding privacy, data protection, and information security creates significant compliance issues for us and our clients and potentially exposes us to additional expense, adverse publicity and liability. While we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, but it is possible that laws, rules and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit PHI and other PII or confidential information to us. If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may eventually operate in a number of countries outside of the United States whose laws, including data privacy laws, may in some cases be more stringent than the requirements in the United States. For example, EU and UK data privacy laws have specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States, have strict requirements relating to personal data collection, use or sharing, and have more stringent requirements relating to organizations&#x2019; privacy programs and provide stronger individual rights. Moreover, we may also be subject to evolving international privacy and data security regulations which could result in greater compliance costs and in turn lead to penalties, where such compliance programs are not implemented correctly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our processing activities are subject to the EU General Data Protection Regulation and the UK General Data Protection Regulation (collectively, the &#x201c;GDPR&#x201d;) &#x2013; including, those involving pseudonymised / key-coded data - as the GDPR applies extra-territorially. The GDPR imposes strict requirements on controllers and processors processing personal data, including, for example, requirements to: (i) identify a legal basis for the processing of personal data, (ii) provide robust disclosures to individuals, (iii) respond to requests from individuals to exercise their data subject rights, (iv) provide personal data breach notifications within 72 hours after discovering the breach, (v) limit the collection and retention of personal data, (vi) impose specific contractual obligations on processors engaged to process personal data on the instructions of the controller, and (vii) apply enhanced protections to health data and other special categories of personal data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EU GDPR also provides that EU Member States may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share such personal data and cause our costs to increase and harm our financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with the requirements of the GDPR may result in fines of up to &#x20ac;20 million (&#163;17.5 million in the case of the UK GDPR) or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. GDPR compliance may require us to put in place additional mechanisms, which may result in compliance costs and other substantial expenditures. This may be onerous and adversely affect our business, financial condition, results of operations and the profitability of our platform of diagnostic tests. Failure to comply with the GDPR and other countries&#x2019; privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payers, and have an adverse effect on our business and financial condition. Currently, the GDPR is only applicable to us as a processor, but as we continue to expand into the European market, the GDPR will have direct applicability to us as a controller.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The GDPR also prohibits the transfer of personal data from the EEA/UK to a country outside of the EEA/UK (e.g., the United States) unless made to a country deemed to have adequate data privacy laws by the European Commission (or UK Government in case of the UK GDPR) or a data transfer mechanism has been put in place. Until recently, one such data transfer mechanism was the EU-US Privacy Shield. However, in July 2020 the Court of Justice of the European Union (CJEU) declared the Privacy Shield to be invalid. Following an executive order on trans-Atlantic data flows issued by President Biden in October 2022, the European Commission in December 2022 announced that it had initiated the process of drafting a new adequacy decision based on a modified data transfer framework that would replace the Privacy Shield. Though adoption of a new adequacy decision may have the effect of making data transfers to the United States easier, it is widely expected that the updated transfer framework and the adequacy decision will also be reviewed by the CJEU. The CJEU also upheld the validity of standard contractual clauses (SCCs) as a legal mechanism to transfer personal data but companies relying on SCCs will need to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. In turn, the findings of the CJEU will have significant implications for cross-border data flows and may lead to increased transaction, compliance, and technological costs to support international data transfers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organizations operating in Canada and covered by the Personal Information Protection and Electronic Documents Act (PIPEDA), or equivalent Canadian provincial laws, must obtain an individual&#x2019;s consent when they collect, use or disclose that individual&#x2019;s personal information. Individuals have the right to access and challenge the accuracy of their personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal information for another purpose, it must again obtain that individual&#x2019;s consent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We regularly monitor, defend against and respond to attacks to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third-party service providers, may be vulnerable to privacy and information security incidents such as data breaches, viruses or other malicious code, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological vulnerabilities or human error. If we, or any of our vendors that support our IT or have access to our data, including any third-party vendors that collect, process and store personal data on our behalf, fail to comply with laws requiring the protection of personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, we may be subject to regulatory enforcement and fines as well as private civil actions. We may be required to expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk that our employees, collaborators, independent contractors and consultants may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA regulations, including those laws requiring the reporting of true, complete, and accurate information to the FDA authorities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal and state healthcare fraud and abuse laws and regulations; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laws that require the true, complete and accurate reporting of financial information or data.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee, contractor, or other agent, or our company, receiving an FDA debarment or exclusion by the HHS Office of Inspector General (OIG) could result in penalties, a loss of business from third parties, and severe reputational harm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics and compliance policies to govern and deter such behaviors, but it is not always possible to identify and deter misconduct by our employees and other agents, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, treble damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ongoing research and development and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting pre-and post-market clinical studies of some of our tests. In the future we may conduct clinical trials to support approval of new diagnostic tests and services, or new indications. Clinical studies may need to be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimately be used to support marketing authorization for these diagnostic tests and services. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign authorities and conformity assessment bodies will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our tests are safe and effective for the proposed indicated uses, which could cause us to abandon development of our tests and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, may impact our ability to commercialize our tests and generate revenues.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval or certification. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions, and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. We and our third-party contractors are required to comply with good clinical practices (GCPs) which are regulations and guidelines enforced by the FDA, and comparable regulations enforced by foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA or comparable foreign regulatory authorities or conformity assessment bodies may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval or certification process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of these factors could be beyond our control. We may not be able to undertake additional trials, repeat trials or enter into new arrangements with third parties without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase and we may not be able to obtain regulatory clearance or approval or certification for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, or to achieve sustained profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be certain that the results of our future clinical trials will support our future product claims or that the FDA or comparable foreign regulatory authorities or conformity assessment bodies will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the future product&#x2019;s profile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our billing, collections and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting claims or failure to comply with applicable billing requirements, could have an adverse effect on our future revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Billing for our tests is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, such as government payers, insurance companies and patients, all of which may have different billing requirements. We may face increased risk in our collection efforts, including long collection cycles and the risk that we may never collect at all, either of which could adversely affect our business, financial condition and results of operations. Several factors make the billing process complex, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differences between the list price for our tests and the reimbursement rates of payers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare and Medicaid, to the extent our tests are covered by such programs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differences in coverage among payers and the effect of patient co-payments or co-insurance;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differences in information and billing requirements among payers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes to codes and coding instructions governing our tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorrect or missing billing information; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the resources required to manage the billing and claims appeals process.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These billing complexities and the related uncertainty in obtaining payment for our tests could negatively affect our revenue and cash flow, our ability to achieve profitability and the consistency and comparability of our results of operations. In addition, if claims for our tests are not submitted to payers on a timely basis, or if we fail to comply with applicable billing requirements, it could have an adverse effect on our revenue and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payers require us to identify the test for which we are seeking reimbursement using a Current Procedural Terminology (CPT) code. The CPT code set is maintained by the American Medical Association (AMA). In cases where there is not a specific CPT code to describe a test, such as with GeneStrat NGS, the test may be billed under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. The Protecting Access to Medicare Act of 2014 (PAMA) authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests as well as advanced diagnostic laboratory tests. The AMA has created a new section of CPT codes, Proprietary Laboratory Analyses codes to facilitate implementation of this section of PAMA. In addition, CMS may assign unique level II Healthcare Common Procedure Coding System codes to tests that are not already described by a unique CPT code. VeriStrat, Nodify XL2, and Nodify CDT have test specific CPT codes, but the GeneStrat NGS test does not at this time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the instance where a code used does not describe a specific test, the insurance claim must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">letter of medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. As a result, obtaining approvals from third-party payers to cover our tests and establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming and costly process and we may never be successful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development activities and our third-party manufacturers&#x2019; and suppliers&#x2019; activities involve the generation, use, storage and disposal of hazardous materials. We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Accordingly, we and our third-party manufacturers and suppliers are subject to federal, state, local and foreign environmental, health and safety laws and regulations, and permitting and licensing requirements, including those governing the generation, use, manufacture, storage, handling, transportation, release and disposal of, and exposure to, these materials, and worker health and safety.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot eliminate the risk of contamination or injury resulting from such hazardous materials. We also cannot guarantee that the procedures utilized by our third-party manufacturers for handling and disposing of hazardous materials and wastes comply with all applicable environmental, health and safety laws and regulations. As a result, we may be held liable for any resulting damages, costs or liabilities, including cleanup costs and liabilities, which could be significant, or our commercialization, research and development efforts and business operations may be restricted or interrupted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. Compliance with such laws and regulations is expensive, and current or future environmental, health and safety laws and regulations may restrict our operations. If we do not comply with applicable environmental health and safety laws and regulations, and permitting and licensing requirements, we may be subject to fines, penalties, a suspension of our business or other sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our success may be impaired if we are unable to obtain, maintain and protect our intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our diagnostic tests, products and services and technology. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, to protect our proprietary technology and prevent others from duplicating our suite of diagnostic tests and products. However, these means may afford only limited protection and may not:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prevent our competitors from duplicating our diagnostic tests and products, including our COVID-19 testing program and Nodify XL2, Nodify CDT, GeneStrat and VeriStrat tests;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prevent our competitors from gaining access to our proprietary information and technology, including the Diagnostic Cortex platform, tech platforms such as the DeepMALDI analysis and intellectual property covering technologies that allow us to develop &#x201c;test algorithms&#x201d;; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">allow us to gain or maintain a competitive advantage.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of our patents, including those we may license, may be challenged, invalidated, rendered unenforceable or circumvented. Consequently, we do not know whether any of our diagnostic tests, products and services will be protectable or remain protected by valid and enforceable patents. We may not prevail if our patents are challenged by competitors or other third parties. The United States federal courts or equivalent national courts or patent offices elsewhere may invalidate our patents, find them unenforceable, or narrow their scope. Furthermore, competitors may be able to design around our patents by developing similar or alternative technologies or products in a non-infringing manner, or obtain patent protection for more effective technologies, designs or methods, including for treating lung cancer. If these developments were to occur, our diagnostic tests and products may become less competitive and sales may decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have filed numerous patent applications seeking protection of diagnostic tests and other inventions originating from our research and development. Our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The scope of a patent may also be reinterpreted and significantly reduced after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with the protection or competitive advantages we are seeking.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain or maintain an exclusive license to any such third-party co-owners&#x2019; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. Various courts, including the United States Supreme Court have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon, or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered unpatentable under applicable law. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Depending on decisions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#x2019; ability to obtain new patents or to enforce our existing owned or in-licensed patents and patents that we might obtain or in-license in the future. Additionally, our pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. The scope of patent protection outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property rights or narrow the scope of our owned and licensed patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our technology, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize diagnostic tests, products and services similar or superior to ours, and our competitive position may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, primarily rely on protecting our software as a trade secret. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our copyrights may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to seeking patent protection for the patents underlying our diagnostic tests, products and services, we also rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain a competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect such proprietary information, in part, through confidentiality agreements with our employees, collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We also have agreements with some of our consultants that require them to assign to us any inventions created as a result of their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a relationship with employees or third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot guarantee that we have entered into such agreements with each party that has or may have had access to our trade secrets or proprietary information. Additionally, despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed. Furthermore, we expect these trade secrets, know-how and proprietary information to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions. Consequently, we may be unable to prevent our proprietary technology from being exploited in the United States and abroad, which could affect our ability to expand in domestic and international markets or require costly efforts to protect our technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known, or be independently discovered by, competitors. To the extent that our employees, consultants, contractors or collaborators use intellectual property rights owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that we or our employees have misappropriated the intellectual property rights of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors, and third parties may claim an ownership interest in intellectual property we regard as our own.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our employees and consultants were previously employed at or engaged by universities or other medical device, diagnostic, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property rights, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, used, infringed, misappropriated or otherwise violated the intellectual property rights or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Any litigation or the threat of litigation may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize potential diagnostic tests, products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property rights we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our diagnostic tests or products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An inability to incorporate technologies or features that are important or essential to our diagnostic tests or products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our rights to our COVID-19 testing program, either of the Nodify XL2 and Nodify CDT tests, or the VeriStrat and GeneStrat tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property rights to execute agreements assigning such intellectual property rights to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property rights. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future diagnostic tests, products and services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a first-to-invent system to a first-inventor-to-file system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings, including post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review and derivation proceedings. Under a first-inventor-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor was the first to invent the claimed invention. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the United States Supreme Court and the United States Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement or dilution claims brought by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not yet registered certain of our trademarks in all of our potential markets, although we have registered several connected to our diagnostic tests, products and services in the United States. If we apply to register these and trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our efforts to enforce or protect our rights related to trademarks, trade secrets, domain names or other intellectual property rights may be ineffective, could result in substantial costs and diversion of resources and could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors or other third parties may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violations. In addition, our patents also may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke those parties to assert counterclaims against us alleging that we infringe their patents or other intellectual property. In any such proceeding, a court or other administrative body may decide that a patent or other intellectual property right owned by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover such technology. Grounds for a validity challenge could include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include reexamination, post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, including opposition proceedings. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our diagnostic tests, products and services or prevent third parties from competing with our diagnostic tests, products and services. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on our diagnostic tests, products and services. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#x2019; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing diagnostic tests, products, services or technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intellectual property landscape in the field of precision oncology is in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future. As we move into new markets and applications for our diagnostic tests, products or services, incumbent participants in such markets may assert their patents and other intellectual property rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success depends in part on our non-infringement of the patents or other intellectual property rights of third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">However, we may in the future be subject to claims that we, or other parties we have agreed to indemnify, infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Because patent applications are published sometime after filing, and because applications can take several years to issue, there may be additional currently pending third-party patent applications that are unknown to us, which may later result in issued patents. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We may not have sufficient resources to bring these actions to a successful conclusion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a substantial amount of litigation and other patent challenges, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review proceedings before the USPTO, and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are developing diagnostic tests and in which we may develop future diagnostic tests, products and services. As the precision oncology industry expands and more patents are issued, the risk increases that our diagnostic tests may be subject to claims of infringement of the patent rights of third parties. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and competitors have and may assert that our diagnostic tests or services infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the inevitable uncertainty in intellectual property litigation, we could lose a patent infringement or other action asserted against us regardless of our perception of the merits of the case. There is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such United States patent in federal court, we would need to overcome a presumption of validity. As this burden is a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">high one requiring us to present clear and convincing evidence as to the invalidity of any such United States patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such United States patent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell diagnostic tests, products or services, and could result in the award of substantial damages against us, including treble damages, attorney&#x2019;s fees, costs, and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, which could be significant, and obtain one or more licenses from third parties, or be prohibited from selling certain diagnostic tests, products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in diagnostic test introductions while we attempt to develop alternative diagnostic tests, products or services to avoid infringing third-party patents or intellectual property rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing diagnostic tests, products or services, and the prohibition of sale of any of our diagnostic tests, products or services could materially affect our business and our ability to gain market acceptance for our diagnostic tests, products and services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the priority or inventorship of our patents and other intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property rights as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#x2019; ownership of our owned or in-licensed patents, trade secrets or other intellectual property rights. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property rights that are important to our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of our diagnostic tests, products or services. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-United States patent agencies. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property rights. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issued patents covering our diagnostic tests and any other or future diagnostic tests, products or services could be found invalid or unenforceable if challenged.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the United States and abroad, in opposition, derivation, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review, post-grant review or interference. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our diagnostic tests, products, services or technologies, the defendant could counterclaim that the patent covering our diagnostic tests, products or services is invalid or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement during prosecution. In addition, the United States now awards patent priority to the first party to file a patent application, and others may submit patent claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our diagnostic tests or any diagnostic tests, products and services that we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights, which could have a material adverse impact on our business. Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future diagnostic tests, products or services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be aware of all third-party intellectual property rights potentially relating to our current or future diagnostic tests, products or services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We, or our current or future license partners or collaborators, might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management&#x2019;s attention and resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on licenses from third parties in relation to certain diagnostic tests, products and services and if we lose these licenses then we may be subjected to future litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a party to license agreements that grant us rights to use certain intellectual property rights, including patents and patent applications, typically in certain specified fields of use, in connection with our diagnostic tests, products and services. Some of those licensed rights could provide us with freedom to operate for aspects of our diagnostic tests, products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The in-licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for product candidates on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects for growth could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, royalty payment, milestone payment, insurance and other obligations on us. If we fail to comply with these obligations or other obligations in our license agreements, our licensors may have the right to terminate these agreements, in which event we may not be able to develop and market any product or use any technology that is covered by these agreements. If our license agreements terminate, or we experience a reduction or elimination of licensed rights under these agreements, we may have to negotiate new or reinstated licenses with less</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">favorable terms or we may not have sufficient intellectual property rights to operate our business. The occurrence of such events could materially harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property rights. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property rights we license, other companies might be able to offer substantially identical diagnostic tests for sale, which could adversely affect our competitive business position and harm our business prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, disputes may also arise between us and our current or future licensors regarding intellectual property rights subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether, and the extent to which, our diagnostic tests, products, services, technology, and processes infringe on intellectual property rights of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether our licensor or its licensor had the right to grant the license agreement;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property rights without their authorization;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our involvement in the prosecution of licensed patents and our licensors&#x2019; overall patent enforcement strategy;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the amounts of royalties, milestones, or other payments due under the license agreement;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property rights by our licensors and us and our collaborators; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the agreements under which we currently license intellectual property rights or technology from third parties are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property rights or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, or are insufficient to provide us the necessary rights to use the intellectual property rights, we may be unable to successfully develop and commercialize any affected diagnostic tests, products or services, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs to us and distract our management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys&#x2019; fees, costs and expenses and royalties or be enjoined from selling our diagnostic tests, products or services, which could adversely affect our ability to offer diagnostic tests, products or services, our ability to continue operations and our financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Some intellectual property that we in-license may have been developed through government funded programs and thus may be subject to federal regulations such as &#x201c;march-in&#x201d; rights, certain reporting requirements and a preference for companies based in the United States. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with manufacturers that are not based in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of the intellectual property that we license may have been developed through the use of United States government funding and therefore may be subject to certain federal regulations. As a result, the United States government may have certain rights to intellectual property embodied in our diagnostic tests, products and services pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act). These United States government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the United States government has the right</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#x201c;march-in rights&#x201d;). To date, none of our commercialized products are subject to march-in rights. The United States government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the United States government requires that any products of the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for United States manufacturers may limit our ability to contract with product manufacturers outside of the United States for products covered by such intellectual property. To the extent any of our current or future owned or licensed intellectual property is generated through the use of United States government funding, the provisions of the Bayh-Dole Act may similarly apply. Any failure by us to comply with federal regulations regarding intellectual property rights that were developed through the use of United States government funding could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our diagnostic tests, products and services for an adequate amount of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if patents covering our diagnostic tests, products and services are obtained, once the patent life has expired, we may be open to competition from competitive diagnostic tests, products and services. Given the amount of time required for the development, testing and regulatory review of potential new diagnostic tests, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing diagnostic tests, products or services similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may attempt to commercialize competitive diagnostic tests, products or services in foreign countries where we do not have any patents or patent applications and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents on our diagnostic tests, products and services in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing diagnostic tests or products made using our inventions in and into the United States or other jurisdictions. Competitors may use our diagnostic tests, products, services and technologies in jurisdictions where we have not obtained patent protection to develop their own diagnostic tests and, further, may export otherwise infringing diagnostic tests or products to territories where we have patent protection but enforcement is not as strong as that in the United States. These diagnostic tests and products may compete with our diagnostic tests, products or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing diagnostic tests, products and services in violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many countries, including India, China, and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our current or future licensors are forced to grant a license to third parties with respect to any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make diagnostic tests or products that are similar to our Nodify XL2, Nodify CDT, GeneStrat or VeriStrat tests or the COVID-19 tests that we use in our COVID-19 testing program or utilize similar technology that is not covered by the claims of our patents or that incorporates certain technology in our Nodify XL2, Nodify CDT, GeneStrat or VeriStrat tests or such COVID-19 tests that is in the public domain;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the applicable issued patent or pending patent application that we own or license now or may own or license in the future;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our current or future pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive diagnostic tests, products and services for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may harm our business; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property rights.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect that the price of our common stock will fluctuate substantially and you may not be able to sell your shares at or above the price you paid for them.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">volume and customer mix for our COVID-19, Nodify XL2, Nodify CDT, GeneStrat ddPCR, GeneStrat NGS, and VeriStrat testing;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the introduction of new diagnostic tests or enhancements to such tests by us or others in our industry;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes or other developments with respect to our or others&#x2019; intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to develop, obtain regulatory clearance or approval or certification for, and market new and enhanced diagnostic tests on a timely basis;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product liability claims or other litigation;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">quarterly variations in our results of operations or those of others in our industry;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">media exposure of our diagnostic tests or of those of others in our industry;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in governmental regulations or in the status of our regulatory approvals or applications;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in earnings estimates or recommendations by securities analysts; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance, and you may not realize any return on your investment in us and may lose some or all of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management&#x2019;s attention and resources from our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a trading market for our common stock develops, the trading market will be influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. As a small reporting company and emerging growth company, we may be slow to attract research coverage and the analysts who publish information about our common stock will have had relatively little experience with us, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act. We may take advantage of certain exemptions and relief from various public reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act. We will be exempt from any rules that could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#x2019;s report on financial statements; we will be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments not previously approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#x201c;emerging growth company&#x201d; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an &#x201c;emerging growth company&#x201d; until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.24 billion in annual revenue; (ii) the date we qualify as a &#x201c;large accelerated filer,&#x201d; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) the last day of the fiscal year ending after the fifth anniversary of the completion of our IPO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year&#x2019;s second fiscal quarter, or (2) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by nonaffiliates exceeds $700 million as of the end of that year&#x2019;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investors may find our common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or become more volatile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with generally accepted accounting principals (GAAP) requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. It is possible that interpretation, industry practice and guidance may evolve over time. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our officers, directors and principal stockholders each holding more than 5% of our common stock collectively control approximately 61.0% of our outstanding common stock as of December 31, 2022. As a result, these stockholders, if they act together, will be able to control the management and affairs of our company and most matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of our other stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating as a public company requires us to incur substantial costs and requires substantial management attention.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we have incurred and will continue to incur costs associated with corporate governance requirements that are applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the Securities Exchange Act of 1934, as amended (the Exchange Act), as well as the rules of NASDAQ. Compliance with these rules and regulations have significantly increased our accounting, legal and financial compliance costs and make some activities more time-consuming. These rules and regulations could make it more expensive for us to maintain directors&#x2019; and officers&#x2019; liability insurance. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our Board of Directors or as executive officers. Accordingly, increases in costs incurred as a result of becoming a publicly traded company may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of becoming a public company, we are required, under Section 404 of the Sarbanes-Oxley Act to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#x2019;s annual and interim financial statements will not be detected or prevented on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">faulty human judgment and simple errors, omissions, or mistakes;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fraudulent action of an individual or collusion of two or more people;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inappropriate management override of procedures; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and accurate financial control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When we cease to be an &#x201c;emerging growth company&#x201d; under the federal securities laws, our auditors will be required to express an opinion on the effectiveness of our internal controls. If we are unable to confirm that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our common stock to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. Notwithstanding the foregoing, the exclusive forum provision will not apply to any claim to enforce any liability or duty created by the Exchange Act or the Securities Act and for which the federal courts have exclusive jurisdiction. We believe this exclusive forum provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated articles of incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Section 145 of the Delaware General Corporate Law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as permitted by the Delaware General Corporate Law, our amended and restated articles of incorporation and our indemnification agreements that we have entered into with our directors and officers provide that:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by applicable law. Such law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#x2019;s conduct was unlawful;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the rights conferred in our amended and restated articles of incorporation are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not retroactively amend our amended and restated articles of incorporation provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="n1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1B. Unresolved S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">taff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our headquarters is located in Boulder, Colorado, where we lease office and laboratory space, under an operating lease agreement that expires in January 2024. We also lease office and laboratory space located in De Soto, Kansas, under an operating lease agreement that expires in October 2023, however, we are currently in discussions to extend this lease agreement. A portion of our employees are located outside of Colorado and Kansas, and others work from home. In March 2022, the Company entered into a lease agreement (the CVP Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company for office and laboratory space in Louisville, Colorado. In August 2022, CVP assigned the lease to CVP I Owner LLC, within the terms allowing for the assignment of the lease. The purpose of the CVP Lease is to replace the Company&#x2019;s current leased premises in Boulder, Colorado. The Company intends to move its corporate headquarters to Louisville, Colorado (the Leased Premises) by mid-2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.612%;"></td>
    <td style="width:1.625%;"></td>
    <td style="width:31.622%;"></td>
    <td style="width:1.17%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.218%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.625%;"></td>
    <td style="width:16.13%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Location</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Square Feet</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Louisville, Colorado</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Office and laboratory</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,980</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2035</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boulder, Colorado</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Office and laboratory</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,722</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 14, 2024</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">De Soto, Kansas</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Office and laboratory</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,066</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 31, 2023</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is traded on The NASDAQ Global Market under the symbol &#x201c;BDSX&#x201d;. The high and low closing prices for our common stock on The NASDAQ Global Market from January 1, 2022 to December 31, 2022 were $5.81 and $0.98, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 2, 2023, there were approximately 241 holders of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. We anticipate that all of our liquidity in the foreseeable future will be used for the operation and growth of our business. Any future determination to declare dividends will be subject to the discretion of our Board of Directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, and any other factors deemed relevant by our Board of Directors. In addition, the terms of our term loan restrict our ability to pay dividends on our common stock, and we may also enter into credit agreements or other borrowing arrangements in the future that will further restrict our ability to declare or pay dividends on our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities and Use of Proceeds</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company entered into subscription agreements (the November 2022 Subscription Agreements) with certain members of management, including the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, for the issuance and sale by the Company of an aggregate of 235,056 shares of the Company&#x2019;s common stock at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $1.15 per share for an aggregate purchase price of approximately $270,000. The November 2022 Subscription Agreements did not include any registration rights and included lock up restrictions in effect during the period ending 90 days subsequent to November 21, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company used the proceeds to, among other things and in conjunction with a public offering, fund the repayment of the promissory note with Streeterville Capital, LLC (Streeterville), the Loan and Security Agreement with Silicon Valley Bank (SVB), and for general corporate purposes (see &#x2013; Part II - Item 8, Financial Statements and Supplementary Data).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into subscription agreements (the April 2022 Subscription Agreements) with a consortium of investors (the April Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of an aggregate of 6,508,376 shares of the Company&#x2019;s common stock at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $1.79 per share, which is equal to the closing price of the Company&#x2019;s common stock on April 7, 2022, generating proceeds of $11.7 million. The three members of our Board of Directors acquired an aggregate of 3,631,284 shares pursuant to the form of the April 2022 Subscription Agreements that did not include any registration rights as they are exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act), and Rule 506 promulgated thereunder. The remaining 2,877,092 shares were acquired by others pursuant to the form of a April 2022 Subscription Agreements whereby we agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the SEC no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company used the proceeds to, among other things, fund the partial repayment of the 2021 Term Loan and for general corporate purposes (see &#x2013; Part II - Item 8, Financial Statements and Supplementary Data).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no sales of unregistered securities for the year ended December 31, 2021. From January 1, 2020 through December 31, 2020, we granted stock options under our 2016 and 2006 Stock Plans to purchase 0.8 million shares of our common stock at exercise prices ranging from $0.77 to $6.83 per share, and issued an aggregate of 0.4 million shares of common stock pursuant to the exercise of stock options with aggregate proceeds of approximately $1.3 million. These issuances were undertaken in reliance upon an exemption from registration under Rule 701 of the Securities Act of 1933.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biodesix, Inc. is referred to throughout this Annual Report on Form 10-K for the period ended December 31, 2022 (Form 10-K) as &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d; or the &#x201c;Company.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following discussion of our financial condition and results of operations should be read together with our audited financial statements and related notes and other financial information included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In addition to historical financial information, this discussion and other parts of this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#x201c;Risk Factors&#x201d; under Part I, Item 1A above. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ from those anticipated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A), is provided to supplement the audited financial statements and the related notes in Part II - Item 8 of this Annual Report on Form10-K. We intend for this discussion to provide you with information that will assist you in understanding our financial statements, the changes in key items in those financial statements from year to year and the primary factors that accounted for those changes. Data for the years ended December 31, 2022 and 2021 has been derived from our audited financial statements included in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology multi-omic approach with a holistic view of the patient&#x2019;s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient&#x2019;s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe helps improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI-based Diagnostic Cortex&#174; platform to discover innovative diagnostic tests for clinical use. The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of diagnostic tests, which we believe overcomes standard machine learning challenges faced in life sciences research. Our data-driven and multi-omic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic treatment landscape to identify additional clinical unmet needs where a diagnostic test could help improve patient care. Additionally, we incorporate clinical and molecular profiling data from our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, to continue to advance our platform. We have a variety of samples with associated data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development initiatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have commercialized five diagnostic tests for our core lung diagnostic business, each of which have Medicare coverage, which are currently available for use by physicians. Our Nodify XL2 and Nodify CDT tests, marketed as part of the Nodify Lung Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. The Nodify Lung Risk Assessment testing strategy has resulted in a change in the calculated risk of malignancy in 80-85% of the cases. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests, marketed as the IQLung testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat targeted tumor profiling test and the VeriStrat immune profiling test now have a turnaround time of two business days, down from the previous three business day turnaround time,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">providing physicians with timely results to facilitate treatment decisions. The GeneStrat NGS test is our blood-based NGS test with results in three business days, was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify all four major mutation classes and genes, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe&#153; testing program, which include three commercialized tests. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two FDA EUA authorized tests, a part of our customizable program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic services. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020. Prior to using the Bio-Rad SARS-CoV-2 tests as part of our testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Beginning in second quarter 2021, we began partnering with GenScript Biotech Corporation to commercialize the blood-based cPass SARS-CoV-2 Neutralizing Antibody testing as a service. The test is the first surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the RBD in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. The EUA declaration under Section 564 of the FDCA is distinct from and independent of the declaration by the Secretary of HHS of a public health emergency under Section 319 of the Public Health Service Act (the PHS Act). On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#x2019;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. Because the EUA declaration from the FDA is distinct from the declaration under Section 319 of the PHS Act, the FDA EUA may remain in effect beyond the duration of the Section 319 declaration. We cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems. We announced multiple partnerships for COVID-19 testing, and maintained an agreement with the State of Colorado to be one of the diagnostic companies to support widespread COVID-19 testing for the State, which expired on August 31, 2022. Additionally, we oversaw and managed onsite testing and validating testing for the Big Ten Conference athletic competitions through the term of our contract which expired on June 30, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the eight diagnostic tests currently on the market, we perform over 30 assays for research use as part of our laboratory services that have been used by over 60 biopharmaceutical companies and academic partners. All of our diagnostic and services testing is performed at one of our two accredited, high-complexity clinical laboratories in Boulder, Colorado and De Soto, Kansas.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have performed over 550,000 clinical diagnostic tests, and continue to generate a large and growing body of clinical evidence consisting of over 300 clinical and scientific peer-reviewed publications, presentations, and abstracts. Through ongoing study of each of our tests, we continue to grow our depth of understanding of disease biology and the broad utility of each of our tests. We believe we are poised for rapid growth by leveraging our scientific development and laboratory operations expertise along with our commercial infrastructure which includes sales, marketing, reimbursement, and regulatory affairs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, we market our tests to clinical customers through our targeted sales organization, which includes sales representatives that are engaged in sales efforts and promotional activities primarily to pulmonologists, oncologists, cancer centers and nodule clinics. We market our tests and services to biopharmaceutical companies globally through our targeted business development team, which promotes the broad utility of our tests and testing capabilities throughout drug development and commercialization which is of value to pharmaceutical companies and their drug-development process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company continues to address our liquidity needs through improvements to our capital structure. During the year ended December 31, 2022, the Company completed various transactions, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a private placement offering that raised approximately $11.7 million in net equity proceeds in April 2022;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the closing of a debt facility with Streeterville in May 2022, raising approximately $12.8 million in net proceeds;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a follow-on public equity offering of common stock and a subscription agreement for the issuance of common stock, including to certain members of the Company&#x2019;s management team and affiliates, raising $37.8 million in net equity proceeds in November 2022;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the closing of a term loan facility with Perceptive for up to $50.0 million in November 2022. The initial funding of the Perceptive Term Loan included $30.0 million in gross proceeds ($27.9 million in net proceeds) (the Tranche A Loan) and the issuance of a warrant to purchase stock of up to 5,000,000 shares of common stock (the Perceptive Warrant), of which 3,000,000 warrants were issued with a per share exercise price equal to $1.0648. Two additional tranches of $10.0 million each are available for future borrowing (the Tranche B and Tranche C Loans), each subject to certain terms and conditions, including revenue milestones, with each tranche also subject to the issuance of 1,000,000 warrants at a per share exercise price determined at the time of issuance;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approximately $23.9 million of the net proceeds from the November 2022 transactions were used to extinguish outstanding debt with Streeterville and SVB;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">common stock sales raising $6.8 million in net equity proceeds through our at-the-market (ATM) and Lincoln Park Capital, LLC (LPC) facilities.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of these transactions is described in further detail within the notes to our financial statements in Item 8 of this Annual Report on Form 10-K as well as our &#x201c;Liquidity and Capital Resources&#x201d; section below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have funded our operations to date principally from net proceeds from the issuances of our common stock, the sale of convertible preferred stock, revenue from diagnostic testing and services, and the incurrence of indebtedness. We had cash and cash equivalents of $43.1 million and $32.7 million as of December 31, 2022 and 2021, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Factors Affecting Our Performance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe there are several important factors that have impacted our operating performance and results of operations, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Testing volume and customer mix. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our revenues and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of our commercial tests, or the number of tests that we perform for patients on behalf of clinicians, as well as tests for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly impact our results of operations, as the average selling price for biopharmaceutical sample testing is currently significantly greater than our average selling price for clinical tests since we are not a contracted provider for, or our tests are not covered by all clinical patients&#x2019; insurance. We evaluate our average selling price for tests that are covered by Medicare, Medicare Advantage and commercial payers to understand the trends in reimbursement and apply those trends to our revenue recognition policies.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reimbursement for clinical diagnostic testing. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. On June 7, 2022, we announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix&#x2019;s De Soto, Kansas laboratory, has provided coverage for the Nodify CDT lung nodule test. All five Biodesix blood-based lung diagnostic tests within the Nodify Lung Nodule Risk Assessment testing strategy and IQLung strategy for lung cancer patients are now covered by Medicare. Payment from third-party payers differs depending on whether we have entered into a contract with the payers as a &#x201c;participating provider&#x201d; or do not have a contract and are considered a &#x201c;non-participating provider.&#x201d; Payers will often reimburse non-participating providers, if at all, at a lower rate than participating providers.</span></div></div>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Historically, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications. Becoming a participating provider generally results in higher reimbursement for covered indications and lack of reimbursement for non-covered indications. As a result, the impact of becoming a participating provider with a specific payer will vary. If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></p>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October, 17, 2022, the Company announced that the U.S. Department of Veterans Affairs (the VA), the largest integrated health care system in the United States, has awarded a Federal Supply Schedule Contract for the Company&#x2019;s entire portfolio of lung cancer diagnostic tests. The VA provides care at 1,298 health care facilities, including 171 VA Medical Centers and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,113 outpatient sites of care of varying complexity to over 9 million veterans enrolled in the VA health care program. All of our existing lung diagnostic tests will be payable when performed and partnering with the VA represents a large opportunity for Biodesix to help improve care for our Veterans by integrating our five diagnostic products and testing strategies into our country&#x2019;s largest health system.</span></p>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 19, 2022, the Company announced the signing of our first four private payer commercial policies covering our Nodify XL2 test. These contracts included three Blue Cross Blue Shield plans in North Carolina, South Carolina, and Kansas City, and a contract with Capital District Physician&#x2019;s Health Plan in New York. In total these new private pay contracts add approximately 4.5 million covered lives, and are in geographic regions of the country where the incidence of lung cancer is high.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in clinical studies and product innovation to support growth. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A significant aspect of our business is our investment in research and development, including the development of new products and our investments in clinical utility studies. We have invested heavily in clinical studies for our on market and pipeline products. Our studies focus primarily on the clinical utility of our tests including the ongoing INSIGHT study which seeks to enroll up to 5,000 patients to continue our clinical understanding of the predictive and prognostic value of the VeriStrat test. The ALTITUDE study, launched during the fourth quarter 2020, seeks to further demonstrate the efficacy of the Nodify XL2 and Nodify CDT tests. A secondary focus of our studies is understanding the economic impact of our tests in assisting with decisions related to patient management and the potential impact of our tests in reducing overall healthcare costs.</span></div></div>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical research has resulted in approximately 90 peer-reviewed publications for our tests. In addition to clinical studies, we are collaborating with investigators from multiple academic cancer centers. On June 3, 2022, we announced the intent to develop a new novel molecular minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and the Company also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. We believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers and expect our investments in research and development to increase. Further we also expect to increase our research and development expenses to fund further innovation and develop new clinically relevant tests.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ability to attract new biopharmaceutical customers and maintain and expand relationships with existing customers. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business development team promotes the broad utility of our products for biopharmaceutical companies in the United States and internationally. Our revenue, business opportunities and growth depend in part on our ability to attract new biopharmaceutical customers and to maintain and expand relationships with existing biopharmaceutical customers. We expect to increase our sales and marketing expenses in furtherance of this as we continue to develop these relationships, we and expect to support a growing number of investigations and clinical trials. If our relationships expand, we believe we may have opportunities to offer our platform for companion diagnostic development, novel target discovery and validation efforts, and to grow into other commercial opportunities. For example, we believe our multi-omic data including genomic and proteomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, including for novel target identification and companion diagnostic discovery and development. </span></div></div>
  <p style="margin-left:8.0%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 30, 2022, the Company announced an arrangement with Royal Philips, a global leader in health care technology, in which our Nodify Lung blood-based lung nodule risk assessment testing will be incorporated into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data &#x2013; along with the radiologic and patient history data currently used to determine treatment decisions &#x2013; can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases, via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator. Philips Lung Cancer Orchestrator solution is designed to enable health systems to operationalize lung cancer screening and lung nodule management programs at scale.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Motivating and expanding our field sales force and customer support team. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our field sales force is the primary point of contact in the clinical setting. These representatives of the company must cover expansive geographic regions which limits their time for interaction and education of our products in the clinical setting. We plan to continue investing in the field sales force, increasing the total number of sales representatives to drive continued growth, and thereby reduce the geographic footprint each representative must cover. This investment will allow the larger sales force to maximize their education and selling efforts and achieve greater returns. Additionally, we plan to invest in the Boulder-based marketing and customer support teams to continue to provide the field team with the resources to be successful in the field.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A. &#x201c;Risk Factors&#x201d; for more information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 Pandemic</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic has disrupted, and may continue to disrupt, our lung diagnostic testing operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees working on-site,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implemented social distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#x2019; public health orders and the guidance from the Centers for Disease Control and Prevention (CDC). Employees who can perform their duties remotely have the option to work from home. Our sales, marketing and business development efforts may be constrained by our operational response to future COVID-19 variant outbreaks. We will continue to adjust our operational norms, as needed, to help slow the spread of COVID-19, including complying with government directives and guidelines as they are modified and supplemented.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic and the surge associated with multiple variants have negatively affected our lung diagnostic testing-related revenue and our clinical studies. Beginning in the third quarter 2020, the Company&#x2019;s COVID-19 testing services began to experience rapid growth with a peak in the first quarter 2021; however, subsequent to this peak, we experienced a rapid decline in COVID-19 testing revenue primarily as a result of a few significant contracts that expired as well as the ongoing increase in COVID-19 vaccination rates across the U.S. and the adoption and availability of at-home testing. We do not anticipate the need for COVID-19 testing to be commensurate with the peak demand experienced during the first quarter 2021 and instead expect the demand to substantially decline as our society adapts to a post-pandemic era. There is no assurance that our COVID-19 testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain and the need for COVID-19 testing could vary which could have a significant effect on our results of operations and profitability. As a result, increases in revenue, if any, due to any increase in demand for these diagnostic tests may not be indicative of our future revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Part I, Item 1A. &#x201c;Risk Factors&#x201d; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Quarter and Full Year 2022 Financial and Operational Highlights</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following were significant developments affecting our business, capital structure and liquidity during the year ended December 31, 2022 as compared to the same period in 2021 unless otherwise noted:</span></p>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenue of $9.6 million and $38.2 million for the fourth quarter and fiscal 2022, respectively, an increase of 33% and decrease of 30%, respectively, with continued growth in core lung diagnostic sales, offset by the expected year-over-year decline in COVID-19 revenue due to the decrease in testing across the year;</span></div></div>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Core lung diagnostic revenue of $8.2 million and $29.3 million for the fourth quarter and fiscal 2022, respectively, an increase of 51% and 57% driven by the increased adoption of Nodify Lung nodule management tests and the highest total tests delivered in Company history;</span></div></div>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biopharmaceutical Services revenue of $1.4 million and $3.7 million for the fourth quarter and fiscal year 2022 respectively, a decrease of 1% and 34%;</span></div></div>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 testing revenue declined to an immaterial amount and $5.2 million for the fourth quarter and fiscal year 2022, respectively, a decrease of 96% and 83% commensurate with the increase in COVID-19 vaccination rates across the U.S. and the adoption and availability of at-home testing, including the expiration of our most significant testing contracts;</span></div></div>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross margin was $6.3 million or 66% and $24.1 million or 63% for the fourth quarter and fiscal 2022, respectively, as a percentage of revenue compared to 65% and 44% primarily driven by the mix shift of sales to higher-margin core lung diagnostics and away from lower-margin COVID-19 testing;</span></div></div>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses (excluding direct costs and expenses) of $20.2 million and $74.6 million for the fourth quarter and fiscal year 2022, an increase of 23% and 15% primarily from year-over-year growth in core lung diagnostic revenue;</span></div></div>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss of $20.3 million and $65.4 million for the fourth quarter and fiscal year 2022, respectively, an increase of 53% and 52%;</span></div></div>
  <div style="margin-left:2.398%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents of $43.1 million, inclusive of $65.7 million of net proceeds during the fourth quarter 2022 through debt and equity offerings and the utilization of $23.9 million to extinguish outstanding debt.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Operating Results</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenues</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diagnostic Tests</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic test revenue is generated from delivery of results from our diagnostic tests. In the United States, we performed tests as both an in-network and out-of-network service provider depending on the test performed and the contracted status of the insurer. We provide diagnostic tests in two primary categories: (i) core lung diagnostics testing and (ii) COVID-19 testing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider diagnostic testing to be completed upon the delivery of test results to our customer, either the prescribing physician or third-party to which we contracted for services to be performed, which is considered the performance obligation. The fees for such services are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. We determine the transaction price related to our contracts by considering the nature of the payer, the historical amount of time until payment by a payer and historical price concessions granted to groups of customers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Services</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services revenue is generated from the delivery of our on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer. At times we collaborate with large biopharmaceutical companies in an attempt to discover biomarkers that would be helpful in their drug development or marketing. The performance obligations and related revenue for these sales is defined by a written agreement between us and our customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer, which is considered the performance obligation. Customers for these services are typically large pharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue derived from services is often unpredictable and can cause dramatic swings in our overall net revenue line from quarter to quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Direct costs and expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of diagnostic testing generally consists of cost of materials, direct labor, including bonuses, employee benefits, share-based compensation, equipment and infrastructure expenses associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties. Costs associated with performing our tests are recorded as the tests are processed regardless of whether revenue was recognized with respect to the tests. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. Under these license agreements, we are obligated to pay aggregate royalties ranging from 1% to 8% of sales in which the patents or know-how are used in the product or service sold, sometimes subject to minimum annual royalties or fees in certain agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the aggregate cost of diagnostic testing to increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions. Cost of services includes costs incurred for the performance of development services requested by our customers. Costs of development services will vary depending on the nature, timing and scope of customer projects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist of costs incurred to develop technology and include salaries, share-based compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, clinical studies, other outside costs and costs to develop our technology capabilities. Research and development expenses account for a significant portion of our operating expenses and consist primarily of external and internal costs incurred in connection with the discovery and development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">External expenses include: (i) payments to third parties in connection with the clinical development of our product candidates, including contract research organizations and consultants; (ii) the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations (CMOs) and consultants; (iii) scientific development services, consulting research fees and for sponsored research arrangements with third parties; (iv) laboratory supplies; and (v) allocated facilities, depreciation and other expenses, which include direct or allocated expenses for IT, rent and maintenance of facilities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We track external costs by the stage of program, clinical or preclinical.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal expenses include employee-related costs, including salaries, share-based compensation and related benefits for employees engaged in research and development functions. We do not track internal costs by product candidate because these costs are deployed across multiple programs and, as such, are not separately classified.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our research and development expenses to increase as we continue to innovate and develop additional products and expand our data management resources. As our services revenue grows, an increasing portion of research and development dollars are expected to be allocated to cost of services for biopharmaceutical service contracts. This expense, though expected to increase in dollars, is expected to decrease as a percentage of revenue in the long term, though it may fluctuate as a percentage of our revenues from period to period due to the timing and extent of these expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales, marketing, general and administrative</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, share-based compensation, and travel, as well as marketing and educational activities and allocated overhead expenses. We expect our sales and marketing expenses to increase in dollars as we expand our sales force, increase our presence within the United States, and increase our marketing activities to drive further awareness and adoption of our tests and our future products. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage of our revenues from period to period due to the timing and extent of these expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our general and administrative expenses include costs for our executive, accounting, finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, share-based compensation, and travel, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in dollars, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Fair Value of Contingent Consideration</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the purchase transaction of Indi, we recorded contingent consideration pertaining to the amounts potentially payable to Indi shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration was assessed at each balance sheet date and changes, if any, to the fair value were recognized as operating expenses within the statement of operations. The Company achieved the gross margin target of $2.0 million for three consecutive months during the three months ended June 30, 2021. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule. The significant unobservable inputs used in the measurement of fair value included the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from 11% to 16%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. During the period ended June 30, 2022, the Company increased the discount rate to reflect current market and Company specific conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which the parties agreed to restructure the milestone payments whereby the Company will make five quarterly installments of $2.0 million each beginning in April 2022, three quarterly installments of $3.0 million beginning in July 2023, one installment of $5.0 million in April 2024, and one installment of approximately $8.4 million in July 2024. In addition, the Company agreed to an exit fee of approximately $6.1 million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to 10%, with such interest to be payable quarterly on the following installment payment date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense and Interest Income</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, interest expense consists of cash and non-cash interest from the secured promissory note (Promissory Note One) with Streeterville, the 2021 Term Loan with SVB, changes in the value of our contingent consideration associated with the passage of time subsequent to the achievement of the gross margin target in the second quarter 2021, and the Perceptive Term Loan. For the year ended December 31, 2021, interest expense primarily consists of cash and non-cash interest from our 2021 Term</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan, the 2018 Innovatus Term Loan, Paycheck Protection Program loan, and changes in the value of our contingent consideration associated with the passage of time subsequent to the achievement of the contingency in the second quarter 2021. Interest income, which is included in &#x2018;Other income, net&#x2019; in the statements of operations consists of income earned on our cash and cash equivalents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the significant components of our results of operations for the periods presented (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.792%;"></td>
    <td style="width:1.121%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.136%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.121%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.331%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.121%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.793%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.581%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,212</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,506</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16,294</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(30</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,154</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,518</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16,364</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(54</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,102</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,789</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">313</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,462</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,517</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,945</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of contingent consideration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,622</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,622</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment loss on intangible assets</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,799</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,446</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,647</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(50,587</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(40,940</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9,647</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(24</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other (expense) income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(8,072</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,508</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,564</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Loss) gain on extinguishment of liabilities, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,981</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,298</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9,279</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">404</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (loss), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(118</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,311</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other expense</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(14,860</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,219</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,641</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">570</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(65,447</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(43,159</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(22,288</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(52</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,961</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,944</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,017</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Amounts represent share-based compensation expense reported in the Company&#x2019;s results of operations above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We generate revenue by providing laboratory testing of our diagnostic tests and services. Our revenues for the periods indicated were as follows (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.896%;"></td>
    <td style="width:1.132%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.953000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.123%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.353000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.123%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.815000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.003%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.602%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,240</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,227</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(24,987</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(83</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lung Diagnostic</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,298</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,710</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,588</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic testing revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,538</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,937</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(14,399</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(29</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services revenue</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,569</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,895</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(34</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,212</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,506</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16,294</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(30</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenue decreased $16.3 million or 30% for the year ended December 31, 2022 compared to the year ended December 31, 2021 primarily as a result of our expected decline in COVID-19 testing demand.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic test revenue decreased $14.4 million or 29% for the year ended December 31, 2022 compared to the year ended December 31, 2021. The decrease for the year ended December 31, 2022 compared to the same period in 2021 is due to a $25.0 million reduction in COVID-19 revenue resulting from an increase in COVID-19 vaccination rates across the U.S. and the adoption and availability of at-home testing, including the expiration of significant testing contracts. The reduction in COVID-19 revenue was partially offset by an increase in our core lung diagnostic revenue of $10.6 million driven primarily from an increase in our Nodify Lung and GeneStrat NGS tests delivered. The Company&#x2019;s core lung diagnostic sales efforts continued to gain momentum throughout the year ended December 31, 2022 with our fourth quarter core lung diagnostic business delivering our highest number of tests in Company history as the COVID-19 pandemic receded and as health care practitioners, including pulmonologists, increasingly returned to pre-pandemic related care.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services revenue decreased $1.9 million or 34% for the year ended December 31, 2022 compared to the same period in 2021 due to lower testing volumes driven by sample shipping logistics impacting timelines for existing and new agreements. In addition to delayed receipts in samples, service revenue can fluctuate due to several factors including contract timing, which can be long under normal circumstances, and currently reflects the slower pace of overall prospective clinical trial enrollment recovering from disruptions put forth by COVID-19.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Direct costs and expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses related to revenue decreased $16.4 million or 54% for the year ended December 31, 2022 compared to the year ended December 31, 2021. The decrease in costs for the year ended December 31, 2022 was driven primarily by the overall decline in COVID-19 testing revenue, as vaccinations increased as well as broader adoption and availability of at-home testing, partially offset by an increase in direct costs and expenses associated with increased lung diagnostic revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses increased $0.3 million or 2% for the year ended December 31, 2022 compared to the year ended December 31, 2021. The increase in cost was due primarily to an increase in clinical trial costs, partially offset by a decrease in other laboratory costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our external and internal costs for the years ended December 31, 2022 and 2021 (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.265%;"></td>
    <td style="width:1.132%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.83%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.123%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.229000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.123%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.69%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.48%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.123%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">External expenses:</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials and associated costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,551</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,061</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">490</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other external costs</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,625</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,810</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(185</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(5</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total external costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,176</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,871</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">305</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal expenses</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,926</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,918</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,102</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,789</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">313</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales, marketing, general and administrative</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative expenses increased $10.9 million or 22% for the year ended December 31, 2022 compared to the year ended December 31, 2021. This increase was driven primarily by increases in employee compensation and benefits associated with an increase in sales team headcount and variable compensation during 2022 as compared to 2021. This is also the result of increases in non-employee costs associated with increased spending on various sales meetings, training, and campaigns resulting from supporting the growth in our core lung diagnostic business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in fair value of contingent consideration</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of contingent consideration decreased $1.6 million or 100% for the year ended December 31, 2022 compared to the year ended December 31, 2021. Changes in the fair value of contingent consideration subsequent to the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule (see &#x2018;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest expense&#x2019;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> below).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense increased $3.6 million or 79% for the year ended December 31, 2022 compared to the year ended December 31, 2021. This increase is primarily related to increased interest associated with the contingent consideration of $1.1 million subsequent to the achievement of the gross margin target (see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x2018;Change in fair value of contingent consideration&#x2019;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above), Promissory Note One with Streeterville of $1.8 million, interest associated with the 2021 Term Loan (including the accelerated accretion of the 2021 Term Loan final payment of $0.7 million), and interest associated with the Perceptive Term Loan of $0.5 million. This increase is partially offset by interest associated with the Innovatus Term Loan in 2021 that is not present in 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Loss) gain on extinguishment of liabilities, net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded a loss on extinguishment of liabilities of $7.0 million for the year ended December 31, 2022. On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which all parties agreed to restructure the milestone payments. During the three months ended June 30, 2022, the Company evaluated Amendment No. 3 to the Indi APA in accordance with applicable accounting standards under U.S. GAAP which resulted in the extinguishment of the original instrument due to the substantially different terms. As a result, during the three months ended June 30, 2022, we recorded a loss on the extinguishment of $2.9 million. Additionally, as a result of the extinguishment of Promissory Note One and the 2021 Term Loan, the Company recorded a loss on debt extinguishment of $3.6 million and $0.5 million, respectively, associated with the prepayment premium and the write-off of unamortized original issue discount (OID) and debt issuance costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, we recognized a $2.3 million net gain on debt extinguishment. The Company recorded a gain on debt extinguishment of $3.1 million related to the legal release and forgiveness of the Paycheck Protection Program Loan in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">full. The gain was partially offset by losses on debt extinguishment of $0.7 million and $0.1 million resulting from the repayment and termination of our 2018 secured promissory note with Innovatus and the write-off of debt issuance costs associated with a $20 million prepayment of our 2021 Term Loan, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in fair value of warrant liability</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan, the Company issued the Perceptive Warrant, with warrants exercisable into 3,000,000 shares of the Company&#x2019;s common stock issued on the funding date of the Tranche A Loan which are equity classified (the Initial Warrants). In addition to the Initial Warrants and to the extent the Company exercises its right to borrow the remaining availability under the Perceptive Term Loan, additional warrants will become exercisable into 1,000,000 shares of common stock concurrently with the borrowing of the Tranche B Loan, and additional warrants will become exercisable into 1,000,000 shares of common stock concurrently with the borrowing of the Tranche C Loan (together, the Additional Warrants). The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity classification. The Company determined the initial fair value of the Additional Warrants to be $0.1 million and during the year ended December 31, 2022, the Company recorded $0.1 million as a change in fair value through the statement of operations due to changes in unobservable inputs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an emerging growth company and, as such, have yet to generate positive cash flows from operations. We have funded our operations to date principally from net proceeds from the sale of our common stock, the sale of convertible preferred stock, revenue from diagnostic testing and services, and the incurrence of indebtedness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the pandemic, the Company diversified its diagnostic testing beyond lung diagnostic testing to include the critical service of COVID-19 diagnostic testing. Beginning in the third quarter 2020, the Company&#x2019;s COVID-19 testing services began to experience rapid growth with a peak in the first quarter 2021; however, subsequent to this peak, we experienced a rapid decline in COVID-19 testing revenue primarily as a result of a few significant contracts that expired as well as the ongoing increase in COVID-19 vaccination rates across the U.S. and the adoption and availability of at-home testing. In addition, the COVID-19 pandemic negatively affected our lung diagnostic testing-related revenue and our clinical studies. We began to see recovery during the fourth quarter 2020 in our core lung diagnostic testing as our delivered tests exceeded first quarter 2020 delivered tests and have continued to grow thereafter. The Company&#x2019;s sales efforts continued to be impacted by the COVID-19 pandemic due to surges associated with variants, which have negatively affected the growth rate of our core lung diagnostic testing-related revenue and our clinical studies. While we have seen recovery in delivered tests during 2022 in lung diagnostic testing as health care practitioners, including pulmonologists, increasingly returned to pre-pandemic related care, we have experienced more variability as compared to pre-pandemic levels as physician practices are adjusting to post-pandemic levels of care. As a result, the items identified above have had an adverse effect on our revenue, results of operations and cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, we completed the closing of our 2021 Term Loan with SVB for a principal amount of $30 million and extinguished our prior 2018 term loan for $25.9 million. During the quarter ending June 30, 2021, we achieved the gross margin target associated with the purchase transaction with Indi, giving rise to the previously disclosed contingent obligations of $37.0 million in the aggregate, payable through the issuance of our shares of common stock subject to a fixed price put option. We entered into an amendment in August 2021 to the original agreement in which all parties agreed to forgo the issuance of our shares of common stock that would otherwise be issued, and we would instead make six quarterly installment payments of $4.6 million beginning in January 2022 and a final payment of approximately $9.3 million in July 2023 for a total of $37.0 million (the Milestone Payments and each individually a Milestone Payment). The aggregate amount of payments owed by us under this amendment is the same as if Indi had exercised the put right or we had exercised the call right provided for in the original agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 30, 2021, we entered into the Consent and First Amendment to Loan and Security Agreement (the 2021 Term Loan Amendment) to, among other things, amend our 2021 Term Loan to eliminate the revenue covenant for the period ended September 30, 2021 and modify the revenue covenant threshold for the three month period ended December 31, 2021. In addition, we agreed to establish a restricted cash collateral account for $15 million for the benefit of SVB if the balance of our cash and cash equivalents declined below $40 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 30, 2021, we raised approximately $16.3 million in gross proceeds from the sale of 3,756,994 common shares at a public offering price of $4.35 per share in an at-the-market offering. We received net proceeds of $15.7 million after deducting underwriting discounts and commissions and offering expenses payable by us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 31, 2021, we entered into the Consent and Second Amendment to Loan and Security Agreement (the 2021 Term Loan Second Amendment) to, among other things, amend our 2021 Term Loan and First Amendment to obtain consent for the $4.6 million January 2022 milestone payment under the Indi APA, repay $20 million in outstanding principal on December 31, 2021, waive the $600,000 prepayment fee on the $20 million Term Loan repayment, and waive the minimum revenue covenant as of December 31, 2021 and modify the minimum revenue requirement for the three months ended March 31, 2022. SVB agreed to apply the full amount of funds previously established within the restricted cash collateral account to partially prepay the $20 million in outstanding principal, thereby eliminating the restricted cash collateral account.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2022 (the Effective Date), we entered into a purchase agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $50.0 million of our common stock (the Purchase Agreement). Under the terms and subject to the conditions of the Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0 million of our common stock. Such sales of common stock by us, if any, will be subject to certain limitations, and may occur from time to time, at our sole discretion, over the 36-month period commencing on the Effective Date. As consideration for Lincoln Park's irrevocable commitment to purchase our common stock upon the terms of and subject to satisfaction of the conditions set forth in the purchase agreement, on the Effective Date, we issued 184,275 shares of common stock to Lincoln Park as a commitment fee valued at $600,000 for which no consideration was received.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, we entered into subscription agreements with a consortium of investors, including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of an aggregate of 6,508,376 shares of our common stock in an offering for an aggregate purchase price of approximately $11.7 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, we entered into the Consent and Third Amendment to Loan and Security Agreement (the 2021 Term Loan Third Amendment) whereby subject to the terms and conditions of the Third Amendment, certain waivers and consents were provided. Under the terms of the Third Amendment to our 2021 Term Loan, we agreed to the repayment of $3.0 million in outstanding principal in April 2022 with an additional $2.0 million to be paid no later than September 30, 2022, in exchange for the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent for a $2.0 million April 2022 mutually agreed upon Milestone Payment under the Indi APA, as amended;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waiver of minimum revenue requirement for the three months ended March 31, 2022 and adjustment of remaining revenue milestones for 2022; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waiver and elimination of the prepayment fee on the $3.0 million 2021 Term Loan partial repayment in April 2022 and subsequent $2.0 million principal repayment.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company further amended the Indi APA agreement in April 2022 in which all parties agreed to restructure the Milestone Payments whereby the Company will make five quarterly installments of $2.0 million each beginning in April 2022, three quarterly installments of $3.0 million beginning in July 2023, one installment of $5.0 million in April 2024, and one installment of approximately $8.4 million in July 2024. In addition, the Company agreed to an exit fee of approximately $6.1 million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to 10%, with such interest to be payable quarterly on the following installment payment date. Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan and commencing January 1, 2024, consent from Perceptive.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 9, 2022, the Company entered into a securities purchase agreement with Streeterville (the Lender), pursuant to which, among other things, the Lender: (i) purchased Promissory Note One in the aggregate principal amount totaling $16.0 million in exchange for $15.0 million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company&#x2019;s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $10.3 million in exchange for $10.0 million in cash proceeds. Each of the Promissory Notes may, at the Company's option, be settled in cash or shares of common stock of the Company, upon the terms and subject to the limitations and conditions set forth in the Promissory Notes. On May 9, 2022, the Company closed on the first tranche for gross proceeds of $15.0 million (approximately $12.8 million, net, after deducting debt issuance costs and OID).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 30, 2022, the Company entered into the Consent and Fourth Amendment to Loan and Security Agreement (the 2021 Term Loan Fourth Amendment). Under the terms of the 2021 Term Loan Fourth Amendment, the Company agreed to a repayment of $2.0 million in outstanding principal on the earlier of (a) November 30, 2022, or (b) the date on which our unrestricted cash held with SVB falls below $10.0 million, which could be extended to December 15, 2022, subject to equity fund raising of at least $5 million, in exchange for: (i) consent for the $2.1 million October 2022 milestone and interest payment under the Indi APA, as amended, and (ii) waiver and elimination of the prepayment fee on the subsequent $2.0 million 2021 Term Loan principal repayment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company funded and/or closed various financing transactions, including: (i) a term loan facility for up to $50.0 million, with funding of $30.0 million and the issuance of warrants exercisable into 3,000,000 shares of the Company&#x2019;s common stock occurring on November 21, 2022, and two additional contingently issuable tranches of $10.0 million each subject to certain terms and conditions, including revenue milestones, (ii) a follow-on equity offering of common stock and (iii) a subscription agreement for the issuance of common stock to certain members of the Company&#x2019;s management team. Collectively, the Company raised gross proceeds of approximately $70.7 million ($65.7 million after deducting commissions, fees and expenses payable). Approximately $23.9 million of the net proceeds were used to retire outstanding debt of the Company and the remaining proceeds of approximately $42.0 million will be used for commercial expansion of sales, supporting the Company&#x2019;s product pipeline, research and development and for general corporate purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As mentioned above, the Company maintains two facilities that enable equity financing on an ongoing basis at the Company&#x2019;s sole discretion, our ATM offering and our common stock purchase agreement with LPC (the LPC facility). During the year ended December 31, 2022, the Company raised approximately $7.3 million ($6.8 million after deducting underwriting discounts and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commissions and offering expenses payable), in gross proceeds from the sale of 3,886,893 common shares at a weighted average price per share of $1.87 under these programs. As of December 31, 2022, the Company had remaining available capacity for share issuances of approximately $29.5 million under the ATM facility and up to $46.9 million under the LPC facility, each subject to the restrictions and limitations of the underlying facilities, as well as volume limitations under applicable SEC rules and regulations that limit their availability as sources of funding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we maintained cash and cash equivalents of $43.1 million and we have $30.0 million in outstanding aggregate principal amount on our Perceptive Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources, including the debt and equity funding and amendments to the Indi APA, and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreement or to obtain waivers or amendments that impact the related covenants. As of December 31, 2022, the Company was in compliance with all restrictive and financial covenants associated with its borrowing. However, due to the continued uncertainty caused by the COVID-19 pandemic and the associated impacts on the recovery of our diagnostic testing and services, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity) or obtain waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration of the outstanding balances. We have taken steps to improve our liquidity through the actions noted above and have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. We plan to raise additional funding through the issuance of equity or debt securities and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period beyond one year from when the December 31, 2022 financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following summarizes our cash flows for the periods indicated (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.932%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.818%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.619%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.012%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash flows provided by (used in):</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(44,972</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(28,223</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,534</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,547</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,882</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,262</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,376</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(29,508</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cash flows resulted in a net increase in cash and cash equivalents and restricted cash of $10.4 million during the year ended December 31, 2022 as compared to the net decrease in cash of $29.5 million for the year ended December 31, 2021. For the year ended December 31, 2022, net cash used in operating activities increased by approximately $16.8 million due to a year-over-year increase in net loss from operations of $22.3 million, partially offset by an increase in non-cash expenses of approximately $14.5 million. In addition to the remaining $7.7 million increase in net loss, the Company had unfavorable changes in net working capital of $9.0 million. The unfavorable changes in net working capital are primarily as a result of the $5.0 million transferred as a refundable deposit to secure the performance of the Company&#x2019;s obligations under the operating lease agreement with Centennial Valley Properties I, LLC (the CVP Lease) and a decrease in cash collections from customers and payments to vendors. Partially offsetting the unfavorable changes in net working capital is $2.5 million in capital expenditures for leasehold improvements related to the CVP Lease pursuant to agreed upon tenant improvement allowances which have been reimbursed from the CVP landlord.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities during the year ended December 31, 2022 totaled $3.5 million, an increase of $1.0 million compared to the same period in 2021. The increase in net cash used in investing activities was primarily due to increases in purchases of property and equipment and capital expenditures for leasehold improvements related to the CVP Lease. These leasehold improvements are tenant improvements and have been reimbursed from the Landlord, as described above in net cash used in operating activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities during the year ended December 31, 2022 totaled $58.9 million, an increase of $57.6 million compared to the same period in 2021. The net cash provided by financing activities for the year ended December 31, 2022 primarily resulted from $56.3 million net proceeds from the issuance of common stock, $41.4 million net proceeds from the issuance of Promissory Note One and the Perceptive Term Loan, and $0.6 million in proceeds from the issuance of common stock under the ESPP and exercise of stock options. These proceeds were partially offset by the repayment of Promissory Note One and the 2021 Term Loan of $28.6 million, and milestone payments to Indi of $10.8 million. The net cash provided by financing activities for the year ended December 31, 2021 primarily resulted from $15.7 million net proceeds from our ATM public offering, net proceeds from our 2021 Term Loan of $29.9 million, and proceeds from the issuance of common stock under the ESPP and exercise of stock options of approximately $1.1 million, primarily offset by the repayment of $25.4 million from our 2018 Term Loan and a $20 million prepayment on our 2021 Term Loan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our non-cancelable contractual obligations and commitments as of December 31, 2022 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.095%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.8500000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.8500000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.87%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.87%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.041%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.299999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments due by period</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than<br />1 year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 to 3<br />years</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 to 5<br />years</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More than<br />5 years</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings and interest </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,981</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,295</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,566</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,120</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,675</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,272</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,403</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease obligations </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,922</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,289</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,329</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,041</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,263</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,578</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,856</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,298</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,161</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,263</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty payments that we may owe are not included as the amount and timing of such payments is uncertain.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes the Perceptive Term Loan payments of principal and interest. Interest amounts associated with the Perceptive Term Loan are variable and estimated based on the interest rate in effect at December 31, 2022.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which all parties agreed to restructure the milestone payments associated with the contingent consideration (see Note 4 to our financial statements in Item 8 of this Annual Report on Form 10-K).</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Does not include the remaining contractually agreed upon tenant improvement allowances associated with the CVP Lease of $18.3 million which are expected to be received during fiscal year 2023 (see Note 9 to our financial statements in Item 8 of this Annual Report on Form 10-K).</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />There have been no other significant changes to our future contractual obligations as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we have not entered into any off-balance sheet arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with accounting principles generally accepted in the United States, we are required to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Certain of these estimates significantly influence the portrayal of our financial condition and results of operations and require us to make difficult, subjective or complex judgments. Our critical accounting policies are described in greater detail below and in Note 2 to our financial statements in Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for our goods or services. To determine revenue recognition for our arrangements with our customers, we perform a five-step process, which includes: (i) identifying the contract(s) with a customer; (ii) identifying the performance obligations in the contract; (iii) determining the transaction price; (iv) allocating the transaction price to the performance obligations in the contract; and (v) recognizing revenue when (or as) we satisfy our performance obligations. The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-based Compensation and Grant Date Fair Value</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation related to stock options granted to our employees, directors and non-employees is measured at the grant date based on the fair value of the award. For our service-based awards, the fair value of each award is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for share-based awards with performance conditions is recognized based upon the probability the performance conditions will be met as defined in the grant. Restricted stock units are measured at their grant date fair value using the closing price of our common stock on the date of grant and recognized to expense on a straight-line basis over the vesting period of each award. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use the Black-Scholes option-pricing model to estimate the fair value of our share-based option awards, which requires assumptions to be made related to expected term of an award, expected volatility, the risk-free rate and expected dividend yield. The fair value of our common stock is based on our closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. Changes in these subjective assumptions can materially affect the estimated value of equity grants and the share-based compensation that we record in our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2016, the FASB issued ASU No. 2016-2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Topic 842). This ASU intends to make accounting for leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. In addition to other related amendments, the FASB issued ASU No. 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Topic 842): </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Targeted Improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. The Company elected this transition method and adopted ASC 842 on January 1, 2022 and as a result, recorded operating lease right-of-use (ROU) assets of $1.3 million, including offsetting deferred rent of $0.1 million, along with the associated operating lease liabilities of $1.3 million. On January 1, 2022, the Company did not have any finance leases. Additional information and disclosures required by this new standard are contained in Note 3 and Note 9 to our financial statements in Part II of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023. The Company evaluated the guidance and determined the overall impact of the adoption will have an immaterial impact on our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the &#x201c;Sarbanes-Oxley Act&#x201d;), certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.24 billion in annual revenue; (ii) the date we qualify as a &#x201c;large accelerated filer,&#x201d; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) until December 31, 2025 (the year ended December 31st following the fifth anniversary of our initial public offering).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we are a &#x201c;smaller reporting company&#x201d; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which: (i) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year&#x2019;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by non-affiliates exceeds $700 million as of the end of that year&#x2019;s second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our indebtedness, including our outstanding Perceptive Term Loan. As of December 31, 2022, we had $30 million outstanding on the Perceptive Term Loan Facility which has an annual rate equal to the greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. and (b) 3.0% per annum, plus an applicable margin of 9.0%. Historically, we have not entered into derivative agreements such as interest rate caps and swaps to manage our floating interest rate exposure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodically throughout the year, we have maintained balances in various operating accounts in excess of federally insured limits. Our cash and cash equivalents are funds held in checking and bank savings accounts, primarily at two U.S. financial institutions. We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. We continually monitor our positions with, and the credit quality of, the financial institutions with which we invest.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, a hypothetical 100 basis point increase in interest rates would have an estimated $0.3 million impact per year on our financial position and results of operations, based on the current Perceptive Term Loan principal remaining outstanding through maturity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial statements and supplementary data are as set forth in the index to the financial statements on page F-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain &#34;disclosure controls and procedures,&#34; as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on their evaluation as of the end of the period covered by this Annual Report on Form 10-K, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company, as such term is defined in Exchange Act Rules 13a-15(f). Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the criteria established in &#34;Internal Control &#x2013; Integrated Framework&#34; issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), using the 2013 framework. Based on our assessment, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2022, the Company's internal control over financial reporting was effective based on the criteria set forth by COSO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This annual report does not include an attestation report of our registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the quarter ended December 31, 2022, there were no changes that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item with respect to directors is incorporated by reference from the information under the captions &#34;Board and Corporate Governance Matters&#x2014;Election of Directors&#34; and &#34;&#x2014;Director Independence&#34; contained in our Proxy Statement to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2022 in connection with the solicitation of proxies for our 2023 Annual Meeting of Stockholders (the Proxy Statement). Certain information required by this item concerning executive officers is set forth in the Proxy Statement under the caption &#34;Executive Compensation&#x2014;Compensation of Named Executive Officers&#34; and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 405 of Regulation S-K calls for disclosure of any known late filing or failure by an insider to file a report required by Section 16(a) of the Exchange Act. This disclosure is contained in the section entitled &#34;Stock Ownership&#x2014;Delinquent Section 16(a) Reports&#34; in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that applies to all of our officers and employees, including our President and Chief Executive Officer, our Chief Financial Officer and other employees who perform financial or accounting functions. The Code of Business Conduct and Ethics sets forth the basic principles that guide the business conduct of our employees. Stockholders may request a free copy of our Code of Business Conduct and Ethics by contacting Biodesix, Inc., Attention: Chief Financial Officer, 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, there have been no waivers under our Code of Business Conduct and Ethics. We intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics or waivers of such Codes granted to executive officers and directors on our website at http://www.biodesix.com within four business days following the date of such amendment or waiver.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Board of Directors has appointed an Audit Committee, comprised of Ms. Jean Franchi, as Chairwoman, Messrs. Hany Massarany, Lawrence T. Kennedy, Jr., and Dr. Matthew Strobeck. The Board of Directors has determined that Ms. Franchi qualifies as an Audit Committee Financial Expert under the definition outlined by the Securities and Exchange Commission. In addition, each of the members of the Audit Committee qualifies as an &#34;independent director&#34; under the current rules of The NASDAQ Stock Market and Securities and Exchange Commission rules and regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information under &#34;Executive Compensation&#34; contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information under the captions &#34;Stock Ownership&#x2014;Security Ownership of Certain Beneficial Owners and Management&#34;, &#34;Executive Compensation&#34;, and &#34;Equity Compensation Plan Information&#34; contained in the Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information under the caption &#34;Board and Corporate Governance Matters&#x2014;Certain Relationships and Related-Party Transactions&#34; and &#34;&#x2014;Director Independence&#34; contained in the Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tant Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information under the caption &#34;Audit Matters&#x2014;Principal Accountant Fees and Services&#34; contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Documents filed as a part of the report. </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements</span></div></div>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference is made to the Index to Financial Statements of Biodesix, Inc. included in Item 8 of Part II hereof.</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All schedules have been omitted because they are not required, not applicable, or the required information is included in the financial statements or notes thereto.</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Item 15(b) below. Each management contract or compensating plan or arrangement required to be filed has been identified. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 10-K Summary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="exhibit_index"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.713%;"></td>
    <td style="width:1.398%;"></td>
    <td style="width:8.611%;"></td>
    <td style="width:82.278%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459020056735/bdsx-ex31_716.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of Biodesix, Inc., dated October 30, 2020 (incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on December 10, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459020056735/bdsx-ex32_717.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of Biodesix, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on October 12, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex41.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen stock certificate evidencing shares of Common Stock (incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eleventh Amended and Restated Investor Rights Agreement, by and among Biodesix, Inc. and the investors listed on Exhibit A thereto, dated October 10, 2018 (incorporated by reference to Exhibit 4.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex43.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant held by Innovatus Life Sciences Lending Fund I, LP, to Purchase Series G Preferred Stock, dated February 23, 3018 (incorporated by reference to Exhibit 4.3 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-ex45_270.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.5 to the Company's Form 10-K filed with the SEC on March 16, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Note, dated November 21, 2022, issued by the Company to Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 4.1 and Exhibit 10.1 in the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.6**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex4_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant to Purchase Stock, dated November 21, 2022, issued by the Company to Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 4.2 in the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc. Amended and Restated 2006 Employee, Director and Consultant Stock Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1021.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Grant Notice under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1022.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Option Agreement under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.2 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2.3+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1023.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Notice of Exercise under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.3 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex103.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc. 2016 Equity Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1041.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Grant Notice under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1042.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Option Agreement under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.2 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4.3+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1043.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Notice of Exercise under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.3 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520275630/d937421dex105.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 26, 2020).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.722%;"></td>
    <td style="width:82.278%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-ex1051_388.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5.1 to the Company's Form 10-K filed with the SEC on March 16, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1052_236.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of Restricted Stock Unit Award Grant Notice and Award Agreement under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5.2 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520275630/d937421dex106.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1051.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc., First Amended Bonus-to-Options Program, adopted by the Board of Directors on October 15, 2010 (incorporated by reference to Exhibit 10.5.1 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1052.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc., Second Amended Bonus-to-Options Program, adopted by the Board of Directors on June 21, 2011 (incorporated by reference to Exhibit 10.5.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7.3+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1053.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc., Third Amended Bonus-to-Options Program, adopted by the Board of Directors on December 31, 2015 (incorporated by reference to Exhibit 10.5.3 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022014433/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022014433/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8.3+*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex10_83.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 2 to the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1061.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Grant Notice under the Biodesix, Inc. Bonus-To-Options Program (incorporated by reference to Exhibit 10.6.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1062.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Option Agreement under the Biodesix, Inc. Bonus-To-Options Program (incorporated by reference to Exhibit 10.6.2 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520268763/d937421dex107.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement, by and between Biodesix, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit 10.7 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11.1&#134;+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1091.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 16, 2018 (incorporated by reference to Exhibit 10.9.1 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11.2&#134;+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1092.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 23, 2020 (incorporated by reference to Exhibit 10.9.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12.1&#134;+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex10101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated March 11, 2011 (incorporated by reference to Exhibit 10.10.1 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12.2&#134;+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex10102.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated February 23, 2020 (incorporated by reference to Exhibit 10.10.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1011.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement, by and between David Brunel and Biodesix, Inc., dated September 19, 2020 (incorporated by reference to Exhibit 10.11 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14.1&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1011.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated October 5, 2011 (incorporated by reference to Exhibit 10.11 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.722%;"></td>
    <td style="width:82.278%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022003495/bdsx-ex10_132.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated January 24, 2022 (incorporated by reference to Exhibit 10.13.2 to the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 14, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1013.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Assignment of De Soto Facility, dated November 1, 2019 (incorporated by reference to Exhibit 10.13 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022009126/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease agreement by and between Centennial Valley Properties I, LLC and Biodesix, Inc. dated March 11, 2022 (incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022009126/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Lease Agreement by and between Centennial Valley Properties I, LLC and Biodesix, Inc. dated March 11, 2022 (incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1015.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent Assignment between Biodesix, Inc., and Integrated Diagnostics, Inc., dated June 30, 2018 (incorporated by reference to Exhibit 10.15 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1015.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IP Assignment Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (incorporated by reference to Exhibit 10.15 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1016.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IP License Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (incorporated by reference to Exhibit 10.16 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1017.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated August 1, 2019 (incorporated by reference to Exhibit 10.17 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1018.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply Agreement between Biodesix, Inc., and Oncimmune, dated October 31, 2019 (incorporated by reference to Exhibit 10.18 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1019.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated August 1, 2019 (incorporated by reference to Exhibit 10.19 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1020.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Co-Development and Collaboration Agreement between AVEO Pharmaceuticals, Inc., and Biodesix, Inc., dated April 9, 2014, as amended October 14, 2016 (incorporated by reference to Exhibit 10.20 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1023.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Purchase Agreement among Biodesix, Inc., Integrated Diagnostics, Inc., and the stockholders of Integrated Diagnostics, Inc., listed therein, dated June 30, 2018 (incorporated by reference to Exhibit 10.23 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1038_489.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 2 to Asset Purchase Agreement and Plan of Reorganization (incorporated by reference to Exhibit 10.38 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022009126/bdsx-ex10_6.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 3 to Asset Purchase Agreement and Plan of Reorganization (incorporated by reference to Exhibit 10.6 to the Company's Form 10-Q filed with the SEC on May 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.25&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1024.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Purchase Agreement between Oncimmune Limited and Biodesix, Inc., dated June 27, 2019, as amended to date (incorporated by reference to Exhibit 10.24 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1029.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract Agreement between Biodesix, Inc. and the Colorado Department of Public Health and Environment, dated September 11, 2020 (incorporated by reference to Exhibit 10.29 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.27&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1030.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated March 23, 2020 (incorporated by reference to Exhibit 10.30 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.722%;"></td>
    <td style="width:82.278%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.27.1&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1031.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc. dated April 3, 2020 (incorporated by reference to Exhibit 10.31 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.28&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1032.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated April 17, 2020 (incorporated by reference to Exhibit 10.32 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.29&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1033.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated May 12, 2020 (incorporated by reference to Exhibit 10.33 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.30**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex1033.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter from Bio-Rad Laboratories, Inc. dated August 7, 2020 (incorporated by reference to Exhibit 10.33 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.31**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex1034.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter from Bio-Rad Laboratories, Inc. dated August 14, 2020 (incorporated by reference to Exhibit 10.34 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.32**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1037_47.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021 (incorporated by reference to Exhibit 10.37 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.33**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021014880/bdsx-ex101_29.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan and Security Agreement, dated March 19, 2021 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on March 23, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.33.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021056811/bdsx-ex1039_135.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent and First Amendment to Loan and Security Agreement, dated September 30, 2021 (incorporated by reference to Exhibit 10.39 to the Company's Form 10-Q filed with the SEC on November 15, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.33.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022000036/bdsx-ex10_40.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent and Second Amendment to Loan and Security Agreement, dated December 30, 2021 (incorporated by reference to Exhibit 10.40 to the Company's current report on Form 8-K filed with the SEC on January 4, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.33.3**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/bdsx-ex10_3.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent and Third Amendment to Loan and Security Agreement, dated April 7, 2022 (incorporated by reference to Exhibit 10.3 to the Company's current report on Form 8-K filed with the SEC on April 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.33.4**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022021488/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent and Fourth Amendment to Loan and Security Agreement, dated September 30, 2022 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on November 3, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.34**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022003002/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on March 7, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.35**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022003002/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Rights Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on March 7, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.36**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022009126/bdsx-ex10_7.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Secured Purchase Agreement by and between Streeterville Capital LLC and Biodesix, Inc. dated May 9, 2022 (incorporated by reference to Exhibit 10.7 to the Company's Form 10-Q filed with the SEC on May 11, 2022)</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.37**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022009126/bdsx-ex10_8.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Secured Convertible Promissory Note #1 by and between Streeterville Capital LLC and Biodesix, Inc. dated May 9, 2022 (incorporated by reference to Exhibit 10.8 to the Company's Form 10-Q filed with the SEC on May 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.38**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Subscription Agreement with resale registration rights provision, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on April 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.39**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Subscription Agreement without registration rights, entered by the three members of our Board of Directors, dated April 7, 2022 (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on April 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.40**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credit Agreement and Guaranty, dated as of November 16, 2022, by and among the Company and Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.722%;"></td>
    <td style="width:82.278%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.41**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Agreement, dated as of November 21, 2022, by and among the Company and Perceptive Credit Holdings IV, LP. (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.42**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022025530/bdsx-ex10_3.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Subscription Agreement, dated November 21, 2022 (incorporated by reference to Exhibit 10.3 to the Company's current report on Form 8-K filed with the SEC on November 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="#power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on the signature page of this Form 10-K).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2*</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134; Portions of this exhibit have been omitted as the Registrant has determined that the omitted information (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">**Previously filed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:  March 6, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ RYAN H. SIUREK</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ryan H. Siurek</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Accounting Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATTORNEY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each person whose signature appears below constitutes and appoints Scott Hutton and Robin Harper Cowie, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file with the Securities and Exchange Commission this Form 10-K and any and all amendments and exhibits thereto, and all documents in connection therewith, granting unto each such attorney-in-fact and agent full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.009%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:50.0%;"></td>
    <td style="width:1.296%;"></td>
    <td style="width:14.657%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ SCOTT HUTTON</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer (Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scott Hutton</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ ROBIN HARPER COWIE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer, Secretary and Treasurer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robin Harper Cowie</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ JOHN PATIENCE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">John Patience</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ JEAN FRANCHI</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jean Franchi</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ JON FAIZ KAYYEM</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jon Faiz Kayyem, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ LAWRENCE T. KENNEDY, JR.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lawrence T. Kennedy, Jr.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ HANY MASSARANY</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hany Massarany</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ JACK SCHULER</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jack Schuler</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MATTHEW STROBECK</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Matthew Strobeck, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ CHARLES WATTS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Charles Watts, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BIODESIX, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.0%;"></td>
    <td style="width:7.0%;"></td>
   </tr>
   <tr style="height:9.35pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_41c0270a-3e17-425f-bdc2-54f41ab62b47" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6984a144-370d-4f4d-9a0d-dd53d5ca5a8c" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denver, CO</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Auditor Firm ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b5871e8-3c61-405f-81f3-836ba5e18563" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations for the Years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Stockholders&#x2019; Equity for the Years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows for the Years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Regist</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Board of Directors and Stockholders of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc.:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying balance sheets of Biodesix, Inc. (the Company) as of December 31, 2022 and 2021, the related statements of operations, stockholders&#x2019; equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and needs to raise additional equity or debt capital to fund its operations. These matters raise substantial doubt about its ability to continue as a going concern. Management&#x2019;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ KPMG LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2016.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denver, Colorado</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 6, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.174%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.715%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.6%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.909%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="8" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dda5464c-adc2-49e2-9291-e7a0e058f986" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,088</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a333e070-dc72-4b5e-ab27-568e632f4056" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable, net of allowance for doubtful accounts of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcda2ee3-e062-4c88-adb2-76c607cab676" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_524813f3-050f-4df3-899c-29ad96f1e9a9" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7c45fcf-1070-4640-bd2a-8310452f1560" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,065</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_577dbc3f-ef9c-43a7-b435-e5c276b152fe" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2322410b-c752-42ca-a73c-7ca422f91443" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22a4228f-7615-4ea8-8f32-b986e01f74e5" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0347dc5-3d26-43e4-9aa8-82ece8f251c3" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ced0f2a-b8ed-4abc-af81-f829ea5e90dc" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,613</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non&#x2011;current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9c7c78f-4bb4-4ca0-9807-1f6bd16152f5" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,848</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c113909b-3b64-4672-98da-0b4512b4ad2f" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec137fd8-1709-449d-b5f8-f36707bb08f7" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_439875c4-f215-4d19-8dd2-e8224af71d80" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e1ab613-426d-4f24-9dbd-ef18adf87fdd" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d08a54ae-09c9-4d15-8b6b-b48d45a92d4e" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_072e7572-5deb-411b-b04c-41fa43ce6324" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ff4f8a7-b46f-40d4-97b5-35446da1a873" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,923</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e5c17bd-7e54-40db-9388-75a62c211ad6" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total non&#x2011;current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9ce929c-cf35-44ca-9c69-3d036f40e74a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,572</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_605b184f-2928-499d-be76-a147749bb2d3" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ecd1af7-9099-4225-b428-417dcc5fd8f1" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e1f5793-53e4-4dd2-a9b1-9941bb9b7b0e" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_917d8dd8-43a1-4cc7-89b6-eef564f43854" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,685</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53410f21-12b1-4cb8-813f-a1a807a7a368" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,662</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee0ca6d9-082e-40ca-9205-41e0bac6b227" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,218</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15f75bfe-d37d-4a70-b444-99357e23a78b" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7c7bbe3-f548-4049-9776-7b198e90c64f" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">962</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7530fc3-8d34-4b11-8f73-9c29a1676bc1" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a0963f7-d94f-4376-a398-6a29ebaea62b" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,543</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of contingent consideration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c310c508-77eb-4626-8ba4-9bb739107032" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a9d717b-c6fe-4800-8763-2e35777dba50" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of notes payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e4bffca-36ca-45f9-ba2c-1a4c25ae3844" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:NotesPayableToBankCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_342851b4-d4fa-4bc1-ad5d-4bbe0c3638fc" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:NotesPayableToBankCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bd08058-5e6e-416b-8928-8ea717f06c0f" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8f25b70-7e12-4eea-82f5-061cfc8e3a9c" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70594bc1-ab6c-4617-96ab-76277449e43c" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,960</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non&#x2011;current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long&#x2011;term notes payable, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bc88d4d-431b-48e1-b090-3dc87d55fc11" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,004</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aca26743-4a38-4fb2-bd08-612374c61960" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb221435-03aa-49ef-af40-d684e784240a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_788b32ae-7ccd-4a9f-9266-43b760e49ce3" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3220f85d-a146-43d1-9d7c-de030a06944d" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2a88761-3445-4829-b7de-d9edc0cf0890" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">558</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23af6b87-4c15-4fa6-83bf-9e6265c8fb46" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total non&#x2011;current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecf388d0-6d72-459a-b6b3-256faccbbd9a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9104aa10-0cf7-4a3e-8e35-3fbd68420676" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,410</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be4756d7-ca8c-4512-98ce-a0058b653f11" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a92f580-904a-48a8-92da-2e21e3e2c062" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_cf430efd-6ac3-4dc9-9262-706a09fd0cf7;"><span style="-sec-ix-hidden:F_b89a5dda-48e9-42c4-9317-c53410857718;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9797de81-3c47-4d64-bffd-4d5372f15282" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_a64eec61-c30b-42d8-a9f6-5e3ff3c2eb58" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d430bf7d-2656-46da-8825-6709cc52dfc5" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_91959079-b51d-4abb-a1e5-fc537435d51a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;authorized; <br />&#160;&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c48f01e-ae77-4b9a-ac0f-68c417e4f3e5" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_be4c50d9-5f13-46a8-9f4e-08607f5c13a3" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_72e04faa-f77f-49d1-a65b-c065aad05167" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_46f5f356-a1ce-4520-85af-0a5e61e0be94" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;(2022 and 2021) issued and outstanding</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_f737795f-9e9a-466d-855d-23c129fc9e09;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_ee27f4b8-44a6-44ae-b187-f23c3af6af75;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c36d3d5-1d2f-418e-b938-4b9e619f3cbb" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_4ad2bad9-7ed2-49b5-9c77-12a589ad0136" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f07b856b-d5cd-4dbc-9745-a958c9f0b986" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_a1e44f3c-8f50-4be0-bacb-b43646211206" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;authorized; <br />&#160;&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60c02517-f4fa-4bec-aa4f-6c60a0461ae0" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_b0847442-7c1d-40e7-b4d3-baf59ae87c41" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">77,614,358</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;(2022) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa5f4218-756e-4df2-87fd-2aada76ce2ed" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_0ae0c62f-f478-4165-b22c-97663adad6ee" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,789,649</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;(2021) shares issued and outstanding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82da3d79-04b5-47e4-b423-a367abbe1938" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b5ba8f7-d426-4318-87ce-b784945c91b8" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid&#x2011;in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55354123-fcc7-4f17-b5fd-3594567a0695" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">387,948</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0ecb209-f830-4239-acc5-3a885b0d6e7f" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">321,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f2a46bf-5b2d-4d20-a700-7cbbde3d3060" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">367,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adc9e0e6-276b-41d8-9bf2-2eab794531db" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">301,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9bcdd85-5a65-4278-9226-233b43806058" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,606</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7251897f-e102-4034-b99b-38bcc94dc97e" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,727</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_584a2bdf-812f-4f25-a22f-0c73f6d9bf39" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4edf7c81-b902-4d38-bf38-7b5d1d8545e9" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.265%;"></td>
    <td style="width:1.498%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.772%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.498%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.966000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4fe5362-54f7-4331-a32b-e68c9c7683bc" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,212</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e510e44-f0e8-482b-bed0-55e4050671c5" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3f135f4-13b8-4e7d-8805-ce829c147f52" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:DirectCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,154</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ca5f658-e2ba-4eac-801d-fd90e16a69e7" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="bdsx:DirectCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a80007e8-fd7c-4668-892a-cc224e647f11" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ca8b7ff-d770-4714-912e-d33ee664fde2" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ca6b272-ddcb-4cf0-a490-52225db57214" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66a18d36-7de2-42cc-bc69-e124e416c414" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,517</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of contingent consideration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_828fe776-1050-458c-819a-0e700a15f9af" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment loss on intangible assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da9a6757-904d-4161-851b-6abde68fd78f" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e724b1fd-68bd-4f82-a0ab-fe19b79bb738" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5396832e-066d-4b24-b78e-eb04af9c07ee" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,446</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eac0e2e2-347b-4ac8-9d52-fb81eef6c9b6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,587</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c296edd-0744-4158-95c9-85936a1f3830" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">40,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other (expense) income:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a19903e-85ce-4e8b-af86-c05369aa92ef" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04243237-6f7c-4666-a0fa-325798ba6214" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Loss) gain on extinguishment of liabilities, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4586f25f-8618-44c4-909a-cc84fe9a0f8a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,981</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd329f5b-7395-43b0-aeb2-ffea679f5938" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cead65e-02b0-4343-aa8f-8b41ad4349bb" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (loss), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cdebd0c-d412-4a35-a304-fbac6ec9024e" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b8012c3-f679-4ddc-880c-5076fac36ecd" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9bab2dc-9aed-41d0-b082-9168b7169fc5" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14,860</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c65c87d-72dc-4655-8441-62f25889fa64" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,219</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c80a8680-7b5f-456d-a874-93dc42d2a154" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">65,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a5c1a36-a85b-4ec0-833f-d1ba0afe64c2" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f6c32d3-71b2-43d5-8cb0-866be02389ec" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_4eeea12f-7ee3-41bd-b38d-4da11132768d" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.55</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d08189d-32c8-4633-9c2a-2a3b8076a983" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_816c4598-e7fd-4b7e-82f5-d9278556b016" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.58</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d6dae2c-aca9-4de9-9221-7602e581416a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_596f08c7-96ba-474e-a7c9-f9e62afb0f85" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">42,103</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd92d7e5-825c-4305-9a5c-4edf29e5b442" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_f03e756b-5000-4c05-9f19-dc54aa610eb4" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">27,365</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.808%;"></td>
    <td style="width:1.003%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.351999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.923%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.923%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.923%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.923%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Paid&#x2011;In</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders'</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2011; January 1, 2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fba87bb-dacd-4bbb-bb24-e282e48c4844" contextRef="C_e91484b1-4de4-45b4-9435-ca540a78f9e3" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">26,562</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae2fad16-60f9-4194-8939-cdb6703b6026" contextRef="C_e91484b1-4de4-45b4-9435-ca540a78f9e3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bc16159-5dc7-4372-8ae3-ab383ae6578d" contextRef="C_f5a69a51-44ec-42e5-af14-fd5467f50c5a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">299,953</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f51c0573-307a-4cfc-b6a3-b094af902233" contextRef="C_15d0eb8a-d853-4db8-a265-c8d1b3c9cc49" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">258,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f141e761-92e8-46f1-9a0a-7721ac277cfe" contextRef="C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,166</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4040b7f-a504-4860-96f8-80df53905f25" contextRef="C_12bd700e-0b10-4fb5-af15-894d72263e90" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">3,757</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e56f4bd-5501-40da-b019-4541690a7542" contextRef="C_12bd700e-0b10-4fb5-af15-894d72263e90" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87e3286c-11cc-4d7d-9280-422dba95d20e" contextRef="C_e75a16fb-16cc-42be-83c6-46117bcf8255" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,675</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1095a31f-d555-4e5b-b0bc-1b52e7512dad" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,679</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03419913-4b96-4776-8f5f-0bf0dbc20210" contextRef="C_12bd700e-0b10-4fb5-af15-894d72263e90" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d89fa647-4d13-4515-9acc-29f5b069ddc6" contextRef="C_e75a16fb-16cc-42be-83c6-46117bcf8255" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed20ecc9-0227-4b23-9811-6eaa45a05136" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7f0ffaa-5910-4539-a278-f4ccdc14df5b" contextRef="C_12bd700e-0b10-4fb5-af15-894d72263e90" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1aa956a8-5f2c-41b1-a16b-c26b8f4784bf" contextRef="C_e75a16fb-16cc-42be-83c6-46117bcf8255" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">769</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_670adf66-ad32-4f24-9df6-4828566da3b6" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">769</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share&#x2011;based compensation</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0517967e-a224-4a47-a061-e44c219c40d1" contextRef="C_e75a16fb-16cc-42be-83c6-46117bcf8255" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12c2e151-47ec-42a1-ae68-ea8ef31649bd" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4cdb1a5-3c6c-41a9-a88e-d4bbe5615714" contextRef="C_a72d645a-776a-4a74-9706-b63f1bd0e7e0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc960c50-7ee8-4084-a57d-a596da74c60e" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2011; December 31, 2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95de331a-54c8-4483-b30c-4926dc89eb32" contextRef="C_059b1c27-6f4f-4d72-9faa-e166f7b41f76" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">30,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a06d547-cb05-4e51-ab7b-3eaed6fa0e00" contextRef="C_059b1c27-6f4f-4d72-9faa-e166f7b41f76" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">31</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1245e5e-62ad-4b8f-a33e-743c29cdd4dd" contextRef="C_5de36142-f81f-4d20-84f5-a31e77b6a83f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">321,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd755c1f-35c4-4674-8953-dcd9f912cd9a" contextRef="C_96c6822f-7b22-47f1-bb03-2ae7e3cb1efc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">301,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4774790f-b4da-4b0b-9d2a-d5d493572248" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,727</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2d18b0f-1c8f-4d3e-8cba-107f42f43a17" contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">45,705</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d0ad8b6-0013-413b-bab5-9a8aad9418d6" contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c987126-498d-4d26-bc9e-9c9c87f71f84" contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7603f63c-1c28-4d20-b161-b5cee18c7bf7" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef835a55-74e2-4025-8e49-0f641fbb4dbb" contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b805e21-fa16-48ca-8bbf-efd80499fb78" contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">355</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d676fa05-63db-407e-a341-17aee45f78a2" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">355</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock for deferred offering costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d03b9e2-c429-4442-b13a-f15ab96a2184" contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40" name="bdsx:StockIssuedDuringPeriodSharesForDeferredOfferingCosts" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9c0e0a8-bc48-47fd-9a02-2ac5d4a8d0dc" contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae" name="bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bae9cd0e-9c7a-4972-a35a-098757883354" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf949c2c-1baa-4b64-8425-21aafbed9fd5" contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30a01444-8cee-47ed-bfa6-56a097995a0e" contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37eb9896-91be-4bcd-821b-e9ec309088c4" contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b245e2e7-7769-4ead-9296-b43e86c546b6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release of restricted stock units</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5861b4b3-0a30-4ad2-9e05-435e0f84061a" contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">357</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Initial Warrants</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d29f66ba-4ee9-4c8d-bed0-191285af0bca" contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e186a5db-e1f3-4dfd-bb3d-689250825aa8" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share&#x2011;based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb9a20f1-1e43-4efd-ae51-2bae98912bd5" contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3607bfc2-7e34-409a-becb-a8245c0e70a6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bce58a86-1111-4cb6-bfad-949e3ebab3f5" contextRef="C_1cd7907e-e91e-4e55-9162-5fb14ec9f02d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">65,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77e1b9fb-beed-463a-b8d7-df3dce4209bd" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">65,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be6482dd-ec83-4ccb-bc67-58797ae177fb" contextRef="C_f7aa72bf-d149-40f3-98f1-4045959748af" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">77,614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fdbb4a6-9505-4bde-818f-f11361d0cc8b" contextRef="C_f7aa72bf-d149-40f3-98f1-4045959748af" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a24c01a8-7821-41e2-aed8-545a90ffd5f5" contextRef="C_d12b5949-e029-409e-b622-3df88edf97a1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">387,948</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_394584fb-89dd-4f92-9de9-5acd3d26c344" contextRef="C_c90072a7-3113-4e95-b308-f449c6e53790" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">367,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2d8fe4c-8c51-4eac-96ba-9b430ef68470" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,606</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.265%;"></td>
    <td style="width:1.498%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.772%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.498%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.966000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a504016-0a80-4e53-b3a0-e55838df891e" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">65,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3d0bd5f-5b7f-4967-97b6-bc10d800d2d9" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted<br />&#160;&#160;&#160;cash used in operating activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd4eea61-0365-4f25-84c9-baa6f2fd7f0b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,597</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_966a266b-0dfd-4f1b-9a65-7a396ae450a4" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,178</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff434549-c48c-4b8e-8164-6b5044d85f84" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss (gain) on extinguishment of liabilities, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c65eb2c7-23cf-47e1-9b5c-a34eb60a1b8b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,981</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a67fb280-f12c-4420-8d9f-6e5edef78048" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share&#x2011;based compensation expense</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85408f0d-333d-4c02-af92-f43fa1f66114" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0db43050-f975-48be-b2b9-69724256d025" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da976039-59d5-4082-bb4f-c3799d0461c0" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in contingent consideration</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5085f588-1145-4b10-b661-077251af16a8" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for doubtful accounts</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bab3bf98-b89f-42bd-b7b4-2cd786021339" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b37ef388-c7af-42e4-9b32-4caf070da65c" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued interest, amortization of debt issuance costs and other</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_087107bd-4d9d-4ad9-bcd3-d90583675938" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f12d7c2-f0a2-4be2-abf8-7cd90582d43d" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory excess and obsolescence</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a9467cc-fe0b-4edc-89f5-0955ed6c24b2" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment loss on intangible assets</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e9b6c4d-d4b2-41f0-9fb2-0740ff04c34a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c43abad-c003-4f3c-bafc-c1e593c9a7ac" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,501</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52c25b5e-866c-44d8-a642-5a572a54eb43" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e7cf839-5197-4a94-a200-bf7b95939e0a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aec93d93-af41-4fa7-a406-1b01a5cb7c38" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1682842e-5133-4060-9028-50e3889428ab" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,504</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93953f9a-f138-4d99-8ae8-e827b6ddc0c8" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">875</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable and other accrued liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62243723-8d8c-48f1-949c-843180a2f750" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">773</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32866ff7-d1ea-4195-8c77-7ae91cf84b45" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b513e37a-cb2f-4bc4-8e18-389354902c40" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c4208de-fb03-4112-b3da-d5330ab62b34" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,682</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tenant improvement allowances received</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78ca7c48-a628-46a4-8e2e-d7b5d14efbaf" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:TenantImprovementAllowancesReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,471</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current and long-term operating lease liabilities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5b17ea0-d05f-4c94-a7fe-760124419b72" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash and cash equivalents and restricted cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe778c07-114c-414a-8f75-3940fdc3878a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8328569-1de0-476c-a274-b05d7d11f8a8" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da164914-1bb6-46b9-84e2-5dbb0a8a68ac" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a456beba-91d4-4832-9df7-97bd1888dd29" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent costs and intangible asset acquisition, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0a19948-b92d-4744-848c-15a42c609096" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd5b2e32-62eb-48d6-9756-775983032a44" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash and cash equivalents and restricted cash used in investing activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_528914dd-cdeb-4a6d-8ff4-ef990d7304af" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b394cfc-261c-4ea4-be8e-9fb3d5d9f07d" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,547</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the issuance of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c48bdd93-38c6-4099-8128-f562b6a7b34f" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9845091b-5578-4855-9c36-62db3684ebcb" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,343</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b12de5f-c94c-4d89-bc2d-0023dac50371" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">355</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3824e46a-ca2b-4c5f-8f5d-57e1a026444a" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fea3f2f7-6e75-4523-8aeb-7692692dd827" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_703df372-8ab4-4a2b-a2ab-896a5145e397" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">769</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of contingent consideration</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59e98be7-7eed-4572-878c-c7222fd22ce4" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from term loan and notes payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1861eebd-cc3d-4747-9316-92f629c27ca7" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c18d8e1-d4d4-41bc-867f-0b66becaa728" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,078</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repayment of term loan and notes payable</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d50a4d1-de3f-4de2-bff9-11ae2da8423a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f44367d0-51bd-45d7-8975-7c551d16a3ef" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of debt issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb9ebc2c-7541-42ee-8139-a4de97e0e651" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80b22d94-3dcc-4139-9f42-a015abbddd62" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ef15803-fc6a-45bf-bb31-33ce97897f72" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:PaymentOfDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity financing costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48323ae4-177d-4258-8a29-b6bff6d5a9f4" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8dd7cf2-da3c-4cd5-94b9-ee802f8ec83a" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68b4f99b-2bc8-4c30-b107-877676d56d94" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash and cash equivalents and restricted cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0b9b288-88e5-471f-898a-a89a3589eb08" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,882</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83f229e8-c3c6-46f6-8fd3-e17164de713f" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,262</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f41d3b76-e5b7-45f6-bef4-94e9697f270c" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,376</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_872bcdaa-dd45-4db8-bc13-37dbf6b2556d" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash &#x2011; beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdaf59f8-5d30-4d05-84e5-c29028e23d76" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,798</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe4e1e6b-ddbb-42c8-a627-9791fd5d3246" contextRef="C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash &#x2011; end of period</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07d68323-3056-4cb0-aa59-7f7f652d25a9" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a38c4ca2-5d4a-4d99-b62b-de89cc42dc8b" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,798</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Continued from the previous page)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental cash flow information</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.607%;"></td>
    <td style="width:1.119%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.581999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.119%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.572%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issued for deferred offering costs</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33c6eb0f-0024-433a-aae0-d97d1a8f4ce0" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:CommonStockIssuedForDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs amortized against Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1415d637-07ce-4b07-a1ea-1696f4a5f503" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Perceptive Warrants</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4211ed3-e747-47ef-a1ac-d950dd02dfd0" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:IssuanceOfPerceptiveWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs included in Accounts payable and other accrued liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9709a3bb-2213-4674-8897-fb5d986b3fec" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_353e4969-e277-4ac8-ae7c-8a32d064fcdf" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity financing costs included in Accounts payable and other accrued liabilities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6216dd0a-252a-4a08-8309-2d19c0ce75ab" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d55ebee-4880-4b03-9c30-741a2c4f544e" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange for lease liabilities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_225e4e5a-1c64-48e3-8db1-d24fec588914" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,936</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finance lease right-of-use assets obtained in exchange for lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6007924c-9ea1-4bc7-af1c-4f2d0776eaa7" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8adbfb42-5526-44dc-a14d-8d0f22c0d77a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28f95d1f-6010-4020-a580-bfa5ce7f7d1f" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,676</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statements</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b08fcb99-90ce-4769-8600-daa9a0071eca" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 1 &#x2013; Organization and Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc. (the &#x201c;Company&#x201d;, &#x201c;Biodesix&#x201d;, &#x201c;we&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#x2019;s headquarters are in Colorado and performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a leading data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. We derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services). Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung&#174; nodule risk assessment testing strategy, consisting of the Nodify XL2&#174; and the Nodify CDT&#174; tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung&#153; strategy for lung cancer patients integrates the GeneStrat&#174; ddPCR test, the GeneStrat NGS&#153; test and the VeriStrat&#174; test to support treatment decisions across all stages of lung cancer.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also offers three SARS-CoV-2 tests. The Bio-Rad SARS-CoV-2 ddPCR test, the cPASS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> neutralization antibody test kit, and the Platelia SARS-CoV-2 Total Ab test have been granted Emergency Use Authorization (EUA) by the Federal Drug Administration (FDA) under Section 564 of the Federal Food, Drug, and Cosmetic Act (FDCA). Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. The EUA declaration under Section 564 of the FDCA is distinct from and independent of the declaration by the Secretary of HHS of a public health emergency under Section 319 of the Public Health Service Act (the PHS Act). On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#x2019;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. Because the EUA declaration from the FDA is distinct from the declaration under Section 319 of the PHS Act, the FDA EUA may remain in effect beyond the duration of the Section 319 declaration. We cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The Company leverages the proprietary and advanced Diagnostic Cortex&#174; AI (Artificial Intelligence) platform, to collaborate with many of the world&#x2019;s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Blood-Based Lung Tests</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company offers </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97ba5a70-48f2-44ec-9049-49ef5776d9bc" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:NumberOfCancerTest" unitRef="U_Test" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> blood-based lung cancer tests across the lung cancer continuum of care:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diagnosis</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nodify XL2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nodify CDT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> tests, marketed as our Nodify Lung Nodule Risk Assessment testing strategy, assess a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2838f492-da19-4af4-92a4-adbdc7f14cad" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:NumberOfCommercialBloodBasedTest" unitRef="U_Test" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treatment &amp; Monitoring</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GeneStrat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ddPCR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VeriStrat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> tests, marketed as part of our IQLung testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a turnaround time of two business days, providing physicians with timely results to facilitate treatment decisions.</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GeneStrat NGS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (NGS) test, also marketed as part of our IQLung testing strategy, is our blood-based NGS test with results in three business days. The NGS test was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations in genes, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner.</span></div></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 Tests</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate and have commercialized the Biodesix WorkSafe&#153; testing program, under which the Company offers </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97c4e258-8c46-48f4-8706-c2f5780ecd0d" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:NumberOfSARSCoV2Test" unitRef="U_Test" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> SARS-CoV-2 tests:</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bio-Rad SARS-CoV-2 ddPCR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">test, which is FDA EUA authorized to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of current infection by the SARS-CoV-2 virus.</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platelia SARS-CoV-2 Total Ab </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">test, which is an antibody test, FDA EUA authorized by the FDA, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection.</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">cPass SARS-CoV-2 Neutralization Antibody </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">test, which is the first blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection. This test was commercially introduced in partnership with GenScript Biotech Corporation.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#x2019;s testing services are made available through its clinical laboratories.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9860e9dc-d8b7-45cc-9ab5-ce35265b21cd" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 2 &#x2013; Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_04828027-6985-426f-b170-6918838adbe2" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation and Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; warrant liabilities; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we maintained cash and cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68f51e60-716c-441a-8de0-92b0bf2e6eb0" contextRef="C_13ad713e-d35e-41ad-b2d9-9738e144f092" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and we have </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f79c57fa-ae73-4b4f-be32-e9f7af4bfeb2" contextRef="C_13ad713e-d35e-41ad-b2d9-9738e144f092" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in outstanding aggregate principal amount on our Perceptive Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources, including the debt and equity funding and amendments to the Integrated Diagnostics, Inc. (Indi) Agreement, and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreement (see Note 8 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic and the associated impacts on the recovery of our diagnostic testing and services, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital during 2022, amendments to our 2021 Term Loan and amended the Indi Agreement to delay near term cash requirements and extend the period of milestone</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payments. We have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company funded and/or closed various financing transactions, including: (i) a term loan facility for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69638340-d772-4dc7-a31b-ce849387072f" contextRef="C_6fd3ded3-11d4-4f58-b776-f582e91d8799" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, with funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2107f846-b688-4446-97a1-10743be6e321" contextRef="C_75178c23-f72c-42e0-a591-2de6aea0caff" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the issuance of warrants exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23d2f9ba-5184-41e1-bf8e-3ee902476577" contextRef="C_4ed704bd-7ad3-4b26-ad05-362e6ae5c9c5" name="bdsx:ClassOfWarrantOrRightWarrantsOrRightsExercisable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock occurring on November 21, 2022, and two additional contingently issuable tranches of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa5711a5-185a-4062-85b3-7d66d0d959a4" contextRef="C_6ad6809c-68cb-4c96-8ae0-d9bd24aa0db0" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_fea52439-b896-4035-b2bc-c10e7c761cb8" contextRef="C_94e70836-502c-461e-9146-5d8aa063080e" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each subject to certain terms and conditions, including revenue milestones, (ii) a follow-on equity offering of common stock and (iii) a subscription agreement for the issuance of common stock to certain members of the Company&#x2019;s management team. Collectively, the Company raised gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98104ead-ac1d-4109-87b4-e5e48d0ed4dd" contextRef="C_60a8bfcb-40c2-4451-aa67-8593932c5757" name="bdsx:GrossProceedsFromFinancingTransactions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">70.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b594606-0d72-498f-8a68-005cd53d5842" contextRef="C_60a8bfcb-40c2-4451-aa67-8593932c5757" name="bdsx:NetProceedFromFinancingTransactionsss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">65.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting commissions, fees and expenses payable). Approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a38560e-4e4b-41fa-916e-2c91234486f4" contextRef="C_60a8bfcb-40c2-4451-aa67-8593932c5757" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the net proceeds were used to retire outstanding debt of the Company with Streeterville Capital, LLC and Silicon Valley Bank. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1d1c0856-4304-42ed-b1c3-1c01fda5b3df" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4d32ba86-04c2-4e99-bbda-0fc5bb64105e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">single</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment focused on providing diagnostic testing services to customers. All of the Company&#x2019;s revenue and long-lived assets were derived or located in the United States for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f07cbd3f-0771-4d31-b8d7-b00f66bfdf3f" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 11 &#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2d08f4a1-5470-4d29-a3d1-82dfe6c4aac9" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:DirectCostsAndExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Direct Costs and Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_572610e9-e1c7-42bf-9a70-e3ff18fd6bfe" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_012b22a2-c1b7-48e0-8b8b-761cf9f7516b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales, Marketing, General and Administrative Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_858afbb4-603d-46df-914d-c89293e81e76" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2022 and 2021, see Note 11 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a2bfe841-6442-43a0-bc69-bb5c6940b1d6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_71eae8ec-1f3c-408f-ae32-1c1820facdbb" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card. As of December 31, 2022 and 2021, the Company had </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51a1fa9e-cf87-4b17-9600-262299611ca4" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_e930179f-c8fb-407e-8e4e-010f36b09bbc" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted cash, respectively, which was included in &#x2018;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_c127f513-dd4b-4997-b27b-a9cd90962444;"><span style="-sec-ix-hidden:F_7fd39517-ff33-41f8-ae14-0d40bd4ae488;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2019; in the accompanying balance sheets.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_73d8bd2a-ad1e-4985-8ed7-76a1de8f36f9" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ce9ed703-b0d6-4495-b6df-0995cf731ead" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:InventorySuppliesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#x2018;Direct c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">osts and expenses&#x2019;. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c20d38b-9aa8-4856-a30c-0abdf4685e47" contextRef="C_3d44de77-80d9-49db-a99d-64d8c9816a6f" name="us-gaap:OtherInventorySupplies" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_495ffb21-05cf-4f7d-afda-ec5d379ee8c9" contextRef="C_9d76dbc1-8a85-42e5-96cd-ef88d8ad1938" name="us-gaap:OtherInventorySupplies" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The Company recorded a reserve for excess inventory of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c9b8ff0-5aac-4a50-814a-d46659b8ac4a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4d63eb9-34bc-4847-b691-7a0c9cabf9f0" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:InventoryValuationReserves" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, primarily associated with the wind down of the COVID-19 testing operation, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c40eb338-2ffc-424a-86be-e278d1e1f738" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c322f1c8-dffc-4f23-a650-6b8327297bec" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, to the statement of operations for excess and obsolete inventory.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b42ff4bb-2a66-4a5d-9e9e-0e47f8bd6674" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_06324b01-1be5-4c23-bbaa-fc1231d74b49;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_67b38028-3a72-49aa-81eb-6a352ab4c65b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0139f82-5b14-4ce9-960c-9716a86e44e0" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6b1b9c89-79e9-4df2-b316-19a5d3e013e6" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments for th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_22bac4ab-5b5a-4a64-a932-b2d7ba0b57ea" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7bed639a-b514-4bc2-b970-0eb2ec691dce" contextRef="C_c2f28597-f68b-4e5f-938b-bbefedd01c35" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1efab707-210d-4b1b-aebd-9864d4140e3a" contextRef="C_a297dcbf-e7eb-4a6b-b8b7-17cecdbd5a6b" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There was an immaterial impairment during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_848b7880-6f01-4528-ac4d-55e71d6a02ad" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments for th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_39e5db12-3519-4b03-9043-0f9d6c20a6f7" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2022, there</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fae733ac-72a7-47d2-99db-29c21317657b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accumulated impairment losses.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_36fd1625-eae3-4566-9f66-f39ca78bca23" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:OtherAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d2af088-3f8b-43a3-87ed-26be604a48a9" contextRef="C_1bdcfef7-9637-41fa-aeb1-09f6ca1e0d5f" name="us-gaap:CustomerFunds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million cash refundable deposit to secure the performance of the Company&#x2019;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1027eb3c-7b29-4931-a601-95f4ed90f6c1" contextRef="C_1bdcfef7-9637-41fa-aeb1-09f6ca1e0d5f" name="us-gaap:CustomerFunds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million refundable deposit is reported within 'Other long-term assets' in the balance sheet.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3b63e3f-319c-47ce-bb08-0d9cb849c42a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.815%;"></td>
        <td style="width:2.083%;"></td>
        <td style="width:86.102%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 4 &#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further discussion related to estimated fair value measurements.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3e8d0a91-e6c3-40f7-b6cc-3c39252143f4" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:ContingentConsiderationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the purchase transaction with Indi, the Company recorded contingent consideration for amounts potentially payable to Indi&#x2019;s shareholder upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6755f2a3-8a68-401e-bd59-336e19f83697" contextRef="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6ccb6271-9abe-4db4-acb4-d97319db4dd4" contextRef="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806" name="bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was achieved is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4380b545-4a7a-40ac-a56a-7cde37f50dff" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:WarrantLiabilityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the Company issued a warrant to purchase common stock to the Lender of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32490aa6-cd14-4b4b-afc9-8f434572dbd5" contextRef="C_6fd3ded3-11d4-4f58-b776-f582e91d8799" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock (the Perceptive Warrant), with warrants exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e231be4-95cf-4405-87db-fa70fc00c753" contextRef="C_6ad6809c-68cb-4c96-8ae0-d9bd24aa0db0" name="bdsx:ClassOfWarrantOrRightWarrantsOrRightsExercisable" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock issued on the funding date of the Tranche A Loan (the Initial Warrants) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as well as up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fdd8a88-1284-4f84-a2e7-d5cd71450ebc" contextRef="C_16894d39-c0b9-473f-996a-ea5e902b6bc7" name="bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional warrants that are contingent upon the Company&#x2019;s borrowing the remaining availability under the Perceptive Term Loan Facility (the Additional Warrants). The Initial Warrants are equity classified (see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) while the Additional Warrants are classified as liabilities and subject to fair value measurement (see Note 4 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4b3a6dc4-535b-46cb-aac4-b679d27b0ce0" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share&#x2011;Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units (RSUs)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 12 &#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information related to share-based compensation.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f9f468b-68ba-41db-827e-bf1098eb0fc2" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">s</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
         <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_628b9e52-ebf3-443c-892c-2f33575477cf" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 14 &#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information related to income taxes.</span></p></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96769fff-faf0-435f-bcff-41d9ea0d02ef" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eb7fb78e-4b4b-47da-9088-a519002022da" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 3 &#x2013; Recent Issued Accounting Standards</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ac9b0423-e538-4b84-9f6a-c960f75b739c" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2016, the FASB issued ASU No. 2016-2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ASC 842). This ASU intends to make accounting for leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases accounted for as operating leases. In addition to other related amendments, the FASB issued ASU No. 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. The Company elected this transition method and adopted ASC 842 on January 1, 2022 and as a result, recorded operating lease </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_7af1e3c8-01b6-4f0f-8209-47648e9fba35;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rig</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ht-of-use</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ROU) assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_873add36-4a8b-40a3-802f-5bad9cf3cbda" contextRef="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, including offsetting deferred rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8247d448-8b25-4820-adda-3c79991f56cd" contextRef="C_7ddc96a7-546d-43f8-87c6-9287c6d330e4" name="bdsx:OffsettingDeferredRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, along with the associated </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_212e7808-bfbd-4077-abc2-795e910b5233;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating lease liabilities</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1efe163f-00cc-4059-a8b1-e1881d69e712" contextRef="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On January 1, 2022, the Company did not have any finance leases. The adoption of ASC 842 did not result in a cumulative effect adjustment to beginn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ing retained earnings, and did not materially affect the Company's statement of operations, statement of stockholders' equity or statement of cash flows for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company elected the following practical expedients permitted under the transition guidance within the new standard:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Package of practical expedients which allows the Company to carry forward the historical lease classification;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of ROU assets;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more, and;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#x201c;major part of remaining economic life of the underlying asset&#x201d; and &#x201c;substantially all of the fair value of the underlying asset.&#x201d; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ef96ecbe-d1bd-45b0-a890-92a0afe40751" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional information and disclosures required by this new standard are contained in Note 9 &#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Standards Being Evaluated</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the guidance and determined the overall impact of the adoption will have an immaterial impact on our financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_0d7f1fd8-bb6e-40ca-ae3b-5007a363299b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 4 - Fair Value</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recurring Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair value of borrowings as of December 31, 2022 is primarily associated with the Perceptive Term Loan entered into with Perceptive Credit Holdings IV, LP, in November 2022 and was determined using a discounted cash flow analysis, excluding the fair value of Perceptive Warrant issued in conjunction with the transaction. The difference between the carrying value and fair value of outstanding borrowings as of December 31, 2022 is due to the debt issuance costs and the fair value of Perceptive Warrant netted against the Perceptive Term Loan. The carrying value of outstanding borrowings as of December 31, 2021, approximates fair value based on interest rates available at that time for similar borrowings. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c53bada6-e9e6-491f-98b0-cf763048a4af" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" escape="true" continuedAt="F_c53bada6-e9e6-491f-98b0-cf763048a4af_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_c53bada6-e9e6-491f-98b0-cf763048a4af_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"></td>
        <td style="width:1.127%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.842%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.127%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.127%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.91%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.127%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.037%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_295fe035-9aa6-44fe-9e00-707df169f534" contextRef="C_94f8365d-9f16-480b-9a94-8b6de443e738" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,053</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e2143ca-70ae-4085-af66-cea274b5729c" contextRef="C_c4d0476a-83e8-40bf-8317-6bc7b409e5d1" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,785</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c21efe50-b0bd-4690-aded-2144c25cc5d5" contextRef="C_fc669b6e-18c4-48ce-89aa-f437eaa9dea7" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81cf9153-de05-4b8f-912a-8ab20573837b" contextRef="C_e895deb9-d4dd-4ee8-a0c9-733eb5b9aee7" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our previous acquisition of Indi and the warrant liabilities granted as consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), which were accounted for as liabilities and remeasured through our statements of operations.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ce546156-995b-4d9b-bae5-c680ea7b054c" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below presents the reported fair values of contingent consideration and warrant liabilities,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.38%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.842%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.774%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6464a83-b97b-4500-8f6b-9f38663d8e7b" contextRef="C_a20eac41-6dd7-40e8-be7a-37569efa0136" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cccbce29-8baa-43a8-9471-7f256170aaf6" contextRef="C_be80ae2a-a108-4cd4-aef7-5a62e28a06e3" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,764</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee7fd393-0d3f-4001-b007-ca8a84eed0d4" contextRef="C_ff1c3404-9746-40e4-8ce6-168f0d8cde24" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,645</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb02f347-e3c7-4857-8f05-6022c99b5256" contextRef="C_21a7ecc0-40b0-408b-8b87-7d9c2a5f031b" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c64b3dd3-a4ac-4b3c-8030-9542a225606f" contextRef="C_a8f8214a-ba5d-4798-9bc4-3c9348a307cc" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cab05f37-d6ce-43dd-a2a4-0bc8d679253c" contextRef="C_4142ff53-afcb-497b-81d5-d370a5bf3011" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfc41e85-9a9e-4e6e-a0fc-8a0ccebd01f0" contextRef="C_a8f8214a-ba5d-4798-9bc4-3c9348a307cc" name="bdsx:WarrantLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9ecea44d-3be1-458b-bcf6-b1caddc3cb04" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the changes in contingent consideration </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and warrant liabilities for the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.871%;"></td>
        <td style="width:1.498%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.263%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.881%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent Consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balances - January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1fe9ef3-82e7-495a-b7ae-b94f90713b80" contextRef="C_21a7ecc0-40b0-408b-8b87-7d9c2a5f031b" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_424ea122-0952-421a-a9bc-aab39c4acd26" contextRef="C_5dc8b832-6352-466d-a5da-07ecf35ded3e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00812bbc-f4ed-4064-b07c-cc09c559cab2" contextRef="C_5dc8b832-6352-466d-a5da-07ecf35ded3e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0fb2e5f-7f99-4ccd-a677-f06f69694730" contextRef="C_0add87f4-39bd-4cf3-8e49-bc5d9b0a3039" name="bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1cc78b2-1d9f-4d2a-a796-063dd0ceee3e" contextRef="C_0add87f4-39bd-4cf3-8e49-bc5d9b0a3039" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3086593-2188-4150-b622-110fb22a5f71" contextRef="C_0add87f4-39bd-4cf3-8e49-bc5d9b0a3039" name="bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,822</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balances - December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5987039c-6e7a-4f6f-8bcd-792c173f49fa" contextRef="C_ff1c3404-9746-40e4-8ce6-168f0d8cde24" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86046503-680f-45cb-bfed-63e00857daae" contextRef="C_9c480ebc-4937-47fd-b5c4-871edf51ca48" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the changes in contingent consideration as of the date indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.136%;"></td>
        <td style="width:1.753%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.11%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balances - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0963af0-95fc-4f47-8585-9aa2d03540e6" contextRef="C_d12dc7db-6c0d-498f-95b8-ead1e40b9fb7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5993ac1-0b71-40ae-b0fe-40cf8664fb69" contextRef="C_cf44b711-ec2f-4b0b-ad81-b0a574373c94" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,622</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d13939bf-a40d-4287-8c3d-c3a3007f71ba" contextRef="C_cf44b711-ec2f-4b0b-ad81-b0a574373c94" name="bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,238</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balances - December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ea17c81-9e8b-422b-8a29-d91f3b7dc14c" contextRef="C_21a7ecc0-40b0-408b-8b87-7d9c2a5f031b" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (the Indi APA). The contingent consideration arrangement </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba80b106-e9f9-4119-8e44-484f148c3c84" contextRef="C_255e0eec-7e39-40eb-adba-086563b7ec90" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa25bb8e-a670-4982-856d-b6d0aa7579ac" contextRef="C_997a32b2-9786-430b-9d46-e8bde7a02bee" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e8672b9-83fc-49e5-84aa-cc50652a57b6" contextRef="C_997a32b2-9786-430b-9d46-e8bde7a02bee" name="bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the acquisition date. Under the terms of the original agreement, when the gross margin target was achieved the Company was required to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a7b0f94-4e27-4c81-b4b1-5de1e063ed28" contextRef="C_64b0a895-45ab-4c6f-ac10-827ab0a951df" name="bdsx:BusinessCombinationContingentConsiderationShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,520,108</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. For the six months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9164cc29-84ab-40a9-8477-21d7241f0a0f" contextRef="C_64b0a895-45ab-4c6f-ac10-827ab0a951df" name="bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2ac82f3-ffc1-49c5-bf9f-0f4f7e282427" contextRef="C_e26e9fe8-1d8c-4a5e-9771-49e0ddbb567d" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">eight</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> equal quarterly installments. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_140e5fc7-c4af-4aa6-9e4e-f1ad1180f029" contextRef="C_2f69117e-f3cb-4597-a131-338489bdc295" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20f126f1-463c-44cf-96a4-4d232b039dc5" contextRef="C_c54806e2-2b86-435c-963e-bcc3bba05c0e" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> equal and consecutive quarterly cash installments totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4fc84d3-d908-4890-9a01-905b67b42085" contextRef="C_973930aa-eb0f-4e7d-b68b-2549035fffb6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company achieved the gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c6861d5-6539-4f26-bd99-e2f9551d214a" contextRef="C_b3c04a86-27e5-41b0-aa97-cc3628b22f88" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for three consecutive months during the three months ended June 30, 2021. The Company entered into an amendment to the original agreement in August 2021 in which all parties agreed to forgo the issuance of common stock and agreed that the Company will in lieu thereof make </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dbc10fe-0654-4c72-8a60-db4203475614" contextRef="C_b9c9e703-63dc-4dfe-8c83-2d95a5dd5cd1" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> quarterly installments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ee05a62-2f21-4170-b7d4-6e419fda7f34" contextRef="C_2f69117e-f3cb-4597-a131-338489bdc295" name="bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each beginning in January 2022 and a final payment of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c89e597f-e20f-4066-9e2b-a83e3bab57ed" contextRef="C_2f69117e-f3cb-4597-a131-338489bdc295" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in July 2023 for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c45896bb-2920-489f-9abe-52edb6718d3f" contextRef="C_2f69117e-f3cb-4597-a131-338489bdc295" name="bdsx:BusinessCombinationContingentConsiderationFinalPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. (the Milestone Payments and each individually a Milestone Payment). The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which the parties agreed to restructure the Milestone Payments whereby the Company will make </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f151efe-557c-4606-8572-0c34f855d57a" contextRef="C_acff4fd7-67d1-4f52-bbff-d251e168be02" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> quarterly installments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05959036-7dcd-4521-a5ab-4b5fb8e03a4e" contextRef="C_7af4e047-0257-4b41-8cb2-aa865601cded" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each beginning in April 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca14ea3f-e956-4a8f-9b7b-359f173b4f73" contextRef="C_086e1296-a025-4723-b82e-9492b0c68ec9" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> quarterly installments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2a664ee-5883-4029-a77c-0f2c326a6b9f" contextRef="C_3a8e4fde-5800-4383-b5b8-8d6b6fb5e8d3" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million beginning in July 2023, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8233b77b-30f6-4f19-8347-e1f84bfa3513" contextRef="C_91b0e376-daf5-48b6-b4e6-bf780df858cf" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> installment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_957eb168-dec3-4bea-bf02-0cec4e8ba7b6" contextRef="C_29c745e0-902e-4e00-abf2-c8cab42148d9" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in April 2024, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5538a853-65dc-49d6-b42b-9e5e61efee5a" contextRef="C_c534b800-3720-4995-a5a1-9c5c21659307" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> installment of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44de5432-f0c9-4e92-951d-2b3fbb5774d2" contextRef="C_2847f431-ac31-433e-ac37-df0cd6d38d6d" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in July 2024. In addition, the Company agreed to an exit fee of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73cb5350-4ab7-4ffd-bf0a-fd2684dfe07a" contextRef="C_949016fe-f937-4caf-b84d-58db21b5e5ec" name="bdsx:ExitFeePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38efa0fb-dc94-4e13-9fdd-e7d944e88b0f" contextRef="C_fd5b1882-de5e-4e68-853c-732d34730afe" name="bdsx:PercentageOfInterestOnContingentConsideration" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, with such interest to be payable quarterly on the following installment payment date. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan and commencing January 1, 2024, consent from Perceptive (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The contingent consideration liability is accounted for at fair value and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd4321bf-df33-4c16-8a35-c0a046de2091" contextRef="C_f60b5bcb-f424-4895-a729-730037e7a52d" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">11</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02cf4d8b-2127-4019-9ea5-02e4ca67c4e8" contextRef="C_f0124565-7566-42cd-9811-8f85b4b00b29" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">16</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. As a result of the achievement of the gross margin target, the only remaining significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate could result in a significantly higher or lower fair value measurement. During the three months ended June 30, 2022, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_142c460c-913c-4ccf-874e-a6ab10d60ae7" contextRef="C_3fbf4b04-42d9-42a3-afc9-b3a2b00cabdd" name="bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in interest expense due to the passage of time and fixed payment schedule, partially offset by a reduction to the contingent consideration balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a7eadb6-891b-4363-a2a6-3008ca8b801b" contextRef="C_3fbf4b04-42d9-42a3-afc9-b3a2b00cabdd" name="bdsx:ReductionInContingentConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million due to an increase in the discount rate to reflect current market and Company specific conditions, resulting in $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5aba036d-335b-4ded-bb9c-5030719f5f9c" contextRef="C_14ac9e9e-e1ed-4025-b9a7-8d5598f7e903" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net recorded as &#x2018;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_bd934ce6-93a4-4c03-8768-1ed24686b2e3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2019; in the statements of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated Amendment No. 3 to the Indi APA in accordance with applicable accounting standards under U.S. GAAP which resulted in the extinguishment of the original instrument due to the substantially different terms. As a result, during the three months ended June 30, 2022, we recorded a loss on extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd4db96a-e4f4-4235-8931-450ff4ccebe3" contextRef="C_5caae45d-0db4-4d63-b236-a9aa359641a3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the statements of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recorde</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfa38d36-a4e5-4010-b730-389836f8b21e" contextRef="C_283a264a-b0e0-4031-81ad-45b20ea79543" name="bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32a30f33-b78e-4da0-b052-fefc42da2a15" contextRef="C_2ba0380c-8303-431e-a874-ef43625cd063" name="bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, r</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">espectively, in interest expense due to the passage of time and fixed payment schedule.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration expected to be paid in the next twelve months is recorded in the balance sheets as &#x2018;Current portion of contingent consideration&#x2019; while the remaining amount to be paid is recorded as &#x2018;Contingent consideration&#x2019; within non-current liabilities. The net change to contingent consideration through the date the gross margin target was achieved is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrant liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the Company issued the Perceptive Warrant to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc33cabe-77ab-43a5-9cf1-86017ce12faf" contextRef="C_cade502d-a93b-4d54-80ee-98f26b9246c9" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, including Initial Warrants and Additional Warrants. The Initial Warrants are equity classified (see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) while the Additional Warrants are classified as liabilities within 'Other long-term liabilities' and recognized at fair value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The fair value of the Additional Warrants is determined using a Black-Scholes model and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the fair value of the Company's common stock, risk-free rate, the volatility of common stock which ranged from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bb43a6b-3902-479b-935e-f4e2f2685683" contextRef="C_903652eb-e3f1-4c1e-a925-53ae57d7cd2b" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" decimals="INF" format="ixt:numdotdecimal">78</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c164fc8-4270-4508-a52a-95c1e477eff3" contextRef="C_46b3650b-f200-468e-a19b-82906029b2e1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" decimals="INF" format="ixt:numdotdecimal">82</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, and the probability of the expected borrowing. Significant increases or decreases in the unobservable inputs could result in a significantly higher or lower fair value measurement. The Company determined the initial fair value of the Additional Warrants to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcb28e4e-0bd6-4a84-97b7-b49187521d66" contextRef="C_26e73e01-b546-4645-b525-02a9ce64f5a1" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e20b421-d4f5-4a07-8068-a1affacf7aa4" contextRef="C_26e73e01-b546-4645-b525-02a9ce64f5a1" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as a change in fair value through the statement of operations due to changes in unobservable inputs.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c3e296c7-6d4b-4d10-aeb0-29be4630da9c" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 5 &#x2013; Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d70193b0-ce50-44a3-8eeb-68ef2fb825b9" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.262%;"></td>
        <td style="width:1.499%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.774000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.499%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.968%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21e6235a-c9a5-416e-a5ce-8ba223853a50" contextRef="C_5208be1b-25c5-466d-81db-5a3e876f9370" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,035</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5497cc3-6c60-45e4-87b2-29d2e455bf7c" contextRef="C_672ae1be-bd0c-48a6-8adf-0a1565ae2ef1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9d35928-e4a1-4636-8d53-d68c4905146a" contextRef="C_f8159f7a-5617-4338-a333-06a6ca7f3337" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,365</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56551b1f-ded6-4aff-b8fd-fa4ffa95ccea" contextRef="C_4b44b5df-e1bf-421f-890e-33e01c1a22ca" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,339</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8820fec7-8866-4686-a09d-1b65ec1b0a81" contextRef="C_9fabf356-719c-4221-916d-d8ca81752d4d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">749</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b89609da-6bc5-46eb-a07e-fe37239191ef" contextRef="C_0f9bbf97-b166-4fc4-9dad-f1870f5628ba" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19035716-68f1-42bd-9f9d-b8404f4a3af0" contextRef="C_ddfc8a81-b490-496e-95ab-ca6e0d3c6f71" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da7c4e3d-047a-4438-8171-d6d931a79356" contextRef="C_59d365ab-7a43-4adf-a882-c16ac6390192" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">391</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b89f9f3-2a9e-4a22-b438-fe8b9ecdca31" contextRef="C_60e05c27-67bc-4257-a0d2-dc24ad762e3a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">324</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfce01ee-dd01-46af-b89c-f4dd7e16c56f" contextRef="C_ba2be62b-8085-45a3-bc77-13c26ae016ff" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vehicles</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e25de03-82d1-4eb9-b9a7-cac91ebdb2e4" contextRef="C_237703f9-d5ea-4653-8904-ce72f3e0e459" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf4219d9-6d0c-4b4d-add6-d02e5b8764ec" contextRef="C_9034f42b-c563-4c25-99ba-56b8bc692ac4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1894e0a6-28d6-4d26-af98-df04e11353b0" contextRef="C_231071bd-b44d-4ace-82af-b86707b2357a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,947</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb5574af-f0ee-498c-81f2-7deaf44d9dfd" contextRef="C_9f73c574-d57f-4230-9899-1c2a407c3ca8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acc383e9-8143-4853-a434-9b5b141dee47" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,866</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fbb1c93-dbcc-47e1-93df-a238f5282313" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,928</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4bafeb0-a90c-411a-b454-0793188375ac" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,018</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c59fafb-af98-420d-89c8-cf74006cdbe2" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,749</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_251b7cde-01b0-4ff7-958d-d27913ed5e33" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,848</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e93e3e7-ce24-4755-953f-8adb9cb1c0b9" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,179</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b3e9e64-8a52-4fe5-ab25-2bba48eab849" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense related to pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operty and equipment was:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.293%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.679%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.489%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.058%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4942a51-06b3-4e64-9337-fef422c71d18" contextRef="C_e2944650-b682-45bf-91f6-43c4a2e81e26" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_637d3c77-4285-49cb-b25f-b59325afa8e8" contextRef="C_744f7b6a-4217-4a66-a0e3-ea5eed3003f2" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">614</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_575f50d1-8059-44f4-b862-37c6af6f5d87" contextRef="C_dc7252ad-b58c-4241-b1ba-4346c1180e60" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce31761a-6630-4bc3-aad6-78d2b23fcca0" contextRef="C_4f705742-9a2c-4dc7-a282-98868e21f468" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">614</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6800cee4-cc57-4bab-b551-f95c0a796f52" contextRef="C_e8fb8fa4-a259-49a8-a73c-91b175e11aa7" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,622</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1119c5af-4f7b-4bb2-b25f-f4e77368cf5f" contextRef="C_dedd5c19-93b3-496c-9876-ed47d4aade8e" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_43f888e4-150a-4cd3-be6b-d7fe8674902a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 6 &#x2013; Goodwill and Intangible Assets</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_59d08d2f-84ac-4635-877c-ea8a66e6f4b6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.602%;"></td>
        <td style="width:0.905%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.3629999999999995%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.792%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.235%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.792%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.005%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.792%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.3629999999999995%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.792%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.28%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.804%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.2749999999999995%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets subject to amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63a7d243-f0cf-46cc-a56d-ae63f4199980" contextRef="C_0281633c-de51-4d41-b3dd-b1224984423b" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce403e8d-a8d0-4510-9b96-6d653add3e38" contextRef="C_0281633c-de51-4d41-b3dd-b1224984423b" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">647</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1f02600-b3f1-432f-b4f4-8f9568fb4ec6" contextRef="C_0281633c-de51-4d41-b3dd-b1224984423b" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c639d05-ba57-4cbe-906b-a8aaf434cb8e" contextRef="C_bf14dbee-c366-4746-bd13-0ca64d12de01" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,755</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1452bc4b-7bef-4563-8b11-db5e87d03d46" contextRef="C_bf14dbee-c366-4746-bd13-0ca64d12de01" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">566</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69c1b8b7-ab3b-4430-8627-235f36d66f1f" contextRef="C_bf14dbee-c366-4746-bd13-0ca64d12de01" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchased technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d497702-f189-4af3-a4e1-0f7db0fa897e" contextRef="C_75202e38-b7dd-49df-9825-87dfcdc551d6" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_907e4155-05f8-4b1c-933c-7d4d59d9883a" contextRef="C_75202e38-b7dd-49df-9825-87dfcdc551d6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,450</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a07b873f-65a1-4ea5-a7d0-3c9d97a62ea3" contextRef="C_75202e38-b7dd-49df-9825-87dfcdc551d6" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,450</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8667dffe-b5db-4919-995d-a72bf7133699" contextRef="C_4716ca07-4302-4a9c-9ea0-0d87608ecb4f" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_392ae529-baab-4119-8995-fa5b62fac162" contextRef="C_4716ca07-4302-4a9c-9ea0-0d87608ecb4f" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,572</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87546274-b32b-42ac-9207-2f97ed99514d" contextRef="C_4716ca07-4302-4a9c-9ea0-0d87608ecb4f" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets not subject to<br />&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trademarks</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd050ed7-23ad-4e5f-ae52-e66b441917cd" contextRef="C_9e152fca-a16d-497a-a116-d749fe3f576a" name="bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3b80956-f00d-49bb-b1ca-f776d6abc720" contextRef="C_9e152fca-a16d-497a-a116-d749fe3f576a" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fceaa76d-4732-45a1-9ed1-26d27bb4b1aa" contextRef="C_599ead4f-c94c-4dc6-8441-4c817adf1b16" name="bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32df8ada-f377-4d0f-82a4-e86b23037df4" contextRef="C_599ead4f-c94c-4dc6-8441-4c817adf1b16" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92c5f8d8-ab93-4c93-9029-593c6b8d956a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,894</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c1b4e18-5af1-4c73-ad0a-71732b48cd4a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,097</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1291bded-b958-409f-beb8-5b116e917042" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3924dec-1a3b-450e-8018-a7549c6c5446" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,755</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8759ab5f-099e-4389-ab01-f13483227665" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,138</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85c9baf6-052f-4a14-ac75-33d7ebf00854" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c7de6d6e-726b-40ee-b3b4-f9833b82fe0e" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.598%;"></td>
        <td style="width:1.901%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.539%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.726%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.235%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d44e5210-0843-4ee7-b6c4-f6d617c29048" contextRef="C_e2944650-b682-45bf-91f6-43c4a2e81e26" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d93832f-d0e9-4df6-a400-39f920d44020" contextRef="C_537fd16e-de8c-489b-89dc-da0dcaa87884" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32b99dfa-2250-4a5e-893e-792f262efa62" contextRef="C_dc7252ad-b58c-4241-b1ba-4346c1180e60" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99890a60-61fa-494b-9653-c0fc64570b71" contextRef="C_9fdff006-70ae-43ff-b822-eb5c9877e323" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b66a5618-85f0-4993-8979-2d2cf580c66d" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42a4b697-a1d9-4157-83f4-a6f8204c05d1" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54eec93b-93c4-4ad1-91ab-2fd1ce696649" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future estimated amortization expense of intangible </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assets is (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.617%;"></td>
        <td style="width:1.732%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.652%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br />December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_257b77d9-a81a-487c-82b0-4321168221bc" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,972</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03e716ed-0605-434c-b745-35f2cf1ee3c2" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42df1039-5ecb-4013-8a82-d21491d745bf" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,957</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12fd2ebb-f744-4b5d-966f-d7d920b8ed3b" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,943</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9388899c-04de-44dd-ab09-70e7a8ea8c65" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">992</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef133341-2fa0-4190-b747-6d322cdada83" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">856</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21a1390f-34ec-4d53-b4b3-d54c60cc57ca" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,683</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe02487b-9f65-4104-b5b1-e7affbf94de0" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 7 &#x2013; Accrued Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f4910e9b-5870-4afd-b02a-fff049a00349" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.293%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.679%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.489%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.058%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation related accruals</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cb10700-1202-429c-a22c-f6f8f05360cb" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,671</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82f9796c-bbc8-48cd-bea3-030977e0765e" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued clinical trial expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_975b8c49-519a-44f9-9c16-39b8285dfd52" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="bdsx:AccruedClinicalTrialExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,232</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cfa3aad-a4be-4c56-a463-a43d0de38b5c" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="bdsx:AccruedClinicalTrialExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">870</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a6883f2-86d6-4326-9268-cf0b838eb220" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d14a53e6-cd8c-4a35-a106-f41f9fcf4492" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3271c3ac-93bd-41b8-a6a8-76d52c82dcc1" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,218</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98a2ad5c-b311-4acb-b848-bf3005900168" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_00021bdd-2a93-4114-a8f3-c5c1229c7f00" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 8 &#x2013; Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our long-term debt primarily consists of notes payable associated with our Perceptive Term Loan which is described in further detail below. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9578f252-cfb2-4592-9bcf-1038069c69ab" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true" continuedAt="F_9578f252-cfb2-4592-9bcf-1038069c69ab_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term notes payable were as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_9578f252-cfb2-4592-9bcf-1038069c69ab_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.716%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.477%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.848%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Perceptive Term Loan</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9ecfa13-a893-427c-9ca2-697f7442aba2" contextRef="C_13ad713e-d35e-41ad-b2d9-9738e144f092" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Term Loan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd2311ed-ecd0-47b6-823c-8025ac07551e" contextRef="C_c2fe46f8-1653-48ec-9a32-c95a2b1ef531" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6d9a93c-70a7-44ca-841a-eb0f6a216532" contextRef="C_b84975b5-0a2a-4c6a-a970-bca06808dbba" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e11ac48-679b-4c79-892c-892f4197b904" contextRef="C_217f72b0-cf7e-4c4d-b942-59ada45d53c1" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a6638d7-90de-40be-a9c1-e76eef1acf47" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,074</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_437db00a-0b5b-4ab9-bdac-b9811f5dcc44" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9966c6e-e334-4b19-aad8-7ab5065c74fa" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,053</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f8379e1-c6d4-4d5d-9fd6-6cb57ad9f0d5" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: current maturities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f4399e4-32b0-4c6d-8ed0-294e6a12154e" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c7b990c-b5ff-4d3d-b670-edd49368e024" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term notes payable</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6529871b-da5b-47ea-a18e-d5b0a19cd0f6" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,004</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46e782b1-1a23-4013-816b-369c196fb78f" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,993</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Perceptive Term Loan Facility</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 16, 2022 (the Closing Date), the Company entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as the lender and administrative agent (the Lender). The Credit Agreement provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b100fe54-e6b0-4627-a063-9db3e72a72dd" contextRef="C_e6d03a98-3b4e-401e-b7cc-82e792333d3e" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the Perceptive Term Loan Facility). The initial funding of the Perceptive Term Loan Facility was subject to a capital raise of at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_252d8c91-dfff-43b6-89d1-0aef6222f233" contextRef="C_70355a48-c284-4639-9391-77b924c70e70" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in gross proceeds from an equity offering of the Company's common stock. On November 21, 2022 (the Funding Date), the Company raised approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_811593a9-5685-4814-a38c-800bc47ac1ae" contextRef="C_e1abda95-a10b-462f-b26e-ff79238c4eda" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in gross proceeds from the sale of common stock (the Public Offering and November 2022 Subscription Agreements, together, &#34;the Equity Offerings&#34;, see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The Tranche A Loan, in an aggregate amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_851c61ed-c757-4db6-8e38-6f0c9230daea" contextRef="C_1bf6cb5e-cf65-4a16-838b-e866908b46c6" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the Tranche A Loan), was funded under the Perceptive Term Loan Facility substantially and concurrently with the closing of the Equity Offerings on the Funding Date. In addition to the Tranche A Loan, the Perceptive Term Loan Facility includes an additional Tranche B Loan, in an aggregate amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a990ee7c-49ad-4505-b966-4fb1090d6d93" contextRef="C_f0afd3f5-8310-4844-a4d2-63f0d27ddf88" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and an additional Tranche C Loan, in an aggregate amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_498ce796-781d-4c7c-8b72-05034f5a040d" contextRef="C_9c393b81-f0da-48af-813c-5c496799a235" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which will be accessible by the Company so long as the Company satisfies certain customary conditions precedent, including revenue milestones. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Tranche B and C loans have loan commitments dates through December 31, 2023 and September 30, 2024, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Perceptive Term Loan Facility has a maturity date of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_babc7029-bb02-4156-b688-dec76634cd51" contextRef="C_281dc173-6094-4689-8129-e75bfea9ac17" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2027</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity Date)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provides for an interest-only period during the term of the loan with principal due at the Maturity Date. The Company's net proceeds from the Tranche A Loan were approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce1577ef-caaa-4688-beab-88ad53b22e53" contextRef="C_7de21cc0-f9c4-4529-94a5-c125fe2ca78f" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">27.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">debt issuance costs and expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Rate</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Perceptive Term Loan Facility will accrue interest at an annual rate equal to the greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. and (b) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f423466b-d348-430e-a7c7-53c93d763af3" contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum, plus an applicable margin of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f4c9606-dd0c-4962-8d93-b2eff5fee3ce" contextRef="C_281dc173-6094-4689-8129-e75bfea9ac17" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the stated interest rate was approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc9f770a-2f22-4133-9f67-74f776fe8e2b" contextRef="C_3d36f7fa-49dc-413d-a2bd-8d9342f8e774" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">13.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amortization and Prepayment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On the Maturity Date, the Company is required to pay the Lender the aggregate outstanding principal amount underlying the Loan and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments under the Perceptive Term Loan Facility. The Perceptive Term Loan Facility may be prepaid at any time, subject to a prepayment premium equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0bae7bd-3c3e-40a1-959f-8769148bd2ae" contextRef="C_70355a48-c284-4639-9391-77b924c70e70" name="bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d800b8ea-7e2d-4e2d-bea0-17cdb14f0bab" contextRef="C_deba999b-e5c6-4df4-a80e-17fb0c1de3fc" name="bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Security Instruments and Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to a Security Agreement, dated as of the Funding Date (the Security Agreement), between the Company and the Lender, substantially all of the Company&#x2019;s obligations under the Credit Agreement are secured by a first lien perfected security interest on all of the Company&#x2019;s assets, subject to customary exceptions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Credit Agreement, the Company has issued, on the Funding Date, the Perceptive Warrant of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a8e8615-7ef7-429c-946f-ba01f266c525" contextRef="C_e6d03a98-3b4e-401e-b7cc-82e792333d3e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including the Initial Warrants which are equity classified at a per share exercise price equal to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4d04fdf-f0aa-4b00-b147-6f494bbbbc8a" contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">1.0648</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which is equal to the lower of (A) the 10-day volume weighted average price (VWAP) of the Company&#x2019;s common stock, on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of Common Stock of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f4ebf90-4f52-40ce-9604-b319a226488b" contextRef="C_281dc173-6094-4689-8129-e75bfea9ac17" name="bdsx:PublicOfferingPricePerShareOfCommonStock" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In addition to the Initial Warrants, the Additional Warrants will each become exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1244c6a6-8bee-4436-b365-81b18b859aec" contextRef="C_186ed4eb-26b5-4313-aca7-752df70e6114" name="bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d02797a8-deac-47a0-bc4f-0a8f6f6350de" contextRef="C_57134a4c-8578-40a1-813d-312feaa45a92" name="bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The per share exercise price for the Additional Warrants will be equal to the lower of (A) the Initial Warrant exercise price or (B) the 10-day VWAP ending on the business day immediately preceding the funding date of the Tranche B Loan or the Tranche C loan, res</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pectively. Each warrant will be exercisable, in whole or in part, until the 10th anniversary of the applicable date of issuance. If the Tranche B or C loans are not drawn by the respective loan commitment dates, the associated Additional Warrants expire and will not become exercisable. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Representations, Warranties, Covenants, and Events of Default</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants, financial covenants, and conditions that are customarily required for similar financings. The affirmative covenants, among other things, require the Company to undertake various reporting and notice requirements, maintain insurance and maintain in full force and effect all Regulatory Approvals, Material Agreements, Material Intellectual Property (each as defined in the Credit Agreement) and other rights, interests or assets (whether tangible or intangible) reasonably necessary for the operations of the Company&#x2019;s business. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s business activities; make certain Investments or Restricted Payments (each as defined in the Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that has the impact of restricting the Company&#x2019;s ability to make loan repayments under the Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc80c15f-8e06-4886-9c72-8022d158d0ae" contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1" name="bdsx:MinimumCashBalanceAtMaturityDate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million; and (ii) as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2023, receive revenue in amounts agreed to between the Company and Perceptive from time to time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Credit Agreement also contains certain customary Events of Default which include, among others, non-payment of principal, interest, or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross- defaults to material contracts, certain regulatory-related events and events constituting a change of control. As of December 31, 2022, the Company was in compliance with all restrictive and financial covenants associated with its borrowings. The occurrence of an Event of Default could result in, among other things, the declaration that all outstanding principal and interest under the Perceptive Term Loan Facility are immediately due and payable in whole or in part.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Initial Warrants and Additional Warrants were valued at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8ca2c32-4f37-4325-81ce-362ffe9d6a7c" contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1" name="bdsx:InitialWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd001db9-535b-40f5-9277-1446c6c57cd5" contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1" name="bdsx:AdditionalWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, using the Black-Scholes option-pricing model, estimated settlement probabilities and estimated exercise prices. As a result of the fees paid to Perceptive and the value of the Perceptive Warrant, the Company recognized a discount on the Perceptive Term Loan in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49abb15b-40df-4ca0-9b78-9ea0657fe7f3" contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company recorded the debt discount as a reduction to the principal amount of the debt and is amortized as interest expense over the life of the debt.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Securities Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 9, 2022 (the First Closing Date), the Company entered into a securities purchase agreement (the SPA) with Streeterville Capital, LLC (Streeterville), pursuan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t to which, among other things, Streeterville: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c4f9a2a6-6069-4aab-9b68-c3fa5ddb3039" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:DescriptionOfSecuritiesPurchaseAgreement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) purchased a secured promissory note (Promissory Note One) in the aggregate principal amount totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e332bf4-0e5d-450e-9267-6332ab926bc3" contextRef="C_b302bad2-98d3-4851-b88b-540dd7c490b7" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in exchange for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dbe8d88-aca4-4c48-9949-b485935b4c67" contextRef="C_ae3277b8-5cce-47e3-bdd2-81eecc7c9a41" name="us-gaap:ProceedsFromNotesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company&#x2019;s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f8c3257-7beb-44a0-954f-b035e831540e" contextRef="C_9e3e3184-45f3-43eb-b6eb-3e2a5df33941" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in exchange for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ae93a49-ace2-4b57-a23e-79636d54fb48" contextRef="C_ac1ef5ae-331a-42b9-b66f-a867d9104059" name="us-gaap:ProceedsFromNotesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash proceeds.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of the Promissory Notes, at the Company's option, could be settled in cash or shares of common stock of the Company, upon the terms and subject to the limitations and conditions set forth in the Promissory Notes. The Company's net proceeds from the issuance of Promissory Note One were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb924076-162e-4966-ba38-7c41c713f297" contextRef="C_ae3277b8-5cce-47e3-bdd2-81eecc7c9a41" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting debt issuance costs and original issue discount (OID).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Promissory Notes had a stated interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_762b6e86-7188-426a-855c-2262cf573d55" contextRef="C_a85d3cdf-c6db-43af-b1d3-58080059098c" name="us-gaap:DerivativeFixedInterestRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum. The maturity date of each Promissory Note was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1d3eb4de-dd29-4429-8312-6f532c35a2de" contextRef="C_9d280c57-4f0c-4087-bfc5-09e23f264b72" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months from the issuance date of such Note. Promissory Note One was issued with an OID of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df13fd2e-093a-4efb-af82-4a91607d6d72" contextRef="C_ae3277b8-5cce-47e3-bdd2-81eecc7c9a41" name="bdsx:DiscountsOnDebtInstrumentIssuance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million while Promissory Note Two, if issued, would have been subject to an OID of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5977e9dc-df85-4cf8-bc36-599bd886a9aa" contextRef="C_ac1ef5ae-331a-42b9-b66f-a867d9104059" name="bdsx:DiscountsOnDebtInstrumentIssuance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million subject to certain contingencies which could increase the OID by an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_603c7899-ecc9-4313-9b48-3d5d8b354a26" contextRef="C_ac1ef5ae-331a-42b9-b66f-a867d9104059" name="bdsx:IncreaseInDiscountsOnDebtInstrumentIssuance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Promissory Notes were eligible for early payment for cash, at the Company&#x2019;s election, subject to a prepayment premium of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8c78737-f321-4483-b4d6-3632dd37a6bd" contextRef="C_9d280c57-4f0c-4087-bfc5-09e23f264b72" name="bdsx:PromissoryNotesEarlyPrepaymentPremiumPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding principal balance. During the year ended</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> December 31, 2022, the Company recorded </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb5cb256-7932-4c92-b8a1-631d3dcdea9b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for accrued interest, amortization of the OID and debt issuance costs to interest expense in the accompanying statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially and concurrently with the completion of the Equity Offerings, the Company fully repaid all outstanding principal, accrued and unpaid interest, and prepayment and other fees due under the existing SPA with Streeterville in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95b9b5b2-f5cb-4db3-accc-b09147597e3f" contextRef="C_eaa55565-82f2-477b-b6d4-79f13c784eb1" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the extinguishment of Promissory Note One, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he Company recorded a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e6246c9-5cfb-4210-812a-235ac94cc477" contextRef="C_037983b4-6196-4ce5-8ade-33f68a42d303" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the three months ended December 31, 2022, associated with the prepayment premium and with the write-off of unamortized debt issuance costs and OID.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Term Loan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 19, 2021 (Effective Date), the Company entered into a Loan and Security Agreement (the 2021 Term Loan) by and between Silicon Valley Bank, a California corporation (SVB) and the Company, as borrower, whereby subject to the terms and conditions of the 2021 Term Loan, SVB advanced to the Company an original principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37c88c8a-7494-430c-9398-0087e55554fc" contextRef="C_cd92a88e-0c45-4130-9ceb-be9f1169e806" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7b4545c5-9d28-4a8e-a226-60530e6debbb" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:DebtInstrumentDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Term Loan provided for an &#x201c;interest-only&#x201d; period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bec97372-52c3-4f6a-9d11-ccda162a9baf" contextRef="C_b8821775-e1c7-4b43-bef0-f192ca32577a" name="bdsx:RevenueMilestone" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan was payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan accrued interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, was payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate were effective on the effective date of any change to the prime rate.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s final payment to SVB included a payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9201a10-f96d-42c5-be57-b3a2b75194f7" contextRef="C_b8821775-e1c7-4b43-bef0-f192ca32577a" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">amortized as interest expense over the term of the 2021 Term Loan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and through the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Closing Date of the Perceptive Term Loan Facility, the Company repaid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21bfe902-1ed2-45a1-b12e-5395a71305e5" contextRef="C_02bbb7a6-c4e5-4790-a0f3-3a027542791f" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in outstanding principal on the 2021 Term Loan.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Substantially and concurrently with the completion of the Equity Offerings, the Company fully repaid all outstanding principal, accrued and unpaid interest, and other fees due under the existing 2021 Term Loan with SVB in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6de3fe87-5873-42f5-a4d3-9264f9b06c6a" contextRef="C_9494a794-f77b-4a40-af81-4b90b746a8d1" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which included $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1be10e2-027f-4a3c-9926-9829c2ddb610" contextRef="C_23d25b67-f820-41e5-bbdb-0e27c1391956" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in remaining outstanding principal. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the extinguishment of the 2021 Term Loan, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he Company recorded a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc771705-35a4-4203-87f4-0819034c44fd" contextRef="C_7a4e3ec5-40de-461c-b6a5-3cb9963618ff" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the three months ended December 31, 2022, associated with the final payment and the write-off of unamortized debt issuance costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5242b471-76db-4e76-931f-47095055197b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true">
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.51%;"></td>
        <td style="width:1.774%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.717000000000002%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of<br />December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b0ee1a4-ea05-44b5-acf0-189d6e0a5499" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bbac0ad-7ce5-4d26-b2b3-605c6718c84d" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dcb91b5-7c8f-4813-af75-9a22f17ba202" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7249baae-95bd-4ff6-86c5-1256fdd92edc" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ca5b1e8-344f-4916-a768-6f62d2f66c06" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16eb4cf8-dfb9-402f-98de-c1aba8e9d961" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f22e224c-a3a1-4f42-8422-2a5c076f88f9" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:LesseeOperatingAndFinanceLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 9 &#x2013; Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company acts as a lessee under all its lease agreements. The Company leases its headquarters and laboratory facilities in Boulder, Colorado, under a non-cancelable lease agreement for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e943cef-7952-44d1-b3da-96122044a636" contextRef="C_c73395a4-9ee2-430d-9509-2e0c8ad1a49e" name="bdsx:AreaOfOfficeSpaceLeased" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">29,722</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet that was set to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_69f529c7-a6b6-4870-92d2-707a07490f78;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2023</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In January 2022, the Company amended the agreement to extend the lease agreement through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1f6e0faa-935f-477f-be66-d4008a184239;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2024</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, resulting in an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e145acc3-4edc-427c-b7b3-261d68eb4c1e" contextRef="C_cf4e748d-3074-47c8-b2fc-51fe7c3e9765" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_2a61c7c9-5224-4a57-925f-27b94669016c" contextRef="C_cf4e748d-3074-47c8-b2fc-51fe7c3e9765" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in ROU assets and lease liabilities recorded during the three months ended March 31, 2022. The Company also leases laboratory and office space in De Soto, Kansas, under a non-cancelable lease agreement for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bf96279-33b1-4105-a994-fc5b12381115" contextRef="C_d74f0750-6f1c-442f-84b0-83d80d96838d" name="bdsx:AreaOfOfficeSpaceLeased" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">9,066</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet that expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9b0044c9-456b-40db-b304-cbb2a4cddf06;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2023, however, we are currently in discussions to extend this lease agreement</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company also holds various copier and storage facility leases under non-cancelable lease agreements that expire in the next </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_558ae46e-8ea1-4c0a-9a4d-100dfe66de89;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0980ea39-5787-4d2b-b800-5afec28cfc63;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Centennial Valley Properties I, LLC Lease Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space in Louisville, Colorado (the Leased Premises). The purpose of the Lease is to replace the Company&#x2019;s current leased premises in Boulder, Colorado. The Company intends to move its corporate headquarters to the Leased Premises by mid-2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_efcba56d-6b25-45c7-b43a-beb1a13aac30" contextRef="C_5556e5f1-5117-4c3b-bc0c-a41a3e2ea92b" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial term of the Lease is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3f041539-c552-457a-bf5c-71937d64b0ba" contextRef="C_c6060929-cc88-48de-ac6e-4ff5aee26e2e" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">twelve years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0278cafc-4fa5-4b55-9cec-fdc490536c2c" contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66" name="bdsx:LeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 1, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_922a4673-68f3-4e6e-9efe-f2aba5084dad" contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66" name="bdsx:LeaseAgreementNumberOfOptionsToExtend" unitRef="U_RenewalOption" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal options to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5e5a5345-1edd-4012-8378-e25262e96e3d" contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extend</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the term of the Lease for an additional seven or ten year terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c405407-ef26-4c51-9cc0-b3867ed3e02e" contextRef="C_38785f87-07c1-43cc-ac73-db1f587fe1ec" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_e599fd71-12ac-409d-8cfc-fc923ed5590f" contextRef="C_38785f87-07c1-43cc-ac73-db1f587fe1ec" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in ROU assets and lease liabilities being recorded. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Lease, the Company will lease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df4e6902-fe12-48f6-822f-5c9d62efe868" contextRef="C_c6060929-cc88-48de-ac6e-4ff5aee26e2e" name="bdsx:LeasedPropertyBuildingCapacity" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">79,980</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2710e769-c08c-4d7e-a420-e67cbf405096" contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66" name="bdsx:BaseRentPerMonthFromCommencementDate" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">227,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per month and escalating, based on fixed escalation provisions, to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e63c373-e444-40b5-8445-6c5f08fdd6b0" contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66" name="bdsx:RentAfterFixedEscalationProvisions" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">326,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d234abdc-0f58-46a3-a563-21eb2cb504aa" contextRef="C_c6060929-cc88-48de-ac6e-4ff5aee26e2e" name="bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">19,980</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2619007e-c656-4970-9385-c9cfb97ff81a" contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66" name="bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million toward the cost of construction and improvements for the Leased Premises and the Company exercised its option for an additional tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7bb06ea-141b-43fc-abc0-ab4767a6d643" contextRef="C_5556e5f1-5117-4c3b-bc0c-a41a3e2ea92b" name="bdsx:AdditionalTenantImprovementAllowanceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b254e0b-fced-4796-a2b5-cea2f269a0f7" contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66" name="bdsx:InterestRateOnExtraAllowanceAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per year over the Initial Term excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount. The Company made an accounting policy election to reduce the right-of-use asset and lease liability at lease commencement because the Lease specifies a maximum level of reimbursement for tenant improvements which are probable of being incurred and within the Company's control. Due to the tenant improvement allowances at the accounting lease commencement date and rent abatement periods described above, the Company expects the lease liability to accrete to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8444c567-a187-491a-9641-741558f777c0" contextRef="C_31da1c0e-91e4-449a-b28c-c8ca4cad2ca2" name="bdsx:AccretionOfLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million by March 2024 after receiving $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73451fcd-6721-4559-b48d-a2e723fc1bfe" contextRef="C_64a79dd5-c87c-429b-863e-00e581d3a825" name="bdsx:LessorReimbursementsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in lessor reimbursements. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Company has incurre</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3be025fb-59d4-4ccb-8827-cc5b629bc767" contextRef="C_38785f87-07c1-43cc-ac73-db1f587fe1ec" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">capital expenditures for leasehold improvements related to the Leased Premises which are tenant improvements and have been reimbursed from the Landlord during the three months ended December 31, 2022. As of December 31, 2022, the Company had remaining capacity under the tenant improvement allowances of approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d801e47c-5262-4ace-9bea-588bfb1bfd92" contextRef="C_5556e5f1-5117-4c3b-bc0c-a41a3e2ea92b" name="bdsx:RemainingCapacityUnderTheTenantImprovementAllowances" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. During the three months ended September 30, 2022, a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33938bde-6e54-4164-9d39-907718e800c2" contextRef="C_394dc411-8890-456c-88fb-38cd9c45e342" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million cash collateralized letter of credit under the operating lease agreement was released and the funds were subsequently transferred to the Landlord as a refundable deposit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#x2019;s obligations. The $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a2cecf9-edcc-4c04-8a78-281a39718b28" contextRef="C_4d3d5033-be47-4149-b009-902d32d7a987" name="us-gaap:CustomerFunds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million refundable deposit is included within '</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_619e0fd9-df0a-4ffa-8df0-66030beb9821;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">' in the balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease expense for all operating leases was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fe62c22-9fb0-4f3f-b45b-f9c4c7a02727" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4bc1de9-0b4b-4b0d-b4f3-d5531dc4b9c5" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2022 and 2021, respectively. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted-average remaining lease term and discount rate associated with our operating leases were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e5419def-0f6a-4108-ae29-51efa8734caa" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c886f13-ff19-426d-8381-3dc3c43f9311" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">11.40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ctively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_cb4b1267-09fa-4bec-95d3-06cd86a4b4e6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments associated with our operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.796%;"></td>
        <td style="width:1.869%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.334%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of<br />December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42206409-eca5-47e9-a86e-2b0ef1c3cb47" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,289</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecd4a2e1-6f37-44e7-a51c-accfbb8a58ae" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,619</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b162190-6681-44a6-b82a-d743849aeb31" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,710</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f8ed8c6-3d9f-437b-827e-79c7ae2afe5a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,978</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47d01c93-35b4-4737-bc94-2cb934484ff9" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,063</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d1ffbce-640b-4050-b630-de333f413d39" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="bdsx:LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,263</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f4caf77-d988-4b14-8064-87ceee223193" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,922</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amount representing interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23287897-5a43-4773-bf74-427d69a6eca8" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,802</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amount representing tenant improvement allowances</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce6d3b60-8e1e-4434-985f-82c8c765bf23" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="bdsx:LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_827c4c63-9ad5-43e7-b21e-3598787369db" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The remaining contractually agreed upon tenant improvement allowances of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d69fb0e7-4bc6-4441-ab1b-5d6ddb96c7dd" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="bdsx:TenantImprovementAllowancesExpectedToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are expected to be received during fiscal year 2023.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c14d7cc2-2439-4078-bef9-0f8a33effdde" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations in accordance with ASC 840 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.784%;"></td>
        <td style="width:1.711%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.506%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br />December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8cfd362-3e94-4b2d-bf20-1d497fab18b8" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5de5cee3-65a5-4e27-91cb-58b90349879c" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f6843a8-132c-4da9-b901-4b19e9f928aa" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65f89d12-9625-4e8f-8ffe-110ab7d26825" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32f7ac60-27ef-4943-a92b-52a6fa9ae72c" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c575325-c038-46c1-9fd6-7708cb82243a" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3b28b908-fe37-4df1-9d5b-c4dc95803bb4" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 10 &#x2013; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_041fd8b2-2b66-4b5c-ae8d-3e0c7a855f4a" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc3ec2fa-b6da-44db-b4b9-079f409a7dc0" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2fd4ab44-815d-4561-9d18-1eb3d6bfd584" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holder of each share of common stock is entitled to one vote per share.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_933186ea-a486-411e-bdd9-0a17d07978cb" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_096023f1-85a6-4af8-a06d-2dba11de1edb" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_279a0a8d-5b30-464c-9bc7-0d1f1955f831" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbaf9d66-3857-4404-83fd-fe85b1520e17" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4fd11a2d-8712-4621-a6ff-0ef2ff00c2fd" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_10508e57-e0d1-48c1-8ff8-8dceb888d581" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_befdda13-1ccb-4fd6-8c10-2b7e2b66c84c" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock were issued or outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Financing Programs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84dce23a-1e00-4ebb-a708-720b3de74c55" contextRef="C_eee382e8-1805-4f39-907d-bfda41055f0b" name="bdsx:NumberOfFacility" unitRef="U_Facility" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> facilities that enable equity financing on an ongoing basis at the Company&#x2019;s sole discretion, our at-the-market offering and our common stock purchase agreement with Lincoln Park Capital Fund, LLC (the LPC facility). In November 2021, the Company entered into a sales agreement with a financial institution, pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d043cbb2-9594-475b-a67f-2607950cc6a0" contextRef="C_d29ffb11-8aeb-454a-b02f-a1cd08996dde" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the Shares), subject to terms and conditions. The Shares will be offered and sold by the Company pursuant to its previously filed and currently effective registration statement on Form S-3. The Shares may only be offered and sold by means of a prospectus, including a prospectus supplement, forming part of the effective registration statement. Sales of the common stock, if any, will be made at market prices by methods deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Global Market, or any other existing trading market for our common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2022 (the LPC Effective Date), the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), pursuant to which Lincoln Park has committed to purchase up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e720f7b-27a2-460b-a97c-01d69672b443" contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09" name="bdsx:StockIssuableDuringPeriodValueCommittedShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the Company's common stock (the Purchase Agreement). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69f5b036-6d0d-43d4-870b-67df0c110e4b" contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09" name="bdsx:StockIssuableDuringPeriodValueCommittedShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the Company&#x2019;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#x2019;s</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sole </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">discretion, over the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d19a1e1f-6cfd-4d7e-9a94-692a9552fbf3" contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808" name="bdsx:PurchaseAgreementTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period commencing on the LPC Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca3d4bca-a721-46c8-85bf-2ff532f7bc55" contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808" name="bdsx:SaleOfStockStockIssuablePerDayShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, but that amount may be increased up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e640aa2-ae2b-4b16-8221-fbc20647f321" contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09" name="bdsx:SaleOfStockStockIssuablePerDayShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, depending upon the market price of the Company&#x2019;s common stock at the time of sale and subject to a maximum limit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a041439-4464-4117-b974-20c760976450" contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09" name="bdsx:SaleOfStockStockIssuablePerDayValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#x2019;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c87aca87-f813-48dc-888a-9c702db68cf4" contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808" name="bdsx:SharesIssuedOrIssuableThresholdLimitDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under applicable rules of the NASDAQ Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#x2019;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35b78f14-a736-4156-a260-cbbc44819700" contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808" name="bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of its common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the LPC Effective Date, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ef216d5-c57a-4a3b-8348-2c105da144f4" contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808" name="bdsx:SaleOfStockSharesIssuedAsCommitmentFee" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">184,275</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to Lincoln Park as a commitment fee (the Initial Commitment Shares) for which the Company did not receive consideration and, upon the available amount being reduced to an amount equal to or less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_235034a2-5c73-4e63-9b93-056fcdc3934a" contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09" name="bdsx:SharesIssuedAsCommitmentFeeValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the Company will be required to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67254794-3e7c-4e27-8cf0-a886340d4df2" contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808" name="bdsx:CommitmentSharesIssuableOnConditionalBasis" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">61,425</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares (the Additional Commitment Shares and together with the Initial Commitment Shares, collectively, the Commitment Shares). The Initial Commitment Shares issued were valued at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93650a8a-e2a8-4151-8b5f-106029026c10" contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808" name="bdsx:StockIssuableDuringPeriodValueCommittedShares" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and, together with due diligence expenses and legal fees of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00ed322b-7419-4002-a360-36787afdcbbd" contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808" name="bdsx:DiligenceExpenseAndLegalFees" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">129,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, reflect deferred offering costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbacc074-c4f3-4162-847b-aa42988103a5" contextRef="C_d6b61263-79d7-4ad5-80e3-c6488dc15d6e" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">729,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which are included on the balance sheet in 'Other long-term assets'. The deferred offering costs will be charged against 'Additional paid-in capital' upon future proceeds from the sale of common stock under the Purchase Agreement. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d7dec7d-f371-4a04-9ccf-8e6214cf928b" contextRef="C_71e6a261-6445-4aef-9b90-6aa8258c393b" name="bdsx:AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">75,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of deferred offering costs were charged against 'Additional paid-in capital'. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6783497b-d282-4ed4-affe-d4499b132328" contextRef="C_7879ad8c-ea5d-4043-a09d-e45c5b04d104" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">654,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of deferred offering costs remain.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company raised approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13cc6847-8b0a-4a65-92ae-4b745b61e6ae" contextRef="C_eee382e8-1805-4f39-907d-bfda41055f0b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_390a142c-f9f5-4a72-bc16-1c0f77547d5e" contextRef="C_b796b863-ace9-4b62-946c-082d3b02817c" name="bdsx:ProceedsFromIssuanceOfCommonStockNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting underwriting discounts and commissions and offering expenses payable), in gross proceeds from the sale of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69b01b31-51ae-42a6-b79b-184c3047b72a" contextRef="C_eee382e8-1805-4f39-907d-bfda41055f0b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,886,893</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares at a weighted average price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1657b1f-5432-4ffd-9848-5895c026a76c" contextRef="C_eee382e8-1805-4f39-907d-bfda41055f0b" name="bdsx:WeightedAveragePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.87</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> under these programs. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had remaining available capacity for share issuances of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91ce25aa-280a-40e0-ba51-c2dce856fc4d" contextRef="C_91f72376-23e0-4941-9051-8d330ee61b8e" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under the at-the-market facility and up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0887d4c-abcc-4d2f-b9c4-e20057e5d78d" contextRef="C_17924754-ecbd-43e7-95c0-61af5078762a" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">46.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under the LPC facility, each subject to the restrictions and limitations of the underlying facilities, as well as volume limitations under applicable SEC rules and regulations that limit their availability as sources of funding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 30, 2021, the Company raised approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5e677b0-8770-4676-b0ee-db5b4d9c043d" contextRef="C_169bf5c0-fabd-48e8-9e19-f178074d2e74" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in gross proceeds from the sale of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c6b334d-7890-4d78-9cdd-18cde0bfe61a" contextRef="C_169bf5c0-fabd-48e8-9e19-f178074d2e74" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,756,994</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43d9180c-9bd5-454f-8b41-33676c6b09ff" contextRef="C_187c775a-a3b7-42da-bfab-78d163765caf" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">per share in an at-the-market offering</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c620c38-e86d-401c-a728-7bf7c9bd72c0" contextRef="C_5cc619c2-53d7-4761-a81a-9a741927fe13" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses payable of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90b14eea-baf5-4e77-8ee4-dcaf9563fed7" contextRef="C_187c775a-a3b7-42da-bfab-78d163765caf" name="bdsx:UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company closed an underwritten public offering (the Public Offering) of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e936491f-d0cd-4847-b621-a9335c8e05d9" contextRef="C_80d972be-0e12-4624-abfc-02988b9d378b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,075,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock (the Public Offering Shares), including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f092a7b-8e42-4a48-8d5d-8b4cc1db46e7" contextRef="C_80d972be-0e12-4624-abfc-02988b9d378b" name="bdsx:StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,575,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares purchased by the underwriter pursuant to an option to purchase additional shares. The Public Offering Shares were issued and sold pursuant to an underwriting agreement, dated November 16, 2022, by and between the Company and William Blair &amp; Company, L.L.C., as sole underwriter, at a public offering price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83ac4625-8b05-43cb-949e-38c779bd8253" contextRef="C_0b08f51c-d57a-4f72-8c72-dd0f2eae99a3" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3221fca-e9a9-4f36-9f5d-865f62c2635f" contextRef="C_438ec078-c687-429c-a769-d3742dbe11a3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the Public Offering after deducting underwriting discounts, commissions, and offering expenses payable by the Company.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Public Offering was made pursuant to the Company&#x2019;s effective Registration Statement on Form S-3 previously filed with the Securities and Exchange Commission on November 29, 2021 and a prospectus supplement, dated November 16, 2022, relating to the Offering.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subscription Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into subscription agreements (the April 2022 Subscription Agreements) with a consortium of investors (the April 2022 Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31094051-3099-4f30-8766-aba077ad83b3" contextRef="C_bd3c756b-0fd0-4580-b35c-5bd0c430ca65" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,508,376</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock in a private placement offering. The three members of our Board of Directors acquired an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9297c2c-3cf3-4998-ab7a-6ce0e18a4bd0" contextRef="C_1a2949cc-e81d-4125-b746-f22e110c97c7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,631,284</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares pursuant to the form of a Subscription Agreement that did not include any registration rights. The remaining </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_114c7296-193c-42e2-8b9c-43899ee81c36" contextRef="C_6a86f3ed-b059-49f8-929d-392ed1b5aefa" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,877,092</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were acquired by others pursuant to the form of a Subscription Agreement whereby the Company agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the Securities and Exchange Commission no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the April 2022 Subscription Agreements, the April 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0eefe225-ac35-47c9-a425-891c4d2fe96e" contextRef="C_fd581c08-91c5-4205-b952-ae033f5f32d1" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">1.79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, which is equal to the closing price of the Company's common stock on April 7, 2022, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2bb34da-f14f-4cdb-b57d-ac05cd04928e" contextRef="C_a9ac9aa4-ea3e-4802-8754-c8e9edd2adc9" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">11.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The April 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company entered into subscription agreements (the November 2022 Subscription Agreements) with certain members of management (the November 2022 Investors), including the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, for the issuance and sale by the Company of an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd28ba07-fdd4-4e45-bfc7-125fd1b7d98d" contextRef="C_e1eeb3ca-40cd-466c-ae9e-ca7ba7b2a2f2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">235,056</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock in a private placement offering. The November 2022 Subscription Agreement did not include any registration rights and included lock up restrictions that will be in effect during the period ending 90 days subsequent to November 21, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the November 2022 Subscription Agreements, the November 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_838fbcb5-6372-42d4-9661-ae0ad8863b02" contextRef="C_c85c73e5-0596-4390-a44f-00d4c2b63b97" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">1.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, which is equal to the public offer price in the Public Offering, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8eac47e4-85a2-4664-ab7b-ecaf95f8dd3c" contextRef="C_b1332991-a124-414c-9607-7eb5c2b60415" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">270,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The November 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2018, the Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain convertible preferred shares and issuance of debt. The Company issued to the lender a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_208eefaa-e598-4267-97dd-3bec04650539" contextRef="C_ba733271-8a6c-457b-aa81-58381d47b3b4" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">613,333</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series G convertible preferred stock, at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_502cd301-62e3-42bc-a053-e32561bfac9b" contextRef="C_ba733271-8a6c-457b-aa81-58381d47b3b4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cb155cf8-088b-421a-8a56-6172b3012bb3" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 23, 2028</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Through the effective date of the Company&#x2019;s initial public offering (IPO) in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black-Scholes pricing model. As a result of the Company&#x2019;s IPO, the preferred stock warrants were automatically converted to warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71f322bf-a108-49d5-947b-c1d0d2336fb8" contextRef="C_26541884-e077-4463-84ef-77608f72fe54" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">103,326</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3aa3cf31-ac89-47de-a975-d88901cf7dcb" contextRef="C_26541884-e077-4463-84ef-77608f72fe54" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.46</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and were also transferred to additional paid-in capital. All Series G common stock warrants remain outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the Company issued the Perceptive Warrant to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0be0d53c-4750-41d6-9efd-f4ae913ce859" contextRef="C_6fd3ded3-11d4-4f58-b776-f582e91d8799" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, including the Initial Warrants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the Initial Warrants, the Additional Warrants will each become exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27129365-1ba6-467a-9002-c5432b082f4b" contextRef="C_94e70836-502c-461e-9146-5d8aa063080e" name="bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The per share exercise price for the Initial Warrants is equal to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d891101-6555-4421-bd08-41d9e69084a7" contextRef="C_6ad6809c-68cb-4c96-8ae0-d9bd24aa0db0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">1.0648</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is equal to the lower of (A) the 10-day VWAP of the Company&#x2019;s common stock on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of common stock of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18b5f6b8-c42d-4049-8b72-d75581b6639d" contextRef="C_75178c23-f72c-42e0-a591-2de6aea0caff" name="bdsx:PublicOfferingPricePerShareOfCommonStock" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Initial Warrants are equity classified and were immediately exercisable upon issuance and expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c163200a-56f9-4aa7-9258-042bf235c7e8" contextRef="C_4ed704bd-7ad3-4b26-ad05-362e6ae5c9c5" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2032</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Initial Warrants were valued at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_289900f1-f66d-4303-9886-528c1f5c6c65" contextRef="C_4ed704bd-7ad3-4b26-ad05-362e6ae5c9c5" name="bdsx:InitialWarrantsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using the Black-Scholes option-pricing model assuming an expected term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_63d301de-c430-4674-a721-c83dcfaea080" contextRef="C_5b9afec0-72f8-4476-a4ee-4fd773a715d4" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, a volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_813bf283-36d0-4100-b84f-7813477c9c2d" contextRef="C_086ca540-28e1-44ca-a323-2ad2636c5784" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf10d5f3-161f-45d3-bae3-8ec936b10754" contextRef="C_d722c30e-d139-43c4-b526-3699892348c1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and a risk-free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_850e02df-864f-4549-998e-57992135400a" contextRef="C_61e5c055-428e-4280-b39a-813cfb48033b" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.67</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. All Initial Warrants remain outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e19512a0-4052-44f0-9463-5afcedf8583b" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 11 &#x2013; Revenue and Accounts Receivable Credit Concentration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a68dc283-ce39-4854-8633-1eb71122ba58" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:PrimarySourcesOfRevenueDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8dcc42de-d115-4034-bd34-9b764e3d1e14" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.726%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.359%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.687999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic tests</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17878fa0-8456-4640-b734-8af72c0ad58b" contextRef="C_5f76d7ba-2692-45b1-bf5a-feaf239555c2" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,538</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff2910cd-4bfc-4c74-9d29-26649b8be72d" contextRef="C_12180992-8c3b-4583-9f45-a6c1fac1d121" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab6f00d1-09ca-4ad3-8658-c9355af2763c" contextRef="C_943b8db7-988c-4af2-94ee-41515857328f" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86a3c95a-9607-421f-8904-cb3109fb7246" contextRef="C_6a0dc852-f2b0-48bc-b2b6-1620c601a50d" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenue</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb20166e-48f8-42f9-9847-2c247f8f1057" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,212</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2d259e0-7df7-41cb-8f6f-1ef54f497a48" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Revenue</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in &#x2018;Revenues&#x2019; in the statements of operations. Of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c493a3b-a223-4305-83c4-6237d03267af" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in &#x2018;Deferred revenue&#x2019; recorded in the balance sheet as of December 31, 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21dd2746-b5ae-4b9c-aa99-e4ab0b5c3c5e" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was recognized in revenues during the year ended December 31, 2022. In addition, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f3bfb3c-1270-420b-bd49-cc7f932306ec" contextRef="C_1c8760f8-4bfb-43a9-838d-4e0b93c9f2aa" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> added to &#x2018;Deferred revenue&#x2019; for up-front cash payments received for which the revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognition criteria have not been met and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be640d83-84b4-411a-9a58-46e1640684bf" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was reclassed to non-current deferred revenue. The &#x2018;Deferred revenue&#x2019; of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fed434d5-1655-4d1f-a514-3bd330b36c1d" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">corded in the balance sheet as of December 31, 2022 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1662fc76-ef03-4014-91ef-9c6d0cfe04e2" contextRef="C_9e1cb9f9-1f35-4466-a46d-cf526d23b935" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a34736b4-94d7-41e9-8fd0-766cd56fcac3" contextRef="C_3422fe75-7e5a-45a7-ac6a-9088eeb3e5b1" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in non-cu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rrent deferred revenue, respectively, recorded within &#x2018;Other long-term liabilities&#x2019; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s customers in excess of 10% of total revenue both pertain to our COVID-19 diagnostic testing services, and their related revenue as a percentage of total revenue were as follows:</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c317432d-4333-4800-a339-5065b1762362" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true" continuedAt="F_c317432d-4333-4800-a339-5065b1762362_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.5%;"></td>
        <td style="width:1.018%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.454%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.02%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The State of Colorado</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f683e05-4c3c-4583-8af2-0c99d1248926" contextRef="C_73bf8719-9ed7-4a80-941c-ebed989aedcd" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_998d3e90-0f8c-42fe-84c5-be723db9421f" contextRef="C_a480b51a-4a24-4df0-bc08-5701140469ea" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ion to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71e3d270-813d-4125-9a49-78fd34ad639a" contextRef="C_efe1b90e-7787-4cc2-bfbe-359fbdc3c5ac" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">37</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27b8df9a-a097-43eb-a8c8-9cf458bf4277" contextRef="C_4844e46c-01bd-4e1b-8bbd-3eb015874131" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">18</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#x2019;s total revenue for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_c317432d-4333-4800-a339-5065b1762362_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.5%;"></td>
        <td style="width:1.018%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.454%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.02%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medicare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88fa8cae-ed9d-40f1-b2c6-ed23f4f62dd0" contextRef="C_965f19ae-0f96-4ce2-8e48-5b6071e81159" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_773038af-2685-445e-8cc0-054d9b280254" contextRef="C_9cfbccdc-31c5-4e8a-bfdc-7649f1ec0117" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Astrazeneca UK</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0ddbd0c-bca2-4903-b574-7e05b69a7300" contextRef="C_0e3f888f-0695-472c-8a11-9658d99a93b6" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Janssen Research and Development, LLC</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a18a0f24-9d7f-4371-bf48-f04387de1f32" contextRef="C_c7401865-053c-4260-997b-b04309ea03f4" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LabCorp DD (formerly Covance)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_532923bc-864e-430b-8f96-2e36fe92ba96" contextRef="C_706d33fb-1152-4e58-a444-b5203cd4a996" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d10300a-099e-4f44-bb64-9b606b78112d" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 12 &#x2013; Share Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Predecessor 2016 and 2006 Equity Incentive Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c9a56de-0818-4951-8a34-04350da18b27" contextRef="C_7fdeca4f-00cf-4beb-b46e-1e1eae6fa90a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional awards may be granted under the 2006 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultant. Awards granted under the 2016 Plan or the 2006</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#x2019;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a64c610d-1b55-4f89-a7a4-ad6877296348" contextRef="C_daba2c85-8b46-41a0-aced-c3772e54ec5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional awards may be granted under the 2016 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective upon the closing of our IPO, the Company&#x2019;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares originally reserved for issuance under the 2020 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a1f6028-f31e-478d-ab6e-b5962ead9e94" contextRef="C_2d5836ee-d2bb-477b-8e85-8cfcb55b699e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,893,395</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2020 Plan includes an annual increase on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_683990ca-ac22-41c7-b6b2-9e39fa64a683" contextRef="C_7b4b65a0-9eab-4198-9d03-64c0e6fc1646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#x2019;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a prior plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all plans as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d249a12-5729-4234-9e2d-b99a6395ed24" contextRef="C_630425c2-c257-4e6f-9752-038cef3e8e65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">233,519</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective with our IPO in October 2020, the Company&#x2019;s Board of Directors and its stockholders approved the Company&#x2019;s Employee Stock Purchase Plan (the ESPP). The number of shares originally reserved for issuance under the ESPP was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5ea8779-b1eb-4c7f-9291-627c0220eebc" contextRef="C_6dc925fe-1445-4fb6-b137-670c99ed2615" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">338,106</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c626070-0125-45bd-8135-753799f07f13" contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_929feae4-44b1-417e-9320-e0ec53ccdf6a" contextRef="C_55e36f95-2f43-434a-8af9-06f6e131a730" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aeb6f080-5183-4aa6-8a81-47bb11315f2d" contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value of the Company&#x2019;s common stock on the first or last day of the offering period, whichever is lower. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8ba12f7-f59d-4779-b94b-f802fe477948" contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf" name="bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_85a1a730-96be-4c01-b890-608fd632195b" contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf" name="bdsx:DescriptionOfOfferingPeriodUnderPlan"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13efa344-98d2-43f9-907b-29b4e5256431" contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">237,961</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the ESPP leaving </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2d721d9-5b3c-4c01-8eab-0bb5c3b542cd" contextRef="C_55e36f95-2f43-434a-8af9-06f6e131a730" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">100,145</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares remaining for future issuance.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Awards Granted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_00470ce3-7ab2-4b0d-9895-a9b0d670ecc5" contextRef="C_1043f2a6-0e14-46df-bbaa-a20764b5e9c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-statutory stock options, which may be issued to employees, non-employees and directors, are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_afad1ea5-778e-4b1b-8c08-bc210e5735c2" contextRef="C_746a7287-f9b5-4d12-831b-35d4b70d784d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance-based options vest in three equal annual installments beginning one year after the grant date</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#x2019;s common stock on the grant date. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_904add92-9c4d-4572-9ca0-a2708c32e13d" contextRef="C_bcd01088-6b6b-4233-b784-8c76ca2c0480" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance-based stock options outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU holders have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bonus-To-Options Program</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also has a Bonus-to-Options Program (the Bonus Option Program) which is separate from previously described plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011, 2015, and 2022. For fiscal year 2022, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the closing market price of the Company's common stock on the grant date, as disclosed below under &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;. Bonus Options issued must be exercised within a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9ee3d0a5-5fb2-4395-8543-e6295f5c851e" contextRef="C_86159b8d-7aed-4b03-b26e-bca866fbd61a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_315ebc86-57bb-49d3-a615-c37bb70b50e0" contextRef="C_585442c6-63fc-4616-91c6-831a62abd477" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.441%;"></td>
        <td style="width:1.001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.754%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.987%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.087%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.754%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.872%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br />Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br />Contractual<br />Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#x2011; January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2d49a34-6b7d-4227-b7be-28b987c0025e" contextRef="C_0cde4147-0171-4e88-8504-bba1e5f0b211" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fecbffc-8d10-4710-8352-7b77c78ea3dd" contextRef="C_0cde4147-0171-4e88-8504-bba1e5f0b211" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">17.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ad055ebd-a8fe-4fb9-bf29-113d7479fb08" contextRef="C_41cb42fe-1fc1-4fe5-95d4-e30f3d31ec21" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66ac03ec-6037-422b-b591-bdc464f5b678" contextRef="C_0cde4147-0171-4e88-8504-bba1e5f0b211" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1769c380-d3ac-4a27-bdf7-ab19212f0184" contextRef="C_585442c6-63fc-4616-91c6-831a62abd477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fff3d5c4-c263-4a64-a631-5784ed7b418e" contextRef="C_585442c6-63fc-4616-91c6-831a62abd477" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba5f717f-e40a-4fdd-9c05-296f7a544d30" contextRef="C_585442c6-63fc-4616-91c6-831a62abd477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f5b0d49-f558-4aba-9698-bbc7c9c562e3" contextRef="C_585442c6-63fc-4616-91c6-831a62abd477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#x2011; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59018cc1-b6d2-49ea-b2f6-ca4ea86647f4" contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3c1ad19-0d24-48d0-be6c-0b2ed359fe54" contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_67dd6062-7775-4031-8d03-cd6787c7f02f" contextRef="C_585442c6-63fc-4616-91c6-831a62abd477" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e011186d-9861-42d3-b39c-9bd7930c2d77" contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable &#x2011; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b57b5286-5373-4423-ab61-b400291246a9" contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca192819-fe87-4f79-8765-489611d536a0" contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a29b277-7e81-47b1-8fa4-9e8f0e8e9021" contextRef="C_585442c6-63fc-4616-91c6-831a62abd477" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bf899b9-0cc6-409d-99dd-066c2de66614" contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company record</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60cd1686-2225-458f-9de0-c80bc7c6c0e1" contextRef="C_585442c6-63fc-4616-91c6-831a62abd477" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba669960-27c7-4651-ba8b-2e12bdd69810" contextRef="C_41cb42fe-1fc1-4fe5-95d4-e30f3d31ec21" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million du</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ring the years ended December 31, 2022 and 2021, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in the first quarter of 2023 and 2022, respectively, by the Compensation Committee of the Board of Directors. In determining the amount of share-based compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88d93e7e-fb3f-4e56-b066-1355f2a82da6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.841%;"></td>
        <td style="width:1.663%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.424%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.275%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.796999999999997%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14adae05-77e6-4dcb-8109-a64fc6d491e6" contextRef="C_e2944650-b682-45bf-91f6-43c4a2e81e26" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf42a52e-ed3c-49d0-a7a0-de09612ecb9a" contextRef="C_537fd16e-de8c-489b-89dc-da0dcaa87884" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5a87459-70f0-4223-80e5-823e33001b8d" contextRef="C_ee837150-7dcc-4823-b2b5-2d0c51a4dd17" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53195ece-232e-4f06-81d0-ef392f960af4" contextRef="C_a8cbb7ea-0740-4eb6-9874-287b74dc5289" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">572</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77d63436-cf15-40ca-b090-8a51a56c765a" contextRef="C_dc7252ad-b58c-4241-b1ba-4346c1180e60" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_695143d7-1df2-4601-87c8-8f5bdb10a68e" contextRef="C_9fdff006-70ae-43ff-b822-eb5c9877e323" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a4d2b03-6def-4caf-9bf9-cd87b38b6a05" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,961</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_448e83f6-51e9-498d-94a4-95abe23df312" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,944</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The unrecognized remaining share-based compensation expense for options and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> RSUs was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5667538-3473-46f3-aefc-60fd7720421d" contextRef="C_d7ae35e9-9d7c-47bb-a677-d141d7cc9457" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and is expected to be amortized to expense over the next </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f1ab148a-634c-4605-ad7c-5db4805cb0df" contextRef="C_fb388fb2-b1a4-41c7-b2e6-24847a05c97b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2845ab2c-7a25-48ea-b3af-da148f09789c" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.441%;"></td>
        <td style="width:1.001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.754%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.987%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.087%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.754%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.551%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.872%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br />Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br />Contractual<br />Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding - January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0dcaa0e-cbb1-447e-8098-74aba043bf2a" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">2,878</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc56d1be-005b-4c09-9ab3-1c357676caeb" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bddb1b82-fa10-4bdd-966a-dab325382953" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71c9fcc1-3871-4453-b973-0c4db8131f10" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_099fdcfe-2a4f-458e-a2ec-b03bdf7358b3" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">380</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3938a6f-a816-41ae-b6ea-1f7bb8a870df" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bce76f2-8123-4550-a3c4-1b07b4bf9568" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccef1064-f279-44ec-bf4a-d588670451e5" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_406d94a0-6f4b-4d80-a9f6-e3a80b9e1fe6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">384</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_705d35ad-5659-491e-b308-0065725cca45" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#x2011; December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73154ce2-44e8-4729-b1a4-305f3c8a776f" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">2,541</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78c53afc-8e94-4b80-9582-991b468e2459" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5ce9ca77-cbf4-4613-894e-9e0ee318579e" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df5aba50-5c4e-48b5-a044-cc2177701610" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,489</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable &#x2011; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b4c5bce-ae8a-4782-a8f3-a09917fd09ba" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">1,525</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1c3ae26-4ecf-4c23-8edb-c30deeb92710" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.28</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cc9e83d4-45bd-4bc0-93ec-e5dd6e61fba9" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5d5868f-a319-4e4d-9847-51fed7a02d00" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,067</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the Company&#x2019;s common stock is determined based on its closing market price on the date of grant. The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca7b2746-8be5-4b4a-a1d0-9df2af0ea476" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_de5abffe-6067-43b5-af45-2aa9e653ae28" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</span></div></div><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_5f312543-537f-49f1-bd71-31961183436f" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.936%;"></td>
        <td style="width:1.203%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.062%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.814%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.985000000000003%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bca11e82-65b3-42b6-9aa5-2f1bbad57479" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_310ac401-829b-4e82-91a7-1a9bc304fb68" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aaa95614-f318-45db-af39-e6356c0676f1" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">72.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4557690b-04d0-4d9a-8386-80f91b2eef67" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">68.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk&#x2011;free rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_204a7a1a-20fe-45fa-ace0-efc77b5781a3" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.32</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b148411-ac91-4a2a-b5e3-49b5b079a16f" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2b642163-304c-4850-98f1-2a8eee1118cf" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock unit activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 was (in thousands, except weighted average grant date fair value per share):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.859%;"></td>
        <td style="width:1.207%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.776000000000003%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.27%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.889%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br />Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#x2011; January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dae50249-d3e9-478f-8c6c-da257057926a" contextRef="C_e0aa9545-138b-4cb5-9486-69e3ff5ba91b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98807ae7-80a9-415e-9c2b-ec5bd6890f4f" contextRef="C_e0aa9545-138b-4cb5-9486-69e3ff5ba91b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87f1ec75-6219-4b31-857f-359ce497feeb" contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">1,473</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e896372-dbf2-4774-83e3-376edff158c1" contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f104fd21-9ace-428d-9f19-e06494d70953" contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a283b6d-9acf-4367-9b5f-0d6582ff7bb4" contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Released</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88740d5a-8ace-4abb-a3db-b4ef2a7176a3" contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">357</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b88950e1-a6e7-4ecf-bed2-107cb2cf7979" contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#x2011; December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12ce876a-c328-4415-992b-76525642f125" contextRef="C_1526a220-9742-4789-9d47-4ce3ee95d398" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">1,211</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83adb810-1942-4797-a272-f07227012a0e" contextRef="C_1526a220-9742-4789-9d47-4ce3ee95d398" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.36</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_510d9ca4-78ae-4a7f-88f5-6bfa9c1e2fda" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 13 &#x2013; Net Loss per Common Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share excludes dilution and is computed by dividing net loss attributable to the common stockholders by the weighted-average shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the Indi APA. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_340bc56e-3177-4ecc-ba62-a59a97bd2c33" contextRef="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e090b5f-951c-43a9-92e2-2723d7d5f3fa" contextRef="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806" name="bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the acquisition date. When the gross margin target was achieved, the Company was required to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83b085a8-c950-4cd0-906b-85213d419b2b" contextRef="C_5407a72b-1be5-441a-baf7-31f7a5742f30" name="bdsx:BusinessCombinationContingentConsiderationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,520,108</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. The Company achieved the gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13c19bb2-ca0a-4dca-b7b7-4d14d3b1a78c" contextRef="C_a5a47bb8-865d-46aa-9b99-e3a31978f62d" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for three consecutive months during the three months ended June 30, 2021. As a result of the achievement of the gross margin target, the Company included the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a34db3b6-7650-4497-b9b3-fee9581764e4" contextRef="C_ec8d24b6-eeb6-4535-a95a-f96122922dc9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_8040c400-b1f0-4780-a2cf-276b32e065ba" contextRef="C_ec8d24b6-eeb6-4535-a95a-f96122922dc9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c0a07386-bc0d-4c21-9baf-d92d22746c3c" contextRef="C_8be89166-bad4-409c-881c-a9f3f86a21e1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_8ed5aae3-fc38-4c9a-8908-872be12b1add" contextRef="C_8be89166-bad4-409c-881c-a9f3f86a21e1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,520,108</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share for the three and six months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which the Company has agreed to forgo the issuance of its common stock. Therefore, these shares are not included in the statements of stockholders' equity or shares issued and outstanding in the balance sheets and are not included in our earnings per share calculation subsequent to August 2021.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4ef15e6-4533-4842-b2df-a9ed0dee8585" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.583%;"></td>
        <td style="width:1.415%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.696%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.415%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.89%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3778d8a0-7415-4afe-991e-34813095ba17" contextRef="C_b5034939-1d40-46e1-96f5-cb3cc77d9692" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">65,447</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c048cb9f-c4a3-4595-a727-0956476bf141" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding used<br />&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8831bd44-15ab-49d1-a81c-09f9a2b6c798" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_1cbe0f48-c0d9-4cc2-ac36-88cc0f20b7a3" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">42,103</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85c84497-4b17-4c54-ba7d-328a105e0667" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_d48eaa7d-f49b-43f7-969b-0e34a6437615" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">27,365</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7682552-51e7-4507-a881-4ccd7e25e99a" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_3a2c5a16-8e62-4899-be73-5b229ec0f7e5" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.55</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69b32d67-6c40-4bd0-9bec-b51236e4a7ae" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_218f162c-d2b9-4887-a8f1-f61c879c328c" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.58</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The potentially dilutive securities as of December 31, 2022 and 2021 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our employee stock purchase plan, the terms of which are described in further detail in Note 12 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The potentially dilutive securities would be subject to the treasury stock method when dilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_37323afd-0d27-46e2-8ea6-4880112572d3" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_37323afd-0d27-46e2-8ea6-4880112572d3_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_37323afd-0d27-46e2-8ea6-4880112572d3_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.309%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.62%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.040999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_677e5bea-8024-4c2b-9dcd-fce98802a461" contextRef="C_82d37d69-01a3-41f1-a628-a553ba9b0c62" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">3,067</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f10689f-b454-4b8f-b79c-f1f94ba5390b" contextRef="C_c8822067-11ee-4730-84e6-37f46f386c88" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">3,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares committed under ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb2b5fc6-eeeb-424c-b4f5-860ac0bb59bc" contextRef="C_305b45e3-aa77-4038-91ca-a8b9641f321c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ed4ae81-2f0b-4264-84ba-31e81e66c185" contextRef="C_214b2dd0-9feb-4b1f-8486-54f0069ba088" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9996cd3-4e23-43af-a8c0-4226f935368a" contextRef="C_313360eb-54d3-44bc-b6b3-5158c6afb114" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">5,103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a2297e6-8731-4590-9cac-33de57087700" contextRef="C_dbc53b33-ca6f-4327-b8af-2aabe16a0af6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5decf434-7dab-4bdc-977f-c4058a8547f5" contextRef="C_ca1e3e4c-8bde-4650-aaca-f298f81e530f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">1,211</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f230c8d2-d181-42df-8485-a983b346e616" contextRef="C_ad7793e4-8ed9-4613-ac91-79c78797a90e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f072a35-cdb2-4cfe-a576-457d0f89cba7" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">9,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d77777f5-e394-4663-9a6e-728ebc3fd225" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">3,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_1d2a92a0-bf63-47f2-8c87-98a4cab5363c" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 14 - Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, the Company has incurred net taxable losses, and accordingly, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a92b170d-ccb7-4a06-8cb7-6b26555a4a19" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> current provision for income taxes has been recorded. </span><span><ix:nonNumeric id="F_57347875-113d-4666-86dc-32941be6fd8f" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_57347875-113d-4666-86dc-32941be6fd8f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_57347875-113d-4666-86dc-32941be6fd8f_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.307%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.664%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.015%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9df1b98f-c594-4ff1-9758-50e1ed1c037e" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_185c5066-12e1-433c-902a-6dce966f2823" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_187e0dd5-1f00-424d-9e42-fcb6ef76bb63" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f8dd606-d70c-45e3-95e6-dc0b0640d42b" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and developments credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a164b2c-c23e-4af3-9f32-9d2ebb2b8a9d" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7b81eb6-099e-4b84-b370-5a9b7fb81cfc" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53240dac-ffb7-4b6d-8ffb-5c1cc8afb228" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ed41def-89dc-4259-ad83-abd399ca9d90" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7054a1ba-133f-45df-b809-9c0e2b3a3edf" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43e87d3d-fd06-4f83-81a2-dba3839fa700" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_1da95340-2be5-45f7-bd49-3343d9ee6cf6" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.266%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.03%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.744%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c32345f-6156-4a73-aec6-fc21004a93f7" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,822</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b20e6fc1-086d-48a7-946b-9dcdd21697fc" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b668d401-a121-4176-bf46-276ab2c09570" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,807</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69a4fe60-178a-4851-9b42-03c3f7eb6418" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense limitation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25503dba-f893-4c88-9d48-99647fc5a238" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetInterestCarryforward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cccfe5e-6ee7-45d6-9167-93e32d649c1d" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetInterestCarryforward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5626c9b-d9e6-4c27-bdae-b3210d80f1eb" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">234</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d10ccd1e-4c46-4f11-9eb5-69d8b15eb291" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51f29960-106b-4e05-b623-2e590e51c103" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="bdsx:DeferredTaxAssetsCapitalizedResearchCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a708d2ab-5438-4895-86ed-2e157eef0659" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,619</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3e37ec5-1d84-4c42-bb34-ca7f82031f37" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,977</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf5f26ff-943b-421c-92fe-eec1d3013bb8" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d3d1861-d07e-4ad5-a13e-0583f8c88d37" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22b6ddc6-4d67-4df2-8099-86385129e73e" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,324</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_987221ff-75cf-4a24-b86f-d114bf61f208" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,610</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74a33b60-9c13-4df7-b40c-779fbc309a21" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,552</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fb8061d-5a66-48e1-8de1-b13e9ce56b3e" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,457</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62f9bf5e-22a5-4517-99de-d3a1dbbf6595" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,772</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85dbd76b-5300-4097-a22f-a40d4ba0dba2" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecf5d1fb-cc26-4227-ad5e-8f3c1ab1c665" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,772</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e30de097-adc5-422c-ad01-d7e705470475" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_326bbcab-fadf-4ade-b056-8c078308d395" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,772</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5622ecbf-2496-466f-b91b-f816c179a928" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company ha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b0377bd-2cec-42ac-8955-e17f80ab72d8" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5">299.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faa378eb-498b-4601-9567-104da256569f" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b6b1ef7c-2317-48b7-a39d-f45b51c81cf1" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:TaxCreditCarryforwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expire beginning in 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bc168a19-863c-407e-9c45-21ade99b7156" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98a90d26-66ad-4f6d-b87d-3fe3c94a8279" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net deferred tax assets.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa3ba37c-332b-47d0-9361-6b356c5c15cb" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a889203-4dca-4762-b79e-c696bd727fac" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that it had uncertain tax positions related to its U.S. research and development credits. As of December 31, 2022 and 2021, there w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ceafeeb2-5a42-4176-a4b2-430400aa1043" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ae50584f-0c13-4be1-a6ec-8ea1199be2c8" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accrued interest related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a91af21f-8783-44d1-8b09-b4f526612119" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true" continuedAt="F_a91af21f-8783-44d1-8b09-b4f526612119_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:continuation id="F_a91af21f-8783-44d1-8b09-b4f526612119_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.297%;"></td>
        <td style="width:1.468%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.928%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.468%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.838000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14929c2c-e9e6-467a-ad18-778f0fb86cfd" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">843</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f9dd717-0def-4138-b4f6-3d32b024cf8e" contextRef="C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions for tax positions related to the current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54a6e1e5-8d55-4f9d-878a-8e01e7848632" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6681cf58-af9c-4abc-9e25-e926b427041b" contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions related to settlements</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions related to a lapse of statute</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca6aa10f-adf6-43b2-b9ae-ae3b3dae3d30" contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">952</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebe0903f-a115-4dd5-9976-cd48c3657392" contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">843</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2022, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_162091f0-90ae-46fc-be84-172495b18c80" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:IncomeTaxExaminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.</span></ix:nonNumeric></span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c722364-2c50-41dd-9c89-ace06f64c172" contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 15 &#x2013; Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Co&#x2011;Development Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#x2019;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3d947d5-58fb-404c-b632-6a74ce520653" contextRef="C_be756e56-47b7-41eb-ad9c-716214c84904" name="bdsx:PercentageOfDevelopmentAndRegulatoryCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2020, the Company exercised its opt-out right with AVEO for the payment of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_109e4c30-922d-4a0e-b61d-c34c6a684d42" contextRef="C_03d24aeb-78a1-4c8d-b568-cfca0d3fc997" name="bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the AVEO Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. The Company ha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf38b8d9-469b-45fe-af3e-38d72997daab" contextRef="C_bbe57b7b-14db-40d9-b4e3-fcea2a1e2a81" name="bdsx:RemainingEstimatedObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> remaining obligations related to the AVEO agreement as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Following the AVEO Effective Date, the Company is entitled to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef6f92ab-fb24-42a4-9236-b0b3e6fc9167" contextRef="C_e6015f8d-bccb-4bb9-99f1-6b9aa57149f5" name="bdsx:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty of net sales of ficlatuzumab and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9e2682f-2625-40dc-b90b-451c291bbb21" contextRef="C_e6015f8d-bccb-4bb9-99f1-6b9aa57149f5" name="bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of license income generated from the licensing of ficlatuzumab from AVEO.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f9182e-06b0-43ea-9212-a4342128150f" contextRef="C_bbe57b7b-14db-40d9-b4e3-fcea2a1e2a81" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ad5a8bd7-6fdc-46eb-8b5f-727bcdb0e011" contextRef="C_c410de4f-8ea6-4061-8764-66e62ab89b16" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> royalties received or expenses related to this agreement for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#x2019;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#153; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_820e2909-5d5d-4eac-bbf2-0dae9cec1dfb" contextRef="C_04d1a84d-a61f-43b4-b180-30e7a26cd32d" name="bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a4c602b-22bf-4d4d-be36-7e26cce42b9b" contextRef="C_dec83647-9b4a-474f-a223-9e24cfba7a30" name="bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in August 2024. Either party may terminate for the other&#x2019;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. There wer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d244b61b-9300-4139-ac74-f44652aa3cb4" contextRef="C_1092db51-6294-44e3-bb69-6fad5f7f2e8a" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expenses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to this agreement for the year ended December 31, 2022 and were insignificant for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 13, 2021 (the CellCarta Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly &#x201c;Caprion Biosciences, Inc.&#x201d;) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30086561-5a55-4483-ae65-bb8bb8f41dbd" contextRef="C_b5dc3743-ca85-4769-8c11-523bc0854b31" name="bdsx:PercentageOfFeePaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% fee on net sales made from the first commercial sale of the Nodify XL2 test to the CellCarta Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aed50647-73e9-425e-b583-b3b889072d82" contextRef="C_b5dc3743-ca85-4769-8c11-523bc0854b31" name="bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue" unitRef="U_pure" scale="-2" decimals="5" format="ixt:numdotdecimal">0.675</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on future Nodify XL2 test net sales worldwide for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a92ce2a9-949f-46c7-9c13-e220fc4d540e" contextRef="C_b5dc3743-ca85-4769-8c11-523bc0854b31" name="bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from the first commercial sale, ending in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f04d2ed0-27a5-46e0-9add-9b8bcb8e3c13" contextRef="C_b5dc3743-ca85-4769-8c11-523bc0854b31" name="bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Royalty expense under the CellCarta License for each of the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 wa</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6920027f-c1fc-424f-9e1f-1fe74e58347c" contextRef="C_d05b24fd-4c4f-402b-8b97-295956c2f519" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_56e801e5-9989-4490-a964-c45b3cfeee2b" contextRef="C_5a129ea3-f356-49fc-afa3-38f6d02880ea" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respective</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ly.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the acquisition of the assets of Oncimmune USA, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to an acquired diagnostic test of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e9917d6-e427-4a8a-b6c2-afe38bc1e4ff" contextRef="C_91cf71d9-5882-46d2-af72-be7057b1fa70" name="bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of recognized revenue for non-screening tests up to an annual minimum volume and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c053429f-a851-4167-a8a3-65b6a5e18540" contextRef="C_91cf71d9-5882-46d2-af72-be7057b1fa70" name="bdsx:MinimumAnnualVolumePercentageThereafter" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% thereafter, with an escalating minimum</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_063417b9-9045-4fa1-86d9-a96ba772f2e1" contextRef="C_91cf71d9-5882-46d2-af72-be7057b1fa70" name="bdsx:PeriodOfEscalationsOfSales"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through the first four years of sales</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Royalty expenses we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">re $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_160c6028-e8ab-4d72-b528-9265375f9790" contextRef="C_91cf71d9-5882-46d2-af72-be7057b1fa70" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_550f19bd-1d0c-485f-b85b-8ed227a98c9b" contextRef="C_3d741d82-1d89-43bd-aeaf-d5d87b0316cf" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Litigation, Claims and Assessments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>bdsx-ex10_83.htm
<DESCRIPTION>EX-10.8.3
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.8.3</font></p>
  <p style="margin-left:32.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:35.963%;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment Number Two To The</font></p>
  <p style="margin-left:25.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:29.722%;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc.</font></p>
  <p style="margin-left:13.28%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:17.12%;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Senior Management Bonus to Equity Plan</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:7.088%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:5.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) heretofore has adopted and maintains the Biodesix, Inc. 2021 Senior Management Bonus to Equity Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), a subplan of the Biodesix, Inc. 2020 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Incentive Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to provide certain designated employees of the Company or its subsidiaries with the opportunity to receive a portion of their annual cash bonus in the form of a Nonstatutory Stock Option (as defined under the Equity Incentive Plan);</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:7.249%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:7.296%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Board of Directors of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) may amend the Plan at any time; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:7.088%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:5.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Board desires to amend the Plan to provide the Company with additional flexibility to limit the amount an eligible employee may elect to forgo in exchange for an Option (as defined in the Plan) and to change the formula used to determine the number of shares of the Company&#x2019;s common stock subject to an Option.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:7.088%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:5.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now, therefore, be it Resolved, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that the Plan hereby is amended, effective for Option Elections (as defined in the Plan) in respect of Bonus Year 2023 and subsequent Bonus Years, as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.935%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7422107449615454%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The second sentence of each of Section 5(a) (relating to Annual Elections) and</font></div></div>
  <p style="margin-left:14.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:5.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b) (relating to Initial Participant Elections) is hereby amended in its entirety, to read as follows: &#x201c;Notwithstanding the foregoing, any election under this paragraph will be limited by the Individual Cap set forth in Section 5(c), and may be limited by either a maximum dollar amount set forth by the Company or the Eligible Employee in such</font></p>
  <p style="margin-left:14.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">election, or by a maximum percentage set forth by the Company in such election.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.935%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7422107449615454%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first sentence of Section 5(d) (relating to the Conversion Formula) is hereby</font></div></div>
  <p style="margin-left:14.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:5.213%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">amended in its entirety, to read as follows: &#x201c;The number of shares of Common Stock subject to an Option shall be determined using the following formula: (Cash Value * 3)/ Average Share Price.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>bdsx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:20.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board of Directors<br>Biodesix, Inc.:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (No. 333-265445, No. 333-269536, and No. 333-249805) on Form S-8 and (No. 333-265448 and No. 333-261095) on Form S-3 of our report dated March 6, 2023, with respect to the financial statements of Biodesix, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denver, Colorado<br>March 6, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>bdsx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Scott Hutton, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Biodesix, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:51.998%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 6, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ SCOTT HUTTON</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scott Hutton</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>bdsx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Robin Harper Cowie, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Biodesix, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.519%;"></td>
    <td style="width:49.476%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 6, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ ROBIN HARPER COWIE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robin Harper Cowie</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>bdsx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Biodesix, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:3.835%;"></td>
    <td style="width:44.882%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 6, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ SCOTT HUTTON</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scott Hutton</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>bdsx-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Biodesix, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:3.835%;"></td>
    <td style="width:44.882%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 6, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ ROBIN HARPER COWIE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robin Harper Cowie</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img34454307_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34454307_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+!#4# 2(  A$! Q$!_\0
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MF*\CI/\ A9>K8_X];;\S2?\ "R]7_P"?6V_,US7]C:E_SXS_ /?!I/[&U/\
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M6/\ H&W'_?!KN]E1[')[2J=5_P +8UO_ )]+7\S1_P +8UO_ )]+7\S7*_\
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M@   < #M734G[-<D2$N;4J66EV6G1JEI;1Q #&57D_4U<HI:Y6[[F@E+110
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MB7;G.)P,^M9\G^ND_P!\_P ZZ$>345D2+>74:A$N950<!0YQBE^W7G_/W/\
M]]FJ]+3L3SR+MI?7?VVW!NYCF5>KGUKW>+)A0G^Z*\!M/^/ZV_ZZK_.O?X?]
M0G^Z*Y<3;0]S*&VI78^BBBN8]H7%&*2B@!<4E%% #9(TE0JZ*RGJ&&:YK6O
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MY17D7_"0ZO\ ]!&?_OJC_A(=8_Z",_\ WU6?L9%>T1Z[17D?_"0ZQ_T$)_\
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M(-7T\7^(HP NL71 [%J;P4MTR?K*6Z/HNBOG?_A-?$G_ $%[G\Z/^$U\2?\
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JEJFGQZII\MK+T<<'T/K5VDQ1L!XQ>VDUA>26T
MZ[70X^H]J@_E7J7B+P]%K,&Y<)=(/D?U]C7FEW9W%A<-!<QLDB^O?W%=<)J2
M,)*S(*7M2=\459(E)2TAHN!+;74UE<+/;R%)%Z%>_P!:Z8&R\5Q#_5VVKJ.G
M19JY/TXX[5HZ/I-YJES_ *,?*2,Y:<G 3WJ));E+4K7%K/:7#V]Q&T<B]5-1
M>G-='XFU6TNTAM(0)Y(?E:[8<L17.546WN)A1113$%%%% !1^M%';T]Z +-M
MIUY>HS6MN\JKU*C.*8UI<*LKM"X6(XD)'W3[ULZ25ET"XMDO8[:8S!E+OMXJ
M_<7EE?K?0+<1J)#$F]CC?@\FH<F4D<O+:W$$<;RPNBR?<8C[WTJ672K^"V%Q
M+:R)#UW$=*Z:\U/2[N,HLV[[',CH'X! X(7U]:BNA8R1WMU=7OG1R_-$$EY]
ME*]L4N=CY3G#87:D@VT@(3S"".B^M/CTN_EM?M,=K*T.,AL=1ZUU<VKV,MM/
M$\L9E2T5(V!^\,<K]<U62>*:]M-134HXK6*(!H"V&&!RH7OFCG861S<6G7DU
MJ;F.VD:$9)<#BB+3;V9XT2UD9W7>H ZCUKI8;NVN]/D,US%'"/,,85MLD>>@
MQWI+>^0FRCBN;?!M=DB2G@^V>QHYF*R.5G@FMIC%/&T<@ZJPYJ.M+7OL_P#:
MC?9Y3*FT9);=@]P#W%9M6G<EA1113 **** "BBB@ HHHH *?%+)!*LL3LDBG
M(*G&*911N!LW=MIWC*#RKLK::NHQ'<@867V;WKSS5-*O-&O6M+^%HI%/7LP]
M0>]=OINF76J7 CMU(5>6D/"I[YJ/QOXCTZ73X]%MPM_/#P]ZXSM/HIJZ,Y*7
M*M414BFKLX#%%)TI:[SE04444#"BBB@04E+24("Y8:5?ZH66QM)+@IRPC&<?
M6K*>&M;DEEC73+AGBP' 7[N>@-3^$;Q++Q-:RRW'DP@-O8M@=.,UT7AG5=-B
ML]134[QQYFH!TQ*0W'0^ZYK"<YQ>AI%19R5KH6K7HE^S6$TGE-LDVK]UO0U
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MSX12>S"H=.U:VMI]+G>YA\R&TEW MP&.>*7/(I8:EI[VYR TZ];R=MM*3/\
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M\CL>9^(_&8N+=M*T-6M=.4[6<</-]:X[I7L/_"H=(S@7UWCTR*7_ (5#I/\
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M_P"?NY_[Z%'_  K'3/\ G[NOS%/V\!?V9B>R/+L#OCGO1@'M7J/_  K'3/\
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M?2 T7"QQDKZY96CRRW<K+(JF1G 'E_.<[??;BI]/GN=4\/ZU&ES-.,NEO(P
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MT8/K0 M%)@^M&#ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKQJUBEL-=\-W>HVEM;0L0L;6F-SGL7KV3/>IK4U!JQ5.?,M1U%%%9&@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2YI*CE ,;J6
M*@@_-Z4">BN/-4=2U:STI(S=2A [A1D\\]ZY";6;[1KI;?3M0&KKNP82N77_
M ($*@\0V5Q<:RFH&"&Z8VX$EC(^&3U(K2,+LXZF+:B^5:H] ^T0B$3&5!&1G
M<6&/SI8IHYXEDB<.C<AAT->?/9V&K>!GN+5KF*&S5\0LY/S>_J!74^%I$3PM
MIFYE!,0QD]:3C9%T\1SSLUI:YH7&JV%I,L-Q=11R-T5FY--O]8T_3$C>]NTA
M60_(3WKSG4X)-3U77+FS@CGB VO).<&,CKLI^L2I>:)X9:V'G R;5$_<@?Q>
MU6J2NCGEC9+FTV_S/0]/U?3]45C8W4<X7KM/2KN:\_\ #2FQ\:745W%%!<3Q
M?)';_P"KP*] [5G**BSJP]5U87>XHI:04M2= 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !59[&UDN1<20(TP& [#)%6,U ]W$CE3NS
M["@ O+."^M7M[B/?$_!6LK3?#5KIXD;<[S."HD)R44] *T_ML/\ M_E1]MA_
MVORIW8K&+%X-L()!)'/<*=P8_/U/O6K<Z5!=:E;7[EA+;@A #QS4OVV'_:_[
MYI?ML/\ M?\ ?-%V%D8\_A&PGN9IS).K3,6<*^,YK7L+"WTVT6VMDVQK1]MA
M]&_*E^VP_P"U^5#;86L6!2U6^W0_[7_?-'VZ'_:_*D,LT56^W0_[7Y4?;H?]
MK\J +-%5OMT/^U^5'VZ'_:_*@"S15;[=#_M?E1]NA_VORH LT56^W0_[7Y4?
M;H?]K\J +-%5OMT/^U^5'VZ'_:_*@"S15;[=#_M?E1]NA_VORH LT56^W0_[
M7Y4?;H?]K\J +-%5OMT/^U^5'VZ'_:_*@"S15;[=#_M?E1]NA_VORH LT56^
MW0_[7Y4?;H?]K\J +-5;[3K34HDBO($FC5MP5QD9I?MT/^U^5'VZ'_:_*@"2
M."*&(0QQ(D8&-JC Q7*-\/=';6A>;&^SD^8;;>=A?/!Q73_;H?\ :_[YI/MD
M./XO^^:I2:%9%6\T#3+Z&6.6SAS*NTN$&[\ZSAX*TH>'CHRJZV[$%G4X9B/4
MUM_;8?\ :_*C[;#_ +?Y4*<A<J.;T[X>Z/I]]!=EKB=X#F,32%@I^E=;5;[;
M#_M?E2_;H?\ :_*E*3EN-)+8LT56^W0_[7Y4?;H?]K\J0RS15;[=#_M?E1]N
MA_VORH LT56^W0_[7Y4?;H?]K\J +-%5OMT/^U^5'VZ'_:_*@"S15;[=#_M?
ME1]NA_VORH LT56^W0_[7Y4?;H?]K\J +-%5OMT/^U^5'VZ'_:_*@"S15;[=
M#_M?E1]NA_VORH LT56^W0_[7Y4?;H?]K\J +-%5OMT/^U^5'VZ'_:_*@"S1
M5;[=#_M?E1]NA_VORH LTQT5T*L,J1@U#]NA_P!K\J/MT/\ M?\ ?- #;73[
M.P39:V\<0//RKC-96N^%K36IH[AMT=PI 9T;!9.X-:WVV'_;_*C[9#_M?E33
M:,Y4XR7+;0JKHEE'HSZ7%'Y=NZ%6VGDY[_6JS^&+-X=-B\R55T\YB ?K]?6M
M/[;#_M?E1]MA_P!K\J+L'2AM8Q+[P7IU[=R7.^>$S?ZU(GPKU+?>$M-OK*SM
M"'BBM#F,1M@UK?;8?]K\J/ML/^U^5/F9+H4]=-S,TGPO8:1=O=1>;).PP7E?
M<1]*W*K?;8?]K\J/ML/^U^5)MLN$%!6B612U5^W0_P"U^5+]NA_VORI%EFBJ
MWVZ'_:_*C[=#_M?E0!9HJM]NA_VORH^W0_[7Y4 6:*K?;H?]K\J/MT/^U^5
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M;26MM+=JL?DS<OUSD>G%!\=7-WLB-BD4%XLGV>42_,N.[#L::HS>PG5BCO\
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MRA\V)1/(R^</FRH_K5^TTE&\423QRJH@&Y\9WNS=<GT]J5K;FD9J33C$UIM
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M&8HR #$I Z J.*4QH008U(/48I]% $9BC(4>4F!T&WI3@JAB0H!/4@=:=10
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M&!%"[0H"_P!T#BJ$6BVD.JS:@B8DFC$3)@;<#VK2HH3:"R(EMX5P%AC&.F%
MQ2&"'+-Y*;F^\=@R:FHH"R(O)CW;O*3/KM%4]-T>VTN*=(@S^?(9)&DY+$^M
M:-%.[%9"*H50   .@%+112&%%%% !1110 A%0W,"W5M) ^=KKM./2IZ*!-7*
MMI8PV=LD$<:A5&.@R?KZU*\*2 ;XU;'3*YQ4M%.X**2L8]_X>M-1NEGG:3'
M:,?=8#UK46%$3:J #&,8J2BB[)4(K5(B^SPA"GDIL/5=HQ1Y$>0?+3*]#MZ5
M+12N59$301, &B1@#D J.M.\M"?N#GKQ3Z* LB-XTD7:Z*R^C#-(88VQNC0X
MZ97I4M% 61&(U&<(HSP>*/*CP08UP>",5)10%D1K#&F-L: #IA>E."*&)"@$
M]2!UIU% [!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img34454307_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34454307_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H!S@# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTE% "[C1N-)10 NXT;C244 +N-&XTE% "[C1N-)10 NXT;C244 +N-&XTE%
M"[C1N-)10 NXT;C244 +N-&XTE% "[C1N-)10 NXT;C244 +N-&XTE% "[C1
MN-)10 NXT;C244 +N-&XTE% "[C1N-)10 NXT;C244 +N-&XTE% #P<BEI%Z
M4M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<\9XKJ',$:Y4"++ L0,<GCGZU91 @]^]"E;8+7*6GVK6=JL49'EA>0.,GO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA."29@"IZ<8X_E5^UFW':3R.*EE%VBBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 !Z5#FICT-09H 7-&:3-&:8A<T9I,T9H 7
M-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3
M-&: %S1FDS1F@!<T9I,T9H 7-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3-&:
M%S1FDS1F@!<T9I,T9H 7-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3-&: %S1F
MDS1F@!<T9I,T9H E3[M.IJ?=IU(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Q'C\SS:AX;L(KRZMHKN]\N4V\IC8K@=Q7-WK:39ZK=Z?
M'<^,[N6U<)*UM,74'&>N:Z;QO_R,?@__ +"/]!3O!_\ R-WC'_K\C_\ 037;
M3ERT[^7ZG#4CS56N[_2YRZ7%AQ^Z\=?B3_C4Z3V/_//QK^)/^->J45F\1?I^
M)HL-;K^!YDL]G_SS\8_B3_C4BSV?_//Q?^)/^-=)>>-+2WO)X8+*]NX[9MMQ
M-!'E(SW&<]JWK.[@O[2*ZMG#PRKN5AW%1*3ZH4:<9.R?X' ">T_YY^+?S/\
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M2 7-&:2B@":/[M.ID?W*?2&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M $,UU%*.R'A/X$/1!1115'0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,^HSTJ_244 +1244 +1244 3Q?<I],B^Y3(KJ*:>6%6_>1'#*?YU(R:BBB@
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M2:&19(W&5=3D$5Q^B:?93^'-2FFM())1+/AWC!88SW-:_@[_ )%+3_\ </\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /)2(_\ L&-_Z'755RL__)2(_P#L&-_Z'28\3M'_ !(=\/\ _D5D_P"N\O\
MZ&:ZBN7^'_\ R*R?]=Y?_0S744H[(>$_@0]$%%%%4= 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHL%V:']M7W_ #U'_?(H_MJ^_P">H_[Y%9]%%@NS0_MJ^_YZC_OD4?VU??\
M/4?]\BL^BBP79H?VU??\]1_WR*/[:OO^>H_[Y%9]%%@NS0_MJ^_YZC_OD4?V
MU??\]1_WR*SZ*+!=FA_;5]_SU'_?(H_MJ^_YZC_OD5GT46"[-#^VK[_GJ/\
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M;Q>>OARV'_;V*3=3JU]Z&E2_E?W,>/!:C_F.ZS_X$_\ UJ</!RC_ )C>L?\
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M ,]A_P!\#_"C_A(-1_Y[#_O@?X5ET46079J?\)!J/_/8?]\#_"C_ (2#4?\
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M?\)!J/\ SV'_ 'P/\*/^$@U'_GL/^^!_A67119!=FI_PD&H_\]A_WP/\*/\
MA(-1_P">P_[X'^%9=%%D%V:G_"0:C_SV'_? _P */^$@U'_GL/\ O@?X5ET4
M6079J?\ "0:C_P ]A_WP/\*/^$@U'_GL/^^!_A67119!=FI_PD&H_P#/8?\
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M*X:;IL6G0;%^:0_??U_^M5VBBLS0**** "BBB@ HHHH **** "BBB@ HHHH
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MZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\
M^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*
MC^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__
M .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4
MX7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*N
MZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\
M^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*
MC^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__
M .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4
MX7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*N
MZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\
M^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*
MC^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__
M .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4
MX7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*N
MZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\
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MOAJUA.JKJB*#Y=TO\29X'4].E#C9 G=F[1114E!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>\LH+Z$Q
MS+GT8=5^E6** .$U#3Y=/N/+?E3RK#H15.N^OK*.^M6AD'NK?W3ZUPMQ ]M.
M\,@PR'!K1.YFU8CKK] U'[5;&"0_O8AQ[K7(5:T^[:RO8YAT!^8>H[T-70)V
M9WM%(K!E#*<@C(-+69H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% %21PC.QZ 5F7]M)=1H8IA')N)96;%:CXWL",@C'3W%5E59E:
M/H$X]>M-"96>1_L@B%PP(4#S@OZT+IB*V-X9G'S$KGCO@=LTYU:,A7[\+A@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(SAOSK1:.,_>0,>N#58J8Y%,2;H]N.#G'L!0@&7P/]GD$='7!]1Z_K5O3_\
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MC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS244 7K7_ %/XFIJ@M?\
M4_B:GJ64%%%%( HHHH **** "BBB@ HHHH **** ,'QKJ$.F>#M3N;BW%Q%Y
M7EF(G ;<0HS[<UY9J^F:UH?PXL;A_$Y^S2M&8K.),!0WS</G)QZ5[3?6-MJ5
MC-9W<0EMYE*NA[BN3M?A;X9MW)DAN+E-I5(YYBRH#Z#BKC)(B2;.DT..>+1+
M-+F]^VR^4";C:%WYY!P/:O*]#L-;O?%/BT:/K<6F!;H"7?&&WY+XP>V.?SKU
M71M'M-"TN+3K%66VB+%0S%B,DD\_4USM]\,?#.H7T]Y<07!FG<NY$Q )/6A-
M*XVF['':)<1CX2^)--2*,/8L\;S1L668D_>!_#^50ZCLA\/_  ^N[Y<Z5$R^
M?D94'(//X _D:]-@\)Z/:^'IM#M[;RK*8$2!6.YL]RW7/%3CP[IAT!-#DMA+
M8(@C$<ASP.G/K[T^="Y69_C2^TV/P3J,EW+$UO-;LL7S ^8Q'R[?4YP?UKSB
M_BN8? W@5+K<)/MH(#=0A?*_^.D5VUI\*_#%K=I.8)YU0Y2*:4L@_#O^-=!K
M'AW3M<%F+V-B+242PA&VX8=.G:DI) TV>:^+M"_X2+XI36*2&.?^S1) X.,2
M+DKGVS3/ NK7.L?$Y[B]B:.\CL/)G#=2Z;5)_'%>F_\ "/:>?$8U[8_V\1>3
MNWG;M^E,@\,:7;>(YM=AA9+Z9-CL&^4].<>O I\ZM8.76YYGX'M/%-P^L-H6
MI6=K;#4'$J3Q[BS>H^4]JV]=DBLOC#HMSJK*MHUJ4@D?[BR_-^7)'YBNUT7P
M_8: ERE@CJ+F4S2;WW98T[6] TWQ%8_9-3MEFC!RISAD/J#VI.6H<NAROQ9N
M;$>#7MIBC7<TJ?94'+;@PR0/]W(_&N>\1?VQ:^+O!_V***;58]/P(Y\A68*<
M@X(YQG\:Z_1_AOX>T>_2]CAEN)XSF,W$F\)Z8'3BMJ[\/V%[KMGK,R.;RS4K
M$P<@ '.<COU-"DEH#39PG@/[1XC\17WBW5)X([NW0VIM(5*F+ ZL#STSZ]_2
MN3\/I<Z79Q>.X=[!=1=+M!_%"^,G\"3^8]*]@C\*:7#J][J<*2Q7%[&8YPDA
M"N",$X]?>IM+\.:9I&C'2;>W#V1)+1S?.&SUSGK3YT'*SQK58KF\6S\<W6]&
MN]658$)^Y"N=O_H)_*NM^*>JF>XTC0H89[D2RBYN(;=-[M&O0 ?]]'\*[;6/
M#6EZWI,>F74&VTB971(3LVD @8QTZFB'PWIT/B!M;"2-?&$0AF<D*H & .W3
M]3ZT<ZW#E9P'@S65MOB+?VO]GWFG6>K+YL,%W%Y9$BC)P/3[U:6G_P#)<=6_
MZ\D_]!2NOU3P[I^KW]A?72/]IL7WP.CE2#D'GU' HB\/:?#XBFUU$?[=-&(W
M;>=NT #I^ I<R'9G(7/_ "7.S_Z\#_Z"U1?"F6&W;6["[94U@7C-.KGYW'J/
M49S^?O7:/X>T]_$<>O%'^W)%Y2MO.W;SV_$UG:_X"T+Q%=B\NH)(KO&#- ^Q
MF^OK1S)JPK/<MZE=Z%?6.KV5Q>6X5(2M[L<;HU(ZMCG@5YS)+J_@O0;6]MM1
ML-=\,>:!''*@W $GI[]>Y^E>B:)X/T30+.>VL[,%;A=LSRG<T@]"3V]JR(?A
M=X:AO%F\FX>)7WK;O,3&#]*$T@:;.OMIEN+6&9 561 X![ C-2T    # ':B
MH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ0!'.X>-64C:&&:9 0 V,;=W\)YJTT:LC+T#=<<54MU"@NN"2Q&0,]/_ -5
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MGPS9V$-OIBS>2BY\JVM9'\O/4-@'#>N>:JZ?%;^.I;FZU&=I+"&8QPZ:'*8
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M4%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNE5Y&*NN0"HSD'J,=^E=ZEI8^MM?5%:^N1<643*-I,F&4D$C@^E6;'<(G52
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#@=0_Y"%Q_P!=&_G5:K.H?\A"X_ZZ-_.JU:F1K^'/
M^0LO^XU=A7'^'/\ D++_ +C5V%1+<N.P4445)04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%%  >E9U]=Q6,$MS-DH@&=HR>N/ZUHGI521$D+HZAE(
MP01D&A S)M7TAMEW%$$=SY@.PYR15?6/$@L'CCMHUE9AN8MD "MJ26*UBQP
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M'(#8&:V)%_=4SM,R\T^-;A[NUC*WI4D2KT.!T.>.:Q(/$41GCC*RJR':AX8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!P.H?\ (0N/^NC?SJM5G4/^0A<?
M]=&_G5:M3(U_#G_(67_<:NPKC_#G_(67_<:NPJ);EQV"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *JRJ2L@'4J1QU[5:-5)7*EL>G?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M59\ Z+#K,RPWMR8)A<1D*7XFPP(&WN1CK57_ (2R[GC3[<Q:_DM0MFUG,BA
M?^>A_#H<8_&NT\!:9!JFK6^LO;3&+2%?;<O<9\U^B#R^PR6/X=ZFHX--HN/-
M?E9L_$&5II$MHE+O+<LRJHR3C@?SJ/P]X7GM$\^6-OM3#@;<A%],^OO78VVG
M17$JS%4-PN/GQE@,Y(]LUHBP59T(MXF5B=['J*\U0][F8?5(NNZ\]7T\AMK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0+K_ (\Y_P#KFW\J\_;[Q^M7$B0E:VB])OPK)K6T7I-^%42C5HHHI%!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ.6*\]B,U6,2) "[N0AWY+'/%-"9*Y*IQ5.\DV6,HSG?A5Y]?_K4ZSU%+PR
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MK+_2NKO?"_FZC/J%EJ=U97,V-_ED%"0,#([_ )UQUK:0WVG:-:S@F*74YE8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!FX&.X%2RS)9VZ*Q=B%PI"%LD#VJ:,N6?<%V@X7%1W%P8,?*2",!AV- RO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%(S*HRQ 'N:4'(R.E !1110 4444 %%%% !1110 4444 %%%% "
M,JNI5@"I&"#WK#'AN$7_ )A;-OU\OOGT^E;M%-.PFKB !0 H  X %+112&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U_NFG4U_NF@"A<-,EG
M(;<*9NB!C@$YI%@4I;^:=LJ8.%;&3W^HJIJ$S)')&I7YDR QYSN_A]_ZXJO#
M<3R2I!,)"5E."K?O -O3Z?CZ5:6A+9+J3>=>Q0 \(-Q'N?\ /ZUKVD>R,5B^
M68]2WOOQ( PW]1[&M^'[@J"B2J[\R?2ISTJOU9C^% $$J1;0"50C)4DXP?6G
M11*F64D[@,G/%9NK6LETZ^0V7C7YD4X;![U:TT3+:+'/!Y3)\N-V0?<55M">
MHXW&T$1Q95>GO2S+'.JNTH"X.U2V!FF&T;S#C[O8YZ5*;6,Q@,H9P" 30,;8
MNK0;5_@.,8_SGZU,DJ.A93D+D'BJZP-%:C:F9@,94XZGUIL%L\9*3?-&0#D,
M<9]Z!$40BNF:9G$;$_(,X(_SQ^M7I(UD4*XW*"#4*6T4LLKNBLC$;<CIQS5J
MAC12OKA+$>>L6YW.T]N*EMKG[3!'(%*[NN:?,%(Q*J>2!EBQX%-BN+9Y#!%(
MA9!G8IZ#_)HZ 2ONV_+2!<J#T/K3ZC+!&QZ\T@(K])GLW6 X?CIU-1V$5REJ
M!<$EMV0#R<?6K6 Y5LGCWIS,%ZFG<!KG# @@>M4K]AO@D4YP2I/^?QJQ)+ -
MJ22!?,R =V!GTSZ^U59(84T]H86/[GC:QR1@\GGGO^M*P&K;-NC%3U1T]]T0
M^E7J0RG.H60-CCH:I26T,=P&BV 1Q[9(4 &0>F>^.O'>M&Y&Y<=S61?.$E+-
MF4@-M7;MVG'!R>&_^O51$R:QN56Z>T2V>.)#F-@IVD=2/8U%I0PQ'H<51L[B
M6$37#!GDPHWXVX!/]T]>N<^]7=*.YV/J2:)*P(WATI:0=*6I&%%%% !1110
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MM,C21)(RF0!22 >PS3?B'#';^&K2&%%2-+A555& !M:NS1%CC5$4*B@!0.@
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MNW4TJX*;E+V;5I:M-7U[HY?X<:5+#'<ZE*A195$<6?XAG)/TZ5WE( %4*H
MX  Z4M:0CRJQUX:@J%-4UT"BBBJ-PHHHH **** "BBB@#3LO^/?\:LU6LO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME6E\*_"5KXBU>XNM0C$MI9!3Y1Z2.V< ^PP3^5>\2V\$-A)%%#&D:QD!%4
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MY)__ %4VUM_*DEE\PMYA_K5G<,X[TVP,TJ65HV X'(/)/_U\]ZT(U<#+-DX
MQZ4_WQ3'[#MWI 96NW5Q8K#/:H#*Q*%BN[ ZXQ5"U^W6,2QW%VF)P L;MD?0
M$].O:NB,>XE\XDV%0W;!]JYC7M'EN;RS,-HV%4*2A)'7OZ?6KBUL2SJ(8UA4
M@1+&,YVJ<UAVPW3M-WW[OUJ:-[RTNOLX!8$YV=1C'7=CC_ZWO6?97AV$8RY)
M^7/0#W[U+3*3-Z^@A=DFD@CE* GYER>.?\:BT[4!=12!8!&(^F#QBI+>=IGC
M*OYBA!EQ@#)[8]:;(Y4-& H!;)VC%'D(()I0\AN)TV$Y0(O0?E39TMYK7RW+
M2$G.6)XJO.C21%%<J3CD4]1M4#.<#K3&,A41CRPF G0^M25%.LI4&$J&![^E
M2T 2P7 A?:>=Q P.N:G<@3+&#N+D]/X1U)/^>XJE.C)'D21B1BNV/'SGGL<\
M54AAD,S,&DDD(D#(C89>>YSS_GK185R]:,/M\P!R-Y.:V_X:YZS.+UAE3P#E
M1@=!70IRHJ"BA.BLV]D!V9Y(!Q69#;_:+EY&Y+'.36W-;[Z;!:B/M0!7@C\L
MM"0-K#CBF36ZF!D&T%1E !CI5NY3 ##J.:RKF\L;;4XFEE;SG3:,?= )'4=!
M36HF:&GS;HP,UH5B6#!;AT5@5#'!'0CM6T.E(8M%%% !1110 4444 %%%% !
M1110 4444 0W7_'G/_US;^5>?M]X_6O0+K_CSG_ZYM_*O/V^\?K5Q(D)6MHO
M2;\*R:UM%Z3?A5$HU:***104444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!IV7_'O^-6:K67_'O^-6:A[EA1112 **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5] )8C]1W4^E-JP)W+%%%%2,**** "BBB@ HHHH **** &R?ZM_H:\]^#O\
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M^LO"QOK>/RHWWG 7!'3IW-/G%RGDMDNJ^(9=/^']XKHFFSN;N4'[T2?=_#G
M^JUU?P@DV:#J5CWMKYACT! _P-=^MM D[SI#&LSC#2! &8>YZFJ&D>'M-T*6
M\DT^%HVNY/,FRY8%N>F>G4TG*ZL"C9W-2BBBH+"BBB@ HHHH **** "BBB@
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MB1@[JWT^Z*D8ZBBB@ JO.@/.,U8I",T 9T<.;AG P">E:*C I @%.H ****
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M/9+8P"9!+(0)>>@)48_6LGXS?\>>B?\ 7TW\A75^-_\ D0-6_P"O4_THTLM
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M<2$./D^OI3EN(6A$RS1F(]'##;^=>?:AX3T6W\<Z+90V:QVES!*;B!6(28H
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MQ!M#X@\9>&K:<&!KVS0,!SY99F_D3345?5"<M-#O?%GC)?#3:5Y=HMVNH2%
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M4L_^$9NY8]IO&N2)S_%C V_AU_6O0Q%;?;#*$B^U% "^!OV9X&>N,YI2LM+
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MH **** "J&L_\@BX_P!T?S%7ZH:S_P @BX_W1_,4UN)['#T44J(SN%4$L3@
M=ZT,Q41I'"J"6)P *Z_1M)^PIYLO,[#IGA1Z4FCZ.MD@FF ,Y'_?'_UZUZB4
MBXH****DH**** (;K_CSG_ZYM_*O/V^\?K7H%U_QYS_]<V_E7G[?>/UJXD2$
MK6T7I-^%9-:VB])OPJB4:M%%%(H**** "BBB@ HHHH ***@NI61%2/\ ULAV
MI[>I_ <TP&M=X9]D,DB(<,ZX_''KBK".KHKH0589!'<4V*-88EC0851BH(?]
M'G-OC$;Y>/V]5_K^/M0!:HHHI %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :=E_Q[_C7(:U_R
M%[C_ 'OZ"NOLO^/?\:Y#6O\ D+W'^]_04EN.6Q0HHK5TC2'OY/,DRMNIY/\
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ME5=.TV+35\F!0RJ"V]OO%C_]:K@ES@;,2$XQ[_6LI6OH:+;4SK@>9JP&<[$
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M[0]DOV?KGRR!CZT*#>H.21UU%5M/NS?64=P87B+#[K?YZ59J1A1112 ****
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M1+,APRQ@DM@^I'%'**YZ,FHV#W)MDO+9IP<&)95+?EG-3RRQ0INFD1%R!EV
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M*.4+G; Y&116+X:O="DT];'0KV.X@M5"X60N5!SC)//K6U4LH**** "BBB@
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M^=6:8!2CJ*2@=12 XJ*-3X>U=NXG!_\ 'O\ ZYKJM*P-)M-O3REZ5AV]HO\
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M)(C;K&J)NR&SWQBMJLS1-(&E6S!F#S2'+L.GL!6G42M?0I7MJ%%%%2,****
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M,,MN(4$4B&,#"X;M3_-C_P">B?\ ?0I#;PL26AC)/<J*3[-;_P#/"+_O@4:
M.\V/_GHG_?0H\V/_ )Z+_P!]"F_9K?\ YX1?]\"C[-;_ //"+_O@4: 58;&S
MAL9;19/W4N[=E\GYNM6+=8+6VC@CD&R-=HW-DXIWV:W_ .>$7_? H^S6_P#S
MPB_[X%.X6'>;'_ST3_OH4>;'_P ]$_[Z%-^S6_\ SPB_[X%'V:W_ .>$7_?
MI: .\V/_ )Z)_P!]"H+-@TEQY9W0[\H1TS_%CVS_ %J7[-!_SPB_[X%2@ #
M  '84 %%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH T[+_CW_ !JS5:R_X]_QJS4/<L****0!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445&UQ K%6FC!'4%A0!)147
MVJW_ .>\7_?8H^U6_P#SWB_[[% $M%1?:K?_ )[Q?]]BC[5;_P#/>+_OL4 2
MT5%]JM_^>\7_ 'V*/M5O_P ]XO\ OL4 2T5$+F D 31DGL&%2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !141N8%)!FC!
M'4%A1]JM_P#GO%_WV* ):*C2>*1MJ2HQ] P-24 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M-.R_X]_QJS5:R_X]_P :LU#W+"BBBD 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9&L:.MZAFA $X'_ 'U_]>M>BA.P-7/.G1HW*."&!P0:
M;78:QHZWJ&:$ 3@?]]?_ %ZY%T:-RC@A@<$&M$[F;5AM%%%,04H!8@ $D] *
M "Q  R3T KJ]%T46H%Q<+F8_=4_P?_7H;L"5PT711:@7%PN9CRJG^#_Z];=%
M%9MW-$K!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <#J'_(0N/\ KHW\ZK59U#_D(7'_ %T;^=5JU,C7\.?\A9?]QJ["N/\
M#G_(67_<:NPJ);EQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ IDGW#3Z;)]TT <KKXD-S:HNZ3>& C Z'UJOIFE.[2BZ
M5T7C9U!/KU[4FNV]Q-K-I]FC=96&%ES@9R?RQ5FV:\M]0B%Y<&3;$48;2VYL
MD@9[GW]JV^SH1U+(T#3W4LT#&0?\M=Y!'OZ<4JZDML%^ULWF(ORONXD&<?\
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -.R_P"/
M?\:LU6LO^/?\:LU#W+"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !61K&CK>H9H0!.!_WU6O10G8&KGG3HT;E'!# X(-( 6( &
M2>@%=?K&CK>H9H0%G _[ZJ/1M%%J!<7"@SG[J_W/_KUIS*QGRNX:+HHM0+BX
M7,Q^ZI_@_P#KUMT45#=RTK!1112&%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 :=E_P >_P"-6:K67_'O^-6:A[EA1112 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[PP3BJBKNQG5FX0<D'_"4Z>>42Z=>S+;L0?I43>)6N+I+;3;"6>5E+$3?NL
M>F>M=  % 50 !T [5@ZH\UGX@M;X6D]Q$('C/DKN()(JH\K>QSU?;0C=RZJ]
ME_P_Y$G]H:[_ - 5/_ E:AGUZ_L&B?4-*\J!WV;HY0YS]!UI8-;%O%Y::1JF
MW)/S1Y/)SU)JI//)?OIUM;Z;?1+#<K(SSIP #D\YII=T92J/E]R;;]%_\BB_
M_P )18_\\;S_ ,!VK0L-2M-2C9[67=M.&4C#*?<&K>:PY46#QE;-& IN+9_,
MQ_%@\&IT>QT-U:;3DTTW;:V_S-RBBBH.D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#3LO^/?\ &K-5
MK+_CW_&K-0]RPHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445%+=6\#!9IXHR1D!W _G0
M!+13(YHYEW12(Z^JL"*(YHI@3%(C@'!*L#@T /HJO)?6<4PADNH$E/1&D ;\
MJF=UC0N[!5')8G % #J*:CI(@=&5E/1E.0:CN+NVM0#<7$4(/3S'"Y_.@":B
MFHZ2('C964\AE.0:CN+NVM0#<7$4(/0R.%S^= $U%-21)(Q(CJR$9#*<@TD4
MT4R[HI$D7IE6!% #Z*KM?V:3^0UW )O^>9D&[\JL$X&3TH **9%-%.I:*5)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<#J'_(0N/^NC?SJM5G4/^0A<?]=&_G5:M3(U_#G_ "%E_P!QJ["N/\.?\A9?
M]QJ["HEN7'8****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% &G9?\ 'O\ C5FJUE_Q[_C5FH>Y84444@"BBB@
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M1+<N.P4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***QK_Q"EEK46DQ:?>7EW+
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M"_O'7S22O&YC[\]!34>\\(:S'#),9;.7!/H5SC..Q%:WAKQ%8+I,-K<SI!+
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M_MY;3=%J$HFN5\QQYC@@@]>/NCIBGS!8YZ_TZTT+QGX:;3H1 ]T\\-RX)W7
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MWC^/2G)W$D:=@N(A5VJMF,1"K524%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $-U_P ><_\ US;^5>?M]X_6O0+K_CSG_P"N;?RK
MS]OO'ZU<2)"5K:+TF_"LFM;1>DWX51*-6BBBD4%%%% !1110 5#=6L-Y;/;W
M$8>)Q@J:FHI@TFK,Q%\.&,!8M6U%$'W5$O04O_"/R?\ 09U'_O[6U15<[,/J
MU+M^+,7_ (1^3_H,ZC_W]H_X1^3_ *#.H_\ ?VMJBCG8?5J7;\68O_"/R?\
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M06WN3)&QX& ,D=<C.*JW6H>(;'1=*TN]2]%Q=:@]N'26+[3); $K\P;:)",
MMNSP><G-/E"YZ%17%P)K%G<ZHR6^IVNE'3G=1?7:S.EP.FQA([ %>>3C(JYX
M&MYG\-Z?J5Y?7EW=W%NI=IIW*@<8 3.W. /FQD\\\TK!<UM0U[3]+O(+2Y>8
MW,ZL\<4-M),S =3A%/3-3:=JMEJT+RV4XD$;F.12I1XV!P596 93[$"N8U^>
M2V^(N@R16DUTXM+@>5"4#'[O/SLH_6L[7+;5-+\.>+/$#EK"ZOGA:&**3YXD
M0JH+,IQN8$Y )'N:=@N>B45R&N1W>C:786=OJ5T;O5+^&UGO))2S+NW%VC4D
MK&3@@!0 ,\=!2WD,FC>)](M+6[O7L]4$L%Q!-=R2D;4+!T9B60CD'!';N,TK
M!<Z.PU.SU2.:2SF\U89F@<[2N'4X8<@=/7I5NO._"R1Z1X<\1ZO$;AYK.ZO6
M1)+J5D;9DC*EL$\?>(S[TZT77Y=/TJ_LK76GU!VBEN9KF]B-O,C<N/+\TA1@
M_+M0$8%/E"YZ%17(Z?%+XEU;7'O+Z\B@L[IK.WAM;IX-F%4ESL(+$D\9R..E
M89\0WCZ/I-OJ>IF&W.K2V5W>)+Y3RI'NV_,,%02 &88Z=1FCE"YZ517FGFS1
M:)XRU"PU+49K*)"FGW+WLD@X0%]A+$$!\@,.?<\UT5M#!IWA-;W4];O8VG@1
M[BZ:X;)R,[44Y"DYVC8 QXP<X-%@N=317#Z7J'E^,KK3[*XU,V+Z6;GR[\3[
MDD5PN5,PW8(/;C-9-D-07X7IXC?6M1?4X8?/C=[AM@"L?D9,[7S@Y+ DYZX
M .4+G?)K%N_B"710DOVF.V6Y+$#9M+%<9SG.1Z4[5=7L]%LS=WSRI #AG2%Y
M ON=@.![GBN1CMCJ_P 2':6:X@C?1H9)([>4QEB7.!O7#  ^A&>_&09])M+G
MQ#X7UW1+B^E/DZA/9Q7$O[QQ&K*5W<C<><9S19!<WX_$VDR7$]O]I>.:"W-U
M+'-!)&R1#JQ#*/4<=>:NV%_;:I8PWMG)YEO,-R/M*Y'T(!%<_JW@N+5M6EOG
MO&C\V2(NBQ_>C4$/&3GH^1VXQ6WHVG?V3I,%CYOF^4"-^W;G))Z9/K2=N@:D
MU]>V^FV,U[=R>7;PH7D?:3M [X'-07>K);6MI<16MW=QW4B(OV:+>5#<AV'&
M%'<]LUE>/8$G\$:KO,@\N!G&R1DR0.^",CGH<CVK)OD?2?#_ (8^Q75Y']HU
M*R67==2/N5NJ_,QPI_NCCVII!<[JBN+MK2?6?&/BBUN-4U".VM_LZP107+QB
M-FA!+ J0?PSM.22"<8Q([S4A\-;/Q3)JMZ^IQO$>9B(V3S1'L,8PIR#DD@MG
MOT .4+GI]8U_XITO3)"EX;R+$@C#FPG*,QX #!,'/;!YK!U^>YL/$%S=:N=6
M31FB1;6ZT^9@EJV#O:5$.3SC!8,O08ZU8\>LKZ#IKHX=6U*U(<$$,-W7BA(+
MF\NN6'V":^FDEMK:#_627<$EOC\)%!/7''?BH8/$VE3W,%OYL\,EQQ#]IM98
M!(?12Z@$\] <UD>,3YFN>%;:4 VLFH%I%/0LJDH#^-2?$95/@347/$D?EO$P
MZJXD7:1[YX_&BR"YJW?B+3;+43I\KW+W8C$IB@M)9B$)P"=BG'(IMSXFTVS2
MV:X^VI]J.V$&PGRS<_+C9D-\I.#S@9Z5SHDU)/B5,;6VMIK@Z/%YJSW!B _>
M'."J/GFNCO-,GU5=*EN6CMIK.[%T\<1,JL0KKM#$*?XLYQVZ460$<OBW0X+2
M_NI+]5AL)S;W)\M\I)G&,8R>>XR.#Z&MJN)O/AXEW)=L=39!<FY9T\G*EI#(
M48C=R4$KCWR#QBNQN($N;=X9#($<8)CD:-OP92"/P-)VZ KD6FZE::O817UC
M+YMM+G8^TKG!(/! /4&K5>9:'.^@_",ZQ922B\,;HIEG=XT+3E P0DJ,9SP/
MKG)K:UFVG\,0Z7?VFHW\\WVN*WN%N+EY%N%<@-\K$JISR"H&.1TI\NH7.SHH
MHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!P.H?\A"X_ZZ-_.JU6=0_P"0A<?]=&_G5:M3(U_#G_(67_<:
MNPKC_#G_ "%E_P!QJ["HEN7'8****DH**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JK)_K?SJU5:3_6?@: ()D!#3)&IF"G
M:V!GZ9KG[J.XFG1"RM/O5BJG@' YQU'?VKHR<'Z],FLF9%?66#*$947#*Q4M
MGKR <]*N+)8]%:._^=G+, QWXR,CIQ6[']P5S?G.=58,6( &UCGIZ<UT4!S&
M*EE(EHHHI %%%% %>;[Z_6JDBA9OF/!Y'/2K4I_>9]!FJKS;DC(CD(D;!&<;
M1ZFFA,8/E*[!\O?L<U3OTVSVQ/4[B?TJ>2Y>-8W6 LRO\X&. ??/TJ"]>1Y[
M5I8]APW<'TIL$;5K_JA5BJ]K_JA5BI&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $-U_QYS_ /7-OY5Y^WWC]:] NO\ CSG_ .N;
M?RKS]OO'ZU<2)"5K:+TF_"LFM;1>DWX51*-6BBBD4%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 :=E_P >_P"-6:K67_'O^-6:A[EA
M1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L;4?#-CJ>N66K3/.L]IC:B, CX.Y=PQDX/(Y%7;W5;+3I[2"ZF\N2\E\F
M ;6.]_3@<?C5F61(8GED.$12S''0#K3 R;SP[%<ZK)J4%_>V5S+"()C;,F)%
M!R,[E;!&3R,&H(/!^G6^F6&GQRW7DV-Z+Z(EP6+AF;#$CE?F/O[UL6%];:G8
MPWMG)YEO,N^-]I&1]#S5BB[%8P[KPO:W&HW=VEW>6PO51;N&"152<+QSE2RD
MC@E2IQ4<?@_3HM"L=+CEN4%@_F6MRK@2Q-DG(.,'J1@@@CJ*Z"HDNK>6XEMX
MYXGGAVF6-7!9-W(W#J,X.,T786*":,_DW"3ZMJ4\DR!!*TJQM&!R-HC55!R>
MN"3T.1Q5"ZT.XLXK_4K6:[U+69;4VT$D\D<912>@VJB@9.XGKQ5Y/$FD/I5U
MJ@O!]BM7:.:4HPVLIP1@C).2!P.<\5>L[R*^@\Z)9U7)&)H'B;_OEP#^E&H$
M6DV<VGZ1:6EQ=274\42K)/(Q+2-CDY//6LVY\+1WD+6MUJVIS6#/N:T>5"K#
M.=I?;YA7V+]..E;U%%QF/=>'8)M134+2ZN=/NQ$(&DM=F'0<A65U9>.QQGWI
M;KP[;7VEQV=S<W<KQR_:([II?WJ2Y)#J<8!&3@ ;0.,8XK7HHNP,N+1F$=RM
MUJ=]>&>(PDS,BA%.<X5%5<\]2"?PJQI6G0Z1I5MIUNSM#;QB-&D(+$#UP!2Z
MEJ=GI%F;N^F\J ,JE]I;EB . ">I%6Z ,Z?1K>XUVTU=WE%Q:Q/$B@C80^,Y
M&,YX]:76](M]>T>XTRZ>5(+@ ,T1 88(/&01V]*T*JW&I6EK?V=E-+MN+PN(
M$VD[]J[FY P,#UHU CU?2;76K!K2[#[=P='C8J\;CE74]B#S4%IH4<.I+J-U
M>W5_=QQF*&2Y* 1*3EMJHJJ"<#)QG  SBM6J<&JV5SJ=WIL,VZ[M AGCVD;
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MMW:XN94DP)<<+%M!R0<DG(QQZUM44@*]]90:C87%E<IO@GC:.1>F01@UE?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTR?4[J4M#<W,C6B%0NR ':O09.<$Y/K3= U.\O=?\16UQ-OAL[E(X%V@;%*
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MZ>EU&RQ1L\N\$[FWAAM7;C QR3S5*PUS6?[-\'RSWLKR:I/_ *3YD48W*4)
M&%&!P"._/4U3U&RT6?QMK(UJ]@TU$CMQ;K<PVY$RA#ED,T;# /RX7N#GT&SI
M-G?^)M/T+5-1E,,UC<O*A,&TW*8*JY7(V%AST^@ (HT$3:9<:MXC_M"]@U9[
M"**ZDM[:&."-T(C."TFX;CDYX5EP/?FE\47[:>EW(?%4&G7"P&2UM"(1OP#]
MX2 LV6!'R[?3DC)L0>';_3IKU=)U:.UM+R9IVBDM/,>)V^\8VW #/4 JP!_*
MHI_"MU]LUB2SU2."'5L?: ]KYDBX7:0C[@ ,=BIQSBEI<9FC4'U;Q%X$U"1
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M>TWPP"1X+8,H)5 /F*@]P??I1JGB&>+P/<:KHFOKJ!^T1)%<20IN3+*&1P%
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M8[[-)C04444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .!U#_D(7'_71OYU6JSJ'_(0N/^NC?SJM6ID:_AS_ )"R
M_P"XU=A7'^'/^0LO^XU=A42W+CL%%%%24%%%% !1110 4444 %%%% !1110
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M/+B51AMX(^@%)H+FQ144+[E!J6D,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"&Z_X\Y_\ KFW\J\_;[Q^M>@W(W6LP'="/TKSX]35Q(D)6MHO2
M;\*R:U=%/,P^AJB4:U%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH T[+_CW_&K-5K+_CW_ !JS4/<L****0!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4449'K0 449'K1D>M !11D>M&1ZT
M%%&1ZT9'K0 449'K10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <#J'_(0N/^NC?SJM4]ZP>^G8=W;^=05J9&OX<_Y"R_[C
M5V%<?X;!.J@^B-785$MRX[!1114E!1110 4444 %%%% !1110 4444 %%%%
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M_P +1YN9Y.RH%_,__6KJ*R/#EOY.F^81S(V?PZ?XUKUG+<TCL%%%%(84444
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M444 %%%% !1110 4444 :=E_Q[_C5FJUE_Q[_C5FH>Y84444@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P]:T47(:YMEQ,.64?Q?
M_7K<HIIV$U<\Y(*D@C!%(!DX%=7K6BBY#7-LN)ARRC^+_P"O3-%T3RMMS=+\
M_5$/;W/O5\RL1RNX:+HOE!;JZ7Y^J(>WN:WZ**ANY:5@HHHI#"BBB@ HHHH
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M*** "BL+5-<GL+PPI%&R@ Y;.:I?\)1<_P#/"']?\:?*Q<R.JHKE?^$HN?\
MGA#^O^-'_"47/_/"']?\:?*Q<R.JHKE?^$HN?^>$/Z_XT?\ "47/_/"']?\
M&CE8<R.JHKE?^$HN?^>$/Z_XT?\ "47/_/"']?\ &CE8<R.JHKE?^$HN?^>$
M/Z_XT?\ "47/_/"']?\ &CE8<R.JHKE?^$HN?^>$/Z_XT?\ "47/_/"']?\
M&CE8<R-K5M-74+7 P)DY0_TKBG1HG*.I5E."#VK;_P"$HN?^>$/Z_P"-9U_?
MF_D$CPQH_<IGGZU2NB6TRG0#@Y'6BBF(T[7560!)P6']X=:U8IHYEW1N&'M7
M+TJLR'*L0?4&@=SJJ*Y^/4KI./,W#_:&:F&L3]TC/X'_ !H"YM45B_VQ/_SS
MC_7_ !H_MB?_ )YQ_K_C0%S:HK%_MB?_ )YQ_K_C1_;$_P#SSC_7_&@+FU16
M+_;$_P#SSC_7_&C^V)_^><?Z_P"- 7-JBL7^V)_^><?Z_P"-']L3_P#/./\
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M7_GFWY4>1+_SS;\J (Z*D\B7_GFWY4>1+_SS;\J (Z*D\B7_ )YM^5'D2_\
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MP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]
M*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
M]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P
M/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2B
MB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#TH
MP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]
M*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7V;9SNSOW9^E;%2QH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img34454307_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34454307_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )H!*0# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@$$9% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11GG%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449H **** "BBB@
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MG4[:72=,CO=+\O$L83>78]0PZ@=,8]Z[NBH6(TBG%-*_XE.AK)IV;M^!Y/\
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MG):2ZFUX.U,MX#TN_P!3O,LT69)[B3J=Q'+&NE!# $'(/((KRRZ&?@-:<?\
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MZ73=/N42.."5=C3..3*5[>E=M112J3YW<<(<JL%%%%06%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %(:6B@!,TF:"*BWX.#0!+FC-
M,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S
M1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F
M@!^:,TS-&: 'YHS3,T9H ?FC-,SBA26/% $E+110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%+'N&1VJ6B@"DL
MI4[6J7=1<0;QN7K5-)C&VQ^G\JJUR=BYFC-,SFC-(8_-&:9FE!Y% #LT9KPJ
MTU3XA^(_%.OVFA:]Y:Z?,<12A -I8@ 97V[UT?A/QWK]KXJ'A3QE;I'>R#_1
M[A  &.,@''!SSR/I6KI-=3-5$SU+-&:\SL_$6KR?'"^T-[Z0Z9' &6WP-H.Q
M3G.,]2>];7Q)\3R^%_!\]S:R;+V=A!;GN&/4CZ#)J>1W2[E<ZLWV.RS1FO,O
MA'XPU#Q!9ZAI^M7+3:E:2!P9%"N4/'( '0_SK8^(?CD>#=+A6VB6?5+LE+:)
MN0/]HCN.V/6ATWS<H*:Y>8[;-)FO&[?PW\5]3M_[2G\1QV=PPWI:LV"/08"X
M'X_C79^ =0\67=K=P>*[%89;:01QSC ,WJ<#@CW'!IN%E>XE.[M8['-&:\,T
M3XGZEI_Q(O-/UJ^:;2I+E[==X $!W?*<@=.QKJ/B7XBU;1M?\,0:;?/;PW=Q
MMG5 ")%W(.X]":;I--(7M%:YZ7FES7 _$/QW-X9%KIFDPK<ZU?$"&,C(0$X!
M([DG@5S+>'/BREM_:8\11-=CY_L089_W?N[?UI*G=7;L-SL[)7/8\TN:X'P!
MX^D\3Z?>P:C L.L:>K&>%1@.!GD#MR,$5P.DZQ\0?&9U#6M'UN*.6TFPNF @
M';GT(QCZFA4G=WZ ZBTL>]YHS7FWC@>.DT&SU/3]1@L7M;0R:@D1!#/_ +.0
M:S?AA=^-=;,6N:GK'VG1V25/*;:&WC@' %'L_=YKAS^]RV/6\TN:\Q^%OBG4
M-3T+7+[7=0:=+.Y;$D@ V(%R>@%8D'B'QQ\2;^X/AN=-(T:%R@G?JWU."2>^
M!TH]D[M/H'M%9>9[3FDS7D]A_P +,\+:Y9VMVR:_IUQ($9U/^K]3N(!7'OQ7
MJN:F4;=1QE<?FC-,S1FI*'YH+ #)J-G"C)/%1INGDP!Q_*@39,NZ1N*LJH48
M%(B!%P*=2&D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *JW5J)063AJM44T[ 8L5P8F\N3@>_:KF[/
M2EOK(3J73AQ^M9D%RT+^5+D#ISVJ[7U1%[:,TLTJGYA]:BW9&12AL'-24>4_
M"O\ Y*!XV_ZZ+_Z,:JGQ#FBU/XL^%[/3W66\@>/S2C9V@2;L'Z $UI7GP=CN
M=6O+^'Q'?6S74ID=85"]3G&0>:WO"'PYTGPE=27J2S7NH."/M,^,J#UP/7WK
MH<HI\R9CRR:Y3F;$_P#&1VI'_IV_]IK6'\5/$=K=?$+3K"YCDGT_2BKSQP\L
M['!8?E@?B:])@\%Q0>/[CQ8+Z0RS1^7]GV#:/E"YSU[5'X:\"6F@:OJ>J3W/
M]H7=^VYFFB4;,DD@?4X_*DIQ3OY X2:MYGEUCXWL%^+T&O65O/9V-]M@NDG4
M#!(VD\=N%-=-\3I$TKXC^%-:OHR^FQMM<XR 0W/^/X5V7B_P78^+=)CLF<6;
MQ2B5)H8ER".*NZCX;LM:\-IHVKYNXUC53+C:^Y1@./0T<\;I_(.25FB'Q1<>
M)Y]+M+CP9]BN9)'+2/,P*&/'!!)]:XWP5XU\7:MX^?0=7:P>*V1VN#:Q@A2.
M@W@XZU7_ .%-W]L?(L/%UY#9'K&=P('M@XKN/"'@[3/!MB\-COEGF(,]S+]^
M0_T'M2]Q1MN-<S?8\H\/^%8/%VK^/-/D"K<+*LEM*?X) [X_ ]#6'=>(+[4K
M[POH^JQR+J&CWOD2,_5EWKMS[C!'X5[9X8\&0^&=:UC4H[V2=M38,R,@ CPQ
M/&.O6J'B+X:Z=KWBBVU];I[2XB9&E6- 1*5.03Z' Q5JJN;78ATW;0YSQ9<1
M:-\<M#U/4@5L9( B2L/E5L,O7V)!/IFO73(HB\XNHB W>9GY<>N?2L+Q/X7T
MSQ;I?V'4HR0IW12H</$WJ/\ "O/O^%,WI;[.?%UW_9^,>5\V<>F,[:S]V25W
M:QI[T6[*X>!KJ'5_C'XEUC3QC31&09<84G@?J034?B_PT=$DF\>^"=0CC2%B
MUW%$P,9Y^;'8C/5:]$T/PGI'A_07T:SM\VTJD3ES\TQ(P2Q_SBN!D^"A666V
MM/$EU!I,K;FML$GZ=<'\:M3CS7N2XNUK'476NKXD^$5WJP01M<6#ET'17'!%
M5/@Z?^+9VW_76;_T*NC/ANTC\(-X;M6:&U^SFW5^K 'O[FH_"7AJ/PIX<CT>
M*Z>X1&=O,=0I.XYZ"LVURM+N4D^9-]CRSP);3WGPQ\:V]NI:5I7VJ.IPH)'Y
M"NS^#6I65UX#M[&W91=6CNL\?\62Q(;'<8(YK7\%^#H?!MI>P17LET+J;SB7
M0+MXQCBN=USX1VMUJ<NI:%JD^D7$IRZ1YV9[D8Y'TJY2C*Z9*C*-F>B7.HV=
ME/!!=74,,UPVV&.1P#(?0"K&:\RT7X1V]MJ<.I:]J]SJUQ"=R(Y(0-U!R3G\
M*]*S64DELS2+;W'YI&<(I).!4;2!%+,< 57C$E[* !A1^GN:EA*5B9 ]U)@#
M _E6E'&L2;5_$^M$42PIM7\3ZT^I'%6W"BBB@H**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S
M]1T\7*EX^)!^M:%%-.VHFKG,6UVUNYAFR #CGM6D&!&0>*=JFF"Z0R1#$H'Y
MUBVMZUM(8)\A0<<_PUK925T1?E=F;.:,U&&!&0<BC-0429J*>ZM[5-]Q<10H
M?XI7"C\S5?4;Y--TR[OI!E+:%I6'J%&:\>\->%[SXG37'B+Q)?3"R:0I;V\3
M8''8>BC\S5QBFKO8F4K.R/:+>]M;M2UK=03@=3%('Q^1J;->8?\ "J#I&L6=
M_P"&-9N+#9(//20[LIWQZ_0TSXD:SJNH>(-.\%:-.;>2\4/<3 X.T]!D=L D
MT^1-V3%SM+5'HXU73C-Y(U&S\W./+\]-V?IG-6\UY:_P2T,V&Q+^]%[MXN2P
MQN]<>E2?#'7]2BU;4?"&M3&:ZT\GR9&.25!P1GT'!'UH<%:\6"D[V:/1AJ-D
M7V"]MBV<;1,N?YU)-<PVZAIYHXE)P#(X4'\Z^;-(TOP[J-QK\NN:S+I\T,KF
MVV-]\Y/;'/.*[/P;H[>.OAQ]DUJZNO)L;IC;2H<,RA>F3U )-5*DEU)C4;Z'
MK:ZC8NZHE[;,S' 59E))]N:5]1LHW*27MLCC@JTR@C\,UX;\)?"-CK<\FKW,
M]PL^G7B-$J,-K8Y^;\JS[ZT\/7WQ,\0)XEU.:PM%=FB>/)+/D<< ]LT_9*[5
M]@]H[)V/H(7]F8C*+NW,0."_FKM!],YJ9)$E17C=71N0RG(/T->?^$_#WA*_
M\(ZGI.CZA+J&GW+XEDD!#(^.,9 Z=:X:#Q=K?@/3=5\'SQ22WR/LT^;J KG'
M&>HYR/>I5.^B&YVU9[K'=VTI<1W,+E.7"R [?KZ5CMXST))2IO'V [3.()/*
M!_W]NW'OG%<=IWA.3PM\.IO.WO>W<D<NI."2PBW#<OT Z_C5#^SY8]2GU2&*
MW33?[<"B5%??Y!]#G9Y6.O'XT*$>X.;/75D5T5T8,K#(93D$>HI<USG@TC^P
M#Y6[[)]IF^R;O^>.\[,>V.GM6_FLVK.Q:=T29IKR+&I9C@"HWE6-"S' %4XU
MFU*X"H,(/R%2W84I6T6Y-&LE_, HP@_3W-;D$"01A$'U/K26]NEM$$0?4^M2
MU(XQMJ]PHHHH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'UJC_,>H;J-U>7_\+IT3_H':A^2?_%4?\+IT3_H':A^2?_%4?4Z_\H?6J/\
M,>H;J-U>7_\ "Z=$_P"@=J'Y)_\ %4?\+IT3_H':A^2?_%4?4Z_\H?6J/\QZ
MANHW5Y?_ ,+IT3_H':A^2?\ Q5'_  NG1/\ H':A^2?_ !5'U.O_ "A]:H_S
M'J&ZC=7E_P#PNG1/^@=J'Y)_\51_PNG1/^@=J'Y)_P#%4?4Z_P#*'UJC_,>H
M;J-U>7_\+IT3_H':A^2?_%4?\+IT3_H':A^2?_%4?4Z_\H?6J/\ ,>H;J-U>
M7_\ "Z=$_P"@=J'Y)_\ %4?\+IT3_H':A^2?_%4?4Z_\H?6J/\QZANHW5Y?_
M ,+IT3_H':A^2?\ Q5'_  NG1/\ H':A^2?_ !5'U.O_ "A]:H_S'J&ZC=7E
M_P#PNG1/^@=J'Y)_\51_PNG1/^@=J'Y)_P#%4?4Z_P#*'UJC_,>H;J-U>7_\
M+IT3_H':A^2?_%4?\+IT3_H':A^2?_%4?4Z_\H?6J/\ ,>H;J-U>7_\ "Z=$
M_P"@=J'Y)_\ %4?\+IT3_H':A^2?_%4?4Z_\H?6J/\QZANHW5Y?_ ,+IT3_H
M':A^2?\ Q5'_  NG1/\ H':A^2?_ !5'U.O_ "A]:H_S'J&ZC=7E_P#PNG1/
M^@=J'Y)_\51_PNG1/^@=J'Y)_P#%4?4Z_P#*'UJC_,>H;J-U>7_\+IT3_H':
MA^2?_%4?\+IT3_H':A^2?_%4?4Z_\H?6J/\ ,>H;J-U>7_\ "Z=$_P"@=J'Y
M)_\ %4?\+IT3_H':A^2?_%4?4Z_\H?6J/\QZANHW5Y?_ ,+IT3_H':A^2?\
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M_/C>_P#CG^-'_"U=*_Y\;W_QS_&CVD>X?VAA?YT>@[J-U>??\+5TK_GQO?\
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M_/C>_P#CG^-'_"U=*_Y\;W_QS_&CVD>X?VAA?YT>@[J-U>??\+5TK_GQO?\
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M5>5WL%%%%0<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BG+&[@E$9@O)(&<4V@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.KM\Z@Y^[TSQUHT%S4];M;=%_P #^NYD4445)R!1110 4444 %%%% !1110
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M]BL=0A\II);N 0)(7_U:[@3Q[XQ6;11222U&VV%%%%,04444 %%%% !1110
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MF]#52E[.+U17M)+1FZ6\/VM[9I:W.H$(Y:6^0!&']W8F>Q[YR:3Q1J5IJ5[
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M>RN-<UWYM&@BM++.!<W(R7]PM;L/ASQ,$#+XFQ)_=, V_P"-6Z=MW8Z55O\
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MVKMC\*/N,/\ P8>B_(Z:UZ"KZ]*H6O05?7I5&P^BBB@!#52^_P"/*X_ZY/\
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M.*9 %('/7'7K5K_A-=86.:.$VENDZ,DRP6RH)0PP2V.IJ72FXV?YLI587O\
MH:-IHVGR_P!E2R6H=4TE[R6%"0;AU/ /]<=A5:REL_$5IJ4$FDV=I);VSW,,
M]HA39MQ\K\G(.<?7%8PUK4$DL9(YS%)8Q^7 \8P57W]>IJ>^\2ZC?VCVK?9X
M(9#F5;:!8O-/J^.M7[.9/M(&^]QI=I?:'IR:%8R+<VUN;J24$N[.HR5.?EZY
M^M$<.F7.LZIH":7;+;VT-P(KG!\_?&"0Q;/.<=,=ZY635+J6\MKIV7S;9(TB
M(48 0 +D=^E/BUF]AU.XU%'07-P)!(2@P1("&P.W4T>R=M_QZB]JK_UL=#8Z
M+8W<6B-);Y!L9[J=(SA[@HS87/J<8K+DUFUOH+B!O#]D@*$Q/:(RO$1W)R=P
M]<U1&L7RBP\N<Q-8 BW>,;67)SU[\FKMUXKU.ZMY(?\ 1H/.&)GM[=8WE'^T
M1UI\DKZZ_/S#GC;3\B_XAALI](CO-)L[+["C(AEBW+/"Q7E90>N2"0:Y6M74
M/$6HZG9K:W#Q"(,'?RXE0RL!@,Y'WCBLJKIQ<8V9%22D[H****LS"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K5TC1WU"3>^5@4
M\GU]A4&EZ>^H7:QCA!RQ]!7H%E:)%&L<:X11@"O/QN+]DN2&_P"1WX/"^T]^
M>PEG9)#&L<2!5'85L6UD6QQ4UI9YQQ6[:VBH 7*J#_>.*\1MMW9[&Q3M]/Z<
M5J0Z?TXI+Z[&GO!:VULUWJ%SGR+=#C('5F/91ZU8AT7Q+(A>?6K6V<C(B@M
MZK[$MR:I0TNW8ASULE<<]O#:V\D\[K'%&I9W8X"@=S6;;/K.M1B?1["""S;[
MEQ?E@9!V*H.0/K4.LQ:M!-IUMXB:WET?[2K3W=NA4,1]U)%[*6QSTKOUQM&W
M&W'&.E4TH*^]R4W-VVM]YQ$R>(-*4S:AI]M>VJC+R6!;>@]=C=1].:T;=+>_
MM([JUD66"5=R.O0BNGKS#Q!XI@^'OB*[M/L+W%K?*MW%&CA1&Y)#_@2,X]Z<
M8^UTBM12G[+63T.DEL/]FLG4=&AN[=X;B%9(V'((K.TKXM:)J%R(+ZUFL-W
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MM!_JXF;(7Z55HHH&Y-[FC?WD%SI6EVZ9,ELDBR97C);(QZ\5)IEY9BRNM.U
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M>CPVDERXM;TSW$DD>-XPO*C\.E<M11S,:Q$EK97[FO<:A;R::L"EO,%_)/\
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M (,/1?D=-:]!5]>E4+7H*OKTJC8?1110 AJI??\ 'E<?]<G_ /035LU4OO\
MCRN/^N3_ /H)IK<3V/DH]:*#UHKZP^9"BBM7PWH\>O:_:Z;+>):),2#*_.,#
M/'O4RDHIMCBG)V1E4Z.*29PD:,['HJC)K2\1:3'H6OW>FQ7:7:0-@3*,!N,_
MG5"WNKBRF$]K/+!,O22)RK#\10GS*\0:L[,)+:XMP'EMY(QG@NA S4VJ:C-J
MVHRWUPJ++)MR$&!PH4?H*[74XYO$/C2PTG4-0NOL;VD,A!E+!6\D$M@\9Z_G
M6'%IFAS17&I^9>Q:3;%(=IVF:XE.3@=E&!GGI64:J=FUK_F:NFU=)Z?Y'-UO
M0^*KA(T^T:?IUY/$H6.YN8-TB@=.A ;'^T#5LZ1H-[HTVH:=/>))'<PPM;3X
M)4.V"V1U'Y8JY<^'O#<7B.3P]%=W[WC2^5'<X7RD<]%(ZL,\$TI5(/1H<:<U
MJF<A=W4]]=RW5U(99Y6W.[=S4-=,/#]E#X9>^G-W+<B22-VMP&CMF4X D'7Y
MO6HO[/T32H8%UAKV:[GB68Q6NU1"K#*Y)ZG&#BK52.R(=.6[.>J>>RNK:"">
M>VECBG!:%W0@2 <$J>]=!8:/H4D&K7LU[=3V5D(6C,2A'DWD@J0>A'K[&KEE
MH=IJ\NBQ37MW'9W$-TZB63>(%3)&!^'..M)UDOZ\KC5)O^O.QQE2_9I_LOVK
MR7\C?Y?F[?EW8SC/KBNAMM-\.ZO<#3M.GOXKULB&:X"F.9@. 0.5SVZU;1=/
M;X;"#[/=?;#J00?.-OG;"!Q_=QQCUH=6W0%2OU..HKJ)M*\.V%\=(O;F^-\&
M$<EU$J^5$Y[;3RP&>3Q3H_#VF:=8:A<:U-<&2SO?LHBMB,R_+G()Z>N:?MHA
M[*1RM3"TN39->"WD-JKB,S;3L#8SMSZX[5TMWI7AO3H[2]GFU":UOX_,@@CV
MK)$ <'>3P>0<8ZX[4^;PQ/'%>:9!=S2,NI0P1)N(C;>K$.R^N .?K2]M$/9,
MY&BNB>V\*I(UD;O4/-4E?MVQ?*R.^S[VWWZ^U.30]/'A)=3=KN2>0N#) H:.
M%E^ZCCJ-WKTI^U747LWT.;HHHK0S"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KJO"%OD3S^X45RM=SX1C TS=_><UQ9A*U%^9V8"-ZM^QV%A#DCBNJT
M^' %86FQYQ6MK#/;^%M3EBR'6V<@CJ.*\&*N['M2=DV5[2ROO$>MOJFEWLFF
MV"1FU:XC +W>&_A!&  <@-UZULGPG(BAK?Q#K,<X_P"6C7 <$^ZD8K8TJWBM
M=(LX( !%'"BKCTP*N5I*H[V6QG&DK7EN</J6I:SD>%[ZQM[J\OE*6]X5 @=
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M=ESRZE'P,J0:+=642*L-G?3P1[1C*ALC^>/PKI&Z5G:!IC:/HL%I(X>?EYI
M/OR,<L?S-,\1:S#H.AW>I3$ 0H2H/\3=A^=*7OS=NHX>[!7/$OBWJXU#Q;]C
M0@QV,8CR#_$>37 U-=W4M[>374YS+,Y=C[FH:^DHT_9TU#L>!6J>TFY!333J
M0UH9D3+FM#2]4-JP@N"3">C'^#_ZU4B*C=:YL10C6CRR*:4E:1[;X0\7>3Y=
MA?RYB/$,Q/3V/M7I<,P8#FOEC2=6-H1;W!)@/"M_<_\ K5Z]X1\6^5Y=C?2[
MHC@13$]/8^U?.U:4Z$N2>W1G;@\6Z;5*J].C/5%;-8OC#0O^$B\-W%FAQ<KB
M6W?^[(O(_P /QJ_#,& YJVC9HC)Q::/6E%23BSCM%DTWQ]H$%MK4!>]L) +J
MV<E2)%&,E1U!KLH((;:)8H(DBC7HJ* !7+:]X--[J0UK1;UM,U@ !I5&4F'H
MZ]_K6-J7B?QOX?2%=0TS3;@32K#%+$[?.YZ<9]JW<?:? _D8*?LOC7S[G>WU
MA::E:O;7EO'-$XP5<9KE] ,WAWQ#)X;FF:2SE0S6+.<E1W3\*ZZ'S3!'YP42
M[1OV=-V.<>U<KXAVGQIX<"?Z[=(3CKLQS64>L2ZJM::W.MKC[F Z%X]M+FV4
MBVU8&*=%''F 9#5V%(5!() )'3/:I3L7.'-;R.3UG_DH6@_]<I/Y&LOPWX=T
M[7'U.YU%)9V2]= K2MMQP>F:U-9_Y*%H/_7*3^1K&\/6>O71U0:9J4%I;_;7
M#;HM[%N.1^E:_9.65O::J^K_ "1W4<6G:+9$(L%I;(.<84"L:P\27.MZNL>E
M6@?3(SB:\ER WL@[U'!X*AGDCGUJ_N=3E7^&5L1Y_P!VKFJ>(=+\/PI:Q@27
M&-L5I;C+$^F!TK/0U;DE>7NI%S6]8M]#TV2\N#DCB.,=9&[ 5F>$])N+>.XU
M741_Q,K]M\@/_+->R5!I>AWNIZDFM>(,><G_ ![68.4A'J?5JM^(_$+Z8T5A
MI\0N=5N#B*'J%']YO05)+EK[6>B6R_KKV+^LZ)9Z[9?9KQ6(!W(ZG#(WJ*YQ
M-4U7PC*EOK1-YI;,$COE^]'Z!Q5JV\9?99EM?$%E)IMQP/,(W1.?9ATJK<R+
MXM\516L3B32=-(DF93E99>P]P*3\C.K.$K2I/W]O^'1V:L&4,#D$9!I:.E%,
M[@JM?7UMIME+=W<RQ01+N9V-+?7UMIUG+=W<JQ01+N9F/^>:\'\9>,+KQ5>^
M7'NBT^-OW4/][_:;W_E6]"C[1W>D5NSGQ&(C1C=[D?C+QA=^+;\11[HM.C;]
MU#G[W^TWO_*L**)8EP.IZFECC$8XZ]S3ZPQ>+]HO94](+\3Y/%8F5:7D%%%%
M<!RA2@X(([4E% '?:1.)H8Y!_$,UV6G/P*\S\,7F&:V8C(^9/ZUZ%ITO2NV$
MN:-S[7"5U7HQG]_J=5;MP*QK[[6-4N#<C53;_+Y!L6PH7'.X9ZYK3M7R!6@A
MXIM7-:D.=6N<C:V&G7VJ-$][J@DN$S+!< J)E7L3CG&16AHBQ:RR:I(T;)"2
MEM;(?E@ XY']_P#EVJQJ;B+Q!HTC':I,R9/3)48_E6=H>DQ76F)=6\LEK=+)
M(@GA/WP'(&X=&%3U.6,>6IRI7M_P'^IT=[_QX7'_ %R;^55])D5-#L#(X'^C
MQ\L?]D55+ZY!$\<]K:WZ$8S$YB8CW!R/UKEA81/#HMXU@;JXGEEB>"27Y=H#
M87G@;=H_*FV74K.,DTOO]5ZW.NN=>L8V,,#&\N#TAMQO)^IZ#\36$D;V4\.G
M:@D'V74Y"$LD;+6QZ@@^GKCH>E:L5KJSJ(X4L]+M\8(B'F28]C@ ?D:KS:9:
M:?JVE'<6EDE=I+B9LNY"' )/\J'<F?/*TG_EO^+^=B@L%G;W]RR7^M7,X/E2
M-""?N_PYQVK5T07OV^<E;Y;'RUVB^8%S)DY(]L8J7PPWFZ2TW_/6>5P?7YC_
M (5LT)=2Z-)64T_,*0TM-8U1U'.^,]2&F>%[V7?MD=/*CQUW-QQ_.O!J[[XG
M:X+O4H]*A?,5M\TN.[GM^ _G7 UR597D?*9K756ORK:.G^9T>K>)X=2\-6.E
M)IL4,EMC=,,<X&./3/>N<HHJ&V]SSZE651WD=#=V%Y>>'-$-K:7$X"S F*)F
M ._V%6[>WBTG3[&QUC"//?I/) 2"8X@ ,L.V?Y"N72XGC7;'/*B^BN0*8S,[
M%F8L3U).33N:JM%/F2ULEY'HA>5=5GDFLM9>( ^;YL\8MFC],[=N,=,<UG:>
MUNWAF$6=MJ4A,SFX%A(H<'/R;N"2,=,<=:XXS2F/RS+(4_NECC\J(Y9(CF.1
MT)[JQ%/F-7B[N]N_X_([V.5_^$FLPD)AODL)]S7DJ.S?(VWS-H !^O;%9^F+
MK2W=VVMBX&G&-OM1NON'@XVYX)SC&VN;L+[['<32NIE,D$D7+<_,I7/X9JLT
MTKH$>61E'0,Q(%',#Q2T>N[_ $W-?PFF?$EI(>D.Z8_\!4FK^F06^NQK?WK*
M!I^Y[L,W,L750/Q^6N75BIRI(/3@XH#$ @$@'K@]:E.QC3K*,5%JZU_3_(ZB
MYDN_$6@PO@O.VILB+Z;U&!]!BKDFL:#9:E#:&*]EAM(39LR2+Y;J<AFQC/4D
M_@*XQ7=1\KL.<\''--I\Q?UIK5+73\#J$TFZ@TC7+"*&2>2.>#'E(6W+\Q#
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MTVKZ>WUIO#S5WMOKU=Q*O!V7IIT1Z/X0\6ZSKWC2XL-2TN!8(5D*@0;6M<#
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M3:)HL^Z1LI<W"'[H[JI]?4UXU7JX#"M?O9_(\_&XE6]G'YA1117JGEA1110
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MM<6Y:)WZF)HVP"/:BR+="%^5=[?B<M11C'%%2<84444 %%%% !1110 4444
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M:;?!)]7T8W5\BA?.BG,8EP,#S%P<GW&,U4.MAM/U2U%G'']NFCE B^5(MA/
M7TYH2G\]/S);AT-V?P_X;@\3#P^+G4'N))1$MR"@CC=N@*XR<9 )R*RHM(T^
MPL#>ZR]RV^9X8+>V*JS[,;F+$$ <@=*@?7 _BT:[]G( NUN?)W^A!QG'MUQ6
MSI&W6[&XAEM;>]3[4\RVINA!/#N[H[<,IQR,=JE\\4KOM<I<LGHO0SM6TO2(
M_#UIJNES79\ZX>%XKC;F/ !ZCKUZUS]=?XIFMK70=/T>."WMYHIY)FAAF\TH
MI  WOT+'GITKD*UI-N-V9U4E*R"BBBM#,**** "BBB@ HHHH **** "BBB@
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M<>+?)OH;B2%2WGQ3Q8BA&TX*C&%]MM5;FYURU\!Z(^DK(D1,XFGMU_>C]ZV
M2.0/IUH]L[\NGW^O^0>Q5KZ_=Z?YG)Z+I?\ :VK)8M*8=R.Q;;DC:I/3\*SR
MCA0Q1@IZ$C@UZ5I;3_VMH%YJL"C5VCN#(K( \D(3Y&D [D[N3R16!I>K7VN6
M^LVNH3F: 6,MQ'&0-L+H,J4'\/X4E5DVWT_X+!TE9+K_ ,,<IM.=N#GTQS5W
M1],DUC6;738F"27$GEAFZ+]:ZR Q2Q1>,I2I-M;>6Z>MVOR)GZC#?A63X*);
MQ6EW*Q/D137#L?9#S^9JG5;C)KI^8E32DD^OY&%?6<VGWT]G<+ME@<HX]Q6O
M/X3OX+K1K5RBSZK&'C5C@)EB &/ZFM32[.VUR*#7KUE\G3D)U!2>7V\Q_P#?
M1(4_0U)<2W_B'2=%N[>0+J!O[D(Q;;A^)% /KS@"I=65TOO^XI4U9O[CG]6T
MFTLH4FLM5AO8]YB<;3&Z./\ 9/)7WJ&QTPW>G:C?-,(X[*-6Z9WLS !1^I_"
MMO7[;[;H$6MWEG]AU,W)MYDV;!<X&?,"]B#P<<'-48,+X#OBOWFU"$-]-CXJ
MHS?+OK<EQ7-\BAJNFG2YH(VE$GG6\<^0,8W#.*OP>'H(;2"YUG4X]/6X7?#$
M(S)*R]F*C[H/;)YJ;Q7;SM<V$BV\K1C3H"6"';]WUJ3Q+I]W?SQZS9Q27-A<
M0Q!7B!81,J!3&<=""/UH4VTM;7!P2;TN9FJ:0EC!%=VM]!>V<S%4DCRK*P[,
MIY4T:%H=QX@O9;2U91+' \PW=#M[?C4=[HE]IUC;W=Y$(%N"1'&[8D8#^+;U
M ]ZU/#$C6FE>(KU'*21V:HCCJ&9QC^5.4FH73N*,4YV:L<\D4DDRPHC&5FV!
M .2V<8_.NAG\'W-IXDDT>XN8XS!;BYGFP2$3:&. .21G%:<,-O:0S>,E$>QH
ML6\787;95AC_ &>6'U%+?'5+B^TG5M*;?=KI*2N#@F0)E'&T_>[Y'IFH=63>
MFG^9:II+77_(Q8_#T%SK5E8V>J0W$-Z#Y,P4@AN0%=3RIR,?K6$RE'9&&&4X
M(KMC8PP^)O"^H6]J;*:^F222S&?W;"3&0#R%;J :Y/5-O]KWNW&WSWQCTW&K
MIS<F14@DBI1116ID%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "4TBGTE $++6QH&OOI4H@G):T8\]RGN*RR*C9:YZU&-6/+(T3N>
M_>&_$B[(XII0\+ >7+G^==J;^&WMVGFD"1H,EC7S)X?U^329A!,2]HQY'4H?
M45V<_BF:ZMTB>1GMD&8E!Z_6O#EA94YVG\/<[J6,]G&TSH/%?BMK]N24ME/[
MJ'/+GU/^>*X.>>2XE,DAR3T'843327$IDD.2>@[ >E1UQXC$<_N0TBCP\9C)
M5Y>04445R'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 =9IU]=7FC06NEW)BNK2)Q)9-]RY4Y
M)8#HS8['TXJ@ECH]MH]E?7SW4DMQY@^SPD*?E8C.2.![8/-%GK]O:"WN/[-0
MZA;1E(IUDVJ>" 60#D@'KGFIY;ZS7P]I4-]9BY5A,X:.3RY$8R'O@\>Q%7H=
MRE"4;MW:7G;I^/X#$\.QZA<V+:9-(UK=LX_>+\\1098$#KQTQUJW+X7CFAE6
MWL-5MI8D+++<H/+EP,XX^YGMR:S7\0O'<6GV&V2WM;7=L@+%]V[AMQ[Y'%,E
MU+2UAF^R:/Y<TJE=\LYD6//7:N!S]<XH]T2E0L_^#VZ:=[]AZV.F:?:V\FJ&
MYFFN8_-6&W(78A. 68@Y)P>,?C6AX972X?%*"*2>YB:)C&P_=LAVG(8$'/'I
M69'J]I/9P6^IV#7+6Z[(I8YO+<+G.T\'(Y-$.M1V^M)?P6,44<:&-($8],$9
M)[GGK232:%"=.,HR5K*W1W\RR]AHT>A1:@5O6EN99(H8!(O&,8+''/7T_*DF
ML-#T^<6%]+>-=# EGB V1,1TVGEL=^16;-J!ETFTL?+V_9W=PX/7=C^6*T'U
MO3[J5+J^TGS[Q0 SK.424CH67'7UP1FBZ%STWV6W3[RPN@V%C::A-JLTY:TN
M%B5(,?O0PR.HX]<_I3;C3]!M+>UOI)+V2WO%)CMT*B2/!P2S8P>>F!S[50N=
M;FO+*[AG0-)<W"SM(#C&!C 'I5:ZO?M-G96_E[?LL;)NSG=EBW]:+H)5*25H
MI?\ !O\ Y&U!X6,FIWT>9Y[6T5'Q!'F20/RH [''4]J;J6@1VUC_ &@MG?VL
M,<BK+!=8#$'NK8Y_+BJ[>(!+>7#SV:RVMQ%''+!O(SL  8-V/'ZU5O;ZRDM!
M;6.G"W7=N>223S)&/89P,#GIBA\HW*ARNR[_ / Z?J=-J-CI&I:LJN;JWCAT
MQ9F?>'X" J,8'XUS]S86ES81W>EI.,W'D/%*X9@2/D.0!UY%*^O%YYI?LX'F
M60M,;NGR@;OTZ59\,7C:='J-ZPC:&*$81_XI<_)CW!YIW393G3JSMWOJ9NL6
MD%AJ+6D#,YA4+*S$',F/FQ[9X_"J%*[M([.[%F8DL3W-)4'%)IR;04444""B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .ST7_CRM_]W^IK
MLM-[5QNB_P#'E;_[O]379:;VKMC\*/N,/_!AZ+\CIK7H*OKTJA:]!5]>E4;#
MZ*** $-5+[_CRN/^N3_^@FK9JI??\>5Q_P!<G_\ 0336XGL?)1ZT4'K17UA\
MR%%%7M'TB\UW5(=.L(P]Q+G:&. ,#))-)M)78TFW9%&G([Q2+)&[(ZG*LIP0
M?4&K>K:5=Z)JD^G7T82YA(# '(Y&00:?H,,=QXATV&9 \<ES&K(W1@6'!I<R
MY>;H/E?-RD<VL:G<;/.U.\EV-N3?<.VT^HR>#45O>W5G*9;6ZG@D/5XI"I/X
M@UV&OVFMPPWZOX;TN"S0L/.CA0.J9X(.[.<>U87BVV@L]>EAMHEBC$,+!5'&
M3&I/ZDUG"<9:)&DX2CK<CN=9-WX>BL)C-)<K=M<--(^[<"N,9/.:ISZE?W4"
MP7%]<S0K]V.29F4?0$XKKX;+3X_%5[;16MHUV;.(V$-Q_J6E**2#[G)QGC-<
MWJR&[UL00:7]AN6*Q/:KD#S>AP#T!/:E"46[)>83C)*[?D9IFE;R]TKGRQA,
ML?E'MZ59EU;4IP!-J-Y(%! #SLV 1@]3Z5O>)-)TVWT^,Z6=TNG,+74&!SOD
M(R''MG*_A7*U<'&:O8B2E!VN%7&U?4WM_L[ZC>-#C'EF=BN/IG%4Z*MI/<E-
MK8=YDGE>5O;RRV[9GY<^N/6GI<SQA0D\JA<[0KD8SUQ]>]1446%<EM[B>TE$
MMM/+#*.CQ.58?B*=+>W<]R+F:ZGDG7!$KR$N,=.2<U!119;CN]AZSRHSLLKJ
MS@AR&(+ ]0?6D$CB(Q!V$;$$IG@D=#BFT4"N6TU34([;[,E_=+!_SR69@GY9
MQ4)N)V:5C-(6E_UA+G+]^?7\:BHHLAW99M=0O;$,+2\N;<-]X0RLF?K@U-IM
M_%:7QGN[<W2N"&_>%)%)_B5AT850HI.*8*31T^H^)+-K">WL?[3GEN8_*DGU
M&X\PHF02J $@9P,FN;DEDF??+([O@#<S$GCIS3**48*.PY3<MRXVKZFZ(CZE
M>,B?=4SN0OTYXJ[-K\PTS2[>REN;:>SCD1Y8Y"N_<Y;C!SWK&HH<(OH"G)=2
M8W=RUP;AKF8SGK*9#N/X]:8DLD6[RY'3<I5MK$9!Z@^U,HJK(F[-*XU*-M!M
M-,MXW0)(TUPQ/^L<\+^ '\ZH1RR1%C'(Z%E*MM8C(/4'VIE%)12&Y-CEED2-
MXUD=4?&]0Q ;'3([THFE6,1B5PBMO"AC@-ZX]?>F44Q7)[F]N[UE:[NI[AE&
M%,TA<@>V35JSU&*#1M1T^:-G%SY;QLN/D=3U/M@L/QK.HI.*:L-2:=RY_:^I
MBV^S?VE>?9]NWRO/?9M],9QBH[6_O+$L;2\N+<MU\F5DS^1JO11RKL',^Y)/
M<37,IEN)I)I#U>1BQ/XFFK)(L;QJ[!'QN4'AL=,CO3:*=A7'^;(8A$9'\H-N
M";CM!]<>M.2ZN(GB>.XE1H?]65<@I_N^GX5%118+LUM(UIK+7X=6OFGNY8<N
MA=]S%P#MR3V!Q64S%W9F.2QR:2BDHI.XW)M6"BBBF(**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#32*?4MM;274PCC&3W/
MI2DTE=CBFW9$4%J]Q*$C&3W/I706MK]GC$8R?<U>LM.2VB"(,GNWK5^.RW=J
M\'%U_;^ZOA/6A@H.FXU-6S&((.#UHK;GTHRQY08<=/>L9T:-RC@JP."#7C3@
MX,^<Q>$GAIV>W1C:***@Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BNCU;7]-OO#5CIMMI2P7,&-
M\_'/'/N<^]<Y3:L74C&+M%W-"XT>ZM](M=4(#6UP64,O\)!Q@U%-8/#IEM?%
MU*7#.H4=1M]:W_[2.G:/HHDC$UI-#*EQ >CKYG;T(Z@UH+I^G1'P] \ZW&GR
M3S/&V0-P/*JWH<X!%5RG4L/&7P]E][M^&IPQ1E4,58*>A(X-&U@0"IR>@QUK
MO&N_M/VN&Z@UB>%8W+PSP1)''@'!!_AP>F*K:0C-HD,DJ1G5E1_[*#_>=>^1
MWQSMSWS2Y1?55>R?X?U\O/0YL:8?[!;4LR;EN!#LV<8VDYS^%5K.TGO[N.UM
MHS)-(<*HK>&HWP\"RPFXD"?;1&5/]TJQ(_.J/AQX_P"T98'E6%[FWD@CE8X"
MNPP.>WI^-%E=&;IP<H)=20:%9F?[-_;UE]HZ8VOLW>F_&*RKJTFLKN2UG7;-
M&VU@"#S[$=:TK/1YH=2-MJ&E7\G\(C@7!W=N<8Q6_9V6F:?JNJK9?:)9K:%/
M+$8221&/^L*YX)' HM<T5#VBVY=?/]3B61D;:RLK>A&#2['"EBC8!P3CH:Z_
M4IUN]*22>+4I7%RBQ7%Y&B%3GE1CD@C\JL76N7A\=OIV4%B]T+=[81C8RD[2
M2,=><Y]:.43PT4]9=NG>YPZJSMM52Q] ,T8.2,'(Z\=*[336@L/#ZRVWVY9F
MN9$GELHT=UP?E4YY QSQUJQ'<)%JB7@M)Q=+IT\C/>1H#+@':2@_KUXHY1K"
MJRO+M^)PGEN'";&W'HN.:0HX)&QL@XQCOZ5U-G>ZC)H-UJ5H6FU-KA4GF"!I
M(X]O&!C@$]2*74;O5O\ A$[:\O4:.Y6^S%,R!9& 0\GCMVI6)]A&U[O:^QF7
M.DVECJ%Q;75S.BI )(F$.2[E0=I]!SUK(5'?.U&;'7 SBNWN[NXN_$M^MQ*T
MHCTQM@;^',:D_K5&:XU33]/TT:(LBVDD"LTD$6XR2_Q!C@\@\8IM(NI0A=M;
M*_37?U.6 )!(!('6AE9#AE*GK@C%=R)?[/FU:Z6"%+T:;&\\6P%8YBRYXZ \
MYQV-8D^H7.K>&;F2^?SIK:YC\N5E&X!PV5R.WRBAQ,YX=1TOKKT[%6QT9;JS
M6[N+Z"SBDE\F(R G>P&3TZ 9')]:SI87BN'@X9T8J=G()'IZUO:&EVMK%'+9
M&]TN]E\MXT&YHV&!N&/NMSQZUIZ9;VNE6NK>0]S)<07GD^=:1J\BQC." >@)
M')%'+<J-!34;:=_S_K\3BR"I(8$$=012['VAMC;3P#C@UV=S]AOKC2&U&&]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRN/^N3_^@FK9JI??\>5Q_P!<G_\ 0336XGL?)1ZT4'K17UA\R%%%%( HHHH
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MJ%74X(-<-2FX,^4QF#GAIV>J>S&4445!QA1110 4444 %%%% !1110 4444
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M^11_PA%M_P _,W_?(KT;^S?]FC^S?]FCZY7_ )@^JT?Y3SG_ (0BV_Y^9O\
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MFC^S?]FCZY7_ )@^JT?Y3SG_ (0BV_Y^9O\ OD4?\(1;?\_,W_?(KT;^S?\
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M?]\BC_A'8_\ GK)_WR*[?^S?]FC^S?\ 9H]G'L']G87^1'$?\(['_P ]9/\
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MW_9H_LW_ &:/9Q[!_9V%_D1Q'_".Q_\ /63_ +Y%'_".Q_\ /63_ +Y%=O\
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M-@H ROL0]*/L0]*U=@HV"@#*^Q#TH^Q#TK5V"C8* ,K[$/2C[$/2M78*-@H
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MF1TB6P'8582("LG4+V[B\5Z9IL,JI#=6UP[Y4'YEV[3^&37/,GBY?%L>A_\
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MHHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:1F
MQ0 R1N/>H=M2'FDQ3$,Q1BGXHQ3 9BC%/Q1B@!F*,4_%&* .<UGQ=::-JT>F
M-8W]W=/!]HV6D)DPF<9/XBI-&\5:;K=Y+90K<V][$@D>VNX3$^WU /4?2L'5
M[R_LOBO%)I^F-J$IT7#1K,L>T>;UR:OV&FZWJGB^+7]7LH-.BM+5X+>W242R
M.7ZEV'  QP*NRL1=W-W2-5MM;L!>VF_RC(\?SC!RK%3^HJ]BN7^'0_XI)?\
MK[N?_1K4?$+Q /#_ (6E,<Z0W=XPM;=VZ*6X+?\  1DTN7WN5#YO=NS8TC6K
M#7;>>?3YQ+'!.\#GT=>#^%8^L^.;/0[QK>ZTO56 D$2S1VQ,;L>@4]\UROA?
M4O#WASQA9:9HNJ6]S8:G;+#($<Y2Y0<.<_WQG\174?$'/]F:3_V%[7_T(U7*
ME*W0GF;C<EN?&=I9Z3;W]QINIQ_:+C[/';M;GS6?!/W?3BK6C>)$UF[:W72M
M3M"J%]]W;E%//0'UYK+^(;W<3>'I+*!)[I=50QQ2/L5CM;@GM4\^K>*8M(U:
MYU'1[6S6WL998GANO-8R*N0,8I630[NX_4?&EG:ZA-IVGV%]J]]"<316,>X1
MGT9CP#[5+H_BZQU6_P#[.FM[O3=2V[A:7L>QF'JIZ-^%+X$L8++P3I7D ;KB
MW2XF?O)(XW,Q/<Y-4OB3;Q#PE)J6\17FG2I<6LW\2N&'R@_[73%%HWY0N[<Q
M>UOQ7::'J,%@]E?7=S-$952TA\PA0<$G\Z=H_BO3=:OI+"-+JUOHT\PVUW"8
MG*^HSU'TKF?%.N76B>-K#58M+FOBFD2O+!$X5D7<I)YZX]*OZ-;:GXF\4:=X
MKN[:WL[&WLW2T2.<2O-YF,EB. !CI3Y5RW%S.]CJ8=0M9]1N=/CE!NK94>6/
MN%89!^E2W5Q#96DUU<.(X(4,DCG^%0,DUYDUS<6'B_5_&0=C:V^HC3;M >#;
M!0H;_@+G/TKI/&).O7-CX1M)2!J"F>\E0_<ME_\ BFP/SI.&J'S:'4VMQ%>6
MD-S VZ*9 Z-Z@]*EQ7/> ;@W/@;2L_>AB,!^J$K_ $KI,5#5G8I.ZN,Q1BGX
MHQ0,9BC%/Q1B@!F*D4]C28HQ2 E&<>M.J-&[5)2&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 $TP\T_%&*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@
M48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@48%%
M% !@48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img34454307_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34454307_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "W M # 2(  A$! Q$!_\0
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MDUIZ5X5TC49/#CQV\1G2TBGO[=AQ-&ZD;_<AAS]10ZT%JT-4Y/J>=?VGJ/\
MT$;S_P "'_QH_M/4?^@C>?\ @0_^-=!?-:#P);3II5BES+=R6K7"QG?M0 @Y
MS]X]ZY6M8M2Z$.ZZEK^T]1_Z"-Y_X$/_ (T?VGJ/_01O/_ A_P#&JM%59$W9
M:_M/4?\ H(WG_@0_^-']IZC_ -!&\_\  A_\:JT46079:_M/4?\ H(WG_@0_
M^-']IZC_ -!&\_\  A_\:JT46079:_M/4?\ H(WG_@0_^-.34]1WK_Q,+SJ/
M^7A_\:ITJ?ZQ?]X460I-V9UYU"]R?],N?^_K?XT?VA>_\_ES_P!_6_QJN>II
M*SY5V/AO:3[LL_VA>_\ /Y<_]_6_QH_M"]_Y_+G_ +^M_C5:BCE78/:3[LL_
MVA>_\_ES_P!_6_QH_M"]_P"?RY_[^M_C5:NKTO0(=2\+JJ(O]HSS%X6[F-2J
ML/I\Q/X5$W&"NSHP].M7DXP>J5SG?[0O?^?RY_[^M_C1_:%[_P _ES_W];_&
MNLO-%TLZWYMM#YMG'8M.D"$CSG1BI'YC)Q5&VCL]9T^6Z;3H+22UGB ,((24
M,V"A!/7O4*I%J]CHE@ZT9.+GKK;?6VMS!_M"]_Y_+G_OZW^-']H7O_/Y<_\
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ME_[_ #?XT?\ "!Z!_P ^TO\ W^;_ !KS/;1/TGV;/)J*]9_X0/0/^?:7_O\
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M>@?\^TO_ '^;_&CVL.P<DCR:BO6?^$#T#_GVE_[_ #?XT?\ "!Z!_P ^TO\
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M1110 4UW6-2SL%4=23@"G52UBUCO=&O+>6%9T>%OW;+N#'&1Q]<4UJP98%S
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M*0PK+TS6X]3OKRV2WFC-JVTNX&"<D?@>.A[5J5S^G>%ETW4ENX[^=P"<QL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M='-I=K=+I2_:'_T"17CP/OD*1@US&KR:1;-JT%OJ]TC3L_FZ7$G,LQ&/EXR
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MBKYXR@H7M_P[_P RSEH^=(\6M'_Q['Q /+QTSN3=C\:[32G8^+O$2EF*J+?
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MMC1_MWV'_B8($F$CX4  *F?E''' Q5SJQDK)6,Z5&4)7<KE^BBBL3H"BBB@
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M!DWNOP6=XUJL,DTJ+O<)C@>V>IQS@5!>>*K*R$KR)*8UL&OHW &)54X91_M
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: '14@    P!110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img34454307_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34454307_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '^!*@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **JSZGI]K+Y5Q?6T,F,[))54_D35H$$9!R#0-IK5A
M1134=9$#HP96&0RG(- AU%%% !1110 4444 %%%% !1110 4444 %%9FH>(=
M(TJX6"^U"""5AD([<@>I]![FM%'61%=&#(PRK*<@CU%*Z*<)))M:,=1113)"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHKDO&WC;_A#OL/_$O^U_:O,_Y;>7MV[?\ 9.<[OTI-I*[+
MITY59*$%=LZVBO)?^%V'_H7_ /R<_P#L*/\ A=A_Z%__ ,G/_L*GVL.YU_V;
MBOY/Q7^9ZU17DO\ PNP_]"__ .3G_P!A1_PNP_\ 0O\ _DY_]A1[6'</[-Q7
M\GXK_,]:HKR7_A=A_P"A?_\ )S_["C_A=A_Z%_\ \G/_ +"CVL.X?V;BOY/Q
M7^9ZU17DO_"[#_T+_P#Y.?\ V%'_  NP_P#0O_\ DY_]A1[6'</[-Q7\GXK_
M #/6J*\E_P"%V'_H7_\ R<_^PH_X78?^A?\ _)S_ .PH]K#N']FXK^3\5_F>
MM45Y+_PNP_\ 0O\ _DY_]A1_PNP_]"__ .3G_P!A1[6'</[-Q7\GXK_,]:HK
MR7_A=A_Z%_\ \G/_ +"C_A=A_P"A?_\ )S_["CVL.X?V;BOY/Q7^9ZU17DO_
M  NP_P#0O_\ DY_]A1_PNP_]"_\ ^3G_ -A1[6'</[-Q7\GXK_,]:HKR7_A=
MA_Z%_P#\G/\ ["C_ (78?^A?_P#)S_["CVL.X?V;BOY/Q7^9ZU17DO\ PNP_
M]"__ .3G_P!A1_PNP_\ 0O\ _DY_]A1[6'</[-Q7\GXK_,]:HKR7_A=A_P"A
M?_\ )S_["C_A=A_Z%_\ \G/_ +"CVL.X?V;BOY/Q7^9ZU17DO_"[#_T+_P#Y
M.?\ V%'_  NP_P#0O_\ DY_]A1[6'</[-Q7\GXK_ #/6J*\E_P"%V'_H7_\
MR<_^PH_X78?^A?\ _)S_ .PH]K#N']FXK^3\5_F>M45YEI'Q>74]6M;%]%\E
M9Y AD^U;MN>^-@S^=>E12K*@93D&J4D]4<]:A4HOEJ*S'T444S$**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJIJ$E
M_';;M.@@FGW#Y9Y2BX]<@&LO[5XK_P"@5I?_ (&O_P#&Z3=C2--R5TU]Z.3G
MO]/OI_$EQ_9%U>?;!MLYQ8-("1%LX;''S UVOAF\BO?#MD\6\&.(0NKJ5970
M;6!!]"#7#Z!XMO-,T>*Q,.G;H'D1A)-*&!WMG.(R/UKJO \[77AYKIU4&>[N
M),(21S*W3(!Q^%94W=G?C*;C3=U9)I+7RM^ALZI?0:9IEQ>7+A(HD+$GOZ >
MYZ5CZ3)<Z#X.TI9;"ZN)$A198[=0SQY&<[<\XZ<<U2M)+?6_%-TFL7"K-8SE
M;/37^48'2;!^^3V["NPJU[SN<LTJ45!J]]7^GYF=IFJ2:D\I_LV]M8D VO=(
M$+GOA<YX]P*T:**I&$FF]%8****9(4444 %%%% !1110 5B:SK,T%PFEZ6BS
MZK.N55ON0)_ST?T'H.I-&M:S+;SQZ9ID:SZK.N40_=A7O(_H!Z=SQ4445AX0
MTJ:[NYGFN9F!FG89EN93T4#] HZ5+?0Z*=.UI25V]EW_ .!^8BP:;X3T>:>\
M=KB:=OW\KKNENI#T4#OGH%Z 59\+65QIWARTMKI/+E4,WE9SY8+$A,^P('X5
M6TK2[J]OEUO6E NL'[+:YRMHI_FY[G\!70THKJ%6>G+>[>K?Z+^O0****LYP
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\E^-G70_\ MO\ ^TZ]:KR7XV==#_[;_P#M.HJ_ SNRW_>H
M?/\ )GDU%%%<!]<%%%% !1110 4444 %%>CZ!X>N-?\ A;<0:?:Q2WO]H9#,
M54[0%S\QK0N]$NM$T7P;:306\&I#4=KLR"09+'&<'YA@CC-:^R?Y?B<,L=!-
MQZW:M?LF[GE%%>A7_A276_%&OW^J:E;6-E9S 3W2PD*6(& J9^G<]>^:S-7\
M%VEAX;;7;'7(K^U\\1($A*DY]<G@CTQ4<CM<UCBZ3:5]7;ON^E['(45[#XH\
M(Z=KOB&RCEUN"QNI[-$M[80EBY&3D\@ ?SQ7DU_9RZ=J%S938\VWD:)\=,@X
MXHG%Q=F/#XJ%>-UO:]OZW*]%>^QZ>7M])2;2=*?0FL%:\N)T4.C;.QS].<?C
M7 RVD]U\/X[:RGMC8RZR8( T.'Y)VL7STZ?PY]ZN5)Q=OZWL<]+,(U.EM>_K
M^.FQP%%=MK7@^R\.7=H$UN*YNTN8TEM6A,;<G.5Y.5]^G\JVO%OA(ZIXMUG4
M;FY33M*M8X]UPT>X,VQ?E5<C)_Q%2X.US7Z[3NNS5^O=+;?J>7T4YPH=@A++
MG@D8)'TIM0=84444 %%%% !1110!H:&2-=LB/^>R_P Z^D=$).GH3Z5\VZ)_
MR'++_KLO\Z^DM#_Y!Z?2NRA\)\WG7\:/H:5%%%;'CA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$:#X<M;Y=3
M>2[U&-DU*Y3;!>21J!O)'R@X[UK>!T">#=.P2=RL^2<DY=CU_&FZ#)Y \1]O
M+U"5_P T5JL>#X_+\':0O_3JA_,9K.*2:.ZO.4HR3?5?DRQKNDVVKZ7/%-:Q
MSRB-C"2/F5\<%3U!SBJ&@^(K>6VL=.O6N;?4_)57CNX6C,CA1NP2,-SD\&F-
M+J6OZI>06=Z]AIUG)Y#RQ*IEFD !8 L"%49 Z9)S7/6^EWWB>YLI;6_UE=,B
ME\[[7=R1@N5R 8U"YZ]SCCM2;UNATZ2=-QJ/1:^EU^O9'HU%<\VE:_9C?8:[
M]JQ_RPU"%2&_X&@!'ZU9TK71>W+V%Y;/9:E$NY[=SD,O]Y&_B7^7>KYNYRNE
MI>+NC8JAJ>I-8_9XH(#<7=R^R&+=M!P,DLV#@ #K@_2K]9^IZ<]Z;>>WG$%W
M;.7BD9-Z\C!5ER,@@^H[51D9MUXEGTZ&Y6]TW;>0^6RPPS[UE5W" JQ4<@GD
M$#MZYK=MFN'MU:ZBCBF/WDCD+J/Q(&?RK$E\/7%\99[^]C>Z<Q!3%"52-$D#
M[0"Q))(Y)/IQQ704]+"ZA1112&%<[XG\2_V/ UO90M<ZBT9<1HI81(.LC@<[
M1^M3>)M?_L6WMHH?+-[>RB"W\UMJ*Q_B8^@_7I6&HG\#74E[?R/J-KJ#*)[@
M(/.6;'  '5#T 'W:B4NB.NA1O:4E?LN_]?CL:=@^E>'=!;57O/M;W6))+L?,
M]TYZ!0/R"CI^=2:7I=U?7RZWK2 7(!^RVF<K:J?YN>Y[=!5/PYX9"7;ZO?6_
MD.\C2VU@&)CM-W4@=-Y[XX&>*ZVB*ON*M446U%W;W?Z+^O33<HHHJSE"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBF3316\+S32+'%&I9W<X"@=230 ^J]W?V>GQ>;>W<%M'_?FD"#\S7GE
M[XVUOQ5>R:9X*M"(E.V74IAA5]QG@?CDGL!5BR^%-K/-]K\2:G=ZM='[P:0J
MOTSG<?S'TJN6VXK]AWB'XJZ7I&H6<=BT.I6[A_M)@?YH\8VD'H?XN/;J*X_X
MF>)M*\36NBSZ9<>9L\[S(V&UXR?+QD?@?;BNZO\ X5^&[RXLS';FUMX V^*$
MG,Q.,;F))P,'\^HKD/BUI-AH]KH5KIUI%;0CS_EC7&?]7R3U)]S45N7D=CNR
MR_UN'S_)GF5%%%><?7A1110 4444 %%%% '70:Y8Q?#*?2!<E=0:^$JQ!6^Y
M@<[L8[>M:%OXETM= \(VTEX?/L+_ ,ZZ!C<[$WDYSCGCTS7 U>TO1M0UJ:2'
M3[9IWC0N^" %7U)) K13E?3R_#_ACEGAJ5FY.RNW]ZM^IZ5;7]EXC/B>TDAO
M)=%NKD3I?6L+,8V '5<;L<#MZU!X@L-.T?X6&VL7NFCEOU82741C:5L<D*<$
M# Q^%>?Z;K&J:#<M+I]W+;2,,,4.0P^G0T:MK^JZ[(CZG?2W)3[H8X"_0#@4
M.:Y;+?3\#%8.:J)I^ZG?\+?UK\CL=5\3:1<_$71=5AN]UE;11+++Y;C:5SG@
MC)Z]A7'^(;J&^\1ZE=VS[X)KF22-L$94L2#@\U7NM.O+&*WENK:6&.X3S(6=
M<!U]0:T+3PCX@O[2.[M=*N)8)!E)%7AA2DY2Z=7^)M3ITJ*4N;I;5KH=X?'&
MB27-EI]Q=&72+C2EM;S]T_[J0 X(&,GTR,]?:N>?5-&3P-%H?]HL\B:KYI:.
M%LF'D;QD 9]LYK!L?"VN:G9O=V6F7$\"$J71>I'4 =3^%*/"NO?9YKA])NX8
M85+R23QF)5 Z\MBJ<Y/5K^KW,HX>A#13V:ZK?;[]?R.WU_Q!H+>'[>S_ +:?
M6)TNHY+::6W*R6\8(R&;'S< ^YS4FO>,]"\27NH:/J%VPTE]LMG?1Q/F&0*,
M@KC)&<]O\1YW_8NH_P!C?VN+8FPW[#,K @-Z$ Y'X^U4*3F]F$,%2W4FVK]M
M']P^9%CF=$E65%8@2*" P]1D _F*91169WA1110 4444 %%%% %_1/\ D.67
M_79?YU]):'_R#T^E?,^GV_VK4+> 2-'YCA=Z]5]Z]7T[X92W-JL@\3ZE'D=%
M)Q_.NW#I<NK/FLZ;]M'T/4Z*\X_X55+_ -#7JGYG_P"*H_X55+_T->J?F?\
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M4O\ T->J?F?_ (JBR[A=GH]%><?\*JE_Z&O5/S/_ ,51_P *JE_Z&O5/S/\
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M;MN/.!3XY8_^%C3(P\Y_[.0(R\^1AV+!O[N[(/OBNEJ8Q3=S:K6G&*BNJO\
M\!=ET\PHHHK0XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\MUNZNOB+XJ/AW3II(M$L6S?3I_RT8'H
M/7D8'OD\X%=AXYUI]!\(7]["<3[1%$?1F.,_ADG\*K?#O0ET/P?:*1_I%THN
M9CWRP! _ 8'US5+17$]=#?TO2[/1M/BL;"!8;>,855[^Y/<^]7***D85Y+\;
M.NA_]M__ &G7K5>2_&SKH?\ VW_]IU%7X&=V6_[U#Y_DSR:BBBN ^N"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .=\3NMI=Z)J,W%M;7F)G[('1D#'T&2/SK?DFBBA
M::21$B5=S.QP /7-$L4<\+Q31K)&XVLC#(8>A%8:^"]#5E!MI6A4Y6W>XD:(
M'_<+;?PQBILT]#=2A**4[JW]=P\(9DTJYO-I$=Y>SW,61@E&<[3^(Y_&M74M
M0ATK3;B^N"?*@0NV.I] /<GBK*J%4*H  & !VJ"]LK?4+4VUU'YD3,K%<D9*
MD,.GN!32:5D3*<9U.:6U_P ##@TO6-8C%SJNI7%BK_,ME8L$\L=@TF-Q/KC
MK5TO1K/2%E^RK(9)B&EEED:220CIEF))J_10HI!*M*2MLNR"BBBF9!6;KFM6
M^@Z6][<@L 0B(O5W/09Z#ZFM*F2PQ7$3131I)&PPR.N01[@TGMH5!Q4DY*Z.
M<TV""S9M>UZ^M?MTJ<,TH$=LG]Q"3^9[TDNN7NM_N- 0Q6[</J=PF$ _Z9J>
M7/OT^M:$/A;0+>;SHM&L4DSD,(%X_2K>H:3I^JQ)%?V<-S&ARBRH"%/M4\KM
M8Z'5IN7,]?R7R_X)'I.DVFC6ACM]S,YWS3R-N>5N[,W<U?#!AD$'Z5 UA:-8
M?8&MXS:>7Y?D[?EVXQC'I3-/TNQTJ%H;"TBMHV;<5B7:"?6J6FAA)J5Y-ZEH
M,I. P)],T%E!P6 /IFJ%KH>EV5])>VMA;PW4F=\J( S9.3S]:+O0]+OKV.\N
MK"WFN8\;)70%EP<CGZT:A:%]W;T_X)?+!1DD >]*"",@Y%5-0TRQU6!8+^TB
MN8E;<$E7< ?7]:FMK:&SMH[>VB2*&,;41!@*/04"]VWF2T444R0HHHH ****
M "BBB@ HHHH **** "BF231PKNED1%]68 5!_:5A_P _MM_W]7_&BP%JBJO]
MI6'_ #^VW_?U?\:/[2L/^?VV_P"_J_XT[,+EJBJO]I6'_/[;?]_5_P :<E]:
M2L%CNH'8]ED!-%F%RQ1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY4G_ #S?_ODT>5)_SS?_ +Y-?2?_  C%I_=H_P"$8M/[M'U==P_MN7\GX_\
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M-GE2?\\W_P"^31Y4G_/-_P#ODU])_P#",6G]VC_A&+3^[1]77</[;E_)^/\
MP#YL\J3_ )YO_P!\FCRI/^>;_P#?)KZ3_P"$8M/[M'_",6G]VCZNNX?VW+^3
M\?\ @'S9Y4G_ #S?_ODT>5)_SS?_ +Y-?2?_  C%I_=H_P"$8M/[M'U==P_M
MN7\GX_\  /GO1(I!K=D2C >:O;WKZ/T08T]/I55?#5HK [:U[>!;>((O05K"
M'(K'GXS%O$S4FK6):***LXPHHHH **** "BBB@ HHHH **** "BBB@ KSC4O
M^2[Z1_UX-_Z#+7H]><:E_P EWTC_ *\&_P#09:J/43/1Z***D84444 %%%%
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M^[)V..*ZWP--=>)+VX\4WT9CW1+:6T9/"A?]8P^K9_*FX"YCN:***@H****
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M^!QZ5HT44 %%%% !116#+J-_JEY+:Z04BAA;;+>.-PW>BCN::5Q-V-ZBL/\
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MO1IG+X_ \5KT4^9[7%9!1112&%%%% !1110!AZ5_R,NN_6#_ - -;E8>E?\
M(RZ[]8/_ $ UN54MQ1V"BBBI&%87AX>1<ZK9I_JH;DE!_=##.*W:P]$_Y#&M
M_P#7=?\ T&J6S$]T;E%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %#7/^0#?_P#7N_\ (T_2/^0+8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *&N?\@&__P"O=_Y&GZ1_R!;#_KWC_P#013-<_P"0#?\
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M!KBC\+=. :"'6-8AL&.6LTN?W?TQCI]:['[?'_SQN?\ OP_^%'V^/_GC<_\
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M -?>+F?8["BN/_L6[_Z J?\ @Q>C^Q;O_H"I_P"#%Z.5=_Z^\.9]CL**X_\
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M_P#?8HYX]PY)=B>BH5O+9V"K<1%CT <<U-UIII["::W"BBBF(**** "BBB@
MHHHH **** "BBB@ HHHH *HR:-ITNL1:L]JAOXD\M)^=RKSQ^I_.KU% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[R]BLHU:3<S.<)&
M@RSGT JQ6;9K]JU2[NWY\E_L\0/\( !8_B3^E9U)-6C'=FE.*=W+9"B35Y1O
M$%I"#T21V9OQ(&*6+49$N%M[Z#R)7.(W4[HY#Z ]C[&M"H+RU2\M7@DZ,.".
MJGL1[@U+A.*O&5WY]2E.#=I*R\B>BJ>EW#W6F032?ZPKACZD'!_E5RM(24HJ
M2ZF<HN,G%] HHHJB0HHHH **** "BBB@"AKG_(!O_P#KW?\ D:?I'_(%L/\
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M^=7&01Z58JEIUOLTRV25065 >1TK#\4^(];T6[@BTOP[/JD<D99Y(]V$.>G
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M:U"BBBD!C:CX6T?5M7AU/4+1;F>"/RXUDY0#).=O0GGOFLGQLJH-/50 H#@
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M11RQS)OBD5UR1E3D9!P1^=/JMI]E'IVGP6<62D*!<GJQ[D^Y/-6:3&@HHHH
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MHK=_X1B[H_X1B[H_LG$]E]X?VIA^[^XPJOZAJ;:E'!YL2B:)=AE!Y<>]7O\
MA&+NC_A&+NJ668M1<5:S\R'F.&;4G>Z,,LQ !)('3)Z4E;O_  C%W1_PC%W4
M_P!DXGR^\O\ M/#^?W&&&(! ) /49ZT!BIRI(/J*W/\ A&+NC_A&+NC^R<3Y
M?>+^T\/Y_<8BNR.'5BK Y# X(-(S,[%F)+$Y))Y-;G_",7='_",7=']E8GR^
M\/[3P_G]QE6MR+>[CGDC$VPY"L>">U%]>27]Y)<R_><YP.@'85J_\(Q=T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH \X^+O_'EH?\ U_C^5>CUYQ\7?^/+0_\ K_'\J]'JGLA+<****D84444
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M6R1QZ5-8>%M:$VDWD]F(Y&UB:_N8UE4^0CC !.>3QVS565_Z[_Y"N[??^O\
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MZ+%9W^G1V4MJ/* A93'(HZ,N#D ^AP:V:F22>@U>VH4444AA1110!YQ\7?\
MCRT/_K_'\J]'KSCXN_\ 'EH?_7^/Y5Z/5/9"6X4445(PHHHH **** "BBB@
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M7C.,9[UNU@IHERGAC3],WP^=;O SMD[3LD5CCC/0'M6]4NW084444AA1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7\4FG&SLKE+V.&*,W*2)Y6T$;TD4G) &2" 3D\&NHHHH;N)*P4444AA1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '"_%JP:[\$O<(#OLYTF!'7'W3_Z%G\*ZK0]135]!L=01@PN(%<X
M[-CD?@<C\*M7=K#?6<UI<('AF0QNI[J1@UYOX%U";PGKMSX*U8E09#)83-]U
MP>P^O4>^1UJMT+9GIU%%%2,*XCXC_P#'E:?5_P":UV]<1\1_^/*T^K?S6A S
MS:BBB@ HHHH ***U_#5G9:AK4=G?;O+F!52K8PW:@-C(HKH=$T!+G7[FTO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^MQE?OX^7TZ?C3<;*]Q7.;HHHJ"@HHHH *DMYGMKB.>,X>-@ZGW!S4=%"T
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M7_H#Z7_WVO\ \<H_M#XJ_P#0'TO_ +[7_P".4<OF%ST>BO./[0^*O_0'TO\
M[[7_ ..4?VA\5?\ H#Z7_P!]K_\ '*.7S"YZ/17G']H?%7_H#Z7_ -]K_P#'
M*/[0^*O_ $!]+_[[7_XY1R^87/1Z*\X_M#XJ_P#0'TO_ +[7_P".4?VA\5?^
M@/I?_?:__'*.7S"YZ/17G']H?%7_ * ^E_\ ?:__ !RC^T/BK_T!]+_[[7_X
MY1R^87/1Z*\X_M#XJ_\ 0'TO_OM?_CE']H?%7_H#Z7_WVO\ \<HY?,+GH]%>
M<?VA\5?^@/I?_?:__'*/[0^*O_0'TO\ [[7_ ..4<OF%ST>BO./[0^*O_0'T
MO_OM?_CE']H?%7_H#Z7_ -]K_P#'*.7S"YZ/17G']H?%7_H#Z7_WVO\ \<H_
MM#XJ_P#0'TO_ +[7_P".4<OF%ST>BO./[0^*O_0'TO\ [[7_ ..4?VA\5?\
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MS8,6A(D7'/K^\YP>1Z&M7^T/BK_T!]+_ .^U_P#CE4U=(2/1Z*\X_M#XJ_\
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M33_.O;R%KN[VPLH7$O/([UL6UL+6+RQ))(,YS(V30T!-1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 )M&X-@;@, ]ZXGXC_\ 'E:?5OYK7;UQ'Q'_ ./*T^K?S6A
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M[ X\X#;@?2M2VDFEBW3P>2^?N[]WZU4_XG/_ $X_DW^-6[;[1Y7^E>5YF?\
MEGG&/QH8(FHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(^(_P#QY6GU;^:UV]9F
MLZ7#J<"B6(.R [<]!G';\!0!XE17H3>%)=QQ##C_ *YK_A2?\(K-_P \H?\
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MRA_[]K_A0!Y]17H/_"*S?\\H?^_:_P"%'_"*S?\ /*'_ +]K_A0!Y]17H/\
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MZ4 Y&1THJ"@P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img34454307_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34454307_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) M # 2(  A$! Q$!_\0
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M (5_X4_Z =K^1_QI?7H=F'U:7<^;*::^E?\ A7_A/_H!VOY'_&D_X5_X3_Z
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M 'O:K&=:_NV'_?3_ .%174.L75I-;M]@42HR$@OQD8]*$#)(TU9XU?[7:#<
M<>0W_P 54EI<W'VM[.[$9E""1'BR RYQT/0@_P ZN1KLB1"<[5 J@?\ D9!_
MUZ'_ -#%+<9HT445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+<I!1114C"BBB@ KGQ_Q46I;NNEVC\>D\H[^ZK^IJ+Q'K$*SII*W/D>;S<3
M$^6GH,?Q&K-OX@T&TMX[>"Z5(HU"JHC;@?E5J+2O8EM-V-RJFI7=M9:?+/=
M-$!@H1G>3T4#N35/_A)]&_Y_E_[X;_"J]FIU_4%U&4'^S[=C]D0C_6-WD/\
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M=#]:X/[1X:_Z!=__ -_?_KUK36A$]S4\K5O^AML_^_\ _P#6H\K5O^AML_\
MO_\ _6K+^T>&O^@7?_\ ?W_Z]'VCPU_T"[__ +^__7K2W]61-S4\K5O^AML_
M^_\ _P#6H\K5O^AML_\ O_\ _6K+^T>&O^@7?_\ ?W_Z]!N/#0'_ ""[_P#[
M^_\ UZ+?U9!<] TB82:?%&U[%=S1J%EDC<-EJ:?^1D'_ %Z'_P!#%&D:19:5
M"_V-'59L,P9BW:@_\C(/^O0_^ABN?2[L:]#1HHHJ1A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!EZCHL6H2!W8@^QJC_ ,(G;_\
M/1_^^C7144 <[_PB=O\ \]'_ .^C1_PB=O\ \]'_ .^C7144 <[_ ,(G;_\
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M:3<PZ5=S^1;WS.N&8G )3J 3T-2V'@J&SNK1I]3O+RTL239VLQ79%Q@<@9;
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M "BBB@ HHHH **** "BBB@ HHHH **** "D;[I^E+D#&3UZ4C?=/TH YM_\
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M.,#K3-.\>V5_J%O;FW,4-T_EP2F=&8MVW(#N7/;-7K?PK;06VCVYN9)$TSS
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M04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]-$_,_X4 ,HI^S_IHGYG_"C9_P!-$_,_X4 ,HI^S_IHGYG_"C9_TT3\S_A0
MRBG[/^FB?F?\*-G_ $T3\S_A0 RBG[/^FB?F?\*-G_31/S/^% #**?L_Z:)^
M9_PHV?\ 31/S/^% #**?L_Z:)^9_PHV?]-$_,_X4 ,HIQ3 SO0_0FFT %%%%
M &CI/^MD^@K6K)TG_6R?05K5F]RD%%%%(84444 %%%% !1110 4444 %%%%
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MZBBBI&%%%% &CI/^MD^@K6K)TG_6R?05K5F]RD%%%%(84444 %%%% !1110
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M44459UA1110 4C?=/TI:1ONGZ4 <V_\ K&_WC3:<_P#K&_WC3:U6Q(5S6I^
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M@_XUUM%%V%CDOL>L_P!V'_O@_P"-'V/6?[L/_?!_QKK:*+L+')?8]9_NP_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img34454307_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34454307_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $C M # 2(  A$! Q$!_\0
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M <<'/3!'/KFJD_@S7;:"::2VB*11><=DZ,7C R64 Y8#/44E3P[[!SU3I/\
MA;^K_P#0,L?^^G_QH_X6_J__ $#+'_OI_P#&N4F\+:Q!IYO9+91&L8E=!*ID
M1#T9DSN ]\5:E\$:W;.GVF&!(_-CCD87"'RPYP"W/ /J:?LL/Y!SU3H?^%OZ
MO_T#+'_OI_\ &C_A;^K_ /0,L?\ OI_\:Y#Q'I T+7[K3EE\U(F&QRP)(([X
MZ'VK+JEAZ+5TA.K43LV>A_\ "W]7_P"@98_]]/\ XT?\+?U?_H&6/_?3_P"-
M>>44_JU+^47MI]ST/_A;^K_] RQ_[Z?_ !H_X6_J_P#T#+'_ +Z?_&O/**/J
MU+^4/;3[GH8^+^KD@?V98_\ ?3_XUL?\+(U'_GQM?S;_ !KR4?>'UKIJEX:E
M_*>/FN.Q%'D]G*U[_H=I_P +(U'_ )\;7\V_QH_X61J/_/C:_FW^-<712^KT
MNQX_]K8W_GX_P.T_X61J/_/C:_FW^-'_  LC4?\ GQM?S;_&N+HH^KTNP?VM
MC?\ GX_P.T_X61J/_/C:_FW^-'_"R-1_Y\;7\V_QKBZ*/J]+L']K8W_GX_P.
MT_X61J/_ #XVOYM_C1_PLC4?^?&U_-O\:XNMGPYH@UV^FMVE:,)"7##'WL@
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M9X9VHKL/^%<:M_S]V7YM_A1_PKC5O^?NR_-O\*Z_:1[F'*SCZ*[#_A7&K?\
M/W9?FW^%'_"N-6_Y^[+\V_PH]I'N'*SCZ*[#_A7&K?\ /W9?FW^%'_"N-6_Y
M^[+\V_PH]I'N'*SCZ*[#_A7&K?\ /W9?FW^%'_"N-6_Y^[+\V_PH]I'N'*SG
M]%U&/2]0-Q-$\L;1/$51@#\PQG)K1M_$5K8I%;6=E*EFB2Y5Y0SN[KMW$XQ@
M#M5__A7&K?\ /W9?FW^%'_"N-6_Y^[+\V_PI.4'U':13C\2609KJ;3YFOWLS
M:M(DP"$;=NX+CKTK4AO]*2V;5)Y[=KXZ>;?$4YRQVX \LKD'IDYQ5?\ X5QJ
MW_/W9?FW^%'_  KC5O\ G[LOS;_"DW#N%I&<?$:&21Q;."VF+8CYAPPQ\WTX
MZ4MSXBMI3>W,5C)'?WT0BN)#+E O&2HQD$X'7I6A_P *XU;_ )^[+\V_PH_X
M5QJW_/W9?FW^%'-#N%I$%QXLAFC9#:3NQM)+;SI9%,AW8QD@#(&/KS6?K>MQ
MZM;6<*PR[K<$&:=E:1@>@R ,@>]:_P#PKC5O^?NR_-O\*/\ A7&K?\_=E^;?
MX4)TUU"TCCZ*[#_A7&K?\_=E^;?X4?\ "N-6_P"?NR_-O\*KVD>XN5G'T5V'
M_"N-6_Y^[+\V_P */^%<:M_S]V7YM_A1[2/<.5G'T5V'_"N-6_Y^[+\V_P *
M/^%<:M_S]V7YM_A1[2/<.5G'T5V'_"N-6_Y^[+\V_P */^%<:M_S]V7YM_A1
M[2/<.5GEUY_Q^S?[YJ&O0Y_A-K<MQ)(M[IX#-D99_P#XFH_^%1:Y_P _VG_]
M]/\ _$UW1Q%*R]XYG2G?8X"BN_\ ^%1:Y_S_ &G_ /?3_P#Q-'_"HM<_Y_M/
M_P"^G_\ B:?UFE_,+V4^QP%%=_\ \*BUS_G^T_\ [Z?_ .)H_P"%1:Y_S_:?
M_P!]/_\ $T?6:7\P>RGV. KIX/%D4+69-G(?L^DOIQ^<?,6S\_TYZ5L?\*BU
MS_G^T_\ [Z?_ .)H_P"%1:Y_S_:?_P!]/_\ $U,JU&6[&J=1;(HV7CM[;1+6
MS=+U)[2 P1-;3K'&P_A+ J3D>QYHT[QC8076FZA?Z7<3ZE80?9DEBG"HR8(!
M*X^]@GVJ]_PJ+7/^?[3_ /OI_P#XFC_A46N?\_VG_P#?3_\ Q-1S8?74JU7L
M8T7BJ*/3!:?9)-PTN73]X<=7?=N^@Z8IR>+(DN;246<G^CZ.VFXWCEB#\_TY
MZ5K_ /"HM<_Y_M/_ .^G_P#B:/\ A46N?\_VG_\ ?3__ !-/VF'[BY:O8IZC
MX^EU#39(]E[%=RPK$^RX40=,,0NW/([$XYJO>^+X;NZUJ9;*51J/V;:"X/E^
M403GUSBM3_A46N?\_P!I_P#WT_\ \31_PJ+7/^?[3_\ OI__ (FDI8=;/^OZ
M0W&J^AR&NZDNL:[>:BD1B6XDWA&.2O [_A6?7?\ _"HM<_Y_M/\ ^^G_ /B:
M/^%1:Y_S_:?_ -]/_P#$UHL112LI$.E4;O8X"BN__P"%1:Y_S_:?_P!]/_\
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MO[ M?^?G4?\ P/F_^*H_L"U_Y^=1_P# ^;_XJG:/<-35HK*_L"U_Y^=1_P#
M^;_XJC^P+7_GYU'_ ,#YO_BJ+1[AJ:M%97]@6O\ S\ZC_P"!\W_Q5']@6O\
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MY/\ XJC^QX/^>][_ .!<G_Q5%H]PYJO\J^__ (!H45G_ -CP?\][W_P+D_\
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M&ZN(==8).0B"']V)3N(;>#M3H?X23V J>\\10Z?JT]G<Q2%$2#RVB4N[O(7
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M:25@2Q P.@ _'J>]:-/\I_[M'E/_ ':")2<G=C**?Y3_ -VCRG_NTR1E%/\
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MS=:G'<V[::CVL"VPC,&%)P6R=_;J!TI+'Q7J-QX72:5U344N8%<[!AXI&&&
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MO##L:[ZM+#>S2A+5?B<5*I7]I><='^!Z?YK_ -[]*/-?^]^E,HKSCN'^:_\
M>_2CS7_O?I3**8#_ #7_ +WZ4>:_][]*910 _P U_P"]^E'FO_>_2F44 /\
M-?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U_P"]^E'FO_>_2F44
M /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U_P"]^E'FO_>_
M2F44 /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U_P"]^E'F
MO_>_2F44 /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U_P"]
M^E'FO_>_2F44 /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U
M_P"]^E'FO_>_2F44 /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910
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M=6NC<3I93HB1*P613N5SF'GCN-Y%=%Y:*V1&H(&W.T9 ]/I[4"-%4*L:!1T
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M144 2^>_M1Y[^U144 2^>_M1Y[^U144 2^>_M1Y[^U144 2^>_M1Y[^U144
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M%^09."1AO3BKU4(=*2&X@D6XG,=N7\F$D;5W#![9/7C)XJ_2 **** "BBB@
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MC'M0 448]J,>U !11CVHQ[4 %4D2\MY)Q'#!(DDS2*6E*G!QQC::NX]J,>U
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M_K1]H_V?UJ"BBP&)KWBZ;0KI8Y-+:2&09CF$V WJ,8X-9/\ PLQ?^@2W_?\
M'_Q-=/J.GV^J64EI<INC<=1U4]B/>O/K3P9>R:Z]E<96UBPSS@<.O;;[G]*U
M@H-:D2YKZ';Z!XDFUQ))O[.-O;KP)&EW;F] ,?K6W]H_V?UJI!!%;01P01B.
M*,;55>@%25F[7T+5R?[1_L_K1]H_V?UJ"BE8"?[1_L_K1]H_V?UJ"BBP$_VC
M_9_6C[1_L_K4%%%@)_M'^S^M'VC_ &?UJ"BBP$_VC_9_6C[1_L_K4%%%@)_M
M'^S^M'VC_9_6H**+ 3_:/]G]:/M'^S^M0446 G^T?[/ZT?:/]G]:@HHL!/\
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M"JGOG!';O6E5*/2K6&99(@\8!!\M7(0D#:"1] /RJ[2 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ;(VR-WQG:I./H*Q;#Q)'-:+<S[%C
M?8$:'.&D(.8_FQRN.3TK;90Z,IZ,"#]*HC1K-4"HLB;2A4J_*LJ[0P]]O!]1
MUH :OB"Q<%DED950.Q"_=!;;@^^<BHK_ %[[)<20Q0O.8\*X'4-OC7 ]1B0&
MII=(LI/+\XRN%0QH'E/&>I'?)_I[4O\ 8]H26<2N['+.[Y9CN5LG\47\!1H!
M8M;R&]61X=^U',9++C)!P<?C4]06]G%;23R(7:2=@\C.V22!@?D*GH ****
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M/_Q5'EW_ /S\V_\ WX/_ ,55JB@"KY=__P _-O\ ]^#_ /%4>7?_ //S;_\
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I$_NC\J-B?W1^5%% !L3^Z/RHV)_='Y444 &Q/[H_*E"J#D "BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img34454307_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34454307_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %\! $# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ$J=1NHI:OH.A&=-*FUHNIT%%%%<ITA1163XD\06GAG1I=2O-Q1"%1%ZNQZ
M4XQ<G9;BE)15V:U>6_&+4KU(M-T:T9L:AN5U!QO(9-H_/^=8OB'Q%\0[2UMM
M8NIUTW3[IP$2*-6\D'D;^">1_+H*S_&,'C&73M/U;5GL[RUM!YL-];$<ABF"
M1QWV]NYKT</AN2I&<FO^"<%?$<\)129Z?X!\1V.L:%%901_9KJPC6&>U;JA
MQD>HXKK:\$UOQEIJ:M;>(O#Z3Z=J^<7EM+'A+A3SGC@_CC/7J*]3\)^-K3Q:
M9OLEG=Q+"BEI)$^0L>J@CN*QQ&'E']XEH_P-J%>+]QO7\SJ****XSJ"BBB@
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M@]K3WYE]YJT52CU:QD2-TGRLD)N%.UO]6,9/3CJ.#S4,GB#3(I4C>X8.Z)(
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M!ZC'2IJ*!\J[%8:=9"S^QBSMQ:G_ )8")=G7/W<8ZU-%%'!$L4,:1QH,*B*
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M8F)"R&90IQUP<U+]NM"C.+J#8J"1F\P8"'HQ]C@\T*Z_KY@X4FV^_G\C*L]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5>^M([ZPGM)<[)D*-CT(JQ
M11L#U.(M)+2[L(?#.N7$EM<6I"-'NV+<QK]T[NX(P2 <\5O7NNZ/H=HB27$:
MJJ[8X8OF8@#@ "KU]I=CJ2!+RTAG4=/,0''TJ"TT#2;%BUMI]O&Q&"P3)_,U
MHY1>YBH2CM8?;W8O]%CNU7:)H/,"YZ9&:XO0;6SN'T]KV".:*'3&DPZ[L8D/
M-;45EK>AI-;6L4>H::0?)C\S9)"#_#SPPK)@TW5[&SMXTTZ221].>V.UU'EL
M6)YII)7LS.;;:;6QJKK6HRVBOHF@,+<KO5YF6,$=>%!R:NRW>G^(/#$TD\GD
MV\J%92YP8F'K[@UJ6%O]ET^WMSC,42H<>PQ5&7PWIDUZ]S) 6+MO:,N?++?W
MBO3-9W1IRSMWN+X:NWO- M)93EPNPM_>VG&X?7&:UJ:B+&@1%"J!@ # %.I&
MD4TDF%%%%!04444 %%%% !1110 4444 %%%% !1110!!+96D]Q'<36L,DT7^
MKD>,%D^A/(J>BB@5DM2!+*TCNWNTM85N7&'F6,!V'H3U/04C6%F]VMV]I UR
M@PLQC!<#V;K5BB@7+'L5[JQM+Y MW:P7"CH)8PX'YTZVM+:SB\JUMXH(_P"Y
M$@4?D*FHH'RJ_-;4@:RM'NUNVM86N4&%F,8+@>@;KW-2NB2QM'(BNC##*PR"
M/0BG44 DEL5TT^RCLS9I:0+:G(,(C 0YZ_+C%5ET#1D=732+!64Y!%L@(/Y5
MHT4[LETX/=(@2RM([M[M+6%;EQAYEC =AZ$]3T%+#9VMO+++!;0Q22G,CH@4
MN?4D=:FHI%<J[%>6PLYKE+F6T@DN(_N2O&"R_0XR*F=%D0HZAE/4,,@TZB@$
MDM2E!H^F6LOFV^G6<4G]^.!5/Y@5=HHH",5'96"BBB@84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LJ:X\0+-
M((=,TQX@Q",^HR*Q7/!($!P?;)^IK5KE;OXD>$[&]GM+G5MD\$C12)]GE.UE
M.",A<'D5<(REM&Y$Y1C\4K&E]I\2?] G2O\ P9R?_&*/M/B3_H$Z5_X,Y/\
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M&Q]I\2?] G2O_!G)_P#&*/M/B3_H$Z5_X,Y/_C%8_P#PM+P9_P!!G_R5F_\
MB*/^%I>#/^@S_P"2LW_Q%'LY_P#/O\&'M:?\_P"*-C[3XD_Z!.E?^#.3_P",
M4?:?$G_0)TK_ ,&<G_QBL?\ X6EX,_Z#/_DK-_\ $4?\+2\&?]!G_P E9O\
MXBCV<_\ GW^##VM/^?\ %&Q]I\2?] G2O_!G)_\ &*/M/B3_ *!.E?\ @SD_
M^,5C_P#"TO!G_09_\E9O_B*/^%I>#/\ H,_^2LW_ ,11[.?_ #[_  8>UI_S
M_BC8^T^)/^@3I7_@SD_^,4?:?$G_ $"=*_\ !G)_\8K'_P"%I>#/^@S_ .2L
MW_Q%'_"TO!G_ $&?_)6;_P"(H]G/_GW^##VM/^?\4;'VGQ)_T"=*_P#!G)_\
M8H^T^)/^@3I7_@SD_P#C%8__  M+P9_T&?\ R5F_^(H_X6EX,_Z#/_DK-_\
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M_@>__P 9H\_7?^@;IW_@>_\ \9K/_P"$^\,_]!/_ ,@2?_$T?\)]X9_Z"?\
MY D_^)HY)!]9H?\ /Y??$T//UW_H&Z=_X'O_ /&://UW_H&Z=_X'O_\ &:S_
M /A/O#/_ $$__($G_P 31_PGWAG_ *"?_D"3_P")HY)!]9H?\_E]\30\_7?^
M@;IW_@>__P 9H\_7?^@;IW_@>_\ \9K/_P"$^\,_]!/_ ,@2?_$T?\)]X9_Z
M"?\ Y D_^)HY)!]9H?\ /Y??$T//UW_H&Z=_X'O_ /&://UW_H&Z=_X'O_\
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M_/Y??$T//UW_ *!NG?\ @>__ ,9H\_7?^@;IW_@>_P#\9K/_ .$^\,_]!/\
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M/Q<T-A"]L;727MM/-PX,C-D<D^N!ZGH:B.)J6YK727Z7_,N6%I)\M[-NR_\
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M &?+^?\ #_@GQ_17V!15?VC_ '?Q_P" 3_9O][\/^"?']%?8%%']H_W?Q_X
M?V;_ 'OP_P""?']%?8%%']H_W?Q_X ?V;_>_#_@GQ_17V!11_:/]W\?^ ']F
M_P![\/\ @GQ_17V!11_:/]W\?^ ']F_WOP_X)\?T5]@44?VC_=_'_@!_9O\
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M$$$LGF,I9!+!)&)%'4H64!Q[KFM*JDV[I]?Z_0F.C370\^T_PIJFEZYHDMO
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MF"Q2?,H^3<IQD8P!7H=%5S"L>;:[8"#5KW_0;(I:V-F'NXH]C6:[Y,O"F#@
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MMMIL;V.+3-I&419D0OO0 D#JP.#@&M74M.>[\'3V.GZ<;%W3$=J!&AC^;/\
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M_HLUQLL"VFAZ_!):VFG%K*W<6L/S0LN3F7HN23PPP/NCDY!KTM$6.-8T&%4
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M#,Q^3:.<8Q@5:B\+%?&>I:\)O)-Q9I;PF)LLC_QR88%0V!&!P<A.?2A_Y_\
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MR<;R>@&>_MUI.]OZ\O\ (-+W_K=EFBBBD,**** "BBB@ HHHH *X827\.O\
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MF6%9]H0@O(8V*L<D#(.X_K6]<6%W/X/6S@L1:3J$WVBRC#*K@NH8'HP!Y/\
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M21JZA@& (W*5/X@\CZ&G4)V5OZ[#W_KSN>?V/AB^_L^ZLY;"1+.74;:9()C
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MB0AG"#9&S\GUV@X'N>!WHMT#S)***@N+R"U>!)I-K3R>5&,$[FP3CCIP#UH
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M.S0I"Y"A1N\UBJ@$L .5Y)( ]:2/PQ;I;/9M>WTE@8VB2T:11'&K @@$*&(
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MD5G<.UF/WK[HU&[:&V@%PW((Y("^]5)?!]D;.YL;>YN+2PN7+R6D"1>7R "
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M^M;E%-R;$EI8****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'3T34+G28H5OQY>Z"X5'5B6SNR<J,J#T]J[62:*$QB25$,C;$#,!N;&<#U.
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M@;2)TTTW5\I$L\LZQ/ CO)OD/S,'5QS@J#V!SV[FBGS.]PMI8****D84444
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M21(8R#A69I6&[!W9.,D# R*LI)JP\:V[1QW\=L;EXYHV6X>,Q>6=KEV8QC)
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M(]__ .$BT3_H,:?_ .!*?XT?\)%HG_08T_\ \"4_QKP"BCV2#^WJG\B/?_\
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M;((95<H?0X/%6JJ_]?=_7S)2TL<AHMGJ<$UA++/J3M)]IBF6XD=E"JQ$1(/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQ]_R).H?]L_\
MT8M=)7-^/O\ D2=0_P"V?_HQ:<=T<V,_W>I_A?Y'B5%%%=9\(%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %17%O!=P-!<PQS1-C='(H93@YY!]ZEHH$TFK,S?\
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MC7*32RK+E;DE>(R>GMMX].]:D6AZC->:Q<1OJ%O>2:9;&&=II5!F 8D'G!Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D95="C
MJ&5A@@C((I:* &0PQ6\*0P1)%$@"HB*%50.@ '04^BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K*O]*:;4%U%+F97BA=%B0\,2/\
M/Z>E:M%)C1R-C%K1VV\TEX-ECYD<S%N9"58*WJP(88/)%6?]-BN-/E<WEQ-(
MH:2#]ZB(S'))8?+A>FUNP_/I:*JY-CGYVO&U,&^CNXT\M?(6Q=W3?N.[<0H'
M3;]X8ZU1FFO9M-L8BVHQR1W#BX?R+@G;A\9V;68=.A]*ZZBD,YW3;;4GUN>X
M>6=+1)2%$LDG[Q=BX 1N  <G=G.<BJ,FK:NDEQYGVR" S1HC/ &< N0P7]V
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@]O-]K,[.LI"O)%Y88?[*E5('US]36I120!1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>bdsx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T02:56:23.6068+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AstrazenecaUkMember" xlink:label="bdsx_AstrazenecaUkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OtherAssetsPolicyTextBlock" xlink:label="bdsx_OtherAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalWarrantsMember" xlink:label="bdsx_AdditionalWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LessorReimbursementsReceived" xlink:label="bdsx_LessorReimbursementsReceived"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SubscriptionAgreementsMember" xlink:label="bdsx_SubscriptionAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TenantImprovementAllowancesReceived" xlink:label="bdsx_TenantImprovementAllowancesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilitiesFairValueDisclosure" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueMilestone" xlink:label="bdsx_RevenueMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ServiceConditionRSUsMember" xlink:label="bdsx_ServiceConditionRSUsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalTenantImprovementAllowanceAmount" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NetProceedFromFinancingTransactionsss" xlink:label="bdsx_NetProceedFromFinancingTransactionsss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SecuritiesPurchaseAgreementsMember" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract" xlink:label="us-gaap_DerivativeTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ExitFeePayment" xlink:label="bdsx_ExitFeePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="bdsx_DescriptionOfSecuritiesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" xlink:label="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LabcorpDdFormerlyCovanceMember" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRightsShares" xlink:label="bdsx_ContingentValueRightsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ReductionInContingentConsideration" xlink:label="bdsx_ReductionInContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_GrossProceedsFromFinancingTransactions" xlink:label="bdsx_GrossProceedsFromFinancingTransactions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationPolicyTextBlock" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OffsettingDeferredRent" xlink:label="bdsx_OffsettingDeferredRent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CashCollateralizedLetterOfCreditMember" xlink:label="bdsx_CashCollateralizedLetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IncomeTaxExaminationPeriodUnderExamination" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventorySuppliesPolicy" xlink:label="us-gaap_InventorySuppliesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LPCFacilityMember" xlink:label="bdsx_LPCFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TheStateOfColoradoMember" xlink:label="bdsx_TheStateOfColoradoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfInterestOnContingentConsideration" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FourthMilestonePaymentAndInterest" xlink:label="bdsx_FourthMilestonePaymentAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentOfDeferredOfferingCosts" xlink:label="bdsx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNoteTwoMember" xlink:label="bdsx_PromissoryNoteTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMarketFacilityMember" xlink:label="bdsx_AtTheMarketFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalWarrantsAmount" xlink:label="bdsx_AdditionalWarrantsAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TenantImprovementAllowancesExpectedToBeReceived" xlink:label="bdsx_TenantImprovementAllowancesExpectedToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CO" xlink:label="stpr_CO"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilityPolicyTextBlock" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance" xlink:label="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfFacility" xlink:label="bdsx_NumberOfFacility"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IssuanceOfPerceptiveWarrants" xlink:label="bdsx_IssuanceOfPerceptiveWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseExpirationMonthYear" xlink:label="bdsx_LeaseExpirationMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRightsPercentage" xlink:label="bdsx_ContingentValueRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="us-gaap_DerivativeFixedInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiscountsOnDebtInstrumentIssuance" xlink:label="bdsx_DiscountsOnDebtInstrumentIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNoteOneMember" xlink:label="bdsx_PromissoryNoteOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CenturaHealthcareMember" xlink:label="bdsx_CenturaHealthcareMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CommonStockIssuedForDeferredOfferingCosts" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRights" xlink:label="bdsx_ContingentValueRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TheBigTenConferenceMember" xlink:label="bdsx_TheBigTenConferenceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ThirdAmendmentToApaAgreementMember" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccretionOfLeaseLiability" xlink:label="bdsx_AccretionOfLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage" xlink:label="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:label="bdsx_PaymentsToAcquireOncimmune"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AreaOfOfficeSpaceLeased" xlink:label="bdsx_AreaOfOfficeSpaceLeased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KS" xlink:label="stpr_KS"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ExistingShareholdersMember" xlink:label="bdsx_ExistingShareholdersMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DefinedContributionPlanNameExtensibleList" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiligenceExpenseAndLegalFees" xlink:label="bdsx_DiligenceExpenseAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:label="bdsx_PutOptionLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PublicOfferingMember" xlink:label="bdsx_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WeightedAveragePricePerShare" xlink:label="bdsx_WeightedAveragePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryLiabilityAmortizationPeriod" xlink:label="us-gaap_RegulatoryLiabilityAmortizationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_EquityFinancingProgramsMember" xlink:label="bdsx_EquityFinancingProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MinimumCashBalanceAtMaturityDate" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AstrazenecaUkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astrazeneca UK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AstrazenecaUkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Astrazeneca UK [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AstrazenecaUkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Astrazeneca UK.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuable per day, number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Policy Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Assets Policy Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Gross (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Testing Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Testing Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Testing services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimentation tax carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets research and experimentation tax carryforwards subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term Line of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit subject to contingent reduction over the term of the lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance deposits.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal in year five and thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets subject to amortization, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diagnostic Tests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Diagnostic Tests [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Diagnostic tests.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non&#8209;current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term notes payable, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final settlement payment to third parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LessorReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessor reimbursements received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LessorReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Reimbursements Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LessorReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor reimbursements received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BDX004</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B D X004 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bdx004.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of common stock allowed to purchase by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage of Common Stock Allowed to Purchase by Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of common stock allowed to purchase by counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Forfeited/canceled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated air value of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Agreements Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Six and Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability, to be paid, year six and thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, warrants or rights exercisable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation related accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, Weighted-average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases future minimum payments due in six years and thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Six Years And Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited/canceled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in value of the warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual volume percentage thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Volume Percentage Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual volume percentage thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board of Directors Chairman [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination details</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche C Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining estimated obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Estimated Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining estimated obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement number of options to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement number of options to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease agreement number of options to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments on net revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciation Expense Related to Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation and amortization expense related to property and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A2 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A2 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition contingent consideration gross margin target</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due, Next 12 Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Two Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowances received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowances Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowances received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of earnings used for purchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less amount representing tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less amount representing tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, operating lease, liability, amount representing tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability, amount representing tenant improvement allowances.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments on net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional warratns exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Additional Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, additional warrants or rights exercisable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Funding amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross proceeds from an equity offering of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Condition R S Us</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Condition R S Us [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service-condition RSUs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock under employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Tenant Improvement Allowance Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tenant improvement allowance amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash &#8209; beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash &#8209; end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Amortization Expense Related to Definite-Lived Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lung Diagnostic Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lung Diagnostic Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lung diagnostic revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Net Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares outstanding used in computing net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Intrinsic Value, Outstanding - December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding - January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding - January 1, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development and regulatory costs exercised using opt-out right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development and regulatory costs exercised using opt-out right.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year of ending royalty payments from first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Year Of Ending Royalty Payments From First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Year of ending royalty payments from first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of common stock issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Patent costs and intangible asset acquisition, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for proceeds from patent costs and intangible asset acquisition, net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series E Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series E convertible preferred stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity financing costs included in Accounts payable and other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financing Costs Included in Accounts Payable and Other Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity financing costs included in Accounts payable and other accrued liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">First Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software and Software Development Costs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TrademarksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trademarks</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TrademarksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trademarks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of license agreement and royalty payment related to acquired diagnostic test recognized revenue for non-screening tests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedFromFinancingTransactionsss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds after deducting commissions, fees and expenses payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedFromFinancingTransactionsss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceed From Financing Transactionsss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedFromFinancingTransactionsss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceed from financing transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets, Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued or issuable, threshold limit description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued or Issuable, Threshold Limit Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued or issuable, threshold limit description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vehicles [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vehicles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series F Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory note, maturity term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExitFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exit fee payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExitFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exit fee payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of valuation allowance equal to net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of valuation allowance equal to net deferred tax assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Share Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Share Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue share agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue share expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Share Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue share expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfSecuritiesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfSecuritiesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Securities Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfSecuritiesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of securities purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonus-To-Options Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bonus To Options Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bonus-to-options program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bio-Rad License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bio Rad License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bio-rad license.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution 401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2022 and 2021) issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (loss), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest, amortization of OID and debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued interest, amortization of original issue discount and debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest, amortization of original issue discount and debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Landlord contribution towards cost of construction and tenant improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Landlord contribution towards cost of construction and tenant improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Landlord contribution towards cost of construction and tenant improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Estimates Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of Presentation and Estimates.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LabCorp DD (formerly Covance).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">LabCorp DD formerly Covance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LabCorp DD (formerly Covance)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes payable, total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ficlatuzumab</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ficlatuzumab [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ficlatuzumab.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Test Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Diagnostic Test Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 diagnostic test revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal contingency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of blood based lung cancer test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Cancer Test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of cancer test.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Exercisable - December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from the sale of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration arrangements, common shares, redemption amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration arrangements common shares redemption amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series G convertible preferred stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2006 Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial warrants amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial warrants amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial warrants amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReductionInContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction in contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReductionInContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction in contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions and offering expenses payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions And Offering Expenses Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue and Accounts Receivable Credit Concentration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_GrossProceedsFromFinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross proceeds from financing transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_GrossProceedsFromFinancingTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from financing transactions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Other Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity for Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares outstanding used in computing net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OffsettingDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offsetting Deferred Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OffsettingDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offsetting deferred rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CashCollateralizedLetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Collateralized Letter Of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CashCollateralizedLetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Collateralized Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CashCollateralizedLetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash collateralized letter of credit member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to additional paid-in capital deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid-in capital deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion at Fair Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://fasb.org/us-gaap/role/label/axisDefault">Portion at Fair Value Measurement [Member] [Default]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax examination, period under examination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Period under Examination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax examination, period under examination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventorySuppliesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventorySuppliesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Supplies, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Industry Sector [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for deferred offering costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, For Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, for deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of warrant liability to additional paid-in capital, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount used to retire outstanding debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of term loan and notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series H Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series H Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LPCFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LPC Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LPCFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">L P C Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LPCFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LPC facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheStateOfColoradoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The State of Colorado</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheStateOfColoradoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The State of Colorado Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheStateOfColoradoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The State of Colorado.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Issued Accounting Standards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of interest on installment payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of interest on contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public offering price per share of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering price per share of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current and long-term operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding - January 1, 2020, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price,Outstanding - December, 31, 2020, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited/canceled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration number of installments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Number Of Installments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration number of installments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FourthMilestonePaymentAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fourth milestone payment and interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FourthMilestonePaymentAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fourth milestone payment and interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of commercial blood-based test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Commercial Blood Based Test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of commercial blood based test.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock issued and sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeasedPropertyBuildingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased property building capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeasedPropertyBuildingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leased property building capacity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeasedPropertyBuildingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leased property building capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of tax credit carryforward expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reported Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination contingent consideration final payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Final Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration final payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments for Operating Lease Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, Marketing, General and Administrative Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock may be issued under incentive plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding - December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding - January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non&#8209;current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from term loan and notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Term Loan And Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of term loan and notes payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration cash payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory Note Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Note Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Promissory note two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition contingent consideration gross margin target period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Gross Margin Target Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration gross margin target period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non&#8209;current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital expenditure for leasehold improvements related to leases premises which are tenant improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Values, For Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, values, for deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional warrants amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalWarrantsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional warrants amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs interest expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest, amortization of debt issuance costs and other.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Amortization Of Debt Issuance Costs And Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest, amortization of debt issuance costs and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Portion of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Portion Of Contingent Consideration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets subject to amortization, Net Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right-of-Use Assets Obtained in Exchange for Lease Liabilities at Adoption of ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued as commitment fee, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued as Commitment Fee, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued as commitment fee, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 200,000,000 authorized; 77,614,358 (2022) and 30,789,649 (2021) shares issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserve for inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about liabilities measured at fair value on recurring basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount and debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series E Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred stock converted into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Preferred Stock Converted Into Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of preferred stock converted into common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Condition Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Condition Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance condition options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable2018 Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes payable 2018 notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesExpectedToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowances expected to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesExpectedToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant improvement allowances expected to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TenantImprovementAllowancesExpectedToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowances expected to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instruments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct costs and expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Notes Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fee payments on net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fee Payments On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fee payments on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Initial Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES act.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of license income generated from licensing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of License Income Generated From Licensing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of license income generated from licensing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CO_lbl" xlink:role="http://www.xbrl.org/2003/role/label">COLORADO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatality rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indefinite lived intangible assets excluding goodwill gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Contingent Consideration Excluding Accretion Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of contingent consideration excluding accretion expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Responsible percentage of development and regulatory costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development And Regulatory Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development and regulatory costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options and Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options And Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options and restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire license rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Payments to Acquire Businesses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining capacity under the tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Capacity Under the Tenant Improvement Allowances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining capacity under the tenant improvement allowances.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in original issue discounts on debt instrument issuance, subject to contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Discounts on Debt Instrument Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in discounts on debt instrument issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount reclassified from non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Reclassified From Non Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability reclassified from non-current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net of allowance for doubtful accounts of $118 and $158</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of offering period under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Offering Period Under Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of offering period under plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fully diluted equity for bonus awarded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fully Diluted Equity For Bonus Awarded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fully diluted equity for bonus awarded.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of SARS-CoV-2 test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of S A R S Co V2 Test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of SARS-CoV-2 test.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IssuanceOfPerceptiveWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Perceptive Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IssuanceOfPerceptiveWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Perceptive Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IssuanceOfPerceptiveWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of perceptive warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, change in fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent per month from commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Base rent per month from commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Base rent per month from commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Units Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial fairvalue of additional warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scheduled Principal Repayments (Maturities) of Long-term Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions related to a lapse of statute</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">POC Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">P O C Clinical Trials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Poc clinical trials.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes, maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value of common stock for purchase under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A3 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A3 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-3 preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets subject to amortization, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Sixteen Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2016 Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants For Convertible Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants for convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of voting power or value of stock for employee participation in offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of voting power or value of stock for employee participation in offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments not required on net revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments Not Required To Pay On Net Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments not required to pay on net revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventorySupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventorySupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Inventory, Supplies, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, stock issuable per day, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Stock Issuable Per Day, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuable per day, number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest related to uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory notes interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Fixed Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds percentage of cash payment to the CVR holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Percentage Of Cash Payment To C V R Holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds percentage of cash payment to the cvr holders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining life of outstanding performance condition options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiscountsOnDebtInstrumentIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Original issue discounts on debt instrument issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiscountsOnDebtInstrumentIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original issuance discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiscountsOnDebtInstrumentIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discounts on Debt Instrument Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiscountsOnDebtInstrumentIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discounts on debt instrument issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest expense due to passage of time and fixed payment schedule</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest expense due to passage of time and fixed payment schedule.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax Aassets capitalized research costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Centennial Valley Properties I, LLC Lease Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Centennial Valley Properties I, LLC Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments for Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Standards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss on extinguishment of liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) gain on extinguishment of liabilities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss (gain) on extinguishment of liabilities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss on debt extinguishment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain (loss) on debt extinguishment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of royalty payments from first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Royalty Payments From First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of royalty payments from first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and developments credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory Note One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Note One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNoteOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Promissory note one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Estimated Amortization Expense of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions related to the current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense limitation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Centura Healthcare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Centura Healthcare [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Centura Healthcare.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued For Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued for deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RentAfterFixedEscalationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent after fixed escalation provisions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RentAfterFixedEscalationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent after fixed escalation provisions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RentAfterFixedEscalationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent after fixed escalation provisions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from net of debt issuance costs and original issue discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from debt, after deducting debt issuance costs and expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable - December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Forefeited/canceled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Intangible Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense related to definite-lived intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized remaining stock based compensation balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturities of Long-Term Debt [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining capacity under tenant improvement allowances prior to reimbursements expected to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining capacity under tenant improvement allowances prior to reimbursements expected to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement with Unobservable Inputs Payments of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs payments of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-Money Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-Money Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Money Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Outstanding Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions for tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, expiration term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lincoln Park.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lincoln Park Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lincoln Park</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, expires period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CellCarta License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cell Carta License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CellCarta License.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Big Ten Conference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The Big Ten Conference [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The Big Ten Conference.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Amendment to APA Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Amendment to APA Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third amendment to APA agreement member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Life and Patent Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Life And Patent Life [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product life and patent life.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant under all plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional stock awards granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccretionOfLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net change to contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of escalations of sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Escalations Of Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of escalations of sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding - December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding - January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and rights outstanding, measurement input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory notes early prepayment premium percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Notes Early Prepayment Premium Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Promissory notes early prepayment premium percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating and Finance Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating and finance leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments to acquire Oncimmune assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Oncimmune</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire Oncimmune.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable to Bank, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 Convertible Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License expiry date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Expiry Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement expiry date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer and Chief Financial Officer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer and Chief Financial Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chief executive officer and chief financial officer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs included in Accounts payable and other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Included in Accounts Payable and Other Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt issuance costs included in Accounts payable and other accrued liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Industry Sector [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen Research and Development, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Research And Development L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen Research and Development, LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space leased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Office Space Leased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space leased.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid&#8209;in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_KS_lbl" xlink:role="http://www.xbrl.org/2003/role/label">KANSAS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares purchased by underwriter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues Shares Purchased by Underwriter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares new issues shares purchased by underwriter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExistingShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Existing Shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExistingShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">existing shareholders member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ExistingShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">existing shareholders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment premium percentage of aggregate outstanding principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment premium percentage of aggregate outstanding principal amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for doubtful accounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at January 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite lived intangible assets amortization expense year six and thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment of Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Weighted average exercise price, Forfeited/canceled, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Exercisable - December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of performance-condition options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Contingent Consideration and WarrantLiabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Accumulated Amortization Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accumulated amortization of intangible assets, excluding goodwill.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate on extra allowance amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest rate on extra allowance amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest rate on extra allowance amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales, Marketing, General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, Marketing, General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non&#8209;current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance, deferred tax asset, explanation of change</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Explanation of Change</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions related to settlements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of equal annual installments for award vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Equal Annual Installments For Award Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of equal annual installments for award vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining available capacity for share issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stock Options, Outstanding - December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stock Options, Outstanding - January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of outstanding stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Perceptive Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Perceptive Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerceptiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Perceptive term loan member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reported Fair values of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares committed under ESPP.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Committed Under E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Committed Under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, Net Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Annual Principal Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal balance outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets and liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatality rate, miinimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Long-term Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument, aggregate principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate loan amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation claims and assessments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Claims And Assessments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Claims and Assessments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss on intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets after valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AVEO Oncology</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A V E O Oncology [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aveo oncology.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Indi</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Integrated Diagnostics, Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Integrated Diagnostics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Integrated Diagnostics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan, 2016 Plan and 2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refundable deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Name [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment shares issuable on conditional basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment Shares Issuable on Conditional Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment shares issuable on conditional basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Excess and obsolete inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory excess and obsolescence</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Write-down</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer discretionary contributions amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased premised obligated to pay base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of leased premised obligated to pay base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of leased premised obligated to pay base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of Stock, stock issuable per day, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Stock Issuable Per Day, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuable per day, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiligenceExpenseAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diligence expenses and legal fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiligenceExpenseAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Diligence Expense and Legal Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiligenceExpenseAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Diligence expense and legal fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial expense current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Basis [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of restricted stock units, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairments loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up Front Cash Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up-front Payment Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, shares issued as commitment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Shares Issued as Commitment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued as commitment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expected term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited/canceled, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued upon exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Primary sources of revenue description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Primary Sources Of Revenue Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Primary sources of revenue, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased Technology</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchased Technology [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchased technology.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Applicable margin rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated value of put option liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Put option liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put Option Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Put option liability current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Description of Acquired Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WeightedAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WeightedAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Notes/Loan payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan principle amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NSCLC POC Trial</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N S C L C P O C Trial [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nsclc poc trial.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuable during period, value, committed shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuable During Period, Value, Committed Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable, committed to purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, marketing, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryLiabilityAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Liability, Amortization Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk&#8209;free rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Financing Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financing Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EquityFinancingProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Financing Programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax examination, likelihood of unfavorable settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Likelihood of Unfavorable Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs amortized against Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Amortized Against Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs amortized against additional paid-in capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medicare [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of RSUs granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum cash balance at maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum cash balance at maturity date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oncimmune Limited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Oncimmune Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Oncimmune Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimate of Fair Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding - January 1, 2020, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding - December 31, 2020, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AstrazenecaUkMember" xlink:to="bdsx_AstrazenecaUkMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpensesMember" xlink:to="bdsx_DirectCostsAndExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OtherAssetsPolicyTextBlock" xlink:to="bdsx_OtherAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchaseAgreementTerm" xlink:to="bdsx_PurchaseAgreementTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TestingServicesMember" xlink:to="bdsx_TestingServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdvanceDeposits" xlink:to="bdsx_AdvanceDeposits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:to="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdditionalWarrantsMember" xlink:to="bdsx_AdditionalWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DiagnosticTestsMember" xlink:to="bdsx_DiagnosticTestsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LessorReimbursementsReceived" xlink:to="bdsx_LessorReimbursementsReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BDX004Member" xlink:to="bdsx_BDX004Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SubscriptionAgreementsMember" xlink:to="bdsx_SubscriptionAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SecondAmendmentMember" xlink:to="bdsx_SecondAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" xlink:to="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:to="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" xlink:to="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MinimumAnnualVolumePercentageThereafter" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RemainingEstimatedObligation" xlink:to="bdsx_RemainingEstimatedObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:to="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA2PreferredStockMember" xlink:to="bdsx_SeriesA2PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TenantImprovementAllowancesReceived" xlink:to="bdsx_TenantImprovementAllowancesReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilitiesFairValueDisclosure" xlink:to="bdsx_WarrantLiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueMilestone" xlink:to="bdsx_RevenueMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" xlink:to="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ServiceConditionRSUsMember" xlink:to="bdsx_ServiceConditionRSUsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdditionalTenantImprovementAllowanceAmount" xlink:to="bdsx_AdditionalTenantImprovementAllowanceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LungDiagnosticRevenueMember" xlink:to="bdsx_LungDiagnosticRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:to="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeaseCommencementDate" xlink:to="bdsx_LeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NetProceedFromFinancingTransactionsss" xlink:to="bdsx_NetProceedFromFinancingTransactionsss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SecuritiesPurchaseAgreementsMember" xlink:to="bdsx_SecuritiesPurchaseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeTermOfContract" xlink:to="us-gaap_DerivativeTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ExitFeePayment" xlink:to="bdsx_ExitFeePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueShareAgreementMember" xlink:to="bdsx_RevenueShareAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueShareExpenses" xlink:to="bdsx_RevenueShareExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfSecuritiesPurchaseAgreement" xlink:to="bdsx_DescriptionOfSecuritiesPurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BonusToOptionsProgramMember" xlink:to="bdsx_BonusToOptionsProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BioRadLicenseMember" xlink:to="bdsx_BioRadLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" xlink:to="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:to="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LabcorpDdFormerlyCovanceMember" xlink:to="bdsx_LabcorpDdFormerlyCovanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FiclatuzumabMember" xlink:to="bdsx_FiclatuzumabMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_COVID19DiagnosticTestRevenueMember" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfCancerTest" xlink:to="bdsx_NumberOfCancerTest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRightsShares" xlink:to="bdsx_ContingentValueRightsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandSixPlanMember" xlink:to="bdsx_TwoThousandSixPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InitialWarrantsAmount" xlink:to="bdsx_InitialWarrantsAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ReductionInContingentConsideration" xlink:to="bdsx_ReductionInContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_GrossProceedsFromFinancingTransactions" xlink:to="bdsx_GrossProceedsFromFinancingTransactions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentConsiderationPolicyTextBlock" xlink:to="bdsx_ContingentConsiderationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OffsettingDeferredRent" xlink:to="bdsx_OffsettingDeferredRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CashCollateralizedLetterOfCreditMember" xlink:to="bdsx_CashCollateralizedLetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IncomeTaxExaminationPeriodUnderExamination" xlink:to="bdsx_IncomeTaxExaminationPeriodUnderExamination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventorySuppliesPolicy" xlink:to="us-gaap_InventorySuppliesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" xlink:to="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesHPreferredStockMember" xlink:to="us-gaap_SeriesHPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LPCFacilityMember" xlink:to="bdsx_LPCFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TheStateOfColoradoMember" xlink:to="bdsx_TheStateOfColoradoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfInterestOnContingentConsideration" xlink:to="bdsx_PercentageOfInterestOnContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:to="bdsx_PublicOfferingPricePerShareOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FourthMilestonePaymentAndInterest" xlink:to="bdsx_FourthMilestonePaymentAndInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfCommercialBloodBasedTest" xlink:to="bdsx_NumberOfCommercialBloodBasedTest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeasedPropertyBuildingCapacity" xlink:to="bdsx_LeasedPropertyBuildingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredRevenueMember" xlink:to="bdsx_DeferredRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMarketOfferingMember" xlink:to="bdsx_AtTheMarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentOfDeferredOfferingCosts" xlink:to="bdsx_PaymentOfDeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandTwentyOneTermLoanMember" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OtherMember" xlink:to="bdsx_OtherMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PromissoryNoteTwoMember" xlink:to="bdsx_PromissoryNoteTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMarketFacilityMember" xlink:to="bdsx_AtTheMarketFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" xlink:to="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdditionalWarrantsAmount" xlink:to="bdsx_AdditionalWarrantsAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CurrentPortionOfContingentConsiderationMember" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" xlink:to="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesIssuedAsCommitmentFeeValue" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PerformanceConditionOptionsMember" xlink:to="bdsx_PerformanceConditionOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NotesPayable2018NotesMember" xlink:to="bdsx_NotesPayable2018NotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TenantImprovementAllowancesExpectedToBeReceived" xlink:to="bdsx_TenantImprovementAllowancesExpectedToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpenses" xlink:to="bdsx_DirectCostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfFeePaymentsOnNetSales" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CARESActMember" xlink:to="bdsx_CARESActMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CO" xlink:to="stpr_CO_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilityPolicyTextBlock" xlink:to="bdsx_WarrantLiabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsAndRestrictedStockUnitsMember" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" xlink:to="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance" xlink:to="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfFacility" xlink:to="bdsx_NumberOfFacility_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LossMember" xlink:to="bdsx_LossMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfSARSCoV2Test" xlink:to="bdsx_NumberOfSARSCoV2Test_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IssuanceOfPerceptiveWarrants" xlink:to="bdsx_IssuanceOfPerceptiveWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BaseRentPerMonthFromCommencementDate" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentConsiderationMember" xlink:to="bdsx_ContingentConsiderationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_POCClinicalTrialsMember" xlink:to="bdsx_POCClinicalTrialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA3PreferredStockMember" xlink:to="bdsx_SeriesA3PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilityMember" xlink:to="bdsx_WarrantLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandAndSixteenPlanMember" xlink:to="bdsx_TwoThousandAndSixteenPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:to="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeaseExpirationMonthYear" xlink:to="bdsx_LeaseExpirationMonthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRightsPercentage" xlink:to="bdsx_ContingentValueRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventorySupplies" xlink:to="us-gaap_OtherInventorySupplies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockStockIssuablePerDayShares" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DiscountsOnDebtInstrumentIssuance" xlink:to="bdsx_DiscountsOnDebtInstrumentIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" xlink:to="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredTaxAssetsCapitalizedResearchCosts" xlink:to="bdsx_DeferredTaxAssetsCapitalizedResearchCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PromissoryNoteOneMember" xlink:to="bdsx_PromissoryNoteOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CenturaHealthcareMember" xlink:to="bdsx_CenturaHealthcareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CommonStockIssuedForDeferredOfferingCosts" xlink:to="bdsx_CommonStockIssuedForDeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RentAfterFixedEscalationProvisions" xlink:to="bdsx_RentAfterFixedEscalationProvisions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRights" xlink:to="bdsx_ContingentValueRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MilestonePayment" xlink:to="bdsx_MilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsToPurchaseCommonStockMember" xlink:to="bdsx_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" xlink:to="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMoneyOfferingMember" xlink:to="bdsx_AtTheMoneyOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LincolnParkMember" xlink:to="bdsx_LincolnParkMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CellCartaLicenseMember" xlink:to="bdsx_CellCartaLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TheBigTenConferenceMember" xlink:to="bdsx_TheBigTenConferenceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ThirdAmendmentToApaAgreementMember" xlink:to="bdsx_ThirdAmendmentToApaAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProductLifeAndPatentLifeMember" xlink:to="bdsx_ProductLifeAndPatentLifeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccretionOfLeaseLiability" xlink:to="bdsx_AccretionOfLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PeriodOfEscalationsOfSales" xlink:to="bdsx_PeriodOfEscalationsOfSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage" xlink:to="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:to="bdsx_LesseeOperatingAndFinanceLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentsToAcquireOncimmune" xlink:to="bdsx_PaymentsToAcquireOncimmune_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LicenseAgreementExpiryDate" xlink:to="bdsx_LicenseAgreementExpiryDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:to="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:to="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="us-gaap_EquitySecuritiesIndustryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AreaOfOfficeSpaceLeased" xlink:to="bdsx_AreaOfOfficeSpaceLeased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_KS" xlink:to="stpr_KS_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" xlink:to="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ExistingShareholdersMember" xlink:to="bdsx_ExistingShareholdersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" xlink:to="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RepurchaseMember" xlink:to="bdsx_RepurchaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InterestRateOnExtraAllowanceAmount" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:to="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PerceptiveTermLoanMember" xlink:to="bdsx_PerceptiveTermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesCommittedUnderESPPMember" xlink:to="bdsx_SharesCommittedUnderESPPMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LitigationClaimsAndAssessmentsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AVEOOncologyMember" xlink:to="bdsx_AVEOOncologyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IntegratedDiagnosticsIncMember" xlink:to="bdsx_IntegratedDiagnosticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationShares" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerFunds" xlink:to="us-gaap_CustomerFunds_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DefinedContributionPlanNameExtensibleList" xlink:to="bdsx_DefinedContributionPlanNameExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockStockIssuablePerDayValue" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DiligenceExpenseAndLegalFees" xlink:to="bdsx_DiligenceExpenseAndLegalFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedClinicalTrialExpenseCurrent" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesGPreferredStockMember" xlink:to="us-gaap_SeriesGPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PrimarySourcesOfRevenueDescription" xlink:to="bdsx_PrimarySourcesOfRevenueDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchasedTechnologyMember" xlink:to="bdsx_PurchasedTechnologyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PutOptionLiabilityCurrent" xlink:to="bdsx_PutOptionLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PublicOfferingMember" xlink:to="bdsx_PublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WeightedAveragePricePerShare" xlink:to="bdsx_WeightedAveragePricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NSCLCPOCTrialMember" xlink:to="bdsx_NSCLCPOCTrialMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryLiabilityAmortizationPeriod" xlink:to="us-gaap_RegulatoryLiabilityAmortizationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_EquityFinancingProgramsMember" xlink:to="bdsx_EquityFinancingProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" xlink:to="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MedicareMember" xlink:to="bdsx_MedicareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MinimumCashBalanceAtMaturityDate" xlink:to="bdsx_MinimumCashBalanceAtMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA1PreferredStockMember" xlink:to="bdsx_SeriesA1PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OncimmuneLimitedMember" xlink:to="bdsx_OncimmuneLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>bdsx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T02:56:19.2379+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://biodesix.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:bdsx="http://biodesix.com/20221231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations" id="Role_StatementStatementsOfOperations">
        <link:definition>100040 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" id="Role_DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandards" id="DisclosureRecentIssuedAccountingStandards">
        <link:definition>100090 - Disclosure - Recent Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinations" id="Role_DisclosureBusinessCombinations">
        <link:definition>100100 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValue" id="Role_DisclosureFairValue">
        <link:definition>100110 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100130 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>100140 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100150 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeases3" id="DisclosureLeases3">
        <link:definition>100160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100170 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock">
        <link:definition>100180 - Disclosure - Warrants to Purchase Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquity" id="Role_DisclosureEquity">
        <link:definition>100190 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" id="DisclosureRevenueAndAccountsReceivableCreditConcentration">
        <link:definition>100200 - Disclosure - Revenue and Accounts Receivable Credit Concentration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100210 - Disclosure - Share Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1" id="DisclosureNetLossPerCommonShare1">
        <link:definition>100220 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100230 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100240 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100250 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" id="Role_DisclosureDefinedContribution401KPlan">
        <link:definition>100260 - Disclosure - Defined Contribution 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueTables" id="Role_DisclosureFairValueTables">
        <link:definition>100280 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100290 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100300 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>100310 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>100320 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>100330 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables">
        <link:definition>100340 - Disclosure - Warrants to Purchase Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationTables">
        <link:definition>100350 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100360 - Disclosure - Share Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>100370 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100380 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails" id="DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Recent Issued Accounting Standards - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" id="Role_DisclosureBusinessCombinationsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Business Combinations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" id="Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
        <link:definition>100430 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" id="Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails">
        <link:definition>100440 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" id="DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails">
        <link:definition>100450 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" id="Role_DisclosureFairValueAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Fair Value - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
        <link:definition>100470 - Disclosure - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
        <link:definition>100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
        <link:definition>100500 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
        <link:definition>100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails">
        <link:definition>100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails" id="DisclosureDebtSummaryOfLongtermNotesPayableDetails">
        <link:definition>100540 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" id="Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
        <link:definition>100560 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails">
        <link:definition>100580 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesParentheticalDetails" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesParentheticalDetails">
        <link:definition>100590 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl">
        <link:definition>100600 - Disclosure - Leases - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, Or Taxes, for Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
        <link:definition>100620 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails">
        <link:definition>100630 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" id="Role_DisclosureEquityAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails">
        <link:definition>100650 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails">
        <link:definition>100670 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Share Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100690 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails">
        <link:definition>100700 - Disclosure - Share Based Compensation - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" id="Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails">
        <link:definition>100710 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" id="DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails">
        <link:definition>100720 - Disclosure - Share Based Compensation - Summary of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" id="DisclosureNetLossPerCommonShareAdditionalInformationDetails">
        <link:definition>100730 - Disclosure - Net Loss per Common Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100740 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
        <link:definition>100750 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100760 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100770 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100780 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100790 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100800 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" id="Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail">
        <link:definition>100810 - Disclosure - Defined Contribution 401(k) Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessAbstract" name="OrganizationAndDescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AccretionOfLeaseLiability" name="AccretionOfLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_AccruedClinicalTrialExpenseCurrent" name="AccruedClinicalTrialExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" name="AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" name="AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AdditionalTenantImprovementAllowanceAmount" name="AdditionalTenantImprovementAllowanceAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AdditionalWarrantsAmount" name="AdditionalWarrantsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" name="AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AdvanceDeposits" name="AdvanceDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" name="AreaOfLeasedPremisedObligatedToPayBaseRent" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AreaOfOfficeSpaceLeased" name="AreaOfOfficeSpaceLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BaseRentPerMonthFromCommencementDate" name="BaseRentPerMonthFromCommencementDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" name="BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" name="BusinessAcquisitionContingentConsiderationNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" name="BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationFinalPayment" name="BusinessCombinationContingentConsiderationFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationShares" name="BusinessCombinationContingentConsiderationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" name="ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" name="ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" name="ClassOfWarrantOrRightWarrantsOrRightsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_CommitmentSharesIssuableOnConditionalBasis" name="CommitmentSharesIssuableOnConditionalBasis" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_CommonStockIssuedForDeferredOfferingCosts" name="CommonStockIssuedForDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ContingentValueRights" name="ContingentValueRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ContingentValueRightsPercentage" name="ContingentValueRightsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContingentValueRightsShares" name="ContingentValueRightsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" name="ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" name="DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" name="DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DeferredTaxAssetsCapitalizedResearchCosts" name="DeferredTaxAssetsCapitalizedResearchCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" name="DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DescriptionOfOfferingPeriodUnderPlan" name="DescriptionOfOfferingPeriodUnderPlan" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DescriptionOfSecuritiesPurchaseAgreement" name="DescriptionOfSecuritiesPurchaseAgreement" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" name="DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DiligenceExpenseAndLegalFees" name="DiligenceExpenseAndLegalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DirectCostsAndExpenses" name="DirectCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DiscountsOnDebtInstrumentIssuance" name="DiscountsOnDebtInstrumentIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" name="EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ExitFeePayment" name="ExitFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" name="FairValueMeasurementWithUnobservableInputsInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" name="FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_FourthMilestonePaymentAndInterest" name="FourthMilestonePaymentAndInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_GrossProceedsFromFinancingTransactions" name="GrossProceedsFromFinancingTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_IncomeTaxExaminationPeriodUnderExamination" name="IncomeTaxExaminationPeriodUnderExamination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance" name="IncreaseInDiscountsOnDebtInstrumentIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_InitialWarrantsAmount" name="InitialWarrantsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" name="IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" name="InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_InterestRateOnExtraAllowanceAmount" name="InterestRateOnExtraAllowanceAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_IssuanceOfPerceptiveWarrants" name="IssuanceOfPerceptiveWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" name="LandlordContributionTowardsCostOfConstructionAndTenantImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_LeaseAgreementNumberOfOptionsToExtend" name="LeaseAgreementNumberOfOptionsToExtend" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LeasedPropertyBuildingCapacity" name="LeasedPropertyBuildingCapacity" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LeaseExpirationMonthYear" name="LeaseExpirationMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" name="LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" name="LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_LessorReimbursementsReceived" name="LessorReimbursementsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_LicenseAgreementExpiryDate" name="LicenseAgreementExpiryDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" name="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" name="MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_MinimumAnnualVolumePercentageThereafter" name="MinimumAnnualVolumePercentageThereafter" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_MinimumCashBalanceAtMaturityDate" name="MinimumCashBalanceAtMaturityDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_NetProceedFromFinancingTransactionsss" name="NetProceedFromFinancingTransactionsss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" name="NetProceedsPercentageOfCashPaymentToCVRHolders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfCancerTest" name="NumberOfCancerTest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfCommercialBloodBasedTest" name="NumberOfCommercialBloodBasedTest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" name="NumberOfEqualAnnualInstallmentsForAwardVesting" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfFacility" name="NumberOfFacility" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" name="NumberOfPreferredStockConvertedIntoCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfSARSCoV2Test" name="NumberOfSARSCoV2Test" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OffsettingDeferredRent" name="OffsettingDeferredRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" name="OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" name="OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PaymentOfDeferredOfferingCosts" name="PaymentOfDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" name="PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PaymentsToAcquireOncimmune" name="PaymentsToAcquireOncimmune" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" name="PercentageOfDevelopmentAndRegulatoryCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" name="PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfFeePaymentsOnNetSales" name="PercentageOfFeePaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" name="PercentageOfFullyDilutedEquityForBonusAwarded" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfInterestOnContingentConsideration" name="PercentageOfInterestOnContingentConsideration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" name="PercentageOfLicenseIncomeGeneratedFromLicensing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" name="PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" name="PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" name="PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" name="PercentageOfRoyaltyPaymentsOnNetRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" name="PercentageOfRoyaltyPaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" name="PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PeriodOfEscalationsOfSales" name="PeriodOfEscalationsOfSales" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" name="PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PrimarySourcesOfRevenueDescription" name="PrimarySourcesOfRevenueDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" name="ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" name="ProceedsFromIssuanceOfTermLoanAndNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage" name="PromissoryNotesEarlyPrepaymentPremiumPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PublicOfferingPricePerShareOfCommonStock" name="PublicOfferingPricePerShareOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PurchaseAgreementTerm" name="PurchaseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PutOptionLiabilityCurrent" name="PutOptionLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ReductionInContingentConsideration" name="ReductionInContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" name="RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" name="RemainingCapacityUnderTheTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_RemainingEstimatedObligation" name="RemainingEstimatedObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_RentAfterFixedEscalationProvisions" name="RentAfterFixedEscalationProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_RevenueMilestone" name="RevenueMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_RevenueShareExpenses" name="RevenueShareExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" name="SaleOfStockSharesIssuedAsCommitmentFee" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SaleOfStockStockIssuablePerDayShares" name="SaleOfStockStockIssuablePerDayShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SaleOfStockStockIssuablePerDayValue" name="SaleOfStockStockIssuablePerDayValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SharesIssuedAsCommitmentFeeValue" name="SharesIssuedAsCommitmentFeeValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" name="SharesIssuedOrIssuableThresholdLimitDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_StockIssuableDuringPeriodValueCommittedShares" name="StockIssuableDuringPeriodValueCommittedShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" name="StockIssuedDuringPeriodSharesForDeferredOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" name="StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" name="StockIssuedDuringPeriodValuesForDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_TenantImprovementAllowancesExpectedToBeReceived" name="TenantImprovementAllowancesExpectedToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_TenantImprovementAllowancesReceived" name="TenantImprovementAllowancesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" name="TermOfRoyaltyPaymentsFromFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" name="UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_WarrantLiabilitiesFairValueDisclosure" name="WarrantLiabilitiesFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_WeightedAveragePricePerShare" name="WeightedAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" name="YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DefinedContributionPlanNameExtensibleList" name="DefinedContributionPlanNameExtensibleList" type="xbrli:tokenItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" name="FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessLineItems" name="OrganizationAndDescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AdditionalWarrantsMember" name="AdditionalWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AstrazenecaUkMember" name="AstrazenecaUkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AtTheMarketFacilityMember" name="AtTheMarketFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AtTheMoneyOfferingMember" name="AtTheMoneyOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AVEOOncologyMember" name="AVEOOncologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BDX004Member" name="BDX004Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BioRadLicenseMember" name="BioRadLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BonusToOptionsProgramMember" name="BonusToOptionsProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CARESActMember" name="CARESActMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CashCollateralizedLetterOfCreditMember" name="CashCollateralizedLetterOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CellCartaLicenseMember" name="CellCartaLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" name="CentennialValleyPropertiesILlcLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CenturaHealthcareMember" name="CenturaHealthcareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" name="ChiefExecutiveOfficerAndChiefFinancialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ContingentConsiderationMember" name="ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_COVID19DiagnosticTestRevenueMember" name="COVID19DiagnosticTestRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CurrentPortionOfContingentConsiderationMember" name="CurrentPortionOfContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DeferredRevenueMember" name="DeferredRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DiagnosticTestsMember" name="DiagnosticTestsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DirectCostsAndExpensesMember" name="DirectCostsAndExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_EquityFinancingProgramsMember" name="EquityFinancingProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ExistingShareholdersMember" name="ExistingShareholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_FiclatuzumabMember" name="FiclatuzumabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_IntegratedDiagnosticsIncMember" name="IntegratedDiagnosticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_JanssenResearchAndDevelopmentLLCMember" name="JanssenResearchAndDevelopmentLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LabcorpDdFormerlyCovanceMember" name="LabcorpDdFormerlyCovanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LincolnParkMember" name="LincolnParkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LitigationClaimsAndAssessmentsMember" name="LitigationClaimsAndAssessmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LossMember" name="LossMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LPCFacilityMember" name="LPCFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LungDiagnosticRevenueMember" name="LungDiagnosticRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_MedicareMember" name="MedicareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_NotesPayable2018NotesMember" name="NotesPayable2018NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_NSCLCPOCTrialMember" name="NSCLCPOCTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OncimmuneLimitedMember" name="OncimmuneLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OptionsAndRestrictedStockUnitsMember" name="OptionsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OtherMember" name="OtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PerceptiveTermLoanMember" name="PerceptiveTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PerformanceConditionOptionsMember" name="PerformanceConditionOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_POCClinicalTrialsMember" name="POCClinicalTrialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ProductLifeAndPatentLifeMember" name="ProductLifeAndPatentLifeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PromissoryNoteOneMember" name="PromissoryNoteOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PromissoryNoteTwoMember" name="PromissoryNoteTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PurchasedTechnologyMember" name="PurchasedTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_RepurchaseMember" name="RepurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_RevenueShareAgreementMember" name="RevenueShareAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SecondAmendmentMember" name="SecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SecuritiesPurchaseAgreementsMember" name="SecuritiesPurchaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesA2PreferredStockMember" name="SeriesA2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesA3PreferredStockMember" name="SeriesA3PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesB1ConvertiblePreferredStockMember" name="SeriesB1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" name="SeriesEConvertiblePreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" name="SeriesGConvertiblePreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ServiceConditionRSUsMember" name="ServiceConditionRSUsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SharesCommittedUnderESPPMember" name="SharesCommittedUnderESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SubscriptionAgreementsMember" name="SubscriptionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TestingServicesMember" name="TestingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TheBigTenConferenceMember" name="TheBigTenConferenceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TheStateOfColoradoMember" name="TheStateOfColoradoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ThirdAmendmentToApaAgreementMember" name="ThirdAmendmentToApaAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandAndSixteenPlanMember" name="TwoThousandAndSixteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandSixPlanMember" name="TwoThousandSixPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandTwentyOneTermLoanMember" name="TwoThousandTwentyOneTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_WarrantLiabilityMember" name="WarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" name="BasisOfPresentationAndEstimatesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContingentConsiderationPolicyTextBlock" name="ContingentConsiderationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DirectCostsAndExpensesPolicyTextBlock" name="DirectCostsAndExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" name="FairValueLiabilitiesMeasuredOnRecurringBasisTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessTable" name="OrganizationAndDescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" name="ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LesseeOperatingAndFinanceLeasesTextBlock" name="LesseeOperatingAndFinanceLeasesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OtherAssetsPolicyTextBlock" name="OtherAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_WarrantsForConvertiblePreferredStockTextBlock" name="WarrantsForConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>bdsx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T02:56:18.3123+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="bdsx-20221231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:href="bdsx-20221231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" xlink:href="bdsx-20221231.xsd#DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureFairValueAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:href="bdsx-20221231.xsd#DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:href="bdsx-20221231.xsd#DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:href="bdsx-20221231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:href="bdsx-20221231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:href="bdsx-20221231.xsd#DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" xlink:href="bdsx-20221231.xsd#DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:href="bdsx-20221231.xsd#DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCancerTest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMoneyOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCommercialBloodBasedTest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfSARSCoV2Test" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_GrossProceedsFromFinancingTransactions" xlink:label="bdsx_GrossProceedsFromFinancingTransactions"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NetProceedFromFinancingTransactionsss" xlink:label="bdsx_NetProceedFromFinancingTransactionsss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_ProductLifeAndPatentLifeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_TestingServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventorySupplies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_GrossProceedsFromFinancingTransactions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_NetProceedFromFinancingTransactionsss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryWriteDown" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CustomerFunds" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilitiesFairValueDisclosure" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_WarrantLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalWarrantsMember" xlink:label="bdsx_AdditionalWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ThirdAmendmentToApaAgreementMember" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ExitFeePayment" xlink:label="bdsx_ExitFeePayment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfInterestOnContingentConsideration" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FourthMilestonePaymentAndInterest" xlink:label="bdsx_FourthMilestonePaymentAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ReductionInContingentConsideration" xlink:label="bdsx_ReductionInContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:label="bdsx_PutOptionLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRightsShares" xlink:label="bdsx_ContingentValueRightsShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRights" xlink:label="bdsx_ContingentValueRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRightsPercentage" xlink:label="bdsx_ContingentValueRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="bdsx_LossMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_SecondAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_AdditionalWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_ThirdAmendmentToApaAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_MilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ExitFeePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfInterestOnContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_FourthMilestonePaymentAndInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ReductionInContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchasedTechnologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_OtherMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SecuritiesPurchaseAgreementsMember" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNoteOneMember" xlink:label="bdsx_PromissoryNoteOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNoteTwoMember" xlink:label="bdsx_PromissoryNoteTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MinimumCashBalanceAtMaturityDate" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalWarrantsAmount" xlink:label="bdsx_AdditionalWarrantsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="bdsx_DescriptionOfSecuritiesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="us-gaap_DerivativeFixedInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract" xlink:label="us-gaap_DerivativeTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiscountsOnDebtInstrumentIssuance" xlink:label="bdsx_DiscountsOnDebtInstrumentIssuance"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance" xlink:label="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage" xlink:label="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" xlink:label="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueMilestone" xlink:label="bdsx_RevenueMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SecuritiesPurchaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PromissoryNoteOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PromissoryNoteTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PerceptiveTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PublicOfferingPricePerShareOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_MinimumCashBalanceAtMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_InitialWarrantsAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_AdditionalWarrantsAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DescriptionOfSecuritiesPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DiscountsOnDebtInstrumentIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_RevenueMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CO" xlink:label="stpr_CO"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CashCollateralizedLetterOfCreditMember" xlink:label="bdsx_CashCollateralizedLetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KS" xlink:label="stpr_KS"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AreaOfOfficeSpaceLeased" xlink:label="bdsx_AreaOfOfficeSpaceLeased"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalTenantImprovementAllowanceAmount" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccretionOfLeaseLiability" xlink:label="bdsx_AccretionOfLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LessorReimbursementsReceived" xlink:label="bdsx_LessorReimbursementsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseExpirationMonthYear" xlink:label="bdsx_LeaseExpirationMonthYear"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CO" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="bdsx_CashCollateralizedLetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_KS" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeasedPropertyBuildingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RentAfterFixedEscalationProvisions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AreaOfOfficeSpaceLeased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AdditionalTenantImprovementAllowanceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AccretionOfLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LessorReimbursementsReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_CustomerFunds" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseExpirationMonthYear" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA1PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA2PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA3PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_EquityFinancingProgramsMember" xlink:label="bdsx_EquityFinancingProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMarketFacilityMember" xlink:label="bdsx_AtTheMarketFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SubscriptionAgreementsMember" xlink:label="bdsx_SubscriptionAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LPCFacilityMember" xlink:label="bdsx_LPCFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ExistingShareholdersMember" xlink:label="bdsx_ExistingShareholdersMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PublicOfferingMember" xlink:label="bdsx_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfFacility" xlink:label="bdsx_NumberOfFacility"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiligenceExpenseAndLegalFees" xlink:label="bdsx_DiligenceExpenseAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WeightedAveragePricePerShare" xlink:label="bdsx_WeightedAveragePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_EquityFinancingProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_LincolnParkMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_AtTheMarketFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SubscriptionAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_LPCFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bdsx_ExistingShareholdersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_PublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfFacility" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_PurchaseAgreementTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_DiligenceExpenseAndLegalFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_WeightedAveragePricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_PublicOfferingPricePerShareOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_InitialWarrantsAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_DiagnosticTestsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bdsx_DeferredRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_PrimarySourcesOfRevenueDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_AdvanceDeposits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_LungDiagnosticRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TheStateOfColoradoMember" xlink:label="bdsx_TheStateOfColoradoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TheBigTenConferenceMember" xlink:label="bdsx_TheBigTenConferenceMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CenturaHealthcareMember" xlink:label="bdsx_CenturaHealthcareMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AstrazenecaUkMember" xlink:label="bdsx_AstrazenecaUkMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LabcorpDdFormerlyCovanceMember" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheStateOfColoradoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheBigTenConferenceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CenturaHealthcareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_AstrazenecaUkMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_LabcorpDdFormerlyCovanceMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ServiceConditionRSUsMember" xlink:label="bdsx_ServiceConditionRSUsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_PerformanceConditionOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandAndSixteenPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_ServiceConditionRSUsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_SharesCommittedUnderESPPMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IncomeTaxExaminationPeriodUnderExamination" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryLiabilityAmortizationPeriod" xlink:label="us-gaap_RegulatoryLiabilityAmortizationPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_IncomeTaxExaminationPeriodUnderExamination" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_RegulatoryLiabilityAmortizationPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_NSCLCPOCTrialMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_RevenueShareAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="bdsx_FiclatuzumabMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BDX004Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_POCClinicalTrialsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_BioRadLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_CellCartaLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RemainingEstimatedObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_LicenseAgreementExpiryDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PeriodOfEscalationsOfSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RevenueShareExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>bdsx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T02:56:19.3512+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="bdsx-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2" xlink:href="bdsx-20221231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="bdsx-20221231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="bdsx-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:href="bdsx-20221231.xsd#DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:href="bdsx-20221231.xsd#DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" xlink:href="bdsx-20221231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl" xlink:href="bdsx-20221231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermNotesPayable" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_Goodwill" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="bdsx_DirectCostsAndExpenses" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bdsx_PaymentsToAcquireOncimmune" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_PaymentOfDeferredOfferingCosts" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="14" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="15" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bdsx_TenantImprovementAllowancesReceived" order="16" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="17" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" order="18" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="19" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="20" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:label="bdsx_PaymentsToAcquireOncimmune"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentOfDeferredOfferingCosts" xlink:label="bdsx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TenantImprovementAllowancesReceived" xlink:label="bdsx_TenantImprovementAllowancesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_LongTermNotesPayable" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bdsx_DeferredTaxAssetsCapitalizedResearchCosts" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>bdsx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-06T02:56:18.2162+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="bdsx-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="bdsx-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="bdsx-20221231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="bdsx-20221231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="bdsx-20221231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="bdsx-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="bdsx-20221231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="bdsx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandards" xlink:href="bdsx-20221231.xsd#DisclosureRecentIssuedAccountingStandards" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinations" xlink:href="bdsx-20221231.xsd#Role_DisclosureBusinessCombinations" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValue" xlink:href="bdsx-20221231.xsd#Role_DisclosureFairValue" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="bdsx-20221231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:href="bdsx-20221231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebt" xlink:href="bdsx-20221231.xsd#Role_DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeases3" xlink:href="bdsx-20221231.xsd#DisclosureLeases3" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:href="bdsx-20221231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:href="bdsx-20221231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquity" xlink:href="bdsx-20221231.xsd#Role_DisclosureEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:href="bdsx-20221231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:href="bdsx-20221231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:href="bdsx-20221231.xsd#DisclosureNetLossPerCommonShare1" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="bdsx-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="bdsx-20221231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" xlink:href="bdsx-20221231.xsd#Role_DisclosureDefinedContribution401KPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="bdsx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueTables" xlink:href="bdsx-20221231.xsd#Role_DisclosureFairValueTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="bdsx-20221231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:href="bdsx-20221231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtTables" xlink:href="bdsx-20221231.xsd#Role_DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesTables" xlink:href="bdsx-20221231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:href="bdsx-20221231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:href="bdsx-20221231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:href="bdsx-20221231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="bdsx-20221231.xsd#DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" xlink:href="bdsx-20221231.xsd#DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureFairValueAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:href="bdsx-20221231.xsd#DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:href="bdsx-20221231.xsd#DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" xlink:href="bdsx-20221231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesParentheticalDetails" xlink:href="bdsx-20221231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl" xlink:href="bdsx-20221231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:href="bdsx-20221231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:href="bdsx-20221231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:href="bdsx-20221231.xsd#DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" xlink:href="bdsx-20221231.xsd#DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:href="bdsx-20221231.xsd#DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:href="bdsx-20221231.xsd#DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="bdsx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:href="bdsx-20221231.xsd#Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Goodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="bdsx_DirectCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" xlink:label="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_14"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_15"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CommonStockIssuedForDeferredOfferingCosts" xlink:label="bdsx_CommonStockIssuedForDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" xlink:label="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IssuanceOfPerceptiveWarrants" xlink:label="bdsx_IssuanceOfPerceptiveWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:label="bdsx_PaymentsToAcquireOncimmune"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:label="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" xlink:label="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" xlink:label="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TenantImprovementAllowancesReceived" xlink:label="bdsx_TenantImprovementAllowancesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PaymentOfDeferredOfferingCosts" xlink:label="bdsx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_CommonStockIssuedForDeferredOfferingCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_IssuanceOfPerceptiveWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bdsx_PaymentsToAcquireOncimmune" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bdsx_TenantImprovementAllowancesReceived" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_PaymentOfDeferredOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandards" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValue" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeases3" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:label="bdsx_LesseeOperatingAndFinanceLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="bdsx_LesseeOperatingAndFinanceLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="bdsx_WarrantsForConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventorySuppliesPolicy" xlink:label="us-gaap_InventorySuppliesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationPolicyTextBlock" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilityPolicyTextBlock" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OtherAssetsPolicyTextBlock" xlink:label="bdsx_OtherAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_DirectCostsAndExpensesPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventorySuppliesPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_ContingentConsiderationPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_WarrantLiabilityPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_OtherAssetsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCancerTest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMoneyOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCommercialBloodBasedTest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfSARSCoV2Test" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_GrossProceedsFromFinancingTransactions" xlink:label="bdsx_GrossProceedsFromFinancingTransactions"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NetProceedFromFinancingTransactionsss" xlink:label="bdsx_NetProceedFromFinancingTransactionsss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_ProductLifeAndPatentLifeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_TestingServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventorySupplies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_GrossProceedsFromFinancingTransactions" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_NetProceedFromFinancingTransactionsss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryWriteDown" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CustomerFunds" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OffsettingDeferredRent" xlink:label="bdsx_OffsettingDeferredRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="bdsx_OffsettingDeferredRent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilitiesFairValueDisclosure" xlink:label="bdsx_WarrantLiabilitiesFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_WarrantLiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalWarrantsMember" xlink:label="bdsx_AdditionalWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ThirdAmendmentToApaAgreementMember" xlink:label="bdsx_ThirdAmendmentToApaAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ExitFeePayment" xlink:label="bdsx_ExitFeePayment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfInterestOnContingentConsideration" xlink:label="bdsx_PercentageOfInterestOnContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FourthMilestonePaymentAndInterest" xlink:label="bdsx_FourthMilestonePaymentAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" xlink:label="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ReductionInContingentConsideration" xlink:label="bdsx_ReductionInContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:label="bdsx_PutOptionLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRightsShares" xlink:label="bdsx_ContingentValueRightsShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRights" xlink:label="bdsx_ContingentValueRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContingentValueRightsPercentage" xlink:label="bdsx_ContingentValueRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="bdsx_LossMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_SecondAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_AdditionalWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_ThirdAmendmentToApaAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_MilestonePayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ExitFeePayment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfInterestOnContingentConsideration" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_VestingAxis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_FourthMilestonePaymentAndInterest" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_StatementScenarioAxis" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ReductionInContingentConsideration" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsShares" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRights" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsPercentage" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchasedTechnologyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_OtherMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SecuritiesPurchaseAgreementsMember" xlink:label="bdsx_SecuritiesPurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNoteOneMember" xlink:label="bdsx_PromissoryNoteOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNoteTwoMember" xlink:label="bdsx_PromissoryNoteTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" xlink:label="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MinimumCashBalanceAtMaturityDate" xlink:label="bdsx_MinimumCashBalanceAtMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalWarrantsAmount" xlink:label="bdsx_AdditionalWarrantsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="bdsx_DescriptionOfSecuritiesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="us-gaap_DerivativeFixedInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract" xlink:label="us-gaap_DerivativeTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiscountsOnDebtInstrumentIssuance" xlink:label="bdsx_DiscountsOnDebtInstrumentIssuance"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance" xlink:label="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage" xlink:label="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" xlink:label="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueMilestone" xlink:label="bdsx_RevenueMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SecuritiesPurchaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PromissoryNoteOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PromissoryNoteTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_PerceptiveTermLoanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PublicOfferingPricePerShareOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_MinimumCashBalanceAtMaturityDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_InitialWarrantsAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_AdditionalWarrantsAmount" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DescriptionOfSecuritiesPurchaseAgreement" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeTermOfContract" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DiscountsOnDebtInstrumentIssuance" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_RevenueMilestone" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CO" xlink:label="stpr_CO"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CashCollateralizedLetterOfCreditMember" xlink:label="bdsx_CashCollateralizedLetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KS" xlink:label="stpr_KS"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AreaOfOfficeSpaceLeased" xlink:label="bdsx_AreaOfOfficeSpaceLeased"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdditionalTenantImprovementAllowanceAmount" xlink:label="bdsx_AdditionalTenantImprovementAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" xlink:label="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" xlink:label="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AccretionOfLeaseLiability" xlink:label="bdsx_AccretionOfLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LessorReimbursementsReceived" xlink:label="bdsx_LessorReimbursementsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerFunds" xlink:label="us-gaap_CustomerFunds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LeaseExpirationMonthYear" xlink:label="bdsx_LeaseExpirationMonthYear"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CO" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="bdsx_CashCollateralizedLetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_KS" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseCommencementDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeasedPropertyBuildingCapacity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RentAfterFixedEscalationProvisions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AreaOfOfficeSpaceLeased" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AdditionalTenantImprovementAllowanceAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_RemainingCapacityUnderTheTenantImprovementAllowances" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCredit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_AccretionOfLeaseLiability" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LessorReimbursementsReceived" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCash" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_CustomerFunds" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bdsx_LeaseExpirationMonthYear" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" xlink:label="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" xlink:label="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TenantImprovementAllowancesExpectedToBeReceived" xlink:label="bdsx_TenantImprovementAllowancesExpectedToBeReceived"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="bdsx_TenantImprovementAllowancesExpectedToBeReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA1PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA2PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA3PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_EquityFinancingProgramsMember" xlink:label="bdsx_EquityFinancingProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMarketFacilityMember" xlink:label="bdsx_AtTheMarketFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SubscriptionAgreementsMember" xlink:label="bdsx_SubscriptionAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LPCFacilityMember" xlink:label="bdsx_LPCFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ExistingShareholdersMember" xlink:label="bdsx_ExistingShareholdersMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerceptiveTermLoanMember" xlink:label="bdsx_PerceptiveTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PublicOfferingMember" xlink:label="bdsx_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" xlink:label="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfFacility" xlink:label="bdsx_NumberOfFacility"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiligenceExpenseAndLegalFees" xlink:label="bdsx_DiligenceExpenseAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" xlink:label="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" xlink:label="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_WeightedAveragePricePerShare" xlink:label="bdsx_WeightedAveragePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" xlink:label="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PublicOfferingPricePerShareOfCommonStock" xlink:label="bdsx_PublicOfferingPricePerShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_InitialWarrantsAmount" xlink:label="bdsx_InitialWarrantsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_EquityFinancingProgramsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_LincolnParkMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_AtTheMarketFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_SubscriptionAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bdsx_LPCFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bdsx_ExistingShareholdersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PerceptiveTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_PublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfFacility" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_PurchaseAgreementTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_DiligenceExpenseAndLegalFees" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_WeightedAveragePricePerShare" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_PublicOfferingPricePerShareOfCommonStock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_InitialWarrantsAmount" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_DiagnosticTestsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bdsx_DeferredRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_PrimarySourcesOfRevenueDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_AdvanceDeposits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_LungDiagnosticRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TheStateOfColoradoMember" xlink:label="bdsx_TheStateOfColoradoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TheBigTenConferenceMember" xlink:label="bdsx_TheBigTenConferenceMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CenturaHealthcareMember" xlink:label="bdsx_CenturaHealthcareMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AstrazenecaUkMember" xlink:label="bdsx_AstrazenecaUkMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LabcorpDdFormerlyCovanceMember" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheStateOfColoradoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheBigTenConferenceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CenturaHealthcareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_AstrazenecaUkMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_LabcorpDdFormerlyCovanceMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_ServiceConditionRSUsMember" xlink:label="bdsx_ServiceConditionRSUsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_PerformanceConditionOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandAndSixteenPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_ServiceConditionRSUsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_SharesCommittedUnderESPPMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_IncomeTaxExaminationPeriodUnderExamination" xlink:label="bdsx_IncomeTaxExaminationPeriodUnderExamination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryLiabilityAmortizationPeriod" xlink:label="us-gaap_RegulatoryLiabilityAmortizationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription_13"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="bdsx_IncomeTaxExaminationPeriodUnderExamination" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_RegulatoryLiabilityAmortizationPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="bdsx_DeferredTaxAssetsCapitalizedResearchCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="bdsx_DeferredTaxAssetsCapitalizedResearchCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_NSCLCPOCTrialMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_RevenueShareAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="bdsx_FiclatuzumabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BDX004Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_POCClinicalTrialsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_BioRadLicenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_CellCartaLicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RemainingEstimatedObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_LicenseAgreementExpiryDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PeriodOfEscalationsOfSales" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RevenueShareExpenses" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20221231.xsd#bdsx_DefinedContributionPlanNameExtensibleList" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="bdsx_DefinedContributionPlanNameExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787065360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Biodesix, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3986492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2970 Wilderness Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-0500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BDSX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,974,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Denver, CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Company&#8217;s definitive Proxy Statement for its 2023 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.)</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787327472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 43,088<span></span>
</td>
<td class="nump">$ 32,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $118 and $158</a></td>
<td class="nump">5,065<span></span>
</td>
<td class="nump">3,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">5,181<span></span>
</td>
<td class="nump">7,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">53,334<span></span>
</td>
<td class="nump">43,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non&#8209;current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">9,797<span></span>
</td>
<td class="nump">11,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">15,031<span></span>
</td>
<td class="nump">15,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">5,923<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non&#8209;current assets</a></td>
<td class="nump">39,572<span></span>
</td>
<td class="nump">32,484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">92,906<span></span>
</td>
<td class="nump">76,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">8,218<span></span>
</td>
<td class="nump">7,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">962<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">10,341<span></span>
</td>
<td class="nump">17,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,839<span></span>
</td>
<td class="nump">28,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non&#8209;current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term notes payable, net of current portion</a></td>
<td class="nump">25,004<span></span>
</td>
<td class="nump">9,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">18,645<span></span>
</td>
<td class="nump">16,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">1,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non&#8209;current liabilities</a></td>
<td class="nump">49,461<span></span>
</td>
<td class="nump">27,410<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">72,300<span></span>
</td>
<td class="nump">56,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2022 and 2021) issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 authorized; 77,614,358 (2022) and 30,789,649 (2021) shares issued and outstanding</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid&#8209;in capital</a></td>
<td class="nump">387,948<span></span>
</td>
<td class="nump">321,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(367,420)<span></span>
</td>
<td class="num">(301,973)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">20,606<span></span>
</td>
<td class="nump">19,727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 92,906<span></span>
</td>
<td class="nump">$ 76,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1),20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787041216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">77,614,358<span></span>
</td>
<td class="nump">30,789,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">77,614,358<span></span>
</td>
<td class="nump">30,789,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787336592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 38,212<span></span>
</td>
<td class="nump">$ 54,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DirectCostsAndExpenses', window );">Direct costs and expenses</a></td>
<td class="nump">14,154<span></span>
</td>
<td class="nump">30,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,102<span></span>
</td>
<td class="nump">12,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, marketing, general and administrative</a></td>
<td class="nump">61,462<span></span>
</td>
<td class="nump">50,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on intangible assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">88,799<span></span>
</td>
<td class="nump">95,446<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(50,587)<span></span>
</td>
<td class="num">(40,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8,072)<span></span>
</td>
<td class="num">(4,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Loss) gain on extinguishment of liabilities, net</a></td>
<td class="num">(6,981)<span></span>
</td>
<td class="nump">2,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income (loss), net</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(14,860)<span></span>
</td>
<td class="num">(2,219)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,447)<span></span>
</td>
<td class="num">$ (43,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">42,103,000<span></span>
</td>
<td class="nump">27,365,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">42,103,000<span></span>
</td>
<td class="nump">27,365,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent consideration excluding accretion expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858786684640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 41,166<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 299,953<span></span>
</td>
<td class="num">$ (258,814)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">15,679<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">15,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,159)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">19,727<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">321,669<span></span>
</td>
<td class="num">(301,973)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">56,235<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">56,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts', window );">Issuance of common stock for deferred offering costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts', window );">Issuance of common stock for deferred offering costs</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">384,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Release of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Initial Warrants</a></td>
<td class="nump">2,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,447)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">$ 20,606<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 387,948<span></span>
</td>
<td class="num">$ (367,420)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, values, for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858786571056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (65,447)<span></span>
</td>
<td class="num">$ (43,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,597<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of lease right-of-use assets</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss (gain) on extinguishment of liabilities, net</a></td>
<td class="nump">6,981<span></span>
</td>
<td class="num">(2,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">5,961<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther', window );">Accrued interest, amortization of debt issuance costs and other</a></td>
<td class="nump">5,037<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory excess and obsolescence</a></td>
<td class="nump">906<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on intangible assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,501)<span></span>
</td>
<td class="nump">11,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet', window );">Other long-term assets</a></td>
<td class="num">(3,504)<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="num">(773)<span></span>
</td>
<td class="num">(7,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,213)<span></span>
</td>
<td class="num">(1,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_TenantImprovementAllowancesReceived', window );">Tenant improvement allowances received</a></td>
<td class="nump">2,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Current and long-term operating lease liabilities</a></td>
<td class="num">(937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and cash equivalents and restricted cash used in operating activities</a></td>
<td class="num">(44,972)<span></span>
</td>
<td class="num">(28,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(3,298)<span></span>
</td>
<td class="num">(2,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet', window );">Patent costs and intangible asset acquisition, net</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and cash equivalents and restricted cash used in investing activities</a></td>
<td class="num">(3,534)<span></span>
</td>
<td class="num">(2,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">59,538<span></span>
</td>
<td class="nump">16,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(10,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable', window );">Proceeds from term loan and notes payable</a></td>
<td class="nump">45,102<span></span>
</td>
<td class="nump">30,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan and notes payable</a></td>
<td class="num">(28,604)<span></span>
</td>
<td class="num">(45,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(3,725)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PaymentOfDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity financing costs</a></td>
<td class="num">(3,069)<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and cash equivalents and restricted cash provided by financing activities</a></td>
<td class="nump">58,882<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">10,376<span></span>
</td>
<td class="num">(29,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8209; beginning of period</a></td>
<td class="nump">32,798<span></span>
</td>
<td class="nump">62,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8209; end of period</a></td>
<td class="nump">43,174<span></span>
</td>
<td class="nump">32,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_CommonStockIssuedForDeferredOfferingCosts', window );">Common stock issued for deferred offering costs</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital', window );">Deferred offering costs amortized against Additional paid-in capital</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_IssuanceOfPerceptiveWarrants', window );">Issuance of Perceptive Warrants</a></td>
<td class="nump">3,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities', window );">Debt issuance costs included in Accounts payable and other accrued liabilities</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities', window );">Equity financing costs included in Accounts payable and other accrued liabilities</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842', window );">Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842</a></td>
<td class="nump">1,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">3,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance lease right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest, amortization of debt issuance costs and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_CommonStockIssuedForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_CommonStockIssuedForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs included in Accounts payable and other accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs amortized against additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity financing costs included in Accounts payable and other accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IssuanceOfPerceptiveWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of perceptive warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IssuanceOfPerceptiveWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for proceeds from patent costs and intangible asset acquisition, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of term loan and notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TenantImprovementAllowancesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowances received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TenantImprovementAllowancesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791781840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessAbstract', window );"><strong>Organization And Description Of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 1 &#8211; Organization and Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biodesix, Inc. (the &#8220;Company&#8221;, &#8220;Biodesix&#8221;, &#8220;we&#8221; &#8220;us&#8221; and &#8220;our&#8221;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#8217;s headquarters are in Colorado and performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a leading data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. We derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services). Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung&#174; nodule risk assessment testing strategy, consisting of the Nodify XL2&#174; and the Nodify CDT&#174; tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung&#153; strategy for lung cancer patients integrates the GeneStrat&#174; ddPCR test, the GeneStrat NGS&#153; test and the VeriStrat&#174; test to support treatment decisions across all stages of lung cancer.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also offers three SARS-CoV-2 tests. The Bio-Rad SARS-CoV-2 ddPCR test, the cPASS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> neutralization antibody test kit, and the Platelia SARS-CoV-2 Total Ab test have been granted Emergency Use Authorization (EUA) by the Federal Drug Administration (FDA) under Section 564 of the Federal Food, Drug, and Cosmetic Act (FDCA). Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. The EUA declaration under Section 564 of the FDCA is distinct from and independent of the declaration by the Secretary of HHS of a public health emergency under Section 319 of the Public Health Service Act (the PHS Act). On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#8217;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. Because the EUA declaration from the FDA is distinct from the declaration under Section 319 of the PHS Act, the FDA EUA may remain in effect beyond the duration of the Section 319 declaration. We cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The Company leverages the proprietary and advanced Diagnostic Cortex&#174; AI (Artificial Intelligence) platform, to collaborate with many of the world&#8217;s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Blood-Based Lung Tests</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company offers </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> blood-based lung cancer tests across the lung cancer continuum of care:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diagnosis</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nodify XL2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nodify CDT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> tests, marketed as our Nodify Lung Nodule Risk Assessment testing strategy, assess a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treatment &amp; Monitoring</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GeneStrat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ddPCR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VeriStrat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> tests, marketed as part of our IQLung testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#8217;s immune system to establish the patient&#8217;s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a turnaround time of two business days, providing physicians with timely results to facilitate treatment decisions.</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GeneStrat NGS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (NGS) test, also marketed as part of our IQLung testing strategy, is our blood-based NGS test with results in three business days. The NGS test was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations in genes, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 Tests</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate and have commercialized the Biodesix WorkSafe&#153; testing program, under which the Company offers </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> SARS-CoV-2 tests:</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bio-Rad SARS-CoV-2 ddPCR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">test, which is FDA EUA authorized to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of current infection by the SARS-CoV-2 virus.</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platelia SARS-CoV-2 Total Ab </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">test, which is an antibody test, FDA EUA authorized by the FDA, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection.</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">cPass SARS-CoV-2 Neutralization Antibody </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">test, which is the first blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection. This test was commercially introduced in partnership with GenScript Biotech Corporation.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#8217;s testing services are made available through its clinical laboratories.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OrganizationAndDescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OrganizationAndDescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858786563312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 2 &#8211; Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation and Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; warrant liabilities; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we maintained cash and cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and we have </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in outstanding aggregate principal amount on our Perceptive Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#8217;s ability to continue as a going concern, management projected its cash flow sources, including the debt and equity funding and amendments to the Integrated Diagnostics, Inc. (Indi) Agreement, and evaluated the conditions and events that could raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#8217;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreement (see Note 8 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic and the associated impacts on the recovery of our diagnostic testing and services, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital during 2022, amendments to our 2021 Term Loan and amended the Indi Agreement to delay near term cash requirements and extend the period of milestone</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payments. We have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company funded and/or closed various financing transactions, including: (i) a term loan facility for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, with funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the issuance of warrants exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock occurring on November 21, 2022, and two additional contingently issuable tranches of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each subject to certain terms and conditions, including revenue milestones, (ii) a follow-on equity offering of common stock and (iii) a subscription agreement for the issuance of common stock to certain members of the Company&#8217;s management team. Collectively, the Company raised gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting commissions, fees and expenses payable). Approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the net proceeds were used to retire outstanding debt of the Company with Streeterville Capital, LLC and Silicon Valley Bank. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4d32ba86-04c2-4e99-bbda-0fc5bb64105e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">single</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment focused on providing diagnostic testing services to customers. All of the Company&#8217;s revenue and long-lived assets were derived or located in the United States for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 11 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Direct Costs and Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales, Marketing, General and Administrative Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2022 and 2021, see Note 11 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card. As of December 31, 2022 and 2021, the Company had </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted cash, respectively, which was included in &#8216;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_c127f513-dd4b-4997-b27b-a9cd90962444;"><span style="-sec-ix-hidden:F_7fd39517-ff33-41f8-ae14-0d40bd4ae488;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8217; in the accompanying balance sheets.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#8216;Direct c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">osts and expenses&#8217;. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The Company recorded a reserve for excess inventory of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, primarily associated with the wind down of the COVID-19 testing operation, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, to the statement of operations for excess and obsolete inventory.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_06324b01-1be5-4c23-bbaa-fc1231d74b49;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_67b38028-3a72-49aa-81eb-6a352ab4c65b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments for th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There was an immaterial impairment during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments for th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2022, there</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accumulated impairment losses.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million cash refundable deposit to secure the performance of the Company&#8217;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million refundable deposit is reported within 'Other long-term assets' in the balance sheet.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.815%;"/>
        <td style="width:2.083%;"/>
        <td style="width:86.102%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 4 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further discussion related to estimated fair value measurements.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the purchase transaction with Indi, the Company recorded contingent consideration for amounts potentially payable to Indi&#8217;s shareholder upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was achieved is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#8216;Interest expense&#8217; in the statements of operations resulting from the passage of time and fixed payment schedule.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the Company issued a warrant to purchase common stock to the Lender of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock (the Perceptive Warrant), with warrants exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock issued on the funding date of the Tranche A Loan (the Initial Warrants) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as well as up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional warrants that are contingent upon the Company&#8217;s borrowing the remaining availability under the Perceptive Term Loan Facility (the Additional Warrants). The Initial Warrants are equity classified (see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) while the Additional Warrants are classified as liabilities and subject to fair value measurement (see Note 4 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share&#8209;Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units (RSUs)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 12 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information related to share-based compensation.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">s</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 14 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information related to income taxes.</span></p></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793345920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Issued Accounting Standards</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 3 &#8211; Recent Issued Accounting Standards</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2016, the FASB issued ASU No. 2016-2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ASC 842). This ASU intends to make accounting for leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases accounted for as operating leases. In addition to other related amendments, the FASB issued ASU No. 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. The Company elected this transition method and adopted ASC 842 on January 1, 2022 and as a result, recorded operating lease </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_7af1e3c8-01b6-4f0f-8209-47648e9fba35;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rig</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ht-of-use</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ROU) assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, including offsetting deferred rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, along with the associated </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_212e7808-bfbd-4077-abc2-795e910b5233;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating lease liabilities</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On January 1, 2022, the Company did not have any finance leases. The adoption of ASC 842 did not result in a cumulative effect adjustment to beginn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ing retained earnings, and did not materially affect the Company's statement of operations, statement of stockholders' equity or statement of cash flows for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company elected the following practical expedients permitted under the transition guidance within the new standard:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Package of practical expedients which allows the Company to carry forward the historical lease classification;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of ROU assets;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more, and;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/>Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#8220;major part of remaining economic life of the underlying asset&#8221; and &#8220;substantially all of the fair value of the underlying asset.&#8221; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional information and disclosures required by this new standard are contained in Note 9 &#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Standards Being Evaluated</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the guidance and determined the overall impact of the adoption will have an immaterial impact on our financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858874090832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 4 - Fair Value</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recurring Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair value of borrowings as of December 31, 2022 is primarily associated with the Perceptive Term Loan entered into with Perceptive Credit Holdings IV, LP, in November 2022 and was determined using a discounted cash flow analysis, excluding the fair value of Perceptive Warrant issued in conjunction with the transaction. The difference between the carrying value and fair value of outstanding borrowings as of December 31, 2022 is due to the debt issuance costs and the fair value of Perceptive Warrant netted against the Perceptive Term Loan. The carrying value of outstanding borrowings as of December 31, 2021, approximates fair value based on interest rates available at that time for similar borrowings. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"/>
        <td style="width:1.127%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.842%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.127%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.127%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.91%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.127%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.037%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,053</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,785</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our previous acquisition of Indi and the warrant liabilities granted as consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), which were accounted for as liabilities and remeasured through our statements of operations.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below presents the reported fair values of contingent consideration and warrant liabilities,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.38%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.842%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.774%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,341</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,764</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,986</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,792</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the changes in contingent consideration </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and warrant liabilities for the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.871%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.263%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent Consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balances - January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,792</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,082</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,934</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,822</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balances - December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,986</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the changes in contingent consideration as of the date indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.136%;"/>
        <td style="width:1.753%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.11%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balances - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,932</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,622</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,238</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balances - December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,792</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (the Indi APA). The contingent consideration arrangement </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the acquisition date. Under the terms of the original agreement, when the gross margin target was achieved the Company was required to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,520,108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. For the six months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eight</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> equal quarterly installments. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> equal and consecutive quarterly cash installments totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company achieved the gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for three consecutive months during the three months ended June 30, 2021. The Company entered into an amendment to the original agreement in August 2021 in which all parties agreed to forgo the issuance of common stock and agreed that the Company will in lieu thereof make </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> quarterly installments of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each beginning in January 2022 and a final payment of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in July 2023 for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. (the Milestone Payments and each individually a Milestone Payment). The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which the parties agreed to restructure the Milestone Payments whereby the Company will make </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> quarterly installments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each beginning in April 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> quarterly installments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million beginning in July 2023, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> installment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in April 2024, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> installment of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in July 2024. In addition, the Company agreed to an exit fee of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, with such interest to be payable quarterly on the following installment payment date. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan and commencing January 1, 2024, consent from Perceptive (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The contingent consideration liability is accounted for at fair value and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. As a result of the achievement of the gross margin target, the only remaining significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate could result in a significantly higher or lower fair value measurement. During the three months ended June 30, 2022, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in interest expense due to the passage of time and fixed payment schedule, partially offset by a reduction to the contingent consideration balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million due to an increase in the discount rate to reflect current market and Company specific conditions, resulting in $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, net recorded as &#8216;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_bd934ce6-93a4-4c03-8768-1ed24686b2e3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8217; in the statements of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated Amendment No. 3 to the Indi APA in accordance with applicable accounting standards under U.S. GAAP which resulted in the extinguishment of the original instrument due to the substantially different terms. As a result, during the three months ended June 30, 2022, we recorded a loss on extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the statements of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recorde</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, r</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">espectively, in interest expense due to the passage of time and fixed payment schedule.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration expected to be paid in the next twelve months is recorded in the balance sheets as &#8216;Current portion of contingent consideration&#8217; while the remaining amount to be paid is recorded as &#8216;Contingent consideration&#8217; within non-current liabilities. The net change to contingent consideration through the date the gross margin target was achieved is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#8216;Interest expense&#8217; in the statements of operations resulting from the passage of time and fixed payment schedule.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrant liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the Company issued the Perceptive Warrant to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, including Initial Warrants and Additional Warrants. The Initial Warrants are equity classified (see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) while the Additional Warrants are classified as liabilities within 'Other long-term liabilities' and recognized at fair value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The fair value of the Additional Warrants is determined using a Black-Scholes model and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the fair value of the Company's common stock, risk-free rate, the volatility of common stock which ranged from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, and the probability of the expected borrowing. Significant increases or decreases in the unobservable inputs could result in a significantly higher or lower fair value measurement. The Company determined the initial fair value of the Additional Warrants to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as a change in fair value through the statement of operations due to changes in unobservable inputs.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858878925680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 5 &#8211; Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.262%;"/>
        <td style="width:1.499%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.774000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.499%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.968%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,035</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,784</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,365</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,339</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">749</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">700</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">349</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">391</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">324</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vehicles</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,947</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,866</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,928</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,018</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,749</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,848</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,179</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense related to pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operty and equipment was:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.293%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.679%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.058%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">614</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">614</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,622</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,228</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791887920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 6 &#8211; Goodwill and Intangible Assets</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.602%;"/>
        <td style="width:0.905%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.3629999999999995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.235%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.005%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.3629999999999995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.28%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.804%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.2749999999999995%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets subject to amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,880</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">647</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,755</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">566</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,189</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchased technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets not subject to<br/>&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trademarks</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,894</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,097</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,755</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,138</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,617</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.598%;"/>
        <td style="width:1.901%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.539%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.726%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.235%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,973</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,945</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future estimated amortization expense of intangible </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assets is (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.617%;"/>
        <td style="width:1.732%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.652%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,972</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,963</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,957</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,943</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">992</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">856</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,683</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858878925680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 7 &#8211; Accrued Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.293%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.679%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.058%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation related accruals</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,671</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,029</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued clinical trial expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,232</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">870</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,315</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,766</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,218</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791913856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 8 &#8211; Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our long-term debt primarily consists of notes payable associated with our Perceptive Term Loan which is described in further detail below. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term notes payable were as follows (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.716%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.477%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.848%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Perceptive Term Loan</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,000</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Term Loan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,074</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,053</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: current maturities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term notes payable</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,004</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,993</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Perceptive Term Loan Facility</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 16, 2022 (the Closing Date), the Company entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as the lender and administrative agent (the Lender). The Credit Agreement provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the Perceptive Term Loan Facility). The initial funding of the Perceptive Term Loan Facility was subject to a capital raise of at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in gross proceeds from an equity offering of the Company's common stock. On November 21, 2022 (the Funding Date), the Company raised approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in gross proceeds from the sale of common stock (the Public Offering and November 2022 Subscription Agreements, together, "the Equity Offerings", see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The Tranche A Loan, in an aggregate amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the Tranche A Loan), was funded under the Perceptive Term Loan Facility substantially and concurrently with the closing of the Equity Offerings on the Funding Date. In addition to the Tranche A Loan, the Perceptive Term Loan Facility includes an additional Tranche B Loan, in an aggregate amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and an additional Tranche C Loan, in an aggregate amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which will be accessible by the Company so long as the Company satisfies certain customary conditions precedent, including revenue milestones. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Tranche B and C loans have loan commitments dates through December 31, 2023 and September 30, 2024, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Perceptive Term Loan Facility has a maturity date of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2027</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity Date)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provides for an interest-only period during the term of the loan with principal due at the Maturity Date. The Company's net proceeds from the Tranche A Loan were approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">debt issuance costs and expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Rate</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Perceptive Term Loan Facility will accrue interest at an annual rate equal to the greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. and (b) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum, plus an applicable margin of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the stated interest rate was approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amortization and Prepayment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On the Maturity Date, the Company is required to pay the Lender the aggregate outstanding principal amount underlying the Loan and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments under the Perceptive Term Loan Facility. The Perceptive Term Loan Facility may be prepaid at any time, subject to a prepayment premium equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Security Instruments and Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to a Security Agreement, dated as of the Funding Date (the Security Agreement), between the Company and the Lender, substantially all of the Company&#8217;s obligations under the Credit Agreement are secured by a first lien perfected security interest on all of the Company&#8217;s assets, subject to customary exceptions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Credit Agreement, the Company has issued, on the Funding Date, the Perceptive Warrant of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including the Initial Warrants which are equity classified at a per share exercise price equal to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0648</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which is equal to the lower of (A) the 10-day volume weighted average price (VWAP) of the Company&#8217;s common stock, on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of Common Stock of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In addition to the Initial Warrants, the Additional Warrants will each become exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The per share exercise price for the Additional Warrants will be equal to the lower of (A) the Initial Warrant exercise price or (B) the 10-day VWAP ending on the business day immediately preceding the funding date of the Tranche B Loan or the Tranche C loan, res</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pectively. Each warrant will be exercisable, in whole or in part, until the 10th anniversary of the applicable date of issuance. If the Tranche B or C loans are not drawn by the respective loan commitment dates, the associated Additional Warrants expire and will not become exercisable. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Representations, Warranties, Covenants, and Events of Default</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants, financial covenants, and conditions that are customarily required for similar financings. The affirmative covenants, among other things, require the Company to undertake various reporting and notice requirements, maintain insurance and maintain in full force and effect all Regulatory Approvals, Material Agreements, Material Intellectual Property (each as defined in the Credit Agreement) and other rights, interests or assets (whether tangible or intangible) reasonably necessary for the operations of the Company&#8217;s business. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s business activities; make certain Investments or Restricted Payments (each as defined in the Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that has the impact of restricting the Company&#8217;s ability to make loan repayments under the Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million; and (ii) as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2023, receive revenue in amounts agreed to between the Company and Perceptive from time to time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Credit Agreement also contains certain customary Events of Default which include, among others, non-payment of principal, interest, or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross- defaults to material contracts, certain regulatory-related events and events constituting a change of control. As of December 31, 2022, the Company was in compliance with all restrictive and financial covenants associated with its borrowings. The occurrence of an Event of Default could result in, among other things, the declaration that all outstanding principal and interest under the Perceptive Term Loan Facility are immediately due and payable in whole or in part.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Initial Warrants and Additional Warrants were valued at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, using the Black-Scholes option-pricing model, estimated settlement probabilities and estimated exercise prices. As a result of the fees paid to Perceptive and the value of the Perceptive Warrant, the Company recognized a discount on the Perceptive Term Loan in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company recorded the debt discount as a reduction to the principal amount of the debt and is amortized as interest expense over the life of the debt.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Securities Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 9, 2022 (the First Closing Date), the Company entered into a securities purchase agreement (the SPA) with Streeterville Capital, LLC (Streeterville), pursuan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t to which, among other things, Streeterville: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) purchased a secured promissory note (Promissory Note One) in the aggregate principal amount totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in exchange for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company&#8217;s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in exchange for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash proceeds.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of the Promissory Notes, at the Company's option, could be settled in cash or shares of common stock of the Company, upon the terms and subject to the limitations and conditions set forth in the Promissory Notes. The Company's net proceeds from the issuance of Promissory Note One were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting debt issuance costs and original issue discount (OID).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Promissory Notes had a stated interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum. The maturity date of each Promissory Note was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months from the issuance date of such Note. Promissory Note One was issued with an OID of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million while Promissory Note Two, if issued, would have been subject to an OID of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million subject to certain contingencies which could increase the OID by an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Promissory Notes were eligible for early payment for cash, at the Company&#8217;s election, subject to a prepayment premium of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding principal balance. During the year ended</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> December 31, 2022, the Company recorded </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for accrued interest, amortization of the OID and debt issuance costs to interest expense in the accompanying statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially and concurrently with the completion of the Equity Offerings, the Company fully repaid all outstanding principal, accrued and unpaid interest, and prepayment and other fees due under the existing SPA with Streeterville in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the extinguishment of Promissory Note One, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he Company recorded a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the three months ended December 31, 2022, associated with the prepayment premium and with the write-off of unamortized debt issuance costs and OID.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Term Loan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 19, 2021 (Effective Date), the Company entered into a Loan and Security Agreement (the 2021 Term Loan) by and between Silicon Valley Bank, a California corporation (SVB) and the Company, as borrower, whereby subject to the terms and conditions of the 2021 Term Loan, SVB advanced to the Company an original principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Term Loan provided for an &#8220;interest-only&#8221; period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan was payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan accrued interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, was payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate were effective on the effective date of any change to the prime rate.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s final payment to SVB included a payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">amortized as interest expense over the term of the 2021 Term Loan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and through the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Closing Date of the Perceptive Term Loan Facility, the Company repaid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in outstanding principal on the 2021 Term Loan.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Substantially and concurrently with the completion of the Equity Offerings, the Company fully repaid all outstanding principal, accrued and unpaid interest, and other fees due under the existing 2021 Term Loan with SVB in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which included $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in remaining outstanding principal. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the extinguishment of the 2021 Term Loan, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he Company recorded a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the three months ended December 31, 2022, associated with the final payment and the write-off of unamortized debt issuance costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.51%;"/>
        <td style="width:1.774%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.717000000000002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of<br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,000</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,127</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793345920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LesseeOperatingAndFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 9 &#8211; Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company acts as a lessee under all its lease agreements. The Company leases its headquarters and laboratory facilities in Boulder, Colorado, under a non-cancelable lease agreement for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,722</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet that was set to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_69f529c7-a6b6-4870-92d2-707a07490f78;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2023</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In January 2022, the Company amended the agreement to extend the lease agreement through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1f6e0faa-935f-477f-be66-d4008a184239;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2024</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, resulting in an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in ROU assets and lease liabilities recorded during the three months ended March 31, 2022. The Company also leases laboratory and office space in De Soto, Kansas, under a non-cancelable lease agreement for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,066</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet that expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9b0044c9-456b-40db-b304-cbb2a4cddf06;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2023, however, we are currently in discussions to extend this lease agreement</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company also holds various copier and storage facility leases under non-cancelable lease agreements that expire in the next </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_558ae46e-8ea1-4c0a-9a4d-100dfe66de89;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0980ea39-5787-4d2b-b800-5afec28cfc63;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Centennial Valley Properties I, LLC Lease Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space in Louisville, Colorado (the Leased Premises). The purpose of the Lease is to replace the Company&#8217;s current leased premises in Boulder, Colorado. The Company intends to move its corporate headquarters to the Leased Premises by mid-2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial term of the Lease is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">twelve years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 1, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal options to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extend</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the term of the Lease for an additional seven or ten year terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in ROU assets and lease liabilities being recorded. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Lease, the Company will lease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,980</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per month and escalating, based on fixed escalation provisions, to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">326,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,980</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million toward the cost of construction and improvements for the Leased Premises and the Company exercised its option for an additional tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per year over the Initial Term excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount. The Company made an accounting policy election to reduce the right-of-use asset and lease liability at lease commencement because the Lease specifies a maximum level of reimbursement for tenant improvements which are probable of being incurred and within the Company's control. Due to the tenant improvement allowances at the accounting lease commencement date and rent abatement periods described above, the Company expects the lease liability to accrete to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million by March 2024 after receiving $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in lessor reimbursements. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Company has incurre</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">capital expenditures for leasehold improvements related to the Leased Premises which are tenant improvements and have been reimbursed from the Landlord during the three months ended December 31, 2022. As of December 31, 2022, the Company had remaining capacity under the tenant improvement allowances of approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. During the three months ended September 30, 2022, a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million cash collateralized letter of credit under the operating lease agreement was released and the funds were subsequently transferred to the Landlord as a refundable deposit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#8217;s obligations. The $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million refundable deposit is included within '</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_619e0fd9-df0a-4ffa-8df0-66030beb9821;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">' in the balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease expense for all operating leases was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the year ended December 31, 2022 and 2021, respectively. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted-average remaining lease term and discount rate associated with our operating leases were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ctively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments associated with our operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.796%;"/>
        <td style="width:1.869%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.334%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of<br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,289</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,619</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,710</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,063</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,263</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,922</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amount representing interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,802</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amount representing tenant improvement allowances</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,323</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The remaining contractually agreed upon tenant improvement allowances of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are expected to be received during fiscal year 2023.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations in accordance with ASC 840 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.784%;"/>
        <td style="width:1.711%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.506%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">775</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">937</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LesseeOperatingAndFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LesseeOperatingAndFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791913856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 10 &#8211; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holder of each share of common stock is entitled to one vote per share.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock were issued or outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Financing Programs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> facilities that enable equity financing on an ongoing basis at the Company&#8217;s sole discretion, our at-the-market offering and our common stock purchase agreement with Lincoln Park Capital Fund, LLC (the LPC facility). In November 2021, the Company entered into a sales agreement with a financial institution, pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the Shares), subject to terms and conditions. The Shares will be offered and sold by the Company pursuant to its previously filed and currently effective registration statement on Form S-3. The Shares may only be offered and sold by means of a prospectus, including a prospectus supplement, forming part of the effective registration statement. Sales of the common stock, if any, will be made at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Global Market, or any other existing trading market for our common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2022 (the LPC Effective Date), the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), pursuant to which Lincoln Park has committed to purchase up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the Company's common stock (the Purchase Agreement). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the Company&#8217;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#8217;s</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sole </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">discretion, over the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period commencing on the LPC Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, but that amount may be increased up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, depending upon the market price of the Company&#8217;s common stock at the time of sale and subject to a maximum limit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#8217;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under applicable rules of the NASDAQ Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#8217;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of its common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the LPC Effective Date, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,275</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock to Lincoln Park as a commitment fee (the Initial Commitment Shares) for which the Company did not receive consideration and, upon the available amount being reduced to an amount equal to or less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the Company will be required to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,425</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares (the Additional Commitment Shares and together with the Initial Commitment Shares, collectively, the Commitment Shares). The Initial Commitment Shares issued were valued at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and, together with due diligence expenses and legal fees of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, reflect deferred offering costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">729,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which are included on the balance sheet in 'Other long-term assets'. The deferred offering costs will be charged against 'Additional paid-in capital' upon future proceeds from the sale of common stock under the Purchase Agreement. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of deferred offering costs were charged against 'Additional paid-in capital'. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">654,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of deferred offering costs remain.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company raised approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting underwriting discounts and commissions and offering expenses payable), in gross proceeds from the sale of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,886,893</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares at a weighted average price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.87</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> under these programs. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had remaining available capacity for share issuances of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under the at-the-market facility and up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under the LPC facility, each subject to the restrictions and limitations of the underlying facilities, as well as volume limitations under applicable SEC rules and regulations that limit their availability as sources of funding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 30, 2021, the Company raised approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in gross proceeds from the sale of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,756,994</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">per share in an at-the-market offering</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and offering expenses payable of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company closed an underwritten public offering (the Public Offering) of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,075,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock (the Public Offering Shares), including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,575,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares purchased by the underwriter pursuant to an option to purchase additional shares. The Public Offering Shares were issued and sold pursuant to an underwriting agreement, dated November 16, 2022, by and between the Company and William Blair &amp; Company, L.L.C., as sole underwriter, at a public offering price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the Public Offering after deducting underwriting discounts, commissions, and offering expenses payable by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Public Offering was made pursuant to the Company&#8217;s effective Registration Statement on Form S-3 previously filed with the Securities and Exchange Commission on November 29, 2021 and a prospectus supplement, dated November 16, 2022, relating to the Offering.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subscription Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 7, 2022, the Company entered into subscription agreements (the April 2022 Subscription Agreements) with a consortium of investors (the April 2022 Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,508,376</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private placement offering. The three members of our Board of Directors acquired an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,631,284</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares pursuant to the form of a Subscription Agreement that did not include any registration rights. The remaining </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,877,092</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were acquired by others pursuant to the form of a Subscription Agreement whereby the Company agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the Securities and Exchange Commission no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the April 2022 Subscription Agreements, the April 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, which is equal to the closing price of the Company's common stock on April 7, 2022, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The April 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company entered into subscription agreements (the November 2022 Subscription Agreements) with certain members of management (the November 2022 Investors), including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, for the issuance and sale by the Company of an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235,056</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock in a private placement offering. The November 2022 Subscription Agreement did not include any registration rights and included lock up restrictions that will be in effect during the period ending 90 days subsequent to November 21, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the November 2022 Subscription Agreements, the November 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#8220;Minimum Value&#8221; of the Company&#8217;s common stock) of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, which is equal to the public offer price in the Public Offering, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">270,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The November 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During 2018, the Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain convertible preferred shares and issuance of debt. The Company issued to the lender a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">613,333</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series G convertible preferred stock, at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 23, 2028</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Through the effective date of the Company&#8217;s initial public offering (IPO) in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black-Scholes pricing model. As a result of the Company&#8217;s IPO, the preferred stock warrants were automatically converted to warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,326</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and were also transferred to additional paid-in capital. All Series G common stock warrants remain outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the Company issued the Perceptive Warrant to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, including the Initial Warrants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the Initial Warrants, the Additional Warrants will each become exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The per share exercise price for the Initial Warrants is equal to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0648</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is equal to the lower of (A) the 10-day VWAP of the Company&#8217;s common stock on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of common stock of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Initial Warrants are equity classified and were immediately exercisable upon issuance and expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 21, 2032</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Initial Warrants were valued at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million using the Black-Scholes option-pricing model assuming an expected term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, a volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and a risk-free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.67</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. All Initial Warrants remain outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791820368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue and Accounts Receivable Credit Concentration</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 11 &#8211; Revenue and Accounts Receivable Credit Concentration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.726%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.359%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.687999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic tests</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,538</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,937</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenue</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,212</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,506</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Revenue</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in &#8216;Revenues&#8217; in the statements of operations. Of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in &#8216;Deferred revenue&#8217; recorded in the balance sheet as of December 31, 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was recognized in revenues during the year ended December 31, 2022. In addition, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> added to &#8216;Deferred revenue&#8217; for up-front cash payments received for which the revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognition criteria have not been met and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was reclassed to non-current deferred revenue. The &#8216;Deferred revenue&#8217; of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">corded in the balance sheet as of December 31, 2022 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in non-cu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rrent deferred revenue, respectively, recorded within &#8216;Other long-term liabilities&#8217; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s customers in excess of 10% of total revenue both pertain to our COVID-19 diagnostic testing services, and their related revenue as a percentage of total revenue were as follows:</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.5%;"/>
        <td style="width:1.018%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.454%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.02%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The State of Colorado</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ion to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#8217;s total revenue for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.5%;"/>
        <td style="width:1.018%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.454%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.02%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medicare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Astrazeneca UK</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Janssen Research and Development, LLC</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LabCorp DD (formerly Covance)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791726272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 12 &#8211; Share Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Predecessor 2016 and 2006 Equity Incentive Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional awards may be granted under the 2006 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultant. Awards granted under the 2016 Plan or the 2006</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#8217;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional awards may be granted under the 2016 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective upon the closing of our IPO, the Company&#8217;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares originally reserved for issuance under the 2020 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,893,395</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The 2020 Plan includes an annual increase on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#8217;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a prior plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all plans as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">233,519</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective with our IPO in October 2020, the Company&#8217;s Board of Directors and its stockholders approved the Company&#8217;s Employee Stock Purchase Plan (the ESPP). The number of shares originally reserved for issuance under the ESPP was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">338,106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period, whichever is lower. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">237,961</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the ESPP leaving </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,145</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares remaining for future issuance.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Awards Granted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#8217;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-statutory stock options, which may be issued to employees, non-employees and directors, are granted at an exercise price per share equal to the closing market price of the Company&#8217;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance-based options vest in three equal annual installments beginning one year after the grant date</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#8217;s common stock on the grant date. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance-based stock options outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU holders have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bonus-To-Options Program</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also has a Bonus-to-Options Program (the Bonus Option Program) which is separate from previously described plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011, 2015, and 2022. For fiscal year 2022, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the closing market price of the Company's common stock on the grant date, as disclosed below under &#8220;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8221;. Bonus Options issued must be exercised within a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.441%;"/>
        <td style="width:1.001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.754%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.987%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.087%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.754%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.872%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">373</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">244</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.29</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">526</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.69</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.69</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company record</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million du</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ring the years ended December 31, 2022 and 2021, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in the first quarter of 2023 and 2022, respectively, by the Compensation Committee of the Board of Directors. In determining the amount of share-based compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.841%;"/>
        <td style="width:1.663%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.424%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.275%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.796999999999997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">427</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">572</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,469</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,323</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,961</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,944</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The unrecognized remaining share-based compensation expense for options and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> RSUs was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and is expected to be amortized to expense over the next </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.441%;"/>
        <td style="width:1.001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.754%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.987%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.087%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.754%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.872%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding - January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,878</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.08</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,288</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">380</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.23</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,541</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.40</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,489</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,525</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.28</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,067</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of the Company&#8217;s common stock is determined based on its closing market price on the date of grant. The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</span></div></div><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.936%;"/>
        <td style="width:1.203%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.062%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.814%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.985000000000003%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk&#8209;free rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.32</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.79</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock unit activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 was (in thousands, except weighted average grant date fair value per share):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.859%;"/>
        <td style="width:1.207%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.776000000000003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.27%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.889%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,473</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.69</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Released</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.01</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,211</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.36</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791755136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 13 &#8211; Net Loss per Common Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share excludes dilution and is computed by dividing net loss attributable to the common stockholders by the weighted-average shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the Indi APA. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the acquisition date. When the gross margin target was achieved, the Company was required to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,520,108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. The Company achieved the gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for three consecutive months during the three months ended June 30, 2021. As a result of the achievement of the gross margin target, the Company included the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,520,108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share for the three and six months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which the Company has agreed to forgo the issuance of its common stock. Therefore, these shares are not included in the statements of stockholders' equity or shares issued and outstanding in the balance sheets and are not included in our earnings per share calculation subsequent to August 2021.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.583%;"/>
        <td style="width:1.415%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.696%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.415%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.89%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,447</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,159</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding used<br/>&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,365</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.55</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.58</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The potentially dilutive securities as of December 31, 2022 and 2021 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our employee stock purchase plan, the terms of which are described in further detail in Note 12 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The potentially dilutive securities would be subject to the treasury stock method when dilutive. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.309%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.62%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.040999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,067</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,251</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares committed under ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,211</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,461</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,535</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791751904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 14 - Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, the Company has incurred net taxable losses, and accordingly, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> current provision for income taxes has been recorded. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.307%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.664%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.015%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and developments credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.266%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.03%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.744%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,822</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,874</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,807</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,372</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense limitation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">554</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">215</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,874</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,619</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,977</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,618</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84,324</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,610</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,552</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,457</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,772</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,772</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,153</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,772</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,153</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, the Company ha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">299.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expire beginning in 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net deferred tax assets.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that it had uncertain tax positions related to its U.S. research and development credits. As of December 31, 2022 and 2021, there w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accrued interest related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span></span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.297%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.928%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.838000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">843</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">715</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions for tax positions related to the current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions related to settlements</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions related to a lapse of statute</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">952</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">843</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2022, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791684640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 15 &#8211; Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Co&#8209;Development Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#8217;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2020, the Company exercised its opt-out right with AVEO for the payment of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the AVEO Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. The Company ha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> remaining obligations related to the AVEO agreement as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Following the AVEO Effective Date, the Company is entitled to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty of net sales of ficlatuzumab and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of license income generated from the licensing of ficlatuzumab from AVEO.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> royalties received or expenses related to this agreement for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#8217;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#153; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in August 2024. Either party may terminate for the other&#8217;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. There wer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expenses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to this agreement for the year ended December 31, 2022 and were insignificant for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 13, 2021 (the CellCarta Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly &#8220;Caprion Biosciences, Inc.&#8221;) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% fee on net sales made from the first commercial sale of the Nodify XL2 test to the CellCarta Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.675</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on future Nodify XL2 test net sales worldwide for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from the first commercial sale, ending in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Royalty expense under the CellCarta License for each of the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 wa</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respective</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ly.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the acquisition of the assets of Oncimmune USA, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to an acquired diagnostic test of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of recognized revenue for non-screening tests up to an annual minimum volume and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% thereafter, with an escalating minimum</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through the first four years of sales</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Royalty expenses we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">re $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Litigation, Claims and Assessments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858790748048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock', window );">Basis of Presentation and Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation and Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; warrant liabilities; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we maintained cash and cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and we have </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in outstanding aggregate principal amount on our Perceptive Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#8217;s ability to continue as a going concern, management projected its cash flow sources, including the debt and equity funding and amendments to the Integrated Diagnostics, Inc. (Indi) Agreement, and evaluated the conditions and events that could raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#8217;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreement (see Note 8 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic and the associated impacts on the recovery of our diagnostic testing and services, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current operating plan, unless we continue to raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital during 2022, amendments to our 2021 Term Loan and amended the Indi Agreement to delay near term cash requirements and extend the period of milestone</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">payments. We have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 21, 2022, the Company funded and/or closed various financing transactions, including: (i) a term loan facility for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, with funding of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the issuance of warrants exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock occurring on November 21, 2022, and two additional contingently issuable tranches of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each subject to certain terms and conditions, including revenue milestones, (ii) a follow-on equity offering of common stock and (iii) a subscription agreement for the issuance of common stock to certain members of the Company&#8217;s management team. Collectively, the Company raised gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting commissions, fees and expenses payable). Approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the net proceeds were used to retire outstanding debt of the Company with Streeterville Capital, LLC and Silicon Valley Bank. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4d32ba86-04c2-4e99-bbda-0fc5bb64105e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">single</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment focused on providing diagnostic testing services to customers. All of the Company&#8217;s revenue and long-lived assets were derived or located in the United States for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 11 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DirectCostsAndExpensesPolicyTextBlock', window );">Direct Costs and Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Direct Costs and Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Sales, Marketing, General and Administrative Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales, Marketing, General and Administrative Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2022 and 2021, see Note 11 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card. As of December 31, 2022 and 2021, the Company had </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted cash, respectively, which was included in &#8216;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_c127f513-dd4b-4997-b27b-a9cd90962444;"><span style="-sec-ix-hidden:F_7fd39517-ff33-41f8-ae14-0d40bd4ae488;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8217; in the accompanying balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventorySuppliesPolicy', window );">Inventory</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#8216;Direct c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">osts and expenses&#8217;. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The Company recorded a reserve for excess inventory of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, primarily associated with the wind down of the COVID-19 testing operation, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, to the statement of operations for excess and obsolete inventory.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_06324b01-1be5-4c23-bbaa-fc1231d74b49;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_67b38028-3a72-49aa-81eb-6a352ab4c65b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments for th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There was an immaterial impairment during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairments for th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2022, there</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accumulated impairment losses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.815%;"/>
        <td style="width:2.083%;"/>
        <td style="width:86.102%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 4 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further discussion related to estimated fair value measurements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the purchase transaction with Indi, the Company recorded contingent consideration for amounts potentially payable to Indi&#8217;s shareholder upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was achieved is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#8216;Interest expense&#8217; in the statements of operations resulting from the passage of time and fixed payment schedule.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Perceptive Term Loan Facility (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the Company issued a warrant to purchase common stock to the Lender of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock (the Perceptive Warrant), with warrants exercisable into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock issued on the funding date of the Tranche A Loan (the Initial Warrants) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as well as up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional warrants that are contingent upon the Company&#8217;s borrowing the remaining availability under the Perceptive Term Loan Facility (the Additional Warrants). The Initial Warrants are equity classified (see Note 10 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) while the Additional Warrants are classified as liabilities and subject to fair value measurement (see Note 4 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share&#8209;Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units (RSUs)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 12 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information related to share-based compensation.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">s</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 14 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information related to income taxes.</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">s</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 14 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for additional information related to income taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OtherAssetsPolicyTextBlock', window );">Other Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million cash refundable deposit to secure the performance of the Company&#8217;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). The $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million refundable deposit is reported within 'Other long-term assets' in the balance sheet.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2016, the FASB issued ASU No. 2016-2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ASC 842). This ASU intends to make accounting for leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases accounted for as operating leases. In addition to other related amendments, the FASB issued ASU No. 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. The Company elected this transition method and adopted ASC 842 on January 1, 2022 and as a result, recorded operating lease </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_7af1e3c8-01b6-4f0f-8209-47648e9fba35;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rig</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ht-of-use</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ROU) assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, including offsetting deferred rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, along with the associated </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_212e7808-bfbd-4077-abc2-795e910b5233;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operating lease liabilities</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On January 1, 2022, the Company did not have any finance leases. The adoption of ASC 842 did not result in a cumulative effect adjustment to beginn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ing retained earnings, and did not materially affect the Company's statement of operations, statement of stockholders' equity or statement of cash flows for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company elected the following practical expedients permitted under the transition guidance within the new standard:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Package of practical expedients which allows the Company to carry forward the historical lease classification;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of ROU assets;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more, and;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/>Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#8220;major part of remaining economic life of the underlying asset&#8221; and &#8220;substantially all of the fair value of the underlying asset.&#8221; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional information and disclosures required by this new standard are contained in Note 9 &#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Standards Being Evaluated</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the guidance and determined the overall impact of the adoption will have an immaterial impact on our financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of Presentation and Estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectCostsAndExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs and expenses policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectCostsAndExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventorySuppliesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for supplies to be consumed directly or indirectly in production. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventorySuppliesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858786928544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of Fair Value of Outstanding Borrowings</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"/>
        <td style="width:1.127%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.842%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.127%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.127%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.91%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.127%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.037%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,053</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,785</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Reported Fair values of Contingent Consideration</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below presents the reported fair values of contingent consideration and warrant liabilities,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.38%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.842%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.774%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,341</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,764</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,986</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,792</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Contingent Consideration and WarrantLiabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the changes in contingent consideration </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and warrant liabilities for the dates indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.871%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.263%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent Consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balances - January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,792</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,082</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,934</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,822</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balances - December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,986</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the changes in contingent consideration as of the date indicated (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.136%;"/>
        <td style="width:1.753%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.11%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balances - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,932</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,622</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,238</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balances - December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,792</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791690352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.262%;"/>
        <td style="width:1.499%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.774000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.499%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.968%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,035</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,784</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,365</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,339</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">749</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">700</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">349</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">391</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">324</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vehicles</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in process</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,947</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,866</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,928</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,018</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,749</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,848</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,179</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock', window );">Schedule of Depreciation Expense Related to Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense related to pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operty and equipment was:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.293%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.679%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.058%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">614</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">614</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,622</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,228</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation and amortization expense related to property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787049232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets, Excluding Goodwill</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.602%;"/>
        <td style="width:0.905%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.3629999999999995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.235%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.005%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.3629999999999995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.28%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.804%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.2749999999999995%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets subject to amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,880</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">647</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,755</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">566</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,189</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchased technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets not subject to<br/>&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trademarks</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,894</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,097</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,755</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,138</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,617</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense Related to Definite-Lived Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.598%;"/>
        <td style="width:1.901%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.539%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.726%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.235%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,973</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,945</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Estimated Amortization Expense of Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future estimated amortization expense of intangible </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assets is (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.617%;"/>
        <td style="width:1.732%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.652%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,972</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,963</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,957</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,943</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">992</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">856</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,683</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791845920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.293%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.679%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.058%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation related accruals</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,671</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,029</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued clinical trial expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,232</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">870</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,315</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,766</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,218</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791803872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long-term Notes Payable</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term notes payable were as follows (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.716%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.477%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.848%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Perceptive Term Loan</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,000</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021 Term Loan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,074</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,053</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: current maturities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term notes payable</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,004</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,993</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Scheduled Principal Repayments (Maturities) of Long-term Obligations</a></td>
<td class="text">
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.51%;"/>
        <td style="width:1.774%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.717000000000002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of<br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,000</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,127</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858873960880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments for Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments associated with our operating leases were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.796%;"/>
        <td style="width:1.869%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.334%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of<br/>December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,289</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,619</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,710</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,063</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,263</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,922</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amount representing interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,802</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less amount representing tenant improvement allowances</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,323</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The remaining contractually agreed upon tenant improvement allowances of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million are expected to be received during fiscal year 2023.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments for Operating Lease Obligations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations in accordance with ASC 840 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.784%;"/>
        <td style="width:1.711%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.506%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of <br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">775</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">937</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858792007760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenue</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.726%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.359%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.687999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diagnostic tests</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,538</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,937</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenue</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,212</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,506</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.5%;"/>
        <td style="width:1.018%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.454%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.02%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The State of Colorado</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ion to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#8217;s total revenue for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.5%;"/>
        <td style="width:1.018%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.454%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.02%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medicare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Astrazeneca UK</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Janssen Research and Development, LLC</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LabCorp DD (formerly Covance)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858790739744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.841%;"/>
        <td style="width:1.663%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.424%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.275%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.796999999999997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">427</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">572</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,469</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,323</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,961</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,944</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.441%;"/>
        <td style="width:1.001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.754%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.987%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.087%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.754%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.872%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding - January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,878</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.08</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,288</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">380</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.23</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,541</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.40</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,489</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,525</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.28</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,067</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.936%;"/>
        <td style="width:1.203%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.062%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.814%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.985000000000003%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.01</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk&#8209;free rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.32</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.79</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock unit activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 was (in thousands, except weighted average grant date fair value per share):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.859%;"/>
        <td style="width:1.207%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.776000000000003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.27%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.889%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; January 1, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,473</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.69</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Released</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.01</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,211</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.36</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.441%;"/>
        <td style="width:1.001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.754%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.987%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.087%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.754%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.551%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.872%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">373</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">244</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.29</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">526</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.69</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable &#8209; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.69</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858791696176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.583%;"/>
        <td style="width:1.415%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.696%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.415%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.89%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,447</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,159</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding used<br/>&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,365</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.55</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.58</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.309%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.62%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.040999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,067</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,251</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares committed under ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,211</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,461</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,535</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793389408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.307%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.664%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.015%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and developments credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.266%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.03%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.744%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,822</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,874</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,807</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,372</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense limitation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">554</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">215</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,874</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,619</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   &#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,977</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,932</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,618</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84,324</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,610</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,552</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,457</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,772</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,772</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,153</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,772</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,153</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.297%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.928%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.468%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.838000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at January 1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">843</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">715</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions for tax positions related to the current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions related to settlements</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions related to a lapse of statute</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">952</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">843</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793446848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>Test</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfCancerTest', window );">Number of blood based lung cancer test</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfCommercialBloodBasedTest', window );">Number of commercial blood-based test</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfSARSCoV2Test', window );">Number of SARS-CoV-2 test</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfCancerTest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of cancer test.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfCancerTest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfCommercialBloodBasedTest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of commercial blood based test.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfCommercialBloodBasedTest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfSARSCoV2Test">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of SARS-CoV-2 test.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfSARSCoV2Test</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OrganizationAndDescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858784758080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,088,000<span></span>
</td>
<td class="nump">$ 32,712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_GrossProceedsFromFinancingTransactions', window );">Gross proceeds from financing transactions</a></td>
<td class="nump">$ 70,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NetProceedFromFinancingTransactionsss', window );">Proceeds after deducting commissions, fees and expenses payable</a></td>
<td class="nump">65,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Amount used to retire outstanding debt</a></td>
<td class="nump">23,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,604,000<span></span>
</td>
<td class="nump">45,428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolete inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product Life and Patent Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product Life and Patent Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Long-term Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerFunds', window );">Refundable deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal balance outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Funding amount</a></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable', window );">Warrants exercisable | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable', window );">Warrants exercisable | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Two Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, additional warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_GrossProceedsFromFinancingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_GrossProceedsFromFinancingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NetProceedFromFinancingTransactionsss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceed from financing transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NetProceedFromFinancingTransactionsss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts received from and refundable to customers unless used by them to obtain goods and services from the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858790821152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Issued Accounting Standards - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 2,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Right of use assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_OffsettingDeferredRent', window );">Offsetting Deferred Rent</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 6,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Operating lease liability<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Description of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OffsettingDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offsetting deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OffsettingDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858786957920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793143424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Summary of Fair Value of Outstanding Borrowings (Details) - Fair Value, Recurring - Level 2 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Borrowings</a></td>
<td class="nump">$ 25,053<span></span>
</td>
<td class="nump">$ 10,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Borrowings</a></td>
<td class="nump">$ 26,785<span></span>
</td>
<td class="nump">$ 10,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787267504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details) - Fair Value, Recurring - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="nump">$ 28,986<span></span>
</td>
<td class="nump">$ 33,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Portion of Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="nump">10,341<span></span>
</td>
<td class="nump">17,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="nump">$ 18,645<span></span>
</td>
<td class="nump">$ 16,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WarrantLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WarrantLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_CurrentPortionOfContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_CurrentPortionOfContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787200368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of liabilities</a></td>
<td class="nump">$ 6,981<span></span>
</td>
<td class="num">$ (2,298)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="nump">33,792<span></span>
</td>
<td class="nump">29,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense', window );">Interest expense</a></td>
<td class="nump">3,082<span></span>
</td>
<td class="nump">2,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of liabilities</a></td>
<td class="nump">2,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration', window );">Payments</a></td>
<td class="num">(10,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balances</a></td>
<td class="nump">28,986<span></span>
</td>
<td class="nump">$ 33,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balances</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs payments of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858779841264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th"><div>Apr. 07, 2022</div></th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,981)<span></span>
</td>
<td class="nump">$ 2,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Net change to contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes | Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule', window );">Interest expense due to passage of time and fixed payment schedule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ReductionInContingentConsideration', window );">Reduction in contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest Expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Integrated Diagnostics, Inc | Third Amendment to APA Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfInterestOnContingentConsideration', window );">Percentage of interest on installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Integrated Diagnostics, Inc | Third Amendment to APA Agreement | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ExitFeePayment', window );">Exit fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Integrated Diagnostics, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount', window );">Contingent consideration arrangements, common shares, redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationFinalPayment', window );">Business combination contingent consideration final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Integrated Diagnostics, Inc | Common Stock | Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Contingent consideration cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember', window );">Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fairvalue of additional warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember', window );">Warrant Liabilities | Minimum | Volatility rate | Tranche B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember', window );">Warrant Liabilities | Maximum | Volatility rate | Tranche B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration number of installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration arrangements common shares redemption amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration final payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ExitFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exit fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ExitFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense due to passage of time and fixed payment schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfInterestOnContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest on contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfInterestOnContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ReductionInContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in contingent consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ReductionInContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_ThirdAmendmentToApaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_ThirdAmendmentToApaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858779730224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 12,866<span></span>
</td>
<td class="nump">$ 10,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(7,018)<span></span>
</td>
<td class="num">(6,749)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">5,848<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,035<span></span>
</td>
<td class="nump">6,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,365<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,947<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858783409520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,622<span></span>
</td>
<td class="nump">$ 1,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property and Equipment | Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property and Equipment | Selling, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793064624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 9,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, Cost</a></td>
<td class="nump">18,894<span></span>
</td>
<td class="nump">$ 18,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(9,097)<span></span>
</td>
<td class="num">(7,138)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, Net Carrying Value</a></td>
<td class="nump">9,797<span></span>
</td>
<td class="nump">11,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross', window );">Intangible assets not subject to amortization, Cost</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets not subject to amortization, Net Carrying Value</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="num">(647)<span></span>
</td>
<td class="num">(566)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember', window );">Purchased Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="num">(8,450)<span></span>
</td>
<td class="num">(6,572)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 8,450<span></span>
</td>
<td class="nump">$ 10,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets excluding goodwill gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858783986256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 1,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">$ 1,973<span></span>
</td>
<td class="nump">$ 1,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787264976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">1,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter', window );">2028 and thereafter</a></td>
<td class="nump">856<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 9,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets amortization expense year six and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793060992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation related accruals</a></td>
<td class="nump">$ 4,671<span></span>
</td>
<td class="nump">$ 4,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expense</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">2,766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 8,218<span></span>
</td>
<td class="nump">$ 7,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858783470688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Long-term Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and debt issuance costs</a></td>
<td class="num">$ (5,074)<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, total</a></td>
<td class="nump">25,053<span></span>
</td>
<td class="nump">10,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Less: current maturities</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term notes payable</a></td>
<td class="nump">25,004<span></span>
</td>
<td class="nump">9,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858779067872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>May 09, 2022</div></th>
<th class="th"><div>Mar. 19, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,538,000<span></span>
</td>
<td class="nump">$ 16,343,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DescriptionOfSecuritiesPurchaseAgreement', window );">Description of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) purchased a secured promissory note (Promissory Note One) in the aggregate principal amount totaling $16.0 million in exchange for $15.0 million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company&#8217;s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $10.3 million in exchange for $10.0 million in cash proceeds.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Promissory notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Promissory note, maturity term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage', window );">Promissory notes early prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts', window );">Accrued interest, amortization of OID and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,981,000)<span></span>
</td>
<td class="nump">2,298,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2021 Term Loan provided for an &#8220;interest-only&#8221; period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan was payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan accrued interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, was payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate were effective on the effective date of any change to the prime rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bdsx_PromissoryNoteOneMember', window );">Promissory Note One | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt, after deducting debt issuance costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DiscountsOnDebtInstrumentIssuance', window );">Original issue discounts on debt instrument issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bdsx_PromissoryNoteTwoMember', window );">Promissory Note Two | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DiscountsOnDebtInstrumentIssuance', window );">Original issue discounts on debt instrument issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance', window );">Increase in original issue discounts on debt instrument issuance, subject to contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 40,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Applicable margin rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PublicOfferingPricePerShareOfCommonStock', window );">Public offering price per share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MinimumCashBalanceAtMaturityDate', window );">Minimum cash balance at maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InitialWarrantsAmount', window );">Initial warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AdditionalWarrantsAmount', window );">Additional warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche A Loan | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt, after deducting debt issuance costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche B Loan | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche C Loan | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from an equity offering of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount', window );">Prepayment premium percentage of aggregate outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount', window );">Prepayment premium percentage of aggregate outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Tranche A Loan | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Tranche B Loan | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Tranche C Loan | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, aggregate principal amount</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_RevenueMilestone', window );">Revenue milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest, amortization of original issue discount and debt issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdditionalWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional warrants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdditionalWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, additional warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfSecuritiesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfSecuritiesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DiscountsOnDebtInstrumentIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discounts on debt instrument issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DiscountsOnDebtInstrumentIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in discounts on debt instrument issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InitialWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial warrants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InitialWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MinimumCashBalanceAtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance at maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MinimumCashBalanceAtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment premium percentage of aggregate outstanding principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory notes early prepayment premium percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PublicOfferingPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering price per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PublicOfferingPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RevenueMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RevenueMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_SecuritiesPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_SecuritiesPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bdsx_PromissoryNoteOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bdsx_PromissoryNoteOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bdsx_PromissoryNoteTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bdsx_PromissoryNoteTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bdsx_PerceptiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bdsx_PerceptiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793649040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 30,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858778620864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 11, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>RenewalOption</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,797,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Assets, Current<span></span>
</td>
<td class="text">Other Assets, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, Weighted-average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseExpirationMonthYear', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AccretionOfLeaseLiability', window );">Accretion of lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember', window );">Centennial Valley Properties I, LLC Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The initial term of the Lease is twelve years (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) April 1, 2023 (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has two renewal options to extend the term of the Lease for an additional seven or ten year terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $2.0 million in ROU assets and lease liabilities being recorded. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Apr.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseAgreementNumberOfOptionsToExtend', window );">Lease agreement number of options to extend | RenewalOption</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeasedPropertyBuildingCapacity', window );">Leased property building capacity | ft&#178;</a></td>
<td class="nump">79,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BaseRentPerMonthFromCommencementDate', window );">Base rent per month from commencement date</a></td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_RentAfterFixedEscalationProvisions', window );">Rent after fixed escalation provisions</a></td>
<td class="nump">$ 326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent', window );">Area of leased premised obligated to pay base rent | ft&#178;</a></td>
<td class="nump">19,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements', window );">Landlord contribution towards cost of construction and tenant improvements</a></td>
<td class="nump">$ 18,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AdditionalTenantImprovementAllowanceAmount', window );">Additional Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InterestRateOnExtraAllowanceAmount', window );">Interest rate on extra allowance amount</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Capital expenditure for leasehold improvements related to leases premises which are tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_RemainingCapacityUnderTheTenantImprovementAllowances', window );">Remaining capacity under the tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LessorReimbursementsReceived', window );">Lessor reimbursements received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember', window );">Centennial Valley Properties I, LLC Lease Agreement | Letter of Credit | Cash Collateralized Letter Of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Long-term Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerFunds', window );">Refundable deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Long-term Assets | Centennial Valley Properties I, LLC Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerFunds', window );">Refundable deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CO', window );">COLORADO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AreaOfOfficeSpaceLeased', window );">Area of office space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseExpirationMonthYear', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_KS', window );">KANSAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AreaOfOfficeSpaceLeased', window );">Area of office space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LeaseExpirationMonthYear', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccretionOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccretionOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdditionalTenantImprovementAllowanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional tenant improvement allowance amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdditionalTenantImprovementAllowanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of leased premised obligated to pay base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AreaOfOfficeSpaceLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office space leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AreaOfOfficeSpaceLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BaseRentPerMonthFromCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rent per month from commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BaseRentPerMonthFromCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InterestRateOnExtraAllowanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate on extra allowance amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InterestRateOnExtraAllowanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Landlord contribution towards cost of construction and tenant improvements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeaseAgreementNumberOfOptionsToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease agreement number of options to extend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeaseAgreementNumberOfOptionsToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease commencement Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeaseExpirationMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeaseExpirationMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeasedPropertyBuildingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leased property building capacity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeasedPropertyBuildingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LessorReimbursementsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor reimbursements received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LessorReimbursementsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RemainingCapacityUnderTheTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining capacity under the tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RemainingCapacityUnderTheTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RentAfterFixedEscalationProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent after fixed escalation provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RentAfterFixedEscalationProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts received from and refundable to customers unless used by them to obtain goods and services from the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bdsx_CashCollateralizedLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bdsx_CashCollateralizedLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_KS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_KS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858786828016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">3,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">4,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter', window );">2028 and thereafter</a></td>
<td class="nump">32,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">48,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amount representing interest</a></td>
<td class="num">(23,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances', window );">Less amount representing tenant improvement allowances</a></td>
<td class="num">(18,323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 6,797<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, liability, amount representing tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, liability, to be paid, year six and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858874046864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments for Operating Leases (Parenthetical) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_TenantImprovementAllowancesExpectedToBeReceived', window );">Tenant improvement allowances expected to be received</a></td>
<td class="nump">$ 18.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TenantImprovementAllowancesExpectedToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowances expected to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TenantImprovementAllowancesExpectedToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793047376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, Or Taxes, for Operating Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858780413696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 16, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 08, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 07, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Facility </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holder of each share of common stock is entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuable per day, number of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,235,000<span></span>
</td>
<td class="nump">15,679,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,538,000<span></span>
</td>
<td class="nump">$ 16,343,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">Nov. 21,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PublicOfferingPricePerShareOfCommonStock', window );">Public offering price per share of common stock | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_InitialWarrantsAmount', window );">Initial warrants amount | $</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expected term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Risk-Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.0367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Tranche A Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="nump">$ 1.0648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember', window );">Perceptive Term Loan | Tranche B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G Preferred Stock | 2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember', window );">Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price | $</a></td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuable per day, number of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Perceptive Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable', window );">Additional warratns exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember', window );">Equity Financing Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_NumberOfFacility', window );">Number of facility | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,756,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,886,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_WeightedAveragePricePerShare', window );">Weighted Average Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember', window );">Equity Financing Programs | At-The-Market Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember', window );">Equity Financing Programs | LPC Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember', window );">Equity Financing Programs | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuableDuringPeriodValueCommittedShares', window );">Common stock issuable, committed to purchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PurchaseAgreementTerm', window );">Purchase agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayShares', window );">Stock issuable per day, number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SharesIssuedOrIssuableThresholdLimitDescription', window );">Shares issued or issuable, threshold limit description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under applicable rules of the NASDAQ Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#8217;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty', window );">Maximum percentage of common stock allowed to purchase by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SaleOfStockSharesIssuedAsCommitmentFee', window );">Shares issued as commitment fee | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_CommitmentSharesIssuableOnConditionalBasis', window );">Commitment shares issuable on conditional basis | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DiligenceExpenseAndLegalFees', window );">Diligence expenses and legal fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts', window );">Adjustments to additional paid-in capital deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember', window );">Equity Financing Programs | Lincoln Park | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuableDuringPeriodValueCommittedShares', window );">Common stock issuable, committed to purchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayShares', window );">Stock issuable per day, number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayValue', window );">Stock issuable per day, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_SharesIssuedAsCommitmentFeeValue', window );">Shares issued as commitment fee, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfCommonStockNet', window );">Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable', window );">Underwriting discounts and commissions and offering expenses payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold | shares</a></td>
<td class="nump">35,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter', window );">Shares purchased by underwriter | shares</a></td>
<td class="nump">4,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placements | Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,508,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placements | Subscription Agreements | Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,631,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placements | Subscription Agreements | Existing Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,877,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placements | Subscription Agreements | Chief Executive Officer and Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold | shares</a></td>
<td class="nump">235,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid-in capital deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, additional warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_CommitmentSharesIssuableOnConditionalBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issuable on conditional basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_CommitmentSharesIssuableOnConditionalBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DiligenceExpenseAndLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diligence expense and legal fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DiligenceExpenseAndLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InitialWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial warrants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InitialWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock allowed to purchase by counterparty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PublicOfferingPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering price per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PublicOfferingPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockSharesIssuedAsCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, shares issued as commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockSharesIssuedAsCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockStockIssuablePerDayShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, stock issuable per day, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockStockIssuablePerDayShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockStockIssuablePerDayValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, stock issuable per day, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockStockIssuablePerDayValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SharesIssuedAsCommitmentFeeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued as commitment fee, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SharesIssuedAsCommitmentFeeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SharesIssuedOrIssuableThresholdLimitDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued or issuable, threshold limit description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SharesIssuedOrIssuableThresholdLimitDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuableDuringPeriodValueCommittedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuable during period, value, committed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuableDuringPeriodValueCommittedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues shares purchased by underwriter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions and offering expenses payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PerceptiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdsx_EquityFinancingProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bdsx_LPCFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bdsx_LPCFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdsx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bdsx_ExistingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bdsx_ExistingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858792936288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 38,212<span></span>
</td>
<td class="nump">$ 54,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember', window );">Diagnostic Tests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">34,538<span></span>
</td>
<td class="nump">48,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,674<span></span>
</td>
<td class="nump">$ 5,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858783966096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PrimarySourcesOfRevenueDescription', window );">Primary sources of revenue, description</a></td>
<td class="text">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 1,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Minimum | Customer Concentration Risk | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Long-term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember', window );">Up Front Cash Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PrimarySourcesOfRevenueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary sources of revenue description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PrimarySourcesOfRevenueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858784636752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details) - Customer Concentration Risk - Minimum<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | The State of Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | The Big Ten Conference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Astrazeneca UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Janssen Research and Development, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | LabCorp DD (formerly Covance)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_TheStateOfColoradoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_TheStateOfColoradoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_TheBigTenConferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_TheBigTenConferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_AstrazenecaUkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_AstrazenecaUkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_JanssenResearchAndDevelopmentLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_JanssenResearchAndDevelopmentLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_LabcorpDdFormerlyCovanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_LabcorpDdFormerlyCovanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858784846240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="nump">2,541,000<span></span>
</td>
<td class="nump">2,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of performance-condition options granted</a></td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 5,961,000<span></span>
</td>
<td class="nump">$ 4,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="nump">526,000<span></span>
</td>
<td class="nump">373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of performance-condition options granted</a></td>
<td class="nump">244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember', window );">Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized remaining stock based compensation balance</a></td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Amortization period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="nump">1,893,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Performance Condition Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting term</a></td>
<td class="text">Performance-based options vest in three equal annual installments beginning one year after the grant date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock issued and outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember', window );">2006 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember', window );">2006 Plan, 2016 Plan and 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="nump">233,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="nump">100,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock issued and outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of earnings used for purchase of common stock</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Percentage of fair market value of common stock for purchase under plan</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod', window );">Description of voting power or value of stock for employee participation in offering period</a></td>
<td class="text">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DescriptionOfOfferingPeriodUnderPlan', window );">Description of offering period under plan</a></td>
<td class="text">The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of December 31, 2022, 237,961 shares have been issued under the ESPP leaving 100,145 shares remaining for future issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock may be issued under incentive plan</a></td>
<td class="nump">237,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfOfferingPeriodUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of offering period under plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfOfferingPeriodUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting power or value of stock for employee participation in offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_PerformanceConditionOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_PerformanceConditionOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858778553872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - January 1, 2022</a></td>
<td class="nump">2,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited/canceled</a></td>
<td class="num">(333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="num">(384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - December 31, 2022</a></td>
<td class="nump">2,541<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable - December 31, 2022</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - January 1, 2022</a></td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/canceled</a></td>
<td class="nump">8.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - December 31, 2022</a></td>
<td class="nump">8.40<span></span>
</td>
<td class="nump">$ 8.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable - December 31, 2022</a></td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Life (Years), Outstanding</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life (Years), Exercisable - December 31, 2022</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - January 1, 2022</a></td>
<td class="nump">$ 6,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - December 31, 2022</a></td>
<td class="nump">1,489<span></span>
</td>
<td class="nump">$ 6,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2022</a></td>
<td class="nump">$ 1,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - January 1, 2022</a></td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited/canceled</a></td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - December 31, 2022</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable - December 31, 2022</a></td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - January 1, 2022</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/canceled</a></td>
<td class="nump">14.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - December 31, 2022</a></td>
<td class="nump">10.69<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable - December 31, 2022</a></td>
<td class="nump">$ 10.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Life (Years), Outstanding</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life (Years), Exercisable - December 31, 2022</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - January 1, 2022</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - December 31, 2022</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858785828496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 5,961<span></span>
</td>
<td class="nump">$ 4,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 5,469<span></span>
</td>
<td class="nump">$ 4,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858783596112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.60%<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk&#8209;free rate</a></td>
<td class="nump">1.32%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858787202400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Outstanding - January 1, 2022 | shares</a></td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Shares, Forfeited/canceled | shares</a></td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Released | shares</a></td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Outstanding - December 31, 2022 | shares</a></td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, January 1, 2022 | $ / shares</a></td>
<td class="nump">$ 5.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="nump">2.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Forefeited/canceled | $ / shares</a></td>
<td class="nump">3.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Released | $ / shares</a></td>
<td class="nump">5.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, December 31, 2022 | $ / shares</a></td>
<td class="nump">$ 2.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858784607776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">2,520,108<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="nump">42,103,000<span></span>
</td>
<td class="nump">27,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">2,520,108<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="nump">42,103,000<span></span>
</td>
<td class="nump">27,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858784629088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (65,447)<span></span>
</td>
<td class="num">$ (43,159)<span></span>
</td>
<td class="num">$ (65,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used in computing net loss per share, basic</a></td>
<td class="nump">2,520,108<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="nump">42,103,000<span></span>
</td>
<td class="nump">27,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding used in computing net loss per share, diluted</a></td>
<td class="nump">2,520,108<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="nump">42,103,000<span></span>
</td>
<td class="nump">27,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858780164784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">9,461<span></span>
</td>
<td class="nump">3,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,067<span></span>
</td>
<td class="nump">3,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember', window );">Shares Committed Under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,103<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858783985744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">299,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration', window );">Research and experimentation tax carryforwards</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Description of tax credit carryforward expiration</a></td>
<td class="text">expire beginning in 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange', window );">Valuation allowance, deferred tax asset, explanation of change</a></td>
<td class="text">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets', window );">Percentage of valuation allowance equal to net deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination details</a></td>
<td class="text">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax examination, likelihood of unfavorable settlement</a></td>
<td class="text">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income Tax Examination, Description</a></td>
<td class="text">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets research and experimentation tax carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation allowance equal to net deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121825205&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858783619536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and developments credits</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.00%)<span></span>
</td>
<td class="num">(26.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858786810304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 70,822<span></span>
</td>
<td class="nump">$ 61,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="nump">3,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest expense limitation</a></td>
<td class="nump">3,036<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_DeferredTaxAssetsCapitalizedResearchCosts', window );">Capitalized research costs</a></td>
<td class="nump">2,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">1,619<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,932<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">84,324<span></span>
</td>
<td class="nump">69,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(82,552)<span></span>
</td>
<td class="num">(67,457)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets after valuation allowance</a></td>
<td class="nump">1,772<span></span>
</td>
<td class="nump">2,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(1,772)<span></span>
</td>
<td class="num">(2,153)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (1,772)<span></span>
</td>
<td class="num">$ (2,153)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredTaxAssetsCapitalizedResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax Aassets capitalized research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredTaxAssetsCapitalizedResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858793367344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to the current year</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139858786629008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 13, 2021</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Dec. 02, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,102,000<span></span>
</td>
<td class="nump">$ 12,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember', window );">Revenue Share Agreement | Oncimmune Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests', window );">Percentage of license agreement and royalty payment related to acquired diagnostic test recognized revenue for non-screening tests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_MinimumAnnualVolumePercentageThereafter', window );">Minimum annual volume percentage thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PeriodOfEscalationsOfSales', window );">Period of escalations of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> through the first four years of sales<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember', window );">Bio-Rad License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue', window );">Percentage of royalty payments on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue', window );">Percentage of royalty payments not required on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember', window );">CellCarta License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue', window );">Percentage of royalty payments on net revenue</a></td>
<td class="nump">0.675%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfFeePaymentsOnNetSales', window );">Percentage of fee payments on net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale', window );">Term of royalty payments from first commercial sale</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale', window );">Year of ending royalty payments from first commercial sale</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember', window );">AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_RemainingEstimatedObligation', window );">Remaining estimated obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember', window );">AVEO Oncology | NSCLC POC Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts', window );">Responsible percentage of development and regulatory costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember', window );">Ficlatuzumab | AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight', window );">Percentage of development and regulatory costs exercised using opt-out right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetSales', window );">Percentage of royalty payments on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing', window );">Percentage of license income generated from licensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MinimumAnnualVolumePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual volume percentage thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MinimumAnnualVolumePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs exercised using opt-out right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfFeePaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fee payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfFeePaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of license income generated from licensing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments not required to pay on net revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PeriodOfEscalationsOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of escalations of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PeriodOfEscalationsOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RemainingEstimatedObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining estimated obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RemainingEstimatedObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of royalty payments from first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year of ending royalty payments from first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>bdsx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bdsx="http://biodesix.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bdsx-20221231.xsd" xlink:type="simple"/>
    <context id="C_73bf8719-9ed7-4a80-941c-ebed989aedcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheStateOfColoradoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a5a47bb8-865d-46aa-9b99-e3a31978f62d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_04d1a84d-a61f-43b4-b180-30e7a26cd32d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_187c775a-a3b7-42da-bfab-78d163765caf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="C_5556e5f1-5117-4c3b-bc0c-a41a3e2ea92b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cf4e748d-3074-47c8-b2fc-51fe7c3e9765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_6a86f3ed-b059-49f8-929d-392ed1b5aefa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bdsx:ExistingShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-07</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="C_d301989c-2ae7-4a05-901c-aeb97c5075f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_d7ae35e9-9d7c-47bb-a677-d141d7cc9457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bcd01088-6b6b-4233-b784-8c76ca2c0480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1a2949cc-e81d-4125-b746-f22e110c97c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-07</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="C_a72d645a-776a-4a74-9706-b63f1bd0e7e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_394dc411-8890-456c-88fb-38cd9c45e342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bdsx:CashCollateralizedLetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_eee382e8-1805-4f39-907d-bfda41055f0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_31da1c0e-91e4-449a-b28c-c8ca4cad2ca2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_1bdcfef7-9637-41fa-aeb1-09f6ca1e0d5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3422fe75-7e5a-45a7-ac6a-9088eeb3e5b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_daba2c85-8b46-41a0-aced-c3772e54ec5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="C_b3c04a86-27e5-41b0-aa97-cc3628b22f88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_949016fe-f937-4caf-b84d-58db21b5e5ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_059b1c27-6f4f-4d72-9faa-e166f7b41f76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_02bbb7a6-c4e5-4790-a0f3-3a027542791f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0b08f51c-d57a-4f72-8c72-dd0f2eae99a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5b9afec0-72f8-4476-a4ee-4fd773a715d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_1c8760f8-4bfb-43a9-838d-4e0b93c9f2aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_438ec078-c687-429c-a769-d3742dbe11a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_a78a8177-5e02-4e56-9772-382439d0939c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fd5b1882-de5e-4e68-853c-732d34730afe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-07</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="C_23d25b67-f820-41e5-bbdb-0e27c1391956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_acff4fd7-67d1-4f52-bbff-d251e168be02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61e5c055-428e-4280-b39a-813cfb48033b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_c73395a4-9ee2-430d-9509-2e0c8ad1a49e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_973930aa-eb0f-4e7d-b68b-2549035fffb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_38785f87-07c1-43cc-ac73-db1f587fe1ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4142ff53-afcb-497b-81d5-d370a5bf3011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a20eac41-6dd7-40e8-be7a-37569efa0136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_03d24aeb-78a1-4c8d-b568-cfca0d3fc997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_d29ffb11-8aeb-454a-b02f-a1cd08996dde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_585442c6-63fc-4616-91c6-831a62abd477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_1092db51-6294-44e3-bb69-6fad5f7f2e8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_91cf71d9-5882-46d2-af72-be7057b1fa70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8be89166-bad4-409c-881c-a9f3f86a21e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_5f76d7ba-2692-45b1-bf5a-feaf239555c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dc7252ad-b58c-4241-b1ba-4346c1180e60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a9ac9aa4-ea3e-4802-8754-c8e9edd2adc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="C_26541884-e077-4463-84ef-77608f72fe54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ec8d24b6-eeb6-4535-a95a-f96122922dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_b796b863-ace9-4b62-946c-082d3b02817c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f5a69a51-44ec-42e5-af14-fd5467f50c5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c7401865-053c-4260-997b-b04309ea03f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_903652eb-e3f1-4c1e-a925-53ae57d7cd2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_46b3650b-f200-468e-a19b-82906029b2e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b8821775-e1c7-4b43-bef0-f192ca32577a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-19</startDate>
            <endDate>2021-03-19</endDate>
        </period>
    </context>
    <context id="C_b5034939-1d40-46e1-96f5-cb3cc77d9692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_305b45e3-aa77-4038-91ca-a8b9641f321c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0e3f888f-0695-472c-8a11-9658d99a93b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:AstrazenecaUkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5a129ea3-f356-49fc-afa3-38f6d02880ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4d3d5033-be47-4149-b009-902d32d7a987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3d44de77-80d9-49db-a99d-64d8c9816a6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_86159b8d-7aed-4b03-b26e-bca866fbd61a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_91f72376-23e0-4941-9051-8d330ee61b8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:AtTheMarketFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_630425c2-c257-4e6f-9752-038cef3e8e65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dedd5c19-93b3-496c-9876-ed47d4aade8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_91b0e376-daf5-48b6-b4e6-bf780df858cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="C_214b2dd0-9feb-4b1f-8486-54f0069ba088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fb388fb2-b1a4-41c7-b2e6-24847a05c97b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1bf6cb5e-cf65-4a16-838b-e866908b46c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_2ba0380c-8303-431e-a874-ef43625cd063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5407a72b-1be5-441a-baf7-31f7a5742f30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_d12dc7db-6c0d-498f-95b8-ead1e40b9fb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9f73c574-d57f-4230-9899-1c2a407c3ca8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3fbf4b04-42d9-42a3-afc9-b3a2b00cabdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_f7aa72bf-d149-40f3-98f1-4045959748af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c90072a7-3113-4e95-b308-f449c6e53790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9494a794-f77b-4a40-af81-4b90b746a8d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f0124565-7566-42cd-9811-8f85b4b00b29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dbc53b33-ca6f-4327-b8af-2aabe16a0af6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c6060929-cc88-48de-ac6e-4ff5aee26e2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_ef9be249-05dd-46fb-9453-58ae75b42808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="C_6fd3ded3-11d4-4f58-b776-f582e91d8799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_6dc925fe-1445-4fb6-b137-670c99ed2615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_60e05c27-67bc-4257-a0d2-dc24ad762e3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1eeb3ca-40cd-466c-ae9e-ca7ba7b2a2f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bdsx:ChiefExecutiveOfficerAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_169bf5c0-fabd-48e8-9e19-f178074d2e74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="C_6852849f-4a20-4832-b763-1f583ecb4c09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="C_80d972be-0e12-4624-abfc-02988b9d378b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_cd92a88e-0c45-4130-9ceb-be9f1169e806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-19</instant>
        </period>
    </context>
    <context id="C_283a264a-b0e0-4031-81ad-45b20ea79543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c85c73e5-0596-4390-a44f-00d4c2b63b97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_ad7793e4-8ed9-4613-ac91-79c78797a90e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5db1c006-3d07-4be3-b5ff-a7b2fbf3e25f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="C_cade502d-a93b-4d54-80ee-98f26b9246c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_c534b800-3720-4995-a5a1-9c5c21659307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_e75a16fb-16cc-42be-83c6-46117bcf8255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0add87f4-39bd-4cf3-8e49-bc5d9b0a3039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6a0dc852-f2b0-48bc-b2b6-1620c601a50d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_14ac9e9e-e1ed-4025-b9a7-8d5598f7e903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_75202e38-b7dd-49df-9825-87dfcdc551d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2f69117e-f3cb-4597-a131-338489bdc295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b84975b5-0a2a-4c6a-a970-bca06808dbba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9e152fca-a16d-497a-a116-d749fe3f576a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ddfc8a81-b490-496e-95ab-ca6e0d3c6f71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4844e46c-01bd-4e1b-8bbd-3eb015874131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9c480ebc-4937-47fd-b5c4-871edf51ca48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a8cbb7ea-0740-4eb6-9874-287b74dc5289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_237703f9-d5ea-4653-8904-ce72f3e0e459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ba2be62b-8085-45a3-bc77-13c26ae016ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_12180992-8c3b-4583-9f45-a6c1fac1d121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="C_1c8b26c8-0d32-4ca1-816d-9b4d8b664166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_16894d39-c0b9-473f-996a-ea5e902b6bc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_281dc173-6094-4689-8129-e75bfea9ac17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_57134a4c-8578-40a1-813d-312feaa45a92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_b5dc3743-ca85-4769-8c11-523bc0854b31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="C_e2944650-b682-45bf-91f6-43c4a2e81e26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a8f8214a-ba5d-4798-9bc4-3c9348a307cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ca1e3e4c-8bde-4650-aaca-f298f81e530f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_59d365ab-7a43-4adf-a882-c16ac6390192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c410de4f-8ea6-4061-8764-66e62ab89b16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_086ca540-28e1-44ca-a323-2ad2636c5784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_9d118b38-1b14-47f9-afe0-3a294fa48513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7af4e047-0257-4b41-8cb2-aa865601cded">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_e91484b1-4de4-45b4-9435-ca540a78f9e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_bbe57b7b-14db-40d9-b4e3-fcea2a1e2a81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_26e73e01-b546-4645-b525-02a9ce64f5a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_186ed4eb-26b5-4313-aca7-752df70e6114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_7ddc96a7-546d-43f8-87c6-9287c6d330e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_2847f431-ac31-433e-ac37-df0cd6d38d6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="C_ae3277b8-5cce-47e3-bdd2-81eecc7c9a41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="C_e0aa9545-138b-4cb5-9486-69e3ff5ba91b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_313360eb-54d3-44bc-b6b3-5158c6afb114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e9aa5426-d887-4faf-a862-0f860b5f1148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_537fd16e-de8c-489b-89dc-da0dcaa87884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_706d33fb-1152-4e58-a444-b5203cd4a996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:LabcorpDdFormerlyCovanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c2f28597-f68b-4e5f-938b-bbefedd01c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e8fb8fa4-a259-49a8-a73c-91b175e11aa7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_21a7ecc0-40b0-408b-8b87-7d9c2a5f031b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_96c6822f-7b22-47f1-bb03-2ae7e3cb1efc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_231071bd-b44d-4ace-82af-b86707b2357a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1cd7907e-e91e-4e55-9162-5fb14ec9f02d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b302bad2-98d3-4851-b88b-540dd7c490b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="C_c2fe46f8-1653-48ec-9a32-c95a2b1ef531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d7bd6b0a-4041-4e97-93ad-79b76be80350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_60a8bfcb-40c2-4451-aa67-8593932c5757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_4f705742-9a2c-4dc7-a282-98868e21f468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_746a7287-f9b5-4d12-831b-35d4b70d784d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ac1ef5ae-331a-42b9-b66f-a867d9104059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="C_7879ad8c-ea5d-4043-a09d-e45c5b04d104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4cc0b66e-7e74-4007-bb02-d314b2b20656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9d280c57-4f0c-4087-bfc5-09e23f264b72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="C_bd3c756b-0fd0-4580-b35c-5bd0c430ca65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-07</startDate>
            <endDate>2022-04-07</endDate>
        </period>
    </context>
    <context id="C_d722c30e-d139-43c4-b526-3699892348c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_7b4b65a0-9eab-4198-9d03-64c0e6fc1646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7a4e3ec5-40de-461c-b6a5-3cb9963618ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f0afd3f5-8310-4844-a4d2-63f0d27ddf88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_82d37d69-01a3-41f1-a628-a553ba9b0c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_12bd700e-0b10-4fb5-af15-894d72263e90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ee837150-7dcc-4823-b2b5-2d0c51a4dd17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9cfbccdc-31c5-4e8a-bfdc-7649f1ec0117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5de36142-f81f-4d20-84f5-a31e77b6a83f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_94e70836-502c-461e-9146-5d8aa063080e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_9034f42b-c563-4c25-99ba-56b8bc692ac4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6ad6809c-68cb-4c96-8ae0-d9bd24aa0db0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_b9c9e703-63dc-4dfe-8c83-2d95a5dd5cd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_037983b4-6196-4ce5-8ade-33f68a42d303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e6d03a98-3b4e-401e-b7cc-82e792333d3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_efe1b90e-7787-4cc2-bfbe-359fbdc3c5ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fd581c08-91c5-4205-b952-ae033f5f32d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-08</instant>
        </period>
    </context>
    <context id="C_a480b51a-4a24-4df0-bc08-5701140469ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f60b5bcb-f424-4895-a729-730037e7a52d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f8159f7a-5617-4338-a333-06a6ca7f3337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d5836ee-d2bb-477b-8e85-8cfcb55b699e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17924754-ecbd-43e7-95c0-61af5078762a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bdsx:LPCFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ff1c3404-9746-40e4-8ce6-168f0d8cde24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dc17e439-b12a-4b73-b3ee-aa4575f60d3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d224c460-5bc5-4c51-b5e3-0c74f540798a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_13ad713e-d35e-41ad-b2d9-9738e144f092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1332991-a124-414c-9607-7eb5c2b60415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_5cc619c2-53d7-4761-a81a-9a741927fe13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="C_cc7c7d02-004c-473a-9400-1eb0a6de7813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d05b24fd-4c4f-402b-8b97-295956c2f519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9fabf356-719c-4221-916d-d8ca81752d4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0f9bbf97-b166-4fc4-9dad-f1870f5628ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3a8e4fde-5800-4383-b5b8-8d6b6fb5e8d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_94f8365d-9f16-480b-9a94-8b6de443e738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_997a32b2-9786-430b-9d46-e8bde7a02bee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_5caae45d-0db4-4d63-b236-a9aa359641a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_d6b61263-79d7-4ad5-80e3-c6488dc15d6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_be756e56-47b7-41eb-ad9c-716214c84904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:NSCLCPOCTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="C_e1abda95-a10b-462f-b26e-ff79238c4eda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_6c1150e6-1985-4c11-9339-33b27033da6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9fdff006-70ae-43ff-b822-eb5c9877e323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_55e36f95-2f43-434a-8af9-06f6e131a730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_29c745e0-902e-4e00-abf2-c8cab42148d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_c54806e2-2b86-435c-963e-bcc3bba05c0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_41cb42fe-1fc1-4fe5-95d4-e30f3d31ec21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_15d0eb8a-d853-4db8-a265-c8d1b3c9cc49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0281633c-de51-4d41-b3dd-b1224984423b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_744f7b6a-4217-4a66-a0e3-ea5eed3003f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fc669b6e-18c4-48ce-89aa-f437eaa9dea7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5208be1b-25c5-466d-81db-5a3e876f9370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_672ae1be-bd0c-48a6-8adf-0a1565ae2ef1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a85d3cdf-c6db-43af-b1d3-58080059098c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="C_e26e9fe8-1d8c-4a5e-9771-49e0ddbb567d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_9c393b81-f0da-48af-813c-5c496799a235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_11b8abe5-606c-445b-ada4-84273d36bcbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4b44b5df-e1bf-421f-890e-33e01c1a22ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9e1cb9f9-1f35-4466-a46d-cf526d23b935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_64b0a895-45ab-4c6f-ac10-827ab0a951df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_ba733271-8a6c-457b-aa81-58381d47b3b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3d741d82-1d89-43bd-aeaf-d5d87b0316cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_086e1296-a025-4723-b82e-9492b0c68ec9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:ThirdAmendmentToApaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_70355a48-c284-4639-9391-77b924c70e70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_dec83647-9b4a-474f-a223-9e24cfba7a30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="C_3d36f7fa-49dc-413d-a2bd-8d9342f8e774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d76dbc1-8a85-42e5-96cd-ef88d8ad1938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_255e0eec-7e39-40eb-adba-086563b7ec90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1526a220-9742-4789-9d47-4ce3ee95d398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d12b5949-e029-409e-b622-3df88edf97a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e6015f8d-bccb-4bb9-99f1-6b9aa57149f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-02</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="C_bf14dbee-c366-4746-bd13-0ca64d12de01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a297dcbf-e7eb-4a6b-b8b7-17cecdbd5a6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_75178c23-f72c-42e0-a591-2de6aea0caff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="C_cf44b711-ec2f-4b0b-ad81-b0a574373c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_be80ae2a-a108-4cd4-aef7-5a62e28a06e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_943b8db7-988c-4af2-94ee-41515857328f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c8822067-11ee-4730-84e6-37f46f386c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_71e6a261-6445-4aef-9b90-6aa8258c393b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:EquityFinancingProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7de21cc0-f9c4-4529-94a5-c125fe2ca78f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_eaa55565-82f2-477b-b6d4-79f13c784eb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="C_5dc8b832-6352-466d-a5da-07ecf35ded3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4716ca07-4302-4a9c-9ea0-0d87608ecb4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0cde4147-0171-4e88-8504-bba1e5f0b211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9e3e3184-45f3-43eb-b6eb-3e2a5df33941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PromissoryNoteTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="C_1043f2a6-0e14-46df-bbaa-a20764b5e9c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_deba999b-e5c6-4df4-a80e-17fb0c1de3fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_217f72b0-cf7e-4c4d-b942-59ada45d53c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d74f0750-6f1c-442f-84b0-83d80d96838d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_599ead4f-c94c-4dc6-8441-4c817adf1b16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_64a79dd5-c87c-429b-863e-00e581d3a825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_e895deb9-d4dd-4ee8-a0c9-733eb5b9aee7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4ed704bd-7ad3-4b26-ad05-362e6ae5c9c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PerceptiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="C_c4d0476a-83e8-40bf-8317-6bc7b409e5d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_965f19ae-0f96-4ce2-8e48-5b6071e81159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7fdeca4f-00cf-4beb-b46e-1e1eae6fa90a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <unit id="U_Test">
        <measure>bdsx:Test</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>bdsx:Segment</measure>
    </unit>
    <unit id="U_Facility">
        <measure>bdsx:Facility</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Installment">
        <measure>bdsx:Installment</measure>
    </unit>
    <unit id="U_RenewalOption">
        <measure>bdsx:RenewalOption</measure>
    </unit>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_1c8b26c8-0d32-4ca1-816d-9b4d8b664166"
      id="F_0980ea39-5787-4d2b-b800-5afec28cfc63">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_4d32ba86-04c2-4e99-bbda-0fc5bb64105e"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      id="F_7fd39517-ff33-41f8-ae14-0d40bd4ae488">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList>
    <bdsx:LeaseExpirationMonthYear
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_69f529c7-a6b6-4870-92d2-707a07490f78">2023-01</bdsx:LeaseExpirationMonthYear>
    <us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      id="F_c127f513-dd4b-4997-b27b-a9cd90962444">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_1533d1c6-8aba-4416-aa35-27b40158e631">0001439725</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_562b0db7-e661-4048-b92b-a268fcb490b2">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_9d118b38-1b14-47f9-afe0-3a294fa48513"
      id="F_558ae46e-8ea1-4c0a-9a4d-100dfe66de89">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_bead42bb-d6fc-4814-b77a-f8147f03c7e2">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      id="F_b89a5dda-48e9-42c4-9317-c53410857718"
      unitRef="U_USD"
      xsi:nil="true"/>
    <bdsx:LeaseExpirationMonthYear
      contextRef="C_6c1150e6-1985-4c11-9339-33b27033da6e"
      id="F_9b0044c9-456b-40db-b304-cbb2a4cddf06">2023-10</bdsx:LeaseExpirationMonthYear>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397"
      id="F_7af1e3c8-01b6-4f0f-8209-47648e9fba35">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_dc17e439-b12a-4b73-b3ee-aa4575f60d3e"
      id="F_06324b01-1be5-4c23-bbaa-fc1231d74b49">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="C_14ac9e9e-e1ed-4025-b9a7-8d5598f7e903"
      id="F_bd934ce6-93a4-4c03-8768-1ed24686b2e3">http://fasb.org/us-gaap/2022#InterestExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <dei:AmendmentFlag
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_fc797632-f319-44da-86cb-db80cce9dc28">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      id="F_f737795f-9e9a-466d-855d-23c129fc9e09"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      id="F_ee27f4b8-44a6-44ae-b187-f23c3af6af75"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_38785f87-07c1-43cc-ac73-db1f587fe1ec"
      id="F_619e0fd9-df0a-4ffa-8df0-66030beb9821">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      id="F_cf430efd-6ac3-4dc9-9262-706a09fd0cf7"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397"
      id="F_212e7808-bfbd-4077-abc2-795e910b5233">http://fasb.org/us-gaap/2022#OperatingLeaseLiability</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d7bd6b0a-4041-4e97-93ad-79b76be80350"
      id="F_67b38028-3a72-49aa-81eb-6a352ab4c65b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <bdsx:LeaseExpirationMonthYear
      contextRef="C_a78a8177-5e02-4e56-9772-382439d0939c"
      id="F_1f6e0faa-935f-477f-be66-d4008a184239">2024-01</bdsx:LeaseExpirationMonthYear>
    <dei:DocumentType
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_90778e32-51ed-4729-997f-b5e8d0215ffd">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_c1eadb48-991f-4a9d-a5e6-c814b69f441b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_1f52dc73-c6e7-45f7-a393-4b96ffc5c7b6">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_c0a30336-fa6c-4cc5-b4f7-60109e9ad243">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_f6c9ddc5-c1f0-4aeb-8c81-c1f10b663092">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_9d8f8674-e4ca-488b-b2e1-d7d47eac04d7">001-39659</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_eb8c15ad-5788-420f-93f8-edc83db3b6be">Biodesix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_3f662a86-b1dd-4bbb-bf48-9eb51e0afb9f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_817b8740-873f-4302-9912-b7ed846f0f03">20-3986492</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_6dcd2cee-8ae5-4eaa-a36c-4522113b4e71">2970 Wilderness Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_770f3be6-875e-4a5d-ac63-3fe1578542e0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_b85faf0a-1124-4004-ad1d-7a22dcf8c2ad">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_814e86d7-49de-4735-929d-e06534cb8470">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_cbd35e6a-cb11-42e5-a464-d90e0e5a2300">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_45a6cfe9-acc6-4a5d-bb27-9079e7045006">303</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_e0877b6e-197d-4f12-b05a-5b6655cc0ad1">417-0500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_cc50ca00-1555-4136-8fbf-7b5cd7e8a1ef">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_5a3993fc-d204-40bd-8d5e-80e40b106f44">BDSX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_d16dcf66-44b3-49aa-9941-2c8aad46557c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_feaf2536-fd16-47ad-9bc6-7c489328cce7">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_734cc776-aa24-4d95-a7d3-bc854d90b345">Yes</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_7f3c0027-6653-4cc0-b8e5-f8a6c0452fe8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_31b792cf-b90c-44c2-96d2-335f476d1c98">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_4cf447cf-a29d-45b5-b252-8c7f5e949eb7">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_a2b6c337-e714-42b9-84e0-e4c8a7895099">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_dd9d45d4-9ed6-4255-8f7c-c8874d6db936">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_445932ba-89f6-423a-a385-07a29f300ece">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_2048fada-f969-49c3-85ae-00498f006a00">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_4e5e8f23-f1a6-4cf4-8526-b7e180679b2f">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_e9aa5426-d887-4faf-a862-0f860b5f1148"
      decimals="-5"
      id="F_75b60db2-1e68-42f9-9a3a-1072bcd782a9"
      unitRef="U_USD">34100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_5db1c006-3d07-4be3-b5ff-a7b2fbf3e25f"
      decimals="INF"
      id="F_82df41c7-4c81-4e44-b529-9661e6407c67"
      unitRef="U_shares">77974861</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_180ae8e7-28ab-4487-b914-1bb67a6b632b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the Company&#x2019;s definitive Proxy Statement for its 2023 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.)&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_41c0270a-3e17-425f-bdc2-54f41ab62b47">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_6984a144-370d-4f4d-9a0d-dd53d5ca5a8c">Denver, CO</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_5b5871e8-3c61-405f-81f3-836ba5e18563">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_dda5464c-adc2-49e2-9291-e7a0e058f986"
      unitRef="U_USD">43088000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_a333e070-dc72-4b5e-ab27-568e632f4056"
      unitRef="U_USD">32712000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_fcda2ee3-e062-4c88-adb2-76c607cab676"
      unitRef="U_USD">118000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_524813f3-050f-4df3-899c-29ad96f1e9a9"
      unitRef="U_USD">158000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_e7c45fcf-1070-4640-bd2a-8310452f1560"
      unitRef="U_USD">5065000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_577dbc3f-ef9c-43a7-b435-e5c276b152fe"
      unitRef="U_USD">3656000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_2322410b-c752-42ca-a73c-7ca422f91443"
      unitRef="U_USD">5181000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_22a4228f-7615-4ea8-8f32-b986e01f74e5"
      unitRef="U_USD">7245000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_a0347dc5-3d26-43e4-9aa8-82ece8f251c3"
      unitRef="U_USD">53334000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_2ced0f2a-b8ed-4abc-af81-f829ea5e90dc"
      unitRef="U_USD">43613000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_c9c7c78f-4bb4-4ca0-9807-1f6bd16152f5"
      unitRef="U_USD">5848000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_c113909b-3b64-4672-98da-0b4512b4ad2f"
      unitRef="U_USD">4179000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_ec137fd8-1709-449d-b5f8-f36707bb08f7"
      unitRef="U_USD">9797000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_439875c4-f215-4d19-8dd2-e8224af71d80"
      unitRef="U_USD">11617000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_0e1ab613-426d-4f24-9dbd-ef18adf87fdd"
      unitRef="U_USD">2973000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_d08a54ae-09c9-4d15-8b6b-b48d45a92d4e"
      unitRef="U_USD">15031000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_072e7572-5deb-411b-b04c-41fa43ce6324"
      unitRef="U_USD">15031000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_0ff4f8a7-b46f-40d4-97b5-35446da1a873"
      unitRef="U_USD">5923000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_7e5c17bd-7e54-40db-9388-75a62c211ad6"
      unitRef="U_USD">1657000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_a9ce929c-cf35-44ca-9c69-3d036f40e74a"
      unitRef="U_USD">39572000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_605b184f-2928-499d-be76-a147749bb2d3"
      unitRef="U_USD">32484000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_3ecd1af7-9099-4225-b428-417dcc5fd8f1"
      unitRef="U_USD">92906000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_1e1f5793-53e4-4dd2-a9b1-9941bb9b7b0e"
      unitRef="U_USD">76097000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_917d8dd8-43a1-4cc7-89b6-eef564f43854"
      unitRef="U_USD">1685000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_53410f21-12b1-4cb8-813f-a1a807a7a368"
      unitRef="U_USD">1662000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_ee0ca6d9-082e-40ca-9205-41e0bac6b227"
      unitRef="U_USD">8218000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_15f75bfe-d37d-4a70-b444-99357e23a78b"
      unitRef="U_USD">7665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_c7c7bbe3-f548-4049-9776-7b198e90c64f"
      unitRef="U_USD">962000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_c7530fc3-8d34-4b11-8f73-9c29a1676bc1"
      unitRef="U_USD">1850000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_0a0963f7-d94f-4376-a398-6a29ebaea62b"
      unitRef="U_USD">1543000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_c310c508-77eb-4626-8ba4-9bb739107032"
      unitRef="U_USD">10341000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_1a9d717b-c6fe-4800-8763-2e35777dba50"
      unitRef="U_USD">17764000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_6e4bffca-36ca-45f9-ba2c-1a4c25ae3844"
      unitRef="U_USD">49000</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_342851b4-d4fa-4bc1-ad5d-4bbe0c3638fc"
      unitRef="U_USD">19000</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_9bd08058-5e6e-416b-8928-8ea717f06c0f"
      unitRef="U_USD">41000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_a8f25b70-7e12-4eea-82f5-061cfc8e3a9c"
      unitRef="U_USD">22839000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_70594bc1-ab6c-4617-96ab-76277449e43c"
      unitRef="U_USD">28960000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_0bc88d4d-431b-48e1-b090-3dc87d55fc11"
      unitRef="U_USD">25004000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_aca26743-4a38-4fb2-bd08-612374c61960"
      unitRef="U_USD">9993000</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_fb221435-03aa-49ef-af40-d684e784240a"
      unitRef="U_USD">5254000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_788b32ae-7ccd-4a9f-9266-43b760e49ce3"
      unitRef="U_USD">18645000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_3220f85d-a146-43d1-9d7c-de030a06944d"
      unitRef="U_USD">16028000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_b2a88761-3445-4829-b7de-d9edc0cf0890"
      unitRef="U_USD">558000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_23af6b87-4c15-4fa6-83bf-9e6265c8fb46"
      unitRef="U_USD">1389000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_ecf388d0-6d72-459a-b6b3-256faccbbd9a"
      unitRef="U_USD">49461000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_9104aa10-0cf7-4a3e-8e35-3fbd68420676"
      unitRef="U_USD">27410000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_be4756d7-ca8c-4512-98ce-a0058b653f11"
      unitRef="U_USD">72300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_0a92f580-904a-48a8-92da-2e21e3e2c062"
      unitRef="U_USD">56370000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_9797de81-3c47-4d64-bffd-4d5372f15282"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_a64eec61-c30b-42d8-a9f6-5e3ff3c2eb58"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_d430bf7d-2656-46da-8825-6709cc52dfc5"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_91959079-b51d-4abb-a1e5-fc537435d51a"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_7c48f01e-ae77-4b9a-ac0f-68c417e4f3e5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_be4c50d9-5f13-46a8-9f4e-08607f5c13a3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_72e04faa-f77f-49d1-a65b-c065aad05167"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_46f5f356-a1ce-4520-85af-0a5e61e0be94"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_1c36d3d5-1d2f-418e-b938-4b9e619f3cbb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_4ad2bad9-7ed2-49b5-9c77-12a589ad0136"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_f07b856b-d5cd-4dbc-9745-a958c9f0b986"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_a1e44f3c-8f50-4be0-bacb-b43646211206"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_60c02517-f4fa-4bec-aa4f-6c60a0461ae0"
      unitRef="U_shares">77614358</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_b0847442-7c1d-40e7-b4d3-baf59ae87c41"
      unitRef="U_shares">77614358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_aa5f4218-756e-4df2-87fd-2aada76ce2ed"
      unitRef="U_shares">30789649</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_0ae0c62f-f478-4165-b22c-97663adad6ee"
      unitRef="U_shares">30789649</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_82da3d79-04b5-47e4-b423-a367abbe1938"
      unitRef="U_USD">78000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_4b5ba8f7-d426-4318-87ce-b784945c91b8"
      unitRef="U_USD">31000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_55354123-fcc7-4f17-b5fd-3594567a0695"
      unitRef="U_USD">387948000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_d0ecb209-f830-4239-acc5-3a885b0d6e7f"
      unitRef="U_USD">321669000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_7f2a46bf-5b2d-4d20-a700-7cbbde3d3060"
      unitRef="U_USD">-367420000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_adc9e0e6-276b-41d8-9bf2-2eab794531db"
      unitRef="U_USD">-301973000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_a9bcdd85-5a65-4278-9226-233b43806058"
      unitRef="U_USD">20606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_7251897f-e102-4034-b99b-38bcc94dc97e"
      unitRef="U_USD">19727000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_584a2bdf-812f-4f25-a22f-0c73f6d9bf39"
      unitRef="U_USD">92906000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_4edf7c81-b902-4d38-bf38-7b5d1d8545e9"
      unitRef="U_USD">76097000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_c4fe5362-54f7-4331-a32b-e68c9c7683bc"
      unitRef="U_USD">38212000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_6e510e44-f0e8-482b-bed0-55e4050671c5"
      unitRef="U_USD">54506000</us-gaap:Revenues>
    <bdsx:DirectCostsAndExpenses
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_c3f135f4-13b8-4e7d-8805-ce829c147f52"
      unitRef="U_USD">14154000</bdsx:DirectCostsAndExpenses>
    <bdsx:DirectCostsAndExpenses
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_1ca5f658-e2ba-4eac-801d-fd90e16a69e7"
      unitRef="U_USD">30518000</bdsx:DirectCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_a80007e8-fd7c-4668-892a-cc224e647f11"
      unitRef="U_USD">13102000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_2ca8b7ff-d770-4714-912e-d33ee664fde2"
      unitRef="U_USD">12789000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_9ca6b272-ddcb-4cf0-a490-52225db57214"
      unitRef="U_USD">61462000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_66a18d36-7de2-42cc-bc69-e124e416c414"
      unitRef="U_USD">50517000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_828fe776-1050-458c-819a-0e700a15f9af"
      unitRef="U_USD">1622000</bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_da9a6757-904d-4161-851b-6abde68fd78f"
      unitRef="U_USD">81000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:OperatingExpenses
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_e724b1fd-68bd-4f82-a0ab-fe19b79bb738"
      unitRef="U_USD">88799000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_5396832e-066d-4b24-b78e-eb04af9c07ee"
      unitRef="U_USD">95446000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_eac0e2e2-347b-4ac8-9d52-fb81eef6c9b6"
      unitRef="U_USD">-50587000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_9c296edd-0744-4158-95c9-85936a1f3830"
      unitRef="U_USD">-40940000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_7a19903e-85ce-4e8b-af86-c05369aa92ef"
      unitRef="U_USD">8072000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_04243237-6f7c-4666-a0fa-325798ba6214"
      unitRef="U_USD">4508000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_4586f25f-8618-44c4-909a-cc84fe9a0f8a"
      unitRef="U_USD">-6981000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_cd329f5b-7395-43b0-aeb2-ffea679f5938"
      unitRef="U_USD">2298000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_6cead65e-02b0-4343-aa8f-8b41ad4349bb"
      unitRef="U_USD">-84000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_6cdebd0c-d412-4a35-a304-fbac6ec9024e"
      unitRef="U_USD">109000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_6b8012c3-f679-4ddc-880c-5076fac36ecd"
      unitRef="U_USD">9000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_b9bab2dc-9aed-41d0-b082-9168b7169fc5"
      unitRef="U_USD">-14860000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_4c65c87d-72dc-4655-8441-62f25889fa64"
      unitRef="U_USD">-2219000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_c80a8680-7b5f-456d-a874-93dc42d2a154"
      unitRef="U_USD">-65447000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_0a5c1a36-a85b-4ec0-833f-d1ba0afe64c2"
      unitRef="U_USD">-43159000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_4f6c32d3-71b2-43d5-8cb0-866be02389ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_4eeea12f-7ee3-41bd-b38d-4da11132768d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_0d08189d-32c8-4633-9c2a-2a3b8076a983"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_816c4598-e7fd-4b7e-82f5-d9278556b016"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_4d6dae2c-aca9-4de9-9221-7602e581416a"
      unitRef="U_shares">42103000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_596f08c7-96ba-474e-a7c9-f9e62afb0f85"
      unitRef="U_shares">42103000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_bd92d7e5-825c-4305-9a5c-4edf29e5b442"
      unitRef="U_shares">27365000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_f03e756b-5000-4c05-9f19-dc54aa610eb4"
      unitRef="U_shares">27365000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_e91484b1-4de4-45b4-9435-ca540a78f9e3"
      decimals="INF"
      id="F_4fba87bb-dacd-4bbb-bb24-e282e48c4844"
      unitRef="U_shares">26562000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e91484b1-4de4-45b4-9435-ca540a78f9e3"
      decimals="-3"
      id="F_ae2fad16-60f9-4194-8939-cdb6703b6026"
      unitRef="U_USD">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f5a69a51-44ec-42e5-af14-fd5467f50c5a"
      decimals="-3"
      id="F_7bc16159-5dc7-4372-8ae3-ab383ae6578d"
      unitRef="U_USD">299953000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_15d0eb8a-d853-4db8-a265-c8d1b3c9cc49"
      decimals="-3"
      id="F_f51c0573-307a-4cfc-b6a3-b094af902233"
      unitRef="U_USD">-258814000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735"
      decimals="-3"
      id="F_f141e761-92e8-46f1-9a0a-7721ac277cfe"
      unitRef="U_USD">41166000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_12bd700e-0b10-4fb5-af15-894d72263e90"
      decimals="INF"
      id="F_a4040b7f-a504-4860-96f8-80df53905f25"
      unitRef="U_shares">3757000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_12bd700e-0b10-4fb5-af15-894d72263e90"
      decimals="-3"
      id="F_9e56f4bd-5501-40da-b019-4541690a7542"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e75a16fb-16cc-42be-83c6-46117bcf8255"
      decimals="-3"
      id="F_87e3286c-11cc-4d7d-9280-422dba95d20e"
      unitRef="U_USD">15675000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_1095a31f-d555-4e5b-b0bc-1b52e7512dad"
      unitRef="U_USD">15679000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_12bd700e-0b10-4fb5-af15-894d72263e90"
      decimals="INF"
      id="F_03419913-4b96-4776-8f5f-0bf0dbc20210"
      unitRef="U_shares">43000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_e75a16fb-16cc-42be-83c6-46117bcf8255"
      decimals="-3"
      id="F_d89fa647-4d13-4515-9acc-29f5b069ddc6"
      unitRef="U_USD">328000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_ed20ecc9-0227-4b23-9811-6eaa45a05136"
      unitRef="U_USD">328000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_12bd700e-0b10-4fb5-af15-894d72263e90"
      decimals="INF"
      id="F_f7f0ffaa-5910-4539-a278-f4ccdc14df5b"
      unitRef="U_shares">428000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_e75a16fb-16cc-42be-83c6-46117bcf8255"
      decimals="-3"
      id="F_1aa956a8-5f2c-41b1-a16b-c26b8f4784bf"
      unitRef="U_USD">769000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_670adf66-ad32-4f24-9df6-4828566da3b6"
      unitRef="U_USD">769000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e75a16fb-16cc-42be-83c6-46117bcf8255"
      decimals="-3"
      id="F_0517967e-a224-4a47-a061-e44c219c40d1"
      unitRef="U_USD">4944000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_12c2e151-47ec-42a1-ae68-ea8ef31649bd"
      unitRef="U_USD">4944000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_a72d645a-776a-4a74-9706-b63f1bd0e7e0"
      decimals="-3"
      id="F_c4cdb1a5-3c6c-41a9-a88e-d4bbe5615714"
      unitRef="U_USD">-43159000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_cc960c50-7ee8-4084-a57d-a596da74c60e"
      unitRef="U_USD">-43159000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_059b1c27-6f4f-4d72-9faa-e166f7b41f76"
      decimals="INF"
      id="F_95de331a-54c8-4483-b30c-4926dc89eb32"
      unitRef="U_shares">30790000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_059b1c27-6f4f-4d72-9faa-e166f7b41f76"
      decimals="-3"
      id="F_1a06d547-cb05-4e51-ab7b-3eaed6fa0e00"
      unitRef="U_USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5de36142-f81f-4d20-84f5-a31e77b6a83f"
      decimals="-3"
      id="F_b1245e5e-62ad-4b8f-a33e-743c29cdd4dd"
      unitRef="U_USD">321669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_96c6822f-7b22-47f1-bb03-2ae7e3cb1efc"
      decimals="-3"
      id="F_dd755c1f-35c4-4674-8953-dcd9f912cd9a"
      unitRef="U_USD">-301973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_4774790f-b4da-4b0b-9d2a-d5d493572248"
      unitRef="U_USD">19727000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40"
      decimals="INF"
      id="F_e2d18b0f-1c8f-4d3e-8cba-107f42f43a17"
      unitRef="U_shares">45705000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40"
      decimals="-3"
      id="F_3d0ad8b6-0013-413b-bab5-9a8aad9418d6"
      unitRef="U_USD">46000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae"
      decimals="-3"
      id="F_4c987126-498d-4d26-bc9e-9c9c87f71f84"
      unitRef="U_USD">56189000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_7603f63c-1c28-4d20-b161-b5cee18c7bf7"
      unitRef="U_USD">56235000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40"
      decimals="INF"
      id="F_ef835a55-74e2-4025-8e49-0f641fbb4dbb"
      unitRef="U_shares">194000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae"
      decimals="-3"
      id="F_1b805e21-fa16-48ca-8bbf-efd80499fb78"
      unitRef="U_USD">355000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_d676fa05-63db-407e-a341-17aee45f78a2"
      unitRef="U_USD">355000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <bdsx:StockIssuedDuringPeriodSharesForDeferredOfferingCosts
      contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40"
      decimals="INF"
      id="F_5d03b9e2-c429-4442-b13a-f15ab96a2184"
      unitRef="U_shares">184000</bdsx:StockIssuedDuringPeriodSharesForDeferredOfferingCosts>
    <bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts
      contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae"
      decimals="-3"
      id="F_d9c0e0a8-bc48-47fd-9a02-2ac5d4a8d0dc"
      unitRef="U_USD">600000</bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts>
    <bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_bae9cd0e-9c7a-4972-a35a-098757883354"
      unitRef="U_USD">600000</bdsx:StockIssuedDuringPeriodValuesForDeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40"
      decimals="INF"
      id="F_cf949c2c-1baa-4b64-8425-21aafbed9fd5"
      unitRef="U_shares">384000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40"
      decimals="-3"
      id="F_30a01444-8cee-47ed-bfa6-56a097995a0e"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae"
      decimals="-3"
      id="F_37eb9896-91be-4bcd-821b-e9ec309088c4"
      unitRef="U_USD">268000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_b245e2e7-7769-4ead-9296-b43e86c546b6"
      unitRef="U_USD">269000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_fbeb17c3-3b6d-4700-baea-e09f5b6edc40"
      decimals="INF"
      id="F_5861b4b3-0a30-4ad2-9e05-435e0f84061a"
      unitRef="U_shares">357000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae"
      decimals="-3"
      id="F_d29f66ba-4ee9-4c8d-bed0-191285af0bca"
      unitRef="U_USD">2906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_e186a5db-e1f3-4dfd-bb3d-689250825aa8"
      unitRef="U_USD">2906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ad7f0cf1-6ef5-4024-abc4-f4453e9d4fae"
      decimals="-3"
      id="F_cb9a20f1-1e43-4efd-ae51-2bae98912bd5"
      unitRef="U_USD">5961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_3607bfc2-7e34-409a-becb-a8245c0e70a6"
      unitRef="U_USD">5961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_1cd7907e-e91e-4e55-9162-5fb14ec9f02d"
      decimals="-3"
      id="F_bce58a86-1111-4cb6-bfad-949e3ebab3f5"
      unitRef="U_USD">-65447000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_77e1b9fb-beed-463a-b8d7-df3dce4209bd"
      unitRef="U_USD">-65447000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_f7aa72bf-d149-40f3-98f1-4045959748af"
      decimals="INF"
      id="F_be6482dd-ec83-4ccb-bc67-58797ae177fb"
      unitRef="U_shares">77614000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f7aa72bf-d149-40f3-98f1-4045959748af"
      decimals="-3"
      id="F_8fdbb4a6-9505-4bde-818f-f11361d0cc8b"
      unitRef="U_USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d12b5949-e029-409e-b622-3df88edf97a1"
      decimals="-3"
      id="F_a24c01a8-7821-41e2-aed8-545a90ffd5f5"
      unitRef="U_USD">387948000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c90072a7-3113-4e95-b308-f449c6e53790"
      decimals="-3"
      id="F_394584fb-89dd-4f92-9de9-5acd3d26c344"
      unitRef="U_USD">-367420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_f2d8fe4c-8c51-4eac-96ba-9b430ef68470"
      unitRef="U_USD">20606000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_2a504016-0a80-4e53-b3a0-e55838df891e"
      unitRef="U_USD">-65447000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_d3d0bd5f-5b7f-4967-97b6-bc10d800d2d9"
      unitRef="U_USD">-43159000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_dd4eea61-0365-4f25-84c9-baa6f2fd7f0b"
      unitRef="U_USD">3597000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_966a266b-0dfd-4f1b-9a65-7a396ae450a4"
      unitRef="U_USD">3178000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_ff434549-c48c-4b8e-8164-6b5044d85f84"
      unitRef="U_USD">2247000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_c65eb2c7-23cf-47e1-9b5c-a34eb60a1b8b"
      unitRef="U_USD">-6981000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_a67fb280-f12c-4420-8d9f-6e5edef78048"
      unitRef="U_USD">2298000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_85408f0d-333d-4c02-af92-f43fa1f66114"
      unitRef="U_USD">5961000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_0db43050-f975-48be-b2b9-69724256d025"
      unitRef="U_USD">4944000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_da976039-59d5-4082-bb4f-c3799d0461c0"
      unitRef="U_USD">-84000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_5085f588-1145-4b10-b661-077251af16a8"
      unitRef="U_USD">1622000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_bab3bf98-b89f-42bd-b7b4-2cd786021339"
      unitRef="U_USD">93000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_b37ef388-c7af-42e4-9b32-4caf070da65c"
      unitRef="U_USD">193000</us-gaap:ProvisionForDoubtfulAccounts>
    <bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_087107bd-4d9d-4ad9-bcd3-d90583675938"
      unitRef="U_USD">5037000</bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther>
    <bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_4f12d7c2-f0a2-4be2-abf8-7cd90582d43d"
      unitRef="U_USD">2706000</bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther>
    <us-gaap:InventoryWriteDown
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_2a9467cc-fe0b-4edc-89f5-0955ed6c24b2"
      unitRef="U_USD">906000</us-gaap:InventoryWriteDown>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_7e9b6c4d-d4b2-41f0-9fb2-0740ff04c34a"
      unitRef="U_USD">81000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_5c43abad-c003-4f3c-bafc-c1e593c9a7ac"
      unitRef="U_USD">1501000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_52c25b5e-866c-44d8-a642-5a572a54eb43"
      unitRef="U_USD">-11454000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_0e7cf839-5197-4a94-a200-bf7b95939e0a"
      unitRef="U_USD">-1113000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_aec93d93-af41-4fa7-a406-1b01a5cb7c38"
      unitRef="U_USD">-1369000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_1682842e-5133-4060-9028-50e3889428ab"
      unitRef="U_USD">3504000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_93953f9a-f138-4d99-8ae8-e827b6ddc0c8"
      unitRef="U_USD">-875000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_62243723-8d8c-48f1-949c-843180a2f750"
      unitRef="U_USD">-773000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_32866ff7-d1ea-4195-8c77-7ae91cf84b45"
      unitRef="U_USD">-7425000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_b513e37a-cb2f-4bc4-8e18-389354902c40"
      unitRef="U_USD">-1213000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_1c4208de-fb03-4112-b3da-d5330ab62b34"
      unitRef="U_USD">-1682000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <bdsx:TenantImprovementAllowancesReceived
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_78ca7c48-a628-46a4-8e2e-d7b5d14efbaf"
      unitRef="U_USD">2471000</bdsx:TenantImprovementAllowancesReceived>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_a5b17ea0-d05f-4c94-a7fe-760124419b72"
      unitRef="U_USD">-937000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_fe778c07-114c-414a-8f75-3940fdc3878a"
      unitRef="U_USD">-44972000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_e8328569-1de0-476c-a274-b05d7d11f8a8"
      unitRef="U_USD">-28223000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_da164914-1bb6-46b9-84e2-5dbb0a8a68ac"
      unitRef="U_USD">3298000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_a456beba-91d4-4832-9df7-97bd1888dd29"
      unitRef="U_USD">2241000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_e0a19948-b92d-4744-848c-15a42c609096"
      unitRef="U_USD">236000</bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet>
    <bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_cd5b2e32-62eb-48d6-9756-775983032a44"
      unitRef="U_USD">306000</bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_528914dd-cdeb-4a6d-8ff4-ef990d7304af"
      unitRef="U_USD">-3534000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_6b394cfc-261c-4ea4-be8e-9fb3d5d9f07d"
      unitRef="U_USD">-2547000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_c48bdd93-38c6-4099-8128-f562b6a7b34f"
      unitRef="U_USD">59538000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_9845091b-5578-4855-9c36-62db3684ebcb"
      unitRef="U_USD">16343000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_2b12de5f-c94c-4d89-bc2d-0023dac50371"
      unitRef="U_USD">355000</bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_3824e46a-ca2b-4c5f-8f5d-57e1a026444a"
      unitRef="U_USD">328000</bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_fea3f2f7-6e75-4523-8aeb-7692692dd827"
      unitRef="U_USD">269000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_703df372-8ab4-4a2b-a2ab-896a5145e397"
      unitRef="U_USD">769000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_59e98be7-7eed-4572-878c-c7222fd22ce4"
      unitRef="U_USD">10822000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_1861eebd-cc3d-4747-9316-92f629c27ca7"
      unitRef="U_USD">45102000</bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable>
    <bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_0c18d8e1-d4d4-41bc-867f-0b66becaa728"
      unitRef="U_USD">30078000</bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_4d50a4d1-de3f-4de2-bff9-11ae2da8423a"
      unitRef="U_USD">28604000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_f44367d0-51bd-45d7-8975-7c551d16a3ef"
      unitRef="U_USD">45428000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_bb9ebc2c-7541-42ee-8139-a4de97e0e651"
      unitRef="U_USD">3725000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_80b22d94-3dcc-4139-9f42-a015abbddd62"
      unitRef="U_USD">164000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <bdsx:PaymentOfDeferredOfferingCosts
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_3ef15803-fc6a-45bf-bb31-33ce97897f72"
      unitRef="U_USD">129000</bdsx:PaymentOfDeferredOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_48323ae4-177d-4258-8a29-b6bff6d5a9f4"
      unitRef="U_USD">3069000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_d8dd7cf2-da3c-4cd5-94b9-ee802f8ec83a"
      unitRef="U_USD">664000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_68b4f99b-2bc8-4c30-b107-877676d56d94"
      unitRef="U_USD">-33000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_d0b9b288-88e5-471f-898a-a89a3589eb08"
      unitRef="U_USD">58882000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_83f229e8-c3c6-46f6-8fd3-e17164de713f"
      unitRef="U_USD">1262000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_f41d3b76-e5b7-45f6-bef4-94e9697f270c"
      unitRef="U_USD">10376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_872bcdaa-dd45-4db8-bc13-37dbf6b2556d"
      unitRef="U_USD">-29508000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_fdaf59f8-5d30-4d05-84e5-c29028e23d76"
      unitRef="U_USD">32798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735"
      decimals="-3"
      id="F_fe4e1e6b-ddbb-42c8-a627-9791fd5d3246"
      unitRef="U_USD">62306000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_07d68323-3056-4cb0-aa59-7f7f652d25a9"
      unitRef="U_USD">43174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_a38c4ca2-5d4a-4d99-b62b-de89cc42dc8b"
      unitRef="U_USD">32798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bdsx:CommonStockIssuedForDeferredOfferingCosts
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_33c6eb0f-0024-433a-aae0-d97d1a8f4ce0"
      unitRef="U_USD">600000</bdsx:CommonStockIssuedForDeferredOfferingCosts>
    <bdsx:DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_1415d637-07ce-4b07-a1ea-1696f4a5f503"
      unitRef="U_USD">75000</bdsx:DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital>
    <bdsx:IssuanceOfPerceptiveWarrants
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_d4211ed3-e747-47ef-a1ac-d950dd02dfd0"
      unitRef="U_USD">3051000</bdsx:IssuanceOfPerceptiveWarrants>
    <bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_9709a3bb-2213-4674-8897-fb5d986b3fec"
      unitRef="U_USD">631000</bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities>
    <bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_353e4969-e277-4ac8-ae7c-8a32d064fcdf"
      unitRef="U_USD">15000</bdsx:DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities>
    <bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_6216dd0a-252a-4a08-8309-2d19c0ce75ab"
      unitRef="U_USD">160000</bdsx:EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities>
    <bdsx:OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_3d55ebee-4880-4b03-9c30-741a2c4f544e"
      unitRef="U_USD">1269000</bdsx:OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_225e4e5a-1c64-48e3-8db1-d24fec588914"
      unitRef="U_USD">3936000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_6007924c-9ea1-4bc7-af1c-4f2d0776eaa7"
      unitRef="U_USD">123000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_8adbfb42-5526-44dc-a14d-8d0f22c0d77a"
      unitRef="U_USD">1009000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_28f95d1f-6010-4020-a580-bfa5ce7f7d1f"
      unitRef="U_USD">1676000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_b08fcb99-90ce-4769-8600-daa9a0071eca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 1 &#x2013; Organization and Description of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Biodesix, Inc. (the &#x201c;Company&#x201d;, &#x201c;Biodesix&#x201d;, &#x201c;we&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#x2019;s headquarters are in Colorado and performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a leading data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. We derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services). Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung&#xae; nodule risk assessment testing strategy, consisting of the Nodify XL2&#xae; and the Nodify CDT&#xae; tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung&#x99; strategy for lung cancer patients integrates the GeneStrat&#xae; ddPCR test, the GeneStrat NGS&#x99; test and the VeriStrat&#xae; test to support treatment decisions across all stages of lung cancer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company also offers three SARS-CoV-2 tests. The Bio-Rad SARS-CoV-2 ddPCR test, the cPASS&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;&#x99;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; neutralization antibody test kit, and the Platelia SARS-CoV-2 Total Ab test have been granted Emergency Use Authorization (EUA) by the Federal Drug Administration (FDA) under Section 564 of the Federal Food, Drug, and Cosmetic Act (FDCA). Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. The EUA declaration under Section 564 of the FDCA is distinct from and independent of the declaration by the Secretary of HHS of a public health emergency under Section 319 of the Public Health Service Act (the PHS Act). On January 30, 2023, the White House issued a Statement of Administration Policy announcing the President&#x2019;s intention to allow the Public Health Emergency declaration under Section 319 to expire on May 11, 2023. Because the EUA declaration from the FDA is distinct from the declaration under Section 319 of the PHS Act, the FDA EUA may remain in effect beyond the duration of the Section 319 declaration. We cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The Company leverages the proprietary and advanced Diagnostic Cortex&#xae; AI (Artificial Intelligence) platform, to collaborate with many of the world&#x2019;s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Blood-Based Lung Tests&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company offers &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; blood-based lung cancer tests across the lung cancer continuum of care:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Diagnosis&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Nodify XL2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Nodify CDT&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; tests, marketed as our Nodify Lung Nodule Risk Assessment testing strategy, assess a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Treatment &amp;amp; Monitoring&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;GeneStrat&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;ddPCR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;VeriStrat&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; tests, marketed as part of our IQLung testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a turnaround time of two business days, providing physicians with timely results to facilitate treatment decisions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;GeneStrat NGS&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (NGS) test, also marketed as part of our IQLung testing strategy, is our blood-based NGS test with results in three business days. The NGS test was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations in genes, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;COVID-19 Tests&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We operate and have commercialized the Biodesix WorkSafe&#x99; testing program, under which the Company offers &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; SARS-CoV-2 tests:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Bio-Rad SARS-CoV-2 ddPCR &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;test, which is FDA EUA authorized to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of current infection by the SARS-CoV-2 virus.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Platelia SARS-CoV-2 Total Ab &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;test, which is an antibody test, FDA EUA authorized by the FDA, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;cPass SARS-CoV-2 Neutralization Antibody &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;test, which is the first blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection. This test was commercially introduced in partnership with GenScript Biotech Corporation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#x2019;s testing services are made available through its clinical laboratories.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <bdsx:NumberOfCancerTest
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_97ba5a70-48f2-44ec-9049-49ef5776d9bc"
      unitRef="U_Test">5</bdsx:NumberOfCancerTest>
    <bdsx:NumberOfCommercialBloodBasedTest
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="0"
      id="F_2838f492-da19-4af4-92a4-adbdc7f14cad"
      unitRef="U_Test">2</bdsx:NumberOfCommercialBloodBasedTest>
    <bdsx:NumberOfSARSCoV2Test
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_97c4e258-8c46-48f4-8706-c2f5780ecd0d"
      unitRef="U_Test">3</bdsx:NumberOfSARSCoV2Test>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_9860e9dc-d8b7-45cc-9ab5-ce35265b21cd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 2 &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; warrant liabilities; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, we maintained cash and cash equivalents of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and we have &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in outstanding aggregate principal amount on our Perceptive Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources, including the debt and equity funding and amendments to the Integrated Diagnostics, Inc. (Indi) Agreement, and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreement (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic and the associated impacts on the recovery of our diagnostic testing and services, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on our current operating plan, unless we continue to raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital during 2022, amendments to our 2021 Term Loan and amended the Indi Agreement to delay near term cash requirements and extend the period of milestone&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;payments. We have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 21, 2022, the Company funded and/or closed various financing transactions, including: (i) a term loan facility for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, with funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the issuance of warrants exercisable into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock occurring on November 21, 2022, and two additional contingently issuable tranches of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million each subject to certain terms and conditions, including revenue milestones, (ii) a follow-on equity offering of common stock and (iii) a subscription agreement for the issuance of common stock to certain members of the Company&#x2019;s management team. Collectively, the Company raised gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million after deducting commissions, fees and expenses payable). Approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the net proceeds were used to retire outstanding debt of the Company with Streeterville Capital, LLC and Silicon Valley Bank. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_4d32ba86-04c2-4e99-bbda-0fc5bb64105e;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating segment focused on providing diagnostic testing services to customers. All of the Company&#x2019;s revenue and long-lived assets were derived or located in the United States for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 11 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for additional information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Direct Costs and Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sales, Marketing, General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For a discussion of credit risk concentration of accounts receivable as of December 31, 2022 and 2021, see Note 11 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card. As of December 31, 2022 and 2021, the Company had &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted cash, respectively, which was included in &#x2018;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_c127f513-dd4b-4997-b27b-a9cd90962444;"&gt;&lt;span style="-sec-ix-hidden:F_7fd39517-ff33-41f8-ae14-0d40bd4ae488;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2019; in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#x2018;Direct c&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;osts and expenses&#x2019;. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The Company recorded a reserve for excess inventory of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, primarily associated with the wind down of the COVID-19 testing operation, as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, to the statement of operations for excess and obsolete inventory.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_06324b01-1be5-4c23-bbaa-fc1231d74b49;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_67b38028-3a72-49aa-81eb-6a352ab4c65b;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairments for th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There was an immaterial impairment during the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairments for th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2022, there&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; accumulated impairment losses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million cash refundable deposit to secure the performance of the Company&#x2019;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million refundable deposit is reported within 'Other long-term assets' in the balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The three levels of the hierarchy and the related inputs are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:11.815%;"/&gt;
        &lt;td style="width:2.083%;"/&gt;
        &lt;td style="width:86.102%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unadjusted quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unadjusted quoted prices in active markets for similar assets and liabilities;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs other than quoted prices that are observable for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 4 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for further discussion related to estimated fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the purchase transaction with Indi, the Company recorded contingent consideration for amounts potentially payable to Indi&#x2019;s shareholder upon attainment of a three-consecutive month gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was achieved is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the Perceptive Term Loan Facility (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;), the Company issued a warrant to purchase common stock to the Lender of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock (the Perceptive Warrant), with warrants exercisable into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock issued on the funding date of the Tranche A Loan (the Initial Warrants) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as well as up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional warrants that are contingent upon the Company&#x2019;s borrowing the remaining availability under the Perceptive Term Loan Facility (the Additional Warrants). The Initial Warrants are equity classified (see Note 10 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) while the Additional Warrants are classified as liabilities and subject to fair value measurement (see Note 4 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 12 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for additional information related to share-based compensation.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxe&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;s&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with ASC 740 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 14 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for additional information related to income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_04828027-6985-426f-b170-6918838adbe2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; warrant liabilities; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, we maintained cash and cash equivalents of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and we have &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in outstanding aggregate principal amount on our Perceptive Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which includes lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources, including the debt and equity funding and amendments to the Integrated Diagnostics, Inc. (Indi) Agreement, and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreement (see Note 8 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic and the associated impacts on the recovery of our diagnostic testing and services, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on our current operating plan, unless we continue to raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our existing loan agreement during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital during 2022, amendments to our 2021 Term Loan and amended the Indi Agreement to delay near term cash requirements and extend the period of milestone&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;payments. We have also undertaken several proactive measures including, among other things, the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 21, 2022, the Company funded and/or closed various financing transactions, including: (i) a term loan facility for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, with funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the issuance of warrants exercisable into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock occurring on November 21, 2022, and two additional contingently issuable tranches of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million each subject to certain terms and conditions, including revenue milestones, (ii) a follow-on equity offering of common stock and (iii) a subscription agreement for the issuance of common stock to certain members of the Company&#x2019;s management team. Collectively, the Company raised gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million after deducting commissions, fees and expenses payable). Approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the net proceeds were used to retire outstanding debt of the Company with Streeterville Capital, LLC and Silicon Valley Bank. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. We expect to continue to incur operating losses in the near term while we make investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period beyond one year after these financial statements are issued. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;</bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_13ad713e-d35e-41ad-b2d9-9738e144f092"
      decimals="-5"
      id="F_68f51e60-716c-441a-8de0-92b0bf2e6eb0"
      unitRef="U_USD">43100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="C_13ad713e-d35e-41ad-b2d9-9738e144f092"
      decimals="-5"
      id="F_f79c57fa-ae73-4b4f-be32-e9f7af4bfeb2"
      unitRef="U_USD">30000000.0</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_6fd3ded3-11d4-4f58-b776-f582e91d8799"
      decimals="INF"
      id="F_69638340-d772-4dc7-a31b-ce849387072f"
      unitRef="U_USD">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_75178c23-f72c-42e0-a591-2de6aea0caff"
      decimals="-5"
      id="F_2107f846-b688-4446-97a1-10743be6e321"
      unitRef="U_USD">30000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <bdsx:ClassOfWarrantOrRightWarrantsOrRightsExercisable
      contextRef="C_4ed704bd-7ad3-4b26-ad05-362e6ae5c9c5"
      decimals="INF"
      id="F_23d2f9ba-5184-41e1-bf8e-3ee902476577"
      unitRef="U_shares">3000000</bdsx:ClassOfWarrantOrRightWarrantsOrRightsExercisable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_6ad6809c-68cb-4c96-8ae0-d9bd24aa0db0"
      decimals="-5"
      id="F_fa5711a5-185a-4062-85b3-7d66d0d959a4"
      unitRef="U_USD">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_94e70836-502c-461e-9146-5d8aa063080e"
      decimals="-5"
      id="F_fea52439-b896-4035-b2bc-c10e7c761cb8"
      unitRef="U_USD">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <bdsx:GrossProceedsFromFinancingTransactions
      contextRef="C_60a8bfcb-40c2-4451-aa67-8593932c5757"
      decimals="-5"
      id="F_98104ead-ac1d-4109-87b4-e5e48d0ed4dd"
      unitRef="U_USD">70700000</bdsx:GrossProceedsFromFinancingTransactions>
    <bdsx:NetProceedFromFinancingTransactionsss
      contextRef="C_60a8bfcb-40c2-4451-aa67-8593932c5757"
      decimals="-5"
      id="F_5b594606-0d72-498f-8a68-005cd53d5842"
      unitRef="U_USD">65700000</bdsx:NetProceedFromFinancingTransactionsss>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_60a8bfcb-40c2-4451-aa67-8593932c5757"
      decimals="-5"
      id="F_0a38560e-4e4b-41fa-916e-2c91234486f4"
      unitRef="U_USD">23900000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_1d1c0856-4304-42ed-b1c3-1c01fda5b3df">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_4d32ba86-04c2-4e99-bbda-0fc5bb64105e;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating segment focused on providing diagnostic testing services to customers. All of the Company&#x2019;s revenue and long-lived assets were derived or located in the United States for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_f07cbd3f-0771-4d31-b8d7-b00f66bfdf3f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 11 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for additional information.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <bdsx:DirectCostsAndExpensesPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_2d08f4a1-5470-4d29-a3d1-82dfe6c4aac9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Direct Costs and Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonuses, benefit and share-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/span&gt;&lt;/p&gt;</bdsx:DirectCostsAndExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_572610e9-e1c7-42bf-9a70-e3ff18fd6bfe">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities, infrastructure expenses, including allocated facility occupancy and information technology costs. Internal expenses include employee-related costs, including salaries, share-based compensation, and related benefits for employees engaged in research and development functions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_012b22a2-c1b7-48e0-8b8b-761cf9f7516b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sales, Marketing, General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and share-based compensation, as well as marketing and educational activities and allocated overhead expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. These expenses consist principally of salaries, bonuses, employee benefits, travel, share-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_858afbb4-603d-46df-914d-c89293e81e76">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For a discussion of credit risk concentration of accounts receivable as of December 31, 2022 and 2021, see Note 11 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_a2bfe841-6442-43a0-bc69-bb5c6940b1d6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_71eae8ec-1f3c-408f-ae32-1c1820facdbb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card. As of December 31, 2022 and 2021, the Company had &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted cash, respectively, which was included in &#x2018;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_c127f513-dd4b-4997-b27b-a9cd90962444;"&gt;&lt;span style="-sec-ix-hidden:F_7fd39517-ff33-41f8-ae14-0d40bd4ae488;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2019; in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-5"
      id="F_51a1fa9e-cf87-4b17-9600-262299611ca4"
      unitRef="U_USD">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-5"
      id="F_e930179f-c8fb-407e-8e4e-010f36b09bbc"
      unitRef="U_USD">100000</us-gaap:RestrictedCash>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_73d8bd2a-ad1e-4985-8ed7-76a1de8f36f9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventorySuppliesPolicy
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_ce9ed703-b0d6-4495-b6df-0995cf731ead">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to &#x2018;Direct c&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;osts and expenses&#x2019;. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The Company recorded a reserve for excess inventory of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, primarily associated with the wind down of the COVID-19 testing operation, as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, to the statement of operations for excess and obsolete inventory.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventorySuppliesPolicy>
    <us-gaap:OtherInventorySupplies
      contextRef="C_3d44de77-80d9-49db-a99d-64d8c9816a6f"
      decimals="-5"
      id="F_1c20d38b-9aa8-4856-a30c-0abdf4685e47"
      unitRef="U_USD">1400000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="C_9d76dbc1-8a85-42e5-96cd-ef88d8ad1938"
      decimals="-5"
      id="F_495ffb21-05cf-4f7d-afda-ec5d379ee8c9"
      unitRef="U_USD">2900000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryValuationReserves
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-5"
      id="F_6c9b8ff0-5aac-4a50-814a-d46659b8ac4a"
      unitRef="U_USD">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-6"
      id="F_a4d63eb9-34bc-4847-b691-7a0c9cabf9f0"
      unitRef="U_USD">0</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryWriteDown
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-5"
      id="F_c40eb338-2ffc-424a-86be-e278d1e1f738"
      unitRef="U_USD">900000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-6"
      id="F_c322f1c8-dffc-4f23-a650-6b8327297bec"
      unitRef="U_USD">0</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_b42ff4bb-2a66-4a5d-9e9e-0e47f8bd6674">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_06324b01-1be5-4c23-bbaa-fc1231d74b49;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_67b38028-3a72-49aa-81eb-6a352ab4c65b;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairments for th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_b0139f82-5b14-4ce9-960c-9716a86e44e0"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="INF"
      id="F_6b1b9c89-79e9-4df2-b316-19a5d3e013e6"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_22bac4ab-5b5a-4a64-a932-b2d7ba0b57ea">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There was an immaterial impairment during the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairments for th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_c2f28597-f68b-4e5f-938b-bbefedd01c35"
      id="F_7bed639a-b514-4bc2-b970-0eb2ec691dce">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_a297dcbf-e7eb-4a6b-b8b7-17cecdbd5a6b"
      id="F_1efab707-210d-4b1b-aebd-9864d4140e3a">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="INF"
      id="F_848b7880-6f01-4528-ac4d-55e71d6a02ad"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_39e5db12-3519-4b03-9043-0f9d6c20a6f7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2022, there&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; accumulated impairment losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_fae733ac-72a7-47d2-99db-29c21317657b"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <bdsx:OtherAssetsPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_36fd1625-eae3-4566-9f66-f39ca78bca23">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million cash refundable deposit to secure the performance of the Company&#x2019;s obligations associated with the operating lease agreement with Centennial Valley Properties I, LLC (see Note 9 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million refundable deposit is reported within 'Other long-term assets' in the balance sheet.&lt;/span&gt;&lt;/p&gt;</bdsx:OtherAssetsPolicyTextBlock>
    <us-gaap:CustomerFunds
      contextRef="C_1bdcfef7-9637-41fa-aeb1-09f6ca1e0d5f"
      decimals="-5"
      id="F_9d2af088-3f8b-43a3-87ed-26be604a48a9"
      unitRef="U_USD">5000000.0</us-gaap:CustomerFunds>
    <us-gaap:CustomerFunds
      contextRef="C_1bdcfef7-9637-41fa-aeb1-09f6ca1e0d5f"
      decimals="-5"
      id="F_1027eb3c-7b29-4931-a601-95f4ed90f6c1"
      unitRef="U_USD">5000000.0</us-gaap:CustomerFunds>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_e3b63e3f-319c-47ce-bb08-0d9cb849c42a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The three levels of the hierarchy and the related inputs are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:11.815%;"/&gt;
        &lt;td style="width:2.083%;"/&gt;
        &lt;td style="width:86.102%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unadjusted quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unadjusted quoted prices in active markets for similar assets and liabilities;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs other than quoted prices that are observable for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other long-term assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 4 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for further discussion related to estimated fair value measurements.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <bdsx:ContingentConsiderationPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_3e8d0a91-e6c3-40f7-b6cc-3c39252143f4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the purchase transaction with Indi, the Company recorded contingent consideration for amounts potentially payable to Indi&#x2019;s shareholder upon attainment of a three-consecutive month gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was achieved is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule.&lt;/span&gt;&lt;/p&gt;</bdsx:ContingentConsiderationPolicyTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806"
      decimals="-5"
      id="F_6755f2a3-8a68-401e-bd59-336e19f83697"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
      contextRef="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806"
      id="F_6ccb6271-9abe-4db4-acb4-d97319db4dd4">P7Y</bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod>
    <bdsx:WarrantLiabilityPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_4380b545-4a7a-40ac-a56a-7cde37f50dff">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the Perceptive Term Loan Facility (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;), the Company issued a warrant to purchase common stock to the Lender of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock (the Perceptive Warrant), with warrants exercisable into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock issued on the funding date of the Tranche A Loan (the Initial Warrants) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as well as up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional warrants that are contingent upon the Company&#x2019;s borrowing the remaining availability under the Perceptive Term Loan Facility (the Additional Warrants). The Initial Warrants are equity classified (see Note 10 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) while the Additional Warrants are classified as liabilities and subject to fair value measurement (see Note 4 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;</bdsx:WarrantLiabilityPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_6fd3ded3-11d4-4f58-b776-f582e91d8799"
      decimals="INF"
      id="F_32490aa6-cd14-4b4b-afc9-8f434572dbd5"
      unitRef="U_shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <bdsx:ClassOfWarrantOrRightWarrantsOrRightsExercisable
      contextRef="C_6ad6809c-68cb-4c96-8ae0-d9bd24aa0db0"
      decimals="0"
      id="F_5e231be4-95cf-4405-87db-fa70fc00c753"
      unitRef="U_shares">3000000</bdsx:ClassOfWarrantOrRightWarrantsOrRightsExercisable>
    <bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable
      contextRef="C_16894d39-c0b9-473f-996a-ea5e902b6bc7"
      decimals="INF"
      id="F_2fdd8a88-1284-4f84-a2e7-d5cd71450ebc"
      unitRef="U_shares">2000000</bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_4b3a6dc4-535b-46cb-aac4-b679d27b0ce0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company grants service-condition RSUs. The grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 12 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for additional information related to share-based compensation.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxe&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;s&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with ASC 740 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 14 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for additional information related to income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_2f9f468b-68ba-41db-827e-bf1098eb0fc2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxe&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;s&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with ASC 740 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;under which deferred income taxes are recognized based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. A valuation allowance is recorded when it is more likely than not that a deferred tax asset will not be realized. The recorded valuation allowance is based on significant estimates and judgments and if the facts and circumstances change, the valuation allowance could materially change. In accounting for uncertainty in income taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 14 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for additional information related to income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_628b9e52-ebf3-443c-892c-2f33575477cf">For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_96769fff-faf0-435f-bcff-41d9ea0d02ef">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_eb7fb78e-4b4b-47da-9088-a519002022da">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 3 &#x2013; Recent Issued Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2016, the FASB issued ASU No. 2016-2, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (ASC 842). This ASU intends to make accounting for leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases accounted for as operating leases. In addition to other related amendments, the FASB issued ASU No. 2018-11, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. The Company elected this transition method and adopted ASC 842 on January 1, 2022 and as a result, recorded operating lease &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_7af1e3c8-01b6-4f0f-8209-47648e9fba35;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;rig&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ht-of-use&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (ROU) assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, including offsetting deferred rent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, along with the associated &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_212e7808-bfbd-4077-abc2-795e910b5233;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. On January 1, 2022, the Company did not have any finance leases. The adoption of ASC 842 did not result in a cumulative effect adjustment to beginn&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ing retained earnings, and did not materially affect the Company's statement of operations, statement of stockholders' equity or statement of cash flows for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, the Company elected the following practical expedients permitted under the transition guidance within the new standard:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Package of practical expedients which allows the Company to carry forward the historical lease classification;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of ROU assets;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more, and;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#x201c;major part of remaining economic life of the underlying asset&#x201d; and &#x201c;substantially all of the fair value of the underlying asset.&#x201d; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional information and disclosures required by this new standard are contained in Note 9 &#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Standards Being Evaluated&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluated the guidance and determined the overall impact of the adoption will have an immaterial impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_ac9b0423-e538-4b84-9f6a-c960f75b739c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2016, the FASB issued ASU No. 2016-2, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (ASC 842). This ASU intends to make accounting for leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases accounted for as operating leases. In addition to other related amendments, the FASB issued ASU No. 2018-11, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. The Company elected this transition method and adopted ASC 842 on January 1, 2022 and as a result, recorded operating lease &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_7af1e3c8-01b6-4f0f-8209-47648e9fba35;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;rig&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ht-of-use&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (ROU) assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, including offsetting deferred rent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, along with the associated &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_212e7808-bfbd-4077-abc2-795e910b5233;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. On January 1, 2022, the Company did not have any finance leases. The adoption of ASC 842 did not result in a cumulative effect adjustment to beginn&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ing retained earnings, and did not materially affect the Company's statement of operations, statement of stockholders' equity or statement of cash flows for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, the Company elected the following practical expedients permitted under the transition guidance within the new standard:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Package of practical expedients which allows the Company to carry forward the historical lease classification;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of ROU assets;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more, and;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the &#x201c;major part of remaining economic life of the underlying asset&#x201d; and &#x201c;substantially all of the fair value of the underlying asset.&#x201d; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional information and disclosures required by this new standard are contained in Note 9 &#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Standards Being Evaluated&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluated the guidance and determined the overall impact of the adoption will have an immaterial impact on our financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397"
      decimals="-5"
      id="F_873add36-4a8b-40a3-802f-5bad9cf3cbda"
      unitRef="U_USD">1300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <bdsx:OffsettingDeferredRent
      contextRef="C_7ddc96a7-546d-43f8-87c6-9287c6d330e4"
      decimals="-5"
      id="F_8247d448-8b25-4820-adda-3c79991f56cd"
      unitRef="U_USD">100000</bdsx:OffsettingDeferredRent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4ae15744-f43c-47a3-97d1-ad8acc7c9397"
      decimals="-5"
      id="F_1efe163f-00cc-4059-a8b1-e1881d69e712"
      unitRef="U_USD">1300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_ef96ecbe-d1bd-45b0-a890-92a0afe40751">For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. </us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_0d7f1fd8-bb6e-40ca-ae3b-5007a363299b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 4 - Fair Value&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair value of borrowings as of December 31, 2022 is primarily associated with the Perceptive Term Loan entered into with Perceptive Credit Holdings IV, LP, in November 2022 and was determined using a discounted cash flow analysis, excluding the fair value of Perceptive Warrant issued in conjunction with the transaction. The difference between the carrying value and fair value of outstanding borrowings as of December 31, 2022 is due to the debt issuance costs and the fair value of Perceptive Warrant netted against the Perceptive Term Loan. The carrying value of outstanding borrowings as of December 31, 2021, approximates fair value based on interest rates available at that time for similar borrowings. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.694%;"/&gt;
        &lt;td style="width:1.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.842%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.91%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.037%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our previous acquisition of Indi and the warrant liabilities granted as consideration for the Perceptive Term Loan Facility (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;), which were accounted for as liabilities and remeasured through our statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below presents the reported fair values of contingent consideration and warrant liabilities,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.38%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.842%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the changes in contingent consideration &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and warrant liabilities for the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.871%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.263%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning balances - January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss on extinguishment of liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending balances - December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the changes in contingent consideration as of the date indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.136%;"/&gt;
        &lt;td style="width:1.753%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.11%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning balances - January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss on extinguishment of liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending balances - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (the Indi APA). The contingent consideration arrangement &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period after the acquisition date. Under the terms of the original agreement, when the gross margin target was achieved the Company was required to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,520,108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. For the six months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;eight&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; equal quarterly installments. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; equal and consecutive quarterly cash installments totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company achieved the gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for three consecutive months during the three months ended June 30, 2021. The Company entered into an amendment to the original agreement in August 2021 in which all parties agreed to forgo the issuance of common stock and agreed that the Company will in lieu thereof make &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; quarterly installments of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million each beginning in January 2022 and a final payment of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in July 2023 for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. (the Milestone Payments and each individually a Milestone Payment). The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which the parties agreed to restructure the Milestone Payments whereby the Company will make &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; quarterly installments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million each beginning in April 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; quarterly installments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million beginning in July 2023, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; installment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in April 2024, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; installment of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in July 2024. In addition, the Company agreed to an exit fee of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, with such interest to be payable quarterly on the following installment payment date. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our ability to make these payments is subject to ongoing compliance under the Perceptive Term Loan and commencing January 1, 2024, consent from Perceptive (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The contingent consideration liability is accounted for at fair value and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. As a result of the achievement of the gross margin target, the only remaining significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate could result in a significantly higher or lower fair value measurement. During the three months ended June 30, 2022, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in interest expense due to the passage of time and fixed payment schedule, partially offset by a reduction to the contingent consideration balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million due to an increase in the discount rate to reflect current market and Company specific conditions, resulting in $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, net recorded as &#x2018;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_bd934ce6-93a4-4c03-8768-1ed24686b2e3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2019; in the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluated Amendment No. 3 to the Indi APA in accordance with applicable accounting standards under U.S. GAAP which resulted in the extinguishment of the original instrument due to the substantially different terms. As a result, during the three months ended June 30, 2022, we recorded a loss on extinguishment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, the Company recorde&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, r&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;espectively, in interest expense due to the passage of time and fixed payment schedule.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent consideration expected to be paid in the next twelve months is recorded in the balance sheets as &#x2018;Current portion of contingent consideration&#x2019; while the remaining amount to be paid is recorded as &#x2018;Contingent consideration&#x2019; within non-current liabilities. The net change to contingent consideration through the date the gross margin target was achieved is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;), the Company issued the Perceptive Warrant to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock, including Initial Warrants and Additional Warrants. The Initial Warrants are equity classified (see Note 10 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) while the Additional Warrants are classified as liabilities within 'Other long-term liabilities' and recognized at fair value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The fair value of the Additional Warrants is determined using a Black-Scholes model and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the fair value of the Company's common stock, risk-free rate, the volatility of common stock which ranged from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, and the probability of the expected borrowing. Significant increases or decreases in the unobservable inputs could result in a significantly higher or lower fair value measurement. The Company determined the initial fair value of the Additional Warrants to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as a change in fair value through the statement of operations due to changes in unobservable inputs.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_c53bada6-e9e6-491f-98b0-cf763048a4af">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.694%;"/&gt;
        &lt;td style="width:1.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.842%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.91%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.037%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_94f8365d-9f16-480b-9a94-8b6de443e738"
      decimals="-3"
      id="F_295fe035-9aa6-44fe-9e00-707df169f534"
      unitRef="U_USD">25053000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_c4d0476a-83e8-40bf-8317-6bc7b409e5d1"
      decimals="-3"
      id="F_7e2143ca-70ae-4085-af66-cea274b5729c"
      unitRef="U_USD">26785000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_fc669b6e-18c4-48ce-89aa-f437eaa9dea7"
      decimals="-3"
      id="F_c21efe50-b0bd-4690-aded-2144c25cc5d5"
      unitRef="U_USD">10012000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_e895deb9-d4dd-4ee8-a0c9-733eb5b9aee7"
      decimals="-3"
      id="F_81cf9153-de05-4b8f-912a-8ab20573837b"
      unitRef="U_USD">10012000</us-gaap:LongTermDebtFairValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_ce546156-995b-4d9b-bae5-c680ea7b054c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below presents the reported fair values of contingent consideration and warrant liabilities,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.38%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.842%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a20eac41-6dd7-40e8-be7a-37569efa0136"
      decimals="-3"
      id="F_f6464a83-b97b-4500-8f6b-9f38663d8e7b"
      unitRef="U_USD">10341000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_be80ae2a-a108-4cd4-aef7-5a62e28a06e3"
      decimals="-3"
      id="F_cccbce29-8baa-43a8-9471-7f256170aaf6"
      unitRef="U_USD">17764000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_ff1c3404-9746-40e4-8ce6-168f0d8cde24"
      decimals="-3"
      id="F_ee7fd393-0d3f-4001-b007-ca8a84eed0d4"
      unitRef="U_USD">18645000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_21a7ecc0-40b0-408b-8b87-7d9c2a5f031b"
      decimals="-3"
      id="F_bb02f347-e3c7-4857-8f05-6022c99b5256"
      unitRef="U_USD">16028000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a8f8214a-ba5d-4798-9bc4-3c9348a307cc"
      decimals="-3"
      id="F_c64b3dd3-a4ac-4b3c-8030-9542a225606f"
      unitRef="U_USD">28986000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_4142ff53-afcb-497b-81d5-d370a5bf3011"
      decimals="-3"
      id="F_cab05f37-d6ce-43dd-a2a4-0bc8d679253c"
      unitRef="U_USD">33792000</us-gaap:LiabilitiesFairValueDisclosure>
    <bdsx:WarrantLiabilitiesFairValueDisclosure
      contextRef="C_a8f8214a-ba5d-4798-9bc4-3c9348a307cc"
      decimals="-3"
      id="F_bfc41e85-9a9e-4e6e-a0fc-8a0ccebd01f0"
      unitRef="U_USD">61000</bdsx:WarrantLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_9ecea44d-3be1-458b-bcf6-b1caddc3cb04">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the changes in contingent consideration &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and warrant liabilities for the dates indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.871%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.263%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning balances - January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss on extinguishment of liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending balances - December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the changes in contingent consideration as of the date indicated (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.136%;"/&gt;
        &lt;td style="width:1.753%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.11%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning balances - January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss on extinguishment of liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending balances - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_21a7ecc0-40b0-408b-8b87-7d9c2a5f031b"
      decimals="-3"
      id="F_e1fe9ef3-82e7-495a-b7ae-b94f90713b80"
      unitRef="U_USD">33792000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_5dc8b832-6352-466d-a5da-07ecf35ded3e"
      decimals="-3"
      id="F_424ea122-0952-421a-a9bc-aab39c4acd26"
      unitRef="U_USD">145000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_5dc8b832-6352-466d-a5da-07ecf35ded3e"
      decimals="-3"
      id="F_00812bbc-f4ed-4064-b07c-cc09c559cab2"
      unitRef="U_USD">-84000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense
      contextRef="C_0add87f4-39bd-4cf3-8e49-bc5d9b0a3039"
      decimals="-3"
      id="F_b0fb2e5f-7f99-4ccd-a677-f06f69694730"
      unitRef="U_USD">3082000</bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0add87f4-39bd-4cf3-8e49-bc5d9b0a3039"
      decimals="-3"
      id="F_e1cc78b2-1d9f-4d2a-a796-063dd0ceee3e"
      unitRef="U_USD">-2934000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration
      contextRef="C_0add87f4-39bd-4cf3-8e49-bc5d9b0a3039"
      decimals="-3"
      id="F_c3086593-2188-4150-b622-110fb22a5f71"
      unitRef="U_USD">-10822000</bdsx:FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_ff1c3404-9746-40e4-8ce6-168f0d8cde24"
      decimals="-3"
      id="F_5987039c-6e7a-4f6f-8bcd-792c173f49fa"
      unitRef="U_USD">28986000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_9c480ebc-4937-47fd-b5c4-871edf51ca48"
      decimals="-3"
      id="F_86046503-680f-45cb-bfed-63e00857daae"
      unitRef="U_USD">61000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_d12dc7db-6c0d-498f-95b8-ead1e40b9fb7"
      decimals="-3"
      id="F_b0963af0-95fc-4f47-8585-9aa2d03540e6"
      unitRef="U_USD">29932000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_cf44b711-ec2f-4b0b-ad81-b0a574373c94"
      decimals="-3"
      id="F_b5993ac1-0b71-40ae-b0fe-40cf8664fb69"
      unitRef="U_USD">1622000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense
      contextRef="C_cf44b711-ec2f-4b0b-ad81-b0a574373c94"
      decimals="-3"
      id="F_d13939bf-a40d-4287-8c3d-c3a3007f71ba"
      unitRef="U_USD">2238000</bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_21a7ecc0-40b0-408b-8b87-7d9c2a5f031b"
      decimals="-3"
      id="F_8ea17c81-9e8b-422b-8a29-d91f3b7dc14c"
      unitRef="U_USD">33792000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_255e0eec-7e39-40eb-adba-086563b7ec90"
      id="F_ba80b106-e9f9-4119-8e44-484f148c3c84">requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_997a32b2-9786-430b-9d46-e8bde7a02bee"
      decimals="-5"
      id="F_aa25bb8e-a670-4982-856d-b6d0aa7579ac"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
      contextRef="C_997a32b2-9786-430b-9d46-e8bde7a02bee"
      id="F_8e8672b9-83fc-49e5-84aa-cc50652a57b6">P7Y</bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod>
    <bdsx:BusinessCombinationContingentConsiderationShares
      contextRef="C_64b0a895-45ab-4c6f-ac10-827ab0a951df"
      decimals="0"
      id="F_2a7b0f94-4e27-4c81-b4b1-5de1e063ed28"
      unitRef="U_shares">2520108</bdsx:BusinessCombinationContingentConsiderationShares>
    <bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
      contextRef="C_64b0a895-45ab-4c6f-ac10-827ab0a951df"
      decimals="-5"
      id="F_9164cc29-84ab-40a9-8477-21d7241f0a0f"
      unitRef="U_USD">37000000.0</bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_e26e9fe8-1d8c-4a5e-9771-49e0ddbb567d"
      decimals="INF"
      id="F_d2ac82f3-ffc1-49c5-bf9f-0f4f7e282427"
      unitRef="U_Installment">8</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_2f69117e-f3cb-4597-a131-338489bdc295"
      id="F_140e5fc7-c4af-4aa6-9e4e-f1ad1180f029">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_c54806e2-2b86-435c-963e-bcc3bba05c0e"
      decimals="INF"
      id="F_20f126f1-463c-44cf-96a4-4d232b039dc5"
      unitRef="U_Installment">2</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_973930aa-eb0f-4e7d-b68b-2549035fffb6"
      decimals="-5"
      id="F_b4fc84d3-d908-4890-9a01-905b67b42085"
      unitRef="U_USD">37000000.0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_b3c04a86-27e5-41b0-aa97-cc3628b22f88"
      decimals="-5"
      id="F_5c6861d5-6539-4f26-bd99-e2f9551d214a"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_b9c9e703-63dc-4dfe-8c83-2d95a5dd5cd1"
      decimals="INF"
      id="F_1dbc10fe-0654-4c72-8a60-db4203475614"
      unitRef="U_Installment">6</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
      contextRef="C_2f69117e-f3cb-4597-a131-338489bdc295"
      decimals="-5"
      id="F_6ee05a62-2f21-4170-b7d4-6e419fda7f34"
      unitRef="U_USD">4600000</bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_2f69117e-f3cb-4597-a131-338489bdc295"
      decimals="-5"
      id="F_c89e597f-e20f-4066-9e2b-a83e3bab57ed"
      unitRef="U_USD">9300000</us-gaap:RepaymentsOfDebt>
    <bdsx:BusinessCombinationContingentConsiderationFinalPayment
      contextRef="C_2f69117e-f3cb-4597-a131-338489bdc295"
      decimals="-5"
      id="F_c45896bb-2920-489f-9abe-52edb6718d3f"
      unitRef="U_USD">37000000.0</bdsx:BusinessCombinationContingentConsiderationFinalPayment>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_acff4fd7-67d1-4f52-bbff-d251e168be02"
      decimals="INF"
      id="F_6f151efe-557c-4606-8572-0c34f855d57a"
      unitRef="U_Installment">5</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:MilestonePayment
      contextRef="C_7af4e047-0257-4b41-8cb2-aa865601cded"
      decimals="-5"
      id="F_05959036-7dcd-4521-a5ab-4b5fb8e03a4e"
      unitRef="U_USD">2000000.0</bdsx:MilestonePayment>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_086e1296-a025-4723-b82e-9492b0c68ec9"
      decimals="INF"
      id="F_ca14ea3f-e956-4a8f-9b7b-359f173b4f73"
      unitRef="U_Installment">3</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:MilestonePayment
      contextRef="C_3a8e4fde-5800-4383-b5b8-8d6b6fb5e8d3"
      decimals="-5"
      id="F_b2a664ee-5883-4029-a77c-0f2c326a6b9f"
      unitRef="U_USD">3000000.0</bdsx:MilestonePayment>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_91b0e376-daf5-48b6-b4e6-bf780df858cf"
      decimals="INF"
      id="F_8233b77b-30f6-4f19-8347-e1f84bfa3513"
      unitRef="U_Installment">1</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:MilestonePayment
      contextRef="C_29c745e0-902e-4e00-abf2-c8cab42148d9"
      decimals="-5"
      id="F_957eb168-dec3-4bea-bf02-0cec4e8ba7b6"
      unitRef="U_USD">5000000.0</bdsx:MilestonePayment>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_c534b800-3720-4995-a5a1-9c5c21659307"
      decimals="INF"
      id="F_5538a853-65dc-49d6-b42b-9e5e61efee5a"
      unitRef="U_Installment">1</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:MilestonePayment
      contextRef="C_2847f431-ac31-433e-ac37-df0cd6d38d6d"
      decimals="-5"
      id="F_44de5432-f0c9-4e92-951d-2b3fbb5774d2"
      unitRef="U_USD">8400000</bdsx:MilestonePayment>
    <bdsx:ExitFeePayment
      contextRef="C_949016fe-f937-4caf-b84d-58db21b5e5ec"
      decimals="-5"
      id="F_73cb5350-4ab7-4ffd-bf0a-fd2684dfe07a"
      unitRef="U_USD">6100000</bdsx:ExitFeePayment>
    <bdsx:PercentageOfInterestOnContingentConsideration
      contextRef="C_fd5b1882-de5e-4e68-853c-732d34730afe"
      decimals="2"
      id="F_38efa0fb-dc94-4e13-9fdd-e7d944e88b0f"
      unitRef="U_pure">0.10</bdsx:PercentageOfInterestOnContingentConsideration>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_f60b5bcb-f424-4895-a729-730037e7a52d"
      decimals="2"
      id="F_dd4321bf-df33-4c16-8a35-c0a046de2091"
      unitRef="U_pure">0.11</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_f0124565-7566-42cd-9811-8f85b4b00b29"
      decimals="2"
      id="F_02cf4d8b-2127-4019-9ea5-02e4ca67c4e8"
      unitRef="U_pure">0.16</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule
      contextRef="C_3fbf4b04-42d9-42a3-afc9-b3a2b00cabdd"
      decimals="-5"
      id="F_142c460c-913c-4ccf-874e-a6ab10d60ae7"
      unitRef="U_USD">1100000</bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule>
    <bdsx:ReductionInContingentConsideration
      contextRef="C_3fbf4b04-42d9-42a3-afc9-b3a2b00cabdd"
      decimals="-5"
      id="F_1a7eadb6-891b-4363-a2a6-3008ca8b801b"
      unitRef="U_USD">1000000.0</bdsx:ReductionInContingentConsideration>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_14ac9e9e-e1ed-4025-b9a7-8d5598f7e903"
      decimals="-5"
      id="F_5aba036d-335b-4ded-bb9c-5030719f5f9c"
      unitRef="U_USD">100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_5caae45d-0db4-4d63-b236-a9aa359641a3"
      decimals="-5"
      id="F_cd4db96a-e4f4-4235-8931-450ff4ccebe3"
      unitRef="U_USD">-2900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule
      contextRef="C_283a264a-b0e0-4031-81ad-45b20ea79543"
      decimals="-5"
      id="F_cfa38d36-a4e5-4010-b730-389836f8b21e"
      unitRef="U_USD">3100000</bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule>
    <bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule
      contextRef="C_2ba0380c-8303-431e-a874-ef43625cd063"
      decimals="-5"
      id="F_32a30f33-b78e-4da0-b052-fefc42da2a15"
      unitRef="U_USD">2200000</bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_cade502d-a93b-4d54-80ee-98f26b9246c9"
      decimals="INF"
      id="F_bc33cabe-77ab-43a5-9cf1-86017ce12faf"
      unitRef="U_shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_903652eb-e3f1-4c1e-a925-53ae57d7cd2b"
      decimals="INF"
      id="F_3bb43a6b-3902-479b-935e-f4e2f2685683"
      unitRef="U_pure">78</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_46b3650b-f200-468e-a19b-82906029b2e1"
      decimals="INF"
      id="F_6c164fc8-4270-4508-a52a-95c1e477eff3"
      unitRef="U_pure">82</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="C_26e73e01-b546-4645-b525-02a9ce64f5a1"
      decimals="-5"
      id="F_dcb28e4e-0bd6-4a84-97b7-b49187521d66"
      unitRef="U_USD">100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_26e73e01-b546-4645-b525-02a9ce64f5a1"
      decimals="-5"
      id="F_8e20b421-d4f5-4a07-8068-a1affacf7aa4"
      unitRef="U_USD">100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_c3e296c7-6d4b-4d10-aeb0-29be4630da9c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 5 &#x2013; Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.262%;"/&gt;
        &lt;td style="width:1.499%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.774000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.499%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.968%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense related to pr&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;operty and equipment was:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.293%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.679%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_d70193b0-ce50-44a3-8eeb-68ef2fb825b9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.262%;"/&gt;
        &lt;td style="width:1.499%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.774000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.499%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.968%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5208be1b-25c5-466d-81db-5a3e876f9370"
      decimals="-3"
      id="F_21e6235a-c9a5-416e-a5ce-8ba223853a50"
      unitRef="U_USD">6035000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_672ae1be-bd0c-48a6-8adf-0a1565ae2ef1"
      decimals="-3"
      id="F_e5497cc3-6c60-45e4-87b2-29d2e455bf7c"
      unitRef="U_USD">6784000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f8159f7a-5617-4338-a333-06a6ca7f3337"
      decimals="-3"
      id="F_c9d35928-e4a1-4636-8d53-d68c4905146a"
      unitRef="U_USD">2365000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4b44b5df-e1bf-421f-890e-33e01c1a22ca"
      decimals="-3"
      id="F_56551b1f-ded6-4aff-b8fd-fa4ffa95ccea"
      unitRef="U_USD">2339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9fabf356-719c-4221-916d-d8ca81752d4d"
      decimals="-3"
      id="F_8820fec7-8866-4686-a09d-1b65ec1b0a81"
      unitRef="U_USD">749000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0f9bbf97-b166-4fc4-9dad-f1870f5628ba"
      decimals="-3"
      id="F_b89609da-6bc5-46eb-a07e-fe37239191ef"
      unitRef="U_USD">700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ddfc8a81-b490-496e-95ab-ca6e0d3c6f71"
      decimals="-3"
      id="F_19035716-68f1-42bd-9f9d-b8404f4a3af0"
      unitRef="U_USD">349000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_59d365ab-7a43-4adf-a882-c16ac6390192"
      decimals="-3"
      id="F_da7c4e3d-047a-4438-8171-d6d931a79356"
      unitRef="U_USD">391000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_60e05c27-67bc-4257-a0d2-dc24ad762e3a"
      decimals="-3"
      id="F_9b89f9f3-2a9e-4a22-b438-fe8b9ecdca31"
      unitRef="U_USD">324000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ba2be62b-8085-45a3-bc77-13c26ae016ff"
      decimals="-3"
      id="F_dfce01ee-dd01-46af-b89c-f4dd7e16c56f"
      unitRef="U_USD">600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_237703f9-d5ea-4653-8904-ce72f3e0e459"
      decimals="-3"
      id="F_2e25de03-82d1-4eb9-b9a7-cac91ebdb2e4"
      unitRef="U_USD">97000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9034f42b-c563-4c25-99ba-56b8bc692ac4"
      decimals="-3"
      id="F_cf4219d9-6d0c-4b4d-add6-d02e5b8764ec"
      unitRef="U_USD">97000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_231071bd-b44d-4ace-82af-b86707b2357a"
      decimals="-3"
      id="F_1894e0a6-28d6-4d26-af98-df04e11353b0"
      unitRef="U_USD">2947000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9f73c574-d57f-4230-9899-1c2a407c3ca8"
      decimals="-3"
      id="F_cb5574af-f0ee-498c-81f2-7deaf44d9dfd"
      unitRef="U_USD">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_acc383e9-8143-4853-a434-9b5b141dee47"
      unitRef="U_USD">12866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_7fbb1c93-dbcc-47e1-93df-a238f5282313"
      unitRef="U_USD">10928000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_f4bafeb0-a90c-411a-b454-0793188375ac"
      unitRef="U_USD">7018000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_0c59fafb-af98-420d-89c8-cf74006cdbe2"
      unitRef="U_USD">6749000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_251b7cde-01b0-4ff7-958d-d27913ed5e33"
      unitRef="U_USD">5848000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_5e93e3e7-ce24-4755-953f-8adb9cb1c0b9"
      unitRef="U_USD">4179000</us-gaap:PropertyPlantAndEquipmentNet>
    <bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_5b3e9e64-8a52-4fe5-ab25-2bba48eab849">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense related to pr&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;operty and equipment was:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.293%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.679%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock>
    <us-gaap:Depreciation
      contextRef="C_e2944650-b682-45bf-91f6-43c4a2e81e26"
      decimals="-3"
      id="F_e4942a51-06b3-4e64-9337-fef422c71d18"
      unitRef="U_USD">591000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_744f7b6a-4217-4a66-a0e3-ea5eed3003f2"
      decimals="-3"
      id="F_637d3c77-4285-49cb-b25f-b59325afa8e8"
      unitRef="U_USD">614000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_dc7252ad-b58c-4241-b1ba-4346c1180e60"
      decimals="-3"
      id="F_575f50d1-8059-44f4-b862-37c6af6f5d87"
      unitRef="U_USD">1031000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_4f705742-9a2c-4dc7-a282-98868e21f468"
      decimals="-3"
      id="F_ce31761a-6630-4bc3-aad6-78d2b23fcca0"
      unitRef="U_USD">614000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_e8fb8fa4-a259-49a8-a73c-91b175e11aa7"
      decimals="-3"
      id="F_6800cee4-cc57-4bab-b551-f95c0a796f52"
      unitRef="U_USD">1622000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_dedd5c19-93b3-496c-9876-ed47d4aade8e"
      decimals="-3"
      id="F_1119c5af-4f7b-4bb2-b25f-f4e77368cf5f"
      unitRef="U_USD">1228000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_43f888e4-150a-4cd3-be6b-d7fe8674902a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 6 &#x2013; Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets, excluding goodwill, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.602%;"/&gt;
        &lt;td style="width:0.905%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.3629999999999995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.235%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.005%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.3629999999999995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.28%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.804%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.2749999999999995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets subject to amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Purchased technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets not subject to&lt;br/&gt;&#160;&#160;&#160;&#160;amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Trademarks&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization expense related to definite-lived intangible assets was (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.598%;"/&gt;
        &lt;td style="width:1.901%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.539%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.726%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.235%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future estimated amortization expense of intangible &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;assets is (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.617%;"/&gt;
        &lt;td style="width:1.732%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.652%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_59d08d2f-84ac-4635-877c-ea8a66e6f4b6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets, excluding goodwill, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.602%;"/&gt;
        &lt;td style="width:0.905%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.3629999999999995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.235%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.005%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.3629999999999995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.28%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.804%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.2749999999999995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets subject to amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Purchased technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets not subject to&lt;br/&gt;&#160;&#160;&#160;&#160;amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Trademarks&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0281633c-de51-4d41-b3dd-b1224984423b"
      decimals="-3"
      id="F_63a7d243-f0cf-46cc-a56d-ae63f4199980"
      unitRef="U_USD">1880000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0281633c-de51-4d41-b3dd-b1224984423b"
      decimals="-3"
      id="F_ce403e8d-a8d0-4510-9b96-6d653add3e38"
      unitRef="U_USD">647000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0281633c-de51-4d41-b3dd-b1224984423b"
      decimals="-3"
      id="F_a1f02600-b3f1-432f-b4f4-8f9568fb4ec6"
      unitRef="U_USD">1233000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_bf14dbee-c366-4746-bd13-0ca64d12de01"
      decimals="-3"
      id="F_8c639d05-ba57-4cbe-906b-a8aaf434cb8e"
      unitRef="U_USD">1755000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_bf14dbee-c366-4746-bd13-0ca64d12de01"
      decimals="-3"
      id="F_1452bc4b-7bef-4563-8b11-db5e87d03d46"
      unitRef="U_USD">566000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_bf14dbee-c366-4746-bd13-0ca64d12de01"
      decimals="-3"
      id="F_69c1b8b7-ab3b-4430-8627-235f36d66f1f"
      unitRef="U_USD">1189000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_75202e38-b7dd-49df-9825-87dfcdc551d6"
      decimals="-3"
      id="F_2d497702-f189-4af3-a4e1-0f7db0fa897e"
      unitRef="U_USD">16900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_75202e38-b7dd-49df-9825-87dfcdc551d6"
      decimals="-3"
      id="F_907e4155-05f8-4b1c-933c-7d4d59d9883a"
      unitRef="U_USD">8450000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_75202e38-b7dd-49df-9825-87dfcdc551d6"
      decimals="-3"
      id="F_a07b873f-65a1-4ea5-a7d0-3c9d97a62ea3"
      unitRef="U_USD">8450000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_4716ca07-4302-4a9c-9ea0-0d87608ecb4f"
      decimals="-3"
      id="F_8667dffe-b5db-4919-995d-a72bf7133699"
      unitRef="U_USD">16900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_4716ca07-4302-4a9c-9ea0-0d87608ecb4f"
      decimals="-3"
      id="F_392ae529-baab-4119-8995-fa5b62fac162"
      unitRef="U_USD">6572000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_4716ca07-4302-4a9c-9ea0-0d87608ecb4f"
      decimals="-3"
      id="F_87546274-b32b-42ac-9207-2f97ed99514d"
      unitRef="U_USD">10328000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
      contextRef="C_9e152fca-a16d-497a-a116-d749fe3f576a"
      decimals="-3"
      id="F_fd050ed7-23ad-4e5f-ae52-e66b441917cd"
      unitRef="U_USD">114000</bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_9e152fca-a16d-497a-a116-d749fe3f576a"
      decimals="-3"
      id="F_f3b80956-f00d-49bb-b1ca-f776d6abc720"
      unitRef="U_USD">114000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
      contextRef="C_599ead4f-c94c-4dc6-8441-4c817adf1b16"
      decimals="-3"
      id="F_fceaa76d-4732-45a1-9ed1-26d27bb4b1aa"
      unitRef="U_USD">100000</bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_599ead4f-c94c-4dc6-8441-4c817adf1b16"
      decimals="-3"
      id="F_32df8ada-f377-4d0f-82a4-e86b23037df4"
      unitRef="U_USD">100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_92c5f8d8-ab93-4c93-9029-593c6b8d956a"
      unitRef="U_USD">18894000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_3c1b4e18-5af1-4c73-ad0a-71732b48cd4a"
      unitRef="U_USD">9097000</bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_1291bded-b958-409f-beb8-5b116e917042"
      unitRef="U_USD">9797000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_e3924dec-1a3b-450e-8018-a7549c6c5446"
      unitRef="U_USD">18755000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_8759ab5f-099e-4389-ab01-f13483227665"
      unitRef="U_USD">7138000</bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_85c9baf6-052f-4a14-ac75-33d7ebf00854"
      unitRef="U_USD">11617000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_c7de6d6e-726b-40ee-b3b4-f9833b82fe0e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization expense related to definite-lived intangible assets was (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.598%;"/&gt;
        &lt;td style="width:1.901%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.539%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.726%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.235%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_e2944650-b682-45bf-91f6-43c4a2e81e26"
      decimals="-3"
      id="F_d44e5210-0843-4ee7-b6c4-f6d617c29048"
      unitRef="U_USD">2000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_537fd16e-de8c-489b-89dc-da0dcaa87884"
      decimals="-3"
      id="F_8d93832f-d0e9-4df6-a400-39f920d44020"
      unitRef="U_USD">5000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_dc7252ad-b58c-4241-b1ba-4346c1180e60"
      decimals="-3"
      id="F_32b99dfa-2250-4a5e-893e-792f262efa62"
      unitRef="U_USD">1973000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_9fdff006-70ae-43ff-b822-eb5c9877e323"
      decimals="-3"
      id="F_99890a60-61fa-494b-9653-c0fc64570b71"
      unitRef="U_USD">1945000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_b66a5618-85f0-4993-8979-2d2cf580c66d"
      unitRef="U_USD">1975000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_42a4b697-a1d9-4157-83f4-a6f8204c05d1"
      unitRef="U_USD">1950000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_54eec93b-93c4-4ad1-91ab-2fd1ce696649">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future estimated amortization expense of intangible &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;assets is (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.617%;"/&gt;
        &lt;td style="width:1.732%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.652%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_257b77d9-a81a-487c-82b0-4321168221bc"
      unitRef="U_USD">1972000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_03e716ed-0605-434c-b745-35f2cf1ee3c2"
      unitRef="U_USD">1963000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_42df1039-5ecb-4013-8a82-d21491d745bf"
      unitRef="U_USD">1957000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_12fd2ebb-f744-4b5d-966f-d7d920b8ed3b"
      unitRef="U_USD">1943000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_9388899c-04de-44dd-ab09-70e7a8ea8c65"
      unitRef="U_USD">992000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_ef133341-2fa0-4190-b747-6d322cdada83"
      unitRef="U_USD">856000</bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_21a1390f-34ec-4d53-b4b3-d54c60cc57ca"
      unitRef="U_USD">9683000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_fe02487b-9f65-4104-b5b1-e7affbf94de0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 7 &#x2013; Accrued Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.293%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.679%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Compensation related accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued clinical trial expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_f4910e9b-5870-4afd-b02a-fff049a00349">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.293%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.679%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Compensation related accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued clinical trial expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_0cb10700-1202-429c-a22c-f6f8f05360cb"
      unitRef="U_USD">4671000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_82f9796c-bbc8-48cd-bea3-030977e0765e"
      unitRef="U_USD">4029000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bdsx:AccruedClinicalTrialExpenseCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_975b8c49-519a-44f9-9c16-39b8285dfd52"
      unitRef="U_USD">1232000</bdsx:AccruedClinicalTrialExpenseCurrent>
    <bdsx:AccruedClinicalTrialExpenseCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_1cfa3aad-a4be-4c56-a463-a43d0de38b5c"
      unitRef="U_USD">870000</bdsx:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_4a6883f2-86d6-4326-9268-cf0b838eb220"
      unitRef="U_USD">2315000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_d14a53e6-cd8c-4a35-a106-f41f9fcf4492"
      unitRef="U_USD">2766000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_3271c3ac-93bd-41b8-a6a8-76d52c82dcc1"
      unitRef="U_USD">8218000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_98a2ad5c-b311-4acb-b848-bf3005900168"
      unitRef="U_USD">7665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_00021bdd-2a93-4114-a8f3-c5c1229c7f00">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 8 &#x2013; Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our long-term debt primarily consists of notes payable associated with our Perceptive Term Loan which is described in further detail below. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term notes payable were as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.716%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.848%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Perceptive Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized debt discount and debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term notes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Perceptive Term Loan Facility&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 16, 2022 (the Closing Date), the Company entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP as the lender and administrative agent (the Lender). The Credit Agreement provides for a senior secured delayed draw term loan facility with Perceptive Advisors LLC (Perceptive), in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (the Perceptive Term Loan Facility). The initial funding of the Perceptive Term Loan Facility was subject to a capital raise of at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in gross proceeds from an equity offering of the Company's common stock. On November 21, 2022 (the Funding Date), the Company raised approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in gross proceeds from the sale of common stock (the Public Offering and November 2022 Subscription Agreements, together, "the Equity Offerings", see Note 10 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). The Tranche A Loan, in an aggregate amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (the Tranche A Loan), was funded under the Perceptive Term Loan Facility substantially and concurrently with the closing of the Equity Offerings on the Funding Date. In addition to the Tranche A Loan, the Perceptive Term Loan Facility includes an additional Tranche B Loan, in an aggregate amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and an additional Tranche C Loan, in an aggregate amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which will be accessible by the Company so long as the Company satisfies certain customary conditions precedent, including revenue milestones. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Tranche B and C loans have loan commitments dates through December 31, 2023 and September 30, 2024, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Perceptive Term Loan Facility has a maturity date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 21, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity Date)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;provides for an interest-only period during the term of the loan with principal due at the Maturity Date. The Company's net proceeds from the Tranche A Loan were approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, after deducting &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;debt issuance costs and expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Interest Rate&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Perceptive Term Loan Facility will accrue interest at an annual rate equal to the greater of (a) forward-looking one-month term SOFR as posted by CME Group Inc. and (b) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per annum, plus an applicable margin of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the stated interest rate was approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Amortization and Prepayment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On the Maturity Date, the Company is required to pay the Lender the aggregate outstanding principal amount underlying the Loan and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments under the Perceptive Term Loan Facility. The Perceptive Term Loan Facility may be prepaid at any time, subject to a prepayment premium equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Security Instruments and Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to a Security Agreement, dated as of the Funding Date (the Security Agreement), between the Company and the Lender, substantially all of the Company&#x2019;s obligations under the Credit Agreement are secured by a first lien perfected security interest on all of the Company&#x2019;s assets, subject to customary exceptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the Credit Agreement, the Company has issued, on the Funding Date, the Perceptive Warrant of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, including the Initial Warrants which are equity classified at a per share exercise price equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0648&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;which is equal to the lower of (A) the 10-day volume weighted average price (VWAP) of the Company&#x2019;s common stock, on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of Common Stock of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (see Note 10 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In addition to the Initial Warrants, the Additional Warrants will each become exercisable into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The per share exercise price for the Additional Warrants will be equal to the lower of (A) the Initial Warrant exercise price or (B) the 10-day VWAP ending on the business day immediately preceding the funding date of the Tranche B Loan or the Tranche C loan, res&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;pectively. Each warrant will be exercisable, in whole or in part, until the 10th anniversary of the applicable date of issuance. If the Tranche B or C loans are not drawn by the respective loan commitment dates, the associated Additional Warrants expire and will not become exercisable. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Representations, Warranties, Covenants, and Events of Default&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants, financial covenants, and conditions that are customarily required for similar financings. The affirmative covenants, among other things, require the Company to undertake various reporting and notice requirements, maintain insurance and maintain in full force and effect all Regulatory Approvals, Material Agreements, Material Intellectual Property (each as defined in the Credit Agreement) and other rights, interests or assets (whether tangible or intangible) reasonably necessary for the operations of the Company&#x2019;s business. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s business activities; make certain Investments or Restricted Payments (each as defined in the Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that has the impact of restricting the Company&#x2019;s ability to make loan repayments under the Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million; and (ii) as of the last day of each fiscal quarter commencing on the fiscal quarter ending March 31, 2023, receive revenue in amounts agreed to between the Company and Perceptive from time to time.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Credit Agreement also contains certain customary Events of Default which include, among others, non-payment of principal, interest, or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross- defaults to material contracts, certain regulatory-related events and events constituting a change of control. As of December 31, 2022, the Company was in compliance with all restrictive and financial covenants associated with its borrowings. The occurrence of an Event of Default could result in, among other things, the declaration that all outstanding principal and interest under the Perceptive Term Loan Facility are immediately due and payable in whole or in part.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Initial Warrants and Additional Warrants were valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, using the Black-Scholes option-pricing model, estimated settlement probabilities and estimated exercise prices. As a result of the fees paid to Perceptive and the value of the Perceptive Warrant, the Company recognized a discount on the Perceptive Term Loan in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company recorded the debt discount as a reduction to the principal amount of the debt and is amortized as interest expense over the life of the debt.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Securities Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 9, 2022 (the First Closing Date), the Company entered into a securities purchase agreement (the SPA) with Streeterville Capital, LLC (Streeterville), pursuan&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t to which, among other things, Streeterville: &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(i) purchased a secured promissory note (Promissory Note One) in the aggregate principal amount totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in exchange for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company&#x2019;s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in exchange for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash proceeds.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Each of the Promissory Notes, at the Company's option, could be settled in cash or shares of common stock of the Company, upon the terms and subject to the limitations and conditions set forth in the Promissory Notes. The Company's net proceeds from the issuance of Promissory Note One were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, after deducting debt issuance costs and original issue discount (OID).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Promissory Notes had a stated interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per annum. The maturity date of each Promissory Note was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months from the issuance date of such Note. Promissory Note One was issued with an OID of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million while Promissory Note Two, if issued, would have been subject to an OID of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million subject to certain contingencies which could increase the OID by an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Promissory Notes were eligible for early payment for cash, at the Company&#x2019;s election, subject to a prepayment premium of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding principal balance. During the year ended&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; December 31, 2022, the Company recorded &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for accrued interest, amortization of the OID and debt issuance costs to interest expense in the accompanying statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Substantially and concurrently with the completion of the Equity Offerings, the Company fully repaid all outstanding principal, accrued and unpaid interest, and prepayment and other fees due under the existing SPA with Streeterville in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the extinguishment of Promissory Note One, t&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;he Company recorded a loss on debt extinguishment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the three months ended December 31, 2022, associated with the prepayment premium and with the write-off of unamortized debt issuance costs and OID.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2021 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 19, 2021 (Effective Date), the Company entered into a Loan and Security Agreement (the 2021 Term Loan) by and between Silicon Valley Bank, a California corporation (SVB) and the Company, as borrower, whereby subject to the terms and conditions of the 2021 Term Loan, SVB advanced to the Company an original principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2021 Term Loan provided for an &#x201c;interest-only&#x201d; period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan was payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan accrued interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, was payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate were effective on the effective date of any change to the prime rate.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s final payment to SVB included a payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;amortized as interest expense over the term of the 2021 Term Loan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022 and through the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Closing Date of the Perceptive Term Loan Facility, the Company repaid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in outstanding principal on the 2021 Term Loan.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Substantially and concurrently with the completion of the Equity Offerings, the Company fully repaid all outstanding principal, accrued and unpaid interest, and other fees due under the existing 2021 Term Loan with SVB in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which included $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in remaining outstanding principal. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the extinguishment of the 2021 Term Loan, t&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;he Company recorded a loss on debt extinguishment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the three months ended December 31, 2022, associated with the final payment and the write-off of unamortized debt issuance costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.51%;"/&gt;
        &lt;td style="width:1.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.717000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_9578f252-cfb2-4592-9bcf-1038069c69ab">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term notes payable were as follows (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.716%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.848%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Perceptive Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized debt discount and debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term notes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_13ad713e-d35e-41ad-b2d9-9738e144f092"
      decimals="-3"
      id="F_b9ecfa13-a893-427c-9ca2-697f7442aba2"
      unitRef="U_USD">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_c2fe46f8-1653-48ec-9a32-c95a2b1ef531"
      decimals="-3"
      id="F_bd2311ed-ecd0-47b6-823c-8025ac07551e"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_b84975b5-0a2a-4c6a-a970-bca06808dbba"
      decimals="-3"
      id="F_e6d9a93c-70a7-44ca-841a-eb0f6a216532"
      unitRef="U_USD">127000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_217f72b0-cf7e-4c4d-b942-59ada45d53c1"
      decimals="-3"
      id="F_3e11ac48-679b-4c79-892c-892f4197b904"
      unitRef="U_USD">75000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_0a6638d7-90de-40be-a9c1-e76eef1acf47"
      unitRef="U_USD">5074000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_437db00a-0b5b-4ab9-bdac-b9811f5dcc44"
      unitRef="U_USD">63000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayable
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_b9966c6e-e334-4b19-aad8-7ab5065c74fa"
      unitRef="U_USD">25053000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_6f8379e1-c6d4-4d5d-9fd6-6cb57ad9f0d5"
      unitRef="U_USD">10012000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_3f4399e4-32b0-4c6d-8ed0-294e6a12154e"
      unitRef="U_USD">49000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_9c7b990c-b5ff-4d3d-b670-edd49368e024"
      unitRef="U_USD">19000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_6529871b-da5b-47ea-a18e-d5b0a19cd0f6"
      unitRef="U_USD">25004000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_46e782b1-1a23-4013-816b-369c196fb78f"
      unitRef="U_USD">9993000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_e6d03a98-3b4e-401e-b7cc-82e792333d3e"
      decimals="INF"
      id="F_b100fe54-e6b0-4627-a063-9db3e72a72dd"
      unitRef="U_USD">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_70355a48-c284-4639-9391-77b924c70e70"
      decimals="INF"
      id="F_252d8c91-dfff-43b6-89d1-0aef6222f233"
      unitRef="U_USD">30000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e1abda95-a10b-462f-b26e-ff79238c4eda"
      decimals="-5"
      id="F_811593a9-5685-4814-a38c-800bc47ac1ae"
      unitRef="U_USD">40600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_1bf6cb5e-cf65-4a16-838b-e866908b46c6"
      decimals="INF"
      id="F_851c61ed-c757-4db6-8e38-6f0c9230daea"
      unitRef="U_USD">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_f0afd3f5-8310-4844-a4d2-63f0d27ddf88"
      decimals="INF"
      id="F_a990ee7c-49ad-4505-b966-4fb1090d6d93"
      unitRef="U_USD">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_9c393b81-f0da-48af-813c-5c496799a235"
      decimals="INF"
      id="F_498ce796-781d-4c7c-8b72-05034f5a040d"
      unitRef="U_USD">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_281dc173-6094-4689-8129-e75bfea9ac17"
      id="F_babc7029-bb02-4156-b688-dec76634cd51">2027-11-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="C_7de21cc0-f9c4-4529-94a5-c125fe2ca78f"
      decimals="-5"
      id="F_ce1577ef-caaa-4688-beab-88ad53b22e53"
      unitRef="U_USD">27900000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1"
      decimals="INF"
      id="F_f423466b-d348-430e-a7c7-53c93d763af3"
      unitRef="U_pure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_281dc173-6094-4689-8129-e75bfea9ac17"
      decimals="3"
      id="F_4f4c9606-dd0c-4962-8d93-b2eff5fee3ce"
      unitRef="U_pure">0.090</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_3d36f7fa-49dc-413d-a2bd-8d9342f8e774"
      decimals="3"
      id="F_bc9f770a-2f22-4133-9f67-74f776fe8e2b"
      unitRef="U_pure">0.133</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount
      contextRef="C_70355a48-c284-4639-9391-77b924c70e70"
      decimals="INF"
      id="F_c0bae7bd-3c3e-40a1-959f-8769148bd2ae"
      unitRef="U_pure">0.02</bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount>
    <bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount
      contextRef="C_deba999b-e5c6-4df4-a80e-17fb0c1de3fc"
      decimals="INF"
      id="F_d800b8ea-7e2d-4e2d-bea0-17cdb14f0bab"
      unitRef="U_pure">0.10</bdsx:PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_e6d03a98-3b4e-401e-b7cc-82e792333d3e"
      decimals="INF"
      id="F_6a8e8615-7ef7-429c-946f-ba01f266c525"
      unitRef="U_shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1"
      decimals="4"
      id="F_a4d04fdf-f0aa-4b00-b147-6f494bbbbc8a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.0648</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bdsx:PublicOfferingPricePerShareOfCommonStock
      contextRef="C_281dc173-6094-4689-8129-e75bfea9ac17"
      decimals="2"
      id="F_7f4ebf90-4f52-40ce-9604-b319a226488b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</bdsx:PublicOfferingPricePerShareOfCommonStock>
    <bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable
      contextRef="C_186ed4eb-26b5-4313-aca7-752df70e6114"
      decimals="INF"
      id="F_1244c6a6-8bee-4436-b365-81b18b859aec"
      unitRef="U_shares">1000000</bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable>
    <bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable
      contextRef="C_57134a4c-8578-40a1-813d-312feaa45a92"
      decimals="INF"
      id="F_d02797a8-deac-47a0-bc4f-0a8f6f6350de"
      unitRef="U_shares">1000000</bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable>
    <bdsx:MinimumCashBalanceAtMaturityDate
      contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1"
      decimals="-5"
      id="F_dc80c15f-8e06-4886-9c72-8022d158d0ae"
      unitRef="U_USD">2500000</bdsx:MinimumCashBalanceAtMaturityDate>
    <bdsx:InitialWarrantsAmount
      contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1"
      decimals="-5"
      id="F_b8ca2c32-4f37-4325-81ce-362ffe9d6a7c"
      unitRef="U_USD">2900000</bdsx:InitialWarrantsAmount>
    <bdsx:AdditionalWarrantsAmount
      contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1"
      decimals="-5"
      id="F_fd001db9-535b-40f5-9277-1446c6c57cd5"
      unitRef="U_USD">100000</bdsx:AdditionalWarrantsAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_d301989c-2ae7-4a05-901c-aeb97c5075f1"
      decimals="-5"
      id="F_49abb15b-40df-4ca0-9b78-9ea0657fe7f3"
      unitRef="U_USD">5200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <bdsx:DescriptionOfSecuritiesPurchaseAgreement
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_c4f9a2a6-6069-4aab-9b68-c3fa5ddb3039">(i) purchased a secured promissory note (Promissory Note One) in the aggregate principal amount totaling $16.0 million in exchange for $15.0 million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company&#x2019;s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $10.3 million in exchange for $10.0 million in cash proceeds.</bdsx:DescriptionOfSecuritiesPurchaseAgreement>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_b302bad2-98d3-4851-b88b-540dd7c490b7"
      decimals="-5"
      id="F_0e332bf4-0e5d-450e-9267-6332ab926bc3"
      unitRef="U_USD">16000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_ae3277b8-5cce-47e3-bdd2-81eecc7c9a41"
      decimals="-5"
      id="F_4dbe8d88-aca4-4c48-9949-b485935b4c67"
      unitRef="U_USD">15000000.0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_9e3e3184-45f3-43eb-b6eb-3e2a5df33941"
      decimals="-5"
      id="F_0f8c3257-7beb-44a0-954f-b035e831540e"
      unitRef="U_USD">10300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_ac1ef5ae-331a-42b9-b66f-a867d9104059"
      decimals="-5"
      id="F_0ae93a49-ace2-4b57-a23e-79636d54fb48"
      unitRef="U_USD">10000000.0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="C_ae3277b8-5cce-47e3-bdd2-81eecc7c9a41"
      decimals="-5"
      id="F_fb924076-162e-4966-ba38-7c41c713f297"
      unitRef="U_USD">12800000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="C_a85d3cdf-c6db-43af-b1d3-58080059098c"
      decimals="2"
      id="F_762b6e86-7188-426a-855c-2262cf573d55"
      unitRef="U_pure">0.06</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeTermOfContract
      contextRef="C_9d280c57-4f0c-4087-bfc5-09e23f264b72"
      id="F_1d3eb4de-dd29-4429-8312-6f532c35a2de">P24M</us-gaap:DerivativeTermOfContract>
    <bdsx:DiscountsOnDebtInstrumentIssuance
      contextRef="C_ae3277b8-5cce-47e3-bdd2-81eecc7c9a41"
      decimals="-5"
      id="F_df13fd2e-093a-4efb-af82-4a91607d6d72"
      unitRef="U_USD">1000000.0</bdsx:DiscountsOnDebtInstrumentIssuance>
    <bdsx:DiscountsOnDebtInstrumentIssuance
      contextRef="C_ac1ef5ae-331a-42b9-b66f-a867d9104059"
      decimals="-5"
      id="F_5977e9dc-df85-4cf8-bc36-599bd886a9aa"
      unitRef="U_USD">300000</bdsx:DiscountsOnDebtInstrumentIssuance>
    <bdsx:IncreaseInDiscountsOnDebtInstrumentIssuance
      contextRef="C_ac1ef5ae-331a-42b9-b66f-a867d9104059"
      decimals="-5"
      id="F_603c7899-ecc9-4313-9b48-3d5d8b354a26"
      unitRef="U_USD">500000</bdsx:IncreaseInDiscountsOnDebtInstrumentIssuance>
    <bdsx:PromissoryNotesEarlyPrepaymentPremiumPercentage
      contextRef="C_9d280c57-4f0c-4087-bfc5-09e23f264b72"
      decimals="2"
      id="F_e8c78737-f321-4483-b4d6-3632dd37a6bd"
      unitRef="U_pure">0.10</bdsx:PromissoryNotesEarlyPrepaymentPremiumPercentage>
    <bdsx:AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-5"
      id="F_bb5cb256-7932-4c92-b8a1-631d3dcdea9b"
      unitRef="U_USD">1800000</bdsx:AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_eaa55565-82f2-477b-b6d4-79f13c784eb1"
      decimals="-5"
      id="F_95b9b5b2-f5cb-4db3-accc-b09147597e3f"
      unitRef="U_USD">18200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_037983b4-6196-4ce5-8ade-33f68a42d303"
      decimals="-5"
      id="F_0e6246c9-5cfb-4210-812a-235ac94cc477"
      unitRef="U_USD">-3600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_cd92a88e-0c45-4130-9ceb-be9f1169e806"
      decimals="-6"
      id="F_37c88c8a-7494-430c-9398-0087e55554fc"
      unitRef="U_USD">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_7b4545c5-9d28-4a8e-a226-60530e6debbb">The 2021 Term Loan provided for an &#x201c;interest-only&#x201d; period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan was payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan accrued interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, was payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate were effective on the effective date of any change to the prime rate.</us-gaap:DebtInstrumentDescription>
    <bdsx:RevenueMilestone
      contextRef="C_b8821775-e1c7-4b43-bef0-f192ca32577a"
      decimals="-6"
      id="F_bec97372-52c3-4f6a-9d11-ccda162a9baf"
      unitRef="U_USD">65000000</bdsx:RevenueMilestone>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_b8821775-e1c7-4b43-bef0-f192ca32577a"
      decimals="-5"
      id="F_c9201a10-f96d-42c5-be57-b3a2b75194f7"
      unitRef="U_USD">2700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_02bbb7a6-c4e5-4790-a0f3-3a027542791f"
      decimals="-5"
      id="F_21bfe902-1ed2-45a1-b12e-5395a71305e5"
      unitRef="U_USD">7000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_9494a794-f77b-4a40-af81-4b90b746a8d1"
      decimals="-5"
      id="F_6de3fe87-5873-42f5-a4d3-9264f9b06c6a"
      unitRef="U_USD">5700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_23d25b67-f820-41e5-bbdb-0e27c1391956"
      decimals="-5"
      id="F_a1be10e2-027f-4a3c-9926-9829c2ddb610"
      unitRef="U_USD">3000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_7a4e3ec5-40de-461c-b6a5-3cb9963618ff"
      decimals="-5"
      id="F_cc771705-35a4-4203-87f4-0819034c44fd"
      unitRef="U_USD">-400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_5242b471-76db-4e76-931f-47095055197b">
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.51%;"/&gt;
        &lt;td style="width:1.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.717000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_2b0ee1a4-ea05-44b5-acf0-189d6e0a5499"
      unitRef="U_USD">49000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_7bbac0ad-7ce5-4d26-b2b3-605c6718c84d"
      unitRef="U_USD">50000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_2dcb91b5-7c8f-4813-af75-9a22f17ba202"
      unitRef="U_USD">21000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_7249baae-95bd-4ff6-86c5-1256fdd92edc"
      unitRef="U_USD">7000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_3ca5b1e8-344f-4916-a768-6f62d2f66c06"
      unitRef="U_USD">30000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebt
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_16eb4cf8-dfb9-402f-98de-c1aba8e9d961"
      unitRef="U_USD">30127000</us-gaap:LongTermDebt>
    <bdsx:LesseeOperatingAndFinanceLeasesTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_f22e224c-a3a1-4f42-8422-2a5c076f88f9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 9 &#x2013; Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company acts as a lessee under all its lease agreements. The Company leases its headquarters and laboratory facilities in Boulder, Colorado, under a non-cancelable lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,722&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet that was set to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_69f529c7-a6b6-4870-92d2-707a07490f78;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In January 2022, the Company amended the agreement to extend the lease agreement through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_1f6e0faa-935f-477f-be66-d4008a184239;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, resulting in an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in ROU assets and lease liabilities recorded during the three months ended March 31, 2022. The Company also leases laboratory and office space in De Soto, Kansas, under a non-cancelable lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,066&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet that expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9b0044c9-456b-40db-b304-cbb2a4cddf06;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;October 2023, however, we are currently in discussions to extend this lease agreement&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company also holds various copier and storage facility leases under non-cancelable lease agreements that expire in the next &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_558ae46e-8ea1-4c0a-9a4d-100dfe66de89;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_0980ea39-5787-4d2b-b800-5afec28cfc63;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Centennial Valley Properties I, LLC Lease Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space in Louisville, Colorado (the Leased Premises). The purpose of the Lease is to replace the Company&#x2019;s current leased premises in Boulder, Colorado. The Company intends to move its corporate headquarters to the Leased Premises by mid-2023.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The initial term of the Lease is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;twelve years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; renewal options to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the term of the Lease for an additional seven or ten year terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in ROU assets and lease liabilities being recorded. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Lease, the Company will lease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,980&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per month and escalating, based on fixed escalation provisions, to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;326,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,980&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million toward the cost of construction and improvements for the Leased Premises and the Company exercised its option for an additional tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per year over the Initial Term excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount. The Company made an accounting policy election to reduce the right-of-use asset and lease liability at lease commencement because the Lease specifies a maximum level of reimbursement for tenant improvements which are probable of being incurred and within the Company's control. Due to the tenant improvement allowances at the accounting lease commencement date and rent abatement periods described above, the Company expects the lease liability to accrete to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million by March 2024 after receiving $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in lessor reimbursements. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, the Company has incurre&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;capital expenditures for leasehold improvements related to the Leased Premises which are tenant improvements and have been reimbursed from the Landlord during the three months ended December 31, 2022. As of December 31, 2022, the Company had remaining capacity under the tenant improvement allowances of approximately&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. During the three months ended September 30, 2022, a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million cash collateralized letter of credit under the operating lease agreement was released and the funds were subsequently transferred to the Landlord as a refundable deposit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#x2019;s obligations. The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million refundable deposit is included within '&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_619e0fd9-df0a-4ffa-8df0-66030beb9821;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;' in the balance sheet as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease expense for all operating leases was&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the year ended December 31, 2022 and 2021, respectively. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the weighted-average remaining lease term and discount rate associated with our operating leases were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, respe&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ctively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments associated with our operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.796%;"/&gt;
        &lt;td style="width:1.869%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.334%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less amount representing tenant improvement allowances&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The remaining contractually agreed upon tenant improvement allowances of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million are expected to be received during fiscal year 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations in accordance with ASC 840 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.784%;"/&gt;
        &lt;td style="width:1.711%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</bdsx:LesseeOperatingAndFinanceLeasesTextBlock>
    <bdsx:AreaOfOfficeSpaceLeased
      contextRef="C_c73395a4-9ee2-430d-9509-2e0c8ad1a49e"
      decimals="0"
      id="F_0e943cef-7952-44d1-b3da-96122044a636"
      unitRef="U_sqft">29722</bdsx:AreaOfOfficeSpaceLeased>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_cf4e748d-3074-47c8-b2fc-51fe7c3e9765"
      decimals="-5"
      id="F_e145acc3-4edc-427c-b7b3-261d68eb4c1e"
      unitRef="U_USD">1200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_cf4e748d-3074-47c8-b2fc-51fe7c3e9765"
      decimals="-5"
      id="F_2a61c7c9-5224-4a57-925f-27b94669016c"
      unitRef="U_USD">1200000</us-gaap:OperatingLeaseLiability>
    <bdsx:AreaOfOfficeSpaceLeased
      contextRef="C_d74f0750-6f1c-442f-84b0-83d80d96838d"
      decimals="0"
      id="F_6bf96279-33b1-4105-a994-fc5b12381115"
      unitRef="U_sqft">9066</bdsx:AreaOfOfficeSpaceLeased>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription
      contextRef="C_5556e5f1-5117-4c3b-bc0c-a41a3e2ea92b"
      id="F_efcba56d-6b25-45c7-b43a-beb1a13aac30">The initial term of the Lease is twelve years (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) April 1, 2023 (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has two renewal options to extend the term of the Lease for an additional seven or ten year terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $2.0 million in ROU assets and lease liabilities being recorded. </us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="C_c6060929-cc88-48de-ac6e-4ff5aee26e2e"
      id="F_3f041539-c552-457a-bf5c-71937d64b0ba">P12Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <bdsx:LeaseCommencementDate
      contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66"
      id="F_0278cafc-4fa5-4b55-9cec-fdc490536c2c">2023-04-01</bdsx:LeaseCommencementDate>
    <bdsx:LeaseAgreementNumberOfOptionsToExtend
      contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66"
      decimals="INF"
      id="F_922a4673-68f3-4e6e-9efe-f2aba5084dad"
      unitRef="U_RenewalOption">2</bdsx:LeaseAgreementNumberOfOptionsToExtend>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend
      contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66"
      id="F_5e5a5345-1edd-4012-8378-e25262e96e3d">true</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_38785f87-07c1-43cc-ac73-db1f587fe1ec"
      decimals="-5"
      id="F_1c405407-ef26-4c51-9cc0-b3867ed3e02e"
      unitRef="U_USD">2000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_38785f87-07c1-43cc-ac73-db1f587fe1ec"
      decimals="-5"
      id="F_e599fd71-12ac-409d-8cfc-fc923ed5590f"
      unitRef="U_USD">2000000.0</us-gaap:OperatingLeaseLiability>
    <bdsx:LeasedPropertyBuildingCapacity
      contextRef="C_c6060929-cc88-48de-ac6e-4ff5aee26e2e"
      decimals="INF"
      id="F_df4e6902-fe12-48f6-822f-5c9d62efe868"
      unitRef="U_sqft">79980</bdsx:LeasedPropertyBuildingCapacity>
    <bdsx:BaseRentPerMonthFromCommencementDate
      contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66"
      decimals="0"
      id="F_2710e769-c08c-4d7e-a420-e67cbf405096"
      unitRef="U_USD">227000</bdsx:BaseRentPerMonthFromCommencementDate>
    <bdsx:RentAfterFixedEscalationProvisions
      contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66"
      decimals="0"
      id="F_1e63c373-e444-40b5-8445-6c5f08fdd6b0"
      unitRef="U_USD">326000</bdsx:RentAfterFixedEscalationProvisions>
    <bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent
      contextRef="C_c6060929-cc88-48de-ac6e-4ff5aee26e2e"
      decimals="INF"
      id="F_d234abdc-0f58-46a3-a563-21eb2cb504aa"
      unitRef="U_sqft">19980</bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent>
    <bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements
      contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66"
      decimals="-5"
      id="F_2619007e-c656-4970-9385-c9cfb97ff81a"
      unitRef="U_USD">18800000</bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements>
    <bdsx:AdditionalTenantImprovementAllowanceAmount
      contextRef="C_5556e5f1-5117-4c3b-bc0c-a41a3e2ea92b"
      decimals="-5"
      id="F_f7bb06ea-141b-43fc-abc0-ab4767a6d643"
      unitRef="U_USD">2000000.0</bdsx:AdditionalTenantImprovementAllowanceAmount>
    <bdsx:InterestRateOnExtraAllowanceAmount
      contextRef="C_5c3dc923-6462-4ff0-b72f-b3b979f83e66"
      decimals="2"
      id="F_1b254e0b-fced-4796-a2b5-cea2f269a0f7"
      unitRef="U_pure">0.06</bdsx:InterestRateOnExtraAllowanceAmount>
    <bdsx:AccretionOfLeaseLiability
      contextRef="C_31da1c0e-91e4-449a-b28c-c8ca4cad2ca2"
      decimals="-5"
      id="F_8444c567-a187-491a-9641-741558f777c0"
      unitRef="U_USD">25700000</bdsx:AccretionOfLeaseLiability>
    <bdsx:LessorReimbursementsReceived
      contextRef="C_64a79dd5-c87c-429b-863e-00e581d3a825"
      decimals="-5"
      id="F_73451fcd-6721-4559-b48d-a2e723fc1bfe"
      unitRef="U_USD">20800000</bdsx:LessorReimbursementsReceived>
    <us-gaap:TenantImprovements
      contextRef="C_38785f87-07c1-43cc-ac73-db1f587fe1ec"
      decimals="-5"
      id="F_3be025fb-59d4-4ccb-8827-cc5b629bc767"
      unitRef="U_USD">2500000</us-gaap:TenantImprovements>
    <bdsx:RemainingCapacityUnderTheTenantImprovementAllowances
      contextRef="C_5556e5f1-5117-4c3b-bc0c-a41a3e2ea92b"
      decimals="-5"
      id="F_d801e47c-5262-4ace-9bea-588bfb1bfd92"
      unitRef="U_USD">18300000</bdsx:RemainingCapacityUnderTheTenantImprovementAllowances>
    <us-gaap:LineOfCredit
      contextRef="C_394dc411-8890-456c-88fb-38cd9c45e342"
      decimals="-5"
      id="F_33938bde-6e54-4164-9d39-907718e800c2"
      unitRef="U_USD">5000000.0</us-gaap:LineOfCredit>
    <us-gaap:CustomerFunds
      contextRef="C_4d3d5033-be47-4149-b009-902d32d7a987"
      decimals="-5"
      id="F_1a2cecf9-edcc-4c04-8a78-281a39718b28"
      unitRef="U_USD">5000000.0</us-gaap:CustomerFunds>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-5"
      id="F_8fe62c22-9fb0-4f3f-b45b-f9c4c7a02727"
      unitRef="U_USD">2600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-5"
      id="F_c4bc1de9-0b4b-4b0d-b4f3-d5531dc4b9c5"
      unitRef="U_USD">1200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      id="F_e5419def-0f6a-4108-ae29-51efa8734caa">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="4"
      id="F_1c886f13-ff19-426d-8381-3dc3c43f9311"
      unitRef="U_pure">0.1140</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_cb4b1267-09fa-4bec-95d3-06cd86a4b4e6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments associated with our operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.796%;"/&gt;
        &lt;td style="width:1.869%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.334%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less amount representing tenant improvement allowances&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The remaining contractually agreed upon tenant improvement allowances of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million are expected to be received during fiscal year 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_42206409-eca5-47e9-a86e-2b0ef1c3cb47"
      unitRef="U_USD">2289000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_ecd4a2e1-6f37-44e7-a51c-accfbb8a58ae"
      unitRef="U_USD">2619000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_7b162190-6681-44a6-b82a-d743849aeb31"
      unitRef="U_USD">3710000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_4f8ed8c6-3d9f-437b-827e-79c7ae2afe5a"
      unitRef="U_USD">3978000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_47d01c93-35b4-4737-bc94-2cb934484ff9"
      unitRef="U_USD">4063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <bdsx:LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_9d1ffbce-640b-4050-b630-de333f413d39"
      unitRef="U_USD">32263000</bdsx:LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_7f4caf77-d988-4b14-8064-87ceee223193"
      unitRef="U_USD">48922000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_23287897-5a43-4773-bf74-427d69a6eca8"
      unitRef="U_USD">23802000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <bdsx:LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_ce6d3b60-8e1e-4434-985f-82c8c765bf23"
      unitRef="U_USD">18323000</bdsx:LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_827c4c63-9ad5-43e7-b21e-3598787369db"
      unitRef="U_USD">6797000</us-gaap:OperatingLeaseLiability>
    <bdsx:TenantImprovementAllowancesExpectedToBeReceived
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-5"
      id="F_d69fb0e7-4bc6-4441-ab1b-5d6ddb96c7dd"
      unitRef="U_USD">18300000</bdsx:TenantImprovementAllowancesExpectedToBeReceived>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_c14d7cc2-2439-4078-bef9-0f8a33effdde">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations in accordance with ASC 840 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.784%;"/&gt;
        &lt;td style="width:1.711%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_a8cfd362-3e94-4b2d-bf20-1d497fab18b8"
      unitRef="U_USD">775000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_5de5cee3-65a5-4e27-91cb-58b90349879c"
      unitRef="U_USD">149000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_3f6843a8-132c-4da9-b901-4b19e9f928aa"
      unitRef="U_USD">9000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_65f89d12-9625-4e8f-8ffe-110ab7d26825"
      unitRef="U_USD">3000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_32f7ac60-27ef-4943-a92b-52a6fa9ae72c"
      unitRef="U_USD">1000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_5c575325-c038-46c1-9fd6-7708cb82243a"
      unitRef="U_USD">937000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_3b28b908-fe37-4df1-9d5b-c4dc95803bb4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 10 &#x2013; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holder of each share of common stock is entitled to one vote per share.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends have been declared as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Financing Programs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company maintains &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; facilities that enable equity financing on an ongoing basis at the Company&#x2019;s sole discretion, our at-the-market offering and our common stock purchase agreement with Lincoln Park Capital Fund, LLC (the LPC facility). In November 2021, the Company entered into a sales agreement with a financial institution, pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (the Shares), subject to terms and conditions. The Shares will be offered and sold by the Company pursuant to its previously filed and currently effective registration statement on Form S-3. The Shares may only be offered and sold by means of a prospectus, including a prospectus supplement, forming part of the effective registration statement. Sales of the common stock, if any, will be made at market prices by methods deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Global Market, or any other existing trading market for our common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 7, 2022 (the LPC Effective Date), the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), pursuant to which Lincoln Park has committed to purchase up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the Company's common stock (the Purchase Agreement). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of the Company&#x2019;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#x2019;s&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;sole &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;discretion, over the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period commencing on the LPC Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, but that amount may be increased up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, depending upon the market price of the Company&#x2019;s common stock at the time of sale and subject to a maximum limit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#x2019;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under applicable rules of the NASDAQ Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#x2019;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the LPC Effective Date, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,275&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock to Lincoln Park as a commitment fee (the Initial Commitment Shares) for which the Company did not receive consideration and, upon the available amount being reduced to an amount equal to or less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, the Company will be required to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,425&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares (the Additional Commitment Shares and together with the Initial Commitment Shares, collectively, the Commitment Shares). The Initial Commitment Shares issued were valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and, together with due diligence expenses and legal fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;129,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, reflect deferred offering costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;729,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which are included on the balance sheet in 'Other long-term assets'. The deferred offering costs will be charged against 'Additional paid-in capital' upon future proceeds from the sale of common stock under the Purchase Agreement. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of deferred offering costs were charged against 'Additional paid-in capital'. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;654,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of deferred offering costs remain.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company raised approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million after deducting underwriting discounts and commissions and offering expenses payable), in gross proceeds from the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,886,893&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares at a weighted average price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.87&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; under these programs. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had remaining available capacity for share issuances of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million under the at-the-market facility and up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million under the LPC facility, each subject to the restrictions and limitations of the underlying facilities, as well as volume limitations under applicable SEC rules and regulations that limit their availability as sources of funding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 30, 2021, the Company raised approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in gross proceeds from the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,756,994&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;per share in an at-the-market offering&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and offering expenses payable of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 21, 2022, the Company closed an underwritten public offering (the Public Offering) of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,075,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock (the Public Offering Shares), including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,575,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares purchased by the underwriter pursuant to an option to purchase additional shares. The Public Offering Shares were issued and sold pursuant to an underwriting agreement, dated November 16, 2022, by and between the Company and William Blair &amp;amp; Company, L.L.C., as sole underwriter, at a public offering price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from the Public Offering after deducting underwriting discounts, commissions, and offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Public Offering was made pursuant to the Company&#x2019;s effective Registration Statement on Form S-3 previously filed with the Securities and Exchange Commission on November 29, 2021 and a prospectus supplement, dated November 16, 2022, relating to the Offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Subscription Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On April 7, 2022, the Company entered into subscription agreements (the April 2022 Subscription Agreements) with a consortium of investors (the April 2022 Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,508,376&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock in a private placement offering. The three members of our Board of Directors acquired an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,631,284&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares pursuant to the form of a Subscription Agreement that did not include any registration rights. The remaining &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,877,092&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were acquired by others pursuant to the form of a Subscription Agreement whereby the Company agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the Securities and Exchange Commission no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the April 2022 Subscription Agreements, the April 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, which is equal to the closing price of the Company's common stock on April 7, 2022, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The April 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 21, 2022, the Company entered into subscription agreements (the November 2022 Subscription Agreements) with certain members of management (the November 2022 Investors), including the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, for the issuance and sale by the Company of an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235,056&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock in a private placement offering. The November 2022 Subscription Agreement did not include any registration rights and included lock up restrictions that will be in effect during the period ending 90 days subsequent to November 21, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the November 2022 Subscription Agreements, the November 2022 Investors purchased shares at a purchase price (determined in accordance with NASDAQ rules relating to the &#x201c;Minimum Value&#x201d; of the Company&#x2019;s common stock) of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, which is equal to the public offer price in the Public Offering, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;270,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The November 2022 Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During 2018, the Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain convertible preferred shares and issuance of debt. The Company issued to the lender a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;613,333&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series G convertible preferred stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 23, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Through the effective date of the Company&#x2019;s initial public offering (IPO) in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black-Scholes pricing model. As a result of the Company&#x2019;s IPO, the preferred stock warrants were automatically converted to warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103,326&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.46&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and were also transferred to additional paid-in capital. All Series G common stock warrants remain outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 21, 2022, as consideration for the Perceptive Term Loan Facility (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;), the Company issued the Perceptive Warrant to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock, including the Initial Warrants. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition to the Initial Warrants, the Additional Warrants will each become exercisable into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock concurrently with the borrowing date of the Tranche B and C Loans, respectively. The Company accounts for the Additional Warrants as liabilities as the Additional Warrants do not meet the criteria for equity treatment (see Note 4 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The per share exercise price for the Initial Warrants is equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0648&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which is equal to the lower of (A) the 10-day VWAP of the Company&#x2019;s common stock on the business day immediately prior to the Closing Date of the Tranche A Loan or (B) the public offering price per share of common stock of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Initial Warrants are equity classified and were immediately exercisable upon issuance and expire on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 21, 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Initial Warrants were valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million using the Black-Scholes option-pricing model assuming an expected term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years, a volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, a dividend yield of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and a risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.67&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. All Initial Warrants remain outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_041fd8b2-2b66-4b5c-ae8d-3e0c7a855f4a"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_dc3ec2fa-b6da-44db-b4b9-079f409a7dc0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_2fd4ab44-815d-4561-9d18-1eb3d6bfd584">The holder of each share of common stock is entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_933186ea-a486-411e-bdd9-0a17d07978cb"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_096023f1-85a6-4af8-a06d-2dba11de1edb"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_279a0a8d-5b30-464c-9bc7-0d1f1955f831"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_fbaf9d66-3857-4404-83fd-fe85b1520e17"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_4fd11a2d-8712-4621-a6ff-0ef2ff00c2fd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_10508e57-e0d1-48c1-8ff8-8dceb888d581"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_befdda13-1ccb-4fd6-8c10-2b7e2b66c84c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <bdsx:NumberOfFacility
      contextRef="C_eee382e8-1805-4f39-907d-bfda41055f0b"
      decimals="INF"
      id="F_84dce23a-1e00-4ebb-a708-720b3de74c55"
      unitRef="U_Facility">2</bdsx:NumberOfFacility>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d29ffb11-8aeb-454a-b02f-a1cd08996dde"
      decimals="-5"
      id="F_d043cbb2-9594-475b-a67f-2607950cc6a0"
      unitRef="U_USD">50000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <bdsx:StockIssuableDuringPeriodValueCommittedShares
      contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09"
      decimals="-5"
      id="F_7e720f7b-27a2-460b-a97c-01d69672b443"
      unitRef="U_USD">50000000.0</bdsx:StockIssuableDuringPeriodValueCommittedShares>
    <bdsx:StockIssuableDuringPeriodValueCommittedShares
      contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09"
      decimals="-5"
      id="F_69f5b036-6d0d-43d4-870b-67df0c110e4b"
      unitRef="U_USD">50000000.0</bdsx:StockIssuableDuringPeriodValueCommittedShares>
    <bdsx:PurchaseAgreementTerm
      contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808"
      id="F_d19a1e1f-6cfd-4d7e-9a94-692a9552fbf3">P36M</bdsx:PurchaseAgreementTerm>
    <bdsx:SaleOfStockStockIssuablePerDayShares
      contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808"
      decimals="0"
      id="F_ca3d4bca-a721-46c8-85bf-2ff532f7bc55"
      unitRef="U_shares">50000</bdsx:SaleOfStockStockIssuablePerDayShares>
    <bdsx:SaleOfStockStockIssuablePerDayShares
      contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09"
      decimals="0"
      id="F_9e640aa2-ae2b-4b16-8221-fbc20647f321"
      unitRef="U_shares">100000</bdsx:SaleOfStockStockIssuablePerDayShares>
    <bdsx:SaleOfStockStockIssuablePerDayValue
      contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09"
      decimals="-5"
      id="F_3a041439-4464-4117-b974-20c760976450"
      unitRef="U_USD">1500000</bdsx:SaleOfStockStockIssuablePerDayValue>
    <bdsx:SharesIssuedOrIssuableThresholdLimitDescription
      contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808"
      id="F_c87aca87-f813-48dc-888a-9c702db68cf4">Under applicable rules of the NASDAQ Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#x2019;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules.</bdsx:SharesIssuedOrIssuableThresholdLimitDescription>
    <bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty
      contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808"
      decimals="4"
      id="F_35b78f14-a736-4156-a260-cbbc44819700"
      unitRef="U_pure">0.0999</bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty>
    <bdsx:SaleOfStockSharesIssuedAsCommitmentFee
      contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808"
      decimals="0"
      id="F_5ef216d5-c57a-4a3b-8348-2c105da144f4"
      unitRef="U_shares">184275</bdsx:SaleOfStockSharesIssuedAsCommitmentFee>
    <bdsx:SharesIssuedAsCommitmentFeeValue
      contextRef="C_6852849f-4a20-4832-b763-1f583ecb4c09"
      decimals="-5"
      id="F_235034a2-5c73-4e63-9b93-056fcdc3934a"
      unitRef="U_USD">20000000.0</bdsx:SharesIssuedAsCommitmentFeeValue>
    <bdsx:CommitmentSharesIssuableOnConditionalBasis
      contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808"
      decimals="0"
      id="F_67254794-3e7c-4e27-8cf0-a886340d4df2"
      unitRef="U_shares">61425</bdsx:CommitmentSharesIssuableOnConditionalBasis>
    <bdsx:StockIssuableDuringPeriodValueCommittedShares
      contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808"
      decimals="0"
      id="F_93650a8a-e2a8-4151-8b5f-106029026c10"
      unitRef="U_USD">600000</bdsx:StockIssuableDuringPeriodValueCommittedShares>
    <bdsx:DiligenceExpenseAndLegalFees
      contextRef="C_ef9be249-05dd-46fb-9453-58ae75b42808"
      decimals="0"
      id="F_00ed322b-7419-4002-a360-36787afdcbbd"
      unitRef="U_USD">129000</bdsx:DiligenceExpenseAndLegalFees>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_d6b61263-79d7-4ad5-80e3-c6488dc15d6e"
      decimals="0"
      id="F_cbacc074-c4f3-4162-847b-aa42988103a5"
      unitRef="U_USD">729000</us-gaap:DeferredOfferingCosts>
    <bdsx:AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts
      contextRef="C_71e6a261-6445-4aef-9b90-6aa8258c393b"
      decimals="0"
      id="F_2d7dec7d-f371-4a04-9ccf-8e6214cf928b"
      unitRef="U_USD">75000</bdsx:AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_7879ad8c-ea5d-4043-a09d-e45c5b04d104"
      decimals="0"
      id="F_6783497b-d282-4ed4-affe-d4499b132328"
      unitRef="U_USD">654000</us-gaap:DeferredOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_eee382e8-1805-4f39-907d-bfda41055f0b"
      decimals="-5"
      id="F_13cc6847-8b0a-4a65-92ae-4b745b61e6ae"
      unitRef="U_USD">7300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bdsx:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_b796b863-ace9-4b62-946c-082d3b02817c"
      decimals="-5"
      id="F_390a142c-f9f5-4a72-bc16-1c0f77547d5e"
      unitRef="U_USD">6800000</bdsx:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_eee382e8-1805-4f39-907d-bfda41055f0b"
      decimals="INF"
      id="F_69b01b31-51ae-42a6-b79b-184c3047b72a"
      unitRef="U_shares">3886893</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bdsx:WeightedAveragePricePerShare
      contextRef="C_eee382e8-1805-4f39-907d-bfda41055f0b"
      decimals="2"
      id="F_f1657b1f-5432-4ffd-9848-5895c026a76c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.87</bdsx:WeightedAveragePricePerShare>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_91f72376-23e0-4941-9051-8d330ee61b8e"
      decimals="-5"
      id="F_91ce25aa-280a-40e0-ba51-c2dce856fc4d"
      unitRef="U_USD">29500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_17924754-ecbd-43e7-95c0-61af5078762a"
      decimals="-5"
      id="F_b0887d4c-abcc-4d2f-b9c4-e20057e5d78d"
      unitRef="U_USD">46900000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_169bf5c0-fabd-48e8-9e19-f178074d2e74"
      decimals="-5"
      id="F_a5e677b0-8770-4676-b0ee-db5b4d9c043d"
      unitRef="U_USD">16300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_169bf5c0-fabd-48e8-9e19-f178074d2e74"
      decimals="INF"
      id="F_8c6b334d-7890-4d78-9cdd-18cde0bfe61a"
      unitRef="U_shares">3756994</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_187c775a-a3b7-42da-bfab-78d163765caf"
      decimals="2"
      id="F_43d9180c-9bd5-454f-8b41-33676c6b09ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.35</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5cc619c2-53d7-4761-a81a-9a741927fe13"
      decimals="-5"
      id="F_3c620c38-e86d-401c-a728-7bf7c9bd72c0"
      unitRef="U_USD">15700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bdsx:UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable
      contextRef="C_187c775a-a3b7-42da-bfab-78d163765caf"
      decimals="-5"
      id="F_90b14eea-baf5-4e77-8ee4-dcaf9563fed7"
      unitRef="U_USD">700000</bdsx:UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_80d972be-0e12-4624-abfc-02988b9d378b"
      decimals="INF"
      id="F_e936491f-d0cd-4847-b621-a9335c8e05d9"
      unitRef="U_shares">35075000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bdsx:StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter
      contextRef="C_80d972be-0e12-4624-abfc-02988b9d378b"
      decimals="INF"
      id="F_3f092a7b-8e42-4a48-8d5d-8b4cc1db46e7"
      unitRef="U_shares">4575000</bdsx:StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0b08f51c-d57a-4f72-8c72-dd0f2eae99a3"
      decimals="2"
      id="F_83ac4625-8b05-43cb-949e-38c779bd8253"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_438ec078-c687-429c-a769-d3742dbe11a3"
      decimals="-5"
      id="F_e3221fca-e9a9-4f36-9f5d-865f62c2635f"
      unitRef="U_USD">37500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_bd3c756b-0fd0-4580-b35c-5bd0c430ca65"
      decimals="INF"
      id="F_31094051-3099-4f30-8766-aba077ad83b3"
      unitRef="U_shares">6508376</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1a2949cc-e81d-4125-b746-f22e110c97c7"
      decimals="INF"
      id="F_c9297c2c-3cf3-4998-ab7a-6ce0e18a4bd0"
      unitRef="U_shares">3631284</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6a86f3ed-b059-49f8-929d-392ed1b5aefa"
      decimals="INF"
      id="F_114c7296-193c-42e2-8b9c-43899ee81c36"
      unitRef="U_shares">2877092</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_fd581c08-91c5-4205-b952-ae033f5f32d1"
      decimals="INF"
      id="F_0eefe225-ac35-47c9-a425-891c4d2fe96e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.79</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_a9ac9aa4-ea3e-4802-8754-c8e9edd2adc9"
      decimals="INF"
      id="F_e2bb34da-f14f-4cdb-b57d-ac05cd04928e"
      unitRef="U_USD">11700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e1eeb3ca-40cd-466c-ae9e-ca7ba7b2a2f2"
      decimals="INF"
      id="F_fd28ba07-fdd4-4e45-bfc7-125fd1b7d98d"
      unitRef="U_shares">235056</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_c85c73e5-0596-4390-a44f-00d4c2b63b97"
      decimals="INF"
      id="F_838fbcb5-6372-42d4-9661-ae0ad8863b02"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_b1332991-a124-414c-9607-7eb5c2b60415"
      decimals="INF"
      id="F_8eac47e4-85a2-4664-ab7b-ecaf95f8dd3c"
      unitRef="U_USD">270000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_ba733271-8a6c-457b-aa81-58381d47b3b4"
      decimals="INF"
      id="F_208eefaa-e598-4267-97dd-3bec04650539"
      unitRef="U_shares">613333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ba733271-8a6c-457b-aa81-58381d47b3b4"
      decimals="2"
      id="F_502cd301-62e3-42bc-a053-e32561bfac9b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      id="F_cb155cf8-088b-421a-8a56-6172b3012bb3">2028-02-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_26541884-e077-4463-84ef-77608f72fe54"
      decimals="INF"
      id="F_71f322bf-a108-49d5-947b-c1d0d2336fb8"
      unitRef="U_shares">103326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_26541884-e077-4463-84ef-77608f72fe54"
      decimals="2"
      id="F_3aa3cf31-ac89-47de-a975-d88901cf7dcb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_6fd3ded3-11d4-4f58-b776-f582e91d8799"
      decimals="INF"
      id="F_0be0d53c-4750-41d6-9efd-f4ae913ce859"
      unitRef="U_shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable
      contextRef="C_94e70836-502c-461e-9146-5d8aa063080e"
      decimals="0"
      id="F_27129365-1ba6-467a-9002-c5432b082f4b"
      unitRef="U_shares">1000000</bdsx:ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6ad6809c-68cb-4c96-8ae0-d9bd24aa0db0"
      decimals="4"
      id="F_4d891101-6555-4421-bd08-41d9e69084a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.0648</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bdsx:PublicOfferingPricePerShareOfCommonStock
      contextRef="C_75178c23-f72c-42e0-a591-2de6aea0caff"
      decimals="2"
      id="F_18b5f6b8-c42d-4049-8b72-d75581b6639d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</bdsx:PublicOfferingPricePerShareOfCommonStock>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_4ed704bd-7ad3-4b26-ad05-362e6ae5c9c5"
      id="F_c163200a-56f9-4aa7-9258-042bf235c7e8">2032-11-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <bdsx:InitialWarrantsAmount
      contextRef="C_4ed704bd-7ad3-4b26-ad05-362e6ae5c9c5"
      decimals="-5"
      id="F_289900f1-f66d-4303-9886-528c1f5c6c65"
      unitRef="U_USD">2900000</bdsx:InitialWarrantsAmount>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_5b9afec0-72f8-4476-a4ee-4fd773a715d4"
      id="F_63d301de-c430-4674-a721-c83dcfaea080">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_086ca540-28e1-44ca-a323-2ad2636c5784"
      decimals="3"
      id="F_813bf283-36d0-4100-b84f-7813477c9c2d"
      unitRef="U_pure">0.813</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_d722c30e-d139-43c4-b526-3699892348c1"
      decimals="2"
      id="F_bf10d5f3-161f-45d3-bae3-8ec936b10754"
      unitRef="U_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_61e5c055-428e-4280-b39a-813cfb48033b"
      decimals="4"
      id="F_850e02df-864f-4549-998e-57992135400a"
      unitRef="U_pure">0.0367</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_e19512a0-4052-44f0-9463-5afcedf8583b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 11 &#x2013; Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.726%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.687999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Diagnostic tests&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in &#x2018;Revenues&#x2019; in the statements of operations. Of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in &#x2018;Deferred revenue&#x2019; recorded in the balance sheet as of December 31, 2021, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;was recognized in revenues during the year ended December 31, 2022. In addition, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; added to &#x2018;Deferred revenue&#x2019; for up-front cash payments received for which the revenue &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognition criteria have not been met and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was reclassed to non-current deferred revenue. The &#x2018;Deferred revenue&#x2019; of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million re&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;corded in the balance sheet as of December 31, 2022 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in non-cu&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;rrent deferred revenue, respectively, recorded within &#x2018;Other long-term liabilities&#x2019; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s customers in excess of 10% of total revenue both pertain to our COVID-19 diagnostic testing services, and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.5%;"/&gt;
        &lt;td style="width:1.018%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.454%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The State of Colorado&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Big Ten Conference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addit&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ion to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company&#x2019;s total revenue for the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.5%;"/&gt;
        &lt;td style="width:1.018%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.454%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Medicare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Astrazeneca UK&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Janssen Research and Development, LLC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;LabCorp DD (formerly Covance)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <bdsx:PrimarySourcesOfRevenueDescription
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_a68dc283-ce39-4854-8633-1eb71122ba58">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</bdsx:PrimarySourcesOfRevenueDescription>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_8dcc42de-d115-4034-bd34-9b764e3d1e14">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.726%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.687999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Diagnostic tests&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_5f76d7ba-2692-45b1-bf5a-feaf239555c2"
      decimals="-3"
      id="F_17878fa0-8456-4640-b734-8af72c0ad58b"
      unitRef="U_USD">34538000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_12180992-8c3b-4583-9f45-a6c1fac1d121"
      decimals="-3"
      id="F_ff2910cd-4bfc-4c74-9d29-26649b8be72d"
      unitRef="U_USD">48937000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_943b8db7-988c-4af2-94ee-41515857328f"
      decimals="-3"
      id="F_ab6f00d1-09ca-4ad3-8658-c9355af2763c"
      unitRef="U_USD">3674000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_6a0dc852-f2b0-48bc-b2b6-1620c601a50d"
      decimals="-3"
      id="F_86a3c95a-9607-421f-8904-cb3109fb7246"
      unitRef="U_USD">5569000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_fb20166e-48f8-42f9-9847-2c247f8f1057"
      unitRef="U_USD">38212000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_d2d259e0-7df7-41cb-8f6f-1ef54f497a48"
      unitRef="U_USD">54506000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-5"
      id="F_8c493a3b-a223-4305-83c4-6237d03267af"
      unitRef="U_USD">1900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-5"
      id="F_21dd2746-b5ae-4b9c-aa99-e4ab0b5c3c5e"
      unitRef="U_USD">1200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_1c8760f8-4bfb-43a9-838d-4e0b93c9f2aa"
      decimals="-5"
      id="F_8f3bfb3c-1270-420b-bd49-cc7f932306ec"
      unitRef="U_USD">700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-5"
      id="F_be640d83-84b4-411a-9a58-46e1640684bf"
      unitRef="U_USD">400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-5"
      id="F_fed434d5-1655-4d1f-a514-3bd330b36c1d"
      unitRef="U_USD">1000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_9e1cb9f9-1f35-4466-a46d-cf526d23b935"
      decimals="-5"
      id="F_1662fc76-ef03-4014-91ef-9c6d0cfe04e2"
      unitRef="U_USD">400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_3422fe75-7e5a-45a7-ac6a-9088eeb3e5b1"
      decimals="-5"
      id="F_a34736b4-94d7-41e9-8fd0-766cd56fcac3"
      unitRef="U_USD">800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_c317432d-4333-4800-a339-5065b1762362">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.5%;"/&gt;
        &lt;td style="width:1.018%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.454%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The State of Colorado&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Big Ten Conference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addit&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ion to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company&#x2019;s total revenue for the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.5%;"/&gt;
        &lt;td style="width:1.018%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.454%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Medicare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Astrazeneca UK&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Janssen Research and Development, LLC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;LabCorp DD (formerly Covance)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_73bf8719-9ed7-4a80-941c-ebed989aedcd"
      decimals="2"
      id="F_1f683e05-4c3c-4583-8af2-0c99d1248926"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_a480b51a-4a24-4df0-bc08-5701140469ea"
      decimals="2"
      id="F_998d3e90-0f8c-42fe-84c5-be723db9421f"
      unitRef="U_pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_efe1b90e-7787-4cc2-bfbe-359fbdc3c5ac"
      decimals="2"
      id="F_71e3d270-813d-4125-9a49-78fd34ad639a"
      unitRef="U_pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_4844e46c-01bd-4e1b-8bbd-3eb015874131"
      decimals="2"
      id="F_27b8df9a-a097-43eb-a8c8-9cf458bf4277"
      unitRef="U_pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_965f19ae-0f96-4ce2-8e48-5b6071e81159"
      decimals="2"
      id="F_88fa8cae-ed9d-40f1-b2c6-ed23f4f62dd0"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_9cfbccdc-31c5-4e8a-bfdc-7649f1ec0117"
      decimals="2"
      id="F_773038af-2685-445e-8cc0-054d9b280254"
      unitRef="U_pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0e3f888f-0695-472c-8a11-9658d99a93b6"
      decimals="2"
      id="F_b0ddbd0c-bca2-4903-b574-7e05b69a7300"
      unitRef="U_pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c7401865-053c-4260-997b-b04309ea03f4"
      decimals="2"
      id="F_a18a0f24-9d7f-4371-bf48-f04387de1f32"
      unitRef="U_pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_706d33fb-1152-4e58-a444-b5203cd4a996"
      decimals="2"
      id="F_532923bc-864e-430b-8f96-2e36fe92ba96"
      unitRef="U_pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_9d10300a-099e-4f44-bb64-9b606b78112d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 12 &#x2013; Share Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Predecessor 2016 and 2006 Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional awards may be granted under the 2006 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultant. Awards granted under the 2016 Plan or the 2006&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Plan &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#x2019;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional awards may be granted under the 2016 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective upon the closing of our IPO, the Company&#x2019;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The number of shares originally reserved for issuance under the 2020 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,893,395&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The 2020 Plan includes an annual increase on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#x2019;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a prior plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all plans as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;233,519&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective with our IPO in October 2020, the Company&#x2019;s Board of Directors and its stockholders approved the Company&#x2019;s Employee Stock Purchase Plan (the ESPP). The number of shares originally reserved for issuance under the ESPP was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;338,106&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the fair market value of the Company&#x2019;s common stock on the first or last day of the offering period, whichever is lower. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;237,961&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares have been issued under the ESPP leaving &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100,145&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;shares remaining for future issuance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Description of Awards Granted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-statutory stock options, which may be issued to employees, non-employees and directors, are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Performance-based options vest in three equal annual installments beginning one year after the grant date&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#x2019;s common stock on the grant date. There are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; performance-based stock options outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU holders have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Bonus-To-Options Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company also has a Bonus-to-Options Program (the Bonus Option Program) which is separate from previously described plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011, 2015, and 2022. For fiscal year 2022, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the closing market price of the Company's common stock on the grant date, as disclosed below under &#x201c;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x201d;. Bonus Options issued must be exercised within a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recorded the following activity related to the Bonus Option Program during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands, excepted weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.441%;"/&gt;
        &lt;td style="width:1.001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.754%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.987%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.087%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.754%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.872%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company record&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million du&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ring the years ended December 31, 2022 and 2021, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in the first quarter of 2023 and 2022, respectively, by the Compensation Committee of the Board of Directors. In determining the amount of share-based compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.841%;"/&gt;
        &lt;td style="width:1.663%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.424%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.275%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.796999999999997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The unrecognized remaining share-based compensation expense for options and&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; RSUs was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and is expected to be amortized to expense over the next &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.441%;"/&gt;
        &lt;td style="width:1.001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.754%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.987%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.087%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.754%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.872%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding - January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of the Company&#x2019;s common stock is determined based on its closing market price on the date of grant. The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends have been declared as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.936%;"/&gt;
        &lt;td style="width:1.203%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.062%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.814%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.985000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk&#x2011;free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock unit activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 was (in thousands, except weighted average grant date fair value per share):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.859%;"/&gt;
        &lt;td style="width:1.207%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.776000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.27%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.889%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_7fdeca4f-00cf-4beb-b46e-1e1eae6fa90a"
      decimals="INF"
      id="F_8c9a56de-0818-4951-8a34-04350da18b27"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_daba2c85-8b46-41a0-aced-c3772e54ec5d"
      decimals="INF"
      id="F_a64c610d-1b55-4f89-a7a4-ad6877296348"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2d5836ee-d2bb-477b-8e85-8cfcb55b699e"
      decimals="INF"
      id="F_2a1f6028-f31e-478d-ab6e-b5962ead9e94"
      unitRef="U_shares">1893395</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_7b4b65a0-9eab-4198-9d03-64c0e6fc1646"
      decimals="2"
      id="F_683990ca-ac22-41c7-b6b2-9e39fa64a683"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_630425c2-c257-4e6f-9752-038cef3e8e65"
      decimals="INF"
      id="F_9d249a12-5729-4234-9e2d-b99a6395ed24"
      unitRef="U_shares">233519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6dc925fe-1445-4fb6-b137-670c99ed2615"
      decimals="INF"
      id="F_b5ea8779-b1eb-4c7f-9291-627c0220eebc"
      unitRef="U_shares">338106</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf"
      decimals="INF"
      id="F_8c626070-0125-45bd-8135-753799f07f13"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_55e36f95-2f43-434a-8af9-06f6e131a730"
      decimals="INF"
      id="F_929feae4-44b1-417e-9320-e0ec53ccdf6a"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf"
      decimals="INF"
      id="F_aeb6f080-5183-4aa6-8a81-47bb11315f2d"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod
      contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf"
      id="F_e8ba12f7-f59d-4779-b94b-f802fe477948">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.</bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod>
    <bdsx:DescriptionOfOfferingPeriodUnderPlan
      contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf"
      id="F_85a1a730-96be-4c01-b890-608fd632195b">The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of December 31, 2022, 237,961 shares have been issued under the ESPP leaving 100,145 shares remaining for future issuance.</bdsx:DescriptionOfOfferingPeriodUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_ee6b7930-2f93-49cf-b529-e29e0ab50ddf"
      decimals="INF"
      id="F_13efa344-98d2-43f9-907b-29b4e5256431"
      unitRef="U_shares">237961</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_55e36f95-2f43-434a-8af9-06f6e131a730"
      decimals="INF"
      id="F_e2d721d9-5b3c-4c01-8eab-0bb5c3b542cd"
      unitRef="U_shares">100145</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_1043f2a6-0e14-46df-bbaa-a20764b5e9c1"
      id="F_00470ce3-7ab2-4b0d-9895-a9b0d670ecc5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_746a7287-f9b5-4d12-831b-35d4b70d784d"
      id="F_afad1ea5-778e-4b1b-8c08-bc210e5735c2">Performance-based options vest in three equal annual installments beginning one year after the grant date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bcd01088-6b6b-4233-b784-8c76ca2c0480"
      decimals="INF"
      id="F_904add92-9c4d-4572-9ca0-a2708c32e13d"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_86159b8d-7aed-4b03-b26e-bca866fbd61a"
      id="F_9ee3d0a5-5fb2-4395-8543-e6295f5c851e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_585442c6-63fc-4616-91c6-831a62abd477"
      id="F_315ebc86-57bb-49d3-a615-c37bb70b50e0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recorded the following activity related to the Bonus Option Program during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands, excepted weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.441%;"/&gt;
        &lt;td style="width:1.001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.754%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.987%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.087%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.754%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.872%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0cde4147-0171-4e88-8504-bba1e5f0b211"
      decimals="-3"
      id="F_c2d49a34-6b7d-4227-b7be-28b987c0025e"
      unitRef="U_shares">373000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0cde4147-0171-4e88-8504-bba1e5f0b211"
      decimals="2"
      id="F_9fecbffc-8d10-4710-8352-7b77c78ea3dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_41cb42fe-1fc1-4fe5-95d4-e30f3d31ec21"
      id="F_ad055ebd-a8fe-4fb9-bf29-113d7479fb08">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0cde4147-0171-4e88-8504-bba1e5f0b211"
      decimals="-3"
      id="F_66ac03ec-6037-422b-b591-bdc464f5b678"
      unitRef="U_USD">76000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_585442c6-63fc-4616-91c6-831a62abd477"
      decimals="-3"
      id="F_1769c380-d3ac-4a27-bdf7-ab19212f0184"
      unitRef="U_shares">244000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_585442c6-63fc-4616-91c6-831a62abd477"
      decimals="2"
      id="F_fff3d5c4-c263-4a64-a631-5784ed7b418e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_585442c6-63fc-4616-91c6-831a62abd477"
      decimals="-3"
      id="F_ba5f717f-e40a-4fdd-9c05-296f7a544d30"
      unitRef="U_shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_585442c6-63fc-4616-91c6-831a62abd477"
      decimals="2"
      id="F_8f5b0d49-f558-4aba-9698-bbc7c9c562e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37"
      decimals="-3"
      id="F_59018cc1-b6d2-49ea-b2f6-ca4ea86647f4"
      unitRef="U_shares">526000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37"
      decimals="2"
      id="F_c3c1ad19-0d24-48d0-be6c-0b2ed359fe54"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_585442c6-63fc-4616-91c6-831a62abd477"
      id="F_67dd6062-7775-4031-8d03-cd6787c7f02f">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37"
      decimals="-3"
      id="F_e011186d-9861-42d3-b39c-9bd7930c2d77"
      unitRef="U_USD">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37"
      decimals="-3"
      id="F_b57b5286-5373-4423-ab61-b400291246a9"
      unitRef="U_shares">526000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37"
      decimals="2"
      id="F_ca192819-fe87-4f79-8765-489611d536a0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_585442c6-63fc-4616-91c6-831a62abd477"
      id="F_8a29b277-7e81-47b1-8fa4-9e8f0e8e9021">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_1daf391b-d2b9-48b9-aaa9-56865fd0fb37"
      decimals="-3"
      id="F_2bf899b9-0cc6-409d-99dd-066c2de66614"
      unitRef="U_USD">2000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_585442c6-63fc-4616-91c6-831a62abd477"
      decimals="-5"
      id="F_60cd1686-2225-458f-9de0-c80bc7c6c0e1"
      unitRef="U_USD">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_41cb42fe-1fc1-4fe5-95d4-e30f3d31ec21"
      decimals="-5"
      id="F_ba669960-27c7-4651-ba8b-2e12bdd69810"
      unitRef="U_USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_88d93e7e-fb3f-4e56-b066-1355f2a82da6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.841%;"/&gt;
        &lt;td style="width:1.663%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.424%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.275%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.796999999999997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e2944650-b682-45bf-91f6-43c4a2e81e26"
      decimals="-3"
      id="F_14adae05-77e6-4dcb-8109-a64fc6d491e6"
      unitRef="U_USD">65000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_537fd16e-de8c-489b-89dc-da0dcaa87884"
      decimals="-3"
      id="F_bf42a52e-ed3c-49d0-a7a0-de09612ecb9a"
      unitRef="U_USD">49000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ee837150-7dcc-4823-b2b5-2d0c51a4dd17"
      decimals="-3"
      id="F_a5a87459-70f0-4223-80e5-823e33001b8d"
      unitRef="U_USD">427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a8cbb7ea-0740-4eb6-9874-287b74dc5289"
      decimals="-3"
      id="F_53195ece-232e-4f06-81d0-ef392f960af4"
      unitRef="U_USD">572000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dc7252ad-b58c-4241-b1ba-4346c1180e60"
      decimals="-3"
      id="F_77d63436-cf15-40ca-b090-8a51a56c765a"
      unitRef="U_USD">5469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9fdff006-70ae-43ff-b822-eb5c9877e323"
      decimals="-3"
      id="F_695143d7-1df2-4601-87c8-8f5bdb10a68e"
      unitRef="U_USD">4323000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_4a4d2b03-6def-4caf-9bf9-cd87b38b6a05"
      unitRef="U_USD">5961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_448e83f6-51e9-498d-94a4-95abe23df312"
      unitRef="U_USD">4944000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_d7ae35e9-9d7c-47bb-a677-d141d7cc9457"
      decimals="-5"
      id="F_c5667538-3473-46f3-aefc-60fd7720421d"
      unitRef="U_USD">7100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_fb388fb2-b1a4-41c7-b2e6-24847a05c97b"
      id="F_f1ab148a-634c-4605-ad7c-5db4805cb0df">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_2845ab2c-7a25-48ea-b3af-da148f09789c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.441%;"/&gt;
        &lt;td style="width:1.001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.754%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.987%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.087%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.754%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.551%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.872%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding - January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_d0dcaa0e-cbb1-447e-8098-74aba043bf2a"
      unitRef="U_shares">2878000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="2"
      id="F_cc56d1be-005b-4c09-9ab3-1c357676caeb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      id="F_bddb1b82-fa10-4bdd-966a-dab325382953">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_71c9fcc1-3871-4453-b973-0c4db8131f10"
      unitRef="U_USD">6288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_099fdcfe-2a4f-458e-a2ec-b03bdf7358b3"
      unitRef="U_shares">380000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_e3938a6f-a816-41ae-b6ea-1f7bb8a870df"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_6bce76f2-8123-4550-a3c4-1b07b4bf9568"
      unitRef="U_shares">333000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_ccef1064-f279-44ec-bf4a-d588670451e5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_406d94a0-6f4b-4d80-a9f6-e3a80b9e1fe6"
      unitRef="U_shares">384000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_705d35ad-5659-491e-b308-0065725cca45"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_73154ce2-44e8-4729-b1a4-305f3c8a776f"
      unitRef="U_shares">2541000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="2"
      id="F_78c53afc-8e94-4b80-9582-991b468e2459"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_5ce9ca77-cbf4-4613-894e-9e0ee318579e">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_df5aba50-5c4e-48b5-a044-cc2177701610"
      unitRef="U_USD">1489000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_1b4c5bce-ae8a-4782-a8f3-a09917fd09ba"
      unitRef="U_shares">1525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="2"
      id="F_c1c3ae26-4ecf-4c23-8edb-c30deeb92710"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_cc9e83d4-45bd-4bc0-93ec-e5dd6e61fba9">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_a5d5868f-a319-4e4d-9847-51fed7a02d00"
      unitRef="U_USD">1067000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:DividendsCommonStock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_ca7b2746-8be5-4b4a-a1d0-9df2af0ea476"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="INF"
      id="F_de5abffe-6067-43b5-af45-2aa9e653ae28"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_5f312543-537f-49f1-bd71-31961183436f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years indicated:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.936%;"/&gt;
        &lt;td style="width:1.203%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.062%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.814%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.985000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk&#x2011;free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_bca11e82-65b3-42b6-9aa5-2f1bbad57479">P5Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      id="F_310ac401-829b-4e82-91a7-1a9bc304fb68">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="3"
      id="F_aaa95614-f318-45db-af39-e6356c0676f1"
      unitRef="U_pure">0.726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="3"
      id="F_4557690b-04d0-4d9a-8386-80f91b2eef67"
      unitRef="U_pure">0.685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="4"
      id="F_204a7a1a-20fe-45fa-ace0-efc77b5781a3"
      unitRef="U_pure">0.0132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="4"
      id="F_5b148411-ac91-4a2a-b5e3-49b5b079a16f"
      unitRef="U_pure">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_2b642163-304c-4850-98f1-2a8eee1118cf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock unit activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 was (in thousands, except weighted average grant date fair value per share):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.859%;"/&gt;
        &lt;td style="width:1.207%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.776000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.27%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.889%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding &#x2011; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_e0aa9545-138b-4cb5-9486-69e3ff5ba91b"
      decimals="-3"
      id="F_dae50249-d3e9-478f-8c6c-da257057926a"
      unitRef="U_shares">151000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e0aa9545-138b-4cb5-9486-69e3ff5ba91b"
      decimals="2"
      id="F_98807ae7-80a9-415e-9c2b-ec5bd6890f4f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a"
      decimals="-3"
      id="F_87f1ec75-6219-4b31-857f-359ce497feeb"
      unitRef="U_shares">1473000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a"
      decimals="2"
      id="F_9e896372-dbf2-4774-83e3-376edff158c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a"
      decimals="-3"
      id="F_f104fd21-9ace-428d-9f19-e06494d70953"
      unitRef="U_shares">56000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a"
      decimals="2"
      id="F_4a283b6d-9acf-4367-9b5f-0d6582ff7bb4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a"
      decimals="-3"
      id="F_88740d5a-8ace-4abb-a3db-b4ef2a7176a3"
      unitRef="U_shares">357000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d224c460-5bc5-4c51-b5e3-0c74f540798a"
      decimals="2"
      id="F_b88950e1-a6e7-4ecf-bed2-107cb2cf7979"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_1526a220-9742-4789-9d47-4ce3ee95d398"
      decimals="-3"
      id="F_12ce876a-c328-4415-992b-76525642f125"
      unitRef="U_shares">1211000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_1526a220-9742-4789-9d47-4ce3ee95d398"
      decimals="2"
      id="F_83adb810-1942-4797-a272-f07227012a0e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_510d9ca4-78ae-4a7f-88f5-6bfa9c1e2fda">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 13 &#x2013; Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share excludes dilution and is computed by dividing net loss attributable to the common stockholders by the weighted-average shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the Indi APA. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period after the acquisition date. When the gross margin target was achieved, the Company was required to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,520,108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. The Company achieved the gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for three consecutive months during the three months ended June 30, 2021. As a result of the achievement of the gross margin target, the Company included the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,520,108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share for the three and six months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which the Company has agreed to forgo the issuance of its common stock. Therefore, these shares are not included in the statements of stockholders' equity or shares issued and outstanding in the balance sheets and are not included in our earnings per share calculation subsequent to August 2021.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted loss per share for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 were (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.583%;"/&gt;
        &lt;td style="width:1.415%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.696%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.415%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares outstanding used&lt;br/&gt;&#160;&#160;&#160;in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The potentially dilutive securities as of December 31, 2022 and 2021 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our employee stock purchase plan, the terms of which are described in further detail in Note 12 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share Based Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The potentially dilutive securities would be subject to the treasury stock method when dilutive. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.309%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.62%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.040999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806"
      decimals="-5"
      id="F_340bc56e-3177-4ecc-ba62-a59a97bd2c33"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
      contextRef="C_1893eb49-6a75-4f78-9bc3-9d44a2ab8806"
      id="F_9e090b5f-951c-43a9-92e2-2723d7d5f3fa">P7Y</bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod>
    <bdsx:BusinessCombinationContingentConsiderationShares
      contextRef="C_5407a72b-1be5-441a-baf7-31f7a5742f30"
      decimals="INF"
      id="F_83b085a8-c950-4cd0-906b-85213d419b2b"
      unitRef="U_shares">2520108</bdsx:BusinessCombinationContingentConsiderationShares>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_a5a47bb8-865d-46aa-9b99-e3a31978f62d"
      decimals="-5"
      id="F_13c19bb2-ca0a-4dca-b7b7-4d14d3b1a78c"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ec8d24b6-eeb6-4535-a95a-f96122922dc9"
      decimals="0"
      id="F_a34db3b6-7650-4497-b9b3-fee9581764e4"
      unitRef="U_shares">2520108</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ec8d24b6-eeb6-4535-a95a-f96122922dc9"
      decimals="0"
      id="F_8040c400-b1f0-4780-a2cf-276b32e065ba"
      unitRef="U_shares">2520108</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8be89166-bad4-409c-881c-a9f3f86a21e1"
      decimals="0"
      id="F_c0a07386-bc0d-4c21-9baf-d92d22746c3c"
      unitRef="U_shares">2520108</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8be89166-bad4-409c-881c-a9f3f86a21e1"
      decimals="0"
      id="F_8ed5aae3-fc38-4c9a-8908-872be12b1add"
      unitRef="U_shares">2520108</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_e4ef15e6-4533-4842-b2df-a9ed0dee8585">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted loss per share for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 were (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.583%;"/&gt;
        &lt;td style="width:1.415%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.696%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.415%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares outstanding used&lt;br/&gt;&#160;&#160;&#160;in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_b5034939-1d40-46e1-96f5-cb3cc77d9692"
      decimals="-3"
      id="F_3778d8a0-7415-4afe-991e-34813095ba17"
      unitRef="U_USD">-65447000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_c048cb9f-c4a3-4595-a727-0956476bf141"
      unitRef="U_USD">-43159000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_8831bd44-15ab-49d1-a81c-09f9a2b6c798"
      unitRef="U_shares">42103000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_1cbe0f48-c0d9-4cc2-ac36-88cc0f20b7a3"
      unitRef="U_shares">42103000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_85c84497-4b17-4c54-ba7d-328a105e0667"
      unitRef="U_shares">27365000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_d48eaa7d-f49b-43f7-969b-0e34a6437615"
      unitRef="U_shares">27365000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_e7682552-51e7-4507-a881-4ccd7e25e99a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_3a2c5a16-8e62-4899-be73-5b229ec0f7e5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_69b32d67-6c40-4bd0-9bec-b51236e4a7ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_218f162c-d2b9-4887-a8f1-f61c879c328c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_37323afd-0d27-46e2-8ea6-4880112572d3">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.309%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.62%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.040999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_82d37d69-01a3-41f1-a628-a553ba9b0c62"
      decimals="-3"
      id="F_677e5bea-8024-4c2b-9dcd-fce98802a461"
      unitRef="U_shares">3067000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c8822067-11ee-4730-84e6-37f46f386c88"
      decimals="-3"
      id="F_9f10689f-b454-4b8f-b79c-f1f94ba5390b"
      unitRef="U_shares">3251000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_305b45e3-aa77-4038-91ca-a8b9641f321c"
      decimals="-3"
      id="F_bb2b5fc6-eeeb-424c-b4f5-860ac0bb59bc"
      unitRef="U_shares">80000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_214b2dd0-9feb-4b1f-8486-54f0069ba088"
      decimals="-3"
      id="F_8ed4ae81-2f0b-4264-84ba-31e81e66c185"
      unitRef="U_shares">30000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_313360eb-54d3-44bc-b6b3-5158c6afb114"
      decimals="-3"
      id="F_f9996cd3-4e23-43af-a8c0-4226f935368a"
      unitRef="U_shares">5103000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_dbc53b33-ca6f-4327-b8af-2aabe16a0af6"
      decimals="-3"
      id="F_5a2297e6-8731-4590-9cac-33de57087700"
      unitRef="U_shares">103000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ca1e3e4c-8bde-4650-aaca-f298f81e530f"
      decimals="-3"
      id="F_5decf434-7dab-4bdc-977f-c4058a8547f5"
      unitRef="U_shares">1211000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ad7793e4-8ed9-4613-ac91-79c78797a90e"
      decimals="-3"
      id="F_f230c8d2-d181-42df-8485-a983b346e616"
      unitRef="U_shares">151000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_3f072a35-cdb2-4cfe-a576-457d0f89cba7"
      unitRef="U_shares">9461000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_d77777f5-e394-4663-9a6e-728ebc3fd225"
      unitRef="U_shares">3535000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_1d2a92a0-bf63-47f2-8c87-98a4cab5363c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 14 - Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Since inception, the Company has incurred net taxable losses, and accordingly, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; current provision for income taxes has been recorded. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.307%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.664%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.015%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and developments credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.266%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.03%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.744%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets after valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, the Company ha&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;299.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;expire beginning in 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of net deferred tax assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that it had uncertain tax positions related to its U.S. research and development credits. As of December 31, 2022 and 2021, there w&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; accrued interest related &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.297%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.928%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.838000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions for tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions related to settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions related to a lapse of statute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2022, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_a92b170d-ccb7-4a06-8cb7-6b26555a4a19"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_57347875-113d-4666-86dc-32941be6fd8f">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.307%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.664%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.015%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and developments credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_9df1b98f-c594-4ff1-9758-50e1ed1c037e"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_185c5066-12e1-433c-902a-6dce966f2823"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_187e0dd5-1f00-424d-9e42-fcb6ef76bb63"
      unitRef="U_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_4f8dd606-d70c-45e3-95e6-dc0b0640d42b"
      unitRef="U_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_8a164b2c-c23e-4af3-9f32-9d2ebb2b8a9d"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_b7b81eb6-099e-4b84-b370-5a9b7fb81cfc"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_53240dac-ffb7-4b6d-8ffb-5c1cc8afb228"
      unitRef="U_pure">0.04</bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_4ed41def-89dc-4259-ad83-abd399ca9d90"
      unitRef="U_pure">0.01</bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="2"
      id="F_7054a1ba-133f-45df-b809-9c0e2b3a3edf"
      unitRef="U_pure">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="2"
      id="F_43e87d3d-fd06-4f83-81a2-dba3839fa700"
      unitRef="U_pure">-0.26</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_1da95340-2be5-45f7-bd49-3343d9ee6cf6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.266%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.03%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.744%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets after valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_7c32345f-6156-4a73-aec6-fc21004a93f7"
      unitRef="U_USD">70822000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_b20e6fc1-086d-48a7-946b-9dcdd21697fc"
      unitRef="U_USD">61874000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_b668d401-a121-4176-bf46-276ab2c09570"
      unitRef="U_USD">3807000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_69a4fe60-178a-4851-9b42-03c3f7eb6418"
      unitRef="U_USD">3372000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_25503dba-f893-4c88-9d48-99647fc5a238"
      unitRef="U_USD">3036000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_8cccfe5e-6ee7-45d6-9167-93e32d649c1d"
      unitRef="U_USD">554000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_a5626c9b-d9e6-4c27-bdae-b3210d80f1eb"
      unitRef="U_USD">234000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_d10ccd1e-4c46-4f11-9eb5-69d8b15eb291"
      unitRef="U_USD">215000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <bdsx:DeferredTaxAssetsCapitalizedResearchCosts
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_51f29960-106b-4e05-b623-2e590e51c103"
      unitRef="U_USD">2874000</bdsx:DeferredTaxAssetsCapitalizedResearchCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_a708d2ab-5438-4895-86ed-2e157eef0659"
      unitRef="U_USD">1619000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_b3e37ec5-1d84-4c42-bb34-ca7f82031f37"
      unitRef="U_USD">1977000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_cf5f26ff-943b-421c-92fe-eec1d3013bb8"
      unitRef="U_USD">1932000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_0d3d1861-d07e-4ad5-a13e-0583f8c88d37"
      unitRef="U_USD">1618000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_22b6ddc6-4d67-4df2-8099-86385129e73e"
      unitRef="U_USD">84324000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_987221ff-75cf-4a24-b86f-d114bf61f208"
      unitRef="U_USD">69610000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_74a33b60-9c13-4df7-b40c-779fbc309a21"
      unitRef="U_USD">82552000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_8fb8061d-5a66-48e1-8de1-b13e9ce56b3e"
      unitRef="U_USD">67457000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_62f9bf5e-22a5-4517-99de-d3a1dbbf6595"
      unitRef="U_USD">1772000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_85dbd76b-5300-4097-a22f-a40d4ba0dba2"
      unitRef="U_USD">2153000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_ecf5d1fb-cc26-4227-ad5e-8f3c1ab1c665"
      unitRef="U_USD">1772000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_e30de097-adc5-422c-ad01-d7e705470475"
      unitRef="U_USD">2153000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_326bbcab-fadf-4ade-b056-8c078308d395"
      unitRef="U_USD">1772000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_5622ecbf-2496-466f-b91b-f816c179a928"
      unitRef="U_USD">2153000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-5"
      id="F_8b0377bd-2cec-42ac-8955-e17f80ab72d8"
      unitRef="U_USD">299900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-5"
      id="F_faa378eb-498b-4601-9567-104da256569f"
      unitRef="U_USD">4800000</bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_b6b1ef7c-2317-48b7-a39d-f45b51c81cf1">expire beginning in 2026</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_bc168a19-863c-407e-9c45-21ade99b7156">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.</us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange>
    <bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="INF"
      id="F_98a90d26-66ad-4f6d-b87d-3fe3c94a8279"
      unitRef="U_pure">1</bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-5"
      id="F_fa3ba37c-332b-47d0-9361-6b356c5c15cb"
      unitRef="U_USD">15100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-5"
      id="F_3a889203-4dca-4762-b79e-c696bd727fac"
      unitRef="U_USD">11400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="INF"
      id="F_ceafeeb2-5a42-4176-a4b2-430400aa1043"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="INF"
      id="F_ae50584f-0c13-4be1-a6ec-8ea1199be2c8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_a91af21f-8783-44d1-8b09-b4f526612119">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.297%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.928%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.468%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.838000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions for tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions related to settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions related to a lapse of statute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_14929c2c-e9e6-467a-ad18-778f0fb86cfd"
      unitRef="U_USD">843000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735"
      decimals="-3"
      id="F_3f9dd717-0def-4138-b4f6-3d32b024cf8e"
      unitRef="U_USD">715000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      decimals="-3"
      id="F_54a6e1e5-8d55-4f9d-878a-8e01e7848632"
      unitRef="U_USD">109000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_cc7c7d02-004c-473a-9400-1eb0a6de7813"
      decimals="-3"
      id="F_6681cf58-af9c-4abc-9e25-e926b427041b"
      unitRef="U_USD">128000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_6b33c356-29a4-4ed3-ab53-62ccb31d0037"
      decimals="-3"
      id="F_ca6aa10f-adf6-43b2-b9ae-ae3b3dae3d30"
      unitRef="U_USD">952000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4cc0b66e-7e74-4007-bb02-d314b2b20656"
      decimals="-3"
      id="F_ebe0903f-a115-4dd5-9976-cd48c3657392"
      unitRef="U_USD">843000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_162091f0-90ae-46fc-be84-172495b18c80">federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_11b8abe5-606c-445b-ada4-84273d36bcbc"
      id="F_2c722364-2c50-41dd-9c89-ace06f64c172">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 15 &#x2013; Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Co&#x2011;Development Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#x2019;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2020, the Company exercised its opt-out right with AVEO for the payment of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the AVEO Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. The Company ha&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; remaining obligations related to the AVEO agreement as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Following the AVEO Effective Date, the Company is entitled to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% royalty of net sales of ficlatuzumab and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of license income generated from the licensing of ficlatuzumab from AVEO.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; royalties received or expenses related to this agreement for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#x2019;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#x99; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in August 2024. Either party may terminate for the other&#x2019;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. There wer&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; expenses &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;related to this agreement for the year ended December 31, 2022 and were insignificant for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 13, 2021 (the CellCarta Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly &#x201c;Caprion Biosciences, Inc.&#x201d;) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% fee on net sales made from the first commercial sale of the Nodify XL2 test to the CellCarta Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.675&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on future Nodify XL2 test net sales worldwide for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years from the first commercial sale, ending in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Royalty expense under the CellCarta License for each of the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 wa&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;s $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respective&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As part of the acquisition of the assets of Oncimmune USA, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to an acquired diagnostic test of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of recognized revenue for non-screening tests up to an annual minimum volume and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% thereafter, with an escalating minimum&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; through the first four years of sales&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Royalty expenses we&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;re $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million f&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;or the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Litigation, Claims and Assessments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCosts
      contextRef="C_be756e56-47b7-41eb-ad9c-716214c84904"
      decimals="2"
      id="F_d3d947d5-58fb-404c-b632-6a74ce520653"
      unitRef="U_pure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCosts>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
      contextRef="C_03d24aeb-78a1-4c8d-b568-cfca0d3fc997"
      decimals="2"
      id="F_109e4c30-922d-4a0e-b61d-c34c6a684d42"
      unitRef="U_pure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight>
    <bdsx:RemainingEstimatedObligation
      contextRef="C_bbe57b7b-14db-40d9-b4e3-fcea2a1e2a81"
      decimals="-5"
      id="F_bf38b8d9-469b-45fe-af3e-38d72997daab"
      unitRef="U_USD">100000</bdsx:RemainingEstimatedObligation>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_e6015f8d-bccb-4bb9-99f1-6b9aa57149f5"
      decimals="2"
      id="F_ef6f92ab-fb24-42a4-9236-b0b3e6fc9167"
      unitRef="U_pure">0.10</bdsx:PercentageOfRoyaltyPaymentsOnNetSales>
    <bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing
      contextRef="C_e6015f8d-bccb-4bb9-99f1-6b9aa57149f5"
      decimals="2"
      id="F_a9e2682f-2625-40dc-b90b-451c291bbb21"
      unitRef="U_pure">0.25</bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bbe57b7b-14db-40d9-b4e3-fcea2a1e2a81"
      decimals="INF"
      id="F_91f9182e-06b0-43ea-9212-a4342128150f"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c410de4f-8ea6-4061-8764-66e62ab89b16"
      decimals="INF"
      id="F_ad5a8bd7-6fdc-46eb-8b5f-727bcdb0e011"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue
      contextRef="C_04d1a84d-a61f-43b4-b180-30e7a26cd32d"
      decimals="3"
      id="F_820e2909-5d5d-4eac-bbf2-0dae9cec1dfb"
      unitRef="U_pure">0.025</bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue>
    <bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue
      contextRef="C_dec83647-9b4a-474f-a223-9e24cfba7a30"
      decimals="3"
      id="F_6a4c602b-22bf-4d4d-be36-7e26cce42b9b"
      unitRef="U_pure">0.025</bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue>
    <us-gaap:RoyaltyExpense
      contextRef="C_1092db51-6294-44e3-bb69-6fad5f7f2e8a"
      decimals="INF"
      id="F_d244b61b-9300-4139-ac74-f44652aa3cb4"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <bdsx:PercentageOfFeePaymentsOnNetSales
      contextRef="C_b5dc3743-ca85-4769-8c11-523bc0854b31"
      decimals="2"
      id="F_30086561-5a55-4483-ae65-bb8bb8f41dbd"
      unitRef="U_pure">0.01</bdsx:PercentageOfFeePaymentsOnNetSales>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue
      contextRef="C_b5dc3743-ca85-4769-8c11-523bc0854b31"
      decimals="5"
      id="F_aed50647-73e9-425e-b583-b3b889072d82"
      unitRef="U_pure">0.00675</bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue>
    <bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale
      contextRef="C_b5dc3743-ca85-4769-8c11-523bc0854b31"
      id="F_a92ce2a9-949f-46c7-9c13-e220fc4d540e">P15Y</bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale>
    <bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale
      contextRef="C_b5dc3743-ca85-4769-8c11-523bc0854b31"
      id="F_f04d2ed0-27a5-46e0-9add-9b8bcb8e3c13">2034</bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale>
    <us-gaap:RoyaltyExpense
      contextRef="C_d05b24fd-4c4f-402b-8b97-295956c2f519"
      decimals="-5"
      id="F_6920027f-c1fc-424f-9e1f-1fe74e58347c"
      unitRef="U_USD">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_5a129ea3-f356-49fc-afa3-38f6d02880ea"
      decimals="-5"
      id="F_56e801e5-9989-4490-a964-c45b3cfeee2b"
      unitRef="U_USD">100000</us-gaap:RoyaltyExpense>
    <bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests
      contextRef="C_91cf71d9-5882-46d2-af72-be7057b1fa70"
      decimals="2"
      id="F_5e9917d6-e427-4a8a-b6c2-afe38bc1e4ff"
      unitRef="U_pure">0.08</bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests>
    <bdsx:MinimumAnnualVolumePercentageThereafter
      contextRef="C_91cf71d9-5882-46d2-af72-be7057b1fa70"
      decimals="2"
      id="F_c053429f-a851-4167-a8a3-65b6a5e18540"
      unitRef="U_pure">0.05</bdsx:MinimumAnnualVolumePercentageThereafter>
    <bdsx:PeriodOfEscalationsOfSales
      contextRef="C_91cf71d9-5882-46d2-af72-be7057b1fa70"
      id="F_063417b9-9045-4fa1-86d9-a96ba772f2e1"> through the first four years of sales</bdsx:PeriodOfEscalationsOfSales>
    <us-gaap:RoyaltyExpense
      contextRef="C_91cf71d9-5882-46d2-af72-be7057b1fa70"
      decimals="-5"
      id="F_160c6028-e8ab-4d72-b528-9265375f9790"
      unitRef="U_USD">900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_3d741d82-1d89-43bd-aeaf-d5d87b0316cf"
      decimals="-5"
      id="F_550f19bd-1d0c-485f-b85b-8ed227a98c9b"
      unitRef="U_USD">700000</us-gaap:RoyaltyExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MHL#=%+C'%K0V!:V,3'XJ&8<!E?3V6O 7(M36H*9>9#"S:CC](%:_^TP*^#:
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M??T<<^R<R9;Q)Y$ 2/2<TDQ,K43*_,:V191 BD6/Y9"I)RO&4RS5D*]MD7/
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MHT1LA3Z13"T"P13-F2"FO'[>+H7DJLA^=:5:>@^ZO?7.NQ$YCF!JJ:TE@&_
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M'D4C$L.2;S+]6>Q^@YI08.(M1*;*3[*K; -O1!8;I45>.R."/"VJ;_Y2)^+
M@88##JQV8%T'?\!A4CN4F1M7R$I:]USS^944.R*--48S%V5N2F]DDQ9F&Q^U
MQ%]3]-/S1\TUX+9H1<22?%R#Y":]BIR3KX_WY.3=*7E'TH)\2<1&\2)65V.-
MRQKG\:)>XK9:@@TL01GY( J=*/)K$4-\'&",>!O0; _ZECDCWL/B@DSH&6$>
M8Q9 =Z]WIPXXDR:'DS+>9"#>0[$0.9 FE>2OFR>E)5;HW[9L5<%\>S#3MI=J
MS1=P/<*^5""W,)K__!,-O5]L3-\HV!%OO^'MNZ+//\,6B@U82Z+RG):>9I1L
MYY.(4=RL[2'ZOE7@!U[86!W!"AI8@7,[ZB(N5@1><-HI4)<VA,%;;L,;!3OB
M&S9\0^<VW*<29R)9"(5-C"W:T+:QKD(%!QFG/@W\SK[TK29>0"/[ODP;G-/_
M*!<%7"Z2$F.,M9.)M6D7&\QI'^:$>MWRL5BQ:32SPXP:F)$3YB//0)WAC)7/
M8*KHC*R@P(K*2MP\QB&<FNXV\F.#'O5 A=0/N]#[5@%F>&J'/FN@SYS0[Q)>
MK,",ZR5/)=GR; -FK"]P_"(3,YKP4J5Q/>5M\)TK_-^VF/4W*&3,3I)ZK61Y
M3IH/^1KIE9,V$PJ%JT#*&JFG3QD0KA1HNTQY/3@1[>R+>^D?[&1ZH,;42>V+
MT%AHHC?!K'1HGTXTG<VZC/IFL\#W!X8L92U4YH3ZNTG]4HI\#Q<KRPJ3]=8_
MQUJ/IEV<%CO?F_G> -!6G:E;GC_J!"0YJ5-YBK5BY-JJ"?1-M?FMHAWS;M69
MNN7YH=" <?6^B*R$_7[2(V_:G58V,Q3J 4&@K5)3IS#.3TP1G9(5_MTP70PO
MIN@WJ4K*YL;)E:7\*<U2G9J17(!5*^HUCL"%LWYG]\T8FPU1:,67NM5W:.;N
MN)3<3*B:P7<K]+[01ETM=J__HU74BC9UJW;5/57/D!,S;T^'=\(BR%YO'O6-
M!A2;MI)-W9I=C\T2JJO:^ZI[3OTH]+H0+7:,T2&8K3Q3MS[_ 95B6;'->N_"
MYR'.Z=Z8M-CY$QH,@&.MJC*WJN[!$9SF1"5<PIGY@YPN;&CK6+.C3%X$00?L
M@-E T[%6)IE;)FU8XS3;Z.[?RQHM?1U:N]D0VE8IF5LIOY5G"1"?\RT*)0Z+
M$C&^MVRTPM>6N'S)'$YU7Q=]1KV)YW7+UF+)II,P.+0\IM!J*'-JU>LHN'9@
M\FH2?<L!$N.#4X\<Y*H\#%+XAKLI='66T#QM#IQNRF.6SO-;>GE7'1NU8:I3
MK ]<KM)"D0R6&-*[F"(L61T,53=:K,NSE2>AM<C+RP0XOE\; _Q]*83>WY@%
MFN.Y^;]02P,$%     @ :3%F5MPDO=KJ!0  O"8  !@   !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6S%FEV/FS@4AO^*E:WV0YH4;+Y"-Q.I35AM+W8UZK3;
M:Y<X$U3 J>W,M/]^;9*!@!TW1.[NS0P0G_?8CP^&%Y@_4?:9;PD1X&M5UOQV
MLA5B]\KS>+XE%>8OZ8[4\I<-9146<I<]>'S'"%XW057I(=^/O0H7]60Q;X[=
ML<6<[D59U.2. ;ZO*LR^O2$E?;J=P,GS@7?%PU:H ]YBOL,/Y)Z(#[L[)O>\
M5F5=5*3F!:T!(YO;R6OX*D.)"FA:_%.0)WZR#=10/E'Z6>V\7=].?-4C4I)<
M* DL_SV2)2E+I23[\>4H.FESJL#3[6?U/YK!R\%\PIPL:?FQ6(OM[60V 6NR
MP?M2O*-/?Y+C@"*EE].2-W_!TZ%M+!OG>RYH=0R6/:B*^O ??SV". F P9D
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M.)Y[CZ= ]58HZ3=9&9JD:1H%_6:9WFR*HMD,AFV[WIB#=LR!=<RG<PJ. &[
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MAJJYZ-Q\$+Q4=X577 B>J\<-HPFKI #\?<VYV'V0+]A?-U_\#U!+ P04
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MF3"V; $<3OL[2APD/AO0.300PB[6(W*#U_%APH$D[)_OQTD61Z+_X>+R-OW
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MH\'[<[Y?H+\2H 1N38BOTKNGW1\B3.+[]WYY_"N&#W"*-C3&S;'U^,E/S_9
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M9#?(7T<>->B,2->KG$&R>*:CW]!U_)$(Y=Q">BFQ08/L#,]!"((@ ,#]B;;
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M\E'(<Z&A]=,MI2+=3."3%^(W;.AT#)Y';*; UVW&^*>Q(QV,<8Z!PW !"?R
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MOK;8QZ?#4R;F()ETQ1S8>C0*0(GQP$.VK?9VY@% -93A"!] 4E@H:IC!EW6
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MQ7V[+]V&AXWQG_^^<\HIUW8PBDY[N^;18YW*1[T!U3<"3"3G\27'%I$6#*]
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M\/TL!PKW'VB#Z@>#[_\?4$L#!!0    ( &DQ9E9U7]((\@H  %T=   9
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M.#T?^,K8_*A,R1_0YJ9"1>1'N@A4EB;@_<*8JOE!&[1?5&_^!U!+ P04
M" !I,696S<OZW&(2   \/   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6S56UMSVSB6_BLH3]*)JVA9%UN6.Y<JQTEFLY6>>.-,YV%K'R 2DM A"0U
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MO;0_ZG*GF=9TK=NI;-\:[8@B[+!E8E[M'L4F0AV/N; =#T]X1/=T-$DFDTE
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MHD"F ;@_-\".\(46J'](^?K_ %!+ P04    " !I,696O]9L$)X&  "W$
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MAOK36GKRW!/ERBCT!Y7SK/.G),YLUIF/?/^-Z>EY7KO:]$A>(]:FZ0RZ8G9
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M"HH\>%K8RL=D3B1 -K:0[,<'N]RX47N1>]MQI<RIC, TQ#T0ZRB+49) #[
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MXGVUWO3XQ<.7W^[<VE_[_I?=NP[^>AA'*:NM;T+5-D7G5]_=>S5[_OW\";Y
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M[DC&$*>6&5!7J(A6WQP+3*.F7"--N*X,Q2\[POO\<O;X8O:DN/_J^JKXT.X
MZOGEDXO'EP\FN4@']/T8Y<5UDA<7Q=]:'/FJ17;9/"]>1\F$[_QBF:@<:=>
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M X-&? .@6FZ\F'TSNPS21(T316D!4174K2!JF-4'U::)- V_DO7A *7HQ+C
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M3\J-)R555;^<(1,+,$"+%U<B94E)!IL"=I:XTD?<RQLXBU$-#_L=.L*8^Y@
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MJQ9(5?[ "?#B=@+OY?\"4$L#!!0    ( &DQ9E8M!H,(3P0  +@,   9
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M:N= ]QNE;'MP";I)G?T%4$L#!!0    ( &DQ9E;X>D@Y*0,  !H'   9
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ME*5>ZLV"?EZHG0/M;Q5IW4[< =WO</474$L#!!0    ( &DQ9E99NMTJL ,
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M")\;U,QRN0^'YEPR_>XZ'W7G0W@?S=$',T85G%DLJ1-M!:K5H$X^1:CE 0F
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M7^;TJ8&&!>A^J;4[;-A!\_$R^1M02P,$%     @ :3%F5H5,*46K!0  8!$
M !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULQ5AM;]LV$/[N7T&X+V@
M1Y:H][P82-INZ["N09*N&(9]H*6S+$02/9*RZW^_(R4K;JT(;K&A7VR*NGON
MCG?WD-3%AHL'N010Y'-95/)RO%1J=3:=RF0))9,67T&%;Q9<E$SAH\BF<B6
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M.P'ZGBME]R_.0?O?9OD?4$L#!!0    ( &DQ9E:BG!(0>0(  /(%   9
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M+TA<O^%?J^2>I:JJFRKYI14U5EPD+&QA1PVL[N+OSP/?.3YV'.=T>K\KW/!
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MXT&[>]XR#QY!0072Q#C9BG$R0HPDERQ?->ULOQA6X%@QD+ 0"8M.!AWD<]U
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M)D=V!\@TN%42TJ04DGQ1ZL9KHWUOQXX.H5!S"$J+H#2*HNER]S93,'NKP6X
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M1E"8!/U^QKEZ#LQYUUQODE]02P,$%     @ :3%F5O70.Z0. P  W@L  !D
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MB6H6JMFHYJ":BVK>6GNU,]7O7?4&>W-]=,P U4)*4PM])Z+4/J7019QER^)
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MIHU4P05WOE@V?J93/\C9[8'4#%0S4<U"-1O5'%1S4<U;:[MGUX8W^S,-<L0
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M98H%V<B-+#L2)U@=%3JN1[A)A\7;R(/3$ZZ:J# *9GJNDX;KQ,CU(Q4X!<5
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MX=\1I-F WQ="Z)>)Z=CM_S;^!U!+ P04    " !I,696&C#@OJ$"   7!P
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M^G-@SY$H?.KBI V+GC1[G\JAC\7F1O8/N04^6KVEGK)E:1,ML876U^S0\.+
MKI,LM:NME#;1$EMH?2D/O30V-]-G.BD\6?S8CX9&.@V*PJ&+K+;2[M&)ACY_
M4C_5-[04*(>U@O<N(S4;;XYTFH%DN_J08\6D9$5]N062 =<!ZOF:*3G:@3XW
MZ0[6XO\ 4$L#!!0    ( &DQ9E81UJ<;I1$  %_2   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0X+GAM;+6=6W/;-AJ&_PK&/4PRX]@B=;)3QS.)21QFDC;3
MI-N+G;V@)5CBEB)5DK*3G?[X!2A*$"0(%INW-XE%$0] ZA7XX7L!Z.:I*/^H
MYE+6Y,LBRZLW9_.Z7KZ^O*PF<[E(JHMB*7/USD-1+I):O2QGE]6RE,FT*;3(
M+L->;W2Y2-+\[/:F.?:QO+TI5G66YO)C2:K58I&47]_)K'AZ<Q:<;0[\FL[F
MM3YP>7NS3&;RDZQ_6WXLU:O++66:+F1>I45.2OGPYNQM\%J,![I <\:_4OE4
M[?Q-]*7<%\4?^H68OCGKZ1;)3$YJC4C4?X_R3F:9)JEV_-E"S[9UZH*[?V_H
MM+EX=3'W227OBNSW=%K/WYQ=G9&I?$A66?UK\<1E>T%#S9L46=7\2Y[:<WMG
M9+*JZF+1%E8M6*3Y^O_D2WLC=@HHCKM V!8(3RW0;POT]POTCQ08M 4&^P4&
M1PH,VP+#4YLT:@N,3BTP;@N,]PH<O:U7;8&K4Z_ANBUPW<AA_?DU'WZ4U,GM
M35D\D5*?K6CZCT9!36GUF:>Y%ONGNE3OIJI<?1O)^YJ\(F^GTU2++\F(R-=?
M(2W%%Y&LDS2K7JI3?OL4D1??O[RYK%6UNO#EI*V"KJL(CU01D@]%7L\K$N=3
M.7649_[R_>?*<W_YP-> 2W6_MC<MW-RT=Z&7^'/Q>$'"X)R$O3!T-.CNA.+!
MZ&CQR%_\0_*5]*Z/EHZ?*UVJRM?% ]>'Z2\>R<D%Z1^_=/9MQ?FW%1>G%P\\
M.NAOOSS]AM?W?7E$7M7E2O7_-?GW>W4"$;5<5/]QM.[=FC9PT_1C[76U3";R
MS9EZ;E6R?)1GMS]^%XQZ/[DTAH1%2%B,A%$DC"%A' D3()@EX\%6Q@,?_?9C
M64RDG%;DH2P6I)Y+DE;5*LDGDA0/9%(L%NI1H)Y$DS]<HO:RNXH:"8N0L!@)
MHT@80\+X&C9N8#I0?KP=7@_[5[U>[^;R<5>PAR<&H_Z@OWNB)<;A5HQ#KQ@C
M64W*=-F$'TI]E9RL2A6:R(HL5^5DKN):DLQ**76'ZY*CE]Y5CDA8A(3%2!A%
MPA@2QOU:>9&^W*IB2I*U6-1?2]6/J2ZL*+^2O*@E>?'1'/A9'_@EER])FC=]
M73)3<IHEZNBR3/-)NE0Q<+(H5NIY7A=UHNJ<D>^#T45/A=]9IF6I"LHOJM)\
M)HF*E=6[PYUW,UE59")+%3CK\]2HM%+B3?(I>9&J]C;BG2KTCIY5(^>R/-K\
MI&X:>E<LEDG^]<?OKL)@_%-%M@/&@\O[_%3H"L]5+3/9H)_2>DX<=^&\(>^]
M4;T\5X/?^_\JO&[GYEHF1;X>)*BO8BDG<JI#'G7\M!O8N^A[;F#/OKV3I)KK
MV] \EBY<STN0RJPN:K3MHD;//2]W/Y]*M;B6JIJ:E.HNN#HE+Z]KIX2$16M8
MT-OIQ]5G,;([^QA9)47"&!+&D3 !@ED*'6\5.NZBT'.BQO/Z,?J5**$N7 KU
M\KHJ% F+_%<:#LBB&=R['I+(=E DC"%A' D3()@EVZNM;*^Z=:PR*;.O^FFS
M3+XV(VSUYR)=+<A2EA/U.IDYNUMO+5W%C(1%5Z[N-MCK;9$U4B2,(6$<"1,@
MF"7;ZZULK[VR?3N9E"L5MVW"@',=_I1U^K]D,XKY141-!#C5":/MX'I25+6K
MWWKGK:ZK?I&P" F+D3"*A#$DC%\?CI3U>/I@1 VJU))PT#,^0,\KXO>%&K8H
MM382E5]J%;6OTFI^;)CMIW75*)0606DQE$:A- :E\9:VJ]17H^NKX%"J[9G#
MG3/#\/KJ:/(GV+&C@F?2/[J'-"GUJ4D'.67HI766(9(606DQE$:A- :E\6<4
M\GDN&_^&?%9#&?*^2'*=*7A,I^H)K),)ZK5.D82]GS;/XU=%GC5IDS#X24>.
M:3$UJ>[XX4$VACN)= JCGI?%:C8G5-Z7JT0%HN%58Q?US]<YE.U0?[J2S2-=
M1:;)?2;7HQ 5K!;KK-)#6JJ3)DDF\VE2DFGR5<<!,IG,UV=>$%X\R4=9GN_F
M=HAZ/U5'=3*K5/_GJI)%FJGZBKQ)QB<UR62BR-^/AMN$B9XS0.HR29M42_TD
MLT?YJJE%SP-(*]76LGEGWER?;!NKPFOMAY(/2:E:M;'%R-,\52^355UH$UA=
M@;HH]3Q8G]N8 [NW=7,_C]VWP05Y)V=IGNL&>.^-?F?=Z(<BRXJG38O529NW
M736O[]^>()Z2:OO!I#G1><))D>O\6O-)RS]72=;T,NKJ=#=3Z1I,]FIS,>L[
ML[XQHW.RS%;5.HFW^;#;84E3/-F+ B^(5NI!2JQ8U:K:?*HO;Z7N:>EJ_SY+
M?^X)><B*1#^7]94K[>5J'*033NWEU$5#FI52'2MUB_1EAQ>]W@\DN2\>9?.V
M:L]"-L7.B?JR-%<SO B'/YRW'[P)8G663NMUDE3JY-U;VE[^!;EK<GC5IFXK
M#T:2Y3)3^M$%VO?WKO*^2=LJ44QLC&DC>5(\(K=?T59 YL!4GZ1OOOKNM G%
M X@S?XCJLNS'7&@><Z&W$_MD;(V/FS3P6Y^MX>=U?M A:1&4%D-I%$IC4!J'
MT@2*9BO:3(4(L',A NAD""@M@M)B*(U":0Q*XU":0-%L09M)$8%_5L2O<O?I
MKH?%3AE#IS] :5'@\.BO0D?J(8;62Z$T!J5Q*$V@:+9$S52)P.]_.PQ=\A?I
M'EM YTQ :1&4%D-I%$IC4!J'T@2*9NO<^.W!"!M;0/UV*"V"TF(HC4)I#$KC
M4)I T6Q!&WL^\+O6>UG.<\\<&J>^H6X]E!:UM-W4L#K5&71 [7DHC4%I'$H3
M*)JM7>/1!WZ3_F=9;Z=FK=.H.C96$G[0::>IG*XF39+*X74V"=/-E#BGL*'.
M/906M31+V*'+R(NA]5(HC4%I'$H3*)HM;./B!WX;WYX&WTR$)!_7&4^G5J$N
M/906M31+JT-W)PPUX:$T!J5Q*$V@:/;Z,^/6AWZW_I<RG:5ZM9[N8"69IM5$
M!PO&P=^Q4#=]L$O$_FJZBAA*B\)#DSEP:AA:+872&)3&H32!HMD:-E9_Z#=R
M.\XX\=,Z2Q5J]4-I,91&H336TJPY(OV1XUO)H?4*%,W6JO'K0K]?YUIA\3<R
M;?Y:.FL8ZN)!:3&41J$T!J5Q*$V@:+;.C8L78EV\$.KB06D1E!9#:11*8U :
MA]($BF8+VKAXH=_%^\9,FY_>6=]0>Z^EV?%QWQD@0^T]*(U!:1Q*$RB:K5UC
M[X7/VGM=$A)^6F>M0FV\EN88RQUH%6K106D,2N-0FD#1;*T:BR[TKXF%)22@
MUAV4%K6T71&[NUNH*0>E,2B-0VD"1;,E;$RYT&_*B7Q22CV$2W-2_ TYVXOF
MBUPG-*2*,-Q6A[\QG84.]?!:FK4+B%/H4 </2F-0&H?2!(IF"]TX>.$SRVSU
MXMEE,W]Z.QG;*5&H&P>E15!:#*51*(U!:1Q*$RB:+63CV(77V&P%U+*#TB(H
M+8;2*)3&H#0.I0D4S=Y.T-AZ?;^M]VT[L?4/UV\.>J[<_)V_&5VE"Z7%4!J%
MTAB4QJ$T@:+9TC5N7K_;PMWMCC/3(WLB^7E=.^-G6K?=L56O01L[10RU\* T
M"J4Q*(U#:0)%LT5L;+Z^W^83SVWDY2_?6;1KVO[N6WV[MXZ@E<90&H72&)3&
MH32!HMG2W-EJV&N4W+XUJVD723E+\^,:Q6XSW'=J]'I?H]@=A+%;"&/W$,9N
M(HS=1?B?,-OZQFSK^\TVLY?"LSLB^DF=10HUUJ"T&$JC+2T(K*]CT-][9K 3
MS^,GGB=05V$KRUAA?;\5]GM2EHFV;^4764[2JG%OW0Z"G]1966M:$.XZ5Q>]
MT>!JOP.$+E2#TBB4QJ T#J4)%,V6J7'!^L_L#+NZ5P]I-59_D,V.*XU(F^TZ
MJGE2GC:(AQI@+>W:4F\PW-<N=$T:E$:A- :E<2A-H&BV=HW]U??;7Q_2/%VL
M%NN]E^^3K,DZ):<,Y*%.5O_0>PI=YE,$K3:&TBB4QJ T#J4)%,T6K;&R^GXK
M2^1IG289>5K'!Y5G*I>?U%FFAZO!PFNG3*%&%91&H30&I7$H3:!HMDR-4=5_
M9H=8\_-:IR@5:E/U'6O!G$*%&E!0&H72&)3&H32!HMD_!&0,J('?@#J8+KN9
M^>+2J9_55:>#P^5>0]=F-1&TVAA*HU :@](XE"90-%NHQFX:^ V=TW9G\D,Z
M*Q2Z9@Q*BZ$T.CA<Y35VS=9ET&HYE"90-%NAQDL:^+VDS^HQ/YE+\G:]V>5?
MY-1I5WYN9]%"%XE!:3&41J$T!J5Q*$V@:+:RC14UP"X2&T -*2@M@M)B*(U"
M:0Q*XU":0-%L0>_\_J7?M_HGM[3Q5]U9_(/#[-C8F7> UAM#:11*8U :A]($
MBF8+V]AF []MMHE!WG6.0: F&I0606DQE$:A- :E<2A-H&BVLHW3-L!N"3F
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M2SEM?;M9QC(1#/.R2: D8K[EWZHB4GHET5S:MB;9MF2995>I],7>V:NYUMZ
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M3UY;&J/9,ZIYJ"903:*:CVH*U32J!91F5D>=4(_M"?57+H!LUUM7"YI#HYI
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M'Y(DWWU2-O I23]N=OOM_P-02P,$%     @ :3%F5C%7NG?\ @  X0H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-34N>&ULM59=;]HP%/TK5E9-K;0U7R1
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MN*ZMU/2%F1O36M'$F5[&%\G5TUBUD],Y;"!; Z)9B.Z#@*TS*= < H@W=)$
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M+26:$NY[Y"-<!R0\L&Y:JPG)EEJ3O\Y(N#.&7&+:X1N[9\GU/>(/KO,/[@Y
M[>;^E69"J 0\5SU2'D3F-_1,!8N$Y:E"OD*/CWXKM-5X9$NM.3=UD,*WUCUO
M-5?94FN>-M3!BG0&EPL\WRUX+GZI=OP&G<C'I Y,I#LPM7O^D2Y\QG,TFZ%W
M^LP2>+)3/P$W5$W"^U;8SE[.AK6DUIR3.I,18MOKQ&HHLZ76Y*]#&>D^S+K
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M2$L?,M]DHP6:,$FG\9Y3\344X_CX?H4H!E/AB#F8D5BL#H8R_UZ!^WQF 5F
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MF#&:WXC)7SA99Y=*'@CG),X>5QC-,4T[B.\+0OCN)550W$L:_P=02P,$%
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ML@+T?RFE.0RL@[I1'G\!4$L#!!0    ( &DQ9E;V-:ZX/@0  #T8   9
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M/"Z7ES%0;$/T KR_X5P=!OH!S3>2X#]02P,$%     @ :3%F5GI?GFDS!0
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M,,S;P(H,4,X Y1B6#9E47RR.G1/KCWVF<1R&481E=#*Q.IA@>8LB^+.K8=Z
M@<6!2"_+-;[:>(4<K@-L30]5"#93O!*QF>*Y!L2>-V#$L7VUL3C P%8!JQV(
M;X\#-67GA"&L*N8-V\$X$L<8 K5HK]$H0K(3P=>^/M@N"<,XMB. V1V$(8;
M;L01S %XP) PK.Z#>_<C;W.?\MI_QX__ E!+ P04    " !I,696EXJ[',
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MVPMM#SY5/G=ZV1[;&8+<)2!WF4/85)5T+^U#UG.CX6<2$LY1GML&$@Z"_$I
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MB%D%FTV_$9.R1,1L"5KY F-2^HB8];'!^1M#24DE8I9*D/]&*$HA$;-"NE'
M1BS*'!'[]($0<#^_4/Z(F/WQD8!7\<2K%I128F:E?.CACA-C4E*)F:6";;RI
M1<:42F)FE9!+ [T6&9,K5-Q+5*288XQ):25FU@JY/-"/)J65F%DKQXW71D''
M@4XSU:8K(';$45& 8RS&I,P2,YL%#7-V!&H!J_,8DW)-S.R:/B946#0PD@#.
M&[6T#D^,8\H],;-[/L0\6<#HIY?4*??$G[9X]=8@C2S7NPUX39IR3[*5%2U
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M:3%F5DT>I8GN    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ :3%F5IE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !I,696PAQ@
MR5P(   Q-0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ :3%F5F6Y)6^F!@  G!\  !@
M ("!GQ   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &DQ
M9E:*M4 @%0,  &T*   8              " @7L7  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " !I,696S+C[?P<%  "J$P  &
M        @('&&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ :3%F5MPDO=KJ!0  O"8  !@              ("! R   'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &DQ9E8T[&U!;PD  'HN   8
M              " @2,F  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " !I,696T)SU>%(-  "J(0  &               @('(+P  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ :3%F5BUO 0FS)0
MO74  !@              ("!4#T  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( &DQ9E:2;YQ&H@D  .H8   8              " @3EC
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !I,69641__
M.#(-  "\*0  &0              @($1;0  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( &DQ9E9<XRG_60,  #T'   9
M  " @7IZ  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M:3%F5OD 'RC% P  C@@  !D              ("!"GX  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " !I,696G=\7'YP"  ##!0  &0
M            @($&@@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( &DQ9E:;0A?9LA(  #PX   9              " @=F$  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ :3%F5G5?T@CR"@
M71T  !D              ("!PI<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " !I,696S<OZW&(2   \/   &0              @('K
MH@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &DQ9E:V
M-8.3N0@  #D7   9              " @82U  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ :3%F5C/17R#B$0  5#D  !D
M     ("!=+X  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &DQ9E8M!H,(3P0  +@,   9              "
M@><7 0!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ :3%F
M5B2476MW P  ^ <  !D              ("!;1P! 'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " !I,696JO3:H P$   B"@  &0
M        @($;( $ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( &DQ9E;IOV/;G0(  +4%   9              " @5XD 0!X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ :3%F5OAZ2#DI P  &@<
M !D              ("!,B<! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " !I,6966;K=*K #  "R"   &0              @(&2*@$
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &DQ9E81<;HA
M] ,  ,@(   9              " @7DN 0!X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ :3%F5H5,*46K!0  8!$  !D
M ("!I#(! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !I
M,6961WC7@K<#  #7"   &0              @(&&. $ >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &DQ9E9SR0'G$@4  .<,   9
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M970S-BYX;6Q02P$"% ,4    " !I,696/^[K-*8"  #J"   &0
M    @($D5P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M &DQ9E;UT#ND#@,  -X+   9              " @0%: 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ :3%F5E^RY!,/!   AQ$  !D
M             ("!1ET! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " !I,696L9O19VX4  !-.P$ &0              @(&,80$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( &DQ9E8B;#RV/00
M !D9   9              " @3%V 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ :3%F5K07>_N8 P  >!(  !D              ("!
MI7H! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !I,696
MX,ZC+?L#  #?$P  &0              @(%T?@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( &DQ9E;(=O7P,0,  -\+   9
M      " @::" 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ :3%F5LI\ RK: @  >P<  !D              ("!#H8! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !I,696&C#@OJ$"   7!P
M&0              @($?B0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( &DQ9E:MO0W1OP,  &03   9              " @?>+ 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ :3%F5A'6IQNE
M$0  7](  !D              ("![8\! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " !I,696+>/BIWD"  !B!@  &0
M@(')H0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( &DQ
M9E:VH34-D X  ,FF   9              " @7FD 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ :3%F5GGM<>MC P  80P  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( &DQ9E:LV9UGO00  ((2   9
M  " @8S7 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M:3%F5I.D]7H_!   ,Q@  !D              ("!@-P! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    " !I,696M)N"M)8*   .6P  &0
M            @('VX $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( &DQ9E;I]FGW_ 4  *,D   9              " @</K 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ :3%F5K01<KF! P
MZ@X  !D              ("!]O$! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    " !I,696+$ZII^("  "Z!P  &0              @(&N
M]0$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( &DQ9E9\
MN_<[;0,  #0+   9              " @<?X 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ :3%F5O8UKK@^!   /1@  !D
M     ("!:_P! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &DQ9E:P-?:(V@,  )$-   9              "
M@8\1 @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ :3%F
M5IK6U!'L @  ?@<  !D              ("!H!4" 'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    " !I,696/LEV+]T(   87P  &0
M        @('#& ( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   ( &DQ9E956$W\: ,  )L7   -              "  =<A @!X;"]S='EL
M97,N>&UL4$L! A0#%     @ :3%F5I>*NQS     $P(   L
M ( !:B4" %]R96QS+RYR96QS4$L! A0#%     @ :3%F5NZL4.E@!0  .BX
M  \              ( !4R8" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M &DQ9E;;=K!Q,0(  (DI   :              "  > K @!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &DQ9E:DR,-W^@$  +0H   3
M              "  4DN @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !.
- $X 614  '0P @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>253</ContextCount>
  <ElementCount>467</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>102</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Recent Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandards</Role>
      <ShortName>Recent Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureLeases3</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Revenue and Accounts Receivable Credit Concentration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Share Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation</Role>
      <ShortName>Share Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/DisclosureLeases3</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Share Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Recent Issued Accounting Standards - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails</Role>
      <ShortName>Recent Issued Accounting Standards - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Business Combinations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails</Role>
      <ShortName>Business Combinations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails</Role>
      <ShortName>Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails</Role>
      <ShortName>Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails</Role>
      <ShortName>Fair Value - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails</Role>
      <ShortName>Debt - Summary of Long-term Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails</Role>
      <ShortName>Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesParentheticalDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments for Operating Leases (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Leases - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, Or Taxes, for Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, Or Taxes, for Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Share Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Share Based Compensation - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share Based Compensation - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share Based Compensation - Summary of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Share Based Compensation - Summary of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Share Based Compensation - Summary of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Net Loss per Common Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss per Common Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bdsx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: bdsx:LeaseExpirationMonthYear, dei:CurrentFiscalYearEndDate, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:NumberOfOperatingSegments, us-gaap:PropertyPlantAndEquipmentUsefulLife -  bdsx-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="bdsx-20221231.htm">bdsx-20221231.htm</File>
    <File>bdsx-20221231.xsd</File>
    <File>bdsx-20221231_cal.xml</File>
    <File>bdsx-20221231_def.xml</File>
    <File>bdsx-20221231_lab.xml</File>
    <File>bdsx-20221231_pre.xml</File>
    <File>bdsx-ex10_83.htm</File>
    <File>bdsx-ex23_1.htm</File>
    <File>bdsx-ex31_1.htm</File>
    <File>bdsx-ex31_2.htm</File>
    <File>bdsx-ex32_1.htm</File>
    <File>bdsx-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img34454307_0.jpg</File>
    <File>img34454307_1.jpg</File>
    <File>img34454307_2.jpg</File>
    <File>img34454307_3.jpg</File>
    <File>img34454307_4.jpg</File>
    <File>img34454307_5.jpg</File>
    <File>img34454307_6.jpg</File>
    <File>img34454307_7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="699">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bdsx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 36,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 699,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 253,
   "dts": {
    "calculationLink": {
     "local": [
      "bdsx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bdsx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bdsx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bdsx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bdsx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bdsx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 846,
   "entityCount": 1,
   "hidden": {
    "http://biodesix.com/20221231": 3,
    "http://fasb.org/us-gaap/2022": 15,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 22
   },
   "keyCustom": 113,
   "keyStandard": 354,
   "memberCustom": 50,
   "memberStandard": 50,
   "nsprefix": "bdsx",
   "nsuri": "http://biodesix.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureLeases3",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Revenue and Accounts Receivable Credit Concentration",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration",
     "shortName": "Revenue and Accounts Receivable Credit Concentration",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Share Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation",
     "shortName": "Share Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss per Common Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1",
     "shortName": "Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables",
     "shortName": "Revenue and Accounts Receivable Credit Concentration (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Share Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables",
     "shortName": "Share Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Net Loss per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "bdsx:NumberOfCancerTest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Test",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Organization and Description of Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Organization and Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "bdsx:NumberOfCancerTest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Test",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_4ae15744-f43c-47a3-97d1-ad8acc7c9397",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Recent Issued Accounting Standards - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails",
     "shortName": "Recent Issued Accounting Standards - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_7ddc96a7-546d-43f8-87c6-9287c6d330e4",
      "decimals": "-5",
      "lang": null,
      "name": "bdsx:OffsettingDeferredRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Business Combinations - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
     "shortName": "Business Combinations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_94f8365d-9f16-480b-9a94-8b6de443e738",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails",
     "shortName": "Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_94f8365d-9f16-480b-9a94-8b6de443e738",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_a8f8214a-ba5d-4798-9bc4-3c9348a307cc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
     "shortName": "Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_a8f8214a-ba5d-4798-9bc4-3c9348a307cc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
     "shortName": "Fair Value - Schedule of Changes in Contingent Consideration and Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_d12dc7db-6c0d-498f-95b8-ead1e40b9fb7",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "lang": null,
      "name": "bdsx:DirectCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Fair Value - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
     "shortName": "Fair Value - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_3fbf4b04-42d9-42a3-afc9-b3a2b00cabdd",
      "decimals": "-5",
      "lang": null,
      "name": "bdsx:InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Property and Equipment - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_e2944650-b682-45bf-91f6-43c4a2e81e26",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_e2944650-b682-45bf-91f6-43c4a2e81e26",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
     "shortName": "Debt - Summary of Long-term Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Debt - Additional Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "lang": "en-US",
      "name": "bdsx:DescriptionOfSecuritiesPurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails",
     "shortName": "Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "bdsx:TenantImprovementAllowancesExpectedToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Leases - Summary of Future Minimum Lease Payments for Operating Leases (Parenthetical) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesParentheticalDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments for Operating Leases (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "bdsx:TenantImprovementAllowancesExpectedToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_4cc0b66e-7e74-4007-bb02-d314b2b20656",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Leases - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, Or Taxes, for Operating Lease Obligations (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl",
     "shortName": "Leases - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, Or Taxes, for Operating Lease Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "bdsx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_4cc0b66e-7e74-4007-bb02-d314b2b20656",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_5f76d7ba-2692-45b1-bf5a-feaf239555c2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:PrimarySourcesOfRevenueDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:PrimarySourcesOfRevenueDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_73bf8719-9ed7-4a80-941c-ebed989aedcd",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_73bf8719-9ed7-4a80-941c-ebed989aedcd",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Share Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_585442c6-63fc-4616-91c6-831a62abd477",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_4cc0b66e-7e74-4007-bb02-d314b2b20656",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Share Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Share Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
     "shortName": "Share Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_e2944650-b682-45bf-91f6-43c4a2e81e26",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails",
     "shortName": "Share Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_e0aa9545-138b-4cb5-9486-69e3ff5ba91b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Share Based Compensation - Summary of Restricted Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
     "shortName": "Share Based Compensation - Summary of Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_e0aa9545-138b-4cb5-9486-69e3ff5ba91b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_ec8d24b6-eeb6-4535-a95a-f96122922dc9",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Net Loss per Common Share - Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
     "shortName": "Net Loss per Common Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_b5034939-1d40-46e1-96f5-cb3cc77d9692",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_6b33c356-29a4-4ed3-ab53-62ccb31d0037",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_4cc0b66e-7e74-4007-bb02-d314b2b20656",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_4ce906a2-ae40-49a7-abd5-1a0f9e06c735",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_91cf71d9-5882-46d2-af72-be7057b1fa70",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Recent Issued Accounting Standards",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandards",
     "shortName": "Recent Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20221231.htm",
      "contextRef": "C_11b8abe5-606c-445b-ada4-84273d36bcbc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 102,
   "tag": {
    "bdsx_AVEOOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aveo oncology.",
        "label": "A V E O Oncology [Member]",
        "terseLabel": "AVEO Oncology"
       }
      }
     },
     "localname": "AVEOOncologyMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AccretionOfLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of lease liability.",
        "label": "Accretion Of Lease Liability",
        "terseLabel": "Accretion of lease liability"
       }
      }
     },
     "localname": "AccretionOfLeaseLiability",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expense current.",
        "label": "Accrued Clinical Trial Expense Current",
        "terseLabel": "Accrued clinical trial expense"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest, amortization of debt issuance costs and other.",
        "label": "Accrued Interest Amortization Of Debt Issuance Costs And Other",
        "terseLabel": "Accrued interest, amortization of debt issuance costs and other"
       }
      }
     },
     "localname": "AccruedInterestAmortizationOfDebtIssuanceCostsAndOther",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest, amortization of original issue discount and debt issuance costs",
        "label": "Accrued interest, amortization of original issue discount and debt issuance costs",
        "terseLabel": "Accrued interest, amortization of OID and debt issuance costs"
       }
      }
     },
     "localname": "AccruedInterestAmortizationOfOriginalIssueDiscountAndDebtIssuanceCosts",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AdditionalTenantImprovementAllowanceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional tenant improvement allowance amount.",
        "label": "Additional Tenant Improvement Allowance Amount",
        "terseLabel": "Additional Tenant improvement allowance"
       }
      }
     },
     "localname": "AdditionalTenantImprovementAllowanceAmount",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AdditionalWarrantsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional warrants amount.",
        "label": "Additional warrants amount"
       }
      }
     },
     "localname": "AdditionalWarrantsAmount",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AdditionalWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional warrants.",
        "label": "Additional Warrants"
       }
      }
     },
     "localname": "AdditionalWarrantsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid-in capital deferred offering costs.",
        "label": "Adjustments to additional paid-in capital deferred offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDeferredOfferingCosts",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AdvanceDeposits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance deposits.",
        "label": "Advance Deposits",
        "terseLabel": "Advance deposits"
       }
      }
     },
     "localname": "AdvanceDeposits",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased premised obligated to pay base rent.",
        "label": "Area of leased premised obligated to pay base rent",
        "terseLabel": "Area of leased premised obligated to pay base rent"
       }
      }
     },
     "localname": "AreaOfLeasedPremisedObligatedToPayBaseRent",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bdsx_AreaOfOfficeSpaceLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office space leased.",
        "label": "Area of Office Space Leased",
        "terseLabel": "Area of office space leased"
       }
      }
     },
     "localname": "AreaOfOfficeSpaceLeased",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bdsx_AstrazenecaUkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astrazeneca UK.",
        "label": "Astrazeneca UK [Member]",
        "terseLabel": "Astrazeneca UK"
       }
      }
     },
     "localname": "AstrazenecaUkMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AtTheMarketFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market facility.",
        "label": "At The Market Facility [Member]",
        "terseLabel": "At-The-Market Facility"
       }
      }
     },
     "localname": "AtTheMarketFacilityMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering [Member]",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-The-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AtTheMoneyOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-Money Offering [Member]",
        "label": "At-the-Money Offering [Member]",
        "terseLabel": "At-the-Money Offering"
       }
      }
     },
     "localname": "AtTheMoneyOfferingMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BDX004Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bdx004.",
        "label": "B D X004 [Member]",
        "terseLabel": "BDX004"
       }
      }
     },
     "localname": "BDX004Member",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BaseRentPerMonthFromCommencementDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base rent per month from commencement date.",
        "label": "Base rent per month from commencement date",
        "terseLabel": "Base rent per month from commencement date"
       }
      }
     },
     "localname": "BaseRentPerMonthFromCommencementDate",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of Presentation and Estimates.",
        "label": "Basis Of Presentation And Estimates Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Estimates"
       }
      }
     },
     "localname": "BasisOfPresentationAndEstimatesPolicyTextBlock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_BioRadLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio-rad license.",
        "label": "Bio Rad License [Member]",
        "terseLabel": "Bio-Rad License"
       }
      }
     },
     "localname": "BioRadLicenseMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BonusToOptionsProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonus-to-options program.",
        "label": "Bonus To Options Program [Member]",
        "terseLabel": "Bonus-To-Options Program"
       }
      }
     },
     "localname": "BonusToOptionsProgramMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition contingent consideration gross margin target period.",
        "label": "Business Acquisition Contingent Consideration Gross Margin Target Period",
        "terseLabel": "Business acquisition contingent consideration gross margin target period"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition contingent consideration number of installments.",
        "label": "Business Acquisition Contingent Consideration Number Of Installments",
        "terseLabel": "Contingent consideration number of installments"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationNumberOfInstallments",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration arrangements common shares redemption amount.",
        "label": "Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount",
        "terseLabel": "Contingent consideration arrangements, common shares, redemption amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_BusinessCombinationContingentConsiderationFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration final payment.",
        "label": "Business Combination Contingent Consideration Final Payment",
        "terseLabel": "Business combination contingent consideration final payment"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationFinalPayment",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_BusinessCombinationContingentConsiderationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration shares.",
        "label": "Business Combination Contingent Consideration Shares",
        "terseLabel": "Contingent consideration shares"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationShares",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_CARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES act.",
        "label": "C A R E S Act [Member]",
        "terseLabel": "CARES Act"
       }
      }
     },
     "localname": "CARESActMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_COVID19DiagnosticTestRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 diagnostic test revenue.",
        "label": "C O V I D19 Diagnostic Test Revenue [Member]",
        "terseLabel": "COVID-19 Test Revenue"
       }
      }
     },
     "localname": "COVID19DiagnosticTestRevenueMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CashCollateralizedLetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash collateralized letter of credit member.",
        "label": "Cash Collateralized Letter of Credit [Member]",
        "terseLabel": "Cash Collateralized Letter Of Credit"
       }
      }
     },
     "localname": "CashCollateralizedLetterOfCreditMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CellCartaLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CellCarta License.",
        "label": "Cell Carta License [Member]",
        "terseLabel": "CellCarta License"
       }
      }
     },
     "localname": "CellCartaLicenseMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centennial Valley Properties I, LLC Lease Agreement.",
        "label": "Centennial Valley Properties I, LLC Lease Agreement"
       }
      }
     },
     "localname": "CentennialValleyPropertiesILlcLeaseAgreementMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CenturaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centura Healthcare.",
        "label": "Centura Healthcare [Member]",
        "terseLabel": "Centura Healthcare"
       }
      }
     },
     "localname": "CenturaHealthcareMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of contingent consideration excluding accretion expense.",
        "label": "Change In Fair Value Of Contingent Consideration Excluding Accretion Expense",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ChiefExecutiveOfficerAndChiefFinancialOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief executive officer and chief financial officer.",
        "label": "Chief Executive Officer and Chief Financial Officer [Member]",
        "terseLabel": "Chief Executive Officer and Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerAndChiefFinancialOfficerMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, additional warrants or rights exercisable.",
        "label": "Class of Warrant or Right, Additional Warrants or Rights Exercisable",
        "terseLabel": "Additional warratns exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdditionalWarrantsOrRightsExercisable",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_ClassOfWarrantOrRightWarrantsOrRightsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, warrants or rights exercisable.",
        "label": "Class of Warrant or Right, Warrants or Rights Exercisable",
        "terseLabel": "Warrants exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsOrRightsExercisable",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_CommitmentSharesIssuableOnConditionalBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment shares issuable on conditional basis.",
        "label": "Commitment Shares Issuable on Conditional Basis",
        "terseLabel": "Commitment shares issuable on conditional basis"
       }
      }
     },
     "localname": "CommitmentSharesIssuableOnConditionalBasis",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_CommonStockIssuedForDeferredOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for deferred offering costs.",
        "label": "Common Stock Issued For Deferred Offering Costs",
        "terseLabel": "Common stock issued for deferred offering costs"
       }
      }
     },
     "localname": "CommonStockIssuedForDeferredOfferingCosts",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contingent consideration.",
        "label": "Contingent Consideration Policy [Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_ContingentValueRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights.",
        "label": "Contingent Value Rights",
        "terseLabel": "Contingent value rights"
       }
      }
     },
     "localname": "ContingentValueRights",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ContingentValueRightsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights percentage.",
        "label": "Contingent Value Rights Percentage",
        "terseLabel": "Contingent value rights percentage"
       }
      }
     },
     "localname": "ContingentValueRightsPercentage",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_ContingentValueRightsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights shares.",
        "label": "Contingent Value Rights Shares",
        "terseLabel": "Contingent value rights shares"
       }
      }
     },
     "localname": "ContingentValueRightsShares",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability reclassified from non-current liabilities.",
        "label": "Contract With Customer Liability Reclassified From Non Current Liabilities",
        "terseLabel": "Amount reclassified from non-current liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_CurrentPortionOfContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of contingent consideration.",
        "label": "Current Portion Of Contingent Consideration [Member]",
        "terseLabel": "Current Portion of Contingent Consideration"
       }
      }
     },
     "localname": "CurrentPortionOfContingentConsiderationMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt issuance costs included in Accounts payable and other accrued liabilities.",
        "label": "Debt Issuance Costs Included in Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Debt issuance costs included in Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs amortized against additional paid-in capital.",
        "label": "Deferred Offering Costs Amortized Against Additional Paid-In Capital",
        "terseLabel": "Deferred offering costs amortized against Additional paid-in capital"
       }
      }
     },
     "localname": "DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DeferredTaxAssetsCapitalizedResearchCosts": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax Aassets capitalized research costs.",
        "label": "Deferred Tax Assets Capitalized Research Costs",
        "terseLabel": "Capitalized research costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchCosts",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets research and experimentation tax carryforwards subject to expiration.",
        "label": "Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration",
        "terseLabel": "Research and experimentation tax carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DefinedContributionPlanNameExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan.",
        "label": "Defined Contribution Plan Name Extensible List",
        "terseLabel": "Defined Contribution Plan Name [Extensible List]"
       }
      }
     },
     "localname": "DefinedContributionPlanNameExtensibleList",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "tokenItemType"
    },
    "bdsx_DescriptionOfOfferingPeriodUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of offering period under plan.",
        "label": "Description Of Offering Period Under Plan",
        "terseLabel": "Description of offering period under plan"
       }
      }
     },
     "localname": "DescriptionOfOfferingPeriodUnderPlan",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_DescriptionOfSecuritiesPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of securities purchase agreement.",
        "label": "Description of Securities Purchase Agreement",
        "terseLabel": "Description of securities purchase agreement"
       }
      }
     },
     "localname": "DescriptionOfSecuritiesPurchaseAgreement",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting power or value of stock for employee participation in offering period.",
        "label": "Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period",
        "terseLabel": "Description of voting power or value of stock for employee participation in offering period"
       }
      }
     },
     "localname": "DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_DiagnosticTestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diagnostic tests.",
        "label": "Diagnostic Tests [Member]",
        "terseLabel": "Diagnostic Tests"
       }
      }
     },
     "localname": "DiagnosticTestsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DiligenceExpenseAndLegalFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diligence expense and legal fees.",
        "label": "Diligence Expense and Legal Fees",
        "terseLabel": "Diligence expenses and legal fees"
       }
      }
     },
     "localname": "DiligenceExpenseAndLegalFees",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DirectCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses.",
        "label": "Direct Costs And Expenses",
        "terseLabel": "Direct costs and expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpenses",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DirectCostsAndExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses.",
        "label": "Direct Costs And Expenses [Member]",
        "terseLabel": "Direct Costs and Expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpensesMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DirectCostsAndExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses policy.",
        "label": "Direct Costs And Expenses Policy [Text Block]",
        "terseLabel": "Direct Costs and Expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpensesPolicyTextBlock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_DiscountsOnDebtInstrumentIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounts on debt instrument issuance.",
        "label": "Discounts on Debt Instrument Issuance",
        "terseLabel": "Original issuance discount",
        "verboseLabel": "Original issue discounts on debt instrument issuance"
       }
      }
     },
     "localname": "DiscountsOnDebtInstrumentIssuance",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "negatedLabel": "Permanent items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity financing costs included in Accounts payable and other accrued liabilities.",
        "label": "Equity Financing Costs Included in Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Equity financing costs included in Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_EquityFinancingProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Financing Programs.",
        "label": "Equity Financing Programs [Member]",
        "terseLabel": "Equity Financing Programs"
       }
      }
     },
     "localname": "EquityFinancingProgramsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ExistingShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "existing shareholders.",
        "label": "existing shareholders member",
        "terseLabel": "Existing Shareholders"
       }
      }
     },
     "localname": "ExistingShareholdersMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ExitFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit fee payment.",
        "label": "Exit fee payment"
       }
      }
     },
     "localname": "ExitFeePayment",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisLineItems",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about liabilities measured at fair value on recurring basis.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTable",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs interest expense.",
        "label": "Fair Value Measurement With Unobservable Inputs Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsInterestExpense",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs payments of contingent consideration.",
        "label": "Fair Value Measurement with Unobservable Inputs Payments of Contingent Consideration",
        "terseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsPaymentsOfContingentConsideration",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, change in fair value.",
        "label": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_FiclatuzumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ficlatuzumab.",
        "label": "Ficlatuzumab [Member]",
        "terseLabel": "Ficlatuzumab"
       }
      }
     },
     "localname": "FiclatuzumabMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets amortization expense year six and thereafter.",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_FourthMilestonePaymentAndInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth milestone payment and interest.",
        "label": "Fourth milestone payment and interest"
       }
      }
     },
     "localname": "FourthMilestonePaymentAndInterest",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_GrossProceedsFromFinancingTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from financing transactions.",
        "label": "Gross proceeds from financing transactions"
       }
      }
     },
     "localname": "GrossProceedsFromFinancingTransactions",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IncomeTaxExaminationPeriodUnderExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax examination, period under examination.",
        "label": "Income Tax Examination, Period under Examination",
        "verboseLabel": "Income tax examination, period under examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationPeriodUnderExamination",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_IncreaseInDiscountsOnDebtInstrumentIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in discounts on debt instrument issuance.",
        "label": "Increase in Discounts on Debt Instrument Issuance",
        "terseLabel": "Increase in original issue discounts on debt instrument issuance, subject to contingencies"
       }
      }
     },
     "localname": "IncreaseInDiscountsOnDebtInstrumentIssuance",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite lived intangible assets excluding goodwill gross.",
        "label": "Indefinite Lived Intangible Assets Excluding Goodwill Gross",
        "terseLabel": "Intangible assets not subject to amortization, Cost"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillGross",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_InitialWarrantsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial warrants amount.",
        "label": "Initial warrants amount",
        "terseLabel": "Initial warrants amount"
       }
      }
     },
     "localname": "InitialWarrantsAmount",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets Accumulated Amortization Excluding Goodwill",
        "negatedLabel": "Intangible assets, Accumulated Amortization"
       }
      }
     },
     "localname": "IntangibleAssetsAccumulatedAmortizationExcludingGoodwill",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IntegratedDiagnosticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integrated Diagnostics, Inc.",
        "label": "Integrated Diagnostics Inc [Member]",
        "terseLabel": "Integrated Diagnostics, Inc",
        "verboseLabel": "Indi"
       }
      }
     },
     "localname": "IntegratedDiagnosticsIncMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense due to passage of time and fixed payment schedule.",
        "label": "Interest expense due to passage of time and fixed payment schedule"
       }
      }
     },
     "localname": "InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_InterestRateOnExtraAllowanceAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate on extra allowance amount",
        "label": "Interest rate on extra allowance amount",
        "terseLabel": "Interest rate on extra allowance amount"
       }
      }
     },
     "localname": "InterestRateOnExtraAllowanceAmount",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_IssuanceOfPerceptiveWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of perceptive warrants.",
        "label": "Issuance of Perceptive Warrants",
        "terseLabel": "Issuance of Perceptive Warrants"
       }
      }
     },
     "localname": "IssuanceOfPerceptiveWarrants",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_JanssenResearchAndDevelopmentLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Research and Development, LLC.",
        "label": "Janssen Research And Development L L C [Member]",
        "terseLabel": "Janssen Research and Development, LLC"
       }
      }
     },
     "localname": "JanssenResearchAndDevelopmentLLCMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LPCFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LPC facility.",
        "label": "L P C Facility [Member]",
        "terseLabel": "LPC Facility"
       }
      }
     },
     "localname": "LPCFacilityMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LabcorpDdFormerlyCovanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LabCorp DD (formerly Covance).",
        "label": "LabCorp DD formerly Covance [Member]",
        "terseLabel": "LabCorp DD (formerly Covance)"
       }
      }
     },
     "localname": "LabcorpDdFormerlyCovanceMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Landlord contribution towards cost of construction and tenant improvements",
        "label": "Landlord contribution towards cost of construction and tenant improvements",
        "terseLabel": "Landlord contribution towards cost of construction and tenant improvements"
       }
      }
     },
     "localname": "LandlordContributionTowardsCostOfConstructionAndTenantImprovements",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_LeaseAgreementNumberOfOptionsToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement number of options to extend",
        "label": "Lease agreement number of options to extend",
        "terseLabel": "Lease agreement number of options to extend"
       }
      }
     },
     "localname": "LeaseAgreementNumberOfOptionsToExtend",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement Date",
        "label": "Lease commencement date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "bdsx_LeaseExpirationMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month year",
        "label": "Lease Expiration Month Year",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationMonthYear",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "bdsx_LeasedPropertyBuildingCapacity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased property building capacity.",
        "label": "Leased property building capacity",
        "terseLabel": "Leased property building capacity"
       }
      }
     },
     "localname": "LeasedPropertyBuildingCapacity",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bdsx_LesseeOperatingAndFinanceLeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating and finance leases.",
        "label": "Lessee Operating and Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeasesTextBlock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeases3"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, liability, amount representing tenant improvement allowances.",
        "label": "Lessee, operating lease, liability, amount representing tenant improvement allowances",
        "negatedLabel": "Less amount representing tenant improvement allowances",
        "terseLabel": "Less amount representing tenant improvement allowances"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityAmountRepresentingTenantImprovementAllowances",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, liability, to be paid, year six and thereafter.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Six and Thereafter",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_LessorReimbursementsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor reimbursements received.",
        "label": "Lessor Reimbursements Received",
        "terseLabel": "Lessor reimbursements received"
       }
      }
     },
     "localname": "LessorReimbursementsReceived",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_LicenseAgreementExpiryDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement expiry date.",
        "label": "License Agreement Expiry Date",
        "terseLabel": "License expiry date"
       }
      }
     },
     "localname": "LicenseAgreementExpiryDate",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "bdsx_LincolnParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park.",
        "label": "Lincoln Park Member",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "localname": "LincolnParkMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LitigationClaimsAndAssessmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation claims and assessments.",
        "label": "Litigation Claims And Assessments [Member]",
        "terseLabel": "Litigation Claims and Assessments"
       }
      }
     },
     "localname": "LitigationClaimsAndAssessmentsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal in year five and thereafter.",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_LossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss member.",
        "label": "Loss [Member]",
        "terseLabel": "Loss"
       }
      }
     },
     "localname": "LossMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LungDiagnosticRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lung diagnostic revenue.",
        "label": "Lung Diagnostic Revenue [Member]",
        "terseLabel": "Lung Diagnostic Revenue"
       }
      }
     },
     "localname": "LungDiagnosticRevenueMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of common stock allowed to purchase by counterparty.",
        "label": "Maximum Percentage of Common Stock Allowed to Purchase by Counterparty",
        "terseLabel": "Maximum percentage of common stock allowed to purchase by counterparty"
       }
      }
     },
     "localname": "MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare.",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_MinimumAnnualVolumePercentageThereafter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum annual volume percentage thereafter.",
        "label": "Minimum Annual Volume Percentage Thereafter",
        "terseLabel": "Minimum annual volume percentage thereafter"
       }
      }
     },
     "localname": "MinimumAnnualVolumePercentageThereafter",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_MinimumCashBalanceAtMaturityDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance at maturity date.",
        "label": "Minimum cash balance at maturity date"
       }
      }
     },
     "localname": "MinimumCashBalanceAtMaturityDate",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_NSCLCPOCTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nsclc poc trial.",
        "label": "N S C L C P O C Trial [Member]",
        "terseLabel": "NSCLC POC Trial"
       }
      }
     },
     "localname": "NSCLCPOCTrialMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_NetProceedFromFinancingTransactionsss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceed from financing transactions",
        "label": "Net Proceed From Financing Transactionsss",
        "terseLabel": "Proceeds after deducting commissions, fees and expenses payable"
       }
      }
     },
     "localname": "NetProceedFromFinancingTransactionsss",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds percentage of cash payment to the cvr holders.",
        "label": "Net Proceeds Percentage Of Cash Payment To C V R Holders",
        "terseLabel": "Net proceeds percentage of cash payment to the CVR holders"
       }
      }
     },
     "localname": "NetProceedsPercentageOfCashPaymentToCVRHolders",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_NotesPayable2018NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes payable 2018 notes.",
        "label": "Notes Payable2018 Notes [Member]",
        "terseLabel": "2018 Notes"
       }
      }
     },
     "localname": "NotesPayable2018NotesMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_NumberOfCancerTest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of cancer test.",
        "label": "Number Of Cancer Test",
        "terseLabel": "Number of blood based lung cancer test"
       }
      }
     },
     "localname": "NumberOfCancerTest",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfCommercialBloodBasedTest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of commercial blood based test.",
        "label": "Number Of Commercial Blood Based Test",
        "terseLabel": "Number of commercial blood-based test"
       }
      }
     },
     "localname": "NumberOfCommercialBloodBasedTest",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal annual installments for award vesting.",
        "label": "Number Of Equal Annual Installments For Award Vesting",
        "terseLabel": "Number of equal annual installments for award vesting"
       }
      }
     },
     "localname": "NumberOfEqualAnnualInstallmentsForAwardVesting",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfFacility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of facility.",
        "label": "Number of Facility",
        "terseLabel": "Number of facility"
       }
      }
     },
     "localname": "NumberOfFacility",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfPreferredStockConvertedIntoCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred stock converted into common stock.",
        "label": "Number Of Preferred Stock Converted Into Common Stock",
        "terseLabel": "Number of preferred stock converted into common stock"
       }
      }
     },
     "localname": "NumberOfPreferredStockConvertedIntoCommonStock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_NumberOfSARSCoV2Test": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of SARS-CoV-2 test.",
        "label": "Number Of S A R S Co V2 Test",
        "terseLabel": "Number of SARS-CoV-2 test"
       }
      }
     },
     "localname": "NumberOfSARSCoV2Test",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_OffsettingDeferredRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offsetting deferred rent.",
        "label": "Offsetting Deferred Rent"
       }
      }
     },
     "localname": "OffsettingDeferredRent",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_OncimmuneLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncimmune Limited.",
        "label": "Oncimmune Limited [Member]",
        "terseLabel": "Oncimmune Limited"
       }
      }
     },
     "localname": "OncimmuneLimitedMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842.",
        "label": "Operating Lease Right-of-Use Assets Obtained in Exchange for Lease Liabilities at Adoption of ASC 842",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases future minimum payments due in six years and thereafter.",
        "label": "Operating Leases Future Minimum Payments Due In Six Years And Thereafter",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_OptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and restricted stock units.",
        "label": "Options And Restricted Stock Units [Member]",
        "terseLabel": "Options and Restricted Stock Units"
       }
      }
     },
     "localname": "OptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Abstract]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessAbstract",
     "nsuri": "http://biodesix.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Line Items]",
        "terseLabel": "Organization And Description Of Business [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessLineItems",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Table]",
        "terseLabel": "Organization And Description Of Business [Table]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessTable",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_OtherAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets Policy Text Block",
        "label": "Other Assets Policy Text Block",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsPolicyTextBlock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other member.",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_POCClinicalTrialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Poc clinical trials.",
        "label": "P O C Clinical Trials [Member]",
        "terseLabel": "POC Clinical Trials"
       }
      }
     },
     "localname": "POCClinicalTrialsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PaymentOfDeferredOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of deferred offering costs.",
        "label": "Payment Of Deferred Offering Costs",
        "negatedLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "PaymentOfDeferredOfferingCosts",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for proceeds from patent costs and intangible asset acquisition, net.",
        "label": "Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net",
        "negatedLabel": "Patent costs and intangible asset acquisition, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PaymentsToAcquireOncimmune": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire Oncimmune.",
        "label": "Payments To Acquire Oncimmune",
        "negatedLabel": "Payments to acquire Oncimmune assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOncimmune",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PercentageOfDevelopmentAndRegulatoryCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development and regulatory costs.",
        "label": "Percentage Of Development And Regulatory Costs",
        "terseLabel": "Responsible percentage of development and regulatory costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentAndRegulatoryCosts",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development and regulatory costs exercised using opt-out right.",
        "label": "Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right",
        "terseLabel": "Percentage of development and regulatory costs exercised using opt-out right"
       }
      }
     },
     "localname": "PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfFeePaymentsOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fee payments on net sales.",
        "label": "Percentage Of Fee Payments On Net Sales",
        "terseLabel": "Percentage of fee payments on net sales"
       }
      }
     },
     "localname": "PercentageOfFeePaymentsOnNetSales",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfFullyDilutedEquityForBonusAwarded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fully diluted equity for bonus awarded.",
        "label": "Percentage Of Fully Diluted Equity For Bonus Awarded",
        "terseLabel": "Percentage of fully diluted equity for bonus awarded"
       }
      }
     },
     "localname": "PercentageOfFullyDilutedEquityForBonusAwarded",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfInterestOnContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest on contingent consideration.",
        "label": "Percentage of interest on installment payments"
       }
      }
     },
     "localname": "PercentageOfInterestOnContingentConsideration",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of license income generated from licensing.",
        "label": "Percentage Of License Income Generated From Licensing",
        "verboseLabel": "Percentage of license income generated from licensing"
       }
      }
     },
     "localname": "PercentageOfLicenseIncomeGeneratedFromLicensing",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.",
        "label": "Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range",
        "terseLabel": "Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range"
       }
      }
     },
     "localname": "PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.",
        "label": "Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests",
        "verboseLabel": "Percentage of license agreement and royalty payment related to acquired diagnostic test recognized revenue for non-screening tests"
       }
      }
     },
     "localname": "PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments not required to pay on net revenue.",
        "label": "Percentage Of Royalty Payments Not Required To Pay On Net Revenue",
        "terseLabel": "Percentage of royalty payments not required on net revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net revenue.",
        "label": "Percentage Of Royalty Payments On Net Revenue",
        "terseLabel": "Percentage of royalty payments on net revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetRevenue",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRoyaltyPaymentsOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net sales.",
        "label": "Percentage Of Royalty Payments On Net Sales",
        "terseLabel": "Percentage of royalty payments on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSales",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of valuation allowance equal to net deferred tax assets.",
        "label": "Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets",
        "terseLabel": "Percentage of valuation allowance equal to net deferred tax assets"
       }
      }
     },
     "localname": "PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PerceptiveTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perceptive term loan member.",
        "label": "Perceptive Term Loan [Member]",
        "terseLabel": "Perceptive Term Loan"
       }
      }
     },
     "localname": "PerceptiveTermLoanMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PerformanceConditionOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance condition options.",
        "label": "Performance Condition Options [Member]",
        "terseLabel": "Performance Condition Options"
       }
      }
     },
     "localname": "PerformanceConditionOptionsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PeriodOfEscalationsOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of escalations of sales.",
        "label": "Period Of Escalations Of Sales",
        "terseLabel": "Period of escalations of sales"
       }
      }
     },
     "localname": "PeriodOfEscalationsOfSales",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment premium percentage of aggregate outstanding principal amount.",
        "label": "Prepayment premium percentage of aggregate outstanding principal amount"
       }
      }
     },
     "localname": "PrepaymentPremiumPercentageOfAggregateOutstandingPrincipalAmount",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PrimarySourcesOfRevenueDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary sources of revenue description.",
        "label": "Primary Sources Of Revenue Description",
        "terseLabel": "Primary sources of revenue, description"
       }
      }
     },
     "localname": "PrimarySourcesOfRevenueDescription",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_ProceedsFromIssuanceOfCommonStockNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock net.",
        "label": "Proceeds From Issuance Of Common Stock Net",
        "terseLabel": "Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock under employee stock purchase plan.",
        "label": "Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of term loan and notes payable.",
        "label": "Proceeds From Issuance Of Term Loan And Notes Payable",
        "terseLabel": "Proceeds from term loan and notes payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfTermLoanAndNotesPayable",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ProductLifeAndPatentLifeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product life and patent life.",
        "label": "Product Life And Patent Life [Member]",
        "terseLabel": "Product Life and Patent Life"
       }
      }
     },
     "localname": "ProductLifeAndPatentLifeMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PromissoryNoteOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note one.",
        "label": "Promissory Note One [Member]",
        "terseLabel": "Promissory Note One"
       }
      }
     },
     "localname": "PromissoryNoteOneMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PromissoryNoteTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note two.",
        "label": "Promissory Note Two [Member]",
        "terseLabel": "Promissory Note Two"
       }
      }
     },
     "localname": "PromissoryNoteTwoMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PromissoryNotesEarlyPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory notes early prepayment premium percentage.",
        "label": "Promissory Notes Early Prepayment Premium Percentage",
        "terseLabel": "Promissory notes early prepayment premium percentage"
       }
      }
     },
     "localname": "PromissoryNotesEarlyPrepaymentPremiumPercentage",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering.",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PublicOfferingPricePerShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering price per share of common stock.",
        "label": "Public offering price per share of common stock",
        "terseLabel": "Public offering price per share of common stock"
       }
      }
     },
     "localname": "PublicOfferingPricePerShareOfCommonStock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_PurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement term.",
        "label": "Purchase Agreement Term",
        "terseLabel": "Purchase agreement term"
       }
      }
     },
     "localname": "PurchaseAgreementTerm",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_PurchasedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased technology.",
        "label": "Purchased Technology [Member]",
        "terseLabel": "Purchased Technology"
       }
      }
     },
     "localname": "PurchasedTechnologyMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PutOptionLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put option liability current.",
        "label": "Put Option Liability Current",
        "terseLabel": "Put option liability",
        "verboseLabel": "Estimated value of put option liability"
       }
      }
     },
     "localname": "PutOptionLiabilityCurrent",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ReductionInContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in contingent consideration",
        "label": "Reduction in contingent consideration"
       }
      }
     },
     "localname": "ReductionInContingentConsideration",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining capacity under tenant improvement allowances prior to reimbursements expected to be received.",
        "label": "Remaining capacity under tenant improvement allowances prior to reimbursements expected to be received"
       }
      }
     },
     "localname": "RemainingCapacityUnderTenantImprovementAllowancesPriorToReimbursementsExpectedToBeReceived",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RemainingCapacityUnderTheTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining capacity under the tenant improvement allowances.",
        "label": "Remaining Capacity Under the Tenant Improvement Allowances",
        "terseLabel": "Remaining capacity under the tenant improvement allowances"
       }
      }
     },
     "localname": "RemainingCapacityUnderTheTenantImprovementAllowances",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RemainingEstimatedObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining estimated obligation.",
        "label": "Remaining Estimated Obligation",
        "terseLabel": "Remaining estimated obligation"
       }
      }
     },
     "localname": "RemainingEstimatedObligation",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RentAfterFixedEscalationProvisions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent after fixed escalation provisions.",
        "label": "Rent after fixed escalation provisions",
        "terseLabel": "Rent after fixed escalation provisions"
       }
      }
     },
     "localname": "RentAfterFixedEscalationProvisions",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase.",
        "label": "Repurchase [Member]",
        "terseLabel": "Repurchase"
       }
      }
     },
     "localname": "RepurchaseMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_RevenueMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue milestone.",
        "label": "Revenue Milestone",
        "terseLabel": "Revenue milestone"
       }
      }
     },
     "localname": "RevenueMilestone",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RevenueShareAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue share agreement.",
        "label": "Revenue Share Agreement [Member]",
        "terseLabel": "Revenue Share Agreement"
       }
      }
     },
     "localname": "RevenueShareAgreementMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_RevenueShareExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue share expenses.",
        "label": "Revenue Share Expenses",
        "terseLabel": "Revenue share expenses"
       }
      }
     },
     "localname": "RevenueShareExpenses",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_SaleOfStockSharesIssuedAsCommitmentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, shares issued as commitment fee.",
        "label": "Sale of Stock, Shares Issued as Commitment Fee",
        "terseLabel": "Shares issued as commitment fee"
       }
      }
     },
     "localname": "SaleOfStockSharesIssuedAsCommitmentFee",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_SaleOfStockStockIssuablePerDayShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, stock issuable per day, shares.",
        "label": "Sale of Stock, Stock Issuable Per Day, Shares",
        "terseLabel": "Stock issuable per day, number of shares"
       }
      }
     },
     "localname": "SaleOfStockStockIssuablePerDayShares",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_SaleOfStockStockIssuablePerDayValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, stock issuable per day, value.",
        "label": "Sale of Stock, Stock Issuable Per Day, Value",
        "terseLabel": "Stock issuable per day, value"
       }
      }
     },
     "localname": "SaleOfStockStockIssuablePerDayValue",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of depreciation and amortization expense related to property and equipment.",
        "label": "Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule of Depreciation Expense Related to Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment.",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SecuritiesPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities purchase agreements.",
        "label": "Securities Purchase Agreements [Member]",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 preferred stock.",
        "label": "Series A1 Preferred Stock [Member]",
        "terseLabel": "Series A-1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA1PreferredStockMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesA2PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 preferred stock.",
        "label": "Series A2 Preferred Stock [Member]",
        "terseLabel": "Series A2 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2PreferredStockMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesA3PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-3 preferred stock.",
        "label": "Series A3 Preferred Stock [Member]",
        "terseLabel": "Series A3 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA3PreferredStockMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesB1ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 Convertible Preferred Stock.",
        "label": "Series B1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series B1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesB1ConvertiblePreferredStockMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesEConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E convertible preferred stock warrants.",
        "label": "Series E Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Series E Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesGConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series G convertible preferred stock warrants.",
        "label": "Series G Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Series G Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "SeriesGConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ServiceConditionRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-condition RSUs.",
        "label": "Service Condition R S Us [Member]",
        "terseLabel": "Service Condition R S Us"
       }
      }
     },
     "localname": "ServiceConditionRSUsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "negatedLabel": "Weighted average exercise price, Forfeited/canceled, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price,Outstanding - December, 31, 2020, warrants",
        "periodStartLabel": "Weighted average exercise price, Outstanding - January 1, 2020, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Life (Years), Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_SharesCommittedUnderESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares committed under ESPP.",
        "label": "Shares Committed Under E S P P [Member]",
        "terseLabel": "Shares Committed Under ESPP"
       }
      }
     },
     "localname": "SharesCommittedUnderESPPMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SharesIssuedAsCommitmentFeeValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued as commitment fee, value.",
        "label": "Shares Issued as Commitment Fee, Value",
        "terseLabel": "Shares issued as commitment fee, value"
       }
      }
     },
     "localname": "SharesIssuedAsCommitmentFeeValue",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_SharesIssuedOrIssuableThresholdLimitDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued or issuable, threshold limit description.",
        "label": "Shares Issued or Issuable, Threshold Limit Description",
        "terseLabel": "Shares issued or issuable, threshold limit description"
       }
      }
     },
     "localname": "SharesIssuedOrIssuableThresholdLimitDescription",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_StockIssuableDuringPeriodValueCommittedShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuable during period, value, committed shares.",
        "label": "Stock Issuable During Period, Value, Committed Shares",
        "terseLabel": "Common stock issuable, committed to purchase"
       }
      }
     },
     "localname": "StockIssuableDuringPeriodValueCommittedShares",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_StockIssuedDuringPeriodSharesForDeferredOfferingCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, for deferred offering costs.",
        "label": "Stock Issued During Period, Shares, For Deferred Offering Costs",
        "terseLabel": "Issuance of common stock for deferred offering costs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesForDeferredOfferingCosts",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares new issues shares purchased by underwriter.",
        "label": "Stock Issued During Period Shares New Issues Shares Purchased by Underwriter",
        "terseLabel": "Shares purchased by underwriter"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesSharesPurchasedByUnderwriter",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_StockIssuedDuringPeriodValuesForDeferredOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, values, for deferred offering costs.",
        "label": "Stock Issued During Period, Values, For Deferred Offering Costs",
        "terseLabel": "Issuance of common stock for deferred offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuesForDeferredOfferingCosts",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_SubscriptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription agreements.",
        "label": "Subscription Agreements Member",
        "terseLabel": "Subscription Agreements"
       }
      }
     },
     "localname": "SubscriptionAgreementsMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items].",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_TenantImprovementAllowancesExpectedToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowances expected to be received.",
        "label": "Tenant improvement allowances expected to be received",
        "terseLabel": "Tenant improvement allowances expected to be received"
       }
      }
     },
     "localname": "TenantImprovementAllowancesExpectedToBeReceived",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_TenantImprovementAllowancesReceived": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowances received.",
        "label": "Tenant Improvement Allowances Received",
        "terseLabel": "Tenant improvement allowances received"
       }
      }
     },
     "localname": "TenantImprovementAllowancesReceived",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of royalty payments from first commercial sale.",
        "label": "Term Of Royalty Payments From First Commercial Sale",
        "terseLabel": "Term of royalty payments from first commercial sale"
       }
      }
     },
     "localname": "TermOfRoyaltyPaymentsFromFirstCommercialSale",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_TestingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Testing services.",
        "label": "Testing Services [Member]",
        "terseLabel": "Testing Services"
       }
      }
     },
     "localname": "TestingServicesMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TheBigTenConferenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Big Ten Conference.",
        "label": "The Big Ten Conference [Member]",
        "terseLabel": "The Big Ten Conference"
       }
      }
     },
     "localname": "TheBigTenConferenceMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TheStateOfColoradoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The State of Colorado.",
        "label": "The State of Colorado Member",
        "terseLabel": "The State of Colorado"
       }
      }
     },
     "localname": "TheStateOfColoradoMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ThirdAmendmentToApaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third amendment to APA agreement member.",
        "label": "Third Amendment to APA Agreement [Member]",
        "terseLabel": "Third Amendment to APA Agreement"
       }
      }
     },
     "localname": "ThirdAmendmentToApaAgreementMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandAndSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Plan.",
        "label": "Two Thousand And Sixteen Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "TwoThousandAndSixteenPlanMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandSixPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2006 Plan.",
        "label": "Two Thousand Six Plan [Member]",
        "terseLabel": "2006 Plan"
       }
      }
     },
     "localname": "TwoThousandSixPlanMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan.",
        "label": "Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2006 Plan, 2016 Plan and 2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandTwentyOneTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one term loan.",
        "label": "Two Thousand Twenty One Term Loan [Member]",
        "terseLabel": "2021 Term Loan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneTermLoanMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions and offering expenses payable.",
        "label": "Underwriting Discounts And Commissions And Offering Expenses Payable",
        "terseLabel": "Underwriting discounts and commissions and offering expenses payable"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_WarrantLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liabilities Fair Value Disclosure",
        "label": "Warrant Liabilities Fair Value Disclosure",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "WarrantLiabilitiesFairValueDisclosure",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability.",
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_WarrantLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrant liability.",
        "label": "Warrant Liability Policy [Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityPolicyTextBlock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_WarrantsForConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants for convertible preferred stock.",
        "label": "Warrants For Convertible Preferred Stock [Text Block]",
        "terseLabel": "Warrants to Purchase Convertible Preferred Stock"
       }
      }
     },
     "localname": "WarrantsForConvertiblePreferredStockTextBlock",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_WeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price per share.",
        "label": "Weighted Average Price Per Share"
       }
      }
     },
     "localname": "WeightedAveragePricePerShare",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year of ending royalty payments from first commercial sale.",
        "label": "Year Of Ending Royalty Payments From First Commercial Sale",
        "terseLabel": "Year of ending royalty payments from first commercial sale"
       }
      }
     },
     "localname": "YearOfEndingRoyaltyPaymentsFromFirstCommercialSale",
     "nsuri": "http://biodesix.com/20221231",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r254",
      "r255",
      "r373",
      "r403",
      "r671",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r316",
      "r690",
      "r769",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r443",
      "r613",
      "r627",
      "r667",
      "r668",
      "r687",
      "r700",
      "r710",
      "r766",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r443",
      "r613",
      "r627",
      "r667",
      "r668",
      "r687",
      "r700",
      "r710",
      "r766",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r316",
      "r690",
      "r769",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r313",
      "r615",
      "r688",
      "r708",
      "r761",
      "r762",
      "r769",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r313",
      "r615",
      "r688",
      "r708",
      "r761",
      "r762",
      "r769",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r434",
      "r443",
      "r474",
      "r475",
      "r476",
      "r589",
      "r613",
      "r627",
      "r667",
      "r668",
      "r687",
      "r700",
      "r710",
      "r758",
      "r766",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r434",
      "r443",
      "r474",
      "r475",
      "r476",
      "r589",
      "r613",
      "r627",
      "r667",
      "r668",
      "r687",
      "r700",
      "r710",
      "r758",
      "r766",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r254",
      "r255",
      "r373",
      "r403",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r444",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r274",
      "r444",
      "r723",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r314",
      "r315",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r689",
      "r709",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r652",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r689",
      "r709",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r274",
      "r444",
      "r723",
      "r724",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r749",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CO": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COLORADO"
       }
      }
     },
     "localname": "CO",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_KS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KANSAS"
       }
      }
     },
     "localname": "KS",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r707"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $118 and $158",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r90",
      "r219"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r707"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid\u2011in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r741",
      "r742",
      "r743",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r135",
      "r136",
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r99",
      "r107",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering",
        "verboseLabel": "Issuance of Initial Warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense",
        "verboseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r227",
      "r319",
      "r328",
      "r330",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r50",
      "r75",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense related to definite-lived intangible assets",
        "totalLabel": "Amortization of Intangible Assets, Total"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r185",
      "r199",
      "r223",
      "r251",
      "r298",
      "r307",
      "r311",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r527",
      "r531",
      "r553",
      "r707",
      "r764",
      "r765",
      "r814"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r215",
      "r229",
      "r251",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r527",
      "r531",
      "r553",
      "r707",
      "r764",
      "r765",
      "r814"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r251",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r527",
      "r531",
      "r553",
      "r764",
      "r765",
      "r814"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non\u2011current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non\u2011current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r522",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r522",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.",
        "label": "Business Acquisition, Description of Acquired Entity",
        "terseLabel": "Business acquisition description"
       }
      }
     },
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r157",
      "r158",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration amount",
        "totalLabel": "Business Combination, Consideration Transferred, Total"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r525",
      "r734"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in contingent consideration",
        "verboseLabel": "Net change to contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r156",
      "r159"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r156",
      "r159"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Noncash purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Business acquisition contingent consideration gross margin target"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r217",
      "r670"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r53",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r47",
      "r52",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash \u2011 end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash \u2011 beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r47",
      "r179"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r251",
      "r279",
      "r280",
      "r282",
      "r284",
      "r291",
      "r292",
      "r324",
      "r361",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r401",
      "r402",
      "r405",
      "r409",
      "r416",
      "r553",
      "r669",
      "r722",
      "r737",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r116",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrant issued to purchase shares",
        "verboseLabel": "Warrant issued to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares of common stock",
        "verboseLabel": "Warrant issued to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r116",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r190",
      "r204"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r354",
      "r355",
      "r654",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r741",
      "r742",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r707"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 authorized; 77,614,358 (2022) and 30,789,649 (2021) shares issued and outstanding",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r176",
      "r177",
      "r316",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r176",
      "r177",
      "r316",
      "r636",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r176",
      "r177",
      "r316",
      "r653",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r196",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r66",
      "r67",
      "r176",
      "r177",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r68",
      "r176",
      "r178",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r176",
      "r177",
      "r316",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.",
        "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure",
        "terseLabel": "Contingent consideration estimated fair value"
       }
      }
     },
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r419",
      "r420",
      "r430"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r419",
      "r420",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Non-current deferred revenue",
        "verboseLabel": "Non-current deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r65",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerFunds": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts received from and refundable to customers unless used by them to obtain goods and services from the entity.",
        "label": "Customer Funds",
        "terseLabel": "Refundable deposit"
       }
      }
     },
     "localname": "CustomerFunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r249",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r386",
      "r393",
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Principal balance outstanding"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r186",
      "r188",
      "r198",
      "r256",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r565",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Applicable margin rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r7",
      "r188",
      "r198",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Loan principle amount",
        "verboseLabel": "Notes/Loan payable"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r5",
      "r7",
      "r108",
      "r186",
      "r188",
      "r194",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument, Description",
        "terseLabel": "Loan description",
        "verboseLabel": "Debt instrument description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r181",
      "r183",
      "r370",
      "r565",
      "r683",
      "r684"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate loan amount",
        "verboseLabel": "Debt instrument, aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r28",
      "r181",
      "r400",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r28",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r230",
      "r682",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Convertible notes, maturity date",
        "verboseLabel": "Debt instrument maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r29",
      "r256",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r565",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r29",
      "r108",
      "r111",
      "r112",
      "r113",
      "r180",
      "r181",
      "r183",
      "r195",
      "r256",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r565",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r180",
      "r183",
      "r767"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt instrument, discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r182",
      "r382",
      "r398",
      "r683",
      "r684"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt discount and debt issuance costs",
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r9",
      "r10",
      "r187",
      "r197",
      "r502"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r754"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r801"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Interest expense limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r800"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r800"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets after valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r149",
      "r801"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r147",
      "r149",
      "r801"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r149",
      "r801"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r149",
      "r801"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r149",
      "r801"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contributions amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution 401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r50",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r50",
      "r88"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Promissory notes interest rate"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Promissory note, maturity term"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r429",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r448",
      "r479",
      "r480",
      "r482",
      "r487",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r114",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends",
        "totalLabel": "Dividends, Common Stock, Total"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r239",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r277",
      "r279",
      "r282",
      "r283",
      "r284",
      "r288",
      "r537",
      "r538",
      "r622",
      "r625",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r239",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r279",
      "r282",
      "r283",
      "r284",
      "r288",
      "r537",
      "r538",
      "r622",
      "r625",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShare1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r252",
      "r492",
      "r516"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r797",
      "r802"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r797",
      "r802"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r797",
      "r802"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and developments credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation related accruals",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized remaining stock based compensation balance",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r107",
      "r212",
      "r234",
      "r235",
      "r236",
      "r257",
      "r258",
      "r259",
      "r263",
      "r271",
      "r273",
      "r290",
      "r325",
      "r418",
      "r483",
      "r484",
      "r485",
      "r509",
      "r510",
      "r536",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r578",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Axis]",
        "terseLabel": "Industry Sector"
       }
      }
     },
     "localname": "EquitySecuritiesByIndustryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Domain]",
        "terseLabel": "Industry Sector"
       }
      }
     },
     "localname": "EquitySecuritiesIndustryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r384",
      "r552",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r50",
      "r103"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability",
        "verboseLabel": "Increase in value of the warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r542",
      "r543",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r167",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r384",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r543",
      "r586",
      "r587",
      "r588",
      "r683",
      "r684",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r171",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r167",
      "r173",
      "r384",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r542",
      "r543",
      "r545",
      "r546",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r384",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r384",
      "r435",
      "r440",
      "r543",
      "r587",
      "r683",
      "r684",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r384",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r543",
      "r588",
      "r683",
      "r684",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Reported Fair values of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contingent Consideration and WarrantLiabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Initial fairvalue of additional warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balances",
        "periodStartLabel": "Beginning balances"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r384",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r586",
      "r587",
      "r588",
      "r683",
      "r684",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r548",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r322",
      "r323",
      "r329",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r395",
      "r414",
      "r533",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r680",
      "r750",
      "r751",
      "r752",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r221",
      "r349"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets subject to amortization, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Amortization Expense Related to Definite-Lived Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r346",
      "r348",
      "r349",
      "r351",
      "r616",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r81",
      "r620"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets subject to amortization, Cost",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r76",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r81",
      "r616"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Intangible assets subject to amortization, Net Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r50",
      "r100",
      "r101"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on debt extinguishment",
        "negatedLabel": "Loss (gain) on extinguishment of liabilities, net",
        "negatedTerseLabel": "Loss on extinguishment of liabilities",
        "terseLabel": "(Loss) gain on extinguishment of liabilities, net",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "verboseLabel": "Gain (loss) on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureFairValueScheduleOfChangesInContingentConsiderationAndWarrantLiabilitiesDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r220",
      "r341",
      "r621",
      "r681",
      "r707",
      "r755",
      "r756"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r344",
      "r345",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r50",
      "r342",
      "r343",
      "r344",
      "r681"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairments loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering",
        "verboseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r50",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets",
        "totalLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r735",
      "r757"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment loss on intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r50",
      "r87",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r252",
      "r493",
      "r500",
      "r507",
      "r514",
      "r517",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income Tax Examination, Description",
        "terseLabel": "Income tax examination details"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "auth_ref": [
      "r139",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.",
        "label": "Income Tax Examination, Likelihood of Unfavorable Settlement",
        "verboseLabel": "Income tax examination, likelihood of unfavorable settlement"
       }
      }
     },
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r253",
      "r272",
      "r273",
      "r297",
      "r491",
      "r515",
      "r518",
      "r626"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r233",
      "r489",
      "r490",
      "r500",
      "r501",
      "r506",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes",
        "totalLabel": "Income Taxes Paid, Net, Total"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r614",
      "r734"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r734",
      "r811"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Current and long-term operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r734"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r347",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "periodEndLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance",
        "periodStartLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance",
        "terseLabel": "Intangible assets not subject to amortization, Net Carrying Value",
        "totalLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r77",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Intangible assets, Cost",
        "totalLabel": "Intangible Assets, Gross (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r74",
      "r79"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, Net Carrying Value"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r182",
      "r192",
      "r237",
      "r296",
      "r564"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r243",
      "r246",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventorySuppliesPolicy": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for supplies to be consumed directly or indirectly in production. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average).",
        "label": "Inventory Supplies, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventorySuppliesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r72",
      "r729"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Reserve for inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory excess and obsolescence",
        "verboseLabel": "Excess and obsolete inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Description of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Description",
        "terseLabel": "Lease description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]",
        "terseLabel": "Lease option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less amount representing interest",
        "terseLabel": "Less amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, expiration term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r251",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r528",
      "r531",
      "r532",
      "r553",
      "r677",
      "r764",
      "r814",
      "r815"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r189",
      "r202",
      "r707",
      "r739",
      "r753",
      "r807"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r216",
      "r251",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r528",
      "r531",
      "r532",
      "r553",
      "r707",
      "r764",
      "r814",
      "r815"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total contingent consideration",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r7",
      "r8",
      "r251",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r528",
      "r531",
      "r532",
      "r553",
      "r764",
      "r814",
      "r815"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non\u2011current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non\u2011current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License Rights"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r7",
      "r188",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Letter of credit subject to contingent reduction over the term of the lease",
        "totalLabel": "Long-term Line of Credit, Total",
        "verboseLabel": "Long-term Line of Credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining available capacity for share issuance"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Final settlement payment to third parties"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r7",
      "r188",
      "r200",
      "r383",
      "r399",
      "r683",
      "r684"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r97",
      "r256",
      "r388"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r97",
      "r256",
      "r388"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r97",
      "r256",
      "r388"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r97",
      "r256",
      "r388"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r97",
      "r256",
      "r388"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      },
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Long-term notes payable, net of current portion",
        "totalLabel": "Long-term notes payable",
        "verboseLabel": "Long-term notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r29",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r356",
      "r357",
      "r358",
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r356",
      "r723"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "terseLabel": "Accrued legal contingency"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-Term Debt [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend Yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r245"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r245"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r47",
      "r48",
      "r51"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r34",
      "r51",
      "r191",
      "r206",
      "r214",
      "r231",
      "r232",
      "r236",
      "r251",
      "r262",
      "r266",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r281",
      "r298",
      "r306",
      "r310",
      "r312",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r538",
      "r553",
      "r678",
      "r764"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r213",
      "r260",
      "r261",
      "r264",
      "r265",
      "r274",
      "r275",
      "r276",
      "r320",
      "r321",
      "r326",
      "r327",
      "r511",
      "r512",
      "r513",
      "r535",
      "r539",
      "r540",
      "r541",
      "r554",
      "r555",
      "r556",
      "r566",
      "r567",
      "r577",
      "r579",
      "r617",
      "r618",
      "r619",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recent Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r7",
      "r188",
      "r200"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "totalLabel": "Notes payable, total"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Less: current maturities",
        "totalLabel": "Notes Payable, Current, Total"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureDebtSummaryOfLongtermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBankCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.",
        "label": "Notes Payable to Bank, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r298",
      "r306",
      "r310",
      "r312",
      "r678"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r808"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total lease liabilities",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsForOperatingLeasesDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r568"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r735"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRecentIssuedAccountingStandardsAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r575",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases, Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r574",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases, Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxesForOperatingLeaseObl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense",
        "totalLabel": "Operating Leases, Rent Expense, Net, Total"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r228",
      "r707"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r163",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r728"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r707"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Long-term Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income (loss), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payments to acquire license rights"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "verboseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Equity financing costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r39",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Contingent consideration cash payment",
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r707"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2022 and 2021) issued and outstanding",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placements"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds from debt, after deducting debt issuance costs and expenses",
        "verboseLabel": "Proceeds from net of debt issuance costs and original issue discounts"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from the sale of common shares",
        "terseLabel": "Proceeds from the issuance of common stock",
        "verboseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Gross proceeds from an equity offering of common stock",
        "terseLabel": "Gross proceeds from sale of common shares",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "verboseLabel": "Funding amount"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "totalLabel": "Proceeds from Notes Payable, Total"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r731",
      "r733"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r133"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r214",
      "r231",
      "r232",
      "r244",
      "r251",
      "r262",
      "r272",
      "r273",
      "r298",
      "r306",
      "r310",
      "r312",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r526",
      "r529",
      "r530",
      "r538",
      "r553",
      "r623",
      "r678",
      "r704",
      "r705",
      "r730",
      "r764"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r89",
      "r218"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r91",
      "r203",
      "r624",
      "r707"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r240",
      "r331"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RegulatoryLiabilityAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period for the recovery of regulatory liability, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Regulatory Liability, Amortization Period"
       }
      }
     },
     "localname": "RegulatoryLiabilityAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r732"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of term loan and notes payable",
        "terseLabel": "Amount used to retire outstanding debt",
        "totalLabel": "Repayments of Long-term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r138",
      "r207",
      "r822"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r725",
      "r736",
      "r823",
      "r824"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as current.",
        "label": "Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Restricted Cash, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r114",
      "r201",
      "r631",
      "r635",
      "r707"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r212",
      "r257",
      "r258",
      "r259",
      "r263",
      "r271",
      "r273",
      "r325",
      "r483",
      "r484",
      "r485",
      "r509",
      "r510",
      "r536",
      "r628",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue and Accounts Receivable Credit Concentration"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r238",
      "r251",
      "r294",
      "r295",
      "r305",
      "r308",
      "r309",
      "r313",
      "r314",
      "r316",
      "r324",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r553",
      "r623",
      "r764"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Revenues, Total",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r573",
      "r706"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance lease right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r573",
      "r706"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r316",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r29",
      "r108",
      "r111",
      "r112",
      "r113",
      "r180",
      "r181",
      "r183",
      "r195",
      "r683",
      "r685",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Long-term Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r60",
      "r63",
      "r279",
      "r280",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r131",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r76",
      "r80",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments for Operating Lease Obligations"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Excluding Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Scheduled Principal Repayments (Maturities) of Long-term Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r445",
      "r447",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r120",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r224",
      "r225",
      "r226",
      "r291",
      "r401",
      "r402",
      "r403",
      "r405",
      "r409",
      "r414",
      "r416",
      "r687",
      "r722",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r116",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Activity for Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r703",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Estimated Amortization Expense of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r68",
      "r176",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Sales, marketing, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, Marketing, General and Administrative",
        "verboseLabel": "Sales, Marketing, General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Sales, Marketing, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r726",
      "r727",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r726",
      "r727",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [
      "r726",
      "r727",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D preferred stock.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "auth_ref": [
      "r726",
      "r727",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E preferred stock.",
        "label": "Series E Preferred Stock [Member]",
        "terseLabel": "Series E Preferred Stock"
       }
      }
     },
     "localname": "SeriesEPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "auth_ref": [
      "r726",
      "r727",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series F preferred stock.",
        "label": "Series F Preferred Stock [Member]",
        "terseLabel": "Series F Preferred Stock"
       }
      }
     },
     "localname": "SeriesFPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "auth_ref": [
      "r726",
      "r727",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series G preferred stock.",
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G Preferred Stock"
       }
      }
     },
     "localname": "SeriesGPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "auth_ref": [
      "r726",
      "r727",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series H preferred stock.",
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series H Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesHPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "share-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Share based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Percentage of fair market value of common stock for purchase under plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Forefeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Number of RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, December 31, 2022",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Released",
        "terseLabel": "Release of restricted stock units, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatality rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatality rate, miinimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk\u2011free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of earnings used for purchase of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "terseLabel": "Exercised, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Forfeited/canceled, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted, warrants",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Outstanding - December 31, 2020, warrants",
        "periodStartLabel": "Outstanding - January 1, 2020, warrants",
        "terseLabel": "RSUs outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in the number of shares under non-option equity instrument agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)",
        "negatedLabel": "Reclassification of warrant liability to additional paid-in capital, warrants",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant under all plans",
        "verboseLabel": "Additional stock awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock Options, Exercisable - December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable - December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Stock Options, Forfeited/canceled",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock Options, Granted",
        "verboseLabel": "Number of performance-condition options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Aggregate Intrinsic Value, Outstanding - December 31, 2022",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding - December 31, 2021",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding - January 1, 2022",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding - January 1, 2021",
        "verboseLabel": "Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock Options, Outstanding - December 31, 2022",
        "periodStartLabel": "Stock Options, Outstanding - January 1, 2022",
        "terseLabel": "Number of outstanding stock options granted",
        "verboseLabel": "Number of outstanding stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding - December 31, 2022",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding - January 1, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of number of shares of common stock issued and outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of common stock may be issued under incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price",
        "verboseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche A Loan",
        "verboseLabel": "First Tranche"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche C Loan"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche B Loan",
        "verboseLabel": "Two Tranche"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r452",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Life (Years), Exercisable - December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of Shares, Outstanding - December 31, 2022",
        "periodStartLabel": "Number of Shares, Outstanding - January 1, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Number of Shares, Forfeited/canceled"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, January 1, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Life (Years), Outstanding",
        "verboseLabel": "Remaining life of outstanding performance condition options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Common Stock Balance, Shares",
        "periodStartLabel": "Common Stock Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r251",
      "r279",
      "r280",
      "r282",
      "r284",
      "r291",
      "r292",
      "r324",
      "r361",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r401",
      "r402",
      "r405",
      "r409",
      "r416",
      "r553",
      "r669",
      "r722",
      "r737",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r33",
      "r107",
      "r212",
      "r234",
      "r235",
      "r236",
      "r257",
      "r258",
      "r259",
      "r263",
      "r271",
      "r273",
      "r290",
      "r325",
      "r418",
      "r483",
      "r484",
      "r485",
      "r509",
      "r510",
      "r536",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r578",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r290",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r12",
      "r13",
      "r107",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r107",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net shares",
        "verboseLabel": "Shares of common stock issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r107",
      "r114",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Stock Options, Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options, shares",
        "verboseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r12",
      "r13",
      "r107",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r107",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock issuable per day, number of shares",
        "verboseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r107",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options",
        "verboseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r16",
      "r17",
      "r70",
      "r707",
      "r739",
      "r753",
      "r807"
     ],
     "calculation": {
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
      "http://biodesix.com/20221231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r250",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r418",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r563",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r563",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r563",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r580",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Description",
        "terseLabel": "Description of tax credit carryforward expiration"
       }
      }
     },
     "localname": "TaxCreditCarryforwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary Equity Balance, Shares",
        "periodStartLabel": "Temporary Equity Balance, Shares",
        "terseLabel": "Convertible preferred stock, outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Capital expenditure for leasehold improvements related to leases premises which are tenant improvements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r322",
      "r323",
      "r395",
      "r414",
      "r533",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r750",
      "r751",
      "r752",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r488",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Reductions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Reductions related to settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r798"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Accrued interest related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "terseLabel": "Reductions related to a lapse of statute"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UpFrontPaymentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of deferred revenue by arrangement wherein all amount due is received from customer before delivery of goods or services, and revenue will be recognized upon customer acceptance of delivered goods or services.",
        "label": "Up-front Payment Arrangement [Member]",
        "terseLabel": "Up Front Cash Payments"
       }
      }
     },
     "localname": "UpFrontPaymentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Explanation of Change",
        "terseLabel": "Valuation allowance, deferred tax asset, explanation of change"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetExplanationOfChange",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrants, expires period"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and rights outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants expected term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Estimated air value of warrants issued",
        "verboseLabel": "Fair value of warrants issued"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r278",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted-average shares outstanding used in computing net loss per share, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r277",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average shares outstanding used in computing net loss per share, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20221231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1),20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235116",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r712": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r713": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r714": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r715": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r716": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r717": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r718": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r719": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r721": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0000950170-23-006092-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-006092-xbrl.zip
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M!AP5WZ#Q#IZO1IQ&<<$+P5P+E*-Q!BE+LF#(VQ*5C-41%2*:WS&"2VA]7]:
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M@&;!MJYJX*XA(M=W<\^^71:WM&94QHI:/@@JN8J<1*Y,Z?>4B3.J# RU$;(
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M[Y7DFB1K#9'9E]TOC?>2K:9!9:3]RDNO[FLH7^EAL0CG*V%R8AI( AM)Z89
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M];D:'W[T,6XV9&U/'[],K2I ]?KR$O3*$O2V8L2G'9>4ES+T=?:VF<^)/[B
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MW;!@#T>Y&>5FE!OGF85R<WRUY_?CT1?*S1@"WBO)&4/ 3<X,+N.^YA-XKR+
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M1GH.XS3/0,?6K%=&9@[+IPIAI%T:@?-?EOA)'9X.6>\>Z(+RC480IH>*:]N
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M6_O>03O=A9"MNG=;E+P7.AJ[,#,^AQRG,STS'Q9.7@2VLRJ;DJ2R7[W_DV[
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MR,(=V1%P%F^/[C[C1^(4^.0ZOX95'4P&)D1GI-UH?=CTF-B92*YQK'LJ$\C
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ME;"8%^R&62'M4;'QL2>*1PHL.5%J&0TZU-&^T:%WE ;Z#/$E81)TT^THA%N
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MY.N]%WL3>]W7\;J,3MFCLZ0+M&:T$MT1Q?'5N?0.'7F,N4WY.AQ-3V_&7C4
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M.H\'Z'4>_7@4T.L<C_,;;MW9OG0NJQL2JM[GID_I_6092;AV7)3&SFJQD+'
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M/-V1\S3 Q+4J,TTA<5^W>%3,LN+L70S D2V%"1-@G**6+_QX@PWDPJW0+6&
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MZ?QYYOV GU191-K]R<G7)T^^/1VU^Q?0[GX!=K2UZ,@R5?-Q/"O--"U,XR+
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M0I?M/4;"JIC=D-1I^)_J.><^4)E'44#Z<C.9(KX-GT"0>(B :A8ZF4B@*D>
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MHJZ[KH"[8".NCT.&YS0K ?.4O9+D9@TLIB#2Y%0EYR>V0]$ -3)$:<(]"P
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M90 KG9N=3XB]8!\G9_F=!LOS?EQ<6KC-T:,Q#P'%>.Z8#Q(]SW@R7,5G/]$
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M&FW1Q16-^M@)]T<E)#_:.*I !Z.>]R CNXJ% >=1I"ZBS*_%FV[;_KC5_8]
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MM.-9=-7,UW5);7+7\DZG"ZYY:F7QM91^>#:UB+G E\74>"QE"N6KQW+7\ZU
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M=0L0\76B565/>-)^(<5@*\88C:09*BR";HKBV(UTK8 6)QWMO#'?'I-J5[I
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M8;E)+YCR8Q5RW[L+W68K]@"*)F#B_4V0^:U<DQI@W#*]""7#.:,24M!UU'L
M?G>2E14)7:YB$N< >(V1_L44MGKRG54?WGU !F) ;AP>IUB-ZQJ/;$6)2GIU
M1_FH6W/R])%=P^X-2X">AQ,4_T0Q,MY3BDV&1H)AC)_AX&TH]^3G:^Q7#7RH
M_&!4ZZCH_7,IO.W-B<_!ZD=7]]3T=3R8_F"^JP/6U2^DG^XDJ,M;4!KVA25*
M@[C__>/MHT-)W&6HGTM+KVP7TD63]N@,K(0T!G9DV [;B8LA1]3Y@"XW0V19
MD$=]1X8/9_!L=911N?/G-@)J2N] )[V 4J<[,+Q;*75E29_9LF8027)"M'1C
MH,ZC;AB_;EZAE')(_4_/2I55-A'-;>>R=@8("1N5#K^N+$8<]9]K/[DN:'+W
M9;;$* CNN]4CAV;+I>B[2!A8SZV3;S06%O0+_BRW]'94!+2)5 '7+:4;#X$(
M"8K5LUF'"FJ.??6B0Q(J@V(MI6\CHA1HKZ=.6>GC>7+);I"+&R(.*QE$@)=%
MDWJ9L6)>TA:>;^U\S ,O@KT S 3.AY/!)(+#,Z-Q.P0 [91XJ9K;D$S5^K^$
M4P3<<%VUVO)1GU@R$<%JU57LYL=PF/$\W#L<1)-V.PY^NKM &L+L4%$O1][H
MVR'9/Z03T/XY;:P\\*Q497A$KF)A)<\>FM?!Z.(VDMJ2.N-]66T_'JV0)HAX
MFPCMI/LU, F13,:G0XNB;=L-FJI"EB<IET\JA^\9A,#/Q,RPL9?H3RL_I(_\
M"Y_2>-I:2ZE(EK*K&M0?,O40XMAMMY!#LXD36)[9G@$-:0H;'QE%.'6*2]?Z
M;V6JI@@Y'4,"A2OOX,FAII-8]W*DS4=/ 5?A:DH2<//:>R]((<4-R.*X?"2R
M.&$W'O)[#YO:64XY)WS:?5'<UDT:.^5L@LC\T(?0+[/(?$FN^U]CM]@?V%/B
MS!!>) F1KNTD,DHCT[1IU:VF<HFG)=(@IA6.KX2]B)MC\R9W,YB'0K\3'_2-
MF'S'V2],KU2I#X9 ;?3LT(!6\P7!3TY,NE FH,["->NZ:%:*-&V@6M!RHYQ0
M"FBFA-,M=G][H.QHI/4B/-QT,8LY/4&AZ[/'8_4&$R0E%P<P5Y E>&22HY,G
MJ,P! 81DFP=\,P>8K.:L4%AJ,@TJKJR[[X*S*+<<T"6+6HELMZYHF,ML*4^(
MWJ2*1AMJ^X0]^V:*/,.&,T")S1LK+/42=$_#F0<UDG'AAF=P!,0>[=,&P6DP
M^:A.?03>ZBJ0@+$?&6!<"'^'?6Q0WE ]X[,1-D<>R-+"=MS OI%*=([<5)">
MO$TE1<I7RKTI-%CTF.ZK8Q8*/577:N!".-XB/AJ?,%[P =XFF #O\ QJC9R3
M?6N!JGD%0AO#^+,T.A]R*" W9.XQ10PD;;UH<DLMM9ES<4QP#7VF3\+^5B]$
M?T,&2 C($FHY=5<EOS,$'/*S&"?MHA4?-<\]:QZ&"GB9AI7I&V.ABV]L;B;%
M3%S$ $\%]W,91T+ARQ"8?=4=R,6[QNFI"1$?%3,8G@#6C[IU>)K\JLWLL%NI
M"69_+4<[5ETBSJ3P"Y@'<<_*F=:)Q0$$R]9%UE^QZ304 %7EZSA92(5"&ZG#
MW!@8:-V1Z)]E-PX>:"8FO(4V(J&.4@#V*H\@]O='(L0T5?D9<Z@D"Z+'9\"D
MYL"IR+!T@2)]YN,:_Y5"H=RJ'8:;6GM"#99Y5=Q!,.W[/-#V>0RS?(%XJ\<.
MY3XXKZIH!R\=J5=5J+(LE23Z-T$W)S[6#N#.M+99F8(_TN ZJJ5IWYV<JA4B
M,5*,8%F0G2F'1-[BO:.%QHR%ME&MBH L$3R)CM4DA0<V[H,42S-E27&G@T1I
M. L*C)5%"ELT*"OU*"J?*D!H*!9I@N5K-4[E"V"Y'NVB\B+!@L9A $8]H\F0
MD-/!YU>*%VQ<WRH\IF5MU[3)_&BXR;LQ1V-N(OANY$9[%<R6ID"XXN*Y2;45
MXU&,BW+)<L*'[X- C,HH_"2W,1BQ54#E30'-T9$AU;5 -M'87P@0#!^6RP23
MJW#GV#1B )6;?\;S665M)3:FD-08N!_;ZK6A+.<:TNI:-1%C$1=@8Q+.$!N,
M=5I/-C\0!,$?HB+J3(QN6J+SLKBNZ@!O9NO00Q OQR*I+S']O\ =7Y;N5HUU
M9<C @5UT3%%DY?=TJN;EG#,R\9DKS&V""^%74&#0*_5Z(#"BOQTH@Q@I'1*!
M9^<?#KDR,2@7+C^><VIH&YMDM;!YHF!X6;YW0L*MN7@C(P,A:3E#72,V$,VF
MZ_!._8KO!YX;/RHK&#N%T"2$$$@:%E'K%Q1)9IX5M.7,$^C,V%I">2C[99K'
M_M1(6+97Y8:+TD(@_E<^Q\LFXQEG3@3>H C\^X<Q/?D-+W2Y4B6P!\,NBCB"
MHJ-LU-B$Z+GK3DC_RHB=7&,K=&!N_"UVB =&G9JW/A)9[42*[5FR.JU;%XWG
MLF:)W'37.^!1RYZ4IH36]<896%;46Q*OT? W@J3V/#^(,(;<;VK!/P[!B)-M
MS/HL4O77.F^T<0(:L4];$T48 A^(%>KPUI=45B]R-82A'>WJ+V!7"^:_[6@=
M/=4!'03FTJ)U_RIDR^NC*&N//1:JK_5D#QUGCIS*\XM*W*QY4RPVR=O.R0YC
M]Y?>^$U 9C+#$2;N>AM>%HX:!VW+?SD]&KN/G:R;<@DZL$?XR;#FY_(5QHKR
MRH[[135"/O^LD,]O1\CG"/E\ !OQEKN]#/D0OO6+A NO3$;^@" BI/$;DY3O
M(BE\J51*GDF3A6>0D:@+*,2:PB^=>85],6^43.950HU;]Q=2_Q<_GVN>S:*&
M,1C$*H*=9[\WG<+Y[R16%YMI@W;6A,=3MFHVZ%@UP3,4#N#)11>JHG)2HNOC
M&=$+ D"E9R<B7?3K341NG0@;V)J%['[(+YRO*C>69V_[(XVR?$F)9&NDK8V$
M& J.<41H%QUD )RV:3C<V%EA8\4E??@ 6JX;<H^%66(' N3AN)JS^TQC='=&
M/F::[OGL:%'8<F5;XJYLW:=L6.8WV[4C+& 8=A#C.>]X_,7&$SN7(?ZK9\_;
M)]=V]OS3!U:Z3>MB -.JKI?#N_N!Z/4_1"#F$ID#[8J&G1]:9HU*ZWYG^KF&
M/(=BG!\K[XXSJR1F-52:RBKT#VS=4/238YZ"K)[[5'.:)H_BQ5,5VJHH)(\3
MXQ+U6L3G@"6)W-$X"KNG!=ZQIY/T'6SDG9[.HJZ8&Z+YS*%OXZ+D,(>BV4S+
MD3+D$H3"AWP#\LQ/;,S,ADGM,\_EW/5FH,E7CI2D0[%KD@[=UP20V:-3F"<G
MRINZ\%0WFZUDZYB9")>U[J/3V".9[G'H=5515362)?,$_->+.!@KO\ !:L.8
M#S0UM%&6 M)F-MUVD GT[U=OHV<GZ+:(BE3GHG7)\.)@XRXL(D+0:11'&^HU
M2#2$! :/2DV9W??OK,Z,*S(YM$?Z+.:&4H!2F+0X<> 3$872CUK>]#O2DPVG
ML@0;1%\+8Y#Q%/\(7*6HB18Z]QG7H',RI[PEIWSMR)[8<+]<K",IP7+-%A;G
M[\C@$*1'W,0Z[CB)=/ZZ*!LF3\7FS0WPV+A%YXVPMM?+B7.[*&^0<NSR7UWC
MP\.FKK_/R!CPI1DA$9Q+X!))]J[E'*.:+/4&O[OI-JB^95"!/(G1FCM@3HRO
M%>&'M_IJ'AS_?A(R9#O3FM[<LI^*A R61I^LJ^TS=/#<>4*N\,U[QXFVD Q0
MFP4^]S;N"GH-]'DEZQ)8GJ79:Z!R76C[1@;?*3I)VXT*"M3P51C63C)6/K<U
M_ U  PHP9R".)=EX>S7EBL%\]&J ^Z32Y4(D&Y/J*E;-'RS."[9"T% RE'#P
MS">S _N35L] 2O'FS)'ZP^$1&IU:+EILE?C$OU42FS"@L>6;DJM%4F' UG02
MF!\MQ'NT6UZX.2,)L1),.I>]:(I.MM%D"C_P57$W9NCN/T/7[R^LZ[#PLU_P
M["]I]CTM*8Z@73@A?7'TMW+V'I_/2]?1XAU,_G9UF"<7D@RX*:>"%BNN8=B1
M2+K9MJ1M,(=NN3@2OG#P]M%SFO=8<GW(\V4I+"UT$NUE[ Z^==S8<IM-:/P'
MS__VEAL5J]*Q5[\HEBV3Y9:K5BY\<38Y)+=?G78@H!(C4SIRL)V2&"A#LS)F
M0KY )H2V#VV"F@'65X"%0[)CY1#J_/K[[.3D])MG!]/#0[^MVNQ]Q>2T"MQ!
M3A'->M!+D7:5(,:*+?^_Y4H&B9[4<=DPJ8VN<HWQ^S&1R'(K!1GV4\XE7OKK
MF?Z;P=.SHKW19LGO2^[G T./](>D&P7*5P*=Z.0HD:IIA9F3=W[&S-AS&LJ\
M VQ2L7]=,R/KG3%4_#_&R],FIY,"VB\C_O2,&78'?Q[N4>9@OD\K,\F<1"=<
M23\'.*TG^2I7TZYII6R 8>'UTO>!)LLK5]K.PA\Q@2O."DGJDQ&P\K@^=20:
M?H#\NYQSYLB"9A'@,O"IN@]H+2.D4%4"VN%(Y4W13%$AJCE*;)@DZ*F02E^%
MC0M07R-E1W I9/ZBMNFR7:16($&5]FMEQB-_WU$+DMO9P<DWV4]79W;$3T\?
M?<[ICL^R/\BY/_2,(.9C_YF'.SVS$L-4K<0Q$@,,H^I:#@1MU!L[B>D1SKK6
MD^[(,6-/TA"%B-1NRM2U6A:TJ['-Y?>+]&8IH_"-G M#"?/I,K"*GC_)S3(X
MV+*M'[DZ;BW&<8+EUB<5^!SS">%UXEKS>>O%5E,P7X^(#!D8Q^&#,V*EY*%H
M9G-3-O,CB!* 9;;L4?/#(W*A3PB%CYYV?E8X[CJ/>XZS]?$=C_47T.3>DONX
M/O_FZZ\/(T"+/_?#H' /68V/2QQAJH\06:#-:%M?"D@XJJ&GP Z5W_EV'&4'
MT<[A-(-77E9/L_])@7\EV+6F=.-SK+5U6]IS?H>S.6!W!=^V7 '#PZ@D7HV<
M WE%Q*O 75)Q(&[*=5"YG@4MDFY*K:!MO$DP")F7(8]<U6K=1E",P>.VZ>!)
MVD+_+X7MU277H\*T%9YQ/:@158V9_R*9PL9@^SM(>C\-NA*KXKU0,G)+(!,X
M3$+XD;60@29F!IOYB6W/7HV$(+CA'E>4>!O%U^T&N26RBA\WY0K#469\"1P4
M:-\?G\36P..O3[\]U Q$&R*6WI,,2K<5QGT[R[".AT1(L">42,^\@5FA6KL6
MVA_^(P+_,_$?%V)1Q"6*0=/I9H*X8)\32'?XC)U0>=*/X;VRKW,U$G;>O"KF
M?+\P..GS8.0WG'C@#2QG3@OEI$X<YW_HY3+\WA!HVF=T;O3]J8G%2$[R4/#C
M;5W.M7"/\:M^KL+]D'73I?7GY;9UJ#VLW-9FR5R%,%M*R:B\MRH'4,2Z$1[:
M\A:'-+*G$"#'N_!GD^RDQ[--9,#0!FXW2S=%,S1VH*8L?XM00C1U-\5R8='H
MW6&!&=*AAC&[+6NK:K>JX3/)9&"N;PHFL]$JR\IMI'A! A+'?&ED@K1)<CY.
M9"E&('*AX"2V&S1A<M@46DZETZ0VCQ89-(X;OA2KXMI9I5HU%T<I'!,:_?\Z
M>9P_??0-1OZ_3K_. >Y;<\ 56T5Z2"3;BO=Y.&><@,%.Y#377XNJP]<^?B0M
M/O.=9H'QU($911:!;_Z1)D@0AKCYY.E#":3^82!TCQ^-$+H10O< -N(;5KDF
M856 <16M5=^1I(CD7C^^&N=F)5?IY6P039XV77*EGW =\"@.#F21'F=V]! =
M$./2FX$^;.7=9K(%&X4F^>?5]D0GFE1HIF\XJX2?H0%".4A9+9:=DI+UGEHK
M(X:/3#I..860W$[L;K<\175$DRN;.[Y*23TLZ:7\C+5T!<=:2 (["6"8*15]
MK 8M]WTB&?Y8,NW>(4-".ED[$O0CAED<,NP5--J5/HWH-]",VZ7Y\L*7\JB+
MRNC9+FO:8-/ , 1RO:[RO^(4P,N+R\DD1)@^926F42?W@=.98C>!"P7-GF0[
MRY^P9NWLQJV, $MW]C;>[KT8# =II1ARNF4P*"ON(6..#C,(_R2)KC9JX(4
MHJ847(O98/);'+PM6L;+W,&Z])URC-Q!H0X?&28G9:M*XRW>19R[9<FI&*33
MP]F"';'[, 2W:-;::!N/8=5[9P<*ITF-\#;8N_!]\PBZJJ4_O=S7ICQZ;\D]
MSH0%<[&-W.= 52F.=#^^7E:W]5)3+!HHY,W!04Q^UQ&@(K0M8ZDK9W%04+S!
M:'/])!X'V"4= [O \*#0X.JZ*ZX-0UPV\<<+Z,$U$%%MRO>WS>:U$,^S<=1K
MPA/%(!E($9(1++^8TZ(-?=/:_C3R:#7>T#.:@8:1$$/2O:(??Q@/RGV3F?2"
MS4;30S8&$Q:%C>Y;NJ'VG(;;;3Q3:H_5/S#^ ,VBQ9B2R1(XCLA'6NGK<K&)
MHY>)*<)A +C3(2H6KDRS;JSQ!>O&>8QD)P8D=XSJZFG<<$?0M8KZK+M-P]WC
MIX5XT9;%2+HGR*>DP]UWD!>. ?&A[[6<4CW/.]W#S=\OKJ_!9KMA^J!J[OU^
M>HU=@E'XW\O#Z*7('$9M71@CIYD!@7B*RSK&].X_O<?T$6U"#X-Z\(BY(547
M:E.4S5PL2,3642.\!VD9'0,1KB%?S&):J-U8!;ED#P"5*)<' N6BJCHFPQ /
M18M\EAXE2*;>LMYZ!*7:SR+]Y0K%+%H[(^%WE* >G1<?&#%+*]GVEAJ0$Y.D
MT.(O\MEZKVZ[ ':;NGV0:?:A\F!0LZ<UIW^7PH!]ZX)?E5M0*<!)5^NF)-M?
MF*+9T&]]QFW'T@]C-]6^BQ%H!T "&),9 <SI<UTWLB]R/]L=\TGJZ$B>=F+\
M,@%;L\)=_$TWW+NP9C9]-EZ$=< )7!:2,I33B%0VJ 0-O65I%V*:K3*)3(&S
M2&88- 4-2H4VTFWMFK-;W.K)N-04G.Q_Q;G3EO<C!QM#D)'I^0<@C[0Y K!I
MUD'V+NWI#(WM#*E8]W=A;MLLKA0JYOA&%QK1X9X('B&WN]XAA>9AI*S4X^!5
M_C721<]OZ(^H@%1A)?%Z_MZ[&]I0=VCS'EX-!ISH(,$Z&P"'1D+!V[?;@4-A
M)R#7L )3FB;GP,.L8TO,[WE-37W6'G\HX<T_!$Z4X89G==-TZ[%\Z MEWQ3L
MJ+.<74H_0"?023K<)]]^_34@E)<3:?9J/B,GE2N3Q-.FG"(:P%J-V^V5&Z2-
MB[M%M]3L B))Z?FWUGQF'0^CVQ%Q@VA96G%(J:GLP.K%B1"!D'-G$\\09=6Z
M\%:5 !9[RH;+8JE-4SZ7$Q\F4@&WX-":C#&W>(MFO22]'Y'%LC ,D48?D*%'
M<9P)OP1YKY,>W5N=F%QI5#4&I:E%J9<H,M968D2T0ERF3^T]TKA5>,Q(8UZ#
MB26*$LWW8Z%8M]GLVY1S/(LYWVKME#SGSN(%(PQ2\P;9/0[_--F\VVP-TJA$
MOPQ#U"PC]!&M YSUF!)X:&E9X?77U1"6T +\&OF*^)(\G=[$]?$4]Y_>"GF2
MC..<96 ]ECCC3HV,X!3$E3'%BJP?[5*W"CI^S]N/Z2@*YBOXE G5J^]G29O^
MO7/K;%K7[\T,1L+80 Y(Q-&[-9RY*,J&R6,62R.?).U7M<4L27G*2[?6*Z1L
M77*Z>.WG-!1VR;8MQZ87)@R6\9Q8=[?C[!=FE>SZ,B.RG(W'%1>E:+%F0\XQ
MX"YB\8HY0SJ:+HQM7?'ON, PF+011[TW@GV.-E<+#S4H_;HN)<K>626<Q3V+
MGNP91(H^*2:/,R[?I GMR$V:H60:LG)V QNQNO;E40/VH8^"\6Q(TKAK)=.
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M8.TY9N)Y: :45Q7'T/\8-V&W"C$F_=EH8$#XV6D=;L*PVB2FW>4C?MB18YC
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MN<(P/I%JH%!RD:_'K4)FPXU8C?3Q_R!EP8@+WEL3X1<SHYW%N,L QB2TMTN
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M^^)U9).24-/3GJDS8?(-6BZH_K,!4+31$-K[A>O?7UJQ+Y0ZSW!I1G^(C)B
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M1Q:!%0(MTT-5<%+[H76OV8FNC]R\BA+Y'K@NK$7E/C?59Q=W7Y0*X/(7X3,
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M7:/X4 J0;2*Q)QA8S;EGRN@4/_H*\@TYA=' $H0E> E>*!4UC_1[-J'JJ'4
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M!6U06B-51IHEYQILV5TI6 M^9Y-?-E"E<:^)#]V#\3P!N.Z[P)H=T73XAY\
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MGK(? IS,RU2)WP>X=6/ XBNW&]G$Z+PXH/7"\(D3Z!&(D<T9,PK+*].IQ]]
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M)NH7]N+XZ?K@MI?[N^XG]^P>'*\C)T#F6-&WA[).'XT=$.$!C!VPBV$\"_>
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MSR==W/"7!NOFHEY?,_EH5_IDHG(Y*P/S-=L2+S0):1/(JE9M7[Z/-M5WS#%
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M6+;U?EY F-7J_5NU&P-W$@O6@VR+G%NP/F9I&GJH@E0:2Y'7ZSK9*B@Y"7)
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MLI^,!6_),.]O&N27$R 0EJ%?Y1%3K/'AZHT3RZ/DQ$%#HE+&=//_GB^^ZWG
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M[$W;6[/&)#V R:N8P+D',5N9\&K4L R4YY&DHD^/6^\HV(_,PM2[RCLOP-;
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M7\I0*J@]1FL>J/#GV<-9;$YFH *2$:.1"O-$A3_1UL[2]"!&:-UWBG-#_=7
M#1\ 9)ST@Z%,,""=FXW?"9^=65Q/QOC-<G%"FS3+Q0/.%_DCJ-TQ)/Q=PT9F
M,3N=/9_%[$&\Q>MFY7$$W_YV$8L,1,4D#% G=UTV?3<S))[4+LZ"\U!A5EX)
M2SK V&_1QSKJHIQI,4Y\+V?QF2=<_>^&NKX4W)Y LGA0BV98;YQ.E5BM2%&5
M^R$ OG6[7D&&0)KDUJ\^1 "2(E0T"FTGW3L"Z LMA&\T8A>"$T%])P#GC:M#
M_$N?].Y\\9W,HV$8F;!.O'&',%)K /+DMHDP_&CIK <4?V\$QJJ#=QB6.!R(
MQ.U HZ% X[$U2>>/8N"D1R!@\';:B# )\FRBY@/2N&6GU+H R7F4ZC][AB[L
M ?(KU]:.,2._[U@<8@H+G9^5 H5K@4#V[;4KJPK'A7E<FIJ)56*F2.E-9# E
MG5V= 3#= F!<%O06$Q#I ()^#/4=H]#C;S$DUS@8KIT-C:.W9\0NW(-4 0ES
MI$?I?/$#CPO#^#9&&Q^DH&*>_J*OW]1<9GF?/H>PRA2$,U@B^I+2OZSMD,=G
MZQ0/SV)FK[C;%_KYDYF]8F:O.(&#F*JLCIO M5MLC=)9O3IDXW8=Z,1,1@AZ
M5R!6\,=\"NM[^#^O?\F4U< <"VEC!UPQ-&>DM?%ZLIE'"G#'.HK2D<WH&1FQ
M'Z5-9]GBNJGZ>J^,1\Q+9D_"2!<V:_%#24=; A(+^+ P DG;2 :6[V;0+0.+
M1$^\[)FJ6='0,1 @F3H=$33X#@;!W:08:NN=X(E;76EY+\%0<]_%:-:C=;8<
M[T8-TPM'O=WF$J/?XB/LS7Z >863[57<XH)>+9:SE,U@.1@Y*F='S[?D0E?'
MHJ(LS&E#2YL?7FFM_1_=AM\W1<R@]6Z%*5J^,9?^@[NFX*][=]6VNW15(?MI
M3?E&ZL$R:F-75PV%DG#G-4J6_C!$R*U32KT0BZK.[X:&P;4MIG1US7I_P_&%
M_4%Y(AAZOA)U;1J>%BJM6SQ.5_4+_SD?*DHYCI7+I;%KL6&OO6;]>R8*VH%?
M,FANI;W0[K,)\IAL,!SVYLJ9?7'"2HDUR8SH@FU3N[AR/'-Z@IQ&1$:GVJUX
MUFW,2+#VHK6T,$9"DS!3D[O)%D^?D,IMWX!:DRD$X/]I[(.G 6LFZ%.8!N62
M=B2O\>(&P=R6EB%+\8/V:(^+>"D9HA EY#P(T9_0R_!01N5CT/6!<46TB-Q\
M])YY7?2WZ^.<(K%"FJ96"5P32J[B&8\B4+89<:QJDD7ER CFI!]]2&2")+9T
M.EN:*._LT<X7KP8*4LANZ  RPVE-_KKT]^T5 #O6B[0<%' Y7>YGC)O:K4K+
M'/FV?CI!)3M84TDI&:"H@'5MZO06FBQ\_A_.%U::S-])IKO"7"]4QCIR$UA2
M]##&CMW'I_0_L)7_P6W*KA+:I";IGR5'D]1_%QB-RKTTHQ8E$TBQ=RW-Q1WG
M"M<8BAEQK?SQ8:+JR=XVO!<J**(3,"0=MW%[__:(HH#..TH"-1/1W9.7\1V"
M("5OYO_-R-KJF1.Z,(JBULAKQ>/1D,Z];.I-ZP?WBHI-R<V4HPQ)1'2-\WD#
M2[B@)<6<ATS?*,3)DCA)TGT13[_^0IA)6*OZF*=UY7;9DW:46(V)C9KU^>([
M3F*^S9E.5TC/_LYO![#1"W9[,"KG!W(WZ"]GKJ"UO_S[Y:^+%T*7C6L]^OO%
M#R]?/*;OPS)(+O[(BY%("E0+!QE97^4WN"_;J(70,JR^II]<EW2!B-F7A$(^
M+;Y&^KTM'.BI5ZUC0RP<2^8LF4DA274;?GT=!:;\+!+C#DD<Q/)B:9+$=.'U
MA?)">+<Y3+>L, @N;.6-XZ)"M_CAQ:\?H3'XD+E[\3LCL@62A4U?%M"6X% D
M*17RODZ<8A(!3IO2RO<I'P-M)J<6E=N+[,<D(V$RFMM(1R9F9^L4X&2<1BOK
M"/_P*PF^L:>3CW\);W,+;REF FLTW5.Y>K._<IZC<(_7RCG\BDFN\-A'#!2Y
MC7[\N,8_<,98-O:>'K**[*UEIHPSQM6DAN0>@\W(PDXPA]+@6>4ZA99%^)UK
M4@8NVUJ"#[V9E,+J0Z:D+K-,W0,34F#.Y(T@C=Q%OE4@01?C)*D\[Y?$Q' A
MWRAU)QUT@=$$HD8S?S 1&QQQG<1ROMN)"][;<2[S8YT*H69[S"T[.M[A?/$Z
MXF$,-'="K)X0YPT]R %SR[NIV(_,%#\=*O8_DRA]X%CE<C#P0&FIPAR!: *"
MBH)/7WN*2,0HB/)_G9IU $L'FH,.:2O6J&4(2G'@7-TV526<O6L2[Y9D78;*
MBZF0,=A:IN[Z4M(>]F=;=I! 9EZ,!VS3*6[I5^?D%4(40CFD,Z3$<-58XQ .
M$H].0/*+ZP364'1,E/T3S^GYD[(K+Y7>&/M8V,0.48[I69B4ARBR5DQ_%0A^
M#?]O36V99G^\?S0URA,<>4MW "<6G([#CI=1^=*<C-W))]KC#,[I/:6!N)(A
M*$I.OG:!40\Q9*!&Q5H2.671;/K]BL>H]+5F*,\7/Y*Y:SP'=92;HM5P!#DA
M_YPDM+=(VV9.''(D:UNK7DG?57WPBV<03'$-ZX.(;'@' U3!UJSSZZ95N)2L
MC"2\RB57D4YAF27J;B7J4I!)?)CB>3.#T;,/J/Y?R4_B&\(U&QS82!M(%DUO
MI44(+L'[Y#$(Y,[Z'7E9S.2C@PE9-U"L@)I*BHWBUVZI<7_99J=^K(A4G1LC
M(_(.O"J6A7VS8HY$<"[O]VT>P[H\ZQYP4EM2!VH_VK)[PW%_UZQ0C$!6.M,+
MNWPOU7YU\Q!SRLMAC($4'CN]Y3593)__7B_"Y.^AR><* [,\;G)Y :8QNSW9
MO<RLVMMRJU?R&QF+=E<:7V'D(\; !1P<$J!2/Q;U1:\:Y?=52[^GQ4 QIMM6
M6H"0K!FKTOT(,,Q!^FE\Y.AE]\Q$68B#(.].RF63;D4YM:=Q=<IM^4%)ZEV[
M8:=XK_H8O*I^QR2.*># L#/C3R&7W,#(.#$P^MTXP##X;30;X=B!P4HGGBGH
M_7!6)=3FZA-8BDE#[$24Y9 V;7QZ9^U\Q]HYSH@BA^%'^OD(>2C.83/I7$6S
MR2?=EZ2T.9B-%K%^VAQ#Y%"2&YB>F [=/?!Z.*8L+A B*MF+)P5,\P;)UU;-
M2:IMKF@[P>E-2J2&FY6 0NOBOR!:['!5#:K*0<Z$MG41AGI ]_)M5ZP\5_&,
MDJVA2I4$.:\.0%@'8+>E((93XE[XR'TWMEP1IFNH1"-@>=!]3BCF!WJ/WZ$@
MYW-6C9RL[A2+;L%+R!\D0_>P.?N]V^[X=8VFRMVF8P*6+$XWJ+U+%S@8Z5>X
M;E?NQ6TE&R^.'AS9X+XZ-4"2V9]XL>D)4B@^+B<KIFV:\;X?*][WZ8SWG?&^
M)W 0PT3F=YK>\\7K'G-"1'L78]T=)[Q6,U;T]#.S"IC:7Y5M(3;<(;3T1/:M
MJPYQ-]!4L*$ #\:X=4AB(G#BQPMS&2*G4,%<"E/D&C%X^;F2GR:A$!+Q.<#8
MJ=OF _UQS H266WB3AS#GT1 M8_O/-[W7"F79M7@^<5SC23=(;B#^ PFIPN9
ME,&AM$SE;:@DCS^,V])PXILZE8DPH,'.*BLL.FGTQZ;=Y'68F&B8BI(T:;GO
MC;/<EI<D+6S*@URQRI=-RW\O71?+'&YMOOI+:U]-95:%*AT.G;?<L= CJB[;
M6,P61;_7(0N1[#3+BA=FQ7E,;#<))!'.BTK9V*?74#L!FPJFE?L>BBR$^G[H
M!LLE$#4K:\:5B 7I !7HLD-VI&VVP"P4O4>?1D7#O+BRUMU8*X5@;XB+2\.D
MM4=7LCF3:9?#DQ7KK6B,3#-6@IJJ02:EX >'2>3_D&Z-0A2:(5!]U?\]U5I<
M"Q4^U<$8\*#&LO< W(X:<:-.V\QC.M[;3MO3#ZT]@Y)'?<PX-&=\:(9)_(%P
M6/9+7J0$BS[S.V6(A)X9>\G'GD,M/6%V^IN/L(_X =I/,&J4DVQ5TP'O&0:]
M*#)"87ITK+I&DB*:2B\A R4&OVBN.F2V!6X_^+2+6U>^?_GJ(IXKLW8<O?.\
MUCT0?/'0I5U;7MLX569?0*-; MXQ03C2U"8 \0&^"8K)IZ%P7;%KT:I9[*\:
M  #39OIXKF4" P]X;SKN0('3VC*;V9=A)BLRT=41",3L<S^HCZ/M%_JFPVS(
MH4*\)DN!:@;G]\P?Z#)ONR.G@?<NERK!^.I^V]U57G$U1.M=RJT R]MQSA\)
M\R/BQO.71"SI6(4#9$*;%#/&HJD*N]8LI6_#&!7J[#TXDJSFX)R59MND*0T^
M0BRR;.?UVD!J#8=.R0CAW4X"&.F[M)QI1B8CKSL_?30>] 5ZCRG5=)""2_2J
M)$R:&@*E4,70;A/Y'C$D#/4Y>:@L*"%$5-$"X_7$*R#K.AK9=0<':CCA*V9-
MF7S50S66-NBD7N7$!*Q%OLG97:9'&,X7MBO:'"#R"4MZ#59=6*'CB9?'108+
M1G<]W7)%+[\6ZR/=,W /BGR;,W1S&5P4C(2]+HL>*5OY@CF5 ^X7,F<H:FV:
MIN#R<F;O)EZT0-'>7Q]/=.-DTZTX.IE,];3BH'A#Z/N]<<_$^^*D"*:=VWN=
MC2;^4+>B"TM>7O+X..I29LC\W#B&&D6P?YYX1@=J:R4 #PV,6P-PG!0B2UL7
M;7CF&7! 1(-T>+='"R&7-7ER6MQF)"/;(%C28I<":*UN4Y6A$45P)ER]$85T
M9KP?R%*)"DG41K9P_#YE8+RVJN,%@]/,U8X]Z Z%V<Y?)+.:PF]UR1=_O1?(
M"__IV]\D:59U[H;CDRS"8'MTB\D?/RC<>Z'!65?]V_/%18>&<CX ./$R9EX>
MD<=B%WFK(Q!C6=JA^KG2YK^J?*.9&Z:M+J-;^ZF,[ 9USN4!QC.;_KO'Z4^<
MDIH/:,-@/W%.Q0'E#R>U:VR1[1<3UM9,HQQJN9Q O2@D(N64Z.3X2^^XEKC,
MHY6:H(W,\"-WOCG/%J_U;Y_Y!DV]Q*]TZAVWJIIMNUCM'V=C8'5DJP?AQ-#Z
MTPTFA%W#C0FK::EI<PVB@?01-T+\%RDQ)A9TEI6[Q@W87%R<(NC7$KHLAT(3
MI-1;K38@*X,0)M^5174X7_S(EEB%2&T1RA!BC8L&U>/82L5>F/? (#")&Q:)
MD -+E"R.^UT_>R(W# /NS:@[Z^>]YA0$2YYP9X4NW1N$CN\1_M(#=$)!JP(@
M;5=F( "1BA<IAE($5Y$QP<S:6%E/_Z9F3.#'N!1M#=D_)HE.M <2<MQK<*YJ
M#%<GCZE)O MV#M#Y[_T"\4[P?H#^]#W1^^27\!>BGI]APFZ D+JDTT^OJ"[S
MT&EG73C\0)>7KR[,E5RZ%:TK()/8 _M;3OX.W>)IMGCVY-D3>6GRHREOW@.G
M!'EMB@B['"W%=*("RM9KM-A+%X__B"\A@;VF>7,D\JR,YO9.';0IU<71^_Z,
M4[KLZZA!%][!(R&"(1/17E&0YU16<'FC+RSY>E?-S2WWY?TG+5R$%V6G6]QJ
MN.>\!,&&??)%]MF3)WREQ779>-<Q= 5J)+=G3!;I%AR]E2_,)#(GEH'N[S/1
M* PH@@2.C!$3\67B0\OO>*.!TC^NRLKYLP&I2KC0<73IXEL2JG*G: ^VO;@W
M>4]<5]*W1'^(-8D!G=>2Z4R@^OP#II34KT1]=XPX&;6^^?5%?CDTAWKR0RZE
MT.=7AX,_9'S41TLAHN+>TZLB[=/LC<B!#DGFM27%2-<-CV%E-?$3F69@FUA>
MLH6PX>G ZD@$7JGG\ MO:\>V'=GJRU>_7.C9H?_2Z+B+D>I#WSR)&FL-]*32
MP0_@^P^YJ=;?/G[$I$M0?14<ML2AHG=)WC22'2I-?2<G.61'>&EH$H2ZDS[;
M3AMMHT<?/@&%D7PFSXZ]HE?AJQ?V580B:T7C[_/NC1SW>-8W:533;'Q(U-$/
MD7(HST?GI%NU/1T)2$BTE,A>&>R*?^OE*'Z:*$DJ.RD*58_M0"1VS5[21I4
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M;-_OJGU_S[8:K1QG@JF=&A,T_J.?J=V6W5T5<Z:-#,VWTFX\&N?CEI.]>-0
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MT4U15;/D#E.Z#YY[.#-(TB#S,SFZ/$/S!KYZ/  %N$!YYD].*.R :,[:09:
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M7CMVEXGQ:4!W3*\!G@]\T[\D"LRN^;=Z(WU)[DR@0(3O85L'(N!;'</>;2?
M:569 "L04M_[\>7;YKXTE-8N\N[Q].Z@7Q?A]^S8:W>;=U<378$I=9;8G]OO
MBT]K!].XM^M*71!2K1E)&IP(15S_QWP?'F]X(>CZP 9GE2O)J>"@Q%OH!N(8
MX]KWKF0)>;?>I@A)!#+3AF2[W\,1)@(]RH$6L%EA\(1);-#16(BCE$4CT#_R
MD$X .@4*JEOQR3&C_>\JVO_9C/:?T?ZW8"%R]L(<!N<8?=8TF$QIC#!*L9=A
MBA%].[ET<%<5.PW!AA223.9H%]KW?3AMRV$]EJ8F/MB&#U9[[RH=9.[$>Z-#
M/X3>EXZ*)&&!B<.@WI6+KH]X%UG5*Z^!NZ7<$N1E186A3H7@+;<E<+VX-E!T
M9#[ *T3>@>^Z^+UCO2+)E&&Y%]XB[NCN'7+8<\X]T*S^4E?$S<IA'$6Q.A5I
MAGS&C'4P+@RY:0UGS-B=I@8Z;J<=.T.I-1TSG9A&SB"M)X&D2:2X[(XUT,V6
M;"R?TH2,RDHBD*4[5*(41(&-AEJ<TE3",6 VP:2X)4!AV\ V@]<F1C(M@J#\
M#Y&*QR+(V!)%H00#D_Q-.LZ%B$U%UI:4"LR6).\UOE---0W^!:2!P.,E6ZGV
MJ+$&B2G,&)>CF2;=HV*7AYH_K+\^7O0A1I.]-,P$/L[]Z&BRU;B\]5PS=BD4
M7X(-';^52GJ3W!FK !/'O!_>3;YK[.$@4P+W2L\J;K+WEJ1!(PW]YX5?)#]P
M<$H_XD*F#(!RD)JT*A>5]-G1_B*;Q@9CQ\9O.0*:1:2$=R\S](EKVN_C0L34
M64-G\<6*0#$%)NPO(;@^D"@TD2,B*1V5(.8\^C4D *>K>_T)Y]KM:)7%3CI_
M3^=^LNQW=8[S7 N\CEK@8/=>7V$P'3$5M[0F>&XA<&S81JN"B]=MD*F,)/ZT
M;D+%G/$$&;Y*$.T=M9C, <<HQ #J@/-;W9IHOQK6*SAA"S='!;?V=+@!-H-E
MCH#>Q!1Z&*M!9GY:1H6K-I2^]0_T %O6MRIXE.I.SLN@KBG]%'([_\]PH$SD
M+TSFF1\WPFTF$8AVBH:9=P5OUMGSN.+-^CU/3!2I+*PZ;KQ&8K0DT(SM!$)-
MSJ/,M DB%RI>JOQ!&/[ 5U7#48BYA?,KP.?T(RBSU\S.+NRF>.*RE4X@V %K
M&KC=F2 ;9)/131E9AAI"KX&S-A!D(AM$7BJS.%=3E38ME.L+8$,U7UD=5J()
M&]-*2,B'K/?\ X[1DH7+,8^DCW\!E=%1%OD^/-4@CA?OX,[^RY)9$)T-'1CQ
M273V]2UGZH=;L%_GEMD;,)%B/B UM73MWA&!Z:+(FQ9[$%W/>NK&=_EV"8TE
M:,5J]$ 1C /F;"9TN$63/.^K&]A70WD/<DR'1 \#977&C/.A95R%T8ZD<%)+
M5Q->6QJ;$JG]8%FF#[\UQ,JD\<27G??O+5I,\_Z]X7,1.S; MSQUK Y IUR
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M0\F'\W2:E*+>PCC#]5. [/-D!' +UGC6P- 8^E3@F>F^TNZ(H"6(W?&KR(R
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MN[=&KME"O;Q8]";Q3K\E=+0C].K72VC30<Y>A&5D(XT_''UAI!H"M-Y#LT]
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MJ,&J*%[>) C''E1I=+L2Y:.4VA,=+90/P$ HE!O[_&RO0K-[&_'1QXQ$=%
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M-YW"?Z_MSE/V?,CQ]=)08S1G@ '?((E""3[\@)I,#*^!1F<8J&3.$"PR#DD
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MARO/T-M"I.^"]G8=%OUE#LJSO"HT.W.N/ZXIFY/%6R,]"P$;D]*?>XFI*;T
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M8T0!T+\/GP'#3PH,GX3W2I?5F3.WA%\#;9?P$FUG /,U )@IA7%DEI%?3#A
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M)-M^$^3SKKQ-2V3>E3?!W<!Z(D4N>U.:)N4@#*+"\VZY15,W[Y8;V"V_=WY
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M+]H!\_G;VL=M=&R\("O^^.&CAXE6.PRJZH>/;,?YBX^^??(TP=?9$@CF'OS
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ML0[_5:52U*MZ5E=UH=AQFU7)-%EA3W-JOH_S;X7(T@34UQ@56&G>OKY$<)7
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M$ 4?(QE<B%/$T*RG0176?"4D^1N/8I!P9]F/6]@?&?$^"W[++]D2&(LE<,,
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M0>\O0BV<6=AB/!B#O@#U_U'.'I#<IVF2D6E99TLP0S*,^(8F'5>SD1PX(>D
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M=+Q$@&(J8U6(\S\+A06RA'L*3,5<^-?*71Z0SG7<S%6&W UUMP(^24F>\@M
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M:]')ITA?A3'9#)^B:"3:)23,07$B#[UA;L![%E?1M2ZFMAOZVD[(D<4Q*JE
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M_<H*T2_8=BBEQL"?6T/A?_GP^KG6 AO=M[;AO?,12W/+;R6?1DJ37#;*#=G
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M*(CKFP" %6I&E3?D7\DJ/7,7/ZU7,*D.9LZGUSJV;KMEP07H]FEPVG6'E/I
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MD'M1TH=;V N >U'R &$Z[]SR<3I?-[?K9/QZ$65S%219,(N2(KB,TEH%^2S
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MX1;V N!>CCR 1>*):<="HCXBVF,QY <@[FFL\UW6&H#8CP2DGEUL3ZBP9SE
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MY6Y/;EIO^58M<]_$?S3)+]7S,/@ "F ">%9<![_EE0K>9XJ1[6-5@%FKBDO
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M^4ECN13;F))!M%I<EPE<4B8[1D9&BE!,<HE9+>@UU=K+J%? DZV8*>D&8$6
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M^&H9)+A_P. 4L>0#8LFS['2_W?"^+.0# <,HX']YNNSAG@\%7&EMGXJ9#YX
MR9<":^-Y"B*7OEIO?"/-LBWE_VR>Q6]<G/R9B-?'[&+CC;A<#]D"X.NUF 3R
M1J[:- 15\R^(5JZSE+].$1M@&07!A#4N[_T"GP\+*/-^KH,TD-CWNOA^?A%<
MY9<I-^)Q_7YW9%M8OO[7'S-_QT5FMV^.[KS&N.L*JSLTAX^_33V+L;N&>?=[
MK]X&?DC6-WLBN3=GULUMWBXJ5J_7*?Z+P@'4EIE:KV6^%OYAN\B((#3HTUQ
MI>!N2Z_:A1B%2!TJO6M[9MWS)GAMI3%11CG* !WPDY]>]%\\+95RN"UWKC?+
M,)$X@./BBA93GIK*VD"[..)?:&:_WTB>5D-X[V"+ZN-@4YK 'XI(.VG2IE.0
M*%,;94[AIFX2E!1A4:K7HT8M4J-'HD;1&Z6&F)+.; WB/B,EU"L2(H@EB#75
MD$N"6/6/)8;3L>SAXTD.FZX:#C?0^_\)TWR63OYR'+*[T%Z*=- @6O'HWT>X
MZZ+TYC%G*2O/17X19E!46.^IAXE,RIJM1!HB#9&&P*VA9"+2J$B:@X48JGN<
MWZD^\[Z:.6)6]ILL_OL6W)7IB\O\?S5.[R3!S^?PC.+FN#L?('1/*%\_D##M
M)TP-Q,Z7CM,9#9XJGD0R61?=7I%,DH(C82(%1PKN#@5GP8'<LDDF&R:36Q7<
MP8)V=-!O@BR?B1+'6@[ZY*I3U@ZZ+VF:A+FMV/#&RT(#H>^EW>G9#DE4&ZP8
M$DE23VH*4RLVO/&RT$3U9'5ZSH DJ@WJB:+I1WW(_K"EFQ[Y1]MFQ=3JV-RW
M4$4Q;&X%8>JO(5)4MAH(I;UA9SA4(K9^[S(B$E52;Z3>2+T]-V%(O:FKWLR.
MU2?MUDA)I>K7EI[>L?HUB#S8^I3C0 CYTZNRB?;6,8"R5[;LQ)[/"R1?;=M,
MHEJ]K*N(:W4MA%QLTQQRM8TBM?VQ#TU$K%GL]J>N^@+:0 PWC8X]Z#="S,FT
M4D!<U1="TI*D)4E+*BR@#=22+ZU1IV<,&R'GRJM)M07^UC0%^!<'+#QB=,9!
M=O1Y5=[#-\.T'KL;3]<#\,!L-W+6=G12^LIF[(I+P-#%:.K7++QAB_3-"^U'
M8L1Z&+%)HX.>8*)TI:6=G*LE.MEI3(NJ'K_[NOEPQMD/L%A'@S6&.&VO,HU5
MC,7B&_WZY3@LEHJ!?&**53Z$&5=2>!S+E> #K%&W5SZ@F+ISR]W-+@XXOW,-
M'?%$\92\L5]EDEEE%&BQ.Z('()O-DOA[@$/;P@6\>[\[K+R[F(K%Q%-U'/RL
MB^=7MQ<?B0/9Y+RPRGPX\:)6UR[NUA&CT^1<N'@\3N%[^/AH]6YQI$LZ%5-9
MX3;K2W26N]?5SJ)R&&6Q[W+"-+[T#X/NH'R;;:M>G=,]83@O>\RNXT2,-/(F
M++J2D^;P"SB-L3I@$=]PU#66:\%!2_?X/@Y+FR4!3F/"67DX<BP?Z)L/Y?VA
MM[R[EB4L2G'&HQB3)J[%>;'B03Z?Q6D@!N>)V:B\F.,T1D',I\=NG117'<(N
M1Q.+P:W+67MBQY;#B<6DNE/4:%&$X]S^"?3D"^T\P:\([CKK:!\_GFHOQ>/^
M>:Y]E YW,:%V4QQP2A//AU[*:<R 4O$4I\'B-V9L44[PNP:VCY.TJYVO\5%6
M".@]]CY(@3LK4BC6LV4^*DJGV .<"5L,/I9+*J;!YUQ7OJLVFR<XLU>00^P<
M<-5,3#+%@:_5F^ (^/A&#%O.APPN9^(E/)BZ<"><GH<;4SPCA'T!2/:/;R#=
M4S5*+< SV%)>N;<^R&+@)?CD!WO)99T5N!.JIB+@Z^HC9=-B%ANN1NH!A)AU
M(+M[T3<LK2"-7X[5%+>18RWG"4A,#K@S*<T+(8*H,6>26:,=@[4?("3B3> 5
M=GP-H7%37-+E#/&=(O(Q%X]\^GGJ)8%;CB#?MF';5"3)UJ%DJ]I^>.N<\GO+
M5V_8'>T6L-Z@V[^_A$5[+W</Z\VJB%YIJ@I^_:'77]I'XJ'P/ _T1;KDY^K\
M=UC_-$8VB+UO'>T'QZS8J7=_&W3T%'Z/DX7V*<ZX]CGBY8#U<Y[@?.T 9.0K
MCM+]&+-(SHS^P:AL( +%WBNLV!/O+\[/)9A\AP<%DC;RHGB6CY^7>%#>_@;G
MCV^S&*6%EQL&=[T7DG3Y1M(F'2Y?2+XB_ *0B8-OJ^;&&<!;<1P8KMIXM;*'
MN9L]S%[%?-TD,([O//GZ&V W&'$>;A%/Q,#Y[9=NVXO1JNSXAR+O-C.^:U:.
M!N46W$+H'ZQ>A>$K[V4.*^\E#<T?K*5BG57N$FW9BGK0_O&.HJ;-]MTYR1=^
M2O*9UY\KYPND#!Q IH$<SDQC?D>8F5?7KJ].^<UG\J[.^I6G:Y#E4!Z1*G2*
MU^CD+>F$AA1(WZ9::^548 ?.W*/>W=-Q;?/1@W@'W6'/J/YGC\<>_<(&+5N*
M\_BE#+O6:.4_--NY_E""TL-[:#Z:0G0H1Q>80QJ0IDYP]* F[WEQ<$3?&IQ=
MI%.A8)%'OAINM.YT^\,5D$?3\;XOW>\.[O_.(K0 AN%KX<L+KOGN%!13D3:\
MK1$$17"-+(2F4Y L!(7H0!-4C\Y ^(KA"C4$LS5,H))(JT1!Y;-K52(<8?'1
M8?%'GJ9:-F'17]U$^_%OIHC.-4*RF\,4*HFX2A0D;"9L)FR^I=874R]L"<P(
MRXJT6FP-0Z@DWBI1D'"9<)EP>3='.(C+/<)EPF7"964)1[A\=+C\6RR*O0I?
M1D\C<&XM.%.3PGT N8'5,6_C)!%INS+W-D >Y&FF/7_^R,:+'SJ#Q%)D0I1B
M3*T( M'P&H6[PBC2!HJ:.QUB<H+1&0U-$LFC[&>HV):3+E*!"J2+2!<]CRX"
M$HUZ))&DBIY_RTD5J4 %4D6DBIY'%0T[O;X2C>$5D\A60""I(C7HT"3&)U5$
MJNAY5!'0Q[0,$DG21<^_Y:2+5* "Z2+21<^CBV1[9X>$4@5MI&#O!,K:J:O-
M81!=85M)^&,:^'GK^^/+VI',_])6I/N+8JS='&NLUB'4BE&A%1M.QM0S'.R=
M3G_PT'@G252S)4JQ+2=5H@(56K'AI$J>89"UV;$&%DG444J48EM.JD0%*K1B
MPTF5/+TJL>R.8]@D44<I48IM.:D2%:C0B@TG5=*X:"')5+-E2K$M)V6B A5:
ML>&D3$B9'+5,4<.8EJ:>?"YG5H=RTG%E>N/QI9^\=*AI3+--J5HS#O=M.Z88
MM5I!F/H[PI%I5A<C.,/.R'IH])$DE"24VK&2SB.)(IW7()UG=:SAB 24!)14
M7@,)1Q*E*&%(Y:FK\OH=VR*51P)**J^)A".)4I0PI/+457G#CN$HT1R;!+2I
M DHJCU0>212IO*:H/-OJ6/V'UG^0A#8\&VLU3:ZZFSUQH_KRL_*=Q1W,[ZT
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MZC2>PELM-'$,XT*<8^T$9-U'>=<^Q5W-UN!/>.U9Y ?:R?D)2AZ\#*A7%H8
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MIO_"(F%3Y%FD>=::" VE(I-+&MWB.+4"P:N@__++Y]]?2>A/93W#LIRABO1
M>KA$W,7GP 7H9!#:"K]C=,WE=U@8PT5EM42E@F)](85*"?C&H[O:YXU77(VG
M^8&_].;C'^1&\U+/G"Q9-(B$LV7I>)8Y]L)-4"8"N@M) :3^DNQYLCXK_# B
M8<T6=]FO6N.<)9EV=O9DR6MD>E=-[U_F$=_'[#;M%IL3RYC6682UC8(W]5-@
M^B#3/L8@^^EK[3?I.ISF,KWRJ6#3;3=IV);M-E$06*698EO]JCU?&M[3ROY4
M%%.A-TIGD2<W+I0;AU;P$ADDS#[)W:_F09$S+5S*(KHMM29Z@(K*H0)-EWIM
M%73M-56%GB#I9D-_=/$,&<S+LZSD9R)Y 9Z<1_J+$$*AW\6J<NB&:PH'5'GY
MH3U%CT_Q;9JK:"=(3DO[1VCAMUR<3R/M_93C!EQI?T_B&U#F90 >*R% &D.P
MH*06PXOR3TF%U>YF1Q,$WN$O?_H.FLI[PPNR7$FRY*4%\F/_C3"\<M,30*5J
MJOXRG\Y$E;#(X7^+,2">IIBZD&3S&0 2"-[+7SZ_O<"?  -/A*6_XWF=HK--
M)KP<_C4KTXCR/C4 6KQP,HM4*^R1$<]3;39W@>.*&^6><)DO*- P/_XO;<\R
M_I<#I' K(SZ(CAJ1K'V0N:<88UJBQO+6+JP1;I9).T]^U^<S+C@2KKL*4EEW
ME2^NZK8)P#Z;S9-TSN0QXX++% ;'<(JMO6")RV W]<_?0[X0.PF?6(9A:2_Q
M\X)XF]<5='O5*?>MN@W5L(8($Y26JU0+W)L+/%]QN^=^=GDB@9>1VR#]]7 V
M_;ZHP&EG^^YB21J@#APGHCAR ^D( BH':0RZX1HM7Q$MS9^_S0Y049PT191'
M>^I#^E0?0O4A"C"BMYZW)/+& <(XMG]*F#>99\L.+B+-8+OVRI,+EKH+U4"H
ME?W;-'1OB,3:7:JQ6VH(TQB4RC?7J\O415E6N/,N(C"[=7FPN$P6^U><1:7[
M2=Q=N"J*50Q>LE<OK5<OW[XJU17 =B+]+K"DCC@-B%(_478@7#?H!8G1+W\M
M"CDJ^K#PC4A7OG3?8X=-S$Z\_6U\T&6+U7- Q5S8]HA\\[-)C 'L\J\W(HE8
M//HFP,B%]"UB7FAPC9Y#^51X/_*IU&^0BF-;Z;2,[\^D\!W);7NSFDPUB"7?
ME!Q3YG3Y<X]7O7JK)E29TRUR0[;R9R <ADOO:7E>W;86\>K"U7F3'Z_1#^F6
M&1:%K98R.'('6$"+Z\@S(F2#1Q2XO5X[S05LQ68.2O3(.TKN?*G"<8]0)\*1
M,JX(5ERT44"<RG7'LJ_-CL>*8&59+DS25;]T"8:2C8MNP],"&"L1"'1$8ZX;
MD@\KH_##D*68_5>F6%?[#@65^CHATS(2C4&1'\RNY<AZ&WF>8-)KG6>JY[5J
M9=X2W. _\#'00(8@BN-.B#$Q49 ?BOHM'YX//W56#JL86D&??:;],#",LI72
M,MLH76JK"0_% 0ZS6ADP88B!A;0H?EOF4:V_F73YYL6'J((2SG6Q"446Z<J[
M&]57QV<!A43?, 01G[M994UYZ1L6U4F:K#?XZ,DCX/8>/?#6XQC;317GW'$P
MQBV)(LR,3YE,CI?GU0"#_H5(BE <?(F*U6IOTU+&C<)%V2YBR=-I[OI:^A;6
M/3"KB;NB=X%IO!R_>FD* ^P+OQ)13."N"_W7;NE+6[]A$3C=[6#9HO@J91,5
M#XHHW$)'4![VQ"!H)[<5A8,H0O/I)A9,*KR A;-D>_1R'::TG9M2P:E]H.AU
M"5S ;M]XMCW#$M,-=V$!9DER#JKS!ZNW!!-6%@AB&J?X$5 ''RVI-GJ#I428
MB%TL"_ L@4.KJ(,18"=JA%=0L'@6;-,/9@6Y\A9OHKQ/-M"0.[E\W2)Q\O$O
M647,![^D*BYU>337 O^G%]AL\G+ +O^#3K<@$T'_2Z%C\I]SGF^\]QW187#2
MU?Y1>5'!'_\H7O:I8FP'?4]XJ7>5H/N)&\\S[3?)_E^"]%NW-@_B05^C'O\A
M*=OU^ ;_/A,M#T76I& *S,<O4FCB!+04FD)P0DK2$BG=/(+1+1A)? =4D$S!
M2<N\?OP"1DPE(*).+<*,*S%&6((\IOIS+@^;:(+QLGX95K.\.%^FR.?/^RHA
M,BMBC36J']O^B0QEC_8O:.4C;JBQW<<BC^-*-7\0K3:T7X:J9-5*(#URPJ1A
MZ43F%>,/>*H#BT<&G^3=A7.F<LS#:XL8G0NWC$2#E4HR&AYRYYGPDX@*ABUM
M^84_YY9^BV"TV9739N5N>?'-UE[_'Y@GB_CD^7+"9#9D;A<B5W*T4@H74-'Z
M#$_D[!7N'Y8AZ6$<?Y-/XCH8>Y@IAT^X^/SABV@($:=YH/+TM_<8?I_/M+/(
MZ\J3IOM*LX&C1?\%?/ 4+/EP+M=1]FK0),?B@T=P<5?[N6R+D)]JMG><]+GP
MH HC!+M!2 ]:T:EB=8*!QV:25.D-_B1X)1)'%(35,):I?JO?$8P%)H B.-D>
MP3W/@[UY_2LL_FJ"-E;A>EC2'(]L>3YCGB0KA+F(SB^3-'./9)JW6L)< 6"G
M,??S*ML@DK6F83 -RLZ NT1=P,IXCJ41XDR##:,FW/LFDTUP*=$W+677(C^W
M>'*G@B68@ LGU-^[%]V*&H8U@-4\SWL&_;%L0"!*(R:P\_#5,(!U^.+:/&\-
MX_D 9&G1UAM(+QNW"\V>(0[EYU2L"!0B*EJ98$U%T4=F[06+I\/6R2;C\*T@
MRVNE"]-"5A!WR@-@GLXE#S;XQ,Y:SG#U_8J^%KEC*XBPD)8$Z:FZ]#)MLIBA
M!T6VOL03ORQLGL5!)/K.)R*K>5,QRG!5D>VV+*O\P:BTCL]-4D1UX2/82($K
MS=.=[3T[JQ7\13^>[2-QRC$XRR;Y52680T@I#:KX"$I&6[H)AI?E)ETNO527
MZ7Q6A%Z2IIC"M[H)AMU*$NY%\:*M< _D_94K%%M@RQ%&;@$53WU/T.UI9R_E
M=(5'?. 1Z9]'UR;&4I)L4K@-<-^_%Y;XUAMB2!H-U@^ZJ0J^K?M 1Y?Y@>LR
MB-#IN;3*+]$<N 13J17@-EKI6("4?E=]66G[B*+U5@!>E+&< 2N%^/C62X1?
M^DL5L?%: B^?X-2MK+2SRSR5.;T4C65]=)>W0\!/L-62?+=6B+ 0U_.22&2J
MJ(@E!]W+][(:*L]66>)UR>=K+*+&UK?GJ/['TIFE_>5/MO.FD@CA54FPA-*.
MN$Z8B^C3%&[78"5?X\L\Y)II,]WLO>28T^/G;<LJ2;/OBTY,>:&'.;(=D2E0
M_:"SS-'S.3:-S9M3":^9_*Q:EUP=2.+RRA@P=X&C.D2ZARSC* HT,)=*-#N?
MN],@JZQT97EY6SJL!.\4S<KQQW0^1<_:?_%GZ5'(&U)5"H@RH$J>(04;-N->
M, [*W.*JL[Y\XFD\G09I*EYH'N:?XDNFA=,+UBZVOOKN@7#YR>I^[A<-4*;S
M" O3EDT.EQUVUX,!IY. CV$513G,9TQ0S+L?R\^6=E7^F>BE*IH\SQ),JNB(
MD!^F8HG7#K%SN!>DPO&6\"N6^)42I6K.3=X@6K0%SHVXO$RR6-T>;%EYMY6^
M>KA=^WP]0N>[:&D\@1>XX:&HB<IG#HIPRDQFX'5$)G:>)BX3?]!M%4>RUPP&
M!)B;QN$<=P3[A"5,SI[)&R#$11.Q,MGD[N7EK0DSZ2+>X_KE3+VJY$RQ;<UR
ML97555+25[.W@@IEJ$;I6&N4!E2C1#5*"C#B/D"^JN>TB*.^EA&P&Y:N6 FR
MZ@5;OY9MZ#%2M]0]LB%WFNDNC\# R62$'C7:))B).2TQJ&J1TWSGRF0?  FF
MLJ7F8B_DQV[M93/,0-1B9;(M;EGW4VE&R=PB9AD&WW@83&+9(#8?FXIYEUEI
M2> P!%1FKBC+6M-58GURM2)5%6P.3)D4SB4/+()K$9O.4ND.Q$DU6 $A;2@Q
M%SQ&HJ&]L!S9FG?I5<0=TQZY>%N)6@5)R<';4UH+@U3.QZCT[=G=6*?S4!NQ
M'!4@9OI(<ZR3+TH8L;XP'/>S\< J2ZHM.'*#:JM!$^((#47XK!5']=]*2%WF
M0B\YY:SH(Y ?W&4?@24[E&TNU*!(>R1_219Y3L6>DU(C8:I9.=&B.%<5IWW9
MC  SK3)^CR80:TUO.K>Y 5;.T%_$439W"HQ?=;7?R[-V.I]A/_JT",R7?<]0
MT04882_\0P\^I]Y(Y3/WY-FXBH\%.!:@$N5).O=KCL&VISRL91/ <1][]*S,
M&2D<+QL")*7,?B-$ZTK6?GU(V)3?Q,DWZ8/)VW"YBX(FTP .L"*[]P+9(!95
M%)^3*P9GX65_&KSX*X"F#X9ZU=WP\O3SQ>=7G4IK>UR -BX>VM7>5AMR8[.D
M-)6^A(=JA^V*84OJ2(7I_B>]!V'0XELJC.WD6(8],5\0]D 1M=$>D!+]M,K2
M'Z$SREE"^;@_D7R9X32LPIDG58N4Q+O;RQ09YUN*I:OB!A267K7-.OY=7KB\
MTA@."NNUO(KP22O,BTKHFFR)9Q+3=[+L#N4BKVO;++>M '+"I4$.1\>5 74;
MLQ#R85AR:'ANJR_D^70ADY[7OM"YG_I5-A;M7L;)9<5-WW0AE6'HMUWMLRB#
M;440^FQ)'@I JZAVCCF9Q;L$YH1MB"[_#=B<^H%HF]*2=);3;C7B_Z6,$'Z0
MKZS]4GUEJ5K.1>%XA@UT9[*%#&6-'*?09MI)6:JEBOBV)]XWI'C?\\7['KT9
M!1\*18)>M,L@")JN,\Y/OGS5SL[.C@GNZ[<H3..RG&YZ63:?O13>N/32BY-9
MW'1&R=L%H7&1OVAGU2O9BF.+()CTK2+11&GPW_& +$9XD%%TG!Z<KZ)H9TM*
M9!'B11"0$99\CB_Z7Y;SCO&*R"L82KI+<58-QY"J:$&>K3UAF3/IL3P%000G
MY)CW7?RI_292[5(9Y'#>O,\;0LHLX'PU>:(IW$+\5%Q;? Z'@*+_N,?EM2MS
M9M"%="YZ=9>5?GEF**9]5N),>_B \XQ.TS*P_U;I/:YVI-KA*1-EVG$4Y>]7
M/C2-P7@-LC((A5W%<07CO-X9)T<4 ?G?.,_R+O07.*04^XJC](NN>&NO^*JK
MG>9I(7<S@DAP%!.=*HW08QF;$<RP41&VOJ$;Y)>T6N)M=39T0<&5>='P4I_8
ME/N;D:,* ZSS)3H?8455]E3$&=\>+!%ZU#%ZFQWW-.R1(%EUM9L^I@Q]B^*;
M2 O%\.D@%&R;X*S?$*]Q%V):2=Y@ *119&"S(MI3Y=*R W0?^W[D E>-*>=C
M6BHK@-]6$$#(67X;3$7*4.P%4PDQTC[?1,!EDV!60@N'!?]GCHR]^G@9<L@9
M<H<H$)\^;S_E8L(; \SQ!3N6 SI.9?!?PCO GU=T_T47 D_SO/4BV%@"H$A$
MG\[">,'Y1O><<U"@@5\0?D?PNQH9WXQ^BZQRX4DOGZ+=3.)BM'TEU('1DTK
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MAV)6]D3;:@V?1;!OV&WO"ZXRU4ZN$BX LB.'=,'E ,;K@WC$![+;D_QZJH4
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M857+'\B6OZ\MCRVHRJY=6*E\S<*U=F[/<=PFL_YQB&HX'<L>[H^H4=P<*CQ
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MIOOAC/?S))[!;B]$GUML<3N;P@>B.XH:KB,RW\F!H8 #@WRFY#/=Z3/U1M[
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M>@-+[_G<U1W3!(UK.![\-&:.[?&^;3EU)$:0VCT2M*'DAV/W?<AADF$<7>D
M_5/*=VB#)Z16!S'-5E$V.$,CHMIGXHW'SG@H!H?WQV"N^8X^&K@]W>XY3M]G
M)AL.ZAXG^2F.O%HG2HXL-?,F",F:BF2;$R45HQ'9!B11C9(HL@V:9QL,>,\S
M!ZZOPP_HRO%=?60/A_J@QT#56Z;)_'[-XR-KM@W,3K]76QT,(5G#74:[TV5H
M@J3"X"0G2$8T6*&5]B'-Y574/J3QXF0?WC&<<N3QD37R=&]L]W3'\9@^\OHC
MW?8-NS]V#+  67W#*6LV#>U1IS>PE P3$HJIE\63&WCW]ANI#V=D*I"0D:E
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MX0Y"'T7=))3)TD@WR3L^YB#JOI;P:Q[-*9.EV3X2\B(KON%DG#4/([<;9][
M&[@NM_5QSQF"H>6,]-%@T-<'KCD:\I'A]9UQ'3Z24[@#/OF/()N<SE.@%$\*
M2VU1IYTVHF 6P9"26T[Z5P4JM&+#2?^V1__V;&/LV?K0MT&7NJ:I#\<#6Q]Y
MH%S-_J#O>AO=;Q_B''DR_6MVACV#-+"*0$3I),?N)RE*^&=Q(C H'FOQC"<L
M"Z(K+>0LY91ITAHKCIS,BF\X67'-0]#M5IS!C%'?'@]T?^2,=<?&,5?V:*CW
MF37B+N.L;VV$N![B1?E<@/5'Q.H#V6\]QZ8X5U,AB-)-U*0+"8+:&]YX7=Q
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M)7,:1+*0@"3.KW^1"8"D1(I2D0DR,NEEW1*$-=,]_)P3'AX>TGJ&>/"FZY)
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M"- @D]0@4!0UW5S8V]5)7%8_;FNAGE5U#Q OREC9*<R])4G1;/7NE7__@?X
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M<-:(0/&U]8BHA"4R.41D]QGJ(M+,2\0E(<KYI/,H>CPF)F(FE0 Z!A@JS>#
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M=W46%ZWM8@]Z68UXH@_5I46;>^P3D_&!'>RD@G@J-YZ 5R .( Z 5R">()Z
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MY1?$4[GQ!+P"<5!T',#D[F%KTR@7D4:%E)(&\6@#,C3/]1QG44LON'1RWUW
M]CFY,S"Y*P^/H /81$O3?HWS:#>5:<O8KI:U7\50[4Y?K*'=UZBG^E"=6[2Y
M09*-#2Z_TNY+2^*X8PA;AA&W@2(3L4"<B8B3YE@2.\@J>%=C]G.&ZW#8G)[%
M16N[BSA8+NWB.)[F*_SY_/(M[^QY]]3!1[L,KWY?UZOSHT4&^'7W9/MV=1*7
MOYW8Q5;$_35C?PQ'BXW&&ZZP32C8: !0!ED6H'2(@U'$P?@H&;:10SR5&T_
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MG*)[ZM^TH[5?NG_O:<',,%7D<ME(P7J$RVK%H?W5*5.^_?*<#/II3"$Y"<>
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M2 ;A JX957.;20GM$>8$ONQ F>J%77A8K9XHM3VY=&5);@+7@&L R0#)(%S
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M0MYT.BUH@YRG(<LVRH+U C-%[M]F[UO"[B\=HK_: GK_S.XDIZY7]3!M882
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M"Y,P.)#M5,B6ZF1$("D3)\&(8XJ1%1HCEZSP42657[M/[\#]DJU44+Y5).9
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MG]H\_-)D%T;3]W:HC" MPLQGDGM@\/(B9)D/9BR7N11)X86"R_V9OFW8@3Q
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MG_36,(8T]BG3/H!ML+[A9,/T#EV?"^'@X;@!12,)<LI4<Q(&^0U]IW<?,RF
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M*LNQ0@J+X,":XKJV70,C[.*$B2D:@WN4;0*^$X>B:L;ZR$? 9.F*7"W2P9!
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M".%D4&<\=X2=&6%G#HPH/UET3,\S\)CA"<-C?NQE)XU5U&#: +0 6?.O0.&
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M/ 1I&>8Y\WD<HU<D6:8RQ5P5)D6:RSA.-NIBOT=H_E;CUBQO?IOQ^1(';EA
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M)4*J("DB5Q;%O7V.?_ :+*WE>QM'&YV-QW4VS/X[[0&,7L8>9?IYL\4C0%$
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M-[6#YW55(!PF04UD+23>D5DG^OMW0JXZJ>[Q/7#6_8WRXV.MNY-+"ZSB_$Q
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MDJ (LX*OQW"*PA-!Z(8L2\*8A:X*62I4S+PX+5R9"JG\\'@FGOCI)$OC@RV
M^2K7C:;J@<C' ]OVT189;9'1%AEMD>.Q1=+8#>/(#5B<N@4+(Y&SO%"2Q8%R
MW31*).<;!;:9"%-7Y8*%69"P,"F KB(!!DGB*5E$GN!A>CRV2.R-=LB)V2']
MD!G\C+2U>UO^].3,!*!V]85 CKYW5SS_OMOR>%/#'UBLOF7;ZA6.\$6\J$<C
M+2=-VWCS@E\H+<L8+^#L7O#9-;]I7O[D_.?(7#TY] .X*U[?EW^NFF59W)P
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MW21EJ;7JLO:41$F9L,@;*Q G,B(K?$3:60HL(9@5>&=Z(L7:1>(0%1X^(V5
MF@2'A&51*YD7D>([9^W_G@=F'"RV8EO%5NSV+:1GF(F#Y59%EQU5 'IC0(HQ
M[P\M3DD BC$OQGQHQCP*;I3W#$DO<W-7Y$@K1Q$U@48NA$MJISY5*FK!ED?D
M O:(:YLW^X6$L"5""AMI3#N%T]_$F"O-BS'OLS$O">>AQV=RR^#%=!RJT>75
M;-H.NJO[$WWM&85/"]O=EQ9%'_8OL5B@60^UYH&!ZB8P8:A&D5N"N&0R+Z9B
M*$CMN<&"<&EW]L9J(DQ2%@E)%.*,:6098PA+*[U5"7Y6CP#-Z!F31XVS%%5T
M^JJH9\=>;'%?*#&80R^V>"BV6$@AB",)A=C,S$@).9T"?!]/R1KA?=RQQ=QQ
M[D1(*!*7$*?P:6UP1"PWG7MB*?7V<6PQ.[PGJJBB'JBB4L8R\#!)GNZQ (5?
M:ED&!LM*R/@$#KW LM/3F ?&_FB*4_0*:2WS"!\MD<4F(.*DB)XX;#79F;.9
MK$M,2*2(\0#+*$&&R(""]O!N)6C@X1%@F>)'!65%$9V^(NK9L1=+W!=*#.;0
MBR4>BB5VVDBPO!9)UQ1X1@>66$64(E.4&6)(W-E/@9-Q+AF%',G6.WF.X H!
M):(53D)2[1XC0*)N63Y1%%$/%%&I(AEX>.27Q0S$>#%;[23,/Y<JDF$ LQ(N
M/H%#+\#L]+3F?F!&#&9"$8FDSFM%J O() /DUQSSQ"VS::=;)X3DM=4DCX3'
MB!L9D1'6(6]EQ(%YF=1C%/BRXX9(BB(Z?474LV,OEK@OE!C,H1=+/!1+'*SR
M/+* ,%<6<<XTTD01%&0PC%AEF-C9NR),8#*;7F4Y0SQWV5BM*?)$6B^9P<30
MQ[#$YO"2@J*(>J"(2@7)P$,D;Z=I_M'.8G^"]3VCZ6E!L1(D/H%#+U#L]/3D
M?BAFG#;))(:H-1%@%:7(93R6HG8F^N MVZD;D3ABX:E"4KE<-R(4LCA0%#P%
M7*8DC>PQLE6,EI[GHHCZ?.S%$O>%$H,Y]&*)AV*)0_(1DQA1"#@WN=K<6&,\
M2CP$%8GT0N[4C3A+7934(8VU0%Q8AIQ7"A'FJ;1P.9G28\P?*74C_59$I6YD
MX$&1?\:+D1^72I&!0+$2%CZ!0R]0[/3TY(&YKI&*$#%#F@: 8M$9Y(Q5R%MO
M2'3!T;B[0YLIA5DR*(AH ;X)EGN<.?)1T<0BCER81X!B1I7T5-%#/3[V8HC[
M0HG!''HQQ$,QQ#YQ2DPP2#;S51T/R(8@4< T"J>5Y'%G)JO!C,/''/)",L0]
M%<@8E^> .>V\--1Z7@QQT4.E3N1IA41>32?U?+;HU,NDNII-?:R_)D)2DE7]
MP0A'C1'?=4-=SR@V&.(<?X%@ 7I]4<,'>G.TX1%;B:C.4^4"E<@FHU%(F$="
MF&!NIS>',H(5<<!+'' AMWGQ#FVR9E)AY2@3ZG&FRAE^5*SW+57;[M+%HN,*
M&"A@H("!O@I* 0.# P/>":$X6/*$8T3<:(\T212I$&T"6V]""KNSS!3S\"D4
MA,HC9AE&1AN#B*>68^69M_H1P  I2&!8"JY4S@P7-I1$V^G2H@2X^R< !7*=
M#.2RWC/-H@&@E;NKM6#(<L:1<<(13D*,7.VT 3G&?!X?2XWEB,< GW'P04F]
M=XP$C!]EPPZA9UK*DFPKNJC'QUZ,<5\H,9A#+\9X*,98)>>(-PP%YSWB*A)D
M6)YW LY_$E131MC.BAWOL9,R(A45&&.,%7(.4Q08X8XZBF4>J?+MC3$^,U07
M8]QG750J7P9>^?);K.L*$/[B<C&V\QA ?.$V_,AF6>Q/)+]GA#XMB%927CV&
M<B7E=0#RG: R_6')!P6Z[H&NB3N;HL/(FERP38A%C@N.L#*,:,V4L#L%VU\2
M1WJYMF8_;1@S^'D<\P^ 9E]>3D%X_F_S^D&D>YPU"6>8'!7CECS?U^F(;R@&
MS_IC%GI&MX*?"GXJ^*G@IX*?[H&?L!<FV>3:ZF=.<4#:>(U\4AQCZ8.+]!BA
MOU[A)WG6YY6/!3\]"GXJA58#CTJ^F\[M.'?A-9JEV6^UV@%^5DWBURP"+\GC
M_H"WHR9LMI4Q/:=9&X?IPHUCO[%UO[7PO_='UNY.X?[#\P)KEP.5!''*AX@P
M<1CQE!0R0@<4J#*$Q2 BV\EH'[6\[/=X'*@JSC3O;SK[L[+3>[ Z&"M6$$5_
M:%$014$4!5$,"U&(:%AD42$?*: #)00@"I:0ML$9[XC'SCQHC=RQ$ 4_(ZJ_
MRSP+HOCZFCKXV<)Y_6U)Y-\7EW!E#_\.HP^'#^O[_L& AST_.(UC$6VE-;JS
M7BH-QZ*)DH.6$!3<D"C I: "4><LU]$ZS7>4!B%.6P?OE%AZQ+EPR 9P2#2G
MB@4FG7=^J31<J#\]?^LO8EB,X^NT&5F_$5#_^=-5G-3QC]B$X-]-EVIF4\.\
MRUSS#N[DQ_'4__E=%4&[7&4^F2WB+4)V.]\0>D_&D3<9YU^+>CY*UP.(0&[2
MIXHM1:I92Y)J/JVN9OMR52?XH/M"K-5'6S_?]WQ]?(!J0T\LM6JC5)<WW?%L
M5FK/[6(^71JN?,NCR?OG^$7S=C2VU]/%'*[^*8(5;+Z)X$9HN@_ TX_M51V?
MU_'*SH 3EN+0P+'VVM_MRTM\&-4C-QJ/YM?/E]<XD)UHOU:J<VK8]UF,#AGX
M[O[.N;[3V_!=WD7/I3+'NQS<VQ&OQLZQ^-)G+?FBXO"7X,LQ: $GGW_[_W\'
MSM C.NIWJLM9GN=CT7,=)GAHB."FX_!@7/&_HYU5/\.IA>JGZ..EB[.*D;/^
MB.R]BS!ZSR,]DOIB.D]971?3V1]:K$PG+:;SB9A.BBGMCWP6.SDH=3L8L>X;
M%8NB?HJ*FIR,9!=%W3.'IDRTZ%,^X*?1+/HY:/%Z7K=IC39[4[:YG(JG] T;
M>'I&B>'6;1U9@DHU5@\U[_YJK,@-IU80A*5CB.<2"\.80BDF3JE7)!!]L[ B
M4L.Y%!@YJ2GBPB5D2)*(,\\MC9I$NE.-M9FQ/TX]MR&];3SLF=X:C+$HAKL_
MM#@E 2B&NQCNH1ENR51@7BG$J1:(&^^0HR(A)PRCPB:KXX[A5IPGY:2%SQ#X
MH)4261P9BE;$&!C&+-$'-]R2\&*X^VRX2U)YX#&8MW$\'DW>GU7PN'_&>?/C
M^SB),SMN0C(VP"=']7P&0O\A]B?RVC/*GQ:^>\#FDC(FZ_23CP7N]44['^B:
M4R()' C26!@$.([G;;D4,>6E33*)H'?6O 2OJ* 6>$EH#YB/$^2( _3'N/2$
M:!PE?G"X1\XP.VJDYELJLM(CUQ.-UK-C+Z:_F/Y^"DHQ_8,S_3XRHB2Q2$J&
M$7>>(6N#1$H'ZBA+WEN\TS"?%!:*4V0L!=,/2 !9JN&?6DL=*4E<[BS5[7ND
MIQC^1]=GI3QGX*&A9K1C?_(1/2/H:<&^!YRE6X8M#2_W5X8M#1 [2HVQCY$C
M[X4"[&@=<D(0E(SPV"HCD]B92AYU<CI9#H@QAYJ,U<@JYI$ACB@1";%V9WSC
M X2-9.[.Z6F>L Q7ZHW5*@BB/[0H"*(@B((@AH4@""'&"YM0+AT"!.%H6V>4
M>%2*2>V32#N)IQB"\,0@PW)1L9$ 'K22* :N K<V1!V_ 8*@Q]U?7!!$#Q#$
M/<8S[GT5/GI"<QOY@QYL/HN'']W(6=):@PM"!+:(^\"0B]*AH%+44G&#J?V:
MT8U+!?+WZ31\'(W'+R?AU\G<3MZ/@#=>UG6<US^-:C^>UHO9XP]E?+3 X8-V
MZ/X^G<=*5O_Q;Y\H)NQ%M:1%4TZVID;5DN,;CPXU >M $S"/!5Z23""ME$?1
M:BMEE(D[>0S^6T\/O<E^P)'+ WF0R:#RGCPXX,&@&[QFF[,_J^(G/UZ$T>1]
M];XCPEFF=CVJY]4T5?.+""AB/)Y^S&_Y832!5Z:+&ABW?O9\6UFV,.&TAU<R
M=2XQO<.D1GQNL#C:@$AUSB0U&_\=[]+X7)F[/-#=KF;.*>OKO8'<'I$DQ[VW
MDR&P/J?'&\J*SS7F1SQ#"G#H"&?8XPK^>X;E5$[,/S8*;V^B+T&Y0HEO1XG5
ML"&"R[2A)S)M:'.,:E5FQ#V9T4/]5;W]B$4]WJ2WHGR?K/(M<]^>AO(M'LM)
MX^1"B;Y0HHQ'?7(V\]6TGO='.HN9?)+*]JG[*$7=/A5U^]+[Q>6B637X5S>K
M_O*WS>V0_1'<HH>+'BYZ^+'%K.CAAZLYBO/JE9W-KG/=QC_M>-&C255%^1;E
M6Y3O8XM94;XEYE#4;5&W1=T6=7O:ZK;$'(H>+GJX9[0H>OC)Z>$2<WBBRO<A
M!I^I,\HQT(.6P6<];!RKZH7[5UY5.)]6]CAHZU@4+^;YN.;YR'3I_W"+OI&J
MD*>0IVBUHM6*V!3R#),\1:L5K5;$II!G6.0I6JUHM2(VA3S#(D_1:D6K%;$I
MY!D6>8I6*UJMB$TASXEER;>+)#;/N[O:\1+GF\,\R<;9EUSZ/9GDC<T_U/TI
MC2FVKR]K%WM&B>&N]CBR!/7?#'XM$4Y0SQY8^<6L"I0SE+!/B$OOD14R(!LE
M2YP88_3.NEA,-9&,>12B((B'O"F>!6 90BDWFG/*W,UYY[^,)O#XOXT^Q)UY
M^W^?3>OZ2$L\M,:]72+;,VTV&!-2S'E_:'%* E#,^6#,^0F:XQ^6]"VP9.\6
M>XY9U(!#=,"("X*1<48B&:1@-@06F7Y@6++11;?9/W><7?=<%9@R!"W]K#]:
MNF=T*SBG+Y3HMP05G%/"%O?'!Y8D3"7&8.$3V'I&$W(\<:23$5(GQZ/?6=-V
M9'SP>YP?:_,H8P4-E*!%CX^]&/.^4*(8\V+,AV;,M9?,!"R0LT(A[EU$!DL'
MOK^UB3-X(2\ WS;F+A$>7(S(,RD15UPB%PA#V%O) Z$A8O)(.0@E1#'GQ9SW
M^-B+.>\+)8HY'XPY/T%S7'(0M\$2P@5UGCND7$R("\F0=H2@X$34*F 6^$Z,
MX<BPY"%S$$+* E.&H*5+#J+@G+Y3HM\25'!."5M\0>FD\<1IIY!US"'.&49:
M4H4H$XG)(&4BZ8'QP?%R$$2;@@;Z'+1X\)F2I5OF%%31F\7,7]@ZAFH>_<4$
M[O#]=7_ZWWHFJ:>%_^Y+BZ(S2P-H@6]?#-]HX$8I3%$"[(.X30Q9'@G"206'
MD]5&[62=E*"81J:14R$@;D)"1E.!M K)!R\$"?)QLD[RS."CMKX4;73ZVJAG
MQU[,<5\H,9A#/WES?(+FM&2-;H,5!JO(B1 (BZ01=\0CDXM.5>!!F&"T9O:!
M8<5#9HWT&1<%9PPBZOTU>:,"5$[79IZ2! WFT$\>J!0#OVP]P<IIQ1*2PA+$
MHQ7(JH 1\V#=E94T6O; !OY8:9]BS(LJZONQ%UO<%TH,YM"++1Z*+=92@@5-
M$3D1'-A58I Q(H!!IBXIPI@TYJ8MYHI(#T8<<88IXM: @QXM1CAH);&.WO%4
M8OA%&_5$&_7LV(LY[@LE!G/H)V^.3]"<EAC^;;""&6JCH 8Y:P%6$( 5&G %
M?)]PDB;KB:0/#"L>=/K4F5"TX(P2PR] Y51MYBE)T& ._>2!2C'PR[B!$EQ2
MQ9%C% P\M6"L@1T034;% *:>\/# !OYHK1OXC%%=K'F?==&#;SHY7J-&#VAT
M@EIF+=R5;:2[FDSG5;UP_XI^7LVG?W6SZB\=D^S^:3< ?G\Z$7O&%7W#<W=?
M 5;HTA_(5VA1:/$T:5'T53_I4FA1:%%H4?35J="ET*+0HM"BZ*M3H4NA1:%%
MH4715Z="ET*+0HM"BZ*O3H4NA1:]H$49#U@2T7#_[V8V1'C4/^O^U$45H>U+
M,8Z#=\?9^K3$U;RJI^-1J+:YN&<4&PQQ/B,H=R5/*33LH>;=7VB8 A8XACP4
MV@;$HT@H=Q:@**7CG!BB_$ZAH8E$T.0MLD3F80$J_T0D"HJ;%%D22MIEH:$+
M]:?GOP*QT^%*PY\_^?$BC";O_SZ=AH^C\?B(+8N$][;R\#/2M E-@1&*UBOP
MH,"# @]Z+"C#@0<G:-[_X]\^44SXJ<AJL6X]$=J>'7NQ;L6Z]5-0AF/=BO.[
M='Z9T]@(B1+&V9%U#CD"?FU22@9IG5<4?XWSN^RRNZ__6US? @YZH?-Z=NP%
M'!1PT$]!*>!@>.# 1VM5MO&*4<3S+%T3 T%4!JJ<XX[8G3GYPIAH T_(&^X1
M#UXBS3E!W&NB;$C$$=F7R'B/)_D5>' :6J]GQU[@08$'_124X<"#$S3O)3)>
MA+98MY[3HEBW'A/GR5BWXOPN!\S2D+0-%B6F%#BR."%-+4=12T<99BHD_C7.
M[^-&QHOK.S"=U^/Y=?T$$R>HJ';'TKV;SNVX]/X, B_>EQ;W4*+TG&8M&J:+
M//ZPUXBQW[.\_[T_LG9W"A?0V4-=?F S,?4BZ:"1=88!;(0_#*8&"<.\=#H8
M(7<R+M(QYIF0B!J ISP&!I\6#$GJO6,D8,"JNZ!SSX:D!X*:^DR;H]9A?%M%
M6?!F3Q1>SXZ]@(L"+@JX. %P<8+@H*Q^NC4RYXGCD6@D;,JQ-06 )V"+%%&,
M.JY]X%\%DKJRE#LM>WH8S&3.L%$%,CU1._ U"Z,*YBJ8JU\TZ[>L%<Q5 CH/
MB54(-<2%")QAA$8<FX1<= !='"$R&J(PWUE3>8R SN]Q_E#01!5H4J(Y!5F<
M$BT*LBC(HB"+82&+R SE8)81L<PA+G!$&A.-K!+<>.D%YW)G/Z;WV$D9D8H*
MD 7&"CF'*0J,<$<=Q5+LJ4_ZEJDB)40!%P5<%'!Q.K0HX** BX& BQ,$!R55
M=!M(TDH8ZT1"V)B(.-,&68<)2H1QS2A54HJO 4F/GRI29X0==;5X@4PG9 =*
MJJA@KH*Y"N8Z8<Q5L,H2JPAOG$T284$3XI9P9+T2B+&@HDL8:['3<':,@,Z#
MI8H(.9.DY(J&%L[9[#2#GRV<U^%C^?[)67[@]MB(TQ>?"J%?>RQK57_BWNTO
M:)][>X(/DO7@BD=6DG2Q:M.\LN]CJ\N034"[YW;\T5[7+[ZK_E*$:T,/;4I7
M9UA^7US"53S\.XP^_.VO\,>Q]./*4G=?T1EJKT*4(1M=*AT8W0B48XZC9#1C
M3M,4<;QIJ EQVKHHD,32(\Z%0S98CC2GB@4FG7?^IJ'^Y7!7^'9<X2I.ZO@N
M*^)W\(T_CJ?^S^^J"!;[*O/,;!%OL5M'5D7R)A/]:U'/1^EZ +IH\\RKV!YZ
M-8M-G*>:3ZME&S\:9XI5HQ7)*MO0K/IHZ^J'T:2:7TP7M9V$^MGS?=JMC\]>
M[6JOOS:6?WG3F]OA[&(^7:*K?,N *Y_C%\W;T=A>3Q=SN/JG"%"M^2:"&S;L
M/@!//[97=7Q>QRL[@[-=,ECC/+37_FY?H_N'43URH_%H?OU\>8T#[>[MUTIV
M+HS^/C/F(13:W=^YP>1.[\-W>1<]%\P<[W+GH(2.=S5Y3IGXPLN5"00G9DM+
MN+"_M%BMTI7?>)7N%TPR6I[G8]'SVWD[;CH.#\85_SO:6?4SG%JH?HH^7KHX
MJQ@YZX_(WGLP3^]YI$=27ZSGB6OL0HO^T.+1%M$7Z_E8UI-B2OLCG\54#DK=
MGNCTU;[1K*CEIZB6R<G(<5'+/?-@ACW._ 1S(#^-9M'/09'7\[JRD[#,@]3]
M&<7=,R+W2$"_]2#GGE%BN-6%1Y:@4C/80\V[OV8P<!X%)1AAS1GB,2KDI.<H
MR2")\M1@KF^6(D1J.)<"PSMUWNKF$C(D2<29YY9&32+=J1G<S'V_3C>K$8Y2
M+4A[.Y"^9WIL,,:C&/+^T.*4!* 8\F+(AV;(=3!,,YI0P-$@'L >6XXQ8B89
MBL',X]T][(*I%(B,*$3M$=?&(6V"1\'BX*W52FO^"(;\J ,<AJS'!A.F&79R
M\P1US%L0VOJL@H?],\Y'D_=GU?LXB3,[;F(V-L#G1O5\!EK@0^Q/=+9G=#\M
MP/> K5$GD^\:#''*ML&GAO\8=<:$9!&E B-N100LQR)2AB8J:4Q6[LP)#5X!
M+K+ 2R+C/\H)<L19Q!F7GA"-H\2/@/_(F5'L1+H^RW;!ONJXGAU[ 0,%#/13
M4 H8&!P8,$8;;"5&D@ BX(8[9*1@R./D)1<*.T5N@@&30DH82Z2PS9.N4D).
M4XJB$]YHI2*C[''  #^5B9X%#)1"GQ)!VN2 8ZX:'C:)3PL?/N"^]C)N;'AY
MQ#)N;( @TTEIA20::9$P@$S#D#;*(!JH3T)C+V4XQA23;Q1QZF_6L<P9ZXT=
M*YBB/[0HF*)@BH(IAH4I.+7<2:.0)<$@3H1"FB6.K$R:8NZQ"#N!*^^55P%3
MA.$-B"MFD<F53R0Z;&6(2I-'"EP)7##%P##%WMFE^^<(GL[0Q=T9?4<]OX<?
MJ"AXC-XPAPSS''$;"#+$.D13(#Y*(R4WQW!%WOJ+&!;C.$VWC%;\93%?S&(9
ML/@(PUZ;DX=SG8,*SD,5[;Z)B].T.5IQ(.-ANPF1HX,#(H<S=U&I<TG4W48;
M,GJ\T8;Z7(HOO5S_:V9/-$E_6B[N8T\C*,0KXT7*>)&MF<QUQ@-_=;/J+W_;
M')I8G=0XJ--AD!Z)_$-4(? SRO374QT(T#==?8*8&$28?4V\Y4C$++F!(^0&
M[DF+4^KB&W#$_[@25.+X/52R^^/X5"BG5##(:F(1U\HC31U&G%%"I*:4Y.#:
M=D!..L8\$Q)18SGB,3!DG6!(4N\=(P%CIKYNP\GO\&7O/L;QA_@/^.:+X]4.
M''?TR(!UW6"0WK'P?4%Z1T)ZO#_.6L_H>5I([ZCE^3VCQ& .O0"UT].1^X$:
M9E$1&0/"$HO<^.N14UP@)A+UB<3(_$[;\,,#M;S)Y-W'Z;'PF>QO-W'14"42
M]R3PF>A/'*%G]#PM?%:\TQ,X](+/3D]''BJ(#8E@9I"(/J\*)@QIJRD*E'!#
M@LK3=Q\)GUW,8CQ:I:PJ$;0^ZZ@201L^0I/]"2#TC)ZGA="*?WH"AUX0VNGI
MR/T(C= 4:'0.)<4!;3D1D)$RH:""H=AI@%_N<1#:+]/%[&@S>$H(K=<JJH30
MA@_05'\B"#VCYVD!M.*>GL"A%X!V>CKRP#!$IK4VQB/,0T2<AP!@"QND<%16
M1ZN]%(\$T."]1P%HQI0*M%XKJ!(_&SX\T\UNC/E%A/-/8!'Z$TWH&7E/"ZV5
M4=@]1G6/WV97T%]?5/!^]!<388QQ@FBR&'%B<"YP4T@&1JD/-EC-O@;]N5!_
M^@+H]W;TZ>4DO%L9BZ/ 0"UD;Z-T1?/U*9JW>;+=U8Z'(#='BI"-4RZ@\IY,
M\M43LTO0KS=(Y:@^=9EN.?1>US+=<H!8E!)+F,$),1X]X@$@I>..H2"XE]A[
MH;Q]X$CD[W%^G(CCF=1'30D7_=@/N/F9H99[7X6/GM"T2_Z@!YO/XN$'7J:(
M*=?*(9.D *\6<^2$(R@JFY)+AH>XL^W[BV;O>P^2.J_?V.O,%>"RPBNS10R_
MC6PSLV\4ZY]&M1]/Z\7LZ+,M94\@R...J/I].H^5JO[CWSY13-B+JJ- M4&"
M?4,L^_<@U:;^^08RP@W!T3@DM,H;41-8%$PM2BEA;BP8SN,.A7V==F7C04:^
MWE<L!CSQ=2D+X_619XK6HWJ>Y[K-+R* F/%X^G$T>3_\R:A2G5/#[C2BE.OC
M#4:EYU*9XUT.[NV(5V/G6'SIL_8X:UM",KU+'A5:W&VXJBS#59_4<-7-L:K]
MD=;!<$6/Y+S_]K)0LUC0T[>@93SY4[&@90IYT;)E:T2_B5?4\E-4R^1D!/IT
M^*!'DEWZ:1\[I_; F8-7T\M<C-NNAIO%<;LO+J<3[+CN3QU0SPC=(PE]XGUL
MI9*N=.H.K3X.>T>PRJN; 6 A3HU'EE*/DDPZ8<$DO.$8]7$_7UZ-I]<Q_M&J
M_8U\_:O%; 9W>)02.7XF%>EMB5S/U-E@;$BQY_VAQ2D)0+'GQ9X/S9YKFHPR
MTB/GO$9<>Z!\M QAAHU2$2LIXDU[SKW'3LJ(5%1@SS%6\&E  X$1[JBC6 KY
M6/8<4U/L>9_M>8\3T"5J<\QZ3S\>3?+A5O/9"/Z,;6-U?T*R/:/T:<&\,AWR
M! Z]H+33TYX'YJ,IX;3G!@EB+.(\&60\D8@9IZD6(07Q52N@F@D9G>)^U>GM
M=UEM=^,PCHG1"""JHXY"*[KH]'51SXZ]&..^4&(PAUZ,\5",,?'),FL#LMQ%
MQ#V86,LE6%?. @Z1:2=V%F??)V3R+8VQ5KB8XCYKHE+D,O!PR>L\C709'2E5
M+<- 9 \X*:6,Y>M9NK@,)!T<PN-6:LT215H&B3BC$ADJ-?().\UT=)3NC&[Y
MDB*71O?O3J0X)L"C9XR(WF;$BFH[9=56VE *:"B254!# 0T9- 3"K6!1(A^T
M1]PR@2S!$B5.DDD^<6YV<C1?4DGS34"#DD<=4UY4VX#B1Z7<ID_*J!E WG9%
M;0]9ZT]NHV=$/BU4^( ;'DYHZ.YP2Z\?M-&X#"4_,6V^'UHRJHAGUB/#7$"<
M.(VLM!HI&03UF@;OR3'B40^+*@'_$=W;;./)JL;!6*ZOU6PE'%6 1P$>O17/
M CQ.#W@8;:D-PB- # 1QZQURFFOD$L-8&(R)U,>(:3TL\%!G4AXU!U948S\"
M6F41RE$6H>S?S8 QIL2%@*@U#)P.PI'5B2$O/*'4>)7P4?:7_!3=O.PG^0;[
M2?1Z/TD^\TT!*TLNOK:*;S&KQM/)>P1PYA(LDYM75S.P/C.X[G+;13-I>P*4
MJ*NK=E=/9>MZZD?-7*N/H_E%-87+O(DS'Z_FHP^Q>I<O]ML43@:>SU]4HQHN
M7?O9R,$'1I,J+69-]6"(<SL:5RZ.IQ_/5RM<CJFK#^QO,4+I1 5%/CF*N# 4
M&><3(IAI+(V7QNY,@_FZ_2V9<W^=U* 3+N'DZT/JHOG.T00PQ<OY76_T_Y#3
MY\/?5CRXS6@?XRQS6[=II3ZX9^6FQ5RKB*,O ^HH9#?AYAVI-)1=,/)<$?G-
M=\&P<Z[447?!''-/C?[BR_4XU5D28;T+)Q9:E%4P96+R0%;![(;^>\\>/1+X
M_AO.0LUB2D_?E);E T_%E)[43IAB/(NZ+>JVJ-N35K>GL^NEJ-N>^2IE'D:?
M,AC[TE_]Z=OK&7U[))A/?)CR<.L$RVSXIUK]YTSTR1*&K,X50%1Y9+RE2!J5
M%.?4.KO3T4J8#8JPB (3$7%B@5MH,,@HIB/A/.'<!;M; ;3.Z;^RL]GU:/+^
MY24<X7$* !D<,S[JH+,AJ[+!V(]BR_M#BU,2@&++!V/+3] 6MT6:O AGGZQ3
MCU.D)>QPK!#B40(.)=C?'Y!2QA&?P*$7C'&2&*/(UNG+5L^.O1B7OE!B,(=^
M\L:E!*.7P>A &2$QH.@#1EPYB31E'FE,A?58"4%V%I5ZFB*722,B!4-<1X^,
M911Y(RQU)";!R#</1I.C!Z.+)CH!=[]4&?1)QS1#5/L32.T904\+B)5HYPD<
M>@%BIZ<D]P.Q*(.Q!I"7PE8ASKU%FA.+HL-)6IJAUDY5@-,\KS 5"%MJ$??2
M(FL41LY;+#76P3G[[8$85:4DH*BA'A][L<-]H<1@#KW8X:'8818)L9YK))5Q
M8%.50=I0G_](G!CE#.8W[3 E*BGJ,/))Y=6E'+C%<(J$R2-X1!#,?_N B.KO
M?JJBA4KMP_"#(?\% C^%<_V_,;2CR\*H]EF\*SOI7AG5]<).? 1]4L_+:HEA
M +8''&-:MO+T+-,UG(5C)ZA@?WB(D8PG> [[@2RV4C(=%#(X "C%+B)K/$%1
MR1@38-S$U3&V6VP#V0VC]U-G[M[,XN5H<?ER$IJW=B;O5;9XO\?C8%UQAA7O
M;>[OU/=]]KMP_UE_K$'/Z%9@4X%-!385V%1@TWV6U#,5',8682<<XM89Y(+U
MR!E-2!+!>[X3__N2W1Q]@$V2%<Q4,%.IT/I2(O=1JU5]RWWUC&:G!8I+VN4$
M#KTD?X<"_IPQ4GH <I$Q '*.&&1MT$A9)P#$><63/4;,+"\.JM^T2T2.@N0H
MP"!Q5#17-,_I:YZ>'7LQO7VAQ& .O9C>H9A>F313)A+D90 S&D1 )@6)I'="
MV6 2#N(8<9>CF][<>$9H,;U]UCREUFK@M5:_Q;I^7OEVNW$%HKJ8-?N.^Y/R
MZ!F-3PN+E=Q@CS%;R0T6;/>9FOK$F3&1(Y:+Y#D@/*1CP(@:'J4EE B^,V3@
M:\,JQ]QTSTW)DQ6M5LS_J="BF/\>$Z>8_Z=F_HU7SACLD1,I(1X8<(A4&,40
MN&%21TR/4E+S4.:?%/,_+*U6JER&'@Z:3MZC>1X[/,DZH;IJE4)_$A,](_%I
MP<&CQL>W-2@]IUF%AND"V*7?@+#?%88]6J=P=PH73-E#77X@72BHT8HX%&PN
MTU;1(DMT1$$X;(GQ 2=YC)!2MB1Y?OV#5.S@H_:L?5NU6*!E3]1;SXZ]0(D"
M)0J4*%#B=* $EU%IZ@@BEC+$,6%($^D0D\83(Y-3.ATC//5@4,*<&=/?VM^"
M)+X^2 4_9V[Y6T/D?('19&$[*H?1A\/']?VMIR6_]K3^M:CGHW3]Y?:$L3.F
MSCCY=LONV\_G^WP^FL-3^'NMS*Y^L7XT'LVO-ZEVJH??&[W\>E+]/OT0+UV<
M542>51136OTPOXC5J_&T'DW>5S_9>7QV5C4O32_A::^KQJK&4(TF\VEEJU?P
M\VA>O7P_BS%WU#9#MOZ^L#,[F5]W%[OQEF?5Q]'\HMJ@<_>._P6,!M]:5[_^
M\ZSZ[4UEZ^:;QQ%(.VLN; ,\RZB>SVSS.?L^?V/S);\U;WIV7KW;\XW5U6SZ
M813@A$"=PTW7<3*"'^KH%[-F2MC87N>_9_9CU80OQYGG4L=S.[?[,GP8U=-9
M7?WVVZOJA_4OX*1&$[A/N"_XYO=P=O#%HXD?7=EQ99L1@]4T58NK"H[NWTL[
M^&T=003C% 5'4>;2%4D5LE@R9()C45&K: @WP4&4 3-K-&*.Y\D[)"*GO$>:
M1F4H8RRP>'L[.&B9^)E1D'(3(/SZ^R^WS\>!DSH($$Y<>51P@7$F6"-^MRKM
M3BI!<N<CD(0$CYF5"XC"9S]:?00E4"_<OZ*?5XW"\?8J&Y!J9D=US->P<] 0
MMIX7B;I5HJB@07M#4$@Y&\SRQAD3",(V)DDI32 A-R5*82:$Y1IYJ@%N2V:0
M87 )I9RAW"L<%;XI46]F4Q]CJ'^932^7TQ->S]Z"\+Q./__/ FAZ'-EB3T&V
MP)S K==U-F#-J58)CC6;F-@<)?!_@BNMA:FSTO]9 R4O+Z?Y$*;^S_-JT]13
MLFGJ?^FD<8^I;T0,C.X5?/LG./5Y'%\7*;M5RC0APH 10D)J@;@F'%FF\UXG
M[#Q7UA.[4W(9B77!&H$LP2[;NH0<!1\WI6RVM.<Q[*P3V"MEZ55#\[>9Y'<3
M,B1N+\#$Y_*IRE@6A!I.+$O6IBQU]@[\Z)&O7B_%+X/3M8!EX7J[<+6?C:X:
MYE@AT1HD;/H^YGT]9]5__!OC+_+56KVXNEK=_"(_0*QRU*(BN$+5B9W[W1V^
M]NE/[/$.CGAIL<X[\'\\_/VR@3.[?D'Q!NZE507Q,F_+\THHQ$/&+I%I)!/V
MH")QL'%G/@!Q*?<P1N23!$UL"7R&:8>BEM)@[;CTGQD.=6QOX$D@ED8[;G,_
MH(J,XC/L!S2Q:)SYSP-_ /WUW$ZRQP"H(^M7^+:NTVS<^>3Y*KX+570 Z*8J
MK>">;L*<\^I7D,401@V+@?3MWO/9'>X0//OQ(@<5[/IJX)@L+_1C$?TCB+XU
M!L>H/.+&!L0%%L@9*1%/CF"#@PQFQVU)V*; D@"!)QA & <0Q@-%DB4<J HA
M:?UM19\\ =$_:R-T>V7A59&%8V3,C/91&8F4)B'O2 &_PBF*L,",)V$QQSM!
M,>.984X3!*QO019L0IHPCX3G1BIC+&6BR,+Q90'NQ%^ E1J/*P=\[GVLZU'.
MO;GK+1^[GE;C:78@ZNV7[7Q4IQ'<@8^SN06Y\0MP/R[M[#H3N!6P[+)$'W/>
MXZRS1MG$S>*'.%G$?"\1/C.)]?FI.0^'SG<36O_8Z)M73:R^KBXL&.DF;)^=
MM=&\<;:J8',9\OP"GO+]1?43'%;CH+$V L*:*[P%"]^]C)N7^1D<87T5?3;\
MX^M!'=[MB.8"N- NV_BOF]/+NODAE/)*Q_T.2F8&KG07][?.*TQ-F];G1$CD
MI-8(M(>2DG$?!-E9 P7:T!/%D,0F1RFU 14'EXA*N!2ML?#+VU7</[HGSN!P
M6W?E(P#7?WX1[/5UM  ^3S_M=S,0J%9)U2V*#$8G-R[)0!YFR:EMN';?0_7Q
MKJO-M#TP6?S4>$Y?FL(G]&MS^.O:L!/GAU_00!B;Z T>:<MO_GJQZA"[LN]C
M6PN%; +*/;?CC_:Z?O%=]9<O9:)!5N%^O6R5\IC5^69P.!#IVJY_R3F/7,13
MS]%T,KZNKN"STU"%19/*R-:R*8+I(FH-J&[";>MBE@#NA9TWO]ZR2%WYS2H)
M.8GS/6F5[5!;]1%NY4:2<2#'7L(9MX4S?"1"J9B0M]9FW*Z1B]8AK6T0S%$:
MQ6Y%0HB4>(]1,AZPO@"8;[@5R!,J4J3>-D7#AW.E&??_'N>OT]9BAZ,D2ZDZ
M/]RP?N*,O!'CR^87#B4LX %!6PSD ?>L!6V" _'359S4L3XOA:</F@/^M3-(
MU1]@ ,I9?].H3Q.DM-[/%G$%#+)USY'ZR631U-K-8ZXX@A^[;-E[P.)9$0!&
M^,$^RVKQHYT%-)Y._VR2<9.(FK!)BR3>OO[ECQSAO *YBB&'0%_]X^?J[W"0
M5]6O$W_>B-H/[MF#1)I.D&;[[67BE'$I'0J,:\09CL@JKY!@WK"@)+-IQUX&
MAHG1QB-JHT+<8H$,)A[9Z(SR BN1/K,B?2F963#?SN&/T'#39 XNV9;=O%K,
MXLIP(GJOS/AP,P+?9W3=R-'E674U7K39XJLK4(:YM:1J]=!#15E/\, .I+X2
M]T9BB4+ .1<L*=+!,.1H3 F07V1^IZ[NZ^/"/]IZ5+^%4[#A]>2?=C;*),N"
M0.[*^9_I(!LPWY]7+^M#;'V"SW,S=T0'\EQMH4O=*/:U]6\,?B[:^;Q;7E34
M,G7E35(*6T03S:DKQI!)4B'%X669HH[4W511+#"95 +OUP2?/Q.0I2XTNHW3
MI*-2_.[F^>>4VJ3E_2WT9R:QL?/#C:XG+@#?%]?N85V[E^V&S:9OM@'Z;V;Q
MREYGYBTG?]QNSIUX['8_QZBN9KEO)/<\@A\'1*C6K9/-C^O*K.EBGLLOFX*2
MG2;&IH9S?+V,%C?N9%O\==TYDJ'Y]V)R94<;9B67O<?IY!Q8(/=?=K[D[AW/
MXJIR9C(%A741PV(,UUS?2,= ]5W+2=O ].U^\"6<A\LMF[&YZ\8#AA,"6IQM
MMZ!=K1@X_YBWQ:Z=XV(B;XOX8@=N*-@WYEGNT+0$&6$2TDH:PK4+=+<[YCX]
M:"[4GYZOU4NWRG=M#5^GETL&?[WF[S=+KMI3Y?853NWAW30GKFB^+WS^&3X/
MN=U+1XM4I 'Q_(>+%B.B?'"$)Q"#'2@8HK/&&(>B\!+QD#BR&D?X3'+8DQ!9
M\KWD<S)<'W:9 KVC672Q?;FQ'V=PA%>QZW1N3?.RGFYM/\Y/LH*G0+6C@^2W
M>11%!B%KSZY-0/VWG>51&G4Y_R-R\YO%+&?Z.CBW.OM5E^99(ZHAIRPZ#;#9
M/M06%.Y^ZMD9:(#YQQ@G6Z@[4W$-L\]N-C8!S-WNW?Z/?_M$,3$OX+L=G+MM
M*[W7.'=WX@K Y>4H$P=7K-)H!F![/((;N8JS'!. W]3+^UVA\>R.W?+MMJYC
M[E?=@+[K&O3XJ0'2<&?%?3XF9[[,C?N3>@3$;AWF7+"SC^K;GETNW,[9ZPAF
M9T_#VTXW6Z=5UHTW!<[=-O36ZJ@E$0#GDD*<&H\,EPDYBTFB4GI!=W9D?LDP
MFE=CD+G7J2/.Z]D?^9%_7^2P\^O4Z9M1K%^!U,;PX_7/UE]LOW<+TM47H!CJ
M>XVK.<,8Y_^'"NBJ]DQN'Y8QD&?=[ C*#_MK-WUG"2BZ#J5L/+I9(CZSWRB-
M8AO[:!*7S8&!M@?5D<?M .3U&Y4 I;[MUM95'C!/(:&$<WV;PQB!\Z>03-QP
M!_]YO=.U_B7Y^KUJX^>.9&\RQ5:_K+O?UML)S/^"'V-HLOMPH9=-^X?]:3H>
MVUG]-G/ RC7$F_J$W^X7GF/)]6!5R4">H]4"HWJ[O&<\_=@5][Q\UKQ , KV
MNOHP'8-O4K6WEO7$!\ I[Y=ZX8=__O?+-\\. LI-);N"*6Y1CR:QSJUZ $TO
M+P'EM+G&J\T0\>8\PN7U;U01PYM_^+&]V:MV.,MJ-E)[=VMU!A=H)^54S:B<
M_.^BR6[39"KQZ)+!B"=! <SXB(S$'#E&C*44Q%SOQ+/N4WW1QK,:JBT'-S1Z
M"Q!KHWYNF6ST99J+?D9S$3%8O?5#F2K4W\<[.%5H(,^Q=_+*363:>JLOUU,D
MUI U)P4CN#V5BV!-5L"TJ:1K!M(6-7Z+&B>4<R^M1-I%\$DYDZ#!I0"][(AV
M6A@;_<X8)2UC .V/J'0"<488LMXJI 0-2>$H">%;:GPO&ET3\R80_7E-P:_T
M7@^D8C!51MG<06X]XLH""/<\(6QUDDDR@<-.RE$HPKCEX*P+I=LTI<ZE.8Q0
ML%R6"VMH/YZ9W.*Q#]1^K5WXK:E\^X=#N>EL-OV8,6#8@QR7$R0R?JQO#GW(
M]0('/>!E5.Z@DG+Q,X#ZAM*[^04;:+:#WAE;5]OYI%NP<QX+LO3\E_-V]Q_!
M$CQOOMH.U6A.9"!LLT'8'#:K/G;'OB+66B2;*44?+Z;CA@KP\Y6=S<] 3N>C
M<4<0X"X[F<#U9G4.AB^SA.NJ[N51+SN*P.[=/'>X]G)V26:PR73>S!^?+ ?$
MK+GQYEB3=JI):R5![TS]J$E6[./%^.EJE)LK@<V;)\W?LFLZM[HV<P%/SF;6
MMS*YK:OQR+I<.).'U'33:_:],TR;;[V,L>T7]3/@A-G(-I?O(D_SW$W2/-H:
MG?(A@]-?[&A6_=..%_'$'O'PV,N2!GI0CODCPGW4N;RCR;J=+05LE#7!J^F'
M.&FA<Q;UGS\TZ6/0/S_%9!?C4F=Y[(:ZG1QL_K4=3=;CNF;;]&I5\ ;);$JC
M#.NR?O=K\DURF<F-U]((?O 9+/AM.F\, IM?V#81O$S1PD.NBSVSJJU'\.!V
MMKS:Y'W=JOT#-V(O\U2R:2[&A(OGMY\MK[>5>01\TZ2FY_;/6'V [YTN<I7I
M5:[Y[>8B@_K/D*;[=#<%^1(.J3DH.+3%K.FZS>_=>!EP"U@LN/7N5[&I;F]2
MUG_$]XNQG4_!]K[,#0H? "R?Y3K2;%C&6].65R_F0OGQ&*Z04=F;V12P75Y0
MTGB38+Y"A(-I6B#VIEN?-;?0'D>SUJL^6R72ZVS+VVQY]</'B]B>F9V\;^:]
M-1AB^:]G< JV!@/I@#R3F(?"90"QM+3YICI^.11$76*^EGB[[))QPQP@Y#Q_
M\1AHWEK=UE1?W[@L4&\?I9MGW4S[=SR]3OHO^?WP@37II\4,[O!CE96, XB2
M[_L% (#<.MJ4)S336=N3>P'8]GT.)>=1=]WW9>!J\\4:UI\!3^4/^@LXS-@4
M)K2DNXRS]X#$&BIXX+%ZU*E(>*%[\RJ.?.@XJ^PE?6C S M@0N#EY4W\.OD
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MSJGX_FPU^7T9J\\=QEF]>EO#FS>/M'O\\^K5]EJ8[5Z2C3U^W>]O/*5K)M0
M4]S8+K.^QZ[>9F51.@9:O["L>,ZJOFN&WKE(Z2 ]B>?8Z+-<5TNEUFOK C]
MVNSH=<L)LDW?6$90#/AM!MP;.%%+P/H:&1"G@)D! RODF*5."6)XV@F?WL>
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M 8QVWBZ7$Y0_@-%47_@.1Q!!+1R/0^'(CO>T(-M!;=83+;@]F\,Y?$GFD4+
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MK+"ZU%&)4!1WL@SA_5ZL;.U+V-EUMRKN=?+>>W.#1'@.//5\.JO&60L%Q8_
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MV:RKU66J00#M/7XL3]\)$N$.",J%--8[0L%N)K(P@IB\$(2S8+FS.97FJR+
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MA@=&BBA*(F4HB<D9-H=QT5IE<F4VVUT](DK[KV!F[S_6!P)G!3LH.!MDTPF
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MR0?3^AX'3\S>;!PJA;.6$YWCQ*H2 V-%&0DO:*ESZEQA-K)Q/-<Q6@;8VP1
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MPHS'6([[BW&7Z]=^;:(=$R,ASK=%Y2USOH,+X:=_W\>E;84JYAV$F:M6H>(
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M&4JJ1$'0-P[?88%H)N%7KXRAA:"*AK4&K5OER>UAWC4.?KD]P7L$"=UO/_]
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MM*8T,A(+'%,IJ"!:J8+D7#D6<U<X[._XY4R:E$AW1$M&O4++]R"-\/G%^79
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M^#'.=B3TE-YQMB.$=SSN+D>14\'ZF^V(3AGK]>&4O.\\Q[U']7FUK"D'3Z7
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M&;"=R;"6WU;#:Z*?V[:MK_XQK1?-@0'(#WVL _L<L>$4(TX :0.!DD&@9$
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M^'IF7F\>0D\;T#W))CGSR_(\?F'7C:&=5HQ0"' J7:$L"& <58 02ISRGMO
M^ZAT>6?/O%M._-NPDWE)/29K;>I)O:A]\SY9H_?Q9C].9O:/;RK?6'V15LA\
MZ6^Q_;>O%_Z5ZX7?7"__6C:+.ER.0!^_/^NBR[X-.3=IPL+"GU_,YGI^6;DZ
M?COW4QNONSC3B^I#BDG/ZR:>,VNS7'6(*&ZZJ.():95VY\=+NA57MP/8NF5O
MVUYP<L7@2L]]_*D*LY1H:ZKOZFF\PFP9UZIKOG^QJV3_T@*4?3D'O5S,UA@R
M4;2>?G@!?V@/!Q-].5LNXLM_]A&0MH1 L%THJQ,B<R;ZHO$O&G^A4ZQ]O09:
MK-]=^YM]Z9F/=5.W+W/Y8GV- TF:[K:<GV+.OTUKYQ#67CW?*95W.@S>Y2AZ
M"DE_5^OUT?"IH/2>ERNM,P9F[TM8+E]>1,JG7__KFVCCGS *=*=JI3R'I!\#
M 9C9Q!UM5;QL3?8K;_VY\?.*H)-\I/6KZU"R7QX9"7PQG -7UH47^?!B8SAQ
M,9S/Q'!BB'$^\EE,95&W1=T^M9@5=7M,=8ORD<^B;H?EF4!Z@HD<JWH>8-IA
MG?6IWNO/59?W>?&0[2^CYF]&LOF5YK?P)1^(6GA1>/$\>5'T59Y\*;S(@A=E
MWVE!Y=TZ^<4OJMF%G^M%/?U0369-4UD]GU^&V?R3GKLRM&( TEP:EF:\]_]/
M^4A0_HU?'LJ$ 2K@ ^WG+,&$L@ X8AQ0+0C0WG(0+$804JU($#>+<KDAQ))X
M.%:: NI=ZMS,".#86D.0@Y"(FT6Y.Z6X;]>VX._1%/RT;0FN-4/YQ[M7FUXH
M9+L5"B"WMD 1\$2F)%IIQ7P7S38:<U),>SZ\&)( %-->3/O83+O!T/-@$8"2
M.T"E%D!1;H!RUCF,N!*[PT>IM=!P[H'P(IIV" 4P!F+@"*(&QRMRQI_:M'-T
M(D49!)6U:3]ZGK7$?0:BF];#AMN]6<Y_])/9Q7G\J=VV9;N!Q"62.PJ ^+6\
M*&HTOU1&P7<9ZM #^(YSZ2A$0"., $6" Q,H!UAP;;"%BHF=7K>]A&XVD^2O
M8;N]4^7OB_'(B82BUR:V13<-7C=E1O9BG'/AQ&B(7HSS6(PSC_8U> X!$E(#
M*AD"RE ,8#2_07C#*=J9PMU+\.51C#,1O:96BFX:0/REU-T,,O[R)MD)WRPJ
M__G"3QM?3>KS>M'V?<HGJY"9S X+V97H]0"(7I#=\%3G?F0760Z),QH$J0B@
M5DJ@'(W_*$Y%L$Q'*'.,L,M:D6_CNI[@'"2]#@PJ"FGX"BDSLA>+G LG1D/T
M8I''8I&EM39XY@'W7J01RAPHQ 50Q!/L.%46N6/$6HYFD1DKY2U9JZ-2WE+"
M*]TZ^76>-C4M+MOR%O_O9=T6M^23,LA,7(>%XTI<>@!$+SAN>%IS/X[3C&-N
ME0%.>0ZHQ6E @/; $(R@DS @;XY2T+)6XK].]'3Q<NI>K_5X+V@.DU[17%%*
MPU=*F9&]6.5<.#$:HA>K/!:K[!"TUB$?#3*-5CD@!)0W#'#EI$',&ZS042I9
MCFR5$2M6.6>E5$I82HRE6R<_Z8MZ$=_H_[RKYNOM1';6/&CC4,F7Y0,N2H!Z
M $0OB&YXFG,_HF,H8*52;3+D!E /&3 <$X ]4] S9!$D#XFS&-=\WH5S6UI\
M78W\4]+A_:"YLB6\J*3,R5YL<BZ<& W1!V^3!VA3_^/_?<80T2);.<E6*<@H
MP8)NG;P[T_&N1C<^-><^3WM>'KK9I21_\K&0)<XZ *(/'I:44,&Z)$- Z; V
M@%$B 96* <F] ]@C)KP/D#-UK!XCZ^]>=QL7?]I2YB^G[D<_]?$-FE;?_YC4
M_?8!*;+02V !G7"D2J*H*+",R9ZC.HEL*;:^B$JQ]3D*YX%^8L03X2T#R$F:
MJCTP,(908+4($D." MEI!=]7RY),;+T2I>E8U@JL%(64.$^W3EY:.U]&J6XW
MWJ2JD/E'7^I!QA'DZ34^?M>YVIEQ;#3,Z7_L>0&2N2CA_4#2!A8P#P$H2@R@
M&%F@</# >XL<@8@8<Y0.*7N Y&\KPQ!!Y-I@] 452;[3A;YZA'S1?04D%)!0
M0$*N@E) PNA  G3$(<D1<%!X0+5C0"/B 622!&FE=(\6;3H>2.!(%I P*MWW
MJ(5&^,@!*%P"4/=?)^]G"SW))]&2F70."TN60/T B%XRC<-3D@=:Z&+#G;,<
M4,=%_"=@(*%20'(B&<+*"^*/$B#ZVWS6](/M)#TAN/1U*3HH9[(7(YP+)T9#
M]&*$QV*$E108HQ" 8#8 JC$%1O( '$+4!(X"AL>94-2?$>;JA"-8C'#..NCH
M%3MC,]H#5#"_Z\FR+<6K]&0R^Z2GUN>3.\B,O</"9"7)EC%V*TFV\>PJ_VZ]
M#@I6W8-5!=6$& Z!LHBD@%'$G11:((0*QA*H--[I0=A+P&ACV5ZN#5L_T2-\
MPEBI'\H(0CWB$O\^'Y6?&=\*-BK8J&"C@HT*-OJ:Z5?!2,B1 TQS#JCT"$@7
M_S&(>&4]BSAH)YG62QSO2-B(BQ/*>MV&5[#1\+'1T>NNQH:E!JC?VHJJJ"@Z
M/5,M].=*MYJFTB&:TNICKV'&<;-_6% :BA-,8>0%+FF7;(E>4K_#4ZG[(2/'
M09G /,!8,T 9$D IYR/\T\@9$SA3["CAM%]\7YT:A.@U?%84T/ 54&9D+Q8X
M%TZ,ANC% H_% DOFC!/< $8@!!0J 33& 6@*'34:.J/Q48(V?5G@N&(9*18X
M9P5T,V12\DS#-,V%%X_)BTCY].M_?1/U;^%+/GPIO"B\*+PH^FHH?"F\R((7
M)6\X_KSAVLFMHI=;_;W6II[4B]HW+TIV,'\!_4HC]E1\05GP!1W@RT_QDF9>
M;_BAIPT8UL;1PHC"B.P94=14ADPIC'AZ1I2V_ 6+=^ODS72AIQ]J,_&KVKWB
M) \$@^=30UTVNY3-+F6S2ZF;V%,WX6U@#@4#K,4<4(P%T(YY( .Q2!MD.>^[
M<G$KH/2WV<Q]JB>3EU-W9>>ZNHJ;?^=9YEAVP@Q_)TP!3@4X%>!4@%,!3@4X
M?05P(M#YMLS469: DXV?( ).> $9%9"*'>#TP(+3)P1.O5>G%N T?.!41C?D
MLAJ>6D7NV6@\N5)6 \PV%.!=6KD.DNB#W]$T0.U7@/)M0)E@;HS5)M[ I;;8
MS@,#&0?20B$)E([TNS?ZS=3.SOUUN)QG\'#,"G6@D+9 D@)),N'$:(A>($F!
M)'E!$L8Q]M8$@*GB@'(>@%$H(A2)N$5":85[G=1Q-$C2_Z;Q$2O4@4*2LNM\
M'%BE\"+/#3!/E+(L_,M'EH:>/WK6S"N\*(IPQ/S+B6=%$99]\CFY9T\=7?C%
M+_9WUYZZDO\>EK@^=D.]ZYH6G^*D:MULF?9Y96T?\XZB_"F?YJ%WYW")@!]%
MW#]CB.AP!#Y[<#4:Q5R,9#Z\*$:R&,EB)(N1+$:RKV!#_*PCO?ZZ3@O_LCR/
M5[;Q;U=_/$RL;V^E%7\HK?ZU;!9UN!R!S+Q<5*^\]>?&SRN"3BH,,3ZI%F>^
M^FEV'E_MLCK3^ZHO!OBJKOI3J2.Y;>B @40(XP"VW@**M052,08\$D%";01V
M.W4DO8S]>7OAYWI13S_\?=8T/^GY_#+,YI_TW#7OEN9?WB[>SUY_OJCG[7"W
M@Y4F_%JE"?OFKUBI4W6PG&3@B[F*%YBTL^ZF95W?OJZ#UD1(;P!5,O[#(0**
M<0$0I$YCQAE7X2'KVKCF\^ZB_LTW7L_MV<NIBXLW/O9Y?,9V!<=#>EODMY53
MT5,Y^M4_"]5(7BGXB!7UI)KZ135;*\1J$C5B*^+SU7)J__#7%U0;K+?;2^HD
M'7\1%U7]T4\N3ZKX<NG4N8\/L:@6L[U$>^B;;>1OA=%6XF>X03X("S!! E!I
M!-!$.1 H,PQ9B6Q -\4/(2.U\0QPR*,IBD<"[:(@2HH%<80;:^Q-LY+$*@I@
MO=@6KE>^L?/ZHI6IP2\1G_2#KXR/T'2:5D<]37B-;W#T38@\"L$XK=Y'-/HF
M.<G3*!^_^8]^NDSPU/EVU>AZVE07\]G'NHE<;B)VU8OJ7%]6D_J\7K10=H],
MM>(RBWY;%*^/NIXD)R,)AO'5LO$ND3:!W\LH=%4=*AL=O'BC*MU\T50S:Y?S
MDWB0G2Q=NF83O8(Z1!=PNJCLF9Y^B.\9#Y]]FL8[G-47\8_X_+Y9G.[C2HYD
MK[:]L^)F/;CO89M-;9JT6-*2G/OXBO_7)54ODQFKX[+:DWV][HO%"S:U2XOV
MTYF//\2UN:CJICJ?1;TPJ?^(RCZM_VDUG2TZ06AFY[ZZF,U;.S&;I]'(Z6[I
MHOMRO:D+0WNR63^B=YT +B>+""L6FR=?K,SOOJO4Z54N?+M,JN5%LE#Q"A_\
MU,\WYX7E8AD?.I[5BE[=%I57;CE?4RB9N)EKQ:@S7XNS61-/\.?Q=?3\LG)U
MB+?V4QO987QWNG?+:/3B!;N'WJ5;NG)CS^)Q$Y^L:M( >K+S(EOY[I.D7!)
MBS_M?>B3UB:GLRXFNE/,S2*^:%33G18XUW]T+Q7ITJV"9+I/JY?-->:Z63P\
MT?Y,?_2M]HDG+&;S%%C:N>7JF5J-=Y":2;\=HN5^_B>(<$7$[LVZZ=IK$FX8
MF"[1/6"[?J_K5[]:N(^),RSB4B,%)"<1,T#A@;*4 8RT\TH9@=*6AH?CC-_7
M8\9?KJ>,W\3^$<?'A= >\S;\U%J#X6NPG55J_*2.XO-%#11_;[7*2IVTR\)$
M51"2QHL+9WJX["2N/VMG\V1A$XH]TTT536A<X743);C2^T:^5_[?RR0OQ\&X
M V3<?J=82:V@PQQPKAV@@3M@I'" !$^LHEIBH1XB+:U3_*N?I^R&_N#?AEVQ
M>9T8]7[VBU_L.,_7_-^+J-DV#C# VQ[PFU]^_N:O",*Q^KG?WB(@I^.&_:W]
MWB??T;9%59(PNKDLD:\O1+Z(T22ZWH1@ ZAP$"C"$>"&,&Z91<R:QS&)G15\
M,WUY'LEZ>,3LUX2W$#M%8Y7[37QKA8=35J9$>K_<G$-+J3 D@#JKXWKG&!BA
M/+!<<>,$%D';F^O=6F&C8&  (8WK71 -%(40(&^@YLX+B4@>ZQV=TF>TWM'I
MXP<@^'@#$-O>L//1H8L')CBQ0NAGVL4UNHYRM;[LK*D[]W+N)SHYOQ%2)\C^
MC]-WI]?#T2ZZ 9/917)J*]N&8)O6N8W892>WW)Z0V-OZA]%G^#22)1Q]DZ*;
M___VKO0W;B/+?]^_@LAN=FQ I6$5BY<]"*#(]B"+C&78RNS,IT5=5'-,D1T>
MDC5__;Y7Q;[4:L5'2^YN51#(4C>/.M[Q>V?=(YN5$84QDI%8<$8X31,B./S)
MHQ#$K1 TY-$VHLN_U:U1S46-GBN0QC^/EN8OH__UK)ZW+S#=B5+M8/2Z>%ZU
M,):E,NF,0LF,F4"=J3?-5I@XC#->D%!14$?24"(2HTAF!*5Y+@U36^G)\-BS
MK9L[5-"!ZB3AUFONNI\+P@.9(,CS#2)_U7FZP>.#1EA3"UG=X(V=/=-G5"<=
M/'A!E_;9<X^/]04MA4O@=A<P0>>D"]9\ZH/^VE3PIDL8[ 2&\XAN1)%343!:
MD"S-@'.YIB2384XD+V*6))0!_V[#9OHP.J'/B@T\_+ZIJC<NBGF.3MUS>-_/
M5:,^_A 8@(]3!$- GVXL90V4>M)_[@3^C^X_HCD)<-EJ55;EW">]"(W:,'EM
M8W-25,(&"4"PW4.8UCD/UR"D[X)GEAJ;H8,'=<]?_(&O!2&J+J_N(,TO/V+-
MT>6XJ6)9IWSFQLXR)VWBY%W-@<70-[/D5-P_6*07X4M[.:G$33/TL-2?C'[I
MEIV&%FB/-P I5&+:F1>=F0J,<LPPM,TB=L_^X:Y248S/NG#7B]DS-A2,NM<F
MR3'+TQ]Q/38E\8[C.^9)]EG7A9]S572<LRT^;KN#8\=9E(6+_^A7/GJ_3N0#
M6VYCI^O=.8YOOTI;_';MV';-6ULD.]K:XH[U_%ZU"HN:F8<&,;*I](-1Q3\Q
MN^@UK)I><93L<0>-G:>1'>+Z!]?!VY/@7EQ_)S[<P8W815LP.(3643LO._=.
MOV+ 80>8V"M3+Y.?EG+TLO8IREJZ \SI9>U>&B[;Z@RW@[)Y#T,K/[N(22#Z
MX']$/6"QQ;?P]O=J^T=W0O=^>01H9\XZ\><A;(NCOJE)T5,[H<;G3(T17\IS
MEBNFB,D-GNR2"B(TS4B:9D58R"Q1A7[ +**M'.J2<7^DRTYW6_(*W"OP7:!^
MK\"] C\T!1X5N=8I34FH34$XC3+,UDI(I",&2IFK(C/K"MSD82(8$8:'A.<B
M)4+JF% 1%KD)$Y5&\6,J\)3&7H'OL@+WN5P[H8R^MP0ZT7HLV,$\UXTE/)AB
MK8:VQ6(=[&ZS.SY;#PL?:R.\3-VA<*)'=;LK4S<<N,M%8JB)2:;CF'# >)B2
M+TAF0FK2C&=)Q+91(K*QN,LU0, 6D]B5J;YXTS:7ITZFO[.=?N#J=S/AOQ40
M2,/-G52]P'J2 LNK:T_]3Y?ZO;K>&W6=)-AC-LZ(*')0O4(JDAL6$Y.S1(+Z
M#3E=ZX+S-5U!=DE=L\VMG[W V@&!]> I--YGLP\"ZS-]-E,0$JWUUNSCZ9L>
M_WD7^/?'?T\N"+>'XG ;!WAYWMI[WO*:Q5/_TZ5^KUF\9GD:O.43%[P1#.-_
M[\Z;>"0KV$=!=@2K>*>BCX)XK/(P6,7SUO[SEM<LGOJ?+O5[S>(UR]/@+1\*
M]E;PJA6\9/-VIN\K@R=K^,CO 2 3[T/T_GF/3+Q_WO.6URQ>LWCJ]YK%:Y:G
MR%L^\NMMWHTVKPCLX4!XGE/7BW[HS>ZX)3U V0G'X>>V^?7"]KMPR5=T8?:
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M\FKS<OUX[VHEW[I:_QJZOBQN#L!7=#XQP6ES"9.X"2X;X,BF[8)IVTR;SNA
MU#HHNV[ Q!#Q*:C$]5'0FHNALIO0'=D+%#;7Q,01;4#@PXN,/>1@VN K2E$%
M)3Q>]9A/,M0*>$64((-JU5R:U68#Q\')BL?J*, #Q(_LTV9CG @=U$T/,@P?
M7I1VD#=++^L&V9G?!_@K,%=8MP&WBSZX;H9*P]U7)A !B!-8E*61U3"RA91:
M'IP<Q55P7?83&#>.I09""/IK4\'#8,WZ27>\3,R>)K='DR[BD+_L@MD*;U-
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MM6JJ,&=:QI0D+.>$HTM1RB0G22%T7*0%,YE8\[HY8;O1S?:MSK6#H-6%U^Q
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M \-9(I=AE7F!7+AW\_G$%L=2=#!#WBFYOL!IWCDER)5[?L.0PCG?-%X=9<?
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M?-T'KT?P>0#700J>+_@N0W,B5W[/ =TGJYF-4'XO(0>WGLA,8..OH^N+C_D
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M$S+ 6V4Q&;J]QD[HBM>OM]Q($27*P09NRT22E08K?HE4WN7;@2WC4RIQ0EE
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MY;S2DSR)BY7V&DH!9O:QP$2+CJN&*U^+>'9;%XG^?>]A:45L>#YQ'5GI-+1
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MW]Y&"2%J]*IH$&H5C(8VL$:87%D^/9#1$":7EH(<L58MZ&&IOEY6E6>@![-
M3IA- 9 L%!-.8^N:DP!G1L-S6-4YK,IZ6!7'*BE=@O)^QO0Q:JCFZV&UOUJ
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MYWN.&S88,LMU6W.6=:8_:"/#FX[/F[,P]-;SZSYRSG(/-DH26B!Q2].#R>P
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M'"S0DW .2=66V%\ZB2X-0P%/T3200]/PXR8D/52<UVK$=YN/X)1/M?2=AE$
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MV458EEV8[(\G% (_J%/,&]#.T<7L1S:)=8B#HM;5@[=+<)%WG=Y@#\)B+]5
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MI,"?AD8^]=/3.>RYGEIKZE>K<]RSV270ZT'K'!8]VA6@_<AU#O =3=X[3V*
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MN6XRSB(R5#50<]9Q%AXU'4'7(0@F' 9/2=5[B[.)4X9N)$QO+&?1&&.5"%S
M8.)D6,ED*^;.ILP9NF!XCG7. J*Q9L2N?# 1&.$PT3+W.)M/J>=>*G"FA G%
M" +">5MQ-G-43U%0\E>%"<H(0L%]='8V79:>W5+BXPL3A1'D@&OY<#8UF,&3
MXN"1[&PB,#-@B-VUG4T-I@&.R/_;W1QAFEMFRX_<W3Q@/5<%QW_=W6Q?&CCH
M^<D;A@3F_;./$[YA8!RX@(WEVV\829CW%^4( ,-H@%/;I3$&A@& J:^R0QH,
MLPY..^T9(&$8%G!ZJ69(A:4,G)T@D0($A(+-^VO:+Z76RNN8;&RXRJY*=W=;
MU:.*X@^%7#VG&?9\<7VH;FLK9:_*#-;B\,YV*ROQ365^6)I(58PNJZ7U7#>'
M]+8<HGFM;>3&*XS_$I!;C:SC6SQBSI=?TO+M0@GE=A]K6%_F&,MW#79;&\C3
M8[)!#0_N;D.[Y)*+@*]*<:TM3&\[A9V1[VI;VX^ >MXI>%DQ-RH^SYT]PG'.
M.=M& P"V[/?4YJI?T_\\$SS_Z_\'4$L#!!0    ( &DQ9E9=@,^+=!D! )"C
M#  5    8F1S>"TR,#(R,3(S,5]L86(N>&UL[+U[<^2XE2?Z_WX*W)X;N]UQ
M5>ZJ\HS7]HQW(_5J:T95J9"RVC/;<<-!D4B)W4@R33(EI3_]XN!!@DP")),
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M%DWB(E7JZBW8"#\9CW[FU;2KW[;;R7OW]I(Z!F]_FNT?=MLMB;&Y>J^NM?-
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M=H\_TXVR2JO:+WW#!X81M9F/'.W"XC9>LW+2+&\%_F%,2S;U.*5+YO,.IBS
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M W0_?2\O ?(@90YG\73R>8S96)(\>S*5 1Q*-0XY(_V8.I,?\*>##^GPV=*
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ML9B60_-XB^\>8A=%-00>4S7>AZ_4HD _<:(.E?C;.,'+]07]$/%@E;5N8H8
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M<BH^H1R$P815P\#I@8$F@[Z<ANEZ NRUG^]:"^ :[T<QQ:C-F@G2.G_'\9"
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M_>=1ZLC']Q]_^[7P1:3@9S"*\L)B#*5X4<N<Y0[[Q,%.SK/BK_<@WHR%UWB
M-QK@  *B(BC-;,;$.%GGJ,%4>HSP)LA^L?#V5K3F.U_2G.JD!8SY[<]$>B'+
MBXC,5<K\7?2)J  R5C@OJD*"HN]U"F6='\(,XX05C!\1OU"O#2PP0#B*I=0T
M)$8?((F*":K (3"\6J!1$@%7),"5EO-D+2<I,3R/)387*!:KQ'% )0)H5L$A
M!G*I%4B3 I8ZJY9:$@&/9D)%C;Q<:FCIKE;4_-:Z+D_6EYK$(<-/#)[H"%68
M?SVXRO+2.UKYS[@0SG,>@":,5Z#^YP%S+>3C:O:4L0/!FOZ:RJP1>"R8>6RS
MB?.<1[*O,>9^<LRED-)$=DILBQL0X#\$<1EA*$V"=?JGQ%OCZ@$>1<2#C"&4
M/!;*. XKI#(;[BC<0343A=E@I\(='#]WHDY[,@C"*JKB0(]((HGYX@;JMP7:
M_Q!NYJ0Y)SV89C=D605A"O3>"EP]OV%QE<N,A:,"I\_TE\\IB6[C35Q<8OI>
MQ2PQR0;@>2[#..EC&(L!SU AAZ0O,!V3/B;EH*XD$\>\J^;X'-V4/-^4/)=#
M(3864@8[398///B#O[6[<_XC?HY#@L=I@9+(!+;4<?-5OX2DY!IM=WS^W#2H
MP*/@@%W#1E\[PK^^GAK_V@HCQ,R#^P@]*C<RA[W$/U](M=!*U*6D7M7?+>F?
M#$>D!S,3A%+:9NL@?+)DKRP(7)H(G(9ST!F Y_ V#0/R[W0.>12'=FJB,-(G
M,W/%[,T]G8PN4@E/\"I7VL)5D($%)[_#F8SIB,/S/:]GS6"P;06ARY$@<8=;
M6TNXLL>]+.[-1CP3 5S,'O&:\E^B3[AX3B/WD?G++8;*A<D3"Q3(KW> 7O I
M3B"92.937.[P37)-J8 [:*QC[5].F1>IY\N!$!_I#/&QD!BLS&@]0W0\B#2#
M$9DWS6DX,$M9CU^HTIMM !(B.0KHH6$M!*,@0*4D:4'W\"8HX$[=(]K*0;:9
M;5[$!ZO(406.$H03*DFZ8Z)YVUS&9%?@41 MGUNP/2-.=O9\B&_1=C->G@@+
MJO9CX,,YV#;=!O312#?XENZ%Q4L0$V822/F[PL1L4-7IQF%OSDC(%]AT?#CT
M+0SX'2J'!&>*>,S44<5;-PD83/6Z+Y(B9H>!GO-*]N-V26Y\OV @N:*:8'-/
M6#>2J@NC5GY&<DK<5"\V#8,IA^5%BZ+(XD<Z3_T"?\W+V2)-J5-!BEA?7TAE
M.NTBV$D46,LUI<8L87=691$>>5F$&19;<[ $%2*E !_YE7 O#I/#.G.N*BKP
M5)*WN+C&,N[@6(F#$@&/MHP$F.5<F]DKC3F[S.X$A5,@IE20<F-QXK@:6X*F
M*(2=2@4'X2NP.WFZ!B'I*QQY^A('9)72Y_8@?= >+,J+'!8%<ER$86!XT &A
MOPP6+H(W9S;T:5>#'"S$<HW*$5$Y)&)C0K09B#PMB9.GOA#&N+!C=H8K;ZH:
MVU4:7\<;*>M1AJ[-XQ:9(,;YNS:(6V2DL0/O:[&(I0W<P;8"0, K*JT7^T44
M05[]79I35?C_Q-L1)10X020HGB%.$U&B#FLJV..BENGL@Q4)IWA-'^& <$S%
M:_J[8V_X$IZ1$Y0HC8SDS#E0O\6T;!P<<9'@,8J%^L&6P9HSGGSK#7LU_WD;
M+U2Y[JZ>:26ZA\KI>K?IJ,-0C<' _$R^TQ-CD[1RZ,.3[XK#QNX<\BU=[=GS
M--GEJU1@HS.4G6 S7K1D9-^MTG<2K%Y0GC\71&$ =)\& ZZ%2XN<-'8;_R1%
M^BX5'&TY<6<[*T[O@^B6YWQ8V%%Q^H[20X+@?"=-RODB9;[.]\WXB3?W"UWP
M+(ADUHY#R]8]SHLLAKS6BR!_'N/LJR@A(.7<P3=RYC4)L9QY2$G-=<JD=9V=
M&ST%7-\R8U5G1F-N<J/G<BWA"-$RXX5VW ?RV&.H:<"5O*23\7*3A!D$UEQB
M_M\*-.H>ASA^&<&5)(V^E<2_JR%!50.<"'NM>,DE.]D$[%Q")6J 1DJXVYI>
M\G>4EA5WNJ"-5.+HG]]_^/:7[Z RAUMH0:M<$0-#0)B>JBF\TM*VO5S3_TIP
MMI%?B%NK4T'1-<:_%0Y(8_*2F&M,_P/7PJ$?8HR8T@I"V>*!<2Z_V.2S]8;[
M\="+<AK<]$ -;?E@+HLFJ1D?H\M8WM71B<_0__O^-^_??T#;(.,U4,_0OYR]
M?_\>_A\%N^(YS2#;_E_1>_0ME(AE4>)0U_*[R0M'6%B)9JQ)(_7E3(9@\&2^
M,UD(YYS'HIP :VHD41=S5:31*?"G7J-=G#F^/"UP0_HPXC!G+_IYEQ<L!'Z5
M+J*(E54(R%T01S?)1;"-Z?I5E0GKM0MY&0;\@+.7.,3<)R,01:#!Z!MJ>I3J
MV:V&LM47=S<7$G;Z40\_6JI-@(8",A)2)N'\0,QM <GAVAF@6XUK-XG0HH J
M'QO5U2KR@]"BT/[CJ3#3)GPI9,_0#QG$8;N,4V-H<EBZ8TK'SP6H[3BCTE*Q
M_QQL\&6Z">)1*?TJ100D3XP7HF$#_<3IN<R- SB7SVF2RG0OG@0Q'M@F%LD4
MD,GSG:-R59:9(.K\57(B,V2JK+XR['@<?I@H_<NNY4D* %OBHJ5\\>GQ4"LY
M+K=1G8_][+D@3088.24NWFGV%SA'[K+T)8YP=+[_D@.4;(DLM@B+^&5T=6R(
MS06/$5/ V0]826%B 'MUUQ+X?=F$(,.YPA\+RMF<XHJ0:C%@!'2G\/@MC$(O
M\^\41+F%0VZ9/U;4R;B!UY"NOXK7NUPOLYCJW %A^AV$W,.KN4BB2_Q8C"J&
MJIY964@D%E,X0X$R"5:>\N:2;9"(#LLAA"#(V9%=V..JD+X+DHH9<)L6BL0<
M?A6+U/#^G\IBW=+A2)K5'$"K%$I^Y+ ,+"6]+/=%UVF%Z150W&S@$N0 (Z-*
M9HC1H?);Y2<J^/B,;UYG5ZDX!LM3L$F@6)G%5[,\S9(<_U@A7<F/N:\,RR!<
MKN]H&_D]*?]7>1%O@@+G=RF)P[T5]S$;";A5QV+<EJ.=)(]$96_98&^ALH?X
M2(Z]RQ.PW PBZ_ZR#@/+N,Z["M[@<%.Q#R?A_C9.\$V!-\<>6X&P +8HA2KZ
M">@B1M@_#-!H=?7D.&A7\_2(/P#XX^Q!>0S3;'L97:?9!F=D?Y&^@!AD)2B3
M$K^@Q-'E)?IV+>@C,<!WKB)Y[7)4/G\E)TU&G%=.L\I/71XT?!Z'>G4*%S='
M?A]E2P Z$D+^#!6.T7%&S)JH$[YSA7E?@]N#4\@*HX,)(2!W*:]"/]*Y49(6
M)=$Y<22I3P+-L\*;;9H%V9[7XE2!C,>Y-+35L,]$U,A)\"2^5$D1<9+"I9@[
M]](?"U"BP2?Y(8@3P"^J2KU*!)Y1'_L9/*E0MQ6M <3DQ0W:R.S71&P6AT N
M9PAF*R&^U*K"<LXN$ZVO8X(_[^R V2Y"R.FE:\ )SG/:+5GA3N<,7MJ'D"KY
M69Q^2?(M#N-UC*-17EE);P)GK/)4@B'^FJ2O8_W_M2>26?<95??X-)IZPE70
M2'Z^K]H(U8*5&_Z<)B*#[P?(R:#W"H]H^0N&S P<+>C#&#SAJS><A7&.[[+X
MB(!B96-*NBC@A!$6E.G#&T,<,9L&Q,2]\BP15_:4>2^9W% L&YR' JG35..!
M<G2^1VK#,F8()LOJJ<G,4#Y?>A-+9(+R:X@Y(SEIQ&;]JUSZMFHEZ#"Z#P7J
M)WC<B\Q]WE!6" O8)TC #2$^P1/_!/0-Y/&OZ-5\(-S#=-43O/ACH>:27P2$
M@ ?T*@B?ZVW'14S(+# 1E5VD52XY6TJ'WMW).:_=@+\BOL4UILW\.Q/"20,^
M@4\ #A5,X:"7^ZA @<:A7$DKVGU$G=8R,E#B?"BD$=!V7K%UX+<7[7+1<&1U
MQ=/9\V/Y;CGI>0N_W&'&4'ASMW58)N9_](DO%TWV<"4 7L<A"8K=WW>;X'&\
M/56E-ML)D\.YNK9@CY]T0QY3";IR(UPL?[RY_/"'9A%:=G./WRJ,^KL/?Y!E
MD!G9D^%$'G"T1#^B&T2)MU1VYF^<XZUEG[?&5BL_U&%17S;(U++Y[;$.X9Z(
M$K=3.(;M<M;UW#AFBIG \!/LF1\P8!1MG^,P(..3+%1J,Y\V.9RQ0^L=2PT!
MR=E.Y:L8#C6=L&+YGMV<B7&ZTUI*U9(1W+EDTV2J4O\?PGDU3<F/W6,>TUL^
MVS\$4*F"3>08=:^VOP)>:\)UH45;<R<MTW:FEH+#8[&+XB+-H(3;B-*Z@@J2
M9*8) SBV)OE!#,.=C&$0%-V7^K' A1I(@O/\CV5E=5'-RVUNQG@&B.D+3%08
M87PB9JT@PIQGW932Q-7B_.$"Q[,2^L@R!0*R*"ZHE+BGO[2$6\%J+*DAEF*@
M21$K'/):P8_H.9T*>,0)F\3,W8EQTY9:1? 3%1O#:BB'\@B5'W*AAG_&]HH_
MS'S&I#99>O*3\'D39"ZK4U?R>5,HAX=MM&#>(HL#W<D$<ORW'7V-KU[ P3J6
MF9(<XO0F8:(,_5)J%5G)0JEBMDYD\J0Y[WKY)O>I)-+A<0&O4P:&PC'K7[DP
M'DF:1L+I3W: 5<@&8&;"V;)":EPL(52)37HUYTDW;+/5)U!6W&4%]E8T(,6+
M*T)6'ILA*R)>182D@*+1"%:YQR %,]Q)7C\8JD;A;//!2IB5#.Q1B*/;>(W1
MMZQX]'=G2)D9>H<N<<B>*_3;#V< F_?Q5[VD\OE0$)ET85C@NVQ%;H(9G\D0
MK-IRGQW&7Y4SKWVPE=/2V'=9&F(<Y5" E;WZ]?4='H9>]_U+\KRD:AG=!&4D
MF!HH(J-.B+]&/?.OC#O2QAC7V&4<84E[&K8D6@!D.)?EJ.U]M.(95P@ D\5E
M6&?0=.J^$A9;MR;PE@N;M>3+44P1STK>Y7&"06_?/,8)>P=*%;Z %/PX8JF=
M]8A6P36;V#V.\(8=I<4&@"A&IBZ)H5D"?CEV+3SUK+XP9R@K9P!@&3MGY8G\
MKY78,G(B2)D)4M:N-I=Z=+4LEL[CMJKYH,77O7+-_'BY@J&R@F&?W5???(=[
MSUD43SDYIG+R8#*^-I9.'$L=0QDC[/;2L<@+.6"#:^2<IMCG\V>C&:MC_"H.
M%</;-'FBVV,#L$;'!@G7_&F4WCL@B(#B&0L.GO?LB3+Q57WBSMS'/(\$9S'.
M?U"R=^M US*4U$*H"!L)_8#43.$&%G89N7J2W)(C&'4=X.>6XV:>C^0\U">#
MESEIKIZLU6NZ>DYW>9!$#_$;5'$9OW?I;W_GJ+2-U3F+'4C)(4D/48*BEHW;
MG6:+A\:>*I?>X?MS4$H$0(3HOV/N1%RG&8/INL<Y#K)P;.4W1D, Y[U@DFZ9
MC0OJRH=LS"DKW=AE5&R_UOHI#$*)#85J8T'R.Q_-T;Z\ 4SW@,B+;KRZ* B6
M%YE;]<_*],G)SKQQ&V@X<'@WW&6 JEWLX0H"Z$WPXK(3:\4+^1 ^XVC'#2]R
M) Z8)H<Y)<XJVQ(C?,;N[:+.CRA4B-S[*ZGRSI$4;W1J_]'Q"8(PI"#KU/>3
M8>J@B+H_YKXD=(!7B'U,GB3:;4YW)IADXCP'NSG]ERP+)ZO&'PDJU>!;';N$
MM^60VF$U/"]\)>O2R1+S$D3+E4@[Z;J(35Y;CW)0AF.I#,O^7=;IDR.[P^B:
M?CG4V]K&'IG&52"1#Z_3C%6'L %#WZR8<;*<M+I OBW!(JED^AWB-36F@9"O
MBC6SN#?@6GJN >7J8D<5YPU$?%@0.&1L'>S1EOJZI8B>)B&&*;C-!G#%,:DS
MRSZP'("C<LDAI@B<8H6+U#U=;JL5%6+S@#VWQ^YB7A5I6]O+59V'0AG@I+AK
MO,[]N7294*H>BOLX_X4?%OAII#.D(LMB^\4A!,+LH/++Z O$:!5!G+B]A2QR
M25H89%R=J2R>E7#8XK^3U%Q>T&6,8K*CUSJN0!2NWCC 'K^1-MM=(2HQ2+2]
M.YQQ6*5].X&QK@N5J@+N\*M8!V)< N?H+O=EY1R G1.)3,Q\94*$O7HKJ'P'
MEN[;>%Q$;#4^P[U3LMDZ86.K2:"KA-Z;_*A]96M%3F>9&H[:FGYNL9*"+OCB
MI!@B9EXFK)7@AK^&)%,%[<,N#;@(#D+,EO,)]4AU9A>'LDV9JJ"4W!09\M&R
M :1[ +M;A[.]M0&QH:0Y*#.22?M4)$J:H+DM0+L-G-V)T#GFL)2DN8IG[<N8
M'BSCV6S64=K&VQ 3((FJ";-EQR"_VVP ]9N>3:'R[T6)8!]!"Y,O!3ET2VB3
MV,Y:<,8FL>ZWEV2_"[)EQD2 B.UX*:&.C0%N0-EO ^=PYV[XJ@=O?RU<D29#
M#YPA2A]V)1]!/"1T#!Z:YU1Y/K!BE5CN%I B2M=ZYCJAUP4GBJAW:(FK@=X[
MAY$ R V,6=V@2YR'6;RU\=YRJF>R[*Q"V?&;66%"CT@&$[#A,\NM$[/Z=:Z9
M?(_+*>ASYR2"^6,+@'D-O!RW8);K<^8^_#H7_@@$<S. >0V\'+=@EF?E)PB5
M3P"!Q1]<VK29'?8Z"-G%.PZ:AIMT):TI0-4:" >CQ=Y#B(-)!%EK?-0UF08S
M[N;?.(0R4?T2C+A4WF/I \M=D1<!0[@9B8,M!GLG#XY$@ZX&0#M> YP=U1VS
MKB2X0(3YD*@0R'J<H8C/[V37I>U!-:S*Z3-,-,*# H?-N5ZJ7%^>.-<JWMUQ
MK#O#PV,O^7*]SG'!@G%*Z/^C=8.*&%+P_IW%J-J9>T-84'B(*GW-89(>N&!2
M0JBJFP4D_CN.;NGP#"J$/<D6X+:A#E-]",3'8- G;)238HYT\E6YX5U#<#MA
ML)G:!XR&=49)R2C/.T ;-I*K7;J(?J::/@NQ6J6+*&(^N8#<!7%TDUP$VYC>
M4/(0RM@]J,E^M!NY&@^*1P3EB%0PCZ-W(!WP0:M#6@;M03UV5_$RDZU#8PN,
M7@^7WB>J^!3X-GZ!8HST]7H".SO/'/D4_)QF#/7R<[#!XQ$_^5#OV%BH&JS,
M4V'C(0ZS"2.>+-/D.'XG4-OJ.N>(2)$#C=-QA,A=FC$C15&Z^%H0WD8]2&($
M% !7I0>T!E7N' K1!I?K(']D' JB"I/?!_0CT0LNV)%B",-T8_).+L-:TGU
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MRY#/EG=9G(3Q.F#7"1"S+%Y22Z;2/XX;C0IP\*'>(YD1##;1?#4305_CA7,
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MW#;>R S4W@1$%8,@?G?@+T..V3)QPD_<.&#P.H1TC:P8(=M$(@4L()C#^7^
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MG%.@]^4;VWFP#L*XV'Y-(G#]TCW4=W:71SD>E*7A@/P\C-!!2TFQCP!OQ!/
MZMC56.2KQB[)_XSQR/0M8*]91J<_?U\^DUGV&"32U8V=-71^34D?<^."W=T<
M",U?8Z@*=TX'C.9>0;,?#&_=^#=QBR8R)6Y^^WZ0X_E:T(HE[#I1W5OR65+-
M3E,EU78Q)$E&!E3PW$R,H=86.Q/K%CI8D1[5$MA4-YV)&6\*_=X<?,\+VYV2
M"W,.:AF)NG7.^)#N!)-*Q$<]=6\A)+Z (,OVU[AX.M_PB_:*9CH3IBRO%U4G
MMVEROLDR6B;+V+(1KK!)4F:,(VI-DC1Y'XJA_/(1]C0)^K(L!B8P,E%#&UE0
MYN"B_H@/3^3X?CD*>YJ9>O1(S1 VU0C5#)5D#D>O'9_$'I)(4O!90VWO+2WD
M5#@AZ\RTX DRE4 FF3+P,(,L2C</Q7+#5((9,L'^Z\>/O^!!^J\?_^.7D: W
MX@P:_=Q 'RRAE'=: 2\+DV_2G-\1Y<#>0P\N43,'@'T64QE]JO":GL\V15X$
MV!_=KB2LVF->"">&]+&@:J@7ZQY:F<@N"' 6P7<1,;K+TC7-BNT=EPB13]UJ
MV,K[*84*4C__79;]H9)+4@U ^ @RKPFHY,0@_"<8!L%Z;"E=Z1QWQ>_Y<,:Y
M:0&XE-(&JC2KZWLU;'U;&_"I>?9H;[RFK]K7)'V ENUPFB ](I 1):!BX(3%
M^(3.<Z9*@K*15)7R3Y#2]PRR^N1-FF<OW9F]29_3)VAB32?03!*A"6\\^D%A
MH[0K_ZJX?135&N1,\2&DVW/-!QD1/K8+;;8D2KB,94BO]MVXH-7K78Y]>KX\
M&F 5.TE& $&R?^/P=)4+"G7TG/=QNI+5LFAOV> 5YM -8]N+F&T**LLSKM+L
M+$TV.083[>@F:Q2B,!2)Q%AH 1>BG.L!AB.!&&^,F-D.7."#1;AR&%4PP@<B
M.!*9CA?N?J+8HYZR1V/OEA:" .CFA!J&:DT\4/@RV#&"HLCBAXWH8EOK"OV4
MLL@KO8D5(--!I. ,5%56:BFII-Z!F)_(M#;[=X$?!XZ;"3<OD]XG_!Q:+X/'
M%PN\X_SW&Q<1Y(I4 F(]QT[=PV$](VDFYMHZ<'*K8 :4W2NC45-S,0R2==*1
MRBU"^;SVD8QY<]Q6_!OWT_G]>?KMTX+F5H^I='" Q/=<Y/M/I*#>"AQ=Z%_U
M*0&K+-+ZWI/SE'S[1!;#UK[5PU1[ -[R(63H>;9$BXA?Z9ZIXH^W2H P>.E+
MR1ZIZ9VC86\%2#TKP0"T+@%)>@IOB3?:&6>T<H& \X[C+:_ZN:INNG+'KI<\
MVE5W5@H7?Y 9J*V+*XU_0E9&NQV,R6],=V2,2D*\VM!R O^6/LP'X<-DY3$8
M-DRSKY4&Z<5SKCE_<[ZD2?$$60L0IZ-\T2/[6%!8.<-!/A'6#-^J5S"$R$D(
MC4$\=9_U!K"V&(['.*:GR/I_@&7GC\9F'_8NN%IOC_=E;X^1@&&'<'1 3F_6
M+4R3Z):K4?X&><0")'%SX#(]3QD?/(4+!#^%33(7)) S_FUPM52^--II8*YF
M@/QVD4+FO%<6T5IB0GF33//\G,_+=IEFX">T\G8UIB<8]TOPZU4&ZX#^T1_P
MFM?)\ @ SM"4/4J [,2'VD4'%/XR/_-[)6VL\YWRU_J9&VX88G92#7N_6:V
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MD1&$\WF7LCC<.O$4B@%D7YY I%3Y;"/K!1!KP#(UL! AG_SFU1WG#U^]FYK
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M.\XW>9&NJ(]FIQU.CK*]U4@P,]5M%*8*FR7R"1%V-([8*<.ND4)S%V2S[+Z
MTF4T]$]-O-V7Y<2?N.^NQ!X0M6<YC1,/JT"1R4Y<..&+3XB75SV/^=Z0(R*"
M2;]2QOXG25^2>QKD:4(CK'@\^?Q F02$OO\=I!(E5A1W9B. 4CG32SSD?[K!
M4T;@)<.#:&(7B)KVWRF+G](T@GY]R^ YS6"SNJ<%-]=7UN0)8D@DLZ#EH!/"
M]+"P:V[*@4FN1Q[Y1+#*#$!&_*4Y S>5&3!&)/<>9T"TH)9I^JK #(GHI;>7
M1M-';BKGQ32*L 8F8- :[SJ1U/%.ZAM259L7PLB0C"Z&)H$8FY2#\QTYCM['
M"0G%^&]@2EAM-G2E(@Y*]*ADNCL;,/#[ZT01^;^!V:CW,#]ZC02M:\17;MT7
M&L4A/SP=-(.1D@:I**OJZ/N>9J=L;?DH83[O8=[Z+W[&M(E3^R_6:I9T \_Y
M_=></(+H<3;OM)L5=Q&3([M2"G5]L@>+MR9.H%L3,/O+..&T^!(40/B]O3@]
MLB3%BHX(#S( &11D)463R$LPR ND^M9P#+0^:NT=\Q^K<:KEZ./$Q:J0&@OM
MNR,]%ME/V*=G^M%3#Z/I^X_^NQ@Y!\*J&'8@>.]XZ1!+/7NL?"YK#0J]1;[,
MS%D2QJO5)J$W\0HZ']FO+2V12)&#UIRU*.U[$;G1OK9\=E#T:9FV)F8VFEHN
M4S*KQNF!O%5I1/5JKO8W515G826-](><CE<8\/FQ33[J-OJD^TSJYH36_&H#
M'9^DJ:IZ7U] FP*@#(/R^%/S+VHIK=#M#<<BRBY6HTT('P_F!D;$BOS.\GE]
MP*\1+/S)'Q9%%#Q;ZO0__4-IH]H%T^40<*\W,OB^\,GCHCWW%N\"9Z49F@8X
M0+=%>Z-'HTVO<,)8Y;N"\R8M)?Y8,R&J*^Z+("N4)5N*)._)7X-D SD*'R>$
MO]H?1MH9U-$T7291XR1=T!!?1?+S#SY-[ER!!]JH5AIU"UV[8EJZB1-Z7="5
MU3%9:R!!?@.I!,5VQM]U,A#6)P9(081^\S"ZFUQ33&HL2M8KOXFF;O1GANJ+
MJNH=))A:MN*TIUKS7630!S[Y2!WU%U6]Y[O,F+9M4-N0,>V]2ZH;%*P_ -=)
M1)?MO'-?@G^DV3D+\AQ*&>PWRW*X]ZR1>(X?SC@FP4$]EWET )[MX&XFW&O
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M_#.*Q43%R3U3973H(L4AYXHOA16H2AUX;&%XO<O#*4AM9LO5N@:: #ESS"J
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M)71OP4&&W;-[D-Q%<?P (/KV+@JSN7P0WQIV_Q%VX#9$;<'*>9.^R @]1^'
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MIH?__-S\<V%NE3Y:"C^FGT)^ SA=!O 62"!Q-MCJF>[V/2POJCZGE5X>09Q
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MF^70*)*T)HB<L+#%]B>Q'"5I&8OFMV(Y3C)B%L=!ID#JHW5I?SL+"#V=<88
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MJ)!L L)7?I F5(JGM=8P\=\ CF,&WN(%H;@!]^GN&<#ENJ6ILTA&;@QS%EG
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MLUX];3#3HF:Y8ZN4*8X(VVI:>898=M?:PQ/9'#@5F%KV1,'$YDJ!V>=2<N+
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M&",X2F9,+LMW9UESQ%EENZMF95,FP(/?3]EA._&O!S0VV./,?91*!/SVREG
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M^5S,#'AB>&\W0G*D?01M3XHCYTY]JI8F[M=L.8+=_>\;Q_GH33U-P 0\LVN
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M-;JZ&N_K-?IRYIY6\(Q'T,HHQVJI?8ON?.?9#^@9Y&BMS9FX8JKJ,JZ.:D(
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M^KYQCL%F;6^-L]'\CRK_(\  (R 18Z1U745%5W!F-@#&R;I)LXSV;6-(=]6
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MI(CM/VW1M1/?QG':,MZ+]%!-R!\E"9G<7@LAH\]OHP!=JW&.TWV4@.RW3_O
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M^;W\QY+O>A>'SZ$'X"OT$\HK>O]1M2B)D0N %^/8BXS;A&[]!J+JB[Q^Z@1
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MNUV,9Q>IVL,HA@C+GP6$+!E5F*A6@ZD 13<Z$&%JJ_CVYO7@VC6("#7L"!.
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MB]Q6PZ0K4\#[>8\NE=-O5NA?L9,+1$P>)SO*2$3]"/9%Q?7%!AUZ/)FL@@>
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MY]#O@DX+YQ@8 UU*] 7V@0*1,%&6@)B"YF )XX: 'Z,!L1E^S-N/N.&%$AQ
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M8GWDTSG"7_TZ_ZUSY'\M[/]02P,$%     @ :3%F5D$G6>"/"   0TP   \
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M)6N^.V_4)@L^M](/=?CN#0R.3_ITP(GA \&'G(&G"TLNE,JH)%V.T0K1BGP
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M>GTB:OLDEGIH)TQA>$]89R@,1/%FKC=H69D#O)THLZ1MB?G=Q/S13F#^[@%
MWO\X:M8;9RU;P+K(#'&OU'$LX'+/[GOX7!-JN <J $^$DB.@" =KAE+8/K9
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M;#?R!HR&IX,+>-\=?>B/H#?\<]#?)H!JW:TJ<I62*B552AXQ)=4Z]DAI'<F
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MW@#\_?+!@_"F59O4ZYXQ\;4!A\N?P\B87/!@TOQI2T8L>MUO]LW4PYU_V"N
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MDP)?^J7"W$' 0*7@*Y*2%CK8=2H;!L=P3$U+8?#3.YNGB3E3P.Z/'\^#Y7.
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M<0I%2KV4.$@+;PJ/CE,,%:O[RP.20M<D02*=66B034K<?2YPD!6!NY,+D;R
MX)J,_%CEL $T[52 E.FT+-6K"B/3U?>6FB7DF8\0@$>C"0DGH]^P]<UT2\UP
M/8#K"2Y@/C3R[+Z]HW&/-2DC/=GJ6R$_XRCMJ2!9;%'B]+A[<NI9J3I'.B%Q
M%AZ2BW22CHA#+^.:ZM&DR^!R@W#D]%0DV8N]3Y2,9\4EQ2^Y=[DE;Y/IV)$1
M8J1.IDXD$ARE5\K'IZZO-#)2:>!(;E[A^5$(O;81+5&LP43<Y<V1H+E+.$_I
M,57\&D/*S=<:]8R><4C106V0*X*U*5BPO6=G3M+#0X"4^]Y= +:KY',MTF)_
M@1VK'^<7(W6RR\0+4A QAKLCC;8M-82B3/#P*%Z:(36YHO[U7CZQYGW?FPNV
MNOCKX-KI)+V"N%OHL98,\2]87JJA(@NGPM'34U0=B0[A,;IA6CC/ F'>)E!2
MX[1T'#)MVF&]#I+H=1]>> ( FSH\,*QZ2>;$6"E0O)U.##?C/E/F(@D6K#]X
M!*,-IOK&(2K93;&8+DI;^S"91IT&CYGW"86:D.)T%X+_!T7(CO%U\#Q!4YJ8
MC9J>!"D=A\2&#FGYS?1-,Z2:-54,RHT8ILPNL OK(Y3I^R?A>C'0/P"3@1(;
M"O'+&$KEN:-Y!6X=</J7FZIM_SO_C7]Q]>5_ 5!+ P04    " !I,696<5:/
M"4-[ 0!LU $ $0   &EM9S,T-#4T,S W7S$N:G!G[+P%5%W-EB=^L:"!0'!-
MD. $MP"70/"@P3VXN]M%@@1W=W=W=W?GXN[N>H>O7[_N>;.Z^WT]Z]_3,__U
MSEV_575N[7.J]JFJO6N?O>M YB%K@'?BPF+" "AH  #J]0> + ($ 0AOWL"_
M@4. AX='1$1 0L%\BX*,C(*'\1X-DPB?A)@(GY#P SD#Y0=2.C)"0BH.:CI&
M)E965A)*+EY.9AX&%E;F/VX"A8B(B(*,@OOV+2[S1\*/S/_I ](.0$> H8+G
MA($B!4"C0\&@0T&Z 22O[82#^J<#\,\'%#0,+-P;> 1$).17@IIW &@H&!AH
M6!@X.%C8UU+WUW( +#H<QD>FKV_>R_Z$)[7&9/:*R$ @$ZCHP)*;."-GT;'Q
M1D3"QL'%PZ?X1$E%3</*QL[!R<4M^$U(6$143/R'O(*BDK**JJZ>OH&AD;&)
MK9V]@Z.3LXO/+U\__X#?@9%1T3&Q<?$)B9E9V3FY>?D%A955U36U=?4-C9U=
MW3V]??T#@Y-3TS.S<_,+X/6-S:WMG=V]_8/SB\NKZYO;N_N'/_B" L! _?7X
M-_E"?^4+&A86!A;^#[Z@H!W_($"'A?O(] ;CJRS\3^OWI,Q>")@"$1D5'8AD
M+')G6#HV$TC8Y*SK%.=_L/9/G/TYQKS_MSC[%\;^E2\P  4&ZK7S8- !0,#M
M U6F)]*_A>\;B:-PABO+.HAR7.'JYE_>6RTG8L#P]V>U<(QJJ>[0UZC,.H0J
M+I/]E&$FM.<B?X;3Y(  ##&*A[-I+%"5<+EZ45GNW&F2E1M",IA3K];6;HO?
MTEQL7%^R6M__%!UT(,O;'3'&P R/!(@8L":64]H\8\G1ICJTO=U7](*5PZV6
M%0)@_@/_;Z+//#/514%EB)EOM:7Z^&$S$&#:2H*WF\LT?E-*;&3P?H!PHFDY
M]F=J=O+UFU+WW(M9)923RK26IA+-B=Q&YGX)KE_>8A9);;TU$M'^!:6H0W9B
M,WKAGT>MIS<3 W$S])A[\%FE8%!9TKX[7!=L!F,NB9*?69FT^#"NFL@+C[<"
M#B]N\G$A $8$/5.;;',*!<#6,TA\?;<UT=7/T0#%)607=LZ:N<ORT^:'L&U*
M8P *JA@,<4S[TNBGEDBG:8:=?NCJ7&J"60_27ZHT*WC!!XS%A0CMUSN-;UGD
M0D^P[+C@YVJ<#VFKWM?\YA4E.LR;,-NM*E>+Z\=@%R#NJG@R2I930J@JAR>-
M3:^-<M.>OO[]4PA3!NK/ IQ0/S4F'NJ)8YUEG9T9CUP_43\IR_]_88+VRF&$
MB]PD(#.0ZA_X^X"*)*0NS/W.\!76<=?K;OJ2F$EAJ8@68X&(VR[WETVC;T?+
M;'/^1/DJ:05\?HF*9<;4QYJ:^&3&WC7_LO&9^>/CK)0\]L=/VW7H4?L2U+])
MC?-"W+*'MN-B>$?4C .[)*<1%!R.G:40:$0X'US0)LOE3D;G-"/>C;2Z%U[0
M6N$^0',;8M58\N#<=.J1=]O O+.575I40R1+.,9V1O[%,,@,=7HG4SV.VV]O
MRI7E!@TKYVR&HG=F U3MYB,RMM2D,E3@:2RB7K?M=2K-&$8OE4>H;*^ (4SE
M>IB)YO=9;4%2G*>WB4TSF74HPM1S_ND,$YP* <SF*+OU:Y #6;9";;WFY92'
MT%5*QOOB"4NGN=J/$VT9$PB,P)B&Z>33%;_SQ!V.>85,%+'23BRV M[[ZKPQ
MM982$NWYSSQC7AKN\*O\?"BCUVGCFQD9"%"EIDJ'^R_+(.+DT+-Q_RA H<H,
M!/P#?P^)?=">'^N[W/+"G0HGZ6"94TK[\LG?2Z6J<WNCN@3+P[ZQ7!'F GXV
M\^"K'O=/[T),[N\.B;=8]7PV9==0G52+K123T(NQC$,.M>$]F.G-,S8+,*0)
M$)/[I1_3T@X!\ 3V6>=]*C2HKDO<2TOYQ>/;S_5TJ1AGS6ZJ!F7Q,Q26E'0>
M#$_<4% #9VM(50<SUDX;D4QXW5="9Q:&O8?I!X]"N%:V+FM3B>+G#/_!*_0M
M0SI%T$H*8\(WD'$'#:[Y6*Z(2=7[9?=4$C8=')0WV[!K+I>2D5_-DI)_XUZM
M^CZQB.EC'EQ*L.9TAT3+P0^V)LMIR_PL^%HJI>V-56='WV3!\>Y+:L.(II=^
M[#3=;\0OSH>W;9TA MOT/ 79BN#LI\?R+#)<X$LAW!Z-B@"-^5(#T$F7/-#5
M2X-/4G+:$Q7G S%+M>*6(0TM'NEEZ:^U2 - P7XOYXN"QZQYGS%/*(V*$)@J
M,QP.4Y;_SP!J7V8GE_?MUT2 ^D3B]XE$'1Q6@RA6 \__"Q,*Z2:IW+SE/#E<
M62%,P-\!5+?3TQA[QGH30AE#2693R\4V^T7\?"F\M?KRH3&[2\E*&M%8\,EV
MC55D377/-*%AJ6GN>=M3L <:!% >=H5Y"@\!]"]ODCP\A4$ 7]D6I=2K3[<?
MDMG(1A1*3Z\:AG)Z_$D:S^<VI.^F]WG#GB[/RUZS<X6R*LU"#QZ?@MY:M'GM
M2/"FO1:$_4$3]$]9T!\T8LZ;$A*N ^O>@S<G7PP6K5G1M\EX>VW!=<4G:VW5
M@0<+75TT)XI$/=^R'S*$D_6.TM:LH%VE[W<W5H<A@)#/:<:O _Q)Y>$U[T(8
M22Y;U3\8D$41OX949ER@HG7R2+'$<ORXHN83.- 4,JZF=<;)PIOW6K7EFO3=
M%,J-$P2@M $!M*>=EXEEYG;S$#V\P">PWH NQWJ!7L#-'_M6^P^UZ;/4CANF
MQMW",@P&U.&<U[=EPJ6*H'MJ= A@GJGMBCLVF-+WQH*^^F1R\07QLQ=E(@BY
M>VJ$?)0BPK&_)]ZSCS!QWS3N#@0!D%:"YIQ!5RP:0O(.(@;O5=]=?17"_,$-
M'4B5_O]K9"6=X$<F?!C$!_0G)'(I"H?'_.SP@(Z81N5K"Z&38PW"]0KW,_M-
MOM48VAK/]M-'E)V0.6J\U'H5.%B$QS.2J?+[/>,WHSEXON07MF\)$ED][%D4
M2QU;8BJ#O>U^,-./#D^%1#A*WL:E\HM#[V0 =KQO7&<7,1L,@XLBL\(KS;6S
M\MNY((#K&7K@MRKEW06NJ&%".$XJWO.5T@<36@=6 ?(I?S%'AM7X+"OGS;Q-
M.1X@.R;<![>\M#XVX5'D_)!._C-?%"@**0ZH43AEG(0ZEF8S)"9%?F<45$9>
M6[GQ07!L.,/Q)+":59;,DOQRLN1W4,#ZMQ@I9HZGIFC7L,XDGJI[':[,;V)2
MG1U5=7R9N<K-=8K.^"* 7TN ]DU>JGID^DIU-6>6R/92Q)<VU1R*YDQY4DLN
M\2,:?BCI[[OY!726X!,)SW$)7!$P3T=PF*R4"+0]G'+?Z-2^<#[2UGT5;,@G
ML&<%[@>O,;=;7EY?L9P&1_H#6ZE4'3IB_E'D@MXUJ%'K?:E)W45<-CJC.2)J
M(\P_)3#^"?X9^;8_B/W2<SU?I:$XU;N&+-9H&>@O1R%IL,>P:_:<9423ISP*
MFP4U!(M:&"##EJ8-9-REW),U;?2K@3&V(X9%]'CHQ:^<1)).3S>:;\Y9M$RP
MZR[VE,XQABM%\_%:!';GQL-RU!$C]EK?U<]]&I=W"ESJ !%$&WSQL,?M(K1"
MD[U32E1W.E0EIHM2#MVQO!/9:,/N_> A4-\GK0[M45^$#PRNP>7#,:G25.>I
M$J%<H-L%-2_Z\]R"F4T9B.![=MOS)"11Y_<OTFKNF_P3I9C15JYP>VDBJQPI
M6OLJ3&][A[I40XZ8?V;5.(9,WRY>1-QMU*?Y>C VSLJ=?I]AT'2MAP#<,2,)
MJR@%@#!A8^#\-'20T=.[>D.W,:22Z-0&%*;[4MI/&NR'79H$9WU!U?U>J50W
MZKF<VMW'E(OP\&?963E^*W6LS>Z;28O2..!]L/Y6>(?1T$T:W:8K!B+\/-J.
MJ>E&;$6!\6PCU^1I3K5I0H)*%F=_YR8PQ>JASE_?9SU_K@PS1>#AV8)HWJV3
M'05^1PJ$OW*7P-1VMNK[201L^-$'=>';3N'@GI*#SN&D4U^[SM2/^G.TFYBJ
MH>T!E*".3<[=\RW%EIN6?(X>#=11Y(8HZ<8:%<U5(/5@PY8'S$4NFI^2XUSL
M:9E3Y*%LG6\=@AK/HUY48-8&;9(&<),OB'=X0FU1R*PI99XFO]O3%AP;S"9B
MO8G<<.1&4KBL.C@AC0D7*<1)8\.%U>GD*G(>%L#ZQ5R61Y\.F9-<N#V24?3P
M3DEZH\548L8-O?136CYXF5E-_Q>S/PTS]T;S99<FR=G,CK^IK?O&;&6#65S=
MHP##,-.1<PY6^LINK8H0'3;[V9+DKB2A2:7$\PU,U%WBI:2M[!P;!!# P4=<
M/3L:8FY*O*6ODRM839SN;9NFZ=W"OJ*<5QNHK*_RT0XEDKI?G\P;S>5\];/8
MN5)83=1&T765!+-.74 _*9Q"P':8.BH(7_:@CVS<C;( "GEO#KSD$EMB(A9?
M&%%MZ)7LMJHZ/VO@Q$HO;!2?'0$>W.O*_XCXIMFU_>:%$(A>VNTH9+[NMM^S
MW1>_Z F3UA(N!>=RT_(JY$\*( !-6]#>F]^TC$&-/%V=LQXLY\*!X)BV((I?
MQ<'>U,PV(FV;&D O'H4"$YPY\)O&HN<"W4AU $\//#SG9OV6_9N*%]R[(.%)
MMP_G)O@I)=69CI8,8@ S;=O0W(([2WF)-GRGI%Z3X$;SEB9? ]P5JPR1#1Q@
M0*')+84=&K%3D3H$\"OQ8%6P,9'6G ;+-8UN#4/9D*]^"7[-M*+-7_[<P2=G
M9<]E8HJG^Y*<!G$Y8BI,,/$2]!9\UW@I-?.YF#7(M)\MY9"UJAPV.'ESAVC@
MJ:CD3BQ?DB@% O O@Y)(X=,1(,X0ZT+K\'K:,QF2\DQ9R0.N=Y^# FK,I3J!
MV.H"LV]K4BH%G[JM]R<;+8E-\6L3\O8:L>,</\XR#!9)X'4QRD#Q+2;=XX_=
M&4( 9/Z!;8>OCVPB1 4'IW&G[9SF4G&<3J?E99CONXY!)]6V[;1M2F]HQOB)
M!^'AY6$J?L]1"<5U=@G*J_IWNH6% #YWUKI)V[+E^=JK)3GC<V761$S,%89S
MDC;/==RJIOF_D$L;%H-SD@Z1U/OP!BW)8\BB5JT.5UIP>DDN/IEJ7>]2OOC(
MS37+N1!KZ7X.LF@F^OP;IV?4^\/QC3/!SA<IIOVQGX$'%CR2!2M/)%%JE_BK
M,O/P222#8AAP2[S,K_.TD=AWG: -GG>GH*2F-!/VEP"E9GI*VR=F6S7%Q)B=
MK#.@W*,AZ8J0'TXOQP<]LD-OT;$:-=%?HY%:>!(9;DQ3;,;S2P<X3+#!_;8-
MH\Z6Z5AQENMM =PIB0>1=PG'%ME:3/0<S/GPX0@D5 _:LXX!=HM!9;]:"5OK
M!#]4R%PPL/ARX3TAD*0XL@/?-;,Y9N=<)29C'U<Q?R73$>)MU\P[*UC4J5O*
M6@O#T3Q$/\!7+/?FU6PGVD*QA E><X2?"A6R7B$"83M%=LFTA/5,J@:I(!W%
MM-[B'8)KW! HYGA^;I!@DDMB)5<T,UG@+B=[I%.-S39H(>RU8L_072.R/:LO
MB$>9APAUYF[WJ;^S'?E"8:VE.\6'?^<O<X[CGQ,ERZ=W<XG[JQUJ!P5F,3@8
M J#9Y)'<E+1V4W)USED69PUA,-J(9;.,&+6RO?[H"^S0I(P3/DL+J*!.'.QZ
MX<G6[]7XC00D1MM52?P4MG'?3.9H;IRUJ*YBTM;JO&V]PY%!PGC",M60IY?T
MTV&2]T?W0U*9E^4U+Y^#,'NFLKZ@-XLWPM-AY!E\B(6]._R/\K9&P^F2]$BC
M'-U+[F-@8=H.36A04<UMQXBI='R$=9[P>&5JAA@<*/^)%G-O#KL5>M)-(2>D
MCGV(7.D#6@L!-A[P^]HCB8DXS:SVXM)!,U/I01P(Z;I%>./!^/-'C'M;%OTX
M)(2.8OGSV3*@SU4)3>>):8C'B^);!IN]IGZ8 ^L[*$6WCQ  N6$WB1@$< 6E
MWN8?>]LINZ_Y611[I]? R8# .6R'1M@5X\W7AT 'U<!3P64[-=H4H&A=74MS
MY,6^$O/(QP$#7NOC>44_D]*T?#63V'<K"X,4=0F.9&B7L\6SPID[P9.RHG C
M>-F9GI_"3J8*(IX'W3_Z_@FKAU I! +8TCT#/?\"I><Y 5^$3W$A@+DMT -B
M[MWJBS#P=?D_+_* Y.CS2F9Q'O;L(0(!I"<>:G7<@X[[2)Y:[R& XSQ#(:R@
M#7?57>%)15?13>>M!-*O# [>?04]-MF+E=S;%%@./_NP&]8K0,:6V2$"H\::
M1MNA_,4P]BAHY#.?W]X%[,UJZ;//X3@ *OQ$R88CDK<CYBKPV,J>RS9X@0I3
M)=>B=IMOMUH5S6]/B)\2R<-DQWF^@AS-<WFO2VYFGP>@LJR8O'G1U&=+;KGH
M#9+5IH9T/ZN?8ZJVU_V>.*ZNH&D.8?@6Y>EQD+Y+_$S-4,-+RJO:>]LUA"R)
M0*J,_EW3!'U<#R!Z=7A=<HIF9$D@77 0>YXBO*,8]?825_Y*!M199JI*T5J0
M(VE6WET9\XD2_&;VR)1#V^Y G$$#1'('1ZN%9WR+@RY(A^/0:FJFE$J?KS;%
M51I8'U1_76(J43>^,YGM%1,N:7>$Y-G6W9H]9\&)]2F:DDLKZ:)<B1;X%!T
M 1SAKCX0V2L,CD$ %*3 QS<<+_YB0>^K0=W^;D (($(%>-C<]H!7FMD \H<
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MQK6R*@O=I'6_'3)1/174W&&^U\P:S*S5*)_FPHI14>Z,LD1,U1A-B&^RF/$
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M%W-_OVIWYBWUA04Z6P"_^='\TXB$(X5LHICQU!E3-=ZZ-,J!Z$5OL7[]O03
M=3;.IVU+;@H"6 (^H&=:PAOAO.>I-#[0&# @%<&CG,>?JZWU&P5_<77JMNIE
M+PSMS*:62]9++M$KEO@;868_\S>&QB<>J0D( (/H?Y5EVR\DKYJD..UZ1>L9
M94Y6_,O'=: 7VC=,62'9\?_VX)G_:LAAP+'V ]+A)V02IAUS$W[O(3Q102N1
M$<X(R:^,]5K['$N3,Y\8W(N.Y6$-LFU?%Q$,#<5XL_)#0Z4Q$GI:KQ0RU2=5
MC+,R@2MBP1/(_<YF:T@Q\57O7M2H\;Y.1RE4SRG6""+WT3!NQPI8][5)Y[S+
M;/]NCNP6$K \3[A;^A::PO>3BG\\KH6FU0)>85V$D#WEB9BQ>2^N_>;#3+Y!
MX+&B;"-OB7=)KPF_(C#)H,\RP1-O;)._I\+NHD?K3=56(.MP1K?R5E3[D_&Y
MU [CH;\ ,Y[4UP(\E\#B.G&7\^L"V ,154!LH%&$M(N#T9\.SB X2<N1'U&S
M;/2(D4J$LA4VILK]:"ML0IT7N,)"7HHE8JO,T7A4J4_O'YNV\D+V@DG^Z<AB
MS!ZN?'BRT)6X+<9@9 -7B10WX7G12_V0Y0NV 7GJUJ2"<JJNQM-7N[XMT6EW
M%ID4B[NTZW10NY"AK%1G$RNPMJQM-_]U 2Q$LJBT>CD-6B6MVLOL<# "F6N!
MQF0A +? ?R4QG!#R/AI_ ;=" *E9+_>8_THSEAD$MY#Q7.,. ?"*/%]0_0L-
M5IH0-G*5X*/)XXM+V..6[+^0T/(%TN$8^-_,W#Y=D]SV9_V50M$=4YEA!.VX
MZ/3^ '@:(?)7@N('JG*-Q']I9-A?"52N9+7_P<:_P09X+PYCV?A%KZ2A+B)9
MIR'EKXI& \T?N(4)7 5.-AS_]3^Y.NHCF0+S$XJ:!/U7]73%AH7U+64TH: G
MORO"-\;C 21[K%3D,Q6[7Z;[^,EMZ4SDN^NCDD-3;<C\<JCU%!N&(FM0?;6L
MD&CGO^.81*7M?16/3'? ET[@N$+2&)2J^D&=RR_NTB)#BD7_&/.\^6RO,''+
MD.H6Q9O=;RV3YKH-L9V'HT:I_ FXUT!Q[=EFR]7.V;8[?-I"!O6(+6.W.=M(
M<9Z+7<FGM)^':^1:]_$U4]=-$,#ACSZO<= P2 UX<PT!S.8R5&RRS'6Q=[VL
MPHFR6>*DMA+6DMS<4'/\*-)RP9=OBWD>=CI3#;L//03>O7^EST.#IX( XE<J
M(  OX+.)T8R;TFK7#01PATDC\=;UA[D-$<>/*;):XRQC]$CS9UJ.L26'G,7+
M]R_H<*\*=;;L+U=IW7U3>O%1K7N!!5T7994:/H*4&EN;_:4F=5-IC8.%P.[9
M$<<JRY5Y2+++'KIAOUXMWF%3I3\\XR\U'\]LTNY##DG^TA@BZ>[G:BK@&?D/
MJ8*-5# LR6LSOJMFS'X^T47SGGZ]S%'E+Y<I3[G16N9HM6;<+"X6/$6]XV ^
M[4QUYRV$*;PKJ_,_A@#.J'ZHR9\;RP'7B>JV=%_X>NA1YF:F&GW:LGW_UENN
M?0>4;)ILYB6J.:"SO0\]RJ@*KN U=4EVX"XOZ U^O])/E1EHL/YO!0RJ/(Q,
MU[HXQV*#USU'652QHC: ][!UCX>2%I05OA  XINLU_GB_WP&[ R[$V4CN3\"
MGGJ]8,4)&>L9.IB .K^^CNBQ5WO$#>TLZP7CK<B+*]KC&LA7?T(H7",Q[2S<
M!'@Y#UJ%>7KMGE\^KV,\M>OECF1=Q4Y6#\<@[XD</^SIAN2V'0)  JY_F ;M
MEK_.#_@[10U,%;B%@O^@=NRO_ZC\'Y7_H_+_,Y6;4@;4P!WLK2I@F9!@BC/M
M\H<<R$>H/V,6^SLX**Y\J$CV/-*QO.DC23'.*LK7TQYT>6>K::](;UEJMFK'
M7/D0VG>6O<%&UI9987?Z3M#FFR- Z.,FL!/465NH6B&V]"J:!/_-'03_+G*_
M;'KQ(PW#">M1YNAIFKZ9W=XPDO!=O)5RHL1CRY06G ITP.J)Z#::%'V4%5:^
M@<Y@X9N@<R4/#@Y)C_VYB'E#T('2 !],' /#WY^3@=P,R)!R\$K[*@!UH0DK
M]\VBO7:&AB7-S<4@51^,^Z[;4UIJ1FYVY0>M5']X.#OIVI9M;/_^B*H><[^P
MN">C]4H2E$QY[ZY<MO6I?(T$[F?M2&H#HZZU<MGDS5PAY9C>=:2/:U9=Z;G%
M'^6IS"Z7KI^,5$U("<RIZ4]T4[GF"TN7T <V<<?R:FG644]0<;9UO86$H)SR
M%LAT05]#\R" &:E'7\^C89>TDK=>": \C:0):S..[;IW:C!M\$\0@*\)7:=H
ME$OXDJ%Q/_RAE .U&7MX2;4N&6?^4[G#,6X?WM55YBT,4"GRX(#5;Q+(C,>I
M \\%?[4O=7:?0+_EK1P(:X&(.W"JE/B.()20\ 0Z-5A3CF3[YQ3\*9JJXV2'
MN1#L<W88(ZBI:7$RK<'Q^ /Q,[>\)!345[/>DB;<K1<V3; S\8X1&5/ ](G2
MJ-B//IAY;R#J53'SNI0-HFR@+'D L\?/ YJ2GK6:!++/.RS0#L>]@--4G_/"
M*/76/,/6GGC8 9TW'*YHNW>R@SCLF_5*1";:7XN)N"7'<7?1"+MV5B" OM/
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M]N!$T ><B#E7IK,+Q_[KXG.HQ;P1S: V%S*C"V>A$:DCBK)2,:>LO'+<WTU
M$?Z?(<L-;N[1=>QULERZ4\UL6!70:(PFIC41VN=85YNIRKI,/2U&7Y[?@9@.
MY%!$"X[@3\2*R0#P)T9P6 W'X3G"*BAKQG,_CU1O[$@<&7@?LX*Q!()D**]9
M<2D#R__4)HE8UE?#T?";6!7$N,<"V588#W%Y9RTHXZF[NBCXM\+L"BXP4Q'
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M&SF-&.JW'3H <5B%LBMW-LMB[%7J9(W/K$2D+.^=?)8D5VYKW<WYK,Q"7Y(
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MES_7UZZ?Z"0?K-HBH6=E#:56%FA*/Z[TX2H\:))UMC2K_0H#$XS5<[16!3X
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M$[.^UTA!!<$O$UY/?7@<KXLPH9OJ(V3#,U5$)MTCL;PF^=_QXO^C)DR.DAA
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M0&_+R[(=',&T_HRFLLNY?F,D:^Y.F;.GLDC#")JNMWM,BM29I3"OYB89I^>
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MFF>MJ#/E^VK-S=J5J(>%\B?!\QU0J \S2=$FF67\[SKZS.^TQ.;[](4)^W3
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MUZ0 >=R6D9FG_#STZUP%KV5Q4A,F9Y,6VL6W? N%8[^Y?F9 T6_R^.L"0@G
M#)7/_7'$#N)X\9J3GN)4%7O7/5J!KF>"$JL3IM0,6A1)QXX;^HWFSRJ0;7]1
M%F4I3\"=:$T]3@>3++T"+PMYROYVH!LJ=$Y'5ZM 7);IL_K2F93(7<G;%"EM
M+!U'4I&&L&RRA)-;;"#O2=1>?6^$67\U6,QPBIA/TIY@\-%-A_-G?)/C_0 O
ML7I_?>3X\'H^F[F<6>RVB$[=WB]3,MZ5K'SASAE=#=_&<OPCBH!G:UVX,"M@
M^.]*K_SBHOFPJ:K_?9 WSG_JLNA2:W"UF"I6AZL!  0NZ?Z!_Z:2[L@YR30
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MP NJL##75P!67TGE5/UB0()0\NDZY ]'G%#I0VB'Q;>M(Q)SUY9'G/[X8)>
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M\ZWN%];FN9B*.7Z#7&0I%Z,O9[#%,(T@F<UZEU< H=8182:WEW[ESA2WSU(
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MT%7.K])_:-7PE6/%YE7<"%MB;#89VAY-7,WR%9E:ZQ@X9$I&U>+<8&];W?N
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M(B9:#D,BP:-/LFH6G[O?D0!WIN9%<,LVWAADCTHRO24=>MMI=TRP&)\O_@W
M9#5%V\GP,(>EG:@?_/[2,H,PP_;0QXQ@U @UFI%A5."&H1-^\N+\&2B+YK,
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M"@<H@G+E1^7WGPYQ+I!O!20UVZ@/ZVV@S5)V7P'FZ88M4B$2>.\AL+>B8?P
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MW,#-B/.SPJC=)')=YU#KQ8DJ=UG*=ZS[!E7F;N*D%68#$3A2GH0J45E2V*R
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M2$]50CE1J@M<AHQAY(+*GO_(7O'T#(X5ADJ,5-+4)^J6'>DF9F*8]1-D((<
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M3Q+V(ZB=]7]D %,F %&RX6_'>A!*DC)%A.\;W':ZX^LH\#X]KRW87K^ZS0W
M?O4 : HK-)Z*4*-16%)&M%T0XK1YKSL!5%3'+FT4&3%6@Z;7@BDGQJT[LJ!?
MB&*?*@-O<K]+B 0RT;[_.S9C/!;2K2%(H9@PI:?0J0A)O7Q63##&O'_+MI1,
MVI7P65+JA"YP2TB0"U_9O4P4I%ZG V]UA[ 4#L@QO\A3E]QL.<^>U8!O32G-
MSK:$([J>2D_8"@R?\"C%1+#RF0;PAO!Z0Y=8/IU6(PX.;F\BYU]_5$9=5=P
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MCI:*8+L]L>GSH$W//*;[-=NPNE+Z,US:T_]3G/Y_Q<FYXH39-3."XD5K%F,
MG(&P*/H+TN.,WJB;D*OWCQG^KU?KT7QX ##_(YKL']7T?^#\@?,'SO_=. 80
MVWGJ\#N\A'*"(-BK*ZL9++65JY$GSU65.Y[\CCN^:=7 NNH-Y7]\D\MU/369
MG6AA,L !6%P )2A(FS.WC#<(,7?(.'];N=\XHCPL2B$R\J(FD\9'??WJ].\+
M3:SF5%ZH9>848.= !P5Z,:3[H#6$?F(,W?"^4N4Y<HJY"V#-YQJT05<FR@PU
M"^PK<YBMSA.5=3*LK9>PCZ.@KYCDUE&2-;\&MYJ/<T>"B3)5[H]-O:\F\U-Q
M9[8(I@CVSG=N\GZJAS*YO"L7U/^\BRK+W+:Y"6'G5$!1U&JQ(3'K3:LJ.^ZK
MZF7P5>4(/Q*QJXS+I>6>%^WZ9)WA3/<#L=C.'Y =*!3T\8T@9C;[EXNQ(/8Z
MP<<D^' EV6NCP.]%6^/F<+JAU"?#LPE+H'(&[1CE+Y9N*S0U_7KX3<5+C:X'
M&Q.[!/"U\WD)F]*,8/[G'@\ %P?:0C9_QV*^+C5!R](=>5,+:U/C<I]RH36G
MU+@#*M24V>6$H)K:F-#SL2DF)GXK_?>EXE[<2C-(GLIE^<&<7L)/BQ2EC@@2
M(6F+V]6"(:>QRT<301,=$<V4=:ID1RE/S,WN@=53II'(Y1,L+]]BE1W/IL_E
M!'N/C$%"-V'^IS9[>\^M>#YBN_I(N]=V$5&D^I@CJP)] "F9F)5Q!9>!_6]=
M:.)965E-AV.L+' BU1_G/1?"TOK1Q#&&D$Q5Z>SQA8N1#U@]>_$:AM!-0Q\U
MU:_C.R\69=A(B=9_\>PQ;981?2!W+UCI6&<]3-%?!C1:]"$B.>V"?P,_%;6#
MG,39LZ'^<H]>/\"-+I_Y2=CAP=DP1;2FS^C$'L#H,44TXP]T1@]A0($PN--)
M4/5BYG,0 E&28M1N@A23H3LPL_DJ3H1KU*K"0D<UQZFB-JI?4KJ7NK:'-A>$
M$Z;UZ\(NPNN=?AJ-XU5VN'AWE8,A@NZ3R;XYUN,+0,MRS63$8T"+]T@)R)DG
M#[:BPZ<00QN+>.]\K.;ZU6F@:Y[T>]1-LZ*Y@(8..8XJ4T4NTU8H X"A!8 T
MHRRYPVQ!0Y8!Z',7*]BST"D=*5R)/<HTC3E_@\Z@*P,>57',Y'HKZ9W.L '"
M/,W"]V=.BQB)&*L]/0I-<;AB7:]NKL(9" >I$W22:PX1>B-2NBI9>>0L=!2&
M%<.;4UW(.CV[>Y $A.O&R_'[OQ%UH6 \#\QXGH;UFBFE["@[#I9;F(FS8!61
M3%UC84\='W> ;+T1.'1X$-PT[UKT #!C&2"HLB_/C$)<6>#IL_5UW\P"?YX$
M_JY&.  =R7-+I5*8<5%UG'Y\G8T,-UAFC3S+UY7X5!BKTGC&95&NN;&ZBGU1
MZRYW&0[._Q@J,'R#_NF>/[<8Y)XYJ[, _L;S+*6W3_L;2U#!:Q@N1;_$-QUR
M;B4@!U I5V-4_$>H!Z97JO: B-!H$=O>W@KA%_D!+P8;='2JB.%#/^$;%7AJ
M,/<=Y[T<M8V[*XB1Q,[4V@3;>Z26G*$<+2,MO83MLVF&QM8YX2!W)&)Q8W</
MW20HG"O8<=CRTX0Z!7=IE==D9LDDZ.:KZY-T>!0G31*!R>[O,S/3\V<66G-G
M6ETMUW[&/\[ EA0[%V;L_%,\:Q2&EM-?LVEVX3_2/]+_[Z?_G>T/&PT&'Z<3
MC)]SU_(@RTS.ZB?V)S _/NERN?++_D2R02AYA#_EA]%1.LA=19*PH E?E,W6
MI'DO.6W0M2]#7/PV/4^VS7R##N;VX]*[O6XPY_S)9+P;GW3#A?R8M!CI:]2S
M BN]]NMHDL+8/#*2Z%%R$2'-C/$B9*CDSC"L(4?T6[%DN@\36NQ&8K7/P6([
M[M[XOL3D0A;ZL82=_<OP])*K;X=<P:M0'9'BG'EME^[VZ5)Q+3236ESIIU=\
MC#ZW/3PCHU+LN[:XFX(9ETP=57)FZ^L[[U,T:'OZ,Z2?"KL%SM\/UST OFZ/
MW?2*FLBS+$$XV<EZ<BC#>4:$,LUT)57%>C_R/TK"E)22%?#J3H&U\>6'<+HN
M5V(X6A3+Y+ZQH070A]$V&TJ]NU97S]B^N$XZ9AD*<,QI"VJ?$UQ+% 8@'QV
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MG#NV+H]EW6;1)5_,UG*:$KDX>P=/) =NW#[> \BB:8/WR.\!<[O\<L#:T[%
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M$P(YU= D\$K3R'4HGG-^YO>#*3!F2EPP.(B#6%Y=[92'WB&>HP46D0,4[![
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MI6\?*@.8R\RVKO*$ADGR8IF0VB;X>J']+ZL")//G+[KUIP(4RGM2U!B'YTU
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M.$G3Q3>\W^2._C \578\T]XX@^Q>F 5-!K1L.UUDEIT;GHV2C\OHB)17OSK
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MN<])KA&)+"9Y"@R)\B7M;1G#2#1*)+U<VFE*VV1)M,C^>PXB_:?\;Y&PY$C
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M)!)<!M9:<'$A80N,_&MK@_8I]>JX>W_CUF,-)%E2>+$Z!'6 YVURO.P^1<>
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MFCN#^#88&?[7:^DU*Z]S3DNE!GS#MH5U4^X [5NC4O<&!/QE@/K_77-BYP[
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MQEFIFE>M0W'2<W+;]['XW^?V]TI(^?I &[/ #+I/_Y>)E?]O)CK?CK3? <2
M6![49<.M2W9;IL<KX#M ;& ,_3^HV=(MW>2$WKK[XM]C7E9@^^18ZT;W^1W@
M'CZHI/Y>C6X,V'$E@W.]>4([X5@I>8] 906!PS$'MZ*W O^H!LP'AY^%D5^,
M;HK?0Z[_/[KD'_3 "N<$__3D/SWY3T_^+_5DUO^#)VW=]'T=2^B*B@P7WI;'
M#S4FF193,F;U598'36:X)"2HV/<6%WY2)<']*T##TVF6VM2E/^UMC2][7+I
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MLJ>$-YUF\<!P'+J_SYBA"+6(]4)'ZMD&8$7FA?_-8*79 :OA;2-LG;9U/5Q
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M#XVIH]Z%L("5+CU7:'8FC"^TO_:(H+%HMKAS/I[3M0S]_PA[KT;D1S\>U(^
M.']X?1G;;7P_=8M]V^*T8PB/R'M]11,;8,Z\6SKDCR"IZ72I\>)8G6 A FG_
M:'TL3=.<0-9T95$5A:J$.=G/S2!P^+-5"+Q^\I)"IS+QW/&JGH#-.LV\%6P(
M9UH/I0M-^/?U^UA:.KOQ%U@'#/OU%P($>WUT_I-\$HVWTNMGY*UST5 -&1!)
M<&(9<"+H'518_.[] &"9;)I(WP .,HN/?@U\<G3<)]&TVG"ODTH1'01KJYI<
M#M&< N7,;[*^YO#@E_C+6&C,XB;/FJ# GWK?TMX725W'4$@$75-'$[6CZ<6G
MST:[N6N\=\N#TU*RK <G$ 4(84^,OEM@.W:>H/9SL(G=7X'W4 OOF$%$5]F\
M,Y7 0XLDX0[\IOV?Q5C"$7XW?)-9$,]$_71C 5)=K6A9&?I*L>(4*G"%I[F#
M1OZ/9PUH@7.M$8Z:78<#XPKY(%5,L=*%?;;?&)#E%M#R*$QRIF[[YC)8_\G%
MS*VLJ6[ZF7Q$\OI.CILU5/?>[U!-/ ?"^NLJ9PJ1@!J.YW<!*=/#J'=6+/H^
MY>OD0-#7%C<B[M9(A'63[).Y@71A#'KAB7V]%40,R5X6;.4PE.1 M*K.A'[P
M1_O&W[0-&]5%A<[3>L/#Q[=L]KX5'ZNKB(E/YE5KAF*-YI_-2I<[OJ*ZS5 Q
M;(&S?=*8L+CYD*0)5&[R*0@Q%;9_+B<2_61S\9$6-SAW"93Z7R\IQ2W-#U.Y
M*[)RK[DS\CD=9-FACPP1G^0T>KTQC<C#=KDD&\I)&)I"V%T((('U:H3S.UA1
M['D[IFXW9>I%6E$RFML3ES[*3;%KQ@M&51$31*]L9Y6B7[J,&D\/CZO]&C>A
M2T>H 5,,$_8$#-T3GLF&(8&_UOHZ,)Q$O>'YY146G"L-)!?$$91E^,3Z'J4H
M=4H#GQL]'ED2@@IZ#@>UCFWT=DMPG;(@%N890Z,"YM\/VMB6,U 1U;A.7;(A
MX1 DI_&;-=S$>_FAD+N"$4RJ!7!R3J2%9I?2-BP]XE/][[NH8J!Y"S(L/E8B
M*2+7W>4*,N;KW -,?A>O9+O/EE.?$/UE/"Y:4DQ2(MU%6\-=J8+^[O%0)L-F
MA-W3\Q>0!D;*'D[N.?PQ.<?CKRC^HO4SQ!YHU:=VAQ:5"M6_[KIB'9E&9DB@
MZ4]I. E/6-/!/LWLN.(563=%M';GK]5(/A^*0ZI6[5,+Z)CO(FOU593EJNLF
MH"B+QJ2]F945+RI1^S?&VM\H69-R(DT2:92!K!=\L-0;L 0^]/:F)<\CQK%1
MZ#?R4=B9RL!1>S2_%KK,4V@L:^R;+6@I;CRN_?5YU5,__(%E@[WN&:;+*RNM
M%@TLP'T'$]O<W.0!Y(R[NJ(H@$TF(F!E]^!JR?3XWH%'J.<^U>5RI1'!U##M
M9<!08>JYX^Y=&X?<T12#E8J,$HX7G%V-&!AXWV&6.NVDL,=[B_+'&C74MO+,
M*])Y+KYO*;H5UF.7I1@"X]-#$VY2+LB"6E)L.O);?OO1/0 \(GXP44>APQS.
M(GAT4ZX1*XK9]3X%#74-^L?:T4^PV])P$P;'Y7D(*M@C?I6?+M!<#ZS\+FA*
M)&'GC6PFZKW0=J.PC--SG1,5* 2_6KJK.U;(==S&B F6N9^T?(9GLV&5LQKA
M0>+#CO//MH;X62>>6#89J-NM6HUJ7<+CK^&IWI,((]Y!:]%747RO-R(_O!D1
M@6PPY:SHK,'NFQ[W= RY(^R>@*U;5Z/L3-<( 2<CQ+ZS\$OJ[.ZF31$C\EN^
MO2=+K;G+1#%HNM\B%<5*B2$<5(N&P.SQ_N+M3JF,J?EYHV22]\C!5W==J=7Z
M$@4\O:TN\1HR'C3Y\B*?LA[-[<__8WU+RG9V8NM_@$CIDX^;+RG B:9[+"SC
M8[6E%7C@5S;N0.RQ./^W ]%RF'S<K>GU%':^[LSSP&%KQT.C#T<?0[ C&UA\
MN_7'4::M\#T[B]$$WFWROW__1N-( .$<;G<FJUHMF(QIZP'83!T=:(?Y8W0*
M7V4+!EE+Y)*X:G@HGI.'T$W8'8,.3&*-KFVM;&HNO1F;:V#CY;3IE+F1NLUL
M3S!(>U@X+V5:I-(+5<U-(THF:&J.,N-?)^XB^4JAPRM"=*W6;D4;5=9OKL#%
M73=Q'@ FVPP1D[++&KG&*=&/D]VE!L]>$,3Q3?3 +V57K=_>W#:6$2*JU4Y\
M(])>-X-/A5+!*DWV1376SHIB;0N3O$$X]8+K/FM'JK6'(S4^-DGO]:LBI7Y=
M")<J2,QJ2CETD"U-N0'):X]891UC'>KK(D"1D\Y]'3P KTVB3X;5O@Y:(-51
M[6IERP\(AB;]E*GG:/9_7'HD?E!,ZM#/J%V:,:J*MQ_N=0FCES05GG^IBC<.
MPOVRRM(PHO99O)6Y'D&57_"K;=I6QT+$U-7-U72+5)'T?-ACYN)\W#/$H"H9
M9=G0!*O#'_2@E:=HUDM@PZ05HE05W*ARV,^I&8\=AYZ"+3)V!-[/S8L.^:LM
ML;<F>*].;2+BP2I(J8%PG3.N_,/@]J<#9I-F6L3*#&=+_E-!(PH7:$1JJN-N
ME#IF/B(F1[W?CT5*:.+&B$W0?6M SZZ+_"#M]@*0S_=C:*,GXFJL[L*G2$A0
M[C\MMG7\>HECPY:B4/:6R3)I]2X[1_WOCNC"TRQQU>U)?4F8H-E>$)JNG=;-
M>_V/#NY)KU83U7EB=KBVX67*RRK.Q*% -6=SN["JZ</9?IP ]\QRUORJJ:Q)
M!UBS[M27V)V>@2VQ 04L9K<K4]V#2+_7W2[7JEGG]Z0SRS>Z_1S$KUZUO;Q]
M /!C?!,>*U%!K5\A[S&=I1SNK(A3*!<BJW#JLO/XYC(8/;,5_X0",#9P"S'>
MG)6XD^$6EDA;PFJ'GM1=1='T_+A&-WDB_J?) 6?)4,8T.[0\6PZRLNOH!6 J
MX F_?FH3L=XP<YK.-FN,D#\'.CVKBYMGHZ=XG43^$YN\7)ZW-:^B8NDB*I9_
M\GJV-Z3S&G;]H^ZE.<W\G^8U14R5L!WE5UQ]!\,:#?4I$\M_&T)S4GAJ8WHP
M^::W_X!]57<F;Y15IW+ GBL-D1M_>V(K+C2EY>?%CL5J],G6=*-W/6)FY_FZ
MJ_NDE88;*J\OKJ?_V T,C:@K"<CY$FH8)O]/:_$!!)*4*D3YV0C?"NT(A8'"
MH:4@%<4BV?Y3CC2*M9RF=./ PI?*O,^^'=U;2$PTI;+:QG1KU830.8$X,NTF
M(5=>PR.J:L6G&I!P;0V\) \G/_2X@@3E1JVA6 O0'TS_GCT/NL/GKHD9Z&/+
MTO90Q+W%S:2Q4$SH^2C:84D&H60;_1'Z09OH=YZ[X1#J<G!%J;/C!)T<BX>S
MX*.]VM9U;VIK=W$@[JCWLXC@5H@@DNH8E51D))K58]VL"&[1<#G/K5&9!IDI
M1BU '-_K1-EU8/M =HIUFCVP=)63JG 6R@3@+H;S;STMI",+&_BZ/4W\"(>7
M^QCJ&B?W-6G&RO0P=_;P(>$-8H["*TT2K\#6>0C,%2K[7*>;9F6WFPFA[=ZL
M'17EY3O.&W)I6"5GZZK:HCA78^@@]5"*T]?*F:*\QL)":4K6+B[C?K[\-9PO
M1<""*^CZES\/ %]@+F?[IC'.$777>\^P[NI1&R0*.B;U^@'@^521%DDW4W)K
M.&G:</BU*2 VB?C'JQU'):XG\3<440-MOBO-A]HKCU^,DJ#459K*+-*K^TH)
MSV\?WS\M#>&PG>45VHM 'DJ,-'"BWTI,?37\N-P-#>"'IR?11^5$GNVD<'9:
M'$XJ\D>4SW<ZT02YT#'M=+CW\%Q/K^QH.;DBI\(I6:IBBQ)#='@!D0G=GIN=
MX+(MYQ]JI[^>Q+Z.=!:.ZFD"B>@U"?M/\/VB#51'&#/32#0U:DR5>SWS,)[^
MMD(1F;#!R.*L"<RH;]9DIV9^I?/S;8#@VPD]Y=5AVAOJ;CV-G(1@TXW>[<"9
MLW*;ML2TJ;]Y39EBFKBOG7R?0IA*WS*/]TPT?"!E^+GZ+Y0%H:<6Q'YP"J^Z
M&3;2'S)S/'HD<+,/>?NY1.Y=DZX3^C3853=#X/*J*GUU&KSBLYR>[B^2/\4+
MX?5[>R?_@MB\?R 6_ _$BI[%$8R,TCD!/4/4JA/WUP-DL$C<Q;X7[^U51;*2
M]XRWKFXM4@:=U^4ZBXX_ #[.Q-W[EBHY;<3*VRD>R\*DLK:X+P=T9MS&ECXS
M\KN37O&?6YP-NY%M_F"O%>-_<WI$&8'*O:JK^>#O_G[/:79&RL&.LH694(&8
M5[TDZS. I8](LY21%4HP^W,\BCT#NN^DN\@U=3IZZH!O)1#&C6O/EGMB&K<4
M&5]/Q3;-YW^NAKLU Z8+1-\_EF"GO?B]"X):+H&;5).$I7R+D$"EW49=@Z>Q
M8E[9B@)Y;J]_Q-9D9,YHI?R2_\N)@__:MT*W-<G*?9=W>&F+U:<SQ6XCM<!4
MO25VY]CBA-[2-HCQ4F\,:_/,P&2JC?;2FSZ&OD[9VEZ]&#N_Z:D$%FHK=?R3
M.^'$AON<5:3R?X;H_$/.ZPC@??O:O73<?_Z\!*YKS'AX8IRJS"K2Q]!@77?U
M0T(B>EOFTM;21]NY7N^*MJ[D)%4Y$<P\Q,U3\)%#BM[7:=N 3 ^"<MAOZ_3
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M 39?7?@&Q_]I%LD:D)OE/F+E[&)\OF54DI;$,<27^1_%DKO@6+C?6K:5Q-F
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MT[16&!J\C#5&8I3+5HT,=0?R%Y3-[1I-?7L%+PC*)#X?+#8,P_6RAHHZ*?G
M/DG& /!5\MC([EY-][?),MU/:4)/Q_#3#6VY[@$+[P,DWJGI*7@O4S!*-2*B
M.+[9[K_ELJ[SHE/!*1-\E#L>/W)]MQS/9W:WDC%>G:+ I&;)KD4V=?$UU9JK
M0? >8'*L/9]9,8HUGU:PP/M3<#=;:RMMMQ^@>I7QL_;LVK9V$]?2)<';:&R@
M!Y'$;T4D2'+RZ)SZ$/9C0-7_^:+(<JM;#<8[3WYQEFR!OA8$?8?#IQ#2TF3'
M^F_AN7AN$T=#45SA;8+%AZ[N&-;4]1-.@J=G=?J'[;3<\GW3(9$-.%;I4%N"
MF<%)?CSV)CCQZ#=Z/XI6EXF<(XX,%V]1]X%4-;TIO7<OM(,(<;F_J9-TO<6X
MM5"W9K>VLY-KYC"#)K_5^4$P!S\EJG7@TH@1+6;%[L^/Y[4 4G0%<9I6UYCB
M=:'V"SB*>'CQ4>P'>^;KS,S-OZ<&^;V'-1I+H_ZN/4.=KQ'EH@5"#&B:99CI
MG*%!*P5FL,@U)34HD=)RF'I:<L40G9H<]\^@3BUK7\!J+2QRL('DALH!LBS'
MZQ'Z=>4U*#1I_<>KEQ9@'R$Z<X)\3/[SJ($5>MQ=BPI;(B/G:2WB>X!Y I6J
MPB<GA= ]1JV1%$_D%C.KOY_)TSA8]>W^)652@9/)?+)W$C190=^[NR.R[9?>
MCI86OWN.P(MY_]5^?#^R*(*QXWQ:*K@1=YRS-+&I($TC&(PISG#8DFD+M<IK
M2:*+Z3>_L*+K?",:8/.-=/5,L15YT0A##'T"C\**\P48I&3I0N)4I: F_ZNQ
M\)]<%'K VSX0Z9.6*XVL/PQ ]()YGY7MS^3%CNJ?R8MAD?3;I58\CN[EY#]T
M0*_^S@F9\MMZ#^F6\Y04,X'OA/'+V25OTN>7>.=A;A3R5*KZJ7?,R=MS-&XD
M>U%F].AE$TU"1J9*SAEML_NY8>>PZD'_#B]6R_/5N%KUZP*'O@SU.]=2;+?5
MNKB>5SUBZ$;O1^5@S#'O8MRQO[MK.'4%M3M<1XTP'1Y][=%.C%*5(NB&_<\*
MZOR'Q7;,TCR=W+(E+7-GOY;":6#TL9Y]\4+T/IL#$5VC(=\2A,5J(TT]/UVH
M*<#6<:I^OLV(#QJ47?3X>"*5WFIKP;XO4:6R33@<%^(4"TW'>!R%+8M>ZE:X
MUE)EB -16= -C3?B"8Q0YG@/?G7@WU5!X$[1JQ)G,X<T<-[Z?8?ZLJUBFXB?
M/4^1%CA7%3G/.80KF8"&W>38!41P!JPDDVC-MVG6)M"Q5<Y^.U[[/BAXG;37
M4S)Y]+P+!CDG,T'4U,Q5/NJXL%E"4%Z2J]./5=<$VE9:W.F-%.H?#YKHG$Q"
M%QW.!IDNWN>^';K#L4EV:37: >=!SFN/H8'KD%+PB1:9/9'Q2Q_=("%&]# O
MOLRE^)&E(WF,G/1UAN P*PGG;N?40#3RHRW=Z.WSV.D?MH53?'V@TN[<"%OV
MGQLBRNBTL>^%QYRO1@Q_@/%5.P-Y?8E/?Y PUF_ Z48L5-($>[FU*A$RWMQ]
M4Q;#FZK0Q[9 4)))"#%::">77Q?YV>E-(4/YK]/+CH!31+CC:_IT:O[W[8Y(
M-RN752TKI&^B7'7%\?EMVER;_Z2S1 *KY%FS^+9&0\O(I^L. $_)&IZ:,*&>
MT]D/DJQ-O=,%4X1R4WD#5D!X7B9_,>\:G(.07I;K^E<;;<'*I$0N_XKR+VOV
M/=N<F',%CPX&$4<6NDATM"HP>OI7\FO-YVDVEGVL=>9O1O1FV?:H!3N?O$;/
MU6IHOE9,BV]-1.Q65/YME5YO((>?)C.]Q<.#YLD]8-5:<@G,D.]):9X^,:QZ
MA.86\^:F +6B2QV94FB!.Z-S#[!@3[LMX>HN9B/2P93<AT=X<[ TNOHHN-F=
M3)?4(G!ER,MM:44 */[.HEXU6N=7O0J2UN#\YTYS]:LQRMS28H%VKX6V0JB8
M9@OL&SGN 8?"7OF*!5-;I DE1>O;\X*.'4D9KEZ/'F434X4[7/ 3)O+CSFU!
M! >ZHH[DE[[BB;^+0C>08MWIV$@VK/)=UWW^P6;KV+?Q=$OK$Y<KTM$]? <#
M29Q)+'/'[' ,GJ6$S/&KIPE7(3RVS78(HW2@[!!4GJ\:;"7MY#V1*933*X=%
M^*5[M%6-A&9T%6(#])(=#*DI#X3[;RD9_[,_(U"KAKU7>A=N%[8M*T<]M,G^
MFI@Q=<-T'29Q:+392IOW]R)6A'\C'M)MFUDA@'?_)OD".EV4N'"T]F>)DXQ[
M@"3OQ+('%3UEM8K[L*'.IVY5*8/AT] !%XTO2N5A8NWU2.)%3,P81881;; <
MPD0UG[9)C2VZD;:PMS+UA:=DL7MMO$L6-'9K<OAS_6>?[^01TI)/,KZU/3P[
M'*?,WASU.)!6"D@__O(DD7MM?5-<>Z!7AK^B<-;JI$:DQYE_=<%NK_HJ+!U+
MRM;#R9PY86+;E4[,@/E9[&]__<!6"+P-ZZHU\+2.[5?Y278 :I&Y'_;N!N5X
MP/*,!=O9EE%ML''8N^>/53L_0)6W%<V?=@+I((+RPK,1&[H"7I0A/\&\B:S.
MDUB\D8UVK&$F)\GYXKG>3H]^P#P=>%DOP#%FIE1OE%C+ ON4(SNT:X>!2+[I
MJJ"I=["[W%RF'/]]>U@ZC]Y\2> !Z(5D[FW@6DC[>7&4Z/P7P"G:>>Y3J4;Z
M]9=A,8U>TI!DK>,+^8T^X@\5ES*(7-U$K;%\@&+!O"S^"]3! 1]I'/4MT#S=
MB..,ISA/;MK(5C^[TQ-TD57:5UVU]JT!]C5VL.3FH)@XBE("6(VGXM[=X%7X
MRKLP-S-GUL@\F,9F,42L1Q'^Q2W&S4#K_+C/9CHC4;SN+#^W_RC@J6@1D<C;
M>N(A/4^/,0U5([V$^64/N?>UHWV8V=GM:SI>-&GL>[,7-.N6A:MI=N_+7G%P
MC<8XJ*A*):PT3KD/L?!4]FX/8M@3^WT_0Y^(DEVF?>&,6X&6YTKG*)@W_*84
MI*BN$C&SV^/M6.X]1)_DYZ7;\=:&T2P^;(0P\=:(P_[V\NP&RL)423%M-JG2
M7(')SLEAW>:YA%F2=+4XAK2^T4KL]&AT<"S%L)W'CY:[HS<:#E#)B@WYF#,\
MNBU.5V7Y=&_7NWHC85V"1>Z,+/)UE@E> 0JU.2I#?3U]C/D"6\2!CP /GNO6
M '>(JE]$6]PL@H._K+"!1CS7M3O#Z</^VUNAY=*!LG[> 8[Y7E *9'<EFE)G
ME;75(6$%76R'-(2<YNI1:J(:V,5^\LE2J1E/>F42]LKOLSRZ2JG&ONA1^WCK
M$FG);9P:[I!B&IL!UG!Y_E_6O'VN<X]D1_6X)';(#UM]J 8+9-BB";FZ-W7E
M:R=HJ<_0D4E2]/B!JU-K">_#5W0I5(^:W[T@H^ 6&0G.U6DWUL: -S&!?>;K
MSB[R5#]H,]8W-S:;6C86[I-(XP^\LD>O5016C1G[2X\Y7F:;$XF#.OLBH\?.
MQ*?8)$@''SP#;5.#S-;?EA6&VE9Y0PP\,VP66(<\4SRY4HVS:UJ;*MBL.3G8
M^YR.34V&5J'-^/:E/_JO8Y1A?/UYH."<Y'?CJ\;M=PS)E;(53=!=W*-ZR:6*
M4=IF_A!G@J[+2N+/TC+'_C9/Z_;0)RFK5QOJ@I==]^FEO]SJ:E/G7[=D!$A)
M$3ZO LE.)/<9?M%J@>RO?>$(6' @ NSUB/EVF/(0.9L)L=E#F'*R8NMF_Y3_
MR_KJ]X^D__\50>,=83YCKZE.5,=8(1$;RF7FC9]:3G%^KP)L;L^D_;/%D;"V
MU3Q,FMMSP*!R- 9)'<3M@8 ;1O2Y0 ]A3K>M#2TO)P*?8:>$*X*X@J@7S[)J
M-T;"*M:>D#M>E)A+A_<*LGQ?]#?@75P<2NU88@Q,2Y\C1C)E?5O]#XN3_4?"
MFCU><\M_W:8E;%T;5Z[W(_SD:(C\.O5Z4DBQF$B-*[1:?^!Y..7V@FS-. :6
MM9WN.\[#*)B_JN+'PZV$R8ZQW#;A  KI!>#"W8BP<V16,.U+H")F(0QE<V?=
M^92V@.];@U<:[N$ICO LY%B9IW,:U4ZT")$YB$*@EZ_6UFF(8WK1Z$6:RB6M
MB:GIE_XY HM,Y\6SU'1_"LLFR];JVU*R K[@)9W9)IX?>#*4*#_0?]NY&Q=#
M, :RWM$5DHS'4UTS2<P['40OD.\-?1I9(QK7W,U8NOW4="I4D4>U2SA6Q;!6
M]V)WNI,_-O6. #@XXG%=MV>=S:WXZF<!?*E@ >=1W].Z*,:9]Z;*%_(5M"=%
MXN2N]X!J4]\U'8/U>5G:^(A'C9C8'NY>O+KZ) UV]G[Z<D\"S,RO!<[/$I'"
M8,O=N:U6XI+B8KF2TM6:-.<!,NN/&*+7N!/5):=NF6/AM9FYACTW-()$Z"XV
ML#"MV[2$I/SMAJ)ISRQ=>*8RFS2>'&[DU<_ZQ>CO69.\&F)9,XF&$F/+NB1D
MEJRL[KC^"A4_$YBFT-%6,DM;U=)L3G-B7&N8]?2R.F!NI*_4TS7 ,1@W11T3
M]:Z?G*^<572:?R$\C(BG>I5&9+L,'#* 0N\/AY5UG;?F-["+!F<T%:C>\$AC
MR_[HWNF2W^.=\&MKVV%'S"28U4<S)O3RNNA1Q2NYH9(?393(V$5#@UW9&8D4
M\I5IQ58M,.O0(4P2909,:Z0_BUG[$,MVZ: O3RL0E*$1D&>"=%96_F'@UEPG
M?I>&L&2LB5P+H+5B*0'C5VH(;:0M,?'BR[$0?>F#/^MM*B&/STA%XEOZU;D?
M1_N\ZUE!0+48IZ0G&Y'7)(G"BKD1F3!K)P=AEC=TP9^%.-8DD9[H8I:O5!=$
M5%,H['A"]O;W]SEN%+P0>-598ERU3^[(.W/N:J0MP]651T^'L]A"(73/!NAP
M;;@5;B0C<*B/0JQIME4"9D"LIY/>Z@F *%DTWXE K7>!:OFE&!TN-(:[ES66
MN7[XS:16MJ(@%)UUMOJ5;Z(;%.'&R@5ZV_,D]3&7-UOP4O#QFBF9C]VT7L0"
M4V;[H*L3!6=ILPB!E:-I0Q6H,723;3G&D(&6FM$#)7;T&PEY!G P@2AD:7$I
MC;APNIO.W7WB/##1TA+??IILCN/<D'U%LC[;R+<.O(\0=9](3[*US 5NS[^;
M[8$]WHC= $J7T73R^*%L/B6/EF'O#7_,1P99.+EK?1E*7?C*%\T)36W7,[.6
M?_2[X.*DN<,YV4[XJQIBVS<Q*Y9Z!BS2^EP7L@:R@T+BIPU.&\%T1[S\B83M
M,\$_FQM_HC'YG M^!S@*9<>)%]7#O=M.!+-R,*/>;(WX80"BWHCQZ//#T1*!
MG%>\[,Q?5.OPW"QCZH5(.BRF0* NA^R9^7:O4:S/E70BDN!7QAK6HB\CWO#:
M!QN!$MFOO1CQNK?">_O2DX@'4,@W,+I0&5&_E0X>;]GRAMX#:J2*]6ADXBV[
MLZ6"CU]+$@OM^2*+MH7/S@(&TVPM=C M(38FFI+7(ZIR[-%#Y*HF>&T_A>LA
MF_8^>&]0Z4X?Y=>$,#2'L';%8"B@T++8F%)^<RFM7$8OS]!+E/WL6<GZ_1N-
MC:NQD)#JV7?&&O403X-]3PY]I4<]YQTZ&PFO*P6*KN(?!ES6NWMQ.NI!OEN!
M(E(BLAHFI&%<QR8"VXD8QWTLA_9"1L5#&PPKT(,D8YTF!("3SB O%*H)5?U<
MQ0JM=?E :83'YX)Y#3$D8S: IZOOCFW.[JKM([=[6C3.[@'^X$BN.D#<1[)\
M]&1KYV3ZBR".&A+CU@AMQ MY/44,S;!=*X(5?SV=+;ELEK@Q->C5Q9\'2G20
MJA0^RO1?4G'"_Q+Q6GGA>W92_7Y]:A@]^O?7QIX;^)65R6<;G3XP[E=_B6KY
MK/Z:IV,)$XN,B00RB5F4E8B;L'B(S*2)[XL4"ZWZ+?/$Q?#XL3QCYO,D9K16
MY9M;&[@=2]1V:+K (V^*L-<9#R==9Q6S_[EM_%YEEK8>51#@!PW'3]8J'W6I
M'X:> ]DBW=RLEU_Q1NS12)[+J$T+=<I]+[R1NPTODN/(M87CB/X@)@R<]ITM
M*)+>7:FQ']-@<88LV"H?LX\M*/=O[>]7BQGJ-EH6!\,G9(T(+XR>8TRKOGLB
M.49.Z:$Y?2.5%^[&1Y^L$.QX_3@0:1Z)Y2!(C$?UP5STZMGR9NZN-NQ:>VJK
M1%37PX%NPGUN-W;K E;M8*/BG%YT@RUKY54S\ *%FMS'_6I$59N8J1GC(8IZ
M\'1!U']R&O3_AR1/(!7J/\,B"W>9Y>59=F&AL97/+2$<Z[B=XODC#7W/T6K"
M:#!CQYLMRLL5+/RH-^KW+:'(L1C!,AR"$*>TQ)\>@E;<.:479-:6J3#@H:X)
M-HNE@GBJ5COA%&K(JG#8#W"7?._X*5]C6--'MFU!B?ESONGG7L*:;GN5@OBY
M!/1FYEIQK)(_+=_UT(4O16='RS>DOI"1MW81G@]$=)N\(5R20;^>[ZP+!KN:
M6*RJE>:C48[_4$OQKQ)7)O%/)W7V< 1;9(7X_X<EA?Y=@5LN8&V[>T5;%^E]
M)YQ8(<.PBDY/HJC2Y>4SSG\JB91OFX?010C.3<>\?LLLRN$FF'-"WDD[/X._
MRN&*/M$PH\"Z\%O&<;IZ#@]YE'/R:8MRVD0(RX?;LUAX>RJ<2"5A>Y")$^^8
MEZ7B\]2S5!^19Z7J$)48[5:%.R(>QG&GYRDP6['=X[?"M$(T69;%@<E"R>;<
MT@#I(1;T#^[&93.2SUUMSEW"/P0[//O2U8__I9LJZJ;X73NS+5:=CF.?4W64
MOZF;[8W"K- =PQEZ% 2D\(4NU6VV%:[DN6\>34&I;>IR0B*WB"B;R"J-?#=2
MLL^[17GQG'V'S)+&%;EH[CTJ:-A9OR$=(AT^5ES(\OV<)C!L0TDU)'9;3]]<
M'61;%?YV]5V8U0DVUY;FJV20FY:.B>NJ>M2VG<S*AZQH#GN/RH&)3#</FAXG
M)[;!5L?&EY&YTC;FEAG527I#C=Y)&2DNI0_4XV6L>ZW.0V1<&9]34Y] 9-ND
M&C0T$5W&8>#&8!E,JHNB;=^>@%[ \"W+9ST>;F]IV1C*_'FBJ@?3!VS/CR6\
M?K=_B.O@P/:]=J4Y>(-X0/MA-^>:4X9K_:[DD<N#=>Y=LR%Z6)@GBX*^_%4'
M"3O'>@#H ,T>I:A:A8^9T;'G<7LO_2/MV\WVU-NCU).= >H$J> L[/=6DJ9#
M:!$9_:-,W[1-0T'7??31UC:YGV5?+PO0.O'/[R^/V HCW6@2KS?;20-#4).!
MEA5\ ^,=JYV@I-5DI92T2NA:;;TG?NW#20NV_A9MV,--_@(;IENM"BOL$<DS
MN!MO^*)2WUB5#G+@#>L"+RZF+EZ-:]<EZ_8?L%:W[W,3BE3M)$>$H PJ.P,;
MQ@[*HM6VCR'Q7MN-,8\EZ2KE?^0XFZG@X[FC?,?O??"?1Z5C2T/$[EQN>[&=
MTH?,(/#OT?PQ3@X;PF6/0I,D\9TJ/)F18M4WE[F6>O'[9C$\9+V[ ?T!<HL5
MVUXU?&D7T_O4D&705YJA?1-&8C'8IL?&1)'J&V;>?<>R907793#*6%X*F.[M
M_B*W5+3?&]18/_=)/BG\F7I-EM[\=GQ5*=K7_X5_:^#[_'^ZB_^W2'Y-3<R^
M$3EXV^/9GU7=I_X&@R#=O\-@>6EEF[*"Q<\_X >9('4'O:<-\U1V &E-U-.&
M'![IY.M.?V*L"6QCD3^ L5O+T8;,5%=M=0B/#.43U-A:/1$L?5=@W5S+U6$A
M0_A87+"<Y6-UNU1EMFNEL&9S=8 %*N7R@M!R?9K#6] JAP_[SPBR!\!K#*;I
M+KD.M8J(YPZ)J>(IEB?XN,3G.$09PQ@H'2'%LFTGN:=8>J+_*^'R^;?G=MF!
M=Q<5I:0ZZ4^!0OC%A3_0:^PT\A:'XCH_;CPPK>)L$BE\#7*C_V1^_^.=-+!*
M4[E?Y_*^'/NW>X V&>5CU:P0=&8AZ/0P<T7+K^HID&[(H"6,VG6.3JC/A"H.
M5\ZJP6-+&^G8T(31N48GERSTK!M O?(\_79'&.NE6GVYY90UQ=XDH]WVFS^?
M\Y*KXDL*[))L<Z;3DW'@W$!<>N^H0E,E9&*1;XRC1<?T!/>=S0_:B&PX*'E#
MH6JX#,[.B5QFG7B'CT-"9?YC<)VQ17 %[N"H5O^L4;Z'8V%RWA'1PE1?%<,J
M1KG('EZ$%O35E\V]RIZGI^>F6 !4CVAI5-@TY)Z5IESB7S%IQEF$9716L=RE
M91M"BUF![RF,.X\'\3%/MRT:W;'&"[7G%OH0F6]#:CSSY[:J,$J7+*;"2MW^
MO-,&A=,2)CL;2;$4FCT3CO55FT,J@EW8X3\#DAF0B^2+OPB=Z['P5=_\DWZS
MN%IMU-76U85+1LP^B=KXQHAZ]@TB4/$87RLP(VMA.UJ./8?EJ/-M(T^1C[)2
M/C)4CY9$#LFR.Y15,C^E#QF]%+"K5@X+.Z4=HUPN5L'BW?T9\A >R97MK]0@
M5$9E[;ZEFORB>^#J^&J5\<;Y!8*\<0!5*46QDHFC'W1%CP;33<R%>E<CU[%0
MS+HMBL^!#-D%(#D8!'K<^04M(N<*9?:6Q1>-G!(+%18C5U.GJL6VF]<2G_7%
M;$TZZL N&[6,(>5<MZ6=DS^2NMMX+F,90 [>M,#6MIP*?!B;Y'_5"VA9(<S_
M;DV$_[.B4U65</Z #!%[4_^$!KR1$86>OP5-K&6CIZ>U070/R)'L&9A&4?)6
M</)!1=;4S+IN4%C^[#!.,S>MV#,J[XUIG+6N*85UV.A.GRXGD<X ]P1>=F"(
MB78]SQA$L$DU;;4\78Z742<+[%K3JQ7^ IKYB,WZ]@$MBJ#NP+.QDD[A=:=[
M &DK?KFL)CA9@*UQC!4U_NQ*O;Q4D%V$P$!?1AD1U25V5JV&77!<%/W[I5J7
MDS5+Y_#LSQUF&NY2#'OAE0D?JA N)?N*3!?3]ZHQ_7;H*QKL3G.4YXLSR.T$
MAP^"4[&/+,KU:K7Y,*---+\XRKQWT701U&1\W!)7DHV6_IB::Y^]"EGOZ2+Y
M=YR*C&]MWK6L-]'6[Y54_^4?92ELD1T]1S#6X+F&'C_TX4JCET6^?Q#.I.G_
M>7Q4U/X/.#'_'9RXFU'U?^%=<6\^4LI>LS4$Z^'_ZD&#XQ=HCBWZZ_$QU_&L
M<7T56LHW+_+@BE.5DOQ/I;HYNM<D?C$Z' CHS' _ABI'"M,X1 AU[PW);S!E
MI;APY(S-C2 R1R&#3A;LO+?'2&C"<'EE'!ZAII"(<N:.OYK.%G^YQ<2%6KBP
M0G%,%]&D.#"K&(PBB98:45_2YXV[ /I!R@*JKI &ARRM]%<4[F)[YQ-@E5:)
MU>1/FP0BMQ>\SB+6Q7Z ZM%>2(EDY_%!( /%B$NRPF^01. 8C4BH$X+_0'18
MRIY$I>SPRRX.^?EZDE,^9'1*GR>-!JGSJXD=XM94*Q$0%YMZ%:;%LY,X5"CC
M14&;P(<,)7TL9;B_MQ51O1-N[P8W181,#(XS2#3S'UES+J#%N)X3YSM*6$H/
M*7^O698JKTX7867%6*9A2I<+Y3+N0*%V\!'*ASP:;^(I>MZ51G.2N8Z/.;U1
M05-Q4&8VQJ'8?NT2KW$I_00?("&I0+$[K*-LTOBI<%KW6*CW]$>NIXWI'GA/
M#YZ7+Y.GG M]^</XO$K!"&PIVMIL)1HY*>HYW*4$C2$C/NWA<W.<TL]-Z?:;
MT_VLNFA2Y1#S0'89>J\LG]*Y.N_', 0C,&]*7D-!6, 5Y4 =@E?)\U9N48,I
M4=&_KOSWF>KEFX!Z"XFS%@VZS?"$"EM3<L,MRO<3_?W#51\I^@;?;.2Y3PRL
MA>?E+Z?9K*^S6JQ42L!RN=A*E%#,Z%8.2[4NM.I:7C_1R0K!.5/YF:+JC6/H
MH(;E? I-) TTYM8S'PS+ ]MY$)QF;>8"DX?A' UN$F/CK:-L9J- S=@/?D=T
MFII5#?.53P37Y.AP)X4*]DU'V/BT1LGD3HR";Y+,(,0?!GY5GOCP_/HX83U?
MP3?^K5J6'0YOL^6:Z:KF<::+D;O9_OD[^<31OHG0?DXZ4VM=UH$:-5_H!^U8
M"(?O>+XG[TRFC37WT'N_X^5U7/<MQXE?G?UO,3'WK>Q=NT@HM@?B6V*+@%,?
M>(=M:;>9T98H0KCC&==ZNF^A$:&N901C/ MO*I66D"*;%^\8#12P-9NWU_/A
M\+2T-'CU>:RBK3T'H";TA4S =U31"J$>WG$$;VA>]D!N(V3A@.;%EH,>U,5[
M>KL6Z-(;);W7H :")AHKHY*OX'>3*8Q5ZVL9[N8@&A&?16V?U_83HD;);1R5
MI(AI;7>>*Q3(VR32O#>=C<!1D8%IY1Q1C$(N"%_/Z,Z ]#CH9%]U[CNDQBBR
M9@N.YS>>;+88!"8@&")SH#0C6(3,;\))M9)E>GK]CS\>G0D5:YW7DGK65JXS
MFU0FC#P/6C)O"^_'T!+O:LW5G+B1)M.X'>,7J) .HHG101#\#/.QYQDJM235
MAY[;(DA,=$E/F>*3W+X+$9_F(3_4C^>3-+K-2$W?KJ7D5C?_&KCAAR$5,7>>
ME[S?M?L>92=''9[?K#M*.-Q$Z\5IDD9[;:+SFAJ<!I^*UBEV8]&1,^&_Y):M
M1)"O2:)F_,;-5=B*54KX;GUL$FUJ(]2-ANW]4MT!8SPDD4=?XF569?W(&<ZL
MG"5O+= ZK-1/IJW17&C%=\@&^O4:GU3[O*G!D5L.QB.%"2@/I,Z.<>N1"#<!
MSO>9,>):MQ_Q<M:9KXG!#M2GMD>G03W6:VUBU5\<W@G;Z%U%?*;*S+>/MVAT
ML-VZ(#V"\ M7C)9^"X;3ILO1IN-;MS$U!G\XZ5Y!%^0#MR4')DD$6]-$RNH0
MN1V;1$ASH_I?G+1Y ;0(.A$>8@/5O5OHT]YC=,\KP%<X1\7EKK7GR,TY$!)R
MI(?@Y ;=#.PLH!YV\(X/O (FQWCHGB_<!/&!=(Q'JG>"5A[IALV#36[:9=_<
M<@$EIOF?U5YP_^PD=AQO2&::P6(E1 KM"I&<$\1:PI5MK2:&'M?T/WE'';$L
M]H/XC!8-5^9\/_.V\/8;O2K_7,I;K!2N\!1WZRZHMC34,;;Q>.MW*.PA= )V
M9\M'()VHVP]%K#O=L(E3CV:-2W_[;0M5#U!H#<[C6;O8A/&_F6\CC^URSW:
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MB>KS9DJVWHLBYAB.E/25R]J<:,!.9F/K#\2E[;GN[.FK  ^-C9\X'],FUG=
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MB^8QPF,9(@,P+9[<P,^/,M08QT,JW;9^JD:]CD^VW-(]N@VHIA(V5=@Q%Y8
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MBIJ%E8V=@Y-+2%A$5$Q<XK.BDK**JIJZAJ&1L8FIF;F%@Z.3LXNKF[O_UX#
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M$8OX=<*?V0>NTTV[N<PRDUK1IJGTQO?HUE%>AXZY,3HS9.&NJQ>",<N(A;"
M%<I?*\!O]1A'Z6<E/'2O]HCY)[+X3T/-[*4S%'W%QNTHUWJM 'I4AC;-( US
M(<&PQB4_-QT^A'+8]J(E[47M+M=]8,['53C E\J(C?W^O58/HB<:%$3OL9RU
M?V#=OXYF"YR?WCT'R.P% 9^'X^ -+F*LHFN&".&05V3<9]S_B^U/GS.G#TTO
M'CXKHEGQ_I>;XJV3OTNDDKBAI-H$!ORL.*M_>I#^)^S]R\C3/3W!4\,T0%[G
M$ Q Z/JY=KG/_ALF_75T?>"E?VV>AO$Y_1#K>4-G_R]WQWFQ[[3>B>0LOX($
MHG_R3,,%$1JY)WV^+K\38'E-"S'_D1;(?\> ]^\0B"A3O.0U?=;IN8UX;4/Z
M+S1H9MLWH/\(*-E_!E32:T!)_".@'G;X/H$!JI6>6[?M%SQQY0(E%IB]RUWV
M_:#8:%J(B\##I59WT[]\X[5^O/]=/_C^J!\H6!(G(8%"8?XM1O$C8$#4+GSA
M:M^-=CQ]WIQ+M*I?(B?/XW2]^V[^%P-V=JM-\E4?2CF\.8!>TM6_5$%7([LU
M^*6[+W=HM/3@58=+HF/+K9NQJ\">/78H*)2ULR<JDYG3$]SM(5NUY:*2-<K[
MGULVUO,8^^UG?F:OA8/BGX5#^C71Y/RSN[.(UWOEN+A\>.KEI6-S:IJBZ?I-
MI;H6<UQ7/(KR@R@$-4HF"<E9 :C64W!$7J_)$9XJT1;BOK^3]TDU[]7:\'^D
MJ?3?:>K/DD\^S!"N^8 !E0YO@==YBZ][.&R)ZZ,D;RN88X/F4_R3;Y6 >]I4
MH97M9MPS\ZG9A.X-' S\%=!RFN_O3&+^;!&O[VU@N+:D^PI8&$C=:G=;BRPP
M7T1FMEJ$_50A7 SGH-)[JXO_A5'5FB2%@])$P@I..<F?EL  D@&S<HV_VHWH
M3QN5?SWH9>1=/-]V_MK'$DJ*N,_]"X,3:;W&P,$-0XO7[8N8A BZ:H)G@;P(
M.N _2&Y5RS-ZT".UN25A4;JQUY8Y>,33D39NX,;^RR-;\^A+,C^WN\=U7HQ!
M8Z6(0_I97 >IZW:=D4TEW;2;%_X/NFJ.]74O5IJ[8'-DVIK9!BHT"4;S.-;0
M"FA*BL+._/ZN1+QI%>O,XF=_(9#DT3'YC.)V(,X L2$)"<^,Z+E(&9GKIINA
MFD$T\!L=B7B/(,3\MG>*@KP5?=@B#:0LJK0Y04?[%.&JZ_'B)LNE4$E1*[_^
M>&@X5?FF.5UVHO75KM\N(]Z;I_'.B7GZ]0YGBJC@+R7TX8'!_2\K1-:8[:8\
MJWC:K_NYG_:\PH>DI*+S$2OINC>!.(@GWGC9%&_)FG,A="M=@U--&^^'O(CX
MSV#*#"C.K :@:8^BJT?OI!C]/BU9,/-'Y *W^_@G[CD;D,/;G1H7S O:*'%V
MFL+U8)":*EE6L*4$;E,Q5Z"U3YKTA_"LI,F/3,5<Q>S\,O 9_3X5]!D%0P[C
M'N-0!05/=RXPEXIV.%"VHT!SX0FL-V2"W4:4^M&4$%>*//,W<:L-<-![F5>Y
MT6J;.%$S<%*5/0"N8.NKP;"A2_N6ZP>%XF)32RA_?__Q<<@)*75#^TXC0=53
M@+NGN7!4:H,3]\LIT.L'X( J2WQAD*;0Z2#C@HIG_OYYT]8Y/<'6\X]%E"="
M8(S)9-[ Y7+Y(%!F^: FRKLP MR3-(;.B9Y"W..?/=HORB0[=5@OOVKH%#.<
MNJJ9&MZ" 0LVWEY7DTT-9>YOT>7%]470Y2"D7=2FJRN4"20X(%.5:D/43ATM
MA]STU2<V;%:J3I#LHOKFT&=+</2T.GKXDYB; [K"O7YDN4KE?:#&@3L+Q'DJ
M'JQE0-'"HX/1F\+Y\$U&M)'*2BHJ^I=VS*1,_ERIA7JOXRFFI7N,AC;P9\ND
MH+\TW6Y82*ATZ(7KXEM'+H0YJ:%%[H,(069AC(1^7Z6-('T?SU\263%XI*(K
MT9\Z]C#V<$5C"A?5#YJL2W.Y10H6@9U#;H-S-$/O?2]B8HD)#^6&] O-\Z6G
M64K9E#V9I0.^?/WN2QIC)-'+Y5\;<2@Y3[,(!LP]<7B(S5_U-@2\XY;&5K#%
MKN@U__*KKMHM* "'PG9=-7;%S 4SB2POWNGM<*7Z@?U)K%58KW+62K,^]*?E
M;J6DNI@B6J[CU50;GLH!<YCJ#GVJ/5%]*/LR#F/@-P,1/GVB7:P:SPA9]0T7
MRNALCH-,7Y9B%ID=3&%3G2)L-)J$LY<(F/*@:\G*_!*9<<VC^,&E:.7Z]6?^
ML0VU=VKORQOJ)JVS9T1KIO#6/D3!M)TF,TSX:H4ZS&8J2-?:-ZX93BBX&AE4
M#H9W%:A !T.?56&A9<K9JGWJM1QR//ZX;9Z4)&#N<A,7X]0-.=1O_N'R8K!:
M#XO,PZ36FHYE_RJD,\O5ZZ8_O@Y99R%;M;O(]GTC5+3=W0P7%;?6Y^RZOB_&
MH=;#W]D\3Q.^M&NHQ+$ZB3HAK:"G2;NE/OO?KY*&3XFU\)F%+>S&01)Y)^2;
MZ7<'+U><9!B46#BC>N:K1<B/GY;7:@:IS:^(X.BA1ZP$V'5[R.JDM4P<J=K>
M1%3^"A3O/6H*2ZF377D8)Q5\A"JT,L79(ZS=Y>J-*J.X.5Z6E[3C5A< .6 K
MB/0SZB<"U373N-%H-'Y.+]WMKII=%>=%BRN;I*F)JW5\?SM ;JNT92ZT%A4L
M$UQ[0CBQ.LM=1)E5P?J']R/P=U3*B8K)[TOJN&R.N)]VO;#X;2Z?A)7^D(3G
MX5CVUG4WUY*>O_I,'1Y3M'C(!N]F3KYMG7&MN$SDWBJN+VUN*(HPFAG!+TN>
MJA7_O70]1HO!*5_6!4_M1\C@US;253L_WOW;XJ]NJ>%?I$U%\0=T'^Y3U:.P
MG/?DZ\MD/XO&L>J5?H0%0NC': G?O$_6C)VF.\F)&:I9/N_9A3PHC>ZZZW7E
MN,X$:4B;2J?MCEKJU57 ")CO!7Q(WED66 CG/!RK-3]2=8@YO&QMY"-B"]]F
MBJ/&MB80=4.?HM67Q'E'R4%AV\':I_96GD?@N93UZQ#,4=C[U 5]G$V>?.7>
MU?9C9:**J.PUS9Y\;3&4="B;Z/E$E+%+R%;\@A.NV^SYXA.43[%EF6M-"]J.
M!^YPR43QNS;:Z:MC1*FL^4%*S)]]-3-I.<OL+R9RSACKZL)24C.52UNJO%VY
M>N&@'E3P%RU+XY()>EKV=X8<]J@7W(;PT!H0$DAL,K-88@ZGG2JG\BT%'RC:
M72R=+X'0_;ZQD@5TX^]G(QB9PPY3C@_7)AOV:NLDASJ+S&Y=ZM$^OVVI[!9G
M7 <A". QKN5R25I&E=96U*3$SY TH[F9#J%^Q2%K,@TUB*_2[KM>\&;0=&K7
MON+:8!%F1/N >-NFWS<;.?:.?U<)P9V@"[;EX2W3"4>M<_2D,K.FS =X>$(3
M(\Z5@Q7&([,8R20@VQMKNEQ1S5OS.!H^QG=NKC"*D4KG=S'*1R3+?8^?<\N/
M7L$=G]#X4_^9S'4'#@60TASU<Z 37I/1=1D"&" [C>%DF4QI[.CAFF$6*L(S
MS0C1J/HXZ(%BIUH&*IU\.3IH$IG9CU4\&L,7Z9#. &$_?N/<"Z]IC3ZQJ+R<
MX="<LVZ-.7XV]VH8PHX98J(' T[VDCSM41<AMM@2-Y(8'\MIV-+T-GF(5AWJ
M";CF=-5'J=FX*JY3=2R+U6MO8=#EY1Q?/_C_3.]6ED*:.8\3@X,,S08(JAC5
M(C82C6KKPVK-N\=[QX/B2*&[.R ;>KF=#K7:$FXE\E=PR.*8?J[$(I6LZC&C
MK!JE\37Q%ZNZ<)/.;?GM[JIKL'GNI+SIMV6K2H/8\^,*GA$I??]Q/_7M6(#5
M"<@:M"@&3RLO^BVT9\</P_=Z-]EIPRB53<2#E(94 GU_I[BDF1\BN(*8G4"$
MKROZZ]2)]%0_@T%LV&G20M=U/QA@BMW+K4(>4ZCC;3'BX!@_H6EAMLMF?*_D
M(^4!'#2MUY!,UA82RHD1JN=",_]4+02M#QDU<*_&?B!VJ)S\L\YD2R[** KS
MTA D%$$U'8>47SDPX@#/ ]<UV7-S&!:E57@Y-+0SZOR^)KWEVUR%E2?UH$SU
M7=*D!#T2\=)2C>TR3YHA&K(MNH_F'/'4CF6!-M[(1EU#^-YQ4^@M\Q"49DYH
M<)M&O18E]D#'WF+DG9GTV[$EAKV&AB36,!/JXIVBU"XS* )1S\.D0%<\D5;_
M1\$]@Q$\O'AS9W$9+]474A[]REZ[J_RA8NT>8%NV13TYG@?'AIF1P;".]I+$
M-7' WOC43KQM$Q?FV7*:E+$39\#B<G)< V,A;8_S\ZJ/0:F:^7NU@_?+B+>N
M)LY1&XR4]]_Q3PZ7<NWJ1<UJ6GD'+\Y(-+5ED:J&+V"LD$)CB6^Q=W.G]]KK
M0C227@TZT]*@+A]Q,A#VN;_U?/Y9!+]TW[8)B!"\=Y7,L77.6T[,%.T'S,PU
MR'8EJX#OD]>&,9H)EJ+,"A;B\=^D> HK!P.TWC_,IG>97]O4#"%)-DOA]VN=
M1;R,M1<4<X$!@65?1+;RE8>=H[J(4MFXG-8]YEP,#4%Y"WWFYN_"L7LQQ"YY
MK[/=U7[4TJH2V%E:)\5EL$IC'CRXY:W8L-C%$^KB*;%Y2;GL:X=AP,^#M+88
MCC:QDB*G63R*%_;X?L6(X=@6UL#(K74(C,IN*9]<M6KS+MB'D-:;Y_= #_F)
M=%!W=@#G\8G  &T71V6'2OL4+5R626U9QPFF!,?Y*.4,Z&;LA'?8H7Y &.40
MR::7I:DRH]HHO2 ZJ*:?4L&=*$(+#EV>(B[3\L?8]FDVY(G%8^8\D/#=+B+7
MY(/O5$3HOI\?R'1I,WR/M0:Q%.97Q6VBVE9)H_W4"IA?43T0<724VW/&S\<R
M?CL2&E<O:6A?-P%<CN27BPMG*JX5W\,A7O>8YG(*;#3'N&[6Y&&VP!PC_B'1
MX/84+=$W$/F*T7WFG$3P-P;M-+Y 6]B&O'VCT5W!-$8ZSM2?#T?B;+N=X@P\
MJ$O./9@=R>:O[/_X3I)4@2MEJ7\B4KX5]@CU^F/S >4>LF)0994NNU3XG%A3
M[;1>K,;!SKB/DN=3^_G)\?6QG.:">-2R$"AWN8]H\7A[C9:4\Z-6+#"9P 6Y
M+RUV=4(VA5-&MRON-?AF;;K=OYQUWQNRG!^#EB*&4C;Z..$J-IN"*0NL3[8^
M=XJ@*^#$;_+=8]8R/-QZ[^A@H2O(?A1!8^[?IBX*C?8L7KF^6[5!6>M!PXI:
M-WY%AB2^:FDH9U_<\6E<G#&E!>9BIH6!<.V%Q2%59,75FEUQB[%Y0=!<.9N:
ML43!X1UIV^ZSM>A*Z.CR(H!_ES"VU]#:MXU#7EKC[Y.NDS:=P !$R4TB;.&+
M]P2A<I2Q?2J<?)2OS6E!,R,SRL9(7,%BR"K_+AW/EZH3'+1T?J!8J7NL" CT
M-K7&^>:\Q+:7K8AR'2'N1^H\F5Y6,!42#8/4[-;T:3E=]*K92#&(?ETO)>J.
MD(MPIE#K)77#>,J)K#G\Q060TML!Z-@[-2S<*RR.H$N]Y3SD&K2]L3@L>!Q#
M0P2ZL4Q983.+-C^-X]';?DH8@&KC4GKGVH29=&Q:=S&Y8@2:&,1/+:^&MJN)
M"86:K=V:^ABADBY'X1B=10PC-E /1&FSY")"6!2V%HA=Y,YU2OT$>Z%6P7FD
MRH%A/EE7L)MBUS(76M-\7"][Z-WO;CDEQ)17F ^,%@\];T\@A3-;%N@3\I&F
MBZMU<K(#Q$NQW5R&330ODQ\YDW&%/IK$$:'L&D>_/&P^B8;A6WX"4.K[R<!1
MX!M-L[U@!'(?6@:=[#9JZM[=2BC;)_Q"A(B&TS-[7KNVE<1R>L7'*^W25]=+
M"CDZ+&B:.I^M;$%;EP#U+B.;A<"M'>"9A_+W)WE2OR'CX,_6VO&,6G[9T$BP
MQ,:-HQS[XFFH?C22R:XG.\J-TE5/V7$H#>S3IAC N6^[;?7!>*4:&S.RIY^^
M9_8*X$-T8A]P%GGU/GCER:L]>HQI>KN\=MCQ\4^8DINJWP^^SK,-O9.1RL B
M#L\N@..$2YG*FSMA7V;-BR<;J2U<8LE2UN$?@H$[-3S+:3P;7)%V(ET,Z+J?
MX!''IKJ8^4YJBD,2#K$OF][5*V%ZP8J7;$8O8QH(;' (18/'41#34GB>N[9?
M[+4$ Q;7R@>7W)[ZC<^-2UP4!3^2B60T!@SI25[$+4WY^SX=6L]ZUZIWVM7;
M)..V+>_AX/08K;AJ#![0%"0F&B919O/#/933OLLAZJT]SL"<K>C K@C"@ ">
M,<KS2GKDBQ(8N*W5U39Y@@';DB+H*J9J?^G-_TD)A#\:LH(!C'^T7L&?F">#
M*0$]V*]_D$+YK(5 F0$9_ ^"!B"M.VU/3OS[(?1_!XE]!KQ6L_\&%8@5]MT,
MT.7BL;5U1^)GXYM:>[#7<FLA7LF+$"-0EJGV:9Q-.AI:OM\\.:5,X"D" ]Y[
MR_9FY<QP-/(&_C#_7#)-TLSEF$0E@=H?+J9=@DQUO9U&-+F3U'.-WBJI%,@?
MOAVI&KH7WI90+C)9GMXO?E)FF,Z82-(@X/L1N9'@>QD/+_LBMPS;?:IK"EKV
MV6<P@$0CN%_;BZF06T,FSKI39=VW/L9'?)3_MAA+(\'O&*1?'[=KW[Q@V+'8
MEI/T2RU86ILY<;P@-8F>MK*9*R>X!QD;*C5_-1G8S5;I%C,812$]:DN34M=0
MQ[9XW7W.W6$"L_58.FYW9*&MX\R5%N<W*&&H0IM-@G)QA0,4:]4[3V_>U2UW
M#HO#6MOQG@U*1:MJ@E- J.@G:<@;8)$[OC027NU4=8"( P)NB^J:0A5[[*5
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MSU-V>:F5BE? *UKPS5^2:38.7D'MRT1@HA%LL&@>>4@+P["PDZUZ+;<9T__
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M@Y!Q'X5G1FOM7$ 01&T,>-^@VN%*+9ZKNU]$QX[N>(8-AY?Y>$R:/M/X8</
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MU5EQZDTV=+'#Z!E);9D2>2F3($$:NGK-.@=>^-J*:G4M:68M!3CX% L_!GZ
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M!0UL<:"!H#'PFBD:Z.A%->=-M-2.(I,A*+56<.+F<]T8--"\!3KB0P-+JVC
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M.T2MVG9&D/>,"==44_%:E5;<T<$5:#Y"?[Y OU:<"WY:]"8OQ]!TW#OL+&U
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M3&ENTO;O.,GX.)$::2A8;[U-0;8>ULGQ/FC2XA*<N&*9>K7;VQ7Q>5>[8]<
M#0QOJ0DGH*IK=XYT0\["%-E#CR.W[8L,_;Y)<:<M39V',NY1O0?SK?F4I+7(
M&ANV\4]N.IX4F ^8<<OP%T0M*R]&O%+3F,F16P=MVG^:3C8=.9&\!SDD(98I
ML/,]K@X!-TR<V4[5QZ(:#S]4'IG8#Z[9?4VKQG@GV_S7<\0_G"761>1X")V>
MF'RBW :L;,=>FN.?ISL?"/'FW:F.-1)1R+(&!?RT.K,::\UF^Y[2Z_GL .YJ
M&'VAS4/Q_9(XI/D$JV&RE_]D[CC&B_V _J$.>)YQ +3&^-O&'(DC=Y.:M\3
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M:@^7Y%3%6;[_^<CLK>J3N5+55"Z=Q6]U'C]7RMT/C?&',VZI4B1<_X)U<-7
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M-&WL0@?QJVF1<,QBDW "[[:@@2#**'WRK2M)VY<+M$B[^^PB(H5%S)4W C@
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M)_6QQ,[K#J7OZU<41!+)IBP2EN!P \0P;M!T-AY^[#8)W!4-D*CM%YLP$W:
M*IV_CZLG:]A#T0#V$TC/R#'>H& '+ZET[%UUAD0AO(_(DCFU?#7:5E;SZ.?
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M-G2:L5)"1S6R0Y.US?Y%W8TO5: 0(;)F.C-!MV%U$J,.=QA: V:VU,?<F_<
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M8/Q28J"HK.0=J+H^1FFTI'A)/FG!JX].O'_MIUMAQ.)D(K?P=0>2KBY2?>P
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M)XFWG)169%J3*EJ0<]1W'TC\V%,\8S96>HNX47XP>,[3G?,=8_W\AL(QB=R
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MC(9BM.!UN*Z-4+ZJORF-<7B PT=9A_'!V\K$E@(;%;#DESH-0ZK' I^]SNH
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MH@M A]03 ^6/!_#G@X**AHZ!B86-@XN'9( ^!*"BH*&AHJ-A8*"C(UO]D.T
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M,*X5DP%JQ98\"Z;29(3RP"57[VX.ED.FXESZ*JKX^AY:NO!).0<X7YEG'R$
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M^O[,YA]%8'9VP/\;W3A>CYB/K7%'*ET*EOP!='7'7X:]:B*R_L7;.N>SM!+
M9X[5)19;_S:-#VF$6T'N">'*S8.%\S8#&,['+3),?&]_Y6A)YZ'=E-:#RASQ
M"AV->+7G['DM'VKI6UN#7T.%R?%E44D ?/KI 0\V2H-C"=Y,,P)3@G:JV<B<
MXCE7'5<DUQBO=<^9(9DL3MGA;/A]C2-D*G5-U8TI?<O(S2\@PHX Z$@\.E2K
M',FI:1!V51.<GS%I=>MYJI =^!W"SG8JKJ^+3,PT_X3I)("P6""'['#F".BC
ML63G*5/][IXD!E#C]<$DZ>\/'WC_&30/_WL,S6>B;IHF]K9@_U87*[F-8H=_
M:E9PP/ZX'%*^EK%L$D(R#AFF:NC9^_,/RH^ZOU(*U=^P7.F9R4F!F;C-GJ%&
MNI& :(.28F.+#3X"\.-]M4FXK.G^GF3@\1"UYI6EJE ["O4)2EEU.P?O2+:E
MF?T]"!57&R7XI@AHR"G)_+MKOO\[A.E><!=Z3G?Y!*YJ*)AFBP \:5&X_PE.
MT#&QZ+KPX8(9S<GQBS,?J>-;,'E*3>B"9G OY$+&N,V]55OSF)28HIB'V![@
MT:0K%OB%J2, F<T9ERO21Z6.5VHU0]>7C4C?U_O]2O'#[2L$(,.W_'8=W%T2
M[_=I(\;5>D\L[!YC#1FSB1" $+JWX]);/"SW5S%W'-3P1_O\<+^#ML/$/UZ!
M2HU);R[LPJ_-CG/B_8)3) ?J!:[CS[D=>$P]HBA)7]EE.G3[$+[5V_W\S^,T
M&JE\;JX.W>"550X<%U;''GB5\[1!J:!2#[DC8T3!NQN.]Q03608WTG?>_<C5
MY0=O=4-P->?(VO_J*O\!H7QT:]H7\V8:90[KC8N EB[MX_LD,L:=Y?<6V*64
M,4XP!W&\6E^J[>7SY:==Z*BS*=XP7Y=E+V;(9M71",!ZSF:3G?OV7RV*P4W&
MS;TPO+4''G">]9?*V>3*NQ 2#<6W!CZ##0_"*P2&^[8Y]CF#/] 6W'%H9C5"
M0R]F]@\8B5^NXN>G0,\?G3PF.1IPJ.YAJ'G5%!S<+0F,'1?$*R<QK4W.JU1Y
M*MU6O]=Y)]ETSXXC(5K:[@23@W0B %:#L[_"LJ.7;F\]R]I>CT%JF@1K:U6+
MQ1(F8HI*1L4@2I.&F&D%1K8>0)!]JK8[2PF=UC_28]VH?WBQ=H%+%!7K?V'I
M_]Q%M=W;RZG'X?UU=?&$G Y\&(-[&5K;X2W_<%M=K/#ET=P)!F%8U(^:5L4.
M!<HW\FJ"N?X,IIT>5YWP]Z5MAT@WH1+Z2[GKEB>L;4O8&P'P5[O2N# C! \[
MG,+O,HX@H'M]Y+$X,=#2RHOT*@Z>VW7I[JB_E"NE^I</;P@6P(L)<!*_Y,[%
M,^IFI#^SW+'6G;]I.W>UYXDXX;>RBKG4N@-6:H0  +QBN*>ISY9OQ:>YY:L]
M-E@(:SJ<G&?S?!XW'\\;]4@H//N9]3DN,MA 6^Y[ 3+\]GQK.S\5AD?:(6,0
M'5QB'8FLOK:=6>B&O*QC^_T9T).0_^:[MO^4M,9!>?7A+ &%*3CHA70Y#['I
M[V4$7<+) JS]JG]?&5:ZXR:+J=V1/L.1OGJ8F",G7M91F78QKP /1*(G5.*_
M-I&;!'5[SOZ^Y)QQAZTL-?O['C03 K DJQM%8N*!1[D(&@=O$8./GK"!Z!OB
MKP\=<A2_=#-$/P5-4_8RW23<E<B&<Y,A05%LQ__RM</_G/!WU:X)=J0/7MRE
M5+V7OU0IE'\R;#Y.WD>9N#HGT[MZ=S,)_8=/G4.H-<=YB(TD=?89L4FRD];6
M3MLACY0-XR]$#X40 /B'7<?;(YM39$:T];H6N;Z8Y<A<B:<,/-S)LX'$;\A$
MX6;S'I\/[@@7+!#PA5L:?)9 'OPWCR!MA^TY \B4-$ML%GY'M3 JH/JZXT[-
MO:37_:&L1"U79/I=RA8[S>ATWJ/HT9RD0PU%Q_<\($<4])ITM1?18E-F-+8D
M0!H[(I*W.O( DAWVIQR?$R/_V1&LMY P>9/G_OT  I!#5<.FXF2$\3M$_"<[
M"8ME%6)ZJ%0W1@ YG2F]-#4>[<%.#-IG":'?C(-5G963F<WQA+$T-47T?3-)
MK0J7LOJDI*F@(T))KZ>V0H"^&_'.HC5I$*C4?+4>1?K1GFCX>*%Z7X+0&B18
M6F6BZG0LV97P]3D"H&B;#"3K>2W)\7(5I&0[IT)'Y9>_\G-^6UA(5V\M0KSH
ML6+L4ER# D<L#F6^D=>2&E?IB:TP[[:>ZS79Y:_=4',GG->9CX;':VEQ0P=W
M1@K&#WFX.)6$/*I)9\@I: *3OHM0YL.N:/%\(]Q RB<F0I..4@OM?=?.K2ZB
MW8KH1S@Y\X1>?5/O085*N7-SVV+N7;J?G"J8LY5)F41TKPG%U1@%)W9A<SZD
MX:_?Q&_8YNG3!TDXQ,MOB6X/G^KK^0.BO3:A80:MP6KQCA(&9:/AMW4TQ/R1
M%P..P!1.L?WPV7[."B6:" '^+J=CQ18*S?>-F 5/6:+<.0C,M!/4QS;".6RX
MCBT:<!X<:%<X7P:NGD!L[TP\'X\9RF0:SYG(H YYT[BRW$@MQS9(>U?P!ZHK
M+1$Y3;F8[.HE\\]COXS_&1&WWKH<  !X_#";D&#E@8HZ[@NJ#$@9??R@Q[#H
MP*PQ)HJ%;DU)LLC:LBKJ3S];EIZ<3,9#K%( W:/O(_SR O0L6NSL;E=+[O@E
MU?Y)NRT:1<@W3SZ5I@_6V[227H)Z\(= S#$W<=%W\3*Y_1N,I)2QUN)&LR)W
M)0K/C]8+PD*.H)S^4TYCM4M2QF<:>Z)WVU)&-H*NYN&LA:RL?]YN^$VK4!SW
M#\?[>1\,9W]827"YF-]*6-O(9N8K#A)*7!1"_)FV+\4B-?R^Y'T;NR::H_[
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M]DW,FH949#X>DQ!BE-!.QM=3^/VT_T+E/+(9%X##OGH9[OLH,&XT?JB=K-+
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M8G[Q5+ 0?F]!J."%#P^%@GN@57?"T.G'BY'>O5I1 :X#ZTU4RV(J"!8NT-?
MP0<4TDHX/16"$5<:-QK3/G+'2;6WVY<HFFA"XCE(CW"\):FY"-H97Y^>V)R?
M]0G_=#4PQ=7]XKWA\V:*D;SRF"Y#P;D=L[C^D<H5$A:FI@AZ#ULY5:9J*)PC
M*)QJ #]!,';K^'1+@8VFLMBBKH7DRN=4..X@ZN/74<9@)!U>^X*<-=[57&VH
MAJ33H/]G[.5)RK"6I5BWC(?0+WMEBTW)8D\T!A[;H9L=OU+$N@% #)]+4HR
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M74D_<NJKD^R"-G-M <]8B*]Y#TB'IZY2Y3SJ/PE6##E;C;!_/]_\L/)005@
M:#0N<%G+#+<OXTA8!TYPF!)TWL=&OM1F2^\NV#,\,B(:H2N/[)*0%(!%NM9I
MX"YL8<FSB+!LJ:LN#3 C/?,2!O24UB*1\K,+_-%775LSL>&^SW]HV@P:3QZ;
M9IR%$_7/4\,AR#KNV;X"1 ?SB]()QD]7? -OK2^@\U7(XG#O'@1PC*/:&F*?
M6C,>]@JE*&:*SBWP S;CFI?S.7>%7C/8/)U;B<+0\W5WKHQ@8.ZL#8&QJCG!
M[!#6]*H;V0+-J>(/Z]J&V:(XIJ>'+%.'.ER6^PO!T&)A(R1"*UB87!>C-9V
M@/NU([%S@ QC9#?1Q/29OBR\E/]R"Z2U*S(]:==U!IOIN2;&5;2[0-,GMPSF
M-Z1^BBR'9X5R8D[+]#E0A[AYG&R\TCGC:Z]W_3FO9\VM($J9[=2*7Q2@2!.$
MS8%-R$1AR')A>W6;34HH7[X\ Y7-SXCYYK%M^9?ZO?7O17/X]AB,/5&YWQQD
ME>R72USA!GOPHVU[@>;H*_A#P#N9HSLU=HU/OUI/PHUFIEB!PF\82"QP25<K
M<Z*'1K]"][6#M\L2?BXHPI1&8'0K'R2SE+ZA,+#9B<@V7-):BK<=;K-N2YU?
M?U]UH3DI9;U?^SRD*1$W@!*'TPC!U!O %L75LBI$JR/(62_#7YRGQ(;7>'[C
MS:ZY2/R$M@S=#<#J#EII0ABZ' B$D5:B-5&>P_T\BR%2H*V RK_0ZI\6^X<F
M'7+AXE(%"]_>K]7 /-44OS/B?KK4"N*UFM%AC##H&LQ]%H1EKV! C3\\C)4Q
MA)2P6% #\7*H<L$&',CG9'!E8GVXZ"@_)S%)D^WLO58H.PNR/"S-#[AU)*:X
M$];DY<Y"^(<!CE.?_*##UG[$E?#%ALC%9YXG><_HH=6.77?PX]AMN'EBG">9
MH0F](]HV,]](6-\QD)[[[:TB1N.#W^$C!\SY?]@_OIY7<@#YC93+MOQ07<_Q
M]E5L?W3H')]O9.LU4*T]8FC\S/,>2![>%S,.D'PA-SXH&CL<^:5TQP6!;IUD
M!XK/-QF-?AS%'?A9/])S/=E95Z_9?:8-$<[3;[)2WD[3\<[7JIR4FFK,'BJV
M%<MQ]*K3IL\^X3YY0'NOUN']R]G=[W<_87?4C4-!4CICBR&ODAVJ;3;L,AF?
M([+\I?H:@U;\&P_&C@5FPREXW&!O1]&<"E=+VG@:N?*\EF=2!%/>O+/@F]97
MM@ H&S%)FE ).0Z*O2ZGM$L>;"AO+YP-%^%T.25&CIA&^ZR&)L$H8R!=\I(&
M[@,NU^36-&T7KP=<['.\=:;S[,Q#7WEVKVHMP^WH4H%$$94O"/H>LRN3LJC6
M=0-M$N;G<12)<:Q,@XDN*[JR-'P!F?>MOH:A_V=] OY'ZM+_G8-NA5SOR=TO
M#95CG>V^J?*OTH4X;? KMJ3F0J[/I)8-K;^F3>FL-'>7W #<:"X7?[7@-9T
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MG6^02=IU#'LK![/&82"2D$D:CP<MW,$Q>GRLU/R>X(8CY<VYS,"4V)1Z8OY
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M+ 71*Y >&]4%=]#U5N8V&?=?B(U&?O'C?NY KR31-EY^<*9D9G,T)\(=N+Z
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MHS^-9,J&;2NSI=B!]";Y\=:%/:2V^;=](I#WS#SG-JUO27-%2$99&NM#I5W
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M"0>IP"86_@P2*<E1E //WEGIEK,>9NH+)K5OR_M)BC'JX%O/3VXWLY4U,<#
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M:7%G<"ZRB^^(\2UZL6.YW^V,1I,^S@R!C<54IP?5%5N$(L4L%)+O;GLW+IX
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M),ZW;$OH5)9>$/P=@_><&T\(-NSY/17<D$YQL)SC(. 9N%6O!<D0CZ3AKE_
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M:WC.PS&%EFOBLJFX5/_9=\N:X# 0$G9EW.W]J!O+!MLLS"]-!OR*VJ<@E%!
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MGL8"% 3\$_1/T!\@@U(ZY1.*D1''_@)02P,$%     @ :3%F5EUH8+ KNP
MD=D  !$   !I;6<S-#0U-#,P-U\W+FIP9^R\!51<:]<F6+B'X"[!@P9W*H0@
M!0&".X00/+AK(0%"X1[<W4*0PDEP)U"XNT-PIZJY__P]/??VWS,]W6O-3,_Z
M3JU=:]4ZY[RUGV?OL]_]G/=4(681JX#GBG(@.0 2,@" ]/0"(!8 ,@!,='0,
M=#1,# P,+"Q,;%QB/%P<'%P*0B)\8AI*.EH:2FIJ>B9N5GH&3D9J:C;AEYRO
M> 4$!.A8125%^"2X^07X_AH$"0L+"Q<'EQP/CYSO!?4+OO_;&^(G@  3R1<5
M"06) 8!,@(1"@(3H!M ]^8F&]&\;X-\W)&045#1T#$PL;)RG ^J? Y"14%"0
M45'0T%!1G_;Z/>T'H!*@$;[@E48G4C/%8' BY@N,R\5D?%/SBT1]_(2)_Z-S
M$!8V*1DY!24S"RO;2W8!02%A$5$QF;>R<O(*($4-32UM'5T]?;-/YA:65M8V
M+JYN[AZ>7M[!7T)"P[Z&0^(3$I.24[ZEIN7E%Q06%9>4EOVHK:MO@#8V-7=V
M=??T]O4/#$[ )J>F9V;GYM?6-S:WMG=V]_9/S\XO+J^N;V[O_L*%!$!!^L_;
M?XB+X D7,BHJ"BK&7[B0D#W^.H  %>T%+SJAM!J&J1,1 U\@)O&;N-R:7UB,
M_.HG)!^=Q[%)F036F$__@O9OR/[[@ 7]#R'[WX']%USS %P4I*?@H1  @(#K
M.[:\ .Q_V?^ E>RDB5LQ95EB$=L8S<5@8S#]1DW428VAN\GN%B8"=[Y8FVRL
M"V](CVCX"2X>SJ'[G&!$%N(K7['OX2'FWI;7D.GC0-F^)1K]WE/<^_J"!9I,
MZZ0#=KN\CS0S)G0W\:N['RV#G/D!^XPE9^RK4V3'!5J^55KPUGS4C%;A;U;+
MPK!9F9'06N?!]T27-'@/.UR?&NX4#DZ.DC8+/JLYQ#CU>'@YA"=25U5U5'@Y
M2>+9LGO1H=+G(NL,QSS5;&>!L=Y_YEW8UX[_5F7Z+@#_(Q+3ZOE*38DOW?K>
M91NK=L<46ENKN["Z?#/]:X(2#%:F<S5V_AC!._]"N8I/"48JS9!SME:O]3\$
M$K6>JEV.0V94B>=5*U3P;+[ B^T&"<:-TOI*;3]\75AT=OG/ED@O<1,:IZQ,
ME\G3Y3)=FW"A.]?V#B<. O3#=GBVU_RXL5JYK_I470>9L5Y]2/Z>M@<'[@2:
MPZN7?S)GQXRG=N_:J]$3<HULJF1D<5G4@J\;5_TE_-WX\T78H),E4Y$%ZU"Y
M$))M.-I-8,5-0K>S=7-F4@%!NH8318BN$%_CJ.Z)C(\V-%C"R&^=R\"DOC5T
M7N1BK]N)/"F0T24FG0D!<'7MT3R!A?P9-[E@$5SC,"B'[KMKZJ0;^KZ9$:S4
MWN[[E<;D,?!Y-GY[[7O4S%,D?3Z=[QFIAK@INZA!&Y7!"I1^D[ADFY\+<J++
M!^ 6B24JO-LI2W[^:V7CB4TZ#_BMNVQYD.[)IS< 6UXZ4SBQ'5-TR5<<?MZ?
M*)-I #?B2;<XDO%@1MQRE%CY2K'_(,\JQI[;6,K_KOJ3Y"$!.L/79D6Y9$C3
M<7]CQ^P.5)N^6&+"AQK+(DFBT*JN3>?4G<I%^/?8U9/3!(QBS3O=3/D1=4V?
MS/=Y^!$:[FNP>>TDVHO'B%#L8KS#;O')M=8Y/6SZ#G6:/03$Y%)/2<GF9NY+
MNO(QM,T(%L0?3RA\%C@DPHVB2V7*OY^5 -CRT5CJM]8&*?SY8M_L8P0\3KR-
M)(_T<3)*#1*W$_A%>!0MTL!V ?B@0[16BY]J2GW&SM1LP*(7,/I)JFXJS9M"
M66"B?<?!##A?P74L,EQ3?GK,KUEP2IOR+.\S4S.6R N5U3>A!U%+_$=ZX-GF
MI<SO8: 9DE7-V;A%.2JKO2Y\Q7KNS*+=9<I4!S.#;V8:3"/T0XJ/8Y(#)3\$
M=C(;ZEO2?P8A8=!/3*N&YB2OO*[3"U\>ZK!F.D+=Y)$*"-2?C/IXG/!$:& (
ML=IKM/^7C&!$0FB_4J"4LA95_1# J0*@.%8ESU$E4CGA+#&7Q1T/I4JD7HV;
MI:;KG^8)]^U) "4NC D6".<9Q#"P)"6BVA7;!"DL07,$DP2K<L$24 *NHYS)
MZC4U!@YY3O?QHD.HZZ(,+MT?G_6Z*/'RE3MX/8-Z+;QU=#2GKC4(OC+6X'=J
M_VFI+EH+DM6^.H/%://=@$F'P#;&0FJ&"83R#L8?SDO('_,-KXG1Z==&-7(\
ME["V-LPUU<'AD&NC[@OCPOSPPI8H'Z_G+'NLCP+V>896&?L" J ?OR\(NX,]
MC,F4+'OF)XMD:>HQC79S(OGB9CR[(>DW-C"6\&Z[N&ZN;VD;2["*+3AC[\V5
MEC+T78- 1Z+Y8Z4/C Z/"SI@W%')Q=0GUO$#N%PN3@R/.;%O6G9HD-;&Z -'
M>=5+RXTZ]F=>CAP].IBUY+5N"T[MA*[J-[167:F]F1C;X;9,?EW-4.ZW%$#T
M$V#)&*V\MSY9$3(I?ND.6U!36)HJ3'9@>HO#1Y""E!V3\C2>YE,QO'SDTU)I
M@%>ZU 2=X:0>OPB_!MFO,5,IS/?(F$G>,!97"BG=6]5C?C8V-!R.8K*NRRC;
M8)7$4)N9;AIYAG- AVFCHWTUP_@^]9@5PA&O;QA980IU5IDR;K/-\I%4D?%Q
MLTB;F0?7KM5#?$(219,M:<VJCM]SC\<"4'Y[,()$!<$WX!M'-\JH(P0 #WPF
M2?AO7\9I_,YP-/(T1]VY/#)C Z7DX$#;-G3ZR,TS7<=(3%G'KB@K%!?$Z 4C
MXUY0\3<+04')^>RZGM,*?CYDBS89Y6=+FN\X\2X"%298(<U+^3D\N)0U7C.2
M:"!779D#>  GIU$2SMTEUGEA:UJ"ISV/Q2-H&\'!)>X5E[HA3%B[);WYJ<3P
M0\89TJC*9T]IA^F)RVK9Q1_ACBED>.RW&Q2+#+'P/PF1 *1>>?*2)($$#WA'
M]8%SXH*UP5W]:%:9GHUV<TSFE8Z';D:^:'@2"#6X_BO2=VD*BBH6G(B+!K$H
MF,UXJ[;+0&E$:#(;-.E6G=X1'5\NYOM!@GZ^:LMO7S22RL!FV\PXK^'(L_X6
M2#@%TD _U5>UE9PRU_CQ-E=X1]6ZA@-,(S=%XT?0NBY+D\(RDQ[3LGM9.6%Y
MLH2S-/F(016.2GT+F8NRP[-*7!VQ1#;:U4'S>PE0:S)/\OQ(XP<$P(=VBCK^
M@%;V7K^A;(AY$+T]'B=SB(B467LVB=$*NR4?Y47M)*5_CRMX.N@JRV2Z8^LF
M*UC6$2;O8VE9+,UT-W44&2$P(8'EF$ A<K8AD:KF978N_ &KAR5+D*=NMUQT
MRI[E^<O&D)%N$%&L80NH$S2 K1;>*Y67\F/B&EZ/ +RXEVG.:XS!'W/[/+%_
MMUWL&\^.EC:O!-J(,IH%H*_W;](B1>+N9&RW>(=WQ<V6#'U[FC&"@IJJOV()
M9*%,DP*4;E%C@<V87'<6S?KRLG$4-#(<N,_EI(G7#V%X8Q(G)1WM-UJF^"$.
M=I5NJ.+&(,WGE8TIJ';V*G[B$(>N1Y]NG67FZ8M,;[AX0PV2=#2S%BYYD#1V
M04PEUUAG4M"500R^9R@"($=$W>H8K[/[:M#IDJ7!EW'5RI?#R<W=C2K]8*@0
MV=K\)^J.:!\KTUV"43V[FE.ZRL.R?O&^TYM,S0TJNYU\X["T&XXNRN*OW/50
MV(.25P&GCJX;%"\<BVN@JUKQ0(IE7MGTI'-Y8OU8J2DWF=@GG+_Y#=)M-.C@
M4I :C.TFKI2>ZOJ'PEBWL#M43N'%IS%6B@7Z47X#'3A:\^0#$5W8'[>]*E:]
M5IB/@.Q<$Q,NV9BO6R6[=G"&^4B>K9)_ Z9ZO(9A<[N=P_+5[X'FR!OY7F_M
M)KJA8EL"YLI5&M)W>)4/'2;ZO\91*T]:>C_RM%T-N%S<NMQ9M,GKGUPV-*T-
M"-@F2QG(D7Q"23(=#UOG$/\%QXOIG.=:3A><[5!*U9?G(OTI_;Z ("$KN_)3
M>=]<RY_B$5;GQ\3$#;OF6W&#4_H;4R9"7RG86S3_UP?T--E>H^#L#<.1[87L
MF&DY&.X'* *@P/' .F3?$:AVJS7G3SQ@[<*Q2\LV*?"-63R-_/K5P]1,3)5M
MWDEQX,4*-D5Q*,B^NA@!,' 3'2*80?EMF:UQH#Q94,Q>IF-_9]"$G:FB,&$K
M:^>'#XR0@Z^<RL=<G"#%S;CJP>\:="Y)WMZ$@HEO9+J6"</'%HH:S[@=O70W
M[@O@J'0W6-6JX[Y, F#B \J5!=^5(T+\A"V[L]LQPPSXF]H+U3"A-)[(JM;7
M*1;2+]Q#5P9_?FW:/!Z3[).>KA*!V/J'"^XG=52_SJ1H6/1N:%=& $R\PG-_
MT53WX2DND^ 0ZWOGL1TB]P+*I% )Z\=BIO$O"S-8[^=22!;U;^0/ER5:3X$+
M4+\\?-;#96VADWSQVK&EBS_*)]#@L% WKH\G)G[%]W*F+&,<EBE#U):L0)^%
M0DOVWZ[S[:VEOL?ZQ<P"$^.*"  ']<XO$+T4:5LX]NV!Y[O@=NPJ?%CP+>5%
M\_F1TMHGU;*ADEVQI>T(@>Y44H#B^0RY.;UEQJ<9F34'7.$P^L;S2Z5*Q>VM
MI,*LU<V,9W-,T<5-)=V*F7+[+VWNGGVQ5&:WLVK.?)JO#8L5U&0_/365I%D4
MXX63U<+$;T@(O%MH S0B#3.3UQ,3M>8JC0U.(]3;%.J6*,?3*4.WW#"H^C_-
M X$[NNTO3LFZQ94,[#[NN\%<[XN1"-FF6F.]J&Y8XQZ:L<=.(VEY4U1@EW9Z
MAW^X[##2\2YKJ$-?!LG37%T=VXYWK36QRSG;PK%^F1",8<FR>(,#?.7-*JS4
M]*3IYJHJ&'4MZ^U+7O?*EZPWSY\H._3JV]A,+S.<W*D6V]SV;-75K'$3GV>)
M */Y9TJJ-4ZRHRHE]"WNF3,7E;!?6C.IQM;LYT2OUW2;;M$M,^<_X)7H1%Q3
MS9R+0=CR&D=S\B!L@'\WI/C!V.ZS_C7&UWJIT0"4-L?FX^)2SW10<XS"Q' #
MYN#ZMORO=#.4,VY1:C/!RO6!]AFA])R7?5>1*^U])B^E+!Y.,#;T-]0G*A7G
M'QM&&0+8>W;8Z-W)1VSIW%[J'_;ZWSNUQ:;)55N669^JH@[$YWN3WL9>H[K3
M3ZOD^SPKK]:=GU]$A_3*N+BQ"P]^(\=6?9<!3W*_[IRG+1>>M_]L&B^WV=]*
M>A<WW33V?%__G9C\%4MFA 9SIS0#9B28^Y 7-3"[D@#4X9H6'Q_3YG N=N!S
M4\_ULBH'?TNL86(H,C#+/ZG/TWEP^FY#.?IX^>5OZX*0.!F ;]>!45=OG&Z=
M4P"!V8O7A[R&%B$.9=)F1?ONI#6&);6\ @[<7=<#ZXGN[M@1RU&7\#@H,*1R
M0\H^26+>=2/6U.S[H^:)-4.RT=N1W(/D@/Z!.':4K>'\1LFO%Z6'@HV76LFC
M;],Z'UZB4\A1.UVG3*I;DUUC>0@EE/33'C^G%'6*$>-_T+VDP5-ID[<R<CZ$
MKV=V/#"1XKJV>*I[)CQJ71S]5/D9O>E:6G<?):\RC19:ZLZMO8?SB_MG@,C]
MP"UU3*'=8O_)_!"G4RK-\Q\Y(HOR-K_&C\RGC1<,.KY)(=GZN)(KM%#?03]/
MAO?T@F1;X&$@6>+WKO^E324*4':>1@">"U MF=RS#ZY5\> D:FIUU@ 20D5H
MVJQ+H#^81WE_.+B4YI4JE>LN&,K:N7C@"A,B-;#&H@.E=?5CNH'X>]XK5\I3
M715K0;6HS)K9&BJ\B0W2+WNQS]S%RCB032AVO^^;J=IFKY#BQ!:4L#;8>E)'
M0I0%WK%W>KSW^%ZG)LLH,_K@9DF;O_Y(.&CA!C&M@5 _QW$?T582.HF)NC@"
M*K5GV?K$H_X6#X[,('R]42S:9U.S4<YV24=NE:S!7^$2%?D^X#77@N#$;A;N
MA !'H),#=?PBX,V0N#U']CL Q@Q) 4U.^KD$:&U+ATPCSB;#[V"_SH ;*A+Q
M"'PW)<5@\]WFNL,<JK7XPZLL6X@,A1/SV%;UE[ID,<3AX@!GCT?@:]XB3;26
M*GG?YS-Y&J?W\OFS!R9$@A$&-^]J,*$!U%54F/R_K@5=.OG:(]:Y9+K(\.[S
ME!:2R5D[-F)=;BBM[\-YMGB+<3Y*YFL;CY=?'N2?F1M0B6?3[:><FQB//4M%
MN77ZA6,FE>EYB"7RYUU';>,)>HVI8-3%F344_X>NN>@Q/PQ%1!0#.09W_\13
M7&.R+O.#!.:$5]S0]^^2+;BKD1KU1W)T5 ?>[ND%%0D&G?!/L$-V@,B8<8;W
M=3$=1&CAKA$$<S5,?[R\/_#9K5PX^3Y&>0-4A;D.91IC5:5YL>!J+2D^]&6O
MC1WH>[-^J1!8(K9]/N)J;_Z=4RO3/6@@(0  K#2^B>K[PHP 5-4@ &+C=0A
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MM+0SQ:M59G/5Y@/P86^1N]+F%=^X5)H<P D@]^K98TU\S62SY;'XU&S(30C
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M0VIDJ5 FU[F8ZEJ^AW6);74GSY 6,,JW?%SL[7 ]/L;\14]]:C#3?!R3.\\
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M 2#0]Q%% ,8Z?J7>ZX/';O+-CJ28$( <E20$(%@4>--#9WW*^HCL6OU ,8
M]'+0P4E3@H&[3PU6?"WXE!C<.7%B^8@./M-V@#/$6 )OKV]>7=4A -FG<GWS
MOD]-V>M,#@0 W1E\"I&"K:O>H>Z9W/ G( "1VL '+AYT\&]+!(#9 @%89T,
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MJ,E_.)SFGPUY]?XIN7HS&O?$3\Y/.GU67238U7;&MFM\"<=%?&-5:*"$_R8
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M>TC@\VQB:</J!)R1OQIVI*U2[6+!GYT@$-&K&+A'P/LLBZ1/:>0R-PIU63S
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M#3"F3S&;=E'7QXC@K#@S+K(W)=P%CO^-=4V\MP-QBM9FJJD2S%'*G@D^&V#
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M*9$AG%"06)9OHUM><.T4-M3%'+^PP"PM+DK\HKK*+NB)>R7Q&N4C&7JG:O\
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MF*V]H[0LUUU]  BK@3S%HH_('P#4/K]T)V2K)$_>+D@Q?PI(EQ6E#N# 59%
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MA:8.)QQU8OI[/"DJQ?ILKV<V\.=3\72U'S?;V.!_E8?X#T+\ #B.A/TYGWD
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MBOJ+^0NAGE>OQ$!^:*"4CYUUTW]*]IU^T$^>&SBH)#(Q\<(%!#YV,9_4ZEF
M&_E-R)R4L]R0-X%<58L&\S:)#>8L6B_;?YBB,GU)'+HR3=S9Z'?Q#\"T*/#"
M2>S3FN3F<:N<LF.% 5BITTV9SCM6RR=@VA:9);N8.=R-X1JQFAL$%4L'V7.V
MH+8X$E-D7C+U@X%1Z_#1V>6)VJ)%O9[&J>FS2PY"K># N.H#<,S'RBTA1:+X
MF5;"7(]7<=H;'K%YX<)ZU0%J0#2T>BEA$^WNV9@^R,J)')O,I^Q!\A.P8U[F
MY9=;&XJ<YH"5GBG=%*L*;]<3GU S/$+:CS4W;9GV;YUY1S@-\BI[^&U30+'(
MJ/!=]'X^M(QE/ROJQH -S XNY^]5XN.5QL3D+_H</?(RSR]QK_^4AJ[2ULZR
M,B<7)JG+K4RDR 9Q-!]^X[1=: CQ@3KSC3I:0Y?T]7^78I8@2CQ>-?MCAMJ_
MX-PH9B>0.JD>Z4HR]@83CV9/,W"UOCEH@W/,Z=P5HWZ:&"L_;]^#DI![3ZK6
M0._K7FIIRG"O"7B7I"(,8O5+5<0/R.O'!EYY/@-TWQL-%0UF>&R1_QHI_$S7
MFB3^U:B#.^\7M"APH"\FL[W8_S.24_^HH%M9$5W(+DK&HO9F<*^J[!Q'Y3F*
M6S&#Z\8C.MIKO)Y?MML_>F-K9P=24)2,5OE2MY8:Y*EE,K]B>I6#G-U'_DN3
M9ZF'H(7??X9,,6IUAR2+DVL=[6Z .;.%J0$B]'O8?4KE<3QG7J5%)D05>D/R
M^XH'B_*LS(#R&R._GMS,FE^(<R"\+68*CGNRJXX7AJME/B:QUWX?Y/MZ"[/+
MQSP6(^8SQ)UI#J.WWVU/2!_!V!S5#)093SKP2I%AICTR-6MJ_/I>PQ&C=W=7
M^!(YXIR \#M\WGGN+D5!6B<G;#YT9G$=,S-U:]X_0,9_BC_.Y< P6$K8SI[)
M"AS2$G+HXR4B+*1Q")Q6F;7NMPMN[,6]%"X\LA J@719.$VO&YVS% UN7),_
MQ8[^_=QAIH$AIHN@Y0/O!]DQ//$</SX^05PO.9C>]<Z]A/7AXPIJ=$KU/UHP
M_F_D\^QMW/B&*F:Z0)P<;!,#+&>>P5\"$U]%;5"G9[TAZ1L>=B70O%2HFHK%
MN_ZYN*-\J)%!ZU@X9:KVHP$GD>WU+_SZ&,-2-3''^@E=*:QR9S,=C(#N "3!
M./:PPO+=ZTZKZX/:^!XS)XK::OAWT9L46FH'O&?L:2]ZD52]R%VF_F2]C,0/
M%\+EN*P)0![JU?[]@-CVO'#926KOSY\5:R/+G>E,_<62A"#&'Q>4=%G]>J#3
M=386B3"ZR5N$_"L(5W7[BCE*)3S7=S"RI8IERDG#OD6^)#'%6[LT#CUC&D4M
M-PG,9EA*AFSE()%I7S?.\SFO1?,73Y+I."*MO6 !/3SM-I?<94>3\N>,^,9!
M-AC(Q&?9,:]U&+\KC2K$KKB[*IN?:[@PG[^NU8LLE-\1-(#Q58M,PQ\N!PPY
M%V+Z-B$HYO0VM.64%J%G;:Z]'&69IZW<=U\!)H!#BCZXQR,FH$X.&*&B(6RT
M?/$8PBX1IM?'@%O&MY4U<7 !2*U_5CBEO@(QX[=E8S R?CD:5\IB(]RV<+#A
M?BQ @\@)4_H!(!U1S(?8O+\LU##ILV=7,?1HWF4:E*FQM-\W.(BS($0 .-90
M..4SQ/J1R"B>'1F@W0*;Z6!2%1?"F1>.]Q8)%^HP*/%"!)CW2'4P=R=^7L:)
M-=T"],L/3\9?GAZ-&CDB@O01S'%FA'>GU"T,7?NDE]4V1Z8HVL=L:#GR?L%J
M(.M8&-C&!9;96T*.BK2)4M3C/-8M-Q#V8_LFT^\2[67*9;F*<[3#(\6M<HA0
M;RLR:ABK$S3:]<&%GURFIJ%Z\C9D;@VU#6&+!#=5W?[X/H#5A.G 8FY\%5F3
M?]$$Y;]$5/3UQ:R0E5RX'+L;%T 1!-**?'2+^>4.?4LGH%VJB]%'M[)PE>^;
M&>86OE,S>.GKE/_("@A#'P!BD2(/@"=JMY8/@*!PR0= 5F_F \"?X9Y[&5]S
M<8!*X*Y5[>K%(VXYCK7,/".>?'R@%>F-_BU;JW2-9?4 ^(V7N6:()$4Y@'9Q
MKK0NT_8 Z)3*\1T#*ST VK\^ $A%5FC&1;;9"Q\ R^]\(SV>XGN#J!#3(K&4
M#X!_7P&5_1A?!_5[2>\'P"U(E^X.E>OQX9G2K]Q[/):7]X&DOO<HA;]G_51D
MJL7^:]44*DN8/@L1D+<J!R$[:>>RBIZW%R.DI_%<_<\0/<D=IA'M'=]P\K!<
MP@P'("P6&O#FPJN,M7_7GC%=_85WXWJ(0:XP3/Q(S.=H:OZJ8@5&"Z*3B+GY
M8;R['6!HLLR4OTR-08>%6\;4 X!SP??O]*+Z.^M:2.$CNQ=J!/FUD_VH[R2#
MHX0<&5]KRIBZ,?YT%".F'M]/<O*UUZB[(EKUOOPWW:<$H_%M^.Y+(_0 ^-M/
MQO_!()MV^EP8]?UB\2.C>_3HW[I6YN_>7P'(B38-O/$J/ $N/0#^+0N>A G%
MX1[L9O9'^_Z#M[A\__X/.L:@OY 5^8]I>2W,AV<9IYUN^%;YYZXS,640Y6JZ
MSC]<M* 1*)R(MQF6Y)@31D__5_W(?5_+HRZ%-WHW'[;V,V02[C*C%P[O+XUV
M,A^1Y>\ AM?'FX7XLA.R%W'?<R(2:14!%,.6XQ+3VE:P^94C9C<YTDWMS>D/
MENLU44]#9#30$2AY],O++],"(RS"TDO=</G)D'B*+Z2F=3YV<*7>!B()#J3W
M0-),,UI_$TS"K37?'M# %A'ZM3*V 20:/ZDD GMTO[>=7_H:<:A.]+W*@>TZ
M*I@PU^PJ3O@4,"2NRIAAE$I*!K;S(F_NN@QPI[&Z-;EV!P.G$S>7I#+X='(3
M(/J1J8Y*B_9D6)Q3R^?EY^:A&QZ)DE; WC.L9_IG_0<I/G_R@GVO(BV=B.KA
MTVFZ":T1\$#)<?C YCO3Y!"=( 0?=GH6Q7<QDC64L+GC6ZUGV?.E#4EOO=-O
MVX1G+'50T09#PP6PUM?C9RE*/N4T-3?4! V["2I+HC_=</S^C)<\TXNLV:8Q
MKD:IJMO*UT8))5RV<)9,.0I.$,7 O(B$E0M@K(R$L#I!:7^HC'H%'[+.^' L
M:2;IX@E"I'=8L&!6$J\QOER=]'Y2Y>W8:O4B8.MZJ1A?*VLFQ5A-0/:5W!1Y
MCARW7\T9VDAK!OXZ8<<=>I2;I!QW)H^3BJ3!4=T]N7%IC^%> [:7 6:D,W$J
M?-:P$SZHX/919?I<A^ "*T!I:9F%S6B_D3NS$XX'QD9@>6'CNUAW]F%,+-ZE
MRB?;G=N-0XNJER W*YL D)57!2"]^E=@%'M*0E1V-5+1 \#&)VA^T3/3_+1E
M_BJS^0&@=;J/2 -'I9?4Y83[=SXN'_HZG$JL1?%=^5RQZ&9N"VSF,*@#UHW[
MNDO&\LQAV\5--*Z4E0VRG)MW-1$:X_?").9VBEQ+DS0WFH:B?*?'?R:VW9,T
M,B3)K6"88#JGPW.K@R)@7IX\EI=EXQF-AAM233\RN1M:Z@#W]BP++2$\+9*V
M.:36HE&R3EB'CL.WY&N\G\LI\HA'^[YESFK5%B$5HI=%:KP.O=N]:D$ZWB>?
MP%R:>=PA>:X2N $R4=+7TEOQM'_#%7W E)3D=AOI&-O??:62V9CE?B4J"'E=
MMQ'&M^I1$&D:.562&Q'RUYG/AH84QG<"T7: ,9)2ZO7]#S&'O>NK<"E\]8A_
MKTSK_Z0PI?ZZO WE_WQ7\P 8#S>@=?GTMY<,6?6YNH!%%G9]@^]E0E6D"&8^
M4O^S&-3<+;^9@IH*Q(I LV> /8V-Q##C/'>E3'SF =#KOCEQI-$8R9*'LLN!
M9NP+Z]B9:&Q]H]TV;J^[II0YD)!D8A<&(T$CIK[&:*6+X-YQ,&GQOIT7+ZUJ
MBTM#W>N=ITS BUSZN91YE9%(1J*8SBNM=6GFTS#M6;X0:83DVS_H\P PK'X
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M[QWQVBQ_-UM#JUIX6W+(4Y%]G)'**0$IW/G57RDT0/4![=(J<KCSHG^M3%A
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MS8JHZ7Y5_:LVU_<!]M\ 4$L! A0#%     @ :3%F5M4Q*\^8504 &'P_ !$
M             ( !     &)D<W@M,C R,C$R,S$N:'1M4$L! A0#%     @
M:3%F5E7/H@U^(   UX4! !$              ( !QU4% &)D<W@M,C R,C$R
M,S$N>'-D4$L! A0#%     @ :3%F5LTD>]T"$P  U!D! !4
M ( !='8% &)D<W@M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( &DQ9E;@
M346#N5D  ,B!!@ 5              "  :F)!0!B9'-X+3(P,C(Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " !I,69678#/BW09 0"0HPP %0
M@ &5XP4 8F1S>"TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ :3%F5DQE
M0,D5@0  K.0) !4              ( !//T& &)D<W@M,C R,C$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( &DQ9E9DTDW/=P8   (P   0              "
M 81^!P!B9'-X+65X,3!?.#,N:'1M4$L! A0#%     @ :3%F5KNW5P*D @
M/ P   \              ( !*84' &)D<W@M97@R,U\Q+FAT;5!+ 0(4 Q0
M   ( &DQ9E9:!,V'?P@  #1,   /              "  ?J'!P!B9'-X+65X
M,S%?,2YH=&U02P$"% ,4    " !I,69602=9X(\(  !#3   #P
M    @ &FD < 8F1S>"UE>#,Q7S(N:'1M4$L! A0#%     @ :3%F5L3%6#X8
M!0  C2D   \              ( !8ID' &)D<W@M97@S,E\Q+FAT;5!+ 0(4
M Q0    ( &DQ9E9N&IZ<'04  )DI   /              "  :>>!P!B9'-X
M+65X,S)?,BYH=&U02P$"% ,4    " !I,696$_;*[!]>  #J:P  $0
M        @ 'QHP< :6UG,S0T-30S,#=?,"YJ<&=02P$"% ,4    " !I,696
M<5:/"4-[ 0!LU $ $0              @ $_ @@ :6UG,S0T-30S,#=?,2YJ
M<&=02P$"% ,4    " !I,696P2B:#:M- 0!<>@$ $0              @ &Q
M?0D :6UG,S0T-30S,#=?,BYJ<&=02P$"% ,4    " !I,696QIF^% M$  "M
M3@  $0              @ &+RPH :6UG,S0T-30S,#=?,RYJ<&=02P$"% ,4
M    " !I,696%Y=L1BRR   @VP  $0              @ '%#PL :6UG,S0T
M-30S,#=?-"YJ<&=02P$"% ,4    " !I,696^\T1J<=G  !/=@  $0
M        @ $@P@L :6UG,S0T-30S,#=?-2YJ<&=02P$"% ,4    " !I,696
M""J(PAY0  !*9@  $0              @ $6*@P :6UG,S0T-30S,#=?-BYJ
M<&=02P$"% ,4    " !I,69676A@L"N[  "1V0  $0              @ %C
J>@P :6UG,S0T-30S,#=?-RYJ<&=02P4&     !0 % #Q!   O34-

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
